

ALIXPARTNERS, LLP

Exhibit A

Detailed Description of Fees, Hours and Descriptions by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Client: 012589

Federal Tax ID 38-3637158

Date	Consultant	Description of Services	Hours
09/16/19	BF	Preparation for First Day hearing.	1.30
09/16/19	MH	Answer client questions regarding uncleared checks.	0.70
09/16/19	MH	Answer client questions on a list of vendors requesting payment under motion.	1.30
09/16/19	MH	Research the Social Responsibility program to determine correct treatment under automatic stay.	1.80
09/16/19	MH	Attend vendor contact training session.	0.90
09/16/19	MH	Answer follow up questions from the vendor contact training session.	0.60
09/16/19	MH	Validate all filed documents match prepared versions.	0.80
09/16/19	MH	Research payment issues related to patent royalties.	0.30
09/16/19	MH	Research question about bank account debits in blocked accounts.	0.50
09/16/19	MH	Prepare summary of foreign vendors in preparation for meeting with the UST.	0.60
09/16/19	MH	Answer client questions regarding changes in payment terms with vendors.	0.40
09/16/19	MH	Research specific compliance payments to determine qualification in the tax motion.	0.50

Please reference the invoice number noted above on any payment remittance. Thank You.

Send check remittance to:

AlixPartners LLP
P.O. Box 5838
Carol Stream, IL 60197-5838

If Remitting in any currency:

Account Name: AlixPartners LLP
Account Number: 003-58897
Bank Name: Deutsche Bank
ABA: 021-001-033
SWIFT: BKTRUS33XXX



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/16/19	MH	Test new invoice releases in accounts payable against control system.	0.90
09/16/19	MH	Prepare a summary of critical vendors in preparation for meeting with the UST.	1.40
09/16/19	MH	Meeting with management team to review priorities.	0.50
09/16/19	IA	Attend client Town Hall meeting.	1.10
09/16/19	IA	Review of J. Lowne declaration schedules and executive bios.	0.60
09/16/19	IA	Gather information on bank account balances and investment accounts in response to US Trustee questions.	0.80
09/16/19	IA	Update summary supporting schedule for government litigation fees	1.30
09/16/19	JD	Prepare for and participate in a conference call with head of HR, E. Vonnegut (Davis Polk) RE: existing wage motions and outstanding US Trustee questions	0.80
09/16/19	JD	Review informational brief filed by Davis Polk	1.30
09/16/19	JD	Review media stories filed post-bankruptcy filing last night.	1.60
09/16/19	JD	Review final first day motions filed with the court in advance of tomorrow's first day hearing	1.70
09/16/19	DS	Review of 1st day filings, particularly informational brief, for purposes of diligence preparation	2.80
09/16/19	ADD	Analyze accounts payroll to check that post filing controls were properly implemented.	2.60
09/16/19	ADD	Update accounts payable controls and training presentation	1.60
09/16/19	ADD	Call with Purdue accounts payable team about bankruptcy procedures and several potential issues.	0.60
09/16/19	ADD	Review documentation available for initial due diligence	1.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		request.	
09/16/19	ADD	Review and consolidate information for SOFAs and schedules received from the client.	2.80
09/17/19	ADD	Research utility provider issue.	1.30
09/17/19	ADD	Update utility exhibit and updated utility spend model for additional utility provider.	1.80
09/17/19	ADD	Review open accounts payable to confirm that controls were still working correctly.	2.10
09/17/19	ADD	Download and distribute accounts payable file. (evening refresh)	0.50
09/17/19	ADD	Download and distribute accounts payable file. (morning refresh)	0.40
09/17/19	ADD	Download and distribute accounts payable file. (afternoon refresh)	0.30
09/17/19	ADD	Consolidate date for SOFAs and Schedule update.	1.40
09/17/19	ADD	Review due diligence request received by the client.	0.60
09/17/19	DS	Team meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: legal fees / OCP motion, business plan materials, update on work streams.	0.30
09/17/19	DS	Review draft DelConte (AlixPartners) Declaration and provide feedback	0.70
09/17/19	JD	Discussions with CFO, GC and Associate GC RE: severance policy and adjustments to relief requested in other motions	0.80
09/17/19	JD	Prepare materials for the team RE: operating on a post-petition basis	1.70
09/17/19	JD	Team meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: legal fees / OCP motion, business plan materials, update on work streams.	0.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/17/19	IA	Team meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) re: legal fees / OCP motion, business plan materials, update on work streams.	0.30
09/17/19	IA	Review of indemnity and other legal fees spend in preparation for hearings.	0.70
09/17/19	IA	Meeting with client legal operations team to discuss OCP motion and process.	1.40
09/17/19	MH	Review requests for approval of potential critical vendors.	0.80
09/17/19	MH	Meeting with the Purdue intellectual property team to review treatment of royalty agreements.	0.60
09/17/19	MH	Meeting with Avrio team to view vendor issues related to prepetition.	0.80
09/17/19	MH	Attend follow up meeting on additional Avrio vendors.	0.40
09/17/19	MH	Research questions from counsel on the tax motion amounts.	0.40
09/17/19	MH	Review issue with two utility disconnect notices.	0.50
09/17/19	MH	Run first accounts payable control process including training staff.	0.80
09/17/19	MH	Correct accounts payable controls based on first day run.	1.10
09/17/19	MH	Discuss Avrio vendor issues with the Purdue Vendor Management Committee to determine best course of action.	0.60
09/17/19	MH	Review list of additional critical vendors submitted by Wilson plant.	0.70
09/17/19	MH	Discuss with senior management issues with a major city owned utility.	0.40
09/17/19	MH	Re-run accounts payable control process to finalize initial releases.	2.10
09/17/19	BF	Attend First Day Hearing.	3.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/17/19	BF	Calls with staff to review status of filing impact on operations.	0.90
09/17/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.30
09/17/19	KAS	Review and circulate updated relationship disclosures for declaration due to added parties.	0.30
09/18/19	HK	Review executory contracts database for noticing requirements.	2.60
09/18/19	HK	Review data for Statements of Financial Affairs support.	2.80
09/18/19	HK	Review company data for Schedules of Assets & Liabilities support.	2.00
09/18/19	SKL	Begin reviewing and consolidating the latest 8/31 trial balance information provided by the company.	1.90
09/18/19	BF	Deal with filing impact related to Ordinary Course Professionals.	1.40
09/18/19	BF	Meeting with staff to review process controls for monitoring first day relief.	0.60
09/18/19	MH	Make changes to the accounts payable release process to prevent debit balance accounts from releasing.	1.60
09/18/19	MH	Run the accounts payable control process to create the release file.	1.30
09/18/19	MH	Meeting with accounts payable to review issues with debit balance accounts.	0.60
09/18/19	MH	Review client requests for additional vendors to be qualify for critical vendor motion.	2.10
09/18/19	MH	Discuss payment schedule with vendor consolidator to start post-petition funding activity.	0.70
09/18/19	MH	Research status of bank accounts including steps to open remaining accounts.	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/18/19	MH	Contact utility regarding disconnect notice.	0.90
09/18/19	JAD	Review current Schedule A/B progress to validate data prior to upload and identify missing information needed from client.	2.10
09/18/19	JD	Review updated communications materials. Provide comments RE: same to Teneo.	2.20
09/18/19	JD	Review news stories from the day	0.50
09/18/19	JD	Review transcript from first day hearing	0.60
09/18/19	DS	Review J. DelConte's (AlixPartners) summary of changes from 1st day hearing	0.40
09/18/19	ADD	Research and respond to inquiry regarding vendor.	0.80
09/18/19	ADD	Download and distribute accounts payable file. (afternoon refresh)	0.50
09/18/19	ADD	Meeting with TXP payroll team lead regarding due diligence payroll request.	0.40
09/18/19	ADD	Configure Interlinks data room.	2.60
09/18/19	ADD	Review SAP accounts payable payment release list.	1.30
09/18/19	ADD	Review a sample of invoices to check for correct coding.	1.40
09/18/19	ADD	Download and distribute accounts payable file. (morning refresh)	0.40
09/18/19	ADD	Update due diligence list status.	0.70
09/18/19	ADD	Review and update SOFAs and Schedules status.	0.30
09/19/19	JD	Listen to Reorg case overview	0.70
09/19/19	JD	Discussion with CFO RE: first day interim orders and open questions. Review relevant orders. Correspondence with DPW RE: same.	1.20
09/19/19	NAS	Review first day orders granted on 9/18 and request for stay of litigation filed 9/18.	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/19/19	HK	Support noticing information requests from Prime Clerk and Davis Polk related to first day motions.	1.60
09/19/19	HK	Review employee payroll data for Schedule of Assets & Liabilities reporting.	2.30
09/19/19	HK	Perform follow-up diligence for US Trustee requests regarding first day motions.	2.50
09/19/19	HK	Review insurance policy data for insurance and surety bond motion noticing requirements.	2.30
09/19/19	HK	Prepare for and attend conversations with J. Lowne and K. Darragh (both Purdue) on prepayments and deposits analysis.	1.60
09/20/19	HK	Attend call with J. Lowne and K. Darragh (both Purdue) on SOFAs and Schedules preparation.	1.00
09/20/19	HK	Conversations with management on SOFAs & Schedules preparation.	0.30
09/20/19	HK	Update SOFAs & Schedules reporting data.	3.20
09/20/19	MH	Review additional vendors submitted by managers for Critical Vendor approval.	0.80
09/20/19	BF	Call with AD Hoc professionals	1.50
09/20/19	LJD	Prepare for and attend call with M. Huebner (Davis Polk)	0.30
09/21/19	DS	Correspondence to team outlining plan for obtaining data requested by ad hoc committee advisors	0.40
09/22/19	DS	Prepare a schedule outlining and categorizing various relief requested in Customer Programs motion (for purpose of addressing data requests by ad hoc committee advisors)	1.10
09/23/19	DS	Meeting with financial analyst (Purdue) re: preview of counterparty data request by FTI	0.20
09/23/19	DS	Call with Controller (Rhodes) re: counterparty details behind Customer Programs motion numbers for purposes	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		of FTI diligence requests	
09/23/19	DS	Meeting with financial analyst (Purdue) re: counterparty details behind Customer Program motion numbers	0.60
09/23/19	DS	Work on developing support schedules templates for customer programs counterparty analysis	2.30
09/23/19	DS	Review counterparty support for Rhodes cash discount reserve	0.80
09/23/19	DS	Review and sent A. DePalma list of insiders for upload (FTI's request)	0.20
09/23/19	DS	Review Medicaid by state support file for Rhodes for purposes of counterparty analysis	0.70
09/23/19	DS	Review fee for service data provided by Rhodes Controller for purposes of counterparty analysis	0.50
09/23/19	MH	Prepare release list for accounts payable.	1.10
09/23/19	MH	Advise plant manager on responses to several vendors asking for early payment terms.	0.30
09/23/19	MH	Research anomalies in the account's payable analysis.	0.50
09/23/19	MH	Research proposed donation payment with counsel.	0.40
09/23/19	JD	Review materials RE: open US Trustee requests. Correspondence with Davis Polk and AlixPartners team RE: same.	1.10
09/24/19	JD	Review draft Lowne supplemental declaration for the wages motion	0.80
09/24/19	JD	Research vendors RE: UCC and meeting with management RE: same.	1.80
09/24/19	JD	Conversations with E. Vonnegut (Davis Polk) and T. Graulich (Davis Polk) RE: UCC committee members.	0.60
09/24/19	JD	Correspondence with management RE: vendor and customer outreach	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/24/19	JD	Review materials related to the Department of Labor audit of the pension and 401K program	1.00
09/24/19	JAD	Review current Schedule A/B progress to validate data prior to upload and identify missing information needed from client.	1.40
09/24/19	MH	Meeting with A. DePalma and M. Hartley (both AlixPartners) to review status and priorities.	0.50
09/24/19	MH	Review transition of J. Doherty (AlixPartners) work on critical vendor assignment.	0.60
09/24/19	MH	Meeting with Rhodes management to review critical vendor request for regulatory related vendor.	0.50
09/24/19	MH	Research additional vendors requesting critical vendor status for the plant manager.	0.80
09/24/19	MH	Develop project plan to provide additional wage related information to counsel as requested.	0.50
09/24/19	MH	Research requested payment of tuition benefit for senior manager.	0.60
09/24/19	MH	Review requested manual releases from accounts payable manager.	0.30
09/24/19	MH	Research sources of data for the plant retention program in the Wage motion.	0.40
09/24/19	MH	Research large balances claimed by critical vendor to determine accuracy.	0.60
09/24/19	MH	Research payments made before filing that were reversed to create prepetition payables.	0.90
09/24/19	MH	Prepare release file for accounts payable.	1.10
09/24/19	MH	Build analysis routines in accounts payable control system to monitor releases.	0.80
09/24/19	MH	Build summarization routines in accounts payable control system to support payment reporting.	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/24/19	DS	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to review customer programs contracts to upload to data room (requested by FTI)	0.60
09/24/19	DS	Provide update to team re: FTI's diligence items related to insurance	0.40
09/24/19	DS	Review AlixPartners data folders to compile key agreements related to Customer Program motion (customers, GPOs, government agencies, etc.)	2.30
09/24/19	ADD	Meeting with controller to discuss FTI diligence request.	0.70
09/24/19	ADD	Meeting with A. DePalma and M. Hartley (both AlixPartners) to review status and priorities.	0.50
09/24/19	ADD	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to review customer programs contracts to upload to data room (requested by FTI)	0.60
09/25/19	ADD	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and Controller re: review status of diligence items to be uploaded to the data room	0.60
09/25/19	DS	Meeting with financial analyst re: open items for PPLP re: counterparty analysis (FTI request)	0.20
09/25/19	DS	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and Controller re: review status of diligence items to be uploaded to the data room	0.60
09/25/19	DS	Provide updated data request list to Rhodes Controller re: items related to Coverage Gap / Medicare Part D, GPO fees, and private insurance program rebates	1.30
09/25/19	DS	Update counterparty model with 2019 customer allocations received from financial analyst (PPLP)	1.80
09/25/19	DS	Update counterparty model with revised 2019 customer allocations for Rhodes	1.20
09/25/19	DS	Revise counterparty model for vendor chargeback data	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		received from Rhodes controller (for purposes of estimating counterparty allocation for 340B, GPO, and Federal Supply wholesaler chargebacks)	
09/25/19	DS	Call with C. Robertson (Davis Polk) re: formation meeting on Thursday	0.30
09/25/19	DS	Assemble a counterparty analysis summary and provide to A. DePalma (AlixPartners) for purposes of responding to FTI diligence requests	0.40
09/25/19	MH	Update Avrio management on status of multiple vendor requests to consider Critical Vendor status.	0.30
09/25/19	MH	Review open accounts payable for first assessment of prepetition balances.	0.80
09/25/19	MH	Add release logic to the accounts payable control system to address payments between Debtors.	0.70
09/25/19	MH	Review requests from Coventry for additional vendors to be considered as critical.	0.70
09/25/19	MH	Review requests from Coventry for additional vendors to be considered as critical.	0.40
09/25/19	MH	Create release file for accounts payable.	1.10
09/25/19	MH	Create a second release file for accounts payable.	0.60
09/25/19	MH	Review exceptions with accounts payable manager.	0.50
09/25/19	MH	Call with B. Folse and M. Hartley (both AlixPartners) to discuss status of all projects.	0.70
09/25/19	MH	Advise client on how to respond to issues with a real property landlord over prepetition charges.	0.90
09/25/19	LJD	Review correspondence on case updates	0.40
09/25/19	BF	Call with B. Folse and M. Hartley (both AlixPartners) to discuss status of all projects.	0.70
09/25/19	BF	Calls with staff to review status of workstreams	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/25/19	NAS	Update overall SOFA/Schedules workplan to ensure progress towards review/filing deadline.	0.20
09/25/19	JD	Discussion with Associate General Counsel RE: various open items	0.40
09/25/19	JD	Catch up with C. Robertson (Davis Polk)	0.40
09/26/19	JAD	Meeting with the client vendor management committee, M. Hartley, and J. Doherty (both AlixPartners) to discuss status of vendor communication since filing.	0.50
09/26/19	BF	Review draft report of value transfer findings	1.10
09/26/19	MH	Build a tracking program to report total prepetition in accounts payable, both open and paid under motion.	2.60
09/26/19	MH	Add a summary program of released accounts payable for the AP manager.	1.30
09/26/19	MH	Update the approved vendors list for taxing authorities withheld payables.	0.30
09/26/19	MH	Update the approved vendors list for clinical providers referred by the management.	0.40
09/26/19	MH	Meeting with the client vendor management committee, M. Hartley, and J. Doherty (both AlixPartners) to discuss status of vendor communication since filing.	0.50
09/26/19	MH	Create the daily release file for accounts payable.	1.00
09/26/19	MH	Research contract sales vendor to ensure the correct vendor ID is on hold.	0.30
09/26/19	MH	Review a series of marketing invoices to approve assignment of post-petition status.	0.40
09/26/19	DS	Review of fee for service data provided by financial analyst (PPLP)	0.70
09/26/19	DS	Incorporate fee for service data into counterparty model	0.90
09/26/19	DS	Review GPO data provided by Rhodes Controller	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/26/19	DS	Incorporate GPO data into counterparty model	1.30
09/26/19	DS	Compile and provided list of requested items to financial analyst (chargebacks)	0.40
09/26/19	DS	Correspondence with Rhodes Controller re: third party administrator of Medicare Part D Coverage Gap program	0.30
09/26/19	DS	Gather list of detailed follow-up items re: chargebacks (GPO, 340B, FSS), private insurance program rebates, Medicaid rebates, Medicare Part D rebates to send to PPLP financial analyst	1.20
09/26/19	DS	Correspondence with T. Melvin (PJT) re: logistics of diligence review and uploading process	0.30
09/26/19	DS	Review logistics of Intralinks site	0.30
09/26/19	ADD	Spoke with Intralinks technical support to resolve permission issue.	0.70
09/27/19	DS	Correspondence with PJT re: calls with FTI on 1st day motions later that day	0.20
09/27/19	DS	Call with CFO re: documents to be uploaded to data room	0.50
09/27/19	DS	Follow up with financial analyst (PPLP) re: open items (FTI's requests) and inquiring about EDI 867 wholesaler reports	0.40
09/27/19	DS	Preparation for call with FTI (particular regarding Customer Programs motion)	1.50
09/27/19	DS	Update counterparty model for chargebacks info received for PPLP	1.20
09/27/19	MH	Answer questions from counsel on the company's credit card program.	0.30
09/27/19	MH	Create summary analysis of prepetition activity.	0.90
09/27/19	NAS	Update SOFAs/Schedules workplan to be shared with Purdue CFO.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/27/19	JD	Call with management RE: open items	0.40
09/27/19	JD	Progress update call with Associate General Counsel	0.40
09/27/19	JD	Catch up on correspondence from the last 3 days.	1.30
09/30/19	JD	Conversation with Associate General Counsel RE: case progress and open items	0.80
09/30/19	JD	Update call with L. Donahue and J. DelConte (both AlixPartners)	0.40
09/30/19	JD	Review correspondence from Davis Polk RE: case updates.	0.30
09/30/19	NAS	Updates to SOFAs and Schedules workplan to ensure progress is on-track to meet timing requirements.	0.50
09/30/19	IA	Review updated OCP and retained firms list for firm run rate analysis.	1.70
09/30/19	MH	Meeting with CFO and Plant Manager to review issues with reagent vendor who refuses to ship new product.	0.80
09/30/19	MH	Research contract with reagent vendor.	0.70
09/30/19	MH	Draft memo advising options to restore reagent supply at the plant.	0.40
09/30/19	MH	Draft a memo to counsel on evaluation of contract provisions for vendors being considered for critical vendor status.	0.40
09/30/19	MH	Review accounts payable for activity related to legal vendors.	0.60
09/30/19	MH	Arrange meeting with legal operations to ensure proper coordination with OCP motion.	0.30
09/30/19	MH	Prepare accounts payable release file for the day.	0.70
09/30/19	MH	Research tax payment anomalies in accounts payable.	0.40
09/30/19	LJD	Update call with L. Donahue and J. DelConte (both AlixPartners)	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/30/19	DS	Update counterparty model with Medicaid data for PPLP	1.60
09/30/19	DS	Address open items from client regarding customer agreements to post to data room	0.90
09/30/19	DS	Review share drive for additional customer agreements to provide for diligence purposes	1.30
09/30/19	DS	Review Medicare Part D and commercial rebates data provided by financial analyst (PPLP) for purposes of counterparty model	1.30
10/01/19	DS	Meeting with Assistant General Counsel re: ability to send contracts to advisors	0.30
10/01/19	DS	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) re: uploading diligence items related to Customer Programs motion and organizing approvals	0.80
10/01/19	DS	Meeting with Assistant General Counsel, D. Samikkannu, and A. DePalma (both AlixPartners) to further discuss specific confidentiality provisions in customer agreements	0.30
10/01/19	DS	Correspondence with Pricing Manager (PPLP) re: confidentiality clauses of customer programs related agreements	0.80
10/01/19	DS	Assembly of diligence item 5.1 (counterparty analysis) to send to CFO and Controller (PPLP) for their review and signoff	0.90
10/01/19	DS	Revise diligence item 5.1 (counterparty analysis) based on comments received from CFO (PPLP)	1.20
10/01/19	DS	Review of A. DePalma's (AlixPartners) summary of follow up items from management re: FTI follow up diligence requests	0.40
10/01/19	DS	Revise further diligence item 5.1 (counterparty analysis) based on additional comments	1.10
10/01/19	DS	Compile employee headcount files as support for	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		contemplated filings	
10/01/19	DS	Develop list of high priority items re: diligence for A. DePalma (AlixPartners)	1.00
10/01/19	ADD	Meeting with A. DePalma, and D. Samikkannu (both AlixPartners) re: uploading diligence items related to Customer Programs motion and organizing approvals	0.80
10/01/19	ADD	Meeting with Assistant General Counsel, D. Samikkannu, and A. DePalma (both AlixPartners) to further discuss specific confidentiality provisions in customer agreements	0.30
10/01/19	MH	Meeting with N. Simon, J. Doherty, S. Lemack, A. DePalma, M. Hartley, and H. Ku (all AlixPartners) to discuss accounts payable release and reporting process.	1.00
10/01/19	MH	Meeting with legal operations manager to define the process of controlling invoices for compliance with the OCP motion.	0.70
10/01/19	MH	Meeting with counsel to review administration of the critical vendor motion.	0.60
10/01/19	MH	Prepare for the meeting with counsel on administration of the critical vendor motion.	0.40
10/01/19	MH	Attend meeting with the vendor management committee to discuss responses to the adhoc advisors on the critical vendor motion.	0.40
10/01/19	MH	Write memo to CFO to establish a process for responding to adequate assurance requests from utilities.	0.30
10/01/19	MH	Build new professional vendor table to support changes in the accounts payable control process for OCP motion.	0.80
10/01/19	SKL	Meeting with M. Hartley, N. Simon, J. Doherty, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) to discuss accounts payable release and reporting process.	1.00
10/01/19	HK	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, H. Ku and A. DePalma (all AlixPartners) to	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		discuss accounts payable release and reporting process.	
10/01/19	JAD	Meeting with M. Hartley, N. Simon, S. Lemack, A. DePalma, J. Doherty and H. Ku (all AlixPartners) to discuss accounts payable release and reporting process.	1.00
10/01/19	NAS	Meeting with M. Hartley, J. Doherty, S. Lemack, N. Simon, and H. Ku (all AlixPartners) to discuss accounts payable release and reporting process.	1.00
10/01/19	JD	Update meeting with Associate General Counsel	0.70
10/02/19	JD	Meeting with M. Hartley J. DelConte, N. Simon (both AlixPartners), and the Vendor Management Committee to review processes to review contract status of critical vendors	1.10
10/02/19	JD	Kickoff meeting with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), UCC advisors (Province) and PJT Partners	0.80
10/02/19	JD	Correspondence with management RE: open wage motion diligence requests	0.60
10/02/19	JD	Discussion with Purdue legal RE: case status, open items and work plan for the remainder of the week	0.70
10/02/19	NAS	Meeting with M. Hartley, J. DelConte, N. Simon (all AlixPartners), and the Vendor Management Committee to review processes to review contract status of critical vendors.	1.10
10/02/19	JAD	Respond to questions raised by R. Haberlin (Rhodes) regarding figures used in Schedule A/B reporting.	0.80
10/02/19	JAD	Follow up correspondence with various Purdue/Rhodes contacts for missing SOFA/Schedules deliverables.	0.50
10/02/19	IA	Kickoff meeting with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), UCC advisors (Province) and PJT Partners	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/02/19	IA	Drafting of summary spreadsheet with backup for all numbers and amounts shown on supplementary wages declaration.	3.50
10/02/19	IA	Review of initial draft of supplementary wages declaration and sourcing of information from prior diligence requests to fill in the blanks.	3.10
10/02/19	MH	Review the proposed supplemental Wages declaration.	0.60
10/02/19	MH	Meeting with vendor management committee to update field personnel on procedures to evaluate vendor contracts.	0.60
10/02/19	MH	Meeting with J. DelConte, N. Simon, M. Hartley (all AlixPartners), and the Vendor Management Committee to review processes to review contract status of critical vendors.	1.10
10/02/19	MH	Consolidate descriptions of top 30 critical vendors including verification research to ensure accuracy.	2.20
10/02/19	MH	Call with Assistant General Counsel to discuss meeting with General Counsel on SOFA and Schedules.	0.20
10/02/19	DS	Provide feedback comments on business plan to PJT and CFO (PPLP)	0.40
10/02/19	DS	Review GPO contracts provided by Chargebacks Analyst (PPLP) as part of the diligence process	1.60
10/02/19	DS	Kickoff meeting with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), UCC advisors (Province) and PJT Partners	0.80
10/02/19	DS	Review correspondence from Assistant General Counsel (PPLP) re: confidentiality clauses of certain customer programs agreements	0.40
10/02/19	DS	Draft correspondence to Assistant General Counsel (PPLP) and A. Kramer (Reed Smith) re: insurance policies to be posted for diligence purposes	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/02/19	DS	Correspondence with FTI re: discussion of Customer Programs	0.20
10/02/19	DS	Correspondence with Davis Polk re: posting insurance policy documentation	0.20
10/03/19	DS	Meeting with J. DelConte, D. Samikkannu (both AlixPartners) and FTI to discuss various customer programs, cash flows, and counter parties	1.00
10/03/19	DS	Correspondence to A. DePalma (AlixPartners) re: draft business plan and review required	0.30
10/03/19	DS	Add insurance policy documentation to Intralinks site	0.70
10/03/19	DS	Draft outline of items needed to satisfy FTI's follow up requests with Customer Programs	1.10
10/03/19	MH	Researched vendor issues including requests for critical vendor status.	1.10
10/03/19	MH	Prepare accounts payable release file.	0.70
10/03/19	MH	Prepare for meeting with General Counsel on preparation of Schedules.	1.40
10/03/19	MH	Research errors in accounts payable reporting system to correct.	1.60
10/03/19	MH	Build a new accounts payable control mechanism to manage release of post-petition invoices for OCP and legal professionals.	1.40
10/03/19	IA	Incorporation of data to latest draft of supplementary wages declaration as requested by Davis Polk	2.60
10/03/19	IA	Consolidation of comments from K. Laurel, J. Lowne, C. DeStefano (all Purdue) and AlixPartners and update to supplementary wages declaration.	2.60
10/03/19	IA	Analysis and drafting of support documents for wages amounts and details included in J. Lowne (Purdue) supplementary declaration	3.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/03/19	JD	Review existing insurance policies prior to sharing with the committee advisors	1.30
10/04/19	JD	Prepare for and attend meeting with management, J. DelConte, and I. Arana (both AlixPartners) RE: Supplemental Lowne declaration	1.10
10/04/19	JD	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) RE: wage motion objections	1.00
10/04/19	JD	Call with management and Davis Polk RE: wage motion negotiations with the advisors	0.70
10/04/19	IA	Prepare for and attend meeting with management, J. DelConte, and I. Arana (both AlixPartners) RE: Supplemental Lowne declaration	1.10
10/04/19	IA	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) RE: wage motion objections	0.60
10/04/19	MH	Provide comments on proposed changes to the final Critical Vendor order.	0.40
10/04/19	MH	Advise client on response to vendor inquiry regarding potential clawbacks.	0.40
10/04/19	MH	Call with Legal Operations manager to refine the methodology of coding legal invoices and passing them to accounts payable.	0.60
10/04/19	MH	Create prepetition Critical Vendor report for client circulation.	1.20
10/04/19	MH	Provide update to assistant general counsel on the status of payment related to product licenses, including an assessment of how to manage the vendors going forward.	0.50
10/04/19	MH	Create accounts payable release file.	0.90
10/04/19	DS	Correspondence with FTI re: timeframe for sales data and projections	0.50
10/04/19	DS	Additional correspondence with FTI: re purpose of EDI	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		852 and 867 wholesaler data	
10/04/19	DS	Correspondence with Davis Polk re: follow up on customer agreements	0.30
10/04/19	DS	Review responses provided by Controller (Rhodes) re: follow up Customer Programs items from FTI	1.10
10/04/19	DS	Draft detailed response to management's inquiries re: FTI's request of sales data and projections	0.70
10/04/19	DS	Draft response to Controller (Rhodes) based on initial data provided for Customer Programs	0.50
10/04/19	DS	Correspondence with CFO (Rhodes) re: questions on projections request	0.30
10/05/19	DS	Correspondence with FTI re: signing TPA agreement to access certain specific sales data	0.40
10/05/19	JD	Update wage motion tracker with status of individual requests and next steps to collect information	0.90
10/05/19	JD	Create wage motion diligence tracker	0.80
10/07/19	JD	Review and provide comments to the proposed UCC stipulation.	1.00
10/07/19	DS	Outline vendor chargebacks questions for financial analyst (PPLP) to ascertain what is possible to report on a monthly basis	0.60
10/07/19	DS	Draft summary outline to J. DelConte (AlixPartners) re: thinking on what is reportable on a monthly basis relating to Customer Programs motion	0.80
10/07/19	DS	Review diligence items posted over the weekend	0.60
10/07/19	DS	Meeting with FTI re: follow up diligence requests	1.00
10/07/19	DS	Meeting with financial analyst re: advisors' reporting requests re: Customer Programs motion	0.60
10/07/19	DS	Prepare draft OCP analysis to hand off to A. DePalma	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		(AlixPartners) for further analysis	
10/07/19	ADD	Review due diligence files provided for upload to data room.	1.50
10/08/19	DS	Correspondence with N. Simon (AlixPartners) re: vendor payment question from client	0.20
10/08/19	DS	Inventory insurance policies currently held with UCC advisors' list of open insurance policies	1.20
10/08/19	DS	Draft email to Assistant General Counsel and A. Kramer (Reed Smith) outlining details around insurance items to post to data room	0.60
10/08/19	DS	Review chargebacks information received from financial analyst (PPLP) re: assessment of monthly reporting capabilities	0.80
10/08/19	DS	Put together analysis in response to DoJ inquiry about Medicare Part D Coverage Gap amounts in motion	1.80
10/08/19	DS	Draft response to Davis Polk's follow up questions on Medicare Part D Coverage Gap item from DoJ	0.70
10/08/19	DS	Draft questions to Controller (PPLP) on diligence item related to products manufactured	1.30
10/08/19	JD	Discussion with management RE: wage motion messaging.	0.40
10/08/19	JD	Case update and go forward planning call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners)	0.50
10/08/19	JD	Review various iterations of the UCC stipulation and proposed edits. Discuss required information requests with management to determine feasibility. Provide comments RE: same.	1.20
10/08/19	JD	Review and provide comments on the draft wages reply. Review correspondence and comments RE: same from management and Davis Polk.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/08/19	JD	Review updated stipulation and provide final comments.	0.50
10/08/19	JD	Review revised Lowne declaration RE: wages and provide comments.	0.80
10/08/19	JD	Review preliminary injunction objections in advance of Friday's hearing.	2.20
10/08/19	IA	Review of latest draft of wages reply document to be filed.	1.90
10/08/19	IA	Review of latest draft of Lowne Supplemental Declaration document to be filed.	2.30
10/08/19	IA	Follow up on information requests and calculation details to support market access program amounts in wage supplementary filing documents.	2.60
10/08/19	LJD	Prepare for and attend case update and go forward planning call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners)	0.60
10/08/19	BF	Work on critical vendor assessments with client.	1.20
10/08/19	BF	Case update and go forward planning call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners)	0.50
10/08/19	SKL	Continue to update the SOFA/Schedules database re: latest feedback and comments provided by K. Darragh (Purdue).	2.40
10/08/19	SKL	Analyze and reviewed print exports of sections of the SOFA/Schedules report to confirm today's updates were captured accordingly.	1.20
10/09/19	SKL	Update the SOFA/Schedule database with the latest AB information re: SOFA/Schedule reviews.	2.20
10/09/19	SKL	Finalize updates to the SOFA/Schedule database re: prepaid assets.	1.40
10/09/19	SKL	Prepare and finalize updates to the SOFA/Schedule database re: gifts and charitable donations.	1.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/09/19	SKL	Prepare and finalize updates to the SOFA/Schedules workplan based on the latest database updates.	1.30
10/09/19	BF	Deal with supply chain issues related to LTS.	0.50
10/09/19	BF	Review of draft reports for SOFA and Schedules.	1.40
10/09/19	IA	Review of FDA and tax payments post filing in preparation for second day hearing.	1.90
10/09/19	JD	Review latest draft UCC stipulation.	0.40
10/09/19	JD	Review latest Purdue media stories	0.40
10/09/19	JD	Review the final wage reply and Lowne declaration.	0.70
10/09/19	DS	Correspondence with Controller (PPLP) re: details of manufacturing list (diligence request)	0.30
10/09/19	DS	Correspondence with FTI re: TPA required for sales data diligence requests	0.20
10/10/19	DS	Correspondence with N. Simon and A. DePalma (AlixPartners) re: terminated employee's data	0.30
10/10/19	DS	Send diligence items to A. DePalma to post (Purdue pipeline, business plan update)	0.30
10/10/19	DS	Correspondence with FTI re: specifics around confidentiality provisions of TPA	0.20
10/10/19	JD	Discussion about process go forward with management and Davis Polk after the hearing.	0.90
10/10/19	IA	Follow up on questions related to Taxes motion.	1.70
10/10/19	IA	Review of Market Access individual goals documents in support of wages motion.	0.70
10/10/19	BF	Review open inquiries related to critical vendor payments.	0.50
10/10/19	SKL	Prepare updated detail and summary report re: first day motion payments.	2.30
10/11/19	SKL	Finalize updated critical vendor detail and summary report per UCC request.	1.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/11/19	JD	Discuss next steps with management and Davis Polk following the hearing.	0.50
10/11/19	DS	Draft correspondence to Davis Polk providing summary of items needing to be reviewed prior to posting	0.70
10/14/19	DS	Correspondence with A. DePalma (AlixPartners) re: review of diligence items related to sales reporting and overall financial statements	0.40
10/14/19	JD	Conversation with management RE: professional fees going forward.	0.30
10/14/19	JD	Conversation with management RE: preparation for Thursday board meeting.	0.50
10/14/19	SKL	Prepare updates to the SOFA/Schedule database re: updates provided from today's review session.	2.10
10/14/19	SKL	Review the latest open AP and release files and prepared the updated release lists for today's distribution including manual releases.	1.80
10/14/19	SKL	Prepare updated action items for Prime Clerk re: opioid litigation.	1.10
10/15/19	SKL	Prepare for and participate in litigation and insider review re: SOFA/Schedules with H. Ku, N. Simon, S. Lemack, B. Folse (all AlixPartners), and R. Aleali (Purdue).	1.40
10/15/19	SKL	Prepare for and participate in Critical Vendor Payment discussion with R. Aleali (Purdue).	0.80
10/15/19	SKL	Review the latest open AP and release files and prepared the updated release lists for today's distribution.	1.40
10/15/19	KAS	Review updated parties in interest list and circulate for purpose of running through conflicts for any further relationship disclosures.	0.30
10/15/19	BF	Calls and research regarding Comdata demands.	1.20
10/15/19	BF	Respond to emails regarding critical vendors, payment	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		releases, and SOFAs and Schedules items.	
10/15/19	IA	Discussion with C. MacDonald (Purdue) to review diligence requests from FTI, in relation to indemnity and legal fee payments.	0.30
10/15/19	IA	Review and update of OCP detailed run rate information to incorporate comments from Davis Polk and the legal operations team.	0.90
10/15/19	DS	Coordinate TPA execution between UCC financial advisors and Company	0.50
10/15/19	DS	Call with C. Robertson (Davis Polk) re: UCC advisors' confidentiality clauses	0.10
10/15/19	JD	Review and provide comments on latest interested parties list	0.30
10/15/19	JD	Catch up call with Associate General Counsel RE: case status and board update	0.20
10/15/19	JD	Review work plan to respond to UCC OCP and indemnification diligence questions	0.30
10/15/19	JD	Correspondence and conversations with Davis Polk RE: UCC hiring their own claims agent.	0.70
10/15/19	JD	Review conflict disclosure list and previous iteration and data pulls. Review updated analysis and list with A. DePalma and J. DelConte (both AlixPartners).	2.30
10/15/19	JD	Correspondence and discussions with Davis Polk RE: go forward plan for the wage motion.	0.80
10/15/19	JD	Review correspondence from management RE: outstanding UCC insurance diligence requests. Review historical policies provided.	0.60
10/16/19	JD	Diligence meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), Company, and Davis Polk	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/16/19	JD	Review correspondence from committee advisors RE: critical vendors. Review analysis RE: open critical vendor. Correspondence with Davis Polk RE: same.	1.90
10/16/19	JD	Correspondence with S. Lemack, M. Hartley, B. Folse, N. Simon, J. DelConte (all AlixPartners), Davis Polk and management RE: critical vendor process and proposed work plan go forward	2.40
10/16/19	JD	Correspondence and conversations with management and Davis Polk RE: indemnification post-petition	0.50
10/16/19	JD	Review and sign off on latest conflicts list. Review and compare to previous versions and source data for previous versions.	1.40
10/16/19	DS	Diligence meeting with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners), Company, Davis Polk	0.80
10/16/19	DS	Meeting with D. Samikkannu, and A. DePalma (both AlixPartners) re: UCC diligence list and UCC stipulation deliverables	1.40
10/16/19	DS	Correspondence with commercial analyst (PPLP) re: TPAs executed	0.30
10/16/19	DS	Create and update UCC Stipulation diligence tracker	1.40
10/16/19	ADD	Diligence meeting with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), Company, and Davis Polk	0.80
10/16/19	ADD	Meeting with A. DePalma and D. Samikkannu (both AlixPartners) re: UCC diligence list and UCC stipulation deliverables	1.40
10/16/19	IA	Diligence meeting with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners), Company, and Davis Polk	0.80
10/16/19	BF	Calls with client and vendors regarding critical vendor compliance.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/16/19	SKL	Review the latest open AP and release files and prepare the updated release lists for today's distribution.	1.20
10/16/19	SKL	Prepare updates to the latest SOFA/Schedule workplan as well as the SOFA/Schedule database re: schedule A-B.	2.30
10/16/19	SKL	Prepare updated analysis on the latest critical vendor update provided by the Purdue specialists and put together updated tracking summary for the team to review.	2.70
10/16/19	SKL	Prepare updated critical vendor cap analysis.	1.30
10/16/19	SKL	Review the latest opioid litigation tracker provided by the Prime Clerk team and prepare updates to the SOFA/Schedule workplan accordingly.	2.80
10/17/19	SKL	Call with management, B. Folse, J. DelConte, S. Lemack, N. Simon, and D. Samikkannu (all AlixPartners) RE: critical vendor process going forward.	0.80
10/17/19	SKL	Prepare updated critical vendor payment and cap analysis summary report.	1.90
10/17/19	SKL	Finalize updated schedule A-B breakdown per J. Lowne request.	2.30
10/17/19	SKL	Review the latest open AP and release files and prepare the updated release lists for today's distribution.	1.10
10/17/19	NAS	Call with management, B. Folse, J. DelConte, S. Lemack, N. Simon, and D. Samikkannu (all AlixPartners) RE: critical vendor process going forward.	0.80
10/17/19	DS	Update PJT's UCC diligence tracker with status updates	1.30
10/17/19	DS	Review CFO comments on critical vendor proposed language	0.70
10/17/19	JD	Call with management, J. DelConte, S. Lemack, N. Simon, and D. Samikkannu (all AlixPartners) RE: critical vendor process going forward.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/17/19	JD	Correspondence with management RE: critical vendor process	0.60
10/17/19	JD	Catch up call with management RE: critical vendors	0.30
10/17/19	JD	Review and comment on updated critical vendor analysis	0.70
10/18/19	JD	Conversation and correspondence with DPW RE: UCC claims agent	0.40
10/18/19	JD	Correspondence with DPW and management RE: open diligence items	1.00
10/18/19	DS	Review diligence list (FTI) for outstanding items	0.60
10/18/19	DS	Update UCC stipulation tracker for comments received from counsel	0.40
10/18/19	SKL	Review the latest open AP and release files and prepare the updated release lists for today's distribution.	1.30
10/18/19	SKL	Prepare for and participate in opioid litigation tracking discussion with Prime Clerk.	1.00
10/18/19	SKL	Review the latest opioid litigation tracker provided by the Prime Clerk team and provided list of action items and updates required.	2.90
10/18/19	SKL	Prepare updated critical vendor cap analysis and payment summary report per J. Lowne (Purdue) request.	2.30
10/18/19	SKL	Continue to review the latest opioid litigation information re: SOFA/Schedules and begin updating the database accordingly.	2.60
10/18/19	SKL	Review wires made outside of SAP re: 90-day payments to update the SOFA/Schedules accordingly.	0.80
10/18/19	BF	Call with team to debrief on board meeting and determine next steps	0.60
10/18/19	BF	Review drafts of SOFAs and Schedules	3.40
10/18/19	BF	Draft memo to BOD related to SOFAs and Schedules	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/18/19	LJD	Prepare for and attend call with team to debrief on board meeting and determine next steps	0.70
10/19/19	LJD	Update call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners) RE: case status update and next steps	0.60
10/19/19	BF	Update call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners) RE: case status update and next steps	0.60
10/19/19	SKL	Prepare updated summary report of all SOFA/Schedule outstanding items per B. Folse (AlixPartners) request.	1.60
10/19/19	JD	Reply to emails RE: open diligence questions	0.70
10/19/19	JD	Update call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners) RE: case status update and next steps	0.60
10/21/19	JD	Correspondence with management RE: critical vendors and process	0.80
10/21/19	JD	Review critical vendor analysis and provide comments	0.70
10/21/19	JD	Review underlying September disbursements analysis	1.20
10/21/19	JD	Review correspondence RE: open TPA agreements with committee advisors	0.40
10/21/19	JD	Conversation with DPW RE: diligence process and information sharing	0.40
10/21/19	JD	Review former employee details RE: wage diligence	0.50
10/21/19	DS	Review UCC / Ad Hoc diligence tracker	1.40
10/21/19	DS	Review PJT's updated diligence tracker	0.90
10/21/19	DS	Create UCC diligence stipulation tracker	1.20
10/21/19	SKL	Review the latest open AP and distribution reports and prepare today's release files.	1.20
10/21/19	SKL	Review the latest information re: 90-day payments for the SOFA/Schedules and update the tracker accordingly.	2.30
10/21/19	SKL	Continue to make updates to the SOFA/Schedule workplan and database re: 90-day payments.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/21/19	SKL	Prepare updated critical vendor payment tracking summary for the company to review.	1.30
10/22/19	SKL	Analyze the latest opioid litigation tracker from Prime Clerk and began formatting for the SOFA/Schedules.	2.80
10/22/19	SKL	Continue to finalize review and analysis of the opioid litigation tracker and finalized updates for the SOFA/Schedules.	2.50
10/22/19	SKL	Review the latest open AP and release files and prepared the updated release lists for today's distribution.	1.00
10/22/19	SKL	Finalize updates to the critical vendor payment and outstanding AP tracker.	1.80
10/22/19	SKL	Update the SOFA/Schedules database with the latest information re: opioid litigation.	1.90
10/22/19	KAS	Review updated relationship disclosures.	0.90
10/22/19	KAS	Review updated disclosures, edit retention pleadings, and circulate to DC.	1.30
10/22/19	IA	Call with DPW, management, I. Arana, and J. DelConte (both AlixPartners) RE: long term incentive plans	0.60
10/22/19	DS	Meeting with D. Samikkannu, and A. DePalma (both AlixPartners) to update UCC diligence tracker sent over from PJT	0.90
10/22/19	DS	Update UCC and Ad Hoc diligence tracker and send to PJT team for discussion	1.30
10/22/19	JD	Meeting with Prime Clerk, DPW, PJT and management RE: noticing budget.	1.00
10/22/19	JD	Call with DPW, management, I. Arana, and J. DelConte (both AlixPartners) RE: long term incentive plans	0.60
10/22/19	JD	Review due diligence request list from the UCC in comparison to the UCC stipulation	1.80
10/22/19	ADD	Meeting with D. Samikkannu and A. DePalma (both	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) to update UCC diligence tracker sent over from PJT	
10/23/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), and M. Ronning re: promotional and marketing diligence request	0.20
10/23/19	JD	Correspondence with management RE: critical vendors	0.50
10/23/19	JD	Review correspondence from management and Prime Clerk RE: certain noticing inquiries	0.30
10/23/19	DS	Review insurance questionnaire provided as response to diligence items	0.40
10/23/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), and M. Ronning re: promotional and marketing diligence request	0.20
10/23/19	DS	Provide comments to PJT re: diligence tracker	0.90
10/23/19	DS	Update diligence tracker to send to PJT	0.80
10/23/19	KAS	Update and recirculate retention pleadings.	0.60
10/24/19	JD	Correspondence with Davis Polk and management RE: insurance diligence questions	0.80
10/24/19	JD	Review information sharing chart for all diligence materials. Compare against materials posted to date.	0.90
10/28/19	DS	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and Controller (PPLP) re: financial statement detail for diligence	0.20
10/28/19	DS	Meeting with D. Samikkannu and J. DelConte (both AlixPartners) re: Customer Programs report	0.30
10/28/19	DS	Update UCC / Ad Hoc tracker to revert back to PJT	1.90
10/28/19	JD	Meeting with D. Samikkannu and J. DelConte (both AlixPartners) re: Customer Programs report	0.30
10/28/19	ADD	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and Controller (PPLP) re: financial	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		statement detail for diligence	
10/29/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), and R. Hoff (Wiggin Dana) re: accessing documents produced from MDL for diligence purposes	0.20
10/29/19	JD	Update call with L. Donahue, and J. DelConte (all AlixPartners)	0.50
10/29/19	JD	Catch up on case progress with Associate General Counsel	0.90
10/29/19	DS	Call with T. Melvin (PJT) re: diligence status and business plan materials	0.30
10/29/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), and R. Hoff (Wiggin Dana) re: accessing documents produced from MDL for diligence purposes	0.20
10/29/19	DS	Correspondence with assistant general counsel (PPLP) re: marketing materials for Adhansia requested as part of the diligence process	0.30
10/29/19	DS	Review pipeline report for diligence purposes	1.30
10/29/19	DS	Update UCC / Ad Hoc diligence tracker to send around to advisors	1.30
10/29/19	DS	Review requested items from Davis Polk re: diligence process	0.40
10/29/19	DS	Review additional diligence tracker from Jefferies	0.90
10/29/19	DS	Draft email to Davis Polk team re: outstanding diligence items and obtaining approval	0.50
10/29/19	LJD	Prepare for and attend update call with B. Folse, L. Donahue, and J. DelConte (all AlixPartners)	0.60
10/29/19	GJK	Call with Davis Polk and PJT providing situation update, planning for UCC meeting	0.90
10/29/19	GJK	Follow up on available public information on Purdue	0.40
10/29/19	GJK	Assess uploaded documents to support IAC diligence	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/30/19	GJK	Business Plan Diligence call with Mgmt., PJT, Province, FTI	1.10
10/30/19	GJK	Review employee materials posted to data room to prep for UCC meeting	0.50
10/30/19	GJK	Review financial materials posted to data room to prep for UCC meeting	0.50
10/30/19	GJK	Follow up on communication and diligence approach to be most responsive and helpful to different interested parties	0.60
10/30/19	GJK	Call with D. Samikkanu and G. Koch (both AlixPartners) re diligence process and IAC available information	0.40
10/30/19	GJK	Review of key material to support diligence and IAC	3.60
10/30/19	GJK	Prep for UCC meeting	0.80
10/30/19	MH	Meeting with N. Simon and M. Hartley (both AlixPartners) to discuss implementation of new critical vendor approval/payment process and project team responsibilities moving forward.	0.40
10/30/19	KAS	Review comments from UST and update pleadings accordingly.	2.80
10/30/19	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss implementation of new critical vendor approval/payment process and project team responsibilities moving forward.	0.40
10/30/19	DS	Call with D. Samikkanu and G. Koch (both AlixPartners) re diligence process and IAC available information	0.40
10/30/19	JD	Call with Davis Polk and Teneo RE: chapter 11 process	0.40
10/31/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), and CFO (Rhodes) re: specific diligence requests	0.30
10/31/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), Davis Polk, Reed Smith, and company counsel re: insurance related diligence requests	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
10/31/19	DS	Follow up re: Avrio marketing materials for diligence	0.20
10/31/19	DS	Correspondence with Davis Polk e-discovery team re: document production	0.40
10/31/19	DS	Research on insurance retention / deductibles for diligence purposes	0.50
10/31/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), and CFO (Rhodes) re: specific diligence requests	0.30
10/31/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), Davis Polk, Reed Smith, and company counsel re: insurance related diligence requests	0.90
10/31/19	MH	Direct staff to create monthly accounts payable summary to support Chapter 11 related accounting entries.	0.20
10/31/19	GJK	Organize notes and follow up points from UCC meeting	0.30
10/31/19	GJK	Outline next steps for IAC work stream following UCC meeting	0.50
11/01/19	MH	Call with M. Hartley, and J. DelConte (all AlixPartners) to discuss staffing plans for the next phase of the project.	0.50
11/01/19	GJK	Prepare for Mundipharma call, including developing questions list	0.90
11/01/19	GJK	Initial diligence call with IAC CFO, FTI, Province, PJT, G. Koch and J. DelConte (both AlixPartners)	2.50
11/01/19	GJK	Call with PJT to discuss next steps in IAC diligence process	0.20
11/01/19	GJK	Due diligence discussion with D. Samikkannu and G. Koch (all AlixPartners)	0.30
11/01/19	GJK	Review transfers deck and questions list	1.50
11/01/19	KAS	Review Pillowtex information, make further updates to retention pleadings to address UST comments, and respond to Davis Polk with updated retention pleadings and answers for UST.	4.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/01/19	SKL	Reconcile latest critical vendor updates and prepare updated analysis for this week's UCC upload.	2.70
11/01/19	SKL	Review the latest AP invoices and prepare updated distribution re: AP releases.	1.40
11/01/19	SKL	Prepare updated reconciliation re: changes to the Critical Vendor cap analysis.	1.60
11/01/19	JD	Call with M. Hartley, B. Folse, and J. DelConte (all AlixPartners) to discuss staffing plans for the next phase of the project.	0.50
11/01/19	JD	Review latest critical vendor analysis. Correspondence re: same.	0.50
11/01/19	IA	Call with Committees to discuss OCP proposal and firms	0.90
11/01/19	IA	Update to OCP firms run rate analysis to split spend by type of work done and break out government litigation firms	3.00
11/01/19	DS	Call with CFO (Rhodes) re: logistics of sharing large files for diligence	0.10
11/02/19	JD	Correspondence with management and Davis Polk RE: 341 meeting.	0.40
11/03/19	JD	Correspondence with Davis Polk RE: Akin Gump requests re: PEO designations	0.70
11/04/19	JD	Meeting with Davis Polk and management re: pre-meeting prior to call with FTI on wage diligence questions	1.00
11/04/19	JD	Review latest critical vendor analysis. Correspondence with regards to process go forward.	0.80
11/04/19	IA	Review of committees OCP proposal and follow up on data requests	1.10
11/04/19	IA	Review payment forecast for November MCO rebates	0.80
11/04/19	IA	Follow up with client and review of job descriptions requested by committees	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/04/19	IA	Follow up and review of files addressing open items for wages diligence as requested by committees	2.90
11/04/19	IA	Response to wages questions and analyses requested by Davis Polk on retention and other wages open items	1.80
11/04/19	SKL	Review latest batch of critical vendor agreements and prepare updated breakdown for the AP team to review.	1.30
11/04/19	SKL	Reconcile latest batch of critical vendor updates to the SharePoint site and update the critical vendor database accordingly.	2.10
11/04/19	GJK	IAC diligence discussion with PJT Partners	0.20
11/04/19	GJK	Begin build out of ex-IAC entity financial performance based on VDR provided by Norton Rose	2.40
11/04/19	GJK	Due diligence question list, including responses from PJT	0.60
11/04/19	GJK	Assess financial statements and structure for 10 IAC entities	2.80
11/04/19	GJK	Call with D. Samikkannu, G. Koch, A. DePalma (all AlixPartners), and Davis Polk re: logistics of document production and current data room	0.40
11/04/19	GJK	Assess financial statements and structure for additional IAC entities	2.40
11/04/19	GJK	Meeting with D. Samikkannu, G. Koch, A. DePalma (all AlixPartners) to discuss diligence process to ensure efficiency and effectiveness	0.30
11/04/19	GJK	Assess financial statements and structure for additional IAC entities	1.00
11/04/19	MH	Review LSTC analysis from accounts payable analyst.	0.40
11/04/19	DS	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) re: G. Cardillo's (Davis Polk) questions on diligence process	0.30
11/04/19	DS	Call with D. Samikkannu, G. Koch, A. DePalma (all	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners), and Davis Polk re: logistics of document production and current data room	
11/04/19	DS	Meeting with D. Samikkannu, G. Koch, and A. DePalma (all AlixPartners) to discuss diligence process to ensure efficiency and effectiveness	0.30
11/04/19	ADD	Meeting with D. Samikkannu, and A. DePalma (both AlixPartners) re: G. Cardillo's (Davis Polk) questions on diligence process	0.30
11/04/19	ADD	Call with D. Samikkannu, G. Koch, A. DePalma (all AlixPartners), and Davis Polk re: logistics of document production and current data room	0.40
11/04/19	ADD	Meeting with D. Samikkannu, G. Koch, and A. DePalma (all AlixPartners) to discuss diligence process to ensure efficiency and effectiveness	0.30
11/05/19	DS	Call with J. DelConte, D. Samikkannu (both AlixPartners), and M. Atkinson (Province) re: cash reporting, customer reporting, and other diligence items	0.20
11/05/19	DS	Weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, J. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	0.70
11/05/19	JD	Conversation with management re: insider disclosures	0.20
11/05/19	JD	Prepare for and attend weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, J. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	1.00
11/05/19	RDS	Weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, J. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		updates	
11/05/19	RDS	Review and edit Business Planning work plan	0.50
11/05/19	GJK	Weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	0.70
11/05/19	GJK	Follow up on project tracking/coordination with AlixPartners and PJT	0.30
11/05/19	GJK	Call with B. Folse and G. Koch (both AlixPartners) to discuss program management going forward	0.50
11/05/19	GJK	Call with Jefferies, Province, FTI, and PJT to discuss IAC diligence approach	0.50
11/05/19	GJK	Assess financial statements and structure for additional IAC entities	2.50
11/05/19	GJK	Assess financial statements and structure for additional IAC entities	2.00
11/05/19	GJK	Summarize and next steps email for IAC diligence approach per advisor's call	0.40
11/05/19	GJK	Assess financial statements and structure for additional IAC entities	2.50
11/05/19	GJK	Assess financial statements and structure for additional IAC entities	2.10
11/05/19	BF	Call with B. Folse and G. Koch (both AlixPartners) to discuss program management going forward	0.50
11/05/19	BF	Weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, J. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	0.70
11/05/19	BF	Call with staff to review open work streams and discuss	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		IAC.	
11/05/19	SKL	Prepare updated critical vendor breakdown and provide update to the UCC.	1.80
11/05/19	SKL	Prepare updated AP release files and review prior to distribution.	1.20
11/05/19	SKL	Reconcile AP releases re: law firms and first day motions.	2.40
11/05/19	SKL	Review latest critical vendor information re: security deposits and provide update to the AP team.	1.30
11/05/19	IA	Prepare for and attend weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, J. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	1.00
11/05/19	JD	Review case calendar put together by Davis Polk	0.40
11/06/19	IA	Call with B. Folse, L. Donahue, J. DelConte, K. Koch, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/06/19	IA	Call with management, Davis Polk, I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion	1.00
11/06/19	IA	Review of LTRP payments to current and former employees and trackers by level to respond to requests by Davis Polk	2.40
11/06/19	IA	Follow up on OCP run rates and work performed details by firm as requested by committees	2.30
11/06/19	SKL	Prepare for and participate in Critical Vendor meeting with J. Lowne (Purdue) and Elliot Ruiz (Purdue).	0.70
11/06/19	SKL	Begin preparing updated critical vendor analysis and breakdown following this afternoon's meeting with J.	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Lowne and Elliot Ruiz (both Purdue).	
11/06/19	SKL	Finalize updated critical vendor breakdown for Purdue review.	0.80
11/06/19	SKL	Review the latest AlixPartners files re: disbursements and open AP and prepare today's release files.	1.10
11/06/19	FOS	Discussion re transfer pricing with G. Koch and F. Silva (both AlixPartners) as relevant to IACs	0.30
11/06/19	BF	Call with B. Folse, L. Donahue, J. DelConte, K. Koch, I. Arana and R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/06/19	BF	Correspondence and calls related to vendor negotiations.	1.30
11/06/19	LJD	Call with B. Folse, L. Donahue, J. DelConte, K. Koch, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/06/19	GJK	Project coordination activities including follow up with Davis Polk on upcoming meetings	0.50
11/06/19	GJK	Review notes from Ad Hoc meeting	0.50
11/06/19	GJK	Discussion with PJT re Ad Hoc meeting	0.20
11/06/19	GJK	Assess financial statements and structure for additional IAC entities	1.50
11/06/19	GJK	Call with L. Donahue, J. DelConte, K. Koch, B. Folse, I. Arana, D. Samikkannu, R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/06/19	GJK	Call with Norton Rose to discuss IAC diligence	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/06/19	GJK	Assess financial statements and structure for additional IAC entities	3.00
11/06/19	GJK	Discussion re transfer pricing with G. Koch and F. Silva (both AlixPartners) as relevant to IACs	0.30
11/06/19	GJK	Assess financial statements and structure for additional IAC entities	2.30
11/06/19	JD	Call with management, Davis Polk, I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion	1.00
11/06/19	JD	Call with L. Donahue, J. DelConte, K. Koch, B. Folse, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/06/19	RDS	Call with L. Donahue, J. DelConte, K. Koch, B. Folse, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re preliminary injunction hearing of 11/6/19 and various workstream updates: business planning, due diligence and investigations	0.70
11/07/19	RDS	Business Planning Objectives / Timeline assembly	0.70
11/07/19	RDS	Call with J. Lowne, D. Fogel, D. Lundie, W. DiNicola (Purdue/Rhodes), J. Turner, T. Melvin (PJT) re API opportunity	0.60
11/07/19	RDS	Call with L. Donahue, J. DelConte, and R. Sublett (all AlixPartners) re: business planning process and preliminary findings.	0.50
11/07/19	ADD	Recap call and discussion with D. Samikkannu, and A. DePalma (both AlixPartners) on diligence reporting process	0.20
11/07/19	JD	Meeting with G. Koch, J. DelConte and I. Arana (all AlixPartners) re: timeline going forward	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/07/19	JD	Call with L. Donahue, J. DelConte, and R. Sublett (all AlixPartners) re: business planning process and preliminary findings.	0.50
11/07/19	JD	Prepare for and participate in weekly meeting with management, Davis Polk, PJT, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners)	1.00
11/07/19	JD	Meeting with D. Samikkannu, J. DelConte, G. Koch (all AlixPartners), and Davis Polk re: IAC diligence process and document production and reporting	0.80
11/07/19	DS	Recap call and discussion with D. Samikkannu, and A. DePalma (both AlixPartners) on diligence reporting process	0.20
11/07/19	DS	Call with J. Chen (Davis Polk) re: labeling of documents in document production	0.20
11/07/19	DS	Provide TXP Manager with PPI balance sheet	0.30
11/07/19	DS	Outline reporting requirements for Customer Programs, Cash Reporting, and Monthly Operating Report for team tracker	0.80
11/07/19	DS	Assemble diligence trackers to send to Davis Polk litigation team, outlining key elements in email	1.20
11/07/19	DS	Correspondence with Davis Polk litigation team re: potential lock down of data room	0.30
11/07/19	DS	Draft email outlining nuances with watermarks and other designations on documents in data room	0.90
11/07/19	DS	Correspondence with J. DelConte and I. Arana (both AlixPartners) re: weekly reports requested by Province	0.20
11/07/19	DS	Meeting with D. Samikkannu, J. DelConte, G. Koch (all AlixPartners), and Davis Polk re: IAC diligence process and document production and reporting	0.80
11/07/19	DS	Review metadata concerns raised by Davis Polk litigation	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		team and draft email response	
11/07/19	GJK	Meeting with D. Samikkannu, J. DelConte, G. Koch (all AlixPartners), and Davis Polk re: IAC diligence process and document production and reporting	0.80
11/07/19	GJK	Call with I. Arana, G Koch (both AlixPartners), and Davis Polk to discuss project workstreams	0.30
11/07/19	GJK	Prepare for and participate in weekly meeting with management, Davis Polk, PJT, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners)	1.00
11/07/19	GJK	Meeting with I. Arana, J. DelConte, and G. Koch (all AlixPartners) to discuss overall project workstreams	0.50
11/07/19	GJK	Assess financial statements and structure for additional IAC entities	2.00
11/07/19	GJK	Assess financial statements and structure for additional IAC entities	3.00
11/07/19	LJD	Prepare for and participate in weekly meeting with management, Davis Polk, PJT, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners)	1.00
11/07/19	LJD	Call with L. Donahue, J. DelConte, and R. Sublett (all AlixPartners) re: business planning process and preliminary findings.	0.50
11/07/19	BF	Prepare for and participate in weekly meeting with management, Davis Polk, PJT, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners)	1.00
11/07/19	SKL	Finalize updated critical vendor analysis.	1.10
11/07/19	IA	Correspondence with client on OCP open items related to firms working with IACs or Sacklers	0.60
11/07/19	IA	Draft summaries by Tier for OCP firms based on monthly run rates and analysis of proposed caps	2.40
11/07/19	IA	Track required reporting under the different motions and	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		as requested by committees during diligence process	
11/07/19	IA	Meeting with G. Koch, J. DelConte and I. Arana (all AlixPartners) re: timeline going forward	0.50
11/07/19	IA	Call with I. Arana, G Koch (both AlixPartners), and Davis Polk to discuss project workstreams	0.30
11/08/19	IA	Update to OCP list and descriptions to be filed with revised OCP motion.	2.30
11/08/19	SKL	Respond to Critical Vendor inquiries and provide status update to the Purdue team.	1.30
11/08/19	GJK	Meeting with I. McClatchy (Norton Rose) to discuss IACs and approach to diligence	1.00
11/08/19	GJK	Post-meeting debrief with PJT, Davis Polk, L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: next steps	0.50
11/08/19	GJK	Call with I. McClatchy (Norton Rose) to discuss next steps and provide follow up to team	1.00
11/08/19	DS	Correspondence with B. Folse (AlixPartners) re: UCC Stipulation and Emergency Fund concept	0.40
11/08/19	DS	Correspondence with M. Pera (Davis Polk) re: Emergency Fund concept and documentation	0.20
11/08/19	JD	Debrief with management re: Ad Hoc Committee meeting and other open items	0.70
11/08/19	JD	Correspondence with Davis Polk re: sharing certain information with the non-consenting states committee	0.60
11/09/19	DS	Review questions from K. Benedict (Davis Polk) re: logistics of data room and document production process; draft email response	0.80
11/09/19	RDS	Review case correspondence, prepare for audience: PJT setting up meetings with advisors to review business plan document	0.30
11/09/19	GJK	Scan through of new IAC documents uploaded	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/10/19	GJK	Review of 2H 2019 board books uploaded	2.00
11/10/19	GJK	Project management support including developing key activities for week ahead	1.50
11/10/19	RDS	Coordinate advisor diligence meetings with management	0.40
11/11/19	ADD	Meeting with D. Samikkannu, G. Koch, and A. DePalma (all AlixPartners) re: recap of Ad Hoc meeting and corresponding diligence requirements.	1.00
11/11/19	DS	Provide G. Koch (AlixPartners) with comments on workstream summary	0.70
11/11/19	DS	Correspondence with A. DePalma (AlixPartners) re: expense line item diligence request	0.30
11/11/19	DS	Incorporate R. Sublett's and I. Arana's (both AlixPartners) comments into G. Koch's workstream summary outline	0.40
11/11/19	DS	Respond to Davis Polk e-discovery and litigation team re: process around Bates stamp, confidentiality designations	0.50
11/11/19	JD	Catch up call with Associate General Counsel after board meeting convened	0.40
11/11/19	RDS	Workstream planning and correspondence with D. Simmikannu and G. Koch (both AlixPartners) re the same	0.80
11/11/19	GJK	Call with PJT to discuss IAC diligence including sending prep email with IAC notes and follow up email to UCC and Ad Hoc	1.00
11/11/19	GJK	Review of Europe folder documents uploaded to Norton Rose website	2.80
11/11/19	GJK	Review of 1H 2019 board books and Budget Book documents	3.20
11/11/19	GJK	Meeting with G. Koch and A. DePalma (both AlixPartners) re: recap of Ad Hoc meeting and corresponding diligence requirements	1.00
11/11/19	GJK	Call with B. Folse, J. DelConte, M. Hartley, R. Collura, and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		G. Koch (all AlixPartners) to discuss staffing and additional work streams.	
11/11/19	MH	Review latest staffing options.	0.40
11/11/19	MH	Call with B. Folse, J. DelConte, M. Hartley, R. Collura, and G. Koch (all AlixPartners) to discuss staffing and additional work streams.	0.70
11/11/19	MH	Meeting with N. Simon and M. Hartley (both AlixPartners) to discuss responsibilities across critical vendor approval and trade agreement reconciliation processes.	0.60
11/11/19	SKL	Prepare updated Critical Vendor breakdown and circulate updates to the company and Davis Polk team.	1.20
11/11/19	IA	Review and response to AdHoc diligence requests on OCP and professional advisory firms.	2.70
11/11/19	IA	Review employee wages open diligence items and follow up with client on data requests.	2.60
11/11/19	IA	Follow up on data room access to advisors for non-consenting states	1.10
11/11/19	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss responsibilities across critical vendor approval and trade agreement reconciliation processes.	0.60
11/11/19	RC	Call with M. Hartley, R. Collura, and G. Koch (all AlixPartners) to discuss staffing and additional work streams.	0.60
11/12/19	IA	Case status update call with Davis Polk, PJT and AlixPartners team.	1.00
11/12/19	IA	Call with Davis Polk, management, J. DelConte and I. Arana (both AlixPartners) re: OCP response	0.70
11/12/19	IA	Meeting with I. Arana and G. Koch (both AlixPartners) to discuss long-term workstreams	0.50
11/12/19	IA	Follow up on committees' requests for information	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		regarding work and billing for OCP and working with the client to request updated estimates from firms.	
11/12/19	GJK	Call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), Norton Rose, UCC and Ad Hoc advisors re Mundipharma LAM operations	1.20
11/12/19	GJK	Prepare for and follow up for Mundipharma LAM call	1.00
11/12/19	GJK	Prepare for and follow up for Mundipharma Europe call	1.00
11/12/19	GJK	Mundipharma due diligence workstreams organization	2.50
11/12/19	GJK	Meeting with I. Arana and G. Koch (both AlixPartners) to discuss long-term workstreams	0.50
11/12/19	GJK	Review and additions to Mundipharma diligence questions	0.80
11/12/19	BF	Participate in weekly catch up call with PJT, Davis Polk, L. Donahue, B. Folse, and J. DelConte (all AlixPartners).	0.80
11/12/19	BF	Calls with staff to review detailed work plan and updates on IAC discussions	1.20
11/12/19	LJD	Participate in weekly catch up call with PJT, Davis Polk, L. Donahue, B. Folse, and J. DelConte (all AlixPartners). (partial attendance)	0.60
11/12/19	JD	Participate in weekly catch up call with PJT, Davis Polk, L. Donahue, B. Folse, and J. DelConte (all AlixPartners).	0.80
11/12/19	JD	Call with Davis Polk, management, J. DelConte and I. Arana (both AlixPartners) re: OCP response	0.70
11/12/19	JD	Correspondence with Davis Polk re: providing access to the non-consenting states to the data room.	0.60
11/12/19	JD	Internal correspondence re: potential staffing for business plan work stream	0.70
11/12/19	JD	Correspondence with Davis Polk and E. Kardos and R. Collura (AlixPartners) re: filing the cash transfer report on the public docket	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/12/19	DS	Debtor advisor's status call (AlixPartners, Davis Polk, PJT Partners)	0.70
11/12/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), and Z. Levine (Davis Polk) re: diligence updates and protective order status	0.30
11/12/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), and Z. Levine (Davis Polk) re: diligence updates and protective order status	0.30
11/13/19	JD	Discussion with G. Koch, J. DelConte and N. Simon (all AlixPartners) re: workstream planning and listing of key questions prior to discussion with PJT.	0.50
11/13/19	JD	Review objections and declarations re: ad hoc committee fee letter assumption agreement	1.70
11/13/19	JD	Review and provide comments on case calendar and work stream tracker	0.70
11/13/19	GJK	Discussion with G. Koch, J. DelConte and N. Simon (all AlixPartners) re: workstream planning and listing of key questions prior to discussion with PJT.	0.50
11/13/19	GJK	Call with I. McClatchy (Norton Rose) to discuss diligence	0.50
11/13/19	GJK	Purdue diligence call (Finance)	1.70
11/13/19	GJK	Prepare for call with S Jamieson (Management Revisions) including analysis of financial performance information	3.00
11/13/19	GJK	Analysis of Canada documents provided in data room	2.50
11/13/19	GJK	Prepare for and follow up on call re: IAC diligence workstreams	0.70
11/13/19	SKL	Update the critical vendor summary with the latest information/format prior to tomorrow's critical vendor meeting with the company.	1.40
11/13/19	FOS	Compose emails to I. Arana de Uriarte and M Rule (both AlixPartners) re: project planning and workflow.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/13/19	IA	Review ongoing workstreams in order to update case calendar and workstream tracker for weekly team update.	2.70
11/13/19	IA	Call with Davis Polk and client to discuss updated OCP proposal from committees and response.	0.80
11/13/19	IA	Analysis of the cost of replacing one employee based on feedback from HR and in response to request from Davis Polk.	1.90
11/13/19	IA	Follow up on committees' request for updated August through October billing for OCP firms, drafting of summaries and analysis of monthly run rates against proposed caps.	3.30
11/13/19	IA	Update to Purdue case calendar and workstream tracker to include board meetings and known deliverables.	1.30
11/13/19	NAS	Discussion with G. Koch, J. DelConte and N. Simon (all AlixPartners) re: workstream planning and listing of key questions prior to discussion with PJT.	0.50
11/14/19	IA	Review of UCC stipulation document for case calendar and deliverable tracking purposes.	0.80
11/14/19	IA	Call with Davis Polk, management, J. DelConte, and I. Arana (both AlixPartners) re: sign on bonuses	0.50
11/14/19	IA	Update and approval follow up to report on post filing employee separations as requested by the committees.	0.90
11/14/19	SJC	Distributions analysis and documentation.	1.70
11/14/19	GJK	IAC diligence planning	1.50
11/14/19	GJK	Update diligence summary tracker	1.90
11/14/19	GJK	Create diligence summary/update and tracker	2.10
11/14/19	GJK	Follow up with I. Arana (AlixPartners) on long-term workstreams	0.50
11/14/19	JD	Call with management and Davis Polk re: professional eyes-only designations	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/14/19	JD	Call with Davis Polk, management, J. DelConte, and I. Arana (both AlixPartners) re: sign on bonuses	0.50
11/14/19	JD	Correspondence with Davis Polk re: PBGC	0.60
11/14/19	JD	Correspondence with Province re: professional eyes-only designations	0.50
11/14/19	JD	Correspondence with Davis Polk and with FTI re: wage motion negotiation	0.70
11/14/19	JD	Update and provide comments on team calendar	0.40
11/14/19	JD	Work to provide data room access to various AGs re: wage motion diligence items	0.50
11/14/19	JD	Correspondence with management re: ongoing wage motion negotiation	0.80
11/14/19	JD	Conversation with Associate General Counsel re: case update and go forward process	0.70
11/14/19	JD	Correspondence with management and Davis Polk re: process for data requests with TXP	0.70
11/15/19	JD	Correspondence with Davis Polk re: process for obtaining information from TXP RE: open diligence questions	0.50
11/15/19	JD	AlixPartners weekly team update call.	1.10
11/15/19	DS	AlixPartners weekly team update call.	1.10
11/15/19	DS	Call with TXP manager re: process surrounding requesting information	0.20
11/15/19	RDS	AlixPartners weekly team update call.	1.10
11/15/19	ADD	AlixPartners weekly team update call.	1.10
11/15/19	JDH	AlixPartners weekly team update call.	1.10
11/15/19	KM	AlixPartners weekly team update call.	1.10
11/15/19	GJK	Prep for IAC Tax Meeting (to cover Germany, UK, Netherlands, Canadian entities)	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/15/19	GJK	Review materials and notes to create summary following IAC Tax meeting	0.80
11/15/19	GJK	Meeting with I. McClatchy (Norton Rose) to discuss IAC diligence	0.80
11/15/19	MFR	AlixPartners weekly team update call.	1.10
11/15/19	LJD	AlixPartners weekly team update call.	1.10
11/15/19	MH	AlixPartners weekly team update call.	1.10
11/15/19	SKL	AlixPartners weekly team update call.	1.10
11/15/19	FOS	AlixPartners weekly team update call.	1.10
11/15/19	HK	AlixPartners weekly team update call.	1.10
11/15/19	IA	AlixPartners weekly team update call.	1.10
11/15/19	IA	Calls and correspondence with HR client team to discuss open items for the wages motion including attrition calculations and updated headcount program numbers.	2.90
11/15/19	IA	Review of updated J. Lowne declaration document.	1.70
11/15/19	SJC	AlixPartners weekly team update call.	1.10
11/15/19	NAS	Finalize Mundipharma diligence workstream summary for weekly AlixPartners internal team coordination call.	0.40
11/15/19	NAS	AlixPartners weekly team update call.	1.10
11/15/19	RC	AlixPartners weekly team update call.	1.10
11/16/19	IA	Review updated OCP order and list of proposed firms and caps.	1.20
11/18/19	IA	Review updated LTRP trackers by employee by level for 2015-2017 performance related grants.	2.80
11/18/19	IA	Update OCP detail by firm summary in preparation for hearing as requested by DPW.	1.70
11/18/19	IA	Update benefit programs analysis including LTRP expected and target payments by employee using	3.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		updated employee roster and trackers.	
11/18/19	IA	Resolve issues with view only platform to grant access to non-consenting states users to wages diligence information	2.10
11/18/19	DS	Call with C. Robertson (Davis Polk) re: DoJ production	0.20
11/18/19	JD	Meeting with management re: Lowne Declaration and wage motion negotiation	0.50
11/18/19	JD	Review updated analysis of wage motion splits on LTRP payments for 2017 and earlier.	0.80
11/18/19	JD	Correspondence with Davis Polk re: diligence materials and providing access to the non-consenting states.	0.40
11/18/19	RDS	Review latest Rhodes cost status	0.20
11/19/19	RDS	Input on AlixPartners team weekly Key Activities presentation	0.30
11/19/19	DS	Draft follow-up email to team re: DoJ production materials	0.30
11/19/19	IA	Update presentation on LTRP options to support ongoing negotiations with UCC	3.30
11/19/19	IA	Update LTRP options by employee file to show exclusion of 2017 objectives from payments to employees by level.	2.90
11/19/19	GJK	LAM document analysis - budget/board book performance	2.40
11/19/19	BF	Review of October MOR	0.50
11/20/19	GJK	Prepare for DLA Piper call	0.50
11/20/19	GJK	Review of AP investigation articles for Italy, Canada, finances re IAC diligence issues	1.00
11/20/19	GJK	Prepare for IAC Advisors call	0.50
11/20/19	GJK	Respond to IAC Advisor questions and follow up questions on LAM sales and marketing	0.50
11/20/19	GJK	China AP study review and follow up with advisors,	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		counsel	
11/20/19	GJK	Project coordination activities, including following up with AlixPartners team on week activities	1.00
11/20/19	GJK	LAM Diligence - budget book reviews	1.30
11/20/19	GJK	Email exchange with I. McClatchy re IAC diligence	0.30
11/20/19	GJK	Follow up on usage of IAC proceeds per Term Sheet	0.20
11/20/19	GJK	Perdue diligence call (Branded Products)	1.20
11/20/19	GJK	Call with T. Melvin (PJT) to update on recent IAC meetings	0.20
11/20/19	IA	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: wage motion negotiation	0.60
11/20/19	IA	Reconcile 2020 LTRP expected amounts by employee to those shown in wages motion and diligence materials.	2.20
11/20/19	IA	Edits to LTRP 2020 payment analysis to separate 2017 performance by level and by employee as proposed by the committees.	3.10
11/20/19	IA	Updates to LTRP 2020 payment presentation to include edits from client, for review by DPW.	2.50
11/20/19	DS	Assemble professional fee advisor summary for assistant general counsel	0.80
11/20/19	JD	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: wage motion negotiation	0.60
11/20/19	JD	Review and provide comments re: weekly work streams activity tracker	0.40
11/20/19	JD	Review stipulation re: meeting purposes	0.30
11/20/19	JD	Review correspondence with Davis Polk, UCC advisors and Norton Rose re: Mundipharma opioid sales and marketing activities	0.80
11/20/19	JD	Review latest Lowne declaration re: wage motion	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/20/19	RDS	Call with R. Schnitzler (PJT) re Avrio business planning workstream	0.20
11/21/19	JD	Call with management, J. DelConte, and I. Arana (both AlixPartners) re: open wage motion diligence and negotiations	0.50
11/21/19	JD	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), restructuring counsel (Davis Polk & Wardwell), B. Folse, J. DelConte, G. Koch, M. Hartley, and N. Simon (all AlixPartners).	0.70
11/21/19	JD	Call with Davis Polk, PJT Partners and management re: Purdue Canada CMO offer	0.50
11/21/19	JD	Call with Davis Polk and management re: wage motion negotiations	1.00
11/21/19	JD	Deal with getting confidentiality agreement finalized prior to IAC meeting tomorrow.	0.50
11/21/19	JD	Review updated break down of LTRP payments and create potential counter proposal	1.10
11/21/19	JD	Correspondence with management re: posting certain presentations	0.50
11/21/19	JD	Review status of open diligence requests and review certain materials prior to posting	0.90
11/21/19	IA	Call with management, J. DelConte, and I. Arana (both AlixPartners) re: open wage motion diligence and negotiations	0.50
11/21/19	IA	Correspondence with DPW to provide details related to latest proposal on wages and benefit programs (LTRP and AIP expected and target payouts).	1.80
11/21/19	NAS	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), restructuring counsel (Davis Polk & Wardwell), B. Folse, J. DelConte, G. Koch, N. Simon, and M. Hartley (all AlixPartners).	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/21/19	NAS	Discussion with G. Koch and N., Simon (both AlixPartners) to align on IAC diligence priorities following weekly update call with Purdue, Davis Polk, and AlixPartners.	0.40
11/21/19	NAS	Review notes regarding key IAC diligence activities over prior week, revise content to be distributed in advance of AlixPartners weekly update call and send to G. Koch (AlixPartners).	1.30
11/21/19	GJK	Prepare notes on IAC for Debtor/Advisor update call	0.50
11/21/19	GJK	Purdue/Advisor call to discuss current activities	0.70
11/21/19	GJK	Update diligence summary including revisions to workplan	2.10
11/21/19	GJK	Review Tax Advisor email and call with J Turner (PJT) to discuss	0.20
11/21/19	GJK	Finalize IAC diligence summary for week for AlixPartners	0.40
11/21/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) to align on IAC diligence priorities following weekly update call with Purdue, Davis Polk, and AlixPartners.	0.40
11/21/19	GJK	Europe board books review - opportunity and risk areas	2.60
11/21/19	GJK	IAC LAM Compliance deck review and comments	0.80
11/21/19	MH	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), restructuring counsel (Davis Polk & Wardwell), B. Folse, J. DelConte, G. Koch, M. Hartley, and N. Simon (all AlixPartners).	0.70
11/21/19	BF	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), restructuring counsel (Davis Polk & Wardwell), B. Folse, J. DelConte, G. Koch, M. Hartley, and N. Simon (all AlixPartners).	0.70
11/22/19	BF	AlixPartners weekly team update call. (partial attendance)	0.50
11/22/19	LJD	Prepare for and attend AlixPartners weekly team update call.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/22/19	HK	AlixPartners weekly team update call.	0.60
11/22/19	FOS	Prepare for and attend AlixPartners weekly team update call.	0.70
11/22/19	FOS	Compose emails to W. DiNicola (Rhodes Tech) re: requests for intercompany settlement files and summary of API sales to IACs.	0.20
11/22/19	SKL	Prepare for and attend AlixPartners weekly team update call.	0.90
11/22/19	SKL	Prepare A/R intercompany reconciliation re: PPI SOFA/Schedules.	1.10
11/22/19	IA	Review updated employee roster and hourly employee detail.	0.40
11/22/19	IA	Incorporate hourly employee detail into wages and benefits proposal analysis by mapping hourly employees to master spreadsheet.	1.10
11/22/19	IA	Draft summary of hourly employees as requested by the committees.	0.30
11/22/19	IA	Prepare for and attend AlixPartners weekly team update call.	0.70
11/22/19	IA	Review of latest proposal on wages and benefit programs received from committees.	1.40
11/22/19	IA	Update to summary of latest committee proposal on benefit programs versus expected amounts, to be reviewed by management and Davis Polk.	2.10
11/22/19	NAS	Prepare to speak to IAC workstream update on AlixPartners engagement team weekly coordination call.	0.40
11/22/19	NAS	AlixPartners weekly team update call.	0.60
11/22/19	RC	AlixPartners weekly team update call.	0.60
11/22/19	JD	AlixPartners weekly team update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/22/19	JD	Pull numbers together for wage motion negotiations	0.70
11/22/19	JD	Pull together responses to Province questions re: wage motion	0.80
11/22/19	JD	Review IAC diligence materials provided at meeting	1.10
11/22/19	DS	AlixPartners weekly team update call.	0.60
11/22/19	KM	AlixPartners weekly team update call.	0.60
11/22/19	JDH	AlixPartners weekly team update call.	0.60
11/22/19	ADD	AlixPartners weekly team update call.	0.60
11/22/19	RDS	AlixPartners weekly team update call.	0.60
11/23/19	IA	Draft and post insider target AIP and LTRP detail to data room.	0.60
11/24/19	IA	Review of updated UCC proposal and calculation of variances in payout to support ongoing negotiations on wages motion benefit programs.	2.50
11/25/19	IA	Consolidate comments from DPW and client to wages and benefits proposals to reflect ongoing negotiations with UCC.	3.90
11/25/19	IA	Validate by employee calculations for LTRP 2020 payment by gran year by performance year.	2.90
11/25/19	IA	Draft summary of LTRP 2020 payment by performance year by employee and reconciled amounts to diligence materials provided.	3.80
11/25/19	JD	Correspondence with management and Davis Polk re: information sharing protocol	0.70
11/25/19	JD	Review and edit latest draft declaration of J. Lowne for wage motion.	2.60
11/25/19	DS	Review details surrounding specific vendor to ensure covered by Customer Programs motion	0.60
11/26/19	DS	Weekly call with management, Davis Polk, PJT Partners	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		and AlixPartners re: case status and ongoing work streams.	
11/26/19	JD	Weekly call with management, Davis Polk, PJT Partners and AlixPartners re: case status and ongoing work streams.	0.50
11/26/19	RDS	Correspondence with AlixPartners team regarding API market research	0.50
11/26/19	IA	Update summaries for final agreement with UCC on wages and benefits programs, one showing individual insider information and one without this detail.	2.40
11/26/19	IA	Review cash actuals for week ended 11/22 and summary actuals report.	2.70
11/26/19	IA	Consolidate comments from DPW and client to wages and benefits proposals to reflect ongoing negotiations with UCC.	3.40
11/26/19	IA	Weekly call with management, Davis Polk, PJT Partners and AlixPartners re: case status and ongoing work streams.	0.50
11/26/19	NAS	Weekly call with management, Davis Polk, PJT Partners and AlixPartners re: case status and ongoing work streams.	0.50
11/26/19	BF	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), restructuring counsel (Davis Polk & Wardwell), B. Folse, J. DelConte, G. Koch, M. Hartley, and N. Simon (all AlixPartners).	0.50
11/26/19	MH	Attend professionals call to review case status.	1.00
11/27/19	IA	Consolidate comments from management and DPW to benefit programs agreement with UCC and update to summaries.	2.50
11/27/19	IA	Review of updated wages declarations and validation of numbers.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/27/19	RDS	Assemble shell of operational turnaround presentation	1.50
11/27/19	DS	Update October board package to create draft monthly flash report	1.90
11/27/19	DS	Update draft monthly flash report based on comments received from J. DelConte (AlixPartners)	1.10
11/29/19	JD	Review KPMG materials and comparison of PWC and KPMG proposals	0.40
11/29/19	JD	Call with Akin Gump, Davis Polk, PJT Partners, Province, Jefferies, J. DelConte, and G. Koch (both AlixPartners) re: KPMG retention.	0.90
11/29/19	GJK	Call with Akin Gump, Davis Polk, PJT Partners, Province, Jefferies, J. DelConte, and G. Koch (both AlixPartners) re: KPMG retention.	0.90
11/30/19	JD	Review latest J. Lowne declaration re: wages.	0.80
12/01/19	JD	Review draft Willis Towers Watson and Lowne declaration re: wage motion support.	1.30
12/01/19	JD	Review correspondence from management and Davis Polk re: OSR next steps	0.60
12/02/19	JD	Call with L. Donahue, and J. DelConte (both AlixPartners) re: go forward work streams.	0.50
12/02/19	JD	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50
12/02/19	IA	Correspondence with client and follow up with firms on billing for Canadian proceedings.	0.60
12/02/19	IA	Review of CEO pay timeline and details in response to requests from Davis Polk.	0.70
12/02/19	IA	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
12/02/19	GJK	Project management - key activities for week ahead	0.50
12/02/19	DS	Meeting with D. Samikkannu, I Arana, and J. DelConte (all AlixPartners) re: various ongoing work streams and plan for December	0.50
12/02/19	RDS	Coordinate North Carolina interview schedule - email correspondence with AlixPartners team and D. McGuire, J. Carlisle, A. Oliveira (all Purdue)	0.50
12/03/19	RDS	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50
12/03/19	RDS	Correspondence with C. Chomiack (Purdue/Avrio) and J. DelConte (AlixPartners) re Avrio business plan review meetings	0.50
12/03/19	RDS	Case management - North Carolina meeting preparation and communication with J. DelConte, and H. Ku (both AlixPartners) re status of business planning workstream	0.60
12/03/19	DS	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination. (partial participation)	0.40
12/03/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), and DPW eDiscovery team re: protective order and Bates stamping process.	0.60
12/03/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), DPW Litigation and Skadden re: DOJ request list.	0.70
12/03/19	GJK	Finalize and send out weekly activity list	0.20
12/03/19	GJK	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50
12/03/19	LJD	Prepare for and participate in weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.60
12/03/19	BF	Weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
12/03/19	IA	Advisors call with PJT, DPW and the company to review open items and key weekly activities.	1.00
12/03/19	JD	Review supplemental L. Donahue declaration. Correspondence re: same.	0.60
12/03/19	JD	Prepare for and participate in weekly call with AlixPartners, Davis Polk and PJT Partners re: work stream coordination.	0.60
12/03/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), and DPW eDiscovery team re: protective order and Bates stamping process.	0.60
12/03/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), DPW Litigation and Skadden re: DOJ request list.	0.70
12/03/19	JD	Conversation with Associate General Counsel re: latest work plan and go forward strategy.	0.80
12/04/19	JD	Finalize supplemental L. Donahue declaration.	0.40
12/04/19	JD	Review final 2020 budget presentation for tomorrow's board meeting.	1.30
12/04/19	JD	Review materials pulled together to be responsive to a diligence question re: intercompany matrices.	0.40
12/04/19	IA	Correspondence with HR in response to questions regarding upcoming wages hearing.	0.90
12/04/19	IA	Review of prior analyses and materials related to headcount in preparation for wages hearing.	1.70
12/04/19	IA	Follow up on Management's request for a summary of employees who may have been involved in prior commercialization of opioids.	0.60
12/04/19	IA	Prepare summary of employees who may have been involved with the commercialization of opioids in the past.	0.90
12/05/19	IA	Reconcile agreed LTRP payments by employee to latest employee roster from HR.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
12/05/19	IA	Review and update calculations of yearly LTRP grants for latest Purdue active employee roster and made adjustments for agreement with UCC.	2.20
12/05/19	IA	Review and update calculations of yearly LTRP grants for latest Rhodes active employee roster and made adjustments for agreement with UCC.	1.40
12/05/19	IA	Review source files for CEO 2018 and 2019 compensation.	0.80
12/05/19	IA	Prepare summary of CEO 2018 and 2019 compensation based on time earned.	1.40
12/05/19	IA	Correspondence with Davis Polk and internal AP team on CEO compensation diligence.	1.20
12/05/19	JD	Correspondence with Davis Polk re: scheduling out employee claims for unpaid bonuses	0.50
12/05/19	JD	Correspondence with Davis Polk re: CEO compensation negotiation	0.80
12/05/19	BF	Call with M Hartley and B. Folse (both AlixPartners) to review status of critical vendor motion and other case developments.	0.40
12/05/19	MH	Call with B. Folse and M. Hartley (both AlixPartners) to review status of critical vendor motion and other case developments.	0.40
12/06/19	BF	Call in to Sackler family defenses meeting.	1.00
12/06/19	JD	Correspondence with Davis Polk, PJT Partners and management re: de-designating certain materials for an AHC presentation	0.70
12/06/19	IA	Follow up on upcoming payment of hourly bonuses for Rhodes and correspondence with company to verify amounts.	1.80
12/06/19	IA	Correspondence with management on timeline of CEO	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
12/06/19	IA	compensation in response to requests from Davis Polk. Review of CEO historical wages and benefits payments and drafting of summaries in response to diligence requests.	1.30
12/06/19	DS	Correspondence with A. DePalma (AlixPartners) re: confidentiality designations and protocol of certain items to be posted	0.40
12/09/19	JD	Discussion with Associate General Counsel re: case progress and upcoming deadlines and work stream progress	0.90
12/09/19	RDS	Weekly key activities tracker	0.20
12/10/19	RDS	Weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.70
12/10/19	JD	Weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.70
12/10/19	JD	Call with B. Folse, G. Koch, J. DelConte, and M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	JD	Review potential rate increases	0.20
12/10/19	IA	Advisor call with PJT and Davis Polk to discuss upcoming deliverable and open items.	0.70
12/10/19	BF	Call with B. Folse, G. Koch, J. DelConte, M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	LJD	Prepare for and attend weekly professional's update call with AlixPartners, Davis Polk and PJT Partners	0.90
12/10/19	GJK	Call with B. Folse, G. Koch, J. DelConte, M. Hartley (all AlixPartners) to discuss current status and staffing needs for the international diligence team.	0.30
12/10/19	GJK	Weekly professional's update call with AlixPartners, Davis	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Polk and PJT Partners	
12/11/19	JD	Review details re: retention plan	0.80
12/11/19	JD	Conversation and correspondence with management and Davis Polk re: professional fee payment process	0.50
12/12/19	JD	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50
12/12/19	JD	Correspondence with management and Davis Polk re: PBGC information sharing process	0.30
12/12/19	JD	Conversation with Associate General Counsel re: open work stream process	0.70
12/12/19	JD	Review progress and status of ongoing work streams. Prepare agenda for update call.	0.90
12/12/19	NAS	Prepare to speak to IAC diligence status on 12/13 AlixPartners engagement team update call.	0.40
12/12/19	BF	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50
12/13/19	BF	Partial attendance AlixPartners weekly team update call.	0.50
12/13/19	LJD	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	MH	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	SKL	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	HK	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	FOS	Attend AlixPartners weekly team update call.	0.80
12/13/19	NAS	Prepare to speak to IAC diligence status on 12/13	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners engagement team update call.	
12/13/19	NAS	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	NAS	Email correspondence with G. Koch (AlixPartners) regarding key takeaways from internal AlixPartners engagement team call (G. Koch couldn't attend call).	0.20
12/13/19	IA	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	IA	Follow up on diligence requests from non-consenting states regarding CEO compensation.	1.60
12/13/19	SJC	Prepare for and attend AlixPartners weekly team update call.	1.00
12/13/19	JD	Attend AlixPartners weekly team update call.	0.80
12/13/19	JD	Call with Davis Polk, J. DelConte, and A. DePalma (both AlixPartners) re: business plan diligence materials.	0.30
12/13/19	JD	Call with Associate General Counsel re: diligence process.	0.40
12/13/19	JD	Review SOFA/SOAL details re: CEO comp. Review detailed information for pre SOFA/SOAL periods to determine how much detail can be provided to non-consenting states.	0.90
12/13/19	JD	Review existing engagement barriers	0.30
12/13/19	JD	Correspondence with Davis Polk re: engagement barriers. Review documentation re: same.	0.70
12/13/19	JD	Correspondence with management and Davis Polk re: diligence designations and go forward planning.	0.70
12/13/19	RC	Attend AlixPartners weekly team update call.	0.80
12/13/19	ADD	Prepare for and attend AlixPartners weekly team update call.	0.90
12/13/19	ADD	Call with Davis Polk, J. DelConte, and A. DePalma (both	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: business plan diligence materials.	
12/13/19	KM	Attend AlixPartners weekly team update call.	0.80
12/13/19	JDH	Prepare for and attend AlixPartners weekly team update call.	1.00
12/16/19	JD	Review cash management motion for cash balances as of the petition date. Correspondence with management and Davis Polk re: same.	0.30
12/16/19	JD	Review AlixPartners information barriers. Correspondence with Davis Polk and E. Kardos (AlixPartners) re: same.	0.80
12/16/19	JD	Review non-consenting states public health filing.	0.40
12/16/19	JD	Review additional barrier details.	0.20
12/16/19	JD	Correspondence with Teneo re: responding to media inquiries.	0.30
12/16/19	JD	Correspondence with management re: confidentiality designations.	0.50
12/16/19	JD	Correspondence with internal AlixPartners team and Davis Polk re: Akin Gump planned statement in court on Thursday re: AlixPartners client disclosure.	0.90
12/17/19	JD	Attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.50
12/17/19	JD	Conversation with L. Donahue (AlixPartners) re: AlixPartners client disclosure process.	0.30
12/17/19	JD	Review correspondence re: client disclosure.	0.50
12/17/19	JD	Conversation with management re: de-designation process and go forward diligence process.	0.80
12/17/19	JD	Review draft declaration re: client disclosure	0.40
12/17/19	JD	Correspondence with management re: vendor forms. Review draft vendor forms.	0.50
12/17/19	JD	Review updated analysis of CEO compensation. Provide	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		comments re: same. Correspondence with Davis Polk re: same.	
12/17/19	IA	Prepare for and attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.80
12/17/19	IA	Follow up on diligence requests from Davis Polk regarding CEO compensation.	1.80
12/17/19	IA	Correspondence with management regarding weekly sales by product reports and edits to final output to posted to the data room.	1.10
12/17/19	IA	Follow up on IT transition diligence requests from Province and coordination for call with management.	0.40
12/17/19	SKL	Prepare for and attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.70
12/17/19	LJD	Attend weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.50
12/17/19	LJD	Conversation with J. DelConte (AlixPartners) re: AlixPartners client disclosure process.	0.30
12/17/19	GJK	Partial attendance at weekly advisor call with Davis Polk, PJT, Prime Clerk and AlixPartners.	0.40
12/18/19	GJK	Review initial draft of Mundipharma business plan model with N. Simon and G. Koch (both AlixPartners).	0.60
12/18/19	GJK	Project management/coordination of Mundi diligence, including planning for next Tax meeting and Advisors meeting	1.50
12/18/19	IA	Review of filed retention applications on docket to inform payment of retained professionals' fees in Purdue cash forecast model.	1.40
12/18/19	NAS	Review initial draft of Mundipharma business plan model with N. Simon and G. Koch (both AlixPartners).	0.60
12/18/19	JD	Correspondence with E. Kardos (AlixPartners) and Davis	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Polk re: filing declaration on AlixPartners client disclosure.	
12/18/19	JD	Review AlixPartners rate change letter and declaration and correspondence with management re: same.	0.60
12/18/19	JD	Conversations with Davis Polk re: settlement payments.	0.40
12/18/19	JD	Correspondence with L. Donahue and Davis Polk re: meeting planning.	0.40
12/19/19	JD	Review correspondence from Davis Polk and the AHC re: ACH investment banker.	0.30
12/19/19	NAS	Follow-up meeting with Norton Rose tax specialists Debevoise & Plimpton tax specialists, financial, legal, and tax advisors to UCC and Ad-Hoc Committee, N Simon and G. Koch (both AlixPartners) to discuss tax implications of sale of Mundipharma entities.	2.00
12/19/19	NAS	Discussion with G. Koch, N. Simon (both AlixPartners), B. Bromberg (FTI), P. Topper (Jefferies), and J. Turner (PJT) to align on current Mundipharma diligence priorities.	0.50
12/19/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss key takeaways from tax and financial advisor meetings and align on next steps.	0.20
12/19/19	GJK	Follow-up meeting with Norton Rose tax specialists; Debevoise & Plimpton tax specialists; financial, legal, and tax advisors to UCC and Ad-Hoc Committee; and G. Koch and N. Simon (both AlixPartners) to discuss tax implications of sale of Mundipharma entities.	2.00
12/19/19	GJK	Discussion with N. Simon, G. Koch (both AlixPartners), B. Bromberg (FTI), P. Topper (Jefferies), and J. Turner (PJT) to align on current Mundipharma diligence priorities.	0.50
12/19/19	GJK	Call with N. Simon and G. Koch (both AlixPartners) to discuss key takeaways from tax and financial advisor meetings and align on next steps.	0.20
12/19/19	GJK	Meeting with M. Hartley and G. Koch (both AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		to discuss current Mundipharma diligence status and next steps	
12/19/19	MH	Call with company counsel to review trade agreement options with polynox supplier.	0.50
12/20/19	MH	Prepare for and attend weekly AlixPartners team call.	0.70
12/20/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) regarding key takeaways from R&D/Medical Affairs overview and key discussion topics for internal AlixPartners workstream updates.	0.20
12/20/19	LJD	Prepare for and attend weekly AlixPartners team call.	0.80
12/20/19	BF	Prepare for and attend weekly AlixPartners team call.	0.60
12/20/19	HK	Prepare for and attend weekly AlixPartners team call.	0.70
12/20/19	NAS	Prepare for and attend weekly AlixPartners team call.	0.60
12/20/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from R&D/Medical Affairs overview and key discussion topics for internal AlixPartners workstream updates.	0.20
12/20/19	SJC	Attend weekly AlixPartners team call.	0.50
12/20/19	JD	Call with Davis Polk, J. DelConte and A. DePalma (both AlixPartners) re: protective order and diligence designations.	0.60
12/20/19	JD	Call with Davis Polk, J. DelConte and A. DePalma (both AlixPartners) re: protective order and diligence designations.	0.60
12/20/19	JD	Prepare updated agenda for AlixPartners update call.	0.70
12/20/19	JD	Correspondence with Davis Polk and management re: scrubbing confidential data out of the various presentations posted in the data room.	0.70
12/20/19	JD	Attend weekly AlixPartners team call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
12/20/19	JD	Correspondence with Davis Polk re: Dr. Landau compensation from Purdue Canada.	0.30
12/20/19	JDH	Attend weekly AlixPartners team call.	0.50
12/20/19	KM	Prepare for and attend weekly AlixPartners team call.	0.80
12/20/19	ADD	Prepare for and attend weekly AlixPartners team call.	0.60
12/23/19	JD	Conversation with Davis Polk re: Dr. Landau compensation from Purdue Canada.	0.30
12/23/19	JD	Correspondence with management re: professional fee payments prior to yearend.	0.70
12/23/19	JD	Correspondence with management and Davis Polk re: insurance renewals.	0.50
12/30/19	JD	Catch up call with Associate General Counsel	0.50
12/30/19	JD	Correspondence with Davis Polk and management re: protective order confidentiality designations. Review data room files for designation purposes.	1.40
12/31/19	JD	Call with DPW, Purdue AGC, J. DelConte, and A. DePalma (both AlixPartners) re: diligence process	0.30
12/31/19	JD	Review meeting timing re: IAC London meetings	0.30
12/31/19	ADD	Call with DPW, Purdue AGC, J. DelConte, and A. DePalma (both AlixPartners) re: diligence process	0.30
12/31/19	RDS	Prepare budgeting outline for RALP management offsite	1.10
01/02/20	JD	Update call with Associate General Counsel re: outstanding issues and go forward planning.	0.70
01/02/20	JD	Update latest work stream tracker for team update call tomorrow.	0.80
01/03/20	JD	Correspondence with Davis Polk re: allocation discussions.	0.40
01/03/20	BF	Review VDD documents.	0.50
01/06/20	HK	Meeting with C. Chomiak, H. Block, J. Tran (all Purdue),	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		R. Sublett, and H. Ku (both AlixPartners) on the Avrio Business Plan model.	
01/06/20	JD	Correspondence with Davis Polk re: allocation issues.	0.50
01/06/20	JD	Review draft list of OCP parties from the company and from Davis Polk.	0.40
01/06/20	RDS	Meeting with C. Chomiak, H. Block, J. Tran (all Purdue), R. Sublett, and H. Ku (both AlixPartners) on the Avrio Business Plan model.	3.00
01/06/20	DS	Review docket for fee applications for purposes of updating professional fees model	1.30
01/07/20	DS	Prepare for and attend weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.60
01/07/20	RDS	Prepare for and attend weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.60
01/07/20	JD	Catch up call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners).	0.60
01/07/20	JD	Weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.50
01/07/20	IA	Prepare for and attend weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/07/20	IA	Follow up on questions from retirees on filing claims related to benefit programs.	1.40
01/07/20	SKL	Weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.50
01/07/20	BF	Partial attendance at weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.40
01/07/20	BF	Catch up call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners).	0.60
01/07/20	LJD	Prepare for and attend weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.80
01/07/20	LJD	Catch up call with L. Donahue, B. Folse, and J. DelConte (all AlixPartners).	0.60
01/07/20	GJK	Weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.50
01/07/20	MH	Prepare for and attend weekly update call with PJT, Davis Polk, G. Koch, L. Donahue, B. Folse, J. DelConte, M. Hartley, R. Sublett, I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners) re: case update and work plan go forward.	0.70
01/08/20	IA	Follow up on approval and payment of advisors on Canadian proceedings.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/09/20	JD	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson (both Davis Polk), M. Hartley, L. Donahue, G. Koch, J. DelConte (all AlixPartners), J. Lowne, and M. Kesselman (both Purdue) re: case update and go forward plan.	0.50
01/09/20	JD	Correspondence and discussions with J. Turner (PJT), C. Robertson (Davis Polk) and K. Knechtel (FTI) re: discussions and information sharing with Pillsbury and the non-consenting state committee members.	1.10
01/09/20	JD	Meeting with J. O'Connell (PJT), M. Huebner (Davis Polk), S. Birnbaum (Dechert), A. Dachuna (Wilmer Hale), P. Fitzgerald (Skadden), J. Adams (McGuire Woods), J. Bucholtz (King and Spalding) and M. Kesselman (Purdue) re: 2020 case timeline and work plan.	5.00
01/09/20	JD	Correspondence with PJT re: proposed business development deal.	0.30
01/09/20	GJK	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson (both Davis Polk), M. Hartley, L. Donahue, G. Koch, J. DelConte (all AlixPartners), J. Lowne, and M. Kesselman (both Purdue) re: case update and go forward plan.	0.50
01/10/20	GJK	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50
01/10/20	GJK	Phone call with G. Koch and N. Simon (both AlixPartners) to prepare for weekly AlixPartners team update call.	0.30
01/10/20	LJD	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/10/20	BF	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	1.00
01/10/20	HK	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.70
01/10/20	FOS	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.60
01/10/20	JD	Review and update agenda for AlixPartners update call.	0.50
01/10/20	JD	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50
01/10/20	JD	Discussion and correspondence with R. Schnitzler (PJT), C. Robertson (Davis Polk), J. Lowne (Purdue) and K. Knechtel (FTI) re: business development opportunity.	1.30
01/10/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian and K. Benedict (both Davis Polk) to discuss diligence designation process under protective order.	0.40
01/10/20	RC	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.80
01/10/20	IA	Prepare for and attend weekly team update call with L.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	
01/10/20	SJC	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50
01/10/20	NAS	Phone call with G. Koch and N. Simon (both AlixPartners) to prepare for weekly AlixPartners team update call.	0.30
01/10/20	NAS	Prepare to discuss Mundipharma diligence status, key take away, and open items on AlixPartners engagement team update call.	0.70
01/10/20	NAS	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.60
01/10/20	RDS	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50
01/10/20	DS	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.60
01/10/20	DS	Update agenda for internal team call	0.20
01/10/20	ADD	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/10/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian and K. Benedict (both Davis Polk) to discuss diligence designation process under protective order.	0.40
01/10/20	KM	Prepare for and attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.60
01/10/20	JDH	Attend weekly team update call with L. Donahue, R. Collura, B. Folse, J. DelConte, K. McCafferty, G. Koch, R. Sublett, I. Arana, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, A. DePalma, H. Ku, and N. Simon (all AlixPartners)	0.50
01/11/20	JD	Correspondence with management re: promotion and title changes	0.30
01/12/20	JD	Review correspondence from management and Davis Polk re: settlement agreements	0.50
01/13/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), K. Benedict, C. McMillian (both Davis Polk) and Purdue AGC re: IMS data access requirements	0.40
01/13/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), and Purdue AGC to discuss diligence designation process under protective order	0.30
01/13/20	JD	Correspondence with Davis Polk re: family asset disclosures.	0.40
01/13/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), and Purdue AGC to discuss diligence designation process under protective order	0.30
01/13/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), K. Benedict, C. McMillian (both Davis Polk), and Purdue AGC re: IMS data access requirements	0.40
01/14/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners),	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/14/20	JD	Purdue AGC and Alliance Management lead to discuss business development agreement disclosures	0.50
01/14/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), Purdue AGC and Alliance Management lead to discuss business development agreement disclosures	0.80
01/14/20	MH	Review confidentiality provisions from various business development agreements prior to call with BD agreement lead.	0.60
01/15/20	NAS	Attend call with advisors to review case priorities.	0.80
01/15/20	DS	Review summary of additional C. Landau (Purdue) compensation data to be included in reply in support of Wages motion.	0.40
01/15/20	DS	Correspondence with Z. Levine (Davis Polk) re: timeline of professional fees analysis	1.30
01/16/20	ADD	Review of data needed for professional's fee analysis requested by Davis Polk	0.30
01/16/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), and C. McMillian (Davis Polk) to discuss Non-Consenting States' diligence requests.	1.90
01/16/20	NAS	Research addressed of vendors for noticing at request of Prime Clerk.	0.50
01/16/20	JD	Final review summary of additional C. Landau (Purdue) compensation data to be included in reply in support of Wages motion.	0.30
01/16/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), and C. McMillian (Davis Polk) to discuss Non-Consenting States' diligence requests.	0.80
01/16/20	JD	Review index of documents on the data site and the current designations for when the protective order is entered.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/16/20	MH	Prepare estimate of fourth quarter UST fees and arrange for payment.	0.60
01/16/20	MH	Create accounts payable release file.	0.60
01/16/20	SKL	Prepare and circulate an updated listing of schedule E/F litigation claimants per Prime Clerk request.	1.20
01/17/20	SKL	Prepare for and attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.60
01/17/20	HK	Prepare for and attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.70
01/17/20	MH	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	MH	Prepare for team status call.	0.80
01/17/20	BF	Debrief call with B. Folse and G. Koch (both AlixPartners)	0.80
01/17/20	LJD	Prepare for and attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.60
01/17/20	GJK	Debrief call with B. Folse and G. Koch (both AlixPartners) and follow up notes	1.00
01/17/20	JD	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	JD	Call with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and Purdue counsel and commercial teams	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		re: protective order and classification of 3rd party agreements	
01/17/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), and C. McMillian (Davis Polk) to Discuss Data Transfer for Diligence.	0.90
01/17/20	JD	Correspondence and discussion with management re: board agenda and discussion topics	1.20
01/17/20	JD	Review ongoing work streams and update agenda for AlixPartners team call.	0.70
01/17/20	RC	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	IA	Review filed wages reply in preparation for upcoming hearing on CEO comp.	1.60
01/17/20	ADD	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	KM	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	ADD	Call with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and Purdue counsel and commercial teams re: protective order and classification of 3rd party agreements.	0.30
01/17/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), and C. McMillian (Davis Polk) to Discuss Data Transfer for Diligence.	0.90
01/17/20	DS	Attend weekly team status call with L. Donahue, R.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/17/20	DS	Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners) Call with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and Purdue counsel and commercial teams re: protective order and classification of 3rd party agreements	0.30
01/17/20	DS	Correspondence with S. Lemack (AlixPartners) re: discussion of professional fees summary	0.40
01/17/20	SR	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/17/20	RDS	Attend weekly team status call with L. Donahue, R. Collura, K. McCafferty, J. DelConte, S. Robertson, M. Hartley, R. Sublett, D. Samikkannu, A. DePalma, S. Lemack, and H. Ku (all AlixPartners)	0.50
01/20/20	JD	Correspondence with Davis Polk re: data room access.	0.30
01/20/20	JD	Discussion with Associate General Counsel re: general case update and historical insider employee list.	0.60
01/21/20	JD	Conversation with J. McClammy, K. Benedict (both Davis Polk), and R. Aleali (Purdue) re: confidential information sharing.	0.70
01/21/20	JD	Conversations and correspondence with M. Huebner (Davis Polk) re: non-consenting state questions re: CEO compensation, check draft non-consenting states objection for factual accuracy, and correspondence with Davis Polk re: same.	1.80
01/22/20	JD	Correspondence with C. McMillian (Davis Polk), A. Kramer (Reed Smith) and C. Ricarte (Purdue) re: insurance document sharing protocol.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/22/20	JD	Review and check draft non-consenting states objection to CEO compensation and correspondence with Davis Polk re: same.	1.50
01/22/20	JD	Discussion with industry advisor re: opioid settlement path forward.	1.00
01/22/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), and J. Doyle (Purdue) re: confidential and competitively sensitive information designation discussion	0.50
01/22/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), and J. Doyle (Purdue) re: confidential and competitively sensitive information designation discussion	0.50
01/23/20	DS	Compile specific public filings requested by TXP Manager	0.30
01/23/20	GJK	Call with B. Folse and H. Koch (both AlixPartners) to follow up on IAC meetings and discuss next steps.	0.50
01/23/20	BF	Attend weekly advisor call with B. Folse, G. Koch, M. Hartley, and management	0.50
01/23/20	BF	Call with B. Folse and H. Koch (both AlixPartners) to follow up on IAC meetings and discuss next steps.	0.50
01/23/20	MH	Prepare for and attend weekly advisor call with B. Folse, G. Koch, M. Hartley, and management	0.70
01/23/20	GJK	Attend weekly advisor call with B. Folse, G. Koch, M. Hartley, and management	0.50
01/23/20	SKL	Continue to finalize address reconciliation re: litigation parties per Prime Clerk request.	0.50
01/24/20	SKL	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	FOS	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	
01/24/20	MH	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	LJD	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/24/20	BF	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	GJK	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	JD	Prepare agenda for work stream coordination call with AlixPartners team.	0.80
01/24/20	JD	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	RC	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	
01/24/20	IA	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/24/20	SJC	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	NAS	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.60
01/24/20	DS	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	KM	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/24/20	JDH	Prepare for and attend call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re:	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		weekly AlixPartners team update call.	
01/24/20	ADD	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, K. McCafferty, J. DelConte, G. Koch, M. Hartley, D. Samikkannu, I. Arana, J. Hecht, S. Caniff, N. Simon, S. Lemack, F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/27/20	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: mediation process and overview	0.30
01/27/20	DS	Meeting to discuss review and redaction process per Protective Order with D. Samikkannu, I. Arana, A. DePalma, and S. Lemack (all AlixPartners)	1.50
01/27/20	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: mediation process and overview	0.30
01/28/20	JD	Review listing of MDL production re: redaction and designation process.	0.60
01/28/20	SKL	Review latest litigation address information provided by A. Green (TXP) and finalize updated summary for Prime Clerk.	1.30
01/30/20	BF	Review latest version of the report and evaluate next steps.	0.50
01/30/20	DS	Review draft OSR Wrap Lease Rejection and New Lease Motion	1.10
01/30/20	DS	Review draft Declaration in Support of OSR Lease Motion	0.90
01/30/20	DS	Provide comments to J. DelConte (AlixPartners) re: draft motions related to OSF Lease	0.70
01/31/20	DS	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		update call.	
01/31/20	DS	Meeting with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and corporate counsel re: redaction of business development data	0.40
01/31/20	JDH	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	ADD	Meeting with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and corporate counsel re: redaction of business development data.	0.40
01/31/20	ADD	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	BF	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.50
01/31/20	LJD	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	GJK	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
01/31/20	MH	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	HK	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	SKL	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	FOS	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	JD	Review ongoing work streams and prepare agenda for team update call.	0.60
01/31/20	JD	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	JD	Meeting with D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners), and corporate counsel re: redaction of business development data	0.40
01/31/20	RC	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	
01/31/20	NAS	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	SJC	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
01/31/20	IA	Follow up on reporting approvals and information sharing process now that protective order is signed.	1.30
01/31/20	IA	Call with C. DeStefano (Purdue) to discuss Willis Tower Watson requests on benefit programs.	0.30
01/31/20	IA	Call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Hartley, I. Arana, N. Simon, J. Hecht, D. Samikkannu, S. Caniff, F. Silva, S. Lemack, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.70
Total			<u>1,070.20</u>



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	102.40	440.00	45,056.00
Hart Ku	26.50	440.00	11,660.00
Andrew D DePalma	44.30	480.00	21,264.00
Nate A Simon	17.40	480.00	8,352.00
Julie A Doherty	6.30	480.00	3,024.00
Kaitlyn A Sundt	10.40	490.00	5,096.00
Andrew D DePalma	8.10	515.00	4,171.50
Sam K Lemack	5.30	515.00	2,729.50
Hart Ku	5.10	515.00	2,626.50
Nate A Simon	4.2	515.00	2,163.00
David Samikkannu	115.40	615.00	70,971.00
Isabel Arana de Uriarte	184.30	615.00	113,344.50
Kyoko Shibuya	2.30	615.00	1,414.50
Fernando O Silva	3.40	615.00	2,091.00
Sam J Canniff	4.30	615.00	2,644.50
Sam J Canniff	1.70	645.00	1,096.50
Fernando O Silva	1.80	645.00	1,161.00
Jon D Hecht	3.20	665.00	2,128.00
David Samikkannu	12.00	690.00	8,280.00
Isabel Arana de Uriarte	7.90	690.00	5,451.00
Jon D Hecht	2.20	690.00	1,518.00
Ryan D Sublett	13.70	725.00	9,932.50
Ryan D Sublett	4.60	735.00	3,381.00
Gabe J Koch	123.20	830.00	102,256.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Michael Hartley	85.80	830.00	71,214.00
Scott Robertson	0.50	840.00	420.00
Gabe J Koch	5.00	840.00	4,200.00
Michael Hartley	5.70	840.00	4,788.00
Kevin M McCafferty	3.30	895.00	2,953.50
Mark F Rule	1.10	895.00	984.50
Jesse DelConte	157.00	945.00	148,365.00
Kevin M McCafferty	1.60	950.00	1,520.00
Jesse DelConte	32.30	950.00	30,685.00
Richard Collura	3.10	1,080.00	3,348.00
Barry Folse	40.30	1,080.00	43,524.00
Barry Folse	5.80	1,090.00	6,322.00
Richard Collura	2.50	1,090.00	2,725.00
Lisa Donahue	12.20	1,165.00	14,213.00
Lisa Donahue	4.00	1,195.00	4,780.00
Total Hours & Fees	1,070.20		771,854.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
09/18/19	DS	Meeting with Controller K. Darragh (Purdue) re: refresh of budget and process	0.40
09/24/19	JD	Review latest professional fee cash forecast. Work on updating for new budget cycle.	2.30
10/22/19	RDS	Review budget documents and data tracker	0.70
10/23/19	RDS	Review aggregated budget documents for LE June 2019	0.80
10/23/19	RDS	Review of Public Health Initiative materials	0.60
10/24/19	RDS	Call with D. Fogel (Rhodes) to discuss business planning / budgeting process	0.30
10/24/19	RDS	Draft email to D. Lundie (Rhodes) re business planning workstream, setting a meeting for next week	0.20
10/24/19	RDS	PPLP Pipeline Review document	0.20
10/24/19	RDS	Review Business Plan Summary ahead of call to discuss updates in preparation for a call with various creditor committee advisors	0.30
10/24/19	RDS	Review Pipeline Review document	0.40
10/24/19	RDS	Call with D. Samikkannu, R. Sublett (both AlixPartners), D. Fogel, W. DiNicola, R. Haberin (all Rhodes), T. Melvin, and G. Sim (both PJT) re Rhodes business plan data requests	0.90
10/24/19	RDS	Review generic pharmaceutical market share information (as updated Q2) to assess impact of competitors leaving the market (both finished dose and API)	0.80
10/24/19	RDS	Assemble business plan presentation shell for committee presentation	2.00
10/24/19	RDS	Correspondence with N. Davis and D. Fogel re Rhodes budget process and timeline	0.50
10/24/19	RDS	Review of consolidated long-term business plan document (LE June 2019) provided by PJT	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
10/24/19	DS	Call with D. Samikkannu, R. Sublett (both AlixPartners), D. Fogel, W. DiNicola, R. Haberlin (all Rhodes), T. Melvin, and G. Sim (both PJT) re Rhodes business plan data requests	0.90
10/25/19	RDS	Continue edits to business plan update presentation - Rhodes Pharma slides	1.40
10/25/19	RDS	Review 2020 Budget Proposal: Corporate & Business Development and Greenfield Projects	0.30
10/25/19	RDS	Review CFO Functions reports ahead of budget meetings	1.00
10/25/19	RDS	Assemble stand-alone 2020 budgetary process checklist based upon received files	0.80
10/28/19	RDS	Review of PJT Business Plan Excel file - tie out understanding of net revenues and inter-company expenses	2.50
10/28/19	RDS	Review of J. Lowne comments to PJT business plan excel file	0.30
10/28/19	RDS	Construction of Rhodes earnings due to competitor exits from generic pain business	0.40
10/28/19	RDS	Analysis of Butrans AG forecast, market share	0.60
10/28/19	RDS	Outline board slides for Rhodes impact of dislocation in generic opioid market	0.50
10/28/19	RDS	Review market share in generic opioids	0.40
10/28/19	RDS	2020 PPLP Budget Review: HR Functions	0.20
10/28/19	RDS	2020 PPLP Budget Review: Medical	0.20
10/28/19	RDS	2020 PPLP Budget Review: Security	0.10
10/29/19	JD	Review of Rhodes business plan assumptions	0.80
10/29/19	JD	Catch up call with G. Koch and J. DelConte (both AlixPartners)	0.40
10/29/19	JD	Meetings with C. Landau, J. Lowne (both Purdue), various	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
		other Purdue management members, J. Turner (PJT), J. DelConte and R. Sublett (both AlixPartners) re 2020 Purdue Budgeting, IT, Corporate Affairs	
10/29/19	JD	Meeting with C. Landau, J. Lowne (both Purdue), various Purdue management team members, J. DelConte and R. Sublett (both AlixPartners) re 2020 budget, HR, Security, Finance, Procurement and Business Development and R&D	2.00
10/29/19	RDS	2020 PPLP Budget Review: Net Sales	0.40
10/29/19	RDS	2020 PPLP Budget Review: Sales & Promotion	0.40
10/29/19	RDS	Meeting with C. Landau, J. Lowne and various Purdue management team members, J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, HR, Security, Finance, Procurement and Business Development and R&D	2.00
10/29/19	RDS	Meetings with C. Landau, J. Lowne and various other Purdue management members, J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re 2020 Purdue Budgeting, IT, Corporate Affairs.	0.70
10/29/19	GJK	Catch up call with G. Koch and J. DelConte (both AlixPartners)	0.40
10/30/19	JD	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski (all Purdue), various other Purdue management team members, J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, GC Functions, Net Sales Budget (excl. OTC)	1.20
10/30/19	JD	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski (all Purdue), various other Purdue management team members, R. Sublett, and J. DelConte (both AlixPartners) re 2020 budget, OTC net sales and S&P budget	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
10/30/19	RDS	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski (all Purdue), various other Purdue management team members, J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, GC Functions, Net Sales Budget (excl. OTC)	1.20
10/30/19	RDS	Review 2020 Budget document for Net Sales and S&M budget - specifically: Adhansia progress / NPV impacts	0.60
10/30/19	RDS	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski and various other Purdue management team members with J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, OTC net sales and S&P budget	1.00
10/30/19	RDS	Market research and ROIC / NPV analysis of Avrio business, compare LE June 2019 plan to 2020 Budget and long-term plan	0.80
10/30/19	RDS	Review objectives for overall business planning timeline - layout next steps for generic business review (Rhodes) and modeling functionality to separate various commercial and pipeline products	0.50
10/30/19	RDS	Review 9/12/19 version of cash forecasting for PPLP, assemble notes / comments for impending refresh	0.80
10/31/19	RDS	Begin assembling model implementation add-ons - cost structure	0.90
11/01/19	RDS	Review Updated LE June 2019 Long-Term Plan v112	0.60
11/04/19	RDS	Prepare outline for business plan scenario analysis	2.20
11/08/19	RDS	Review and outline potential API strategic options	0.40
11/08/19	RDS	Correspondence with PJT team on the strategic scenario's materials for Monday board meeting	0.30
11/11/19	RDS	Next steps on Avrio budget review, analyze revenue projection cuts and investment in S&M and R&D	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
11/11/19	RDS	Avrio product loading, historical product launch pattern-matching	2.10
11/11/19	RDS	Review budget process documents in data room, aggregate likely questions and answers for committee meetings	1.20
11/11/19	RDS	Correspondence with J. Lowne (Purdue) regarding skinny Rhodes and NC organization	0.20
11/11/19	RDS	Review June LE 2019 excel version to ensure it is ready to share with UCC and other external parties	1.40
11/11/19	RDS	Workplan and preliminary analysis for Avrio business plan investigation	0.70
11/12/19	RDS	Assemble team skeleton for Rhodes / North Carolina cost structure analysis; outline scenarios for D. Fogel (Purdue) to begin constructing	0.40
11/12/19	RDS	Meeting with J. Lowne (Purdue) (Called D. Fogel as well) to work-plan scenarios for board presentation at Rhodes organization	1.00
11/12/19	RDS	Advisor call with PJT and Davis Polk teams re financial diligence work streams	0.50
11/12/19	RDS	Outline next steps and work plan for strategic analysis: NC shift rationalization; Rhodes Tech cost structure and Avrio revenue projections	0.70
11/12/19	RDS	Review Avrio SKU level data	1.00
11/12/19	RDS	Review and outline Avrio data compilation project	0.80
11/12/19	RDS	Review Avrio Budget Presentation for old plan	1.30
11/12/19	RDS	Avrio Business Plan NPV scenario analysis	2.20
11/13/19	RDS	North Carolina and Rhodes tech transfer cost consolidation analysis	1.40
11/13/19	RDS	Valuation analysis of various operation scenarios for Avrio	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
11/13/19	RDS	Create outline of Avrio strategic recommendation presentation	1.00
11/13/19	RDS	Review of Med Affairs department-level budgets	1.60
11/14/19	RDS	Correspondence with PJT team regarding business planning work stream - valuation of pipeline, etc.	0.10
11/14/19	RDS	Review Avrio product-level analysis - growth and launch S&P expense ROI analysis	0.20
11/15/19	RDS	Review and refine strategic options work plan, lay out next week to dos and communicate with interested Purdue and AlixPartners team	0.70
11/17/19	RDS	Strategic options decision architecture	2.20
11/19/19	RDS	Review New BD Opportunity	0.70
11/20/19	RDS	Review of questions ahead of Branded P&L diligence calls with advisors	0.70
11/20/19	RDS	Correspondence with C. Mazzi (Purdue) re strategic analysis / business planning project update	0.50
11/21/19	RDS	Associate Rhodes Pharma R&D headcount to outstanding projects and allocate overhead expenses accordingly.	0.80
11/22/19	RDS	Correspondence with K. Derragh re diligence follow up and scenario planning exercise	0.30
11/25/19	RDS	Set up meetings to Rhodes Technology lieutenants under R. Shamblan (Rhodes)	0.40
11/26/19	JD	Review and provide comments on draft budget board presentation	1.80
11/27/19	RDS	Review finance presentation to board for 12/5/19 meeting and provide comments	1.50
12/02/19	RDS	Review 5-year G&A plan from J. Lowne (Purdue)	1.40
12/05/19	RDS	Correspondence with D. McGuire (Purdue) re supply chain organization structure	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Date	Consultant	Description of Services	Hours
12/05/19	RDS	Follow up with Rhodes Tech personnel on discussion follow ups	0.40
12/23/19	JD	Call with management re: updated professional fee forecast	0.20
12/31/19	RDS	Review latest Rhodes third-party volume budget	0.70
01/03/20	JD	Review and provide comments on draft 2020 professional fee forecast and review fee statements filed to date on the docket.	1.10
01/07/20	JD	Review draft professional fee forecast details.	0.40
01/20/20	JD	Correspondence with management re: professional fee accruals.	0.30
Total			75.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Budget Process Management
Client/Matter # 012589.00102

Fee Recap:

Consultant	Hours	Rate	Amount
David Samikkannu	1.30	615.00	799.50
Ryan D Sublett	61.90	725.00	44,877.50
Gabe J Koch	0.40	830.00	332.00
Jesse DelConte	10.40	945.00	9,828.00
Jesse DelConte	1.80	950.00	1,710.00
Total Hours & Fees	75.80		57,547.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/16/19	IA	Review of cash reporting source files received from TXP for week ended 09.06	1.10
09/16/19	IA	Update cash tracking model for week ended 09.06.	2.80
09/16/19	DS	Respond to cash inquiries from C. Robertson (Davis Polk)	0.40
09/17/19	DS	Correspondence with A. DePalma (AlixPartners) re: checks cleared report	0.20
09/18/19	DS	Correspondence with R. Collura (AlixPartners) re: supporting JP Morgan documentation requested in connection with outside party data request	0.20
09/19/19	IA	Review of source files and update to actuals model for the weeks ended 09/06 and 09/13	3.80
09/20/19	IA	Follow up on diligence questions on investment accounts.	1.40
09/30/19	IA	Review of questions on actuals tracking transactions for the week ended 9/6.	1.40
10/05/19	DS	Report cash actuals for the week ended 9/13	2.60
10/09/19	IA	Review of source files for cash tracking for the week ended 09/13 including detail on EastWest transition.	2.60
10/09/19	JD	Review historical IAC payment schedule	0.30
10/10/19	IA	Review of cash source files for week ended 09/20 actuals tracking.	2.20
10/11/19	IA	Update to cash tracking file for week ended 09/06	3.60
10/11/19	DS	Cash reporting - provide Paysource details for East West disbursements (week ended 9/13)	2.10
10/11/19	DS	Cash reporting - review checks listing to identify rebates payments for week ended 9/13	1.10
10/12/19	IA	Update cash tracking for week ended 09/20	3.10
10/13/19	DS	Cash actuals reporting - tie-out transaction data to opening and closing balances	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

10/13/19	DS	Cash actuals reporting - categorize individual Paysource transactions	1.80
10/13/19	DS	Cash actuals reporting - prepare list of outstanding items within Chase transactions report to discuss with TXP services	1.30
10/13/19	DS	Prepare reconciliation of all source data to Chase and East West balances	0.40
10/14/19	DS	Cash actuals reporting - categorize all East West transactions (week ended 9/13)	2.30
10/14/19	DS	Cash actuals reporting - identify all IAC and affiliates transactions and identify business purpose (week ended 9/13)	1.60
10/14/19	DS	Cash actuals reporting - compare outstanding items to previous cash reports to identify categories and counterparties (week ended 9/13)	1.50
10/14/19	IA	Update of cash tracking files for week ended 09/06	1.60
10/14/19	IA	Update of cash tracking files for week ended 09/20	2.20
10/15/19	IA	Update of actuals tracking weeks prior to filing to reflect inclusion of PPI account, adjustments to closed JPM accounts, and other transition items for East West accounts.	2.80
10/15/19	IA	Follow up with J. Beck-Sechow (TXP) to understand changes to bi-weekly payroll disbursements post filing.	0.60
10/15/19	IA	Update of cash tracking files for week ended 09/27	2.40
10/15/19	IA	Update of cash tracking files for week ended 09/20	2.80
10/15/19	DS	Cash actuals reporting - categorize individual Paysource transactions (week ended 10/4)	1.70
10/15/19	DS	Cash actuals reporting - reconcile opening and closing balances with transaction activity from East West accounts (week ended 10/4)	2.30
10/15/19	DS	Cash actuals reporting - categorize check detail with	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		Small Disbursements report (week ended 10/4)	
10/15/19	DS	Cash actuals reporting - match disbursements from East West transaction activity to corresponding batches in Paysource report (week ended 10/4)	1.60
10/15/19	DS	Cash actuals reporting - identify intercompany and IAC transactions and identifying business purpose (week ended 10/4)	1.40
10/16/19	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and TXP cash accountant re: cash reporting questions	0.90
10/16/19	IA	Meeting with D. Samikkannu, and I. Arana (both AlixPartners) with TXP cash accountant re: cash reporting questions	0.90
10/16/19	IA	Review of source documents and update of cash tracking model for the week ended 10/11 for Purdue and Rhodes,	3.90
10/16/19	IA	Follow up on cash week ended 10/04 and 9/27 open items.	1.80
10/17/19	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Controller (PPLP) re: IAC cash transactions	0.70
10/17/19	DS	Review of Isosceles trust agreement for purposes of disclosure in actuals cash report	0.60
10/17/19	DS	Draft email to J. DelConte (AlixPartners) re: cash report	0.30
10/17/19	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Controller (PPLP) re: IAC cash transactions	0.70
10/17/19	DS	Prepare cash actuals cash report - Overview section	1.20
10/17/19	DS	Assemble Purdue cash actuals (post-petition) for cash report	0.60
10/17/19	DS	Assemble Rhodes cash actuals (post-petition) for cash report	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

10/17/19	DS	Assemble IAC & affiliates summary for Purdue (post-petition)	1.40
10/17/19	DS	Assemble IAC & affiliates summary for Rhodes (post-petition)	1.30
10/17/19	DS	Tie out cash report to ensure accuracy	1.10
10/18/19	DS	Tie-out cash disbursements from GAAP report to disbursements per Paysource report	2.10
10/19/19	DS	Draft email to CFO (PPLP) re: IAC and affiliates schedule in cash report	0.40
10/21/19	DS	Draft email to Davis Polk outlining key topics to review in cash report	0.30
10/21/19	DS	Update footnotes in cash report in IAC schedule	0.90
10/21/19	DS	Reformat cash report prior to posting for review	0.60
10/21/19	JD	Review and provide comments on latest cash actuals presentation.	1.10
10/22/19	JD	Meeting with D. Samikkannu, J. DelConte (both AlixPartners), CFO and Controller (PPLP) re: UST disbursements reporting	0.40
10/22/19	DS	Meeting with D. Samikkannu, J. DelConte (both AlixPartners), CFO and Controller (PPLP) re: UST disbursements reporting	0.40
10/23/19	IA	Follow up on IAC and East West transaction questions for the week ended 10/18.	1.40
10/23/19	IA	Update and review of cash tracking model for the week ended 10/18.	3.10
10/24/19	DS	Roll forward summary schedule of 13-week cash flow	0.60
10/24/19	DS	Update budget for cash flow forecast for January	0.90
10/24/19	DS	Update sales forecast schedule for cash flow forecast	1.10
10/24/19	DS	Run open A/R report for cash flow forecast	1.20
10/24/19	DS	Run open A/P report for cash flow forecast, categorizing	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		items and assessing whether covered by motions	
10/24/19	DS	Run open A/P report for cash flow forecast, categorizing items and assessing whether covered by motions	1.20
10/25/19	DS	Update operating expenses schedule of 13-week cash flow forecast, utilizing historical DPO data	1.90
10/25/19	DS	Update royalties and profit share data for cash flow forecast	0.90
10/25/19	DS	Update IAC schedule for cash forecast	1.10
10/28/19	IA	Review of EastWest transactions source files and update of cash tracking model for the week ended 08/25 for cash reporting purposes.	3.60
10/29/19	IA	Review of EastWest transactions source files and update of cash tracking model for the week ended 08/25 for cash reporting purposes.	3.90
10/29/19	IA	Follow up on IAC transaction details and checks paid for cash reporting purposes.	1.70
10/30/19	IA	Update and review of IAC transactions schedule and explanations for the week ended 08/25.	1.80
10/30/19	DS	Draft email to S. Lemack (AlixPartners) on cash workstream (cash reporting, cash forecast, forecast-to-actuals analysis.	1.10
10/31/19	DS	Assemble post-petition cash actuals summary for Purdue and Rhodes	1.40
10/31/19	DS	Draft language for disbursements detailed schedules in cash report	1.30
10/31/19	DS	Draft language for disbursements detailed schedules in cash report	1.20
10/31/19	DS	Update IAC summary schedules for cash report	1.40
10/31/19	DS	Correspondence with Controller (Rhodes) re: specific transaction with Purdue Pharma Canada	0.40
10/31/19	DS	Meeting with D. Samikkannu, I. Arana (both	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		AlixPartners), and Controller (PPLP) re: categorizing IAC transactions for the previous week	
10/31/19	RDS	Review of cash flow forecasting updated plan, comparison to 9/13 update with regards to 2020 budget implications	1.30
10/31/19	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Controller (PPLP) re: categorizing IAC transactions for the previous week.	0.20
10/31/19	IA	Review of updated cash actuals report to be shared with UCC and Adhoc Committee	0.40
10/31/19	IA	Correspondence with client and update of bank account balances report as of 09/30 in response to request by the US Trustee.	1.10
11/01/19	SKL	Analyze and review the latest weekly cash-actuals report.	1.40
11/01/19	DS	Correspondence with Davis Polk re: approval of draft weekly cash report	0.30
11/01/19	DS	Meeting with G. Koch and D. Samikkannu (all AlixPartners) re: diligence status and process	0.20
11/01/19	DS	Update draft cash report for CFO (PPLP) comments re: IACs, zero-balance account language, One Stamford Realty	1.20
11/01/19	DS	Call with CFO (PPLP) re: language in draft Cash Report	0.20
11/01/19	DS	Review draft cash report and draft email to send to management and counsel summarizing significant points	0.50
11/04/19	SKL	Begin review of the Cash-Actuals process and begin putting together this week's file.	2.30
11/05/19	SKL	Continue to review the weekly Cash Actuals process and procedures.	2.30
11/05/19	IA	Review of cash tracking source files for the week ended 11/1	1.40
11/05/19	IA	Classification of cash transactions on East west and Paysource reports for the week ended 11/01	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/06/19	DS	Put together analysis outlining Amex payments made 90 days prior to filing	1.70
11/07/19	DS	Inquire with TXP analyst re: two specific payments for purposes of cash reporting	0.50
11/07/19	DS	Discuss Bank of Oklahoma account with TXP Manager	0.30
11/07/19	DS	Review data sent by TXP analyst on specific transaction detail requested	0.40
11/07/19	DS	Update cash report for details received from Rhodes analysts on IAC transactions	0.60
11/07/19	DS	Inquire with Rhodes Pharma financial analyst re: IAC transactions for the week for cash reporting	0.40
11/07/19	DS	Inquire with Rhodes Tech financial analyst re: IAC transactions for the week for cash reporting	0.40
11/07/19	IA	Follow up on comments from management on OCP motion and process, update to OCP list by Tier and firm descriptions.	2.00
11/08/19	IA	Review of cash actuals report for the week ended 11/01	1.30
11/08/19	IA	Update of Purdue cash flow model operating expenses calculations	1.80
11/08/19	DS	Review IAC transaction detail sent by Controller (PPLP)	0.90
11/08/19	DS	Update cash report for IAC transaction detail for PPLP	0.80
11/08/19	DS	Refine Paysource categorizations to add more color to disbursements for purposes of cash reporting	2.10
11/08/19	DS	Correspondence with S. Lemack (AlixPartners) re: updates to rebate classifications	0.40
11/08/19	DS	Quality check on cash actuals model	1.00
11/08/19	JD	Review cash actuals report prior to providing it to management for review.	0.40
11/11/19	DS	Cash forecast - run open A/R report and categorize for cash forecasting purposes	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/11/19	DS	Update A/R rollforward in cash forecast	1.80
11/11/19	DS	Run open A/P report and categorize for cash forecasting purposes	2.10
11/11/19	DS	Rollforward sales forecast by week in cash forecast model	1.10
11/11/19	DS	Update operating expenses detailed schedule for cash forecast	1.00
11/11/19	IA	Update of Purdue cash forecast model actuals and summary pages.	3.10
11/11/19	SKL	Review formatting of the MOR-disbursement report and begin preparing for October's MOR.	2.60
11/12/19	SKL	Continue to finalize the October MOR-Disbursement report.	2.90
11/12/19	SKL	Begin preparing the weekly Cash-Actuals report.	2.10
11/12/19	SKL	Review weekly distributions and categorize accordingly re: Cash Actuals report.	1.60
11/12/19	SKL	Begin reviewing the weekly IAC transactions and prepare update re: Cash Actuals report.	2.10
11/12/19	SKL	Finalize updates to the summary reports re: Cash Actuals.	1.30
11/12/19	DS	Call with Controller (Rhodes) re: timing of rebates for cash forecast	0.20
11/12/19	DS	Update royalties/profit sharing portion of cash forecast	1.60
11/12/19	DS	Update IAC receipts and disbursements portion of cash forecast model, including counterparty descriptions	1.30
11/12/19	DS	Roll forward other receipts portion of cash forecast	0.40
11/12/19	DS	Create OCP legal portion of cash forecast	1.30
11/12/19	DS	Create Rebates Summary schedule for purposes of cash forecasting deck	0.90
11/12/19	DS	Draft "Overview" section of cash forecast presentation materials	0.80
11/12/19	DS	Review rebates detail with Controller (Rhodes)	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/12/19	DS	Further refine operating expenses section of cash forecast, incorporating A/P and payment data	1.40
11/12/19	DS	Update rebates portion of cash forecast: Med Part D, Medicaid, Savings Cards, Tricare, Commercial Rebates utilizing data provided by Controller (Rhodes)	3.30
11/13/19	DS	Meeting with D. Samikkannu, and S. LeMack (both AlixPartners) to review cash actuals reporting and make updates	0.70
11/13/19	DS	Draft assumptions for cash forecast materials: working capital, rebates, restructuring items, legal fees	2.20
11/13/19	DS	Update monthly actuals and forecast data for all retained restructuring professionals in the restructuring fees model	3.20
11/13/19	DS	Update section, by professional, of restructuring fees model that calculates allowed amounts in bankruptcy and payment timing	2.60
11/13/19	DS	Update specific forecasts of professionals based on PJT's 15-month case model	1.80
11/13/19	DS	Review actual fee and retainer data in restructuring fees model for accuracy	0.60
11/13/19	SKL	Meeting with D. Samikkannu and S. LeMack (both AlixPartners) to review cash actuals reporting and make updates.	0.70
11/13/19	SKL	Finalize Actuals report for the week and prepared for distribution.	2.40
11/13/19	SKL	Finalize updates to the IAC section re: Cash Actuals and updated footnotes accordingly.	1.30
11/13/19	SKL	Review latest diligence request re: cash reports and provided updates accordingly.	1.40
11/14/19	SKL	Continue to finalize the Cash Actuals report and update the deck for distribution.	2.30
11/14/19	SKL	Prepare for and participate in weekly Critical Vendor	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		update discussion with the Purdue vendor team.	
11/14/19	SKL	Finalize review of the latest Cash Actuals deck and update the source documentation based on feedback.	1.30
11/14/19	SKL	Analyze and review the October MOR re: cash disbursements and receipts.	1.40
11/14/19	SKL	Continue to prepare updates to the October MOR re: cash disbursements and receipts.	1.20
11/14/19	IA	Update of actuals in cash forecast model for Purdue.	1.90
11/14/19	IA	Update of Purdue cash forecast model tabs to extend to 2020 period.	2.70
11/14/19	IA	Follow up with client on one-time items and timing assumptions for Purdue forecast.	1.10
11/14/19	DS	Draft detailed response to K. Knechtel's (FTI) questions re: cash report	1.80
11/14/19	DS	Create retained professionals forecast model for legal professionals being retained	2.10
11/14/19	DS	Meeting with legal analyst (PPLP) re: retained legal professional fee forecast	0.40
11/14/19	DS	Review data sent by Controller (Rhodes Tech) re: specific cash transaction (for cash report)	0.50
11/14/19	DS	Analyze data re: Q2 Med Part D rebate for cash forecasting purposes	0.80
11/14/19	DS	Review legal fee forecast and compare to actual run-rates	1.20
11/15/19	DS	Review draft cash report and provide comments to S. LeMack (AlixPartners)	1.00
11/15/19	JD	Review latest cash actuals presentation	0.50
11/15/19	IA	Review of post filing payments of customer rebates and update of Purdue cash forecast rebate schedule	2.60
11/15/19	SKL	Continue to prepare updates to the October MOR re: cash disbursements and receipts.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/15/19	SKL	Finalize updates to the October MOR and circulate to the AlixPartners team for review.	1.00
11/15/19	SKL	Finalize updates to the weekly Cash Actuals report and prepare for circulation to the Purdue team for sign-off.	2.30
11/18/19	SKL	Review latest Cash Actuals source information and prepare updated weekly reporting.	1.70
11/18/19	SKL	Prepare updates to the October MOR re: cash disbursements and receipts.	2.40
11/18/19	DS	Review weekly cash files sent by TXP	0.60
11/19/19	DS	Request additional legal fees forecast detail from PPLP analyst	0.40
11/19/19	DS	Request additional legal fees forecast detail from PPLP analyst	1.80
11/19/19	SKL	Begin review of source information and pull down Paysource information to begin cash reconciliation.	2.30
11/19/19	SKL	Continue to finalize updates to the cash account balances re: October MOR.	2.00
11/19/19	SKL	Reconcile the latest files re: October bank balances and meeting with W. Chang (Purdue), S. Lemack, and D. Samikkannu (both AlixPartners) to review.	0.80
11/19/19	SKL	Review the latest Investment account info and prepare updates to the weekly cash report.	1.30
11/19/19	SKL	Finalize reconciliation of credits and disbursements re: October bank balances/MOR.	1.60
11/19/19	SKL	Continue to prepare updates to the cash actuals report re: weekly cash reporting.	1.90
11/20/19	SKL	Finalize mapping of EastWest bank transactions.	1.40
11/20/19	SKL	Update summaries and IAC balances re: Cash Actuals reporting.	1.80
11/20/19	SKL	Finalize updates to the October MOR and circulate to the AlixPartners and Purdue team accordingly.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/20/19	SKL	Begin preparing the weekly cash actuals deck and prepare updated notes for the latest IAC transactions.	2.10
11/20/19	SKL	Working session with D. Samikkannu and S. Lemack (both AlixPartners) re: restricted investments reporting.	0.70
11/20/19	SKL	Continue to finalize updates and reconciliation to the weekly Cash Actuals report.	2.40
11/20/19	DS	Working session with D. Samikkannu, and S. LeMack (both AlixPartners) re: restricted investments reporting	0.70
11/21/19	DS	Review draft weekly cash actuals report and provide comments to S. LeMack (AlixPartners)	1.30
11/21/19	DS	Collect and review data needed to address FTI's questions to previous week's cash report	0.40
11/21/19	DS	Call with TXP Manager re: receipts question send by FTI	0.40
11/21/19	DS	Review checks detail sent by TXP analyst related to questions sent by FTI	0.90
11/21/19	SKL	Finalize updates to the weekly cash reporting and circulate updates to the AlixPartners team accordingly.	1.90
11/21/19	SKL	Finalize updates notes re: weekly cash actual transactions and incorporate into the weekly deck.	1.40
11/21/19	SKL	Reconcile latest cash actual UCC inquiry and prepare updates accordingly.	1.20
11/21/19	IA	Review of updated cash actuals report for the week ended 11/15.	0.60
11/22/19	SKL	Finalize reconciliation of the latest UCC Cash Actual inquiry and circulate updates accordingly.	1.20
11/22/19	SKL	Finalize review of and made final updates to the weekly cash reporting.	2.60
11/22/19	DS	Draft email to management and counsel outlining significant items in weekly cash report	0.40
11/22/19	DS	Answer FTI's detailed cash questions and include in email to send out	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/22/19	JD	Review and provide comments to latest cash reports.	0.60
11/25/19	DS	Update cash report for two specific vendors regarding customer rebates classification	0.90
11/25/19	DS	Draft outline to S. LeMack (AlixPartners) re: treatment of PPI and specific insurance deposit for purposes of cash reporting	0.70
11/25/19	DS	Roll forward sales forecast for cash forecast update (Rhodes)	1.10
11/25/19	DS	Run open A/R report from SAP and categorize for cash forecast models	1.20
11/25/19	DS	Run open A/P report from SAP and categorize for cash forecast models	1.90
11/25/19	DS	Review historical collections and payments to update DSO and DPO assumptions in Rhodes cash forecast model	1.30
11/25/19	DS	Meeting with D. Samikkannu, S. Lemack, and I. Arana (all AlixPartners) and client to discuss IAC invoices and transaction processing.	0.70
11/25/19	SKL	Begin pulling this week's information re: cash actuals and review the latest East West cash transactions.	2.70
11/25/19	SKL	Begin putting together updates to the prepetition cash actuals report re: FTI diligence request.	1.30
11/25/19	SKL	Continue to reconcile the latest EastWest and Paysource transactions re: weekly cash actuals.	2.10
11/25/19	SKL	Continue to finalize updates to this week's cash actuals report.	0.70
11/25/19	SKL	Meeting with D. Samikkannu, S. Lemack, and I. Arana (all AlixPartners) and client to discuss IAC invoices and transaction processing.	0.70
11/25/19	IA	Meeting with D. Samikkannu, S. Lemack, and I. Arana (all AlixPartners) and client to discuss IAC invoices and transaction processing.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/26/19	IA	Call with D. Samikkannu, I. Arana, and S. Lemack (all AlixPartners) re: FTI's requests for prepetition presentation of cash activity.	0.40
11/26/19	SKL	Call with D. Samikkannu, I. Arana, and S. Lemack (all AlixPartners) re: FTI's requests for prepetition presentation of cash activity.	0.40
11/26/19	SKL	Prepare responses to FTI's latest diligence request re: cash activity.	2.40
11/26/19	SKL	Continue to update previous week's cash actuals reports with latest updates re: Investments and PPI.	2.60
11/26/19	SKL	Finalize updates to previous week's cash actuals reports with latest updates re: Investments and PPI.	2.70
11/26/19	DS	Update retained non-restructuring professional fees model (primarily for law firms)	1.30
11/26/19	DS	Update and revise forecast materials to incorporate support schedules and commentary to distribute internally to team	1.00
11/26/19	DS	Call with D. Samikkannu, I. Arana, and S. LeMack (all AlixPartners) re: FTI's requests for prepetition presentation of cash activity	0.40
11/26/19	DS	Update and rollforward Rhodes customer rebates forecast to incorporate actual payments made and contemplated future payments	2.20
11/26/19	DS	Update IAC forecast for Rhodes for both receipts and disbursements	1.90
11/26/19	DS	Update legal fees/OCPs forecast for Rhodes	0.80
11/26/19	DS	Update retained restructuring fees forecast model, incorporating latest assumptions on timing of applications and amounts	2.10
11/27/19	DS	Update weekly cash report for comments received by team	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

11/27/19	DS	Draft email to management explaining significant items in cash report and seeking comments	0.80
11/27/19	DS	Draft email to Davis Polk explaining significant items in cash report for purposes of posting to data room	0.30
11/27/19	JD	Review prepetition cash report prepared for AHC diligence question.	0.50
11/27/19	SKL	Prepare updated deck re: latest FTI diligence request on Cash Actuals.	2.40
11/27/19	SKL	Review final deck of prepetition Cash Actuals prior to distribution.	1.30
11/27/19	SKL	Continue to update this week's cash actual reporting re: investments and transaction mapping.	1.50
12/02/19	SKL	Prepare updated bridge analysis re: FTI inquiry on cash actuals.	1.10
12/02/19	SKL	Continue to finalize the 11.22 Cash Actuals report.	2.60
12/02/19	SKL	Finalize review of IAC transactions and transaction mapping re: Cash Actuals.	1.70
12/02/19	IA	Review of actual weekly operating expenses and editing of assumptions in cash forecast model to reflect latest run rate assumptions.	2.10
12/02/19	IA	Correspondence with client and review of updated Purdue commercial rebates forecast for December.	1.30
12/02/19	IA	Correspondence with management on R&D upcoming payments.	0.30
12/02/19	IA	Update Purdue cash forecast model to reflect latest assumptions on R&D payments.	0.80
12/02/19	IA	Review and update of summary on UCC negotiations on wages and benefits.	2.50
12/02/19	DS	Draft email to TXP financial analyst re: cash data needed for weekly report	0.20
12/02/19	DS	Follow up with C. Robertson (Davis Polk) re: 8-weeks pre-	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		petition cash report approval, outlining key items	
12/03/19	DS	Review and update retained professionals and restructuring professionals fee models and send to J. DelConte (AlixPartners)	1.40
12/03/19	DS	Put together Rhodes Rebates per cash report summary report (outlining discrepancies with GAAP report) and send to Controller (Rhodes) as basis for call	1.90
12/03/19	DS	In response to Controller's (PPLP) request for backup supporting 12/31/2019 cash balance, draft detailed outline of points to consider	0.80
12/03/19	IA	Update rebate forecast for Purdue to include latest payments and latest estimate of Q3 amounts.	2.80
12/03/19	IA	Prepare file showing agreed LTRP payments for Below VP for Rhodes	1.90
12/03/19	SKL	Finalize updates to the bridge analysis re: Cash Actuals.	0.50
12/03/19	SKL	Finalize cash report for week ending 11.22.	2.70
12/03/19	SKL	Begin putting to together the weekly cash actuals report for week ending 11/29	2.70
12/03/19	SKL	Reconcile latest pay source and East West cash transactions and categorize for the weekly cash actuals report.	2.30
12/03/19	SKL	Prepare the updated IAC summary and categorize the IAC and Intercompany transactions according to the latest feedback provided by the company.	2.10
12/04/19	SKL	Continue to work through the 11/29 cash actuals report to finalize for distribution.	2.50
12/04/19	SKL	Finalize updates to the 11/29 cash actuals report re: Purdue/Rhodes summaries.	2.30
12/04/19	SKL	Finalize pre-petition cash actual roll forward and begin finalizing updates to the June cash actuals per FTI request.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

12/04/19	SKL	Begin review and categorization of the weekly A/P SAP report for the cash forecast.	1.20
12/04/19	SKL	Begin review and categorization of the weekly A/R SAP report for the cash forecast.	1.20
12/04/19	IA	Prepare summary of end of year cash flow for discussion with management team.	1.70
12/04/19	IA	Update Purdue cash flow forecast model for latest actuals and updated professional fees forecast.	3.20
12/04/19	DS	Put together analysis supporting AlixPartners' illustrative cash forecast support including: (1) support details for Rhodes net operating cash flow, (2) Rhodes' rebate payments, and (3) restructuring professionals and retained professional legal fees	2.20
12/04/19	DS	Draft outline to J. DelConte (AlixPartners) re: cash summary, significant assumptions, and projected end of year balance	0.80
12/04/19	DS	Draft email to CFO (PPLP) outlining back support and assumptions to compare forecasted 12/31/2019 cash balance with draft number in Board of Directors package	1.10
12/05/19	DS	Provide analysis and commentary on Rhodes' cash flows post-petition to FTI	1.70
12/05/19	DS	Draft email to management seeking approval for pre-petition cash reporting requested by FTI	0.30
12/05/19	DS	Review CFO's comments about pre-petition cash reporting and incorporate into report	0.90
12/05/19	DS	Meeting with D. Samikkannu, I. Arana, S. LeMack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	DS	Provide analysis and commentary re: IAC activity for the pre- and post-petition periods to FTI	1.60
12/05/19	DS	Provide information on Debtors' cash management system to FTI, specifically regarding zero-balance	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		accounts	
12/05/19	IA	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	JD	Review final pre-petition cash actuals presentation	0.40
12/05/19	SKL	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and PPLP controller re: estimated end of year cash position	1.10
12/05/19	SKL	Finalize weekly cash actuals report and circulate to the AlixPartners team to review.	2.30
12/05/19	SKL	Finalize pre-petition cash actuals report per FTI diligence request.	2.60
12/06/19	SKL	Finalize last updates to the pre-petition cash actuals report.	2.30
12/06/19	SKL	Finalize updates to the current week's cash actuals report.	1.90
12/06/19	SKL	Update the cash actuals deck with the latest comments re: weekly IAC transactions.	1.30
12/06/19	SKL	Roll the pre-petition cash actuals activity forward into the latest cash actuals report.	1.00
12/06/19	SKL	Continue to review the IAC activity for the 11/29 cash actuals report to confirm the IAC summary was in sync with the latest East West information.	1.30
12/06/19	JD	Analysis of accrued and unpaid professional fees	0.60
12/06/19	IA	Review actuals for week ended 11/29	1.30
12/06/19	DS	Review further revised 11/29 cash report received from S. LeMack (AlixPartners)	0.50
12/06/19	DS	Draft summary to send to J. DelConte (AlixPartners) re: significant items in 11/29 cash report	0.70
12/06/19	DS	Review updated cash forecast for Rhodes	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

12/06/19	DS	Update assumptions re: professional fees in forecast package	0.40
12/06/19	DS	Update cash forecast summary page for cash forecast package	0.50
12/06/19	DS	Update IAC transaction supporting schedule for cash forecast package	0.90
12/06/19	DS	Update rebates supporting schedule for cash forecast package	1.00
12/06/19	DS	Review and provide comments to S. LeMack (AlixPartners) re: 11/29 weekly cash actuals report	1.60
12/09/19	DS	Follow up correspondence with counsel (PPLP) re: approval needed to post cash report to data room	0.20
12/09/19	JD	Correspondence with management re: expense reimbursements	0.60
12/09/19	JD	Review and provide comments on last two weeks cash actuals reports	0.70
12/09/19	DS	Put together analysis and materials in response to Treasurer's (PPLP) questions on cash forecast	1.20
12/09/19	DS	Correspondence with J. DelConte (AlixPartners) re: approval of 11/29 week ended cash report	0.30
12/09/19	DS	Draft summary outline to management outlining key points of cash report and seeking feedback and comments	0.80
12/09/19	DS	Draft summary outline to C. Robertson (Davis Polk) outlining key points of cash report and seeking feedback and comments prior to posting to data room	0.40
12/09/19	SKL	Begin preparing the reporting of cash activity re: monthly operating report.	2.60
12/09/19	SKL	Continue to finalize the analysis of cash disbursements and credits for the monthly operating report.	2.50
12/09/19	SKL	Begin preparing the analysis of account balances re: monthly operating report cash activity.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

12/09/19	SKL	Continue to reconcile the cash activity re: investment accounts for the monthly operating report.	2.40
12/10/19	SKL	Continue to finalize the cash reports for the monthly operating report.	2.30
12/10/19	SKL	Begin reviewing the EastWest cash activity and categorizing transactions for the weekly cash actuals report.	2.30
12/10/19	SKL	Prepare updated 13-week cash actual summary to track cash activity across Purdue and Rhodes entities.	1.90
12/10/19	IA	Update Purdue OCP payment forecast based on approved caps by Tier.	1.30
12/10/19	IA	Draft detailed schedule of payments to restructuring professionals, to be included in cash forecast overview presentation.	1.80
12/10/19	IA	Update Purdue and Rhodes cash forecast overview presentation to reflect latest edits and assumption changes.	3.10
12/10/19	IA	Update Purdue Medicaid and Commercial rebate payment assumptions in 13-week cash flow forecast.	1.60
12/10/19	IA	Update Purdue customer collections forecast to reflect actual sales and anticipated fee for services credit deductions.	1.70
12/10/19	IA	Review updated report on voluntary terminations received from HR.	0.70
12/11/19	SKL	Continue to finalize the weekly cash actuals and update the report to include the disbursement/credit summary for the monthly operating report.	2.40
12/11/19	SKL	Continue to reconcile and categorize all Paysource cash transactions for the weekly cash actuals report.	2.40
12/11/19	SKL	Reconcile the latest investment account activity and prepare for the cash actuals reporting.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

12/11/19	SKL	Update the Purdue and Rhodes cash summaries re: weekly cash actuals.	2.70
12/12/19	SKL	Review the updated IAC cash activity and notes provided by K. Darragh (Purdue) and update the cash actuals report accordingly.	2.30
12/12/19	SKL	Update the past month's cash actuals reports with the latest investment activity re: Trustee Charges provided by J. Liceaga (Purdue) and rolled forward to the current week.	2.30
12/12/19	SKL	Finalize the weekly cash actuals with the latest feedback provided by the company and distribute to J. Lowne (Purdue) for final review.	2.10
12/12/19	SKL	Prepare updated agenda for tomorrow's call re: case management update.	0.60
12/13/19	SKL	Review the October monthly operating report and ensure that the updated investment activity re: Trustee Charges flowed through into the November monthly operating report.	2.40
12/13/19	SKL	Finalize updates to the monthly Purdue Separations report.	1.70
12/13/19	SKL	Finalize review and closing out of weekly cash-actuals report.	1.20
12/13/19	JD	Review final cash actuals report for the week.	0.50
12/13/19	JD	Review final draft 13-week cash flow forecast and provide final comments. Review against budget cash flow outlook.	1.60
12/16/19	IA	Correspondence with Davis Polk on cash balances at the time of filing.	0.40
12/16/19	IA	Review of legal expense actuals post filing and upcoming payments.	1.90
12/16/19	IA	Follow up on review and approvals to post cash forecast for Purdue and Rhodes.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

12/16/19	IA	Review of actuals for two weeks ended 12/6 and 12/13	1.90
12/16/19	IA	Follow up on upcoming Q3 end of year payments for Purdue cash forecast.	2.70
12/16/19	IA	Update professional fees forecast schedule to reflect filed applications and approved retentions.	1.80
12/16/19	IA	Update rebate schedule in forecast to reflect transition of Medicare and commercial rebates third party payment vendor.	0.60
12/16/19	IA	Follow up on backup information for Medicare coverage gap payment by Purdue.	0.90
12/16/19	SKL	Begin reviewing the weekly Paysource information re: weekly cash report.	1.20
12/16/19	SKL	Review and reconcile the latest East West cash transactions as I began preparing the weekly cash report.	2.40
12/16/19	SKL	Review and reconcile weekly Intercompany and IAC transactions for this past week's cash report.	2.10
12/17/19	SKL	Begin categorization of all East West cash transactions re: cash reporting.	2.60
12/17/19	SKL	Update bank summary information re: Rhodes and Purdue cash reporting.	2.30
12/17/19	SKL	Review latest investment activity and update the cash summaries accordingly.	1.30
12/17/19	IA	Prepare responses to cash forecast and actuals diligence requests received from FTI.	1.60
12/17/19	IA	Correspondence with management on variances to cash forecast for prior weeks, including large Rhodes receipts and large non-recurring operating payments.	1.30
12/18/19	SKL	Finalize the cash summaries and IAC summaries re: weekly cash reporting.	2.60
12/18/19	SKL	Review and reconcile the past month's weekly rebates and began to update the customer programs report	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		accordingly.	
12/18/19	SKL	Continue to update the customer program's report re: Purdue weekly rebate information.	2.60
12/18/19	SKL	Continue to finalize the Purdue rebate categorization re: customer programs reporting.	2.10
12/19/19	SKL	Begin preparing the two-week weekly cash actuals to cash forecast reconciliation.	2.10
12/19/19	SKL	Finalize the weekly Rhodes cash actuals to cash forecast reconciliation.	2.00
12/19/19	IA	Review of questions on cash actuals received from FTI and drafting of responses.	1.50
12/19/19	IA	Review IAC and intercompany transactions for weeks ended 12/6 and 12/13	0.80
12/19/19	IA	Review filed application fees for retained professionals on docket	1.70
12/19/19	JD	Review draft cash actuals presentation to post for committee advisors. Provide comments re: same.	0.50
12/20/19	JD	Review and provide comments re: forecast to actual analysis.	0.80
12/20/19	IA	Review actuals tracking for the weeks ended 12/6 and 12/13.	1.40
12/20/19	IA	Update Purdue and Rhodes forecast to actuals analysis for weeks ended 12/6 and 12/13	1.80
12/20/19	IA	Update cash report overview presentation for the weeks ended 12/6 and 12/13	1.70
12/20/19	SKL	Finalize the weekly cash report with the latest feedback and information provided by K. Darragh (Purdue) and J. Licega (Purdue).	2.20
12/20/19	SKL	Prepare the weekly cash reporting deck and prepare for distribution to the Purdue team for final sign-off.	2.30
12/20/19	SKL	Update the weekly cash report with additional slides re:	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		cash actuals to cash forecast reconciliation.	
12/20/19	SKL	Finalize the Rhodes rebate section of the customer programs report and began to review the Purdue piece.	2.50
12/23/19	SKL	Begin reviewing and reconciling this past week's East West cash transactions report.	2.70
12/23/19	SKL	Begin categorizing the East West cash transactions re: weekly cash actuals.	2.20
12/23/19	SKL	Review and reconcile the weekly Paysource transactions re: weekly cash reporting.	2.40
12/23/19	SKL	Continue to categorize and map the weekly Paysource transactions re: weekly cash reporting.	1.80
12/23/19	IA	Review cash actuals for the week ended 12/20.	1.40
12/23/19	IA	Correspondence with company and Davis Polk on professional fees forecast detail requested by committees.	0.30
12/23/19	IA	Draft professional fees detailed schedule as requested by committees.	0.40
12/24/19	JD	Correspondence with management re: professional fee payments	0.50
12/24/19	SKL	Continue to finalize the weekly cash actuals report.	2.40
12/24/19	SKL	Review the latest IAC cash transactions and prepare the weekly cash summaries re: weekly cash actuals.	2.10
12/26/19	SKL	Review and reconcile the latest PPLP information provided re: monthly customer programs reporting.	2.10
12/27/19	JD	Correspondence with Davis Polk re: cash forecast diligence materials.	0.40
12/30/19	SKL	Review latest responses re: weekly cash inquiries and prepare updates to the weekly cash report accordingly.	0.90
01/02/20	SKL	Continue to review and prepare the November Customer Programs Report.	2.10
01/02/20	SKL	Review latest feedback provided by J. Licega (TXP) re: cash actuals and prepare updates to the cash actuals	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		report accordingly.	
01/02/20	IA	Review and reconciliation of cash transactions in East West report to pay source detail for the weeks ended 12/20 and 12/27.	1.80
01/02/20	IA	Review of cash transactions for weeks ended 12/27 and 12/20	0.70
01/03/20	IA	Update professional fees overview presentation for 12/06 forecast to incorporate edits requested by management.	1.60
01/03/20	IA	Follow up with management and DPW on approvals and posting of cash forecast detail files and weekly sales detail.	0.40
01/03/20	IA	Review of end of year cash payments to professional firms and filed fee applications on docket.	1.20
01/03/20	SKL	Continue to reconcile the latest East West cash transaction buildup provided by J. Licega (TXP) and finalize updates to the cash actuals report.	2.40
01/03/20	SKL	Continue to make updates to the November Customer Programs report based on the latest Purdue information provided by E. Nowakowski (Purdue).	2.20
01/03/20	SKL	Continue to make updates to the November Customer Programs report based on the latest Purdue information provided by R. Haberlin (Purdue).	2.30
01/03/20	SKL	Finalize updates to the weekly cash actuals summary and IAC cash activity summary.	1.30
01/06/20	SKL	Meeting with D. Samikkannu, S. Lemack, I. Arana (all AlixPartners), and Purdue Controller re: cash reporting and OSR payments	0.80
01/06/20	SKL	Prepare updates to the week ending 12/20 Cash Actuals report based on the latest IAC cash activity provided by K. Darragh (Purdue) and J. Licega (TXP).	1.40
01/06/20	SKL	Prepare updates to the November Customer Programs report based on the information provided by A. Graziano	0.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		(Purdue) re: vendor chargebacks	
01/06/20	SKL	Continue to map the Paysource cash transactions and East West cash transactions re: Cash Actuals reporting (week ending 12/27).	1.60
01/06/20	IA	Meeting with D. Samikkannu, I. Arana, S. LeMack (all AlixPartners), and Purdue Controller re: cash reporting and OSR payments	0.80
01/06/20	IA	Review filed fee applications to compile actual billing information for professional fees forecast ad tracking.	1.80
01/06/20	IA	Prepare summary of actual billing and professional fee estimates as requested by UCC advisors.	1.40
01/06/20	IA	Update cash forecast to reflect updated third party vendor actual and scheduled payments based on latest funding request.	1.60
01/06/20	DS	Review cash actuals model to ensure accuracy and completeness	2.10
01/06/20	DS	Update professional fees model for (a) fee applications and (b) fee estimates	1.20
01/06/20	DS	Review OSR cash payments and reversals from the past few months for purposes of reconciling and confirming actual rent payments	0.90
01/06/20	DS	Meeting with D. Samikkannu, I. Arana, S. LeMack (all AlixPartners), and Purdue Controller re: cash reporting and OSR payments	0.80
01/07/20	DS	Prepare for and participate in meeting with J. Liceaga (TXP), D. Samikkannu, and S. Lemack (both AlixPartners) to discuss IAC transactions re: weekly cash report	0.50
01/07/20	DS	Further revise professional fees model based on real time updates on filings and estimates	1.70
01/07/20	IA	Update commercial rebates forecast to reflect payment timing for transition to third party payment administrator.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/07/20	IA	Follow up on payments to OCPs and review of recently filed affidavits.	2.40
01/07/20	IA	Review actual pay source end of year payments to update forecast model for Purdue	1.30
01/07/20	SKL	Review the latest Customer Programs report and update the previous week's cash actuals reports with the latest rebate information and rolled forward to current week.	2.70
01/07/20	SKL	Prepare for and participate in meeting with J. Liceaga (TXP), D. Samikkannu, and S. Lemack (both AlixPartners) to discuss IAC transactions re: weekly cash report.	0.50
01/07/20	SKL	Finalize East West and Paysource transactions categorization for the 12.27 Cash Report.	2.30
01/07/20	SKL	Reconcile latest IAC transactions and update the 12.27 Cash Report with the latest information provided by J. Liceaga (TXP).	1.60
01/07/20	SKL	Review latest weekly Cash Report and prepare list of open items for K. Darragh (Purdue) and J. Liceaga (TXP).	0.50
01/07/20	SKL	Finalize updates to the Purdue and Rhodes summaries for the 12.27 Cash Report.	1.40
01/08/20	SKL	Review and reconcile the latest IAC activity provided by K. Darragh (Purdue) and update the weekly cash report accordingly.	2.60
01/08/20	SKL	Review the latest rebate information provided in the monthly Customer Programs report and ensure the rebate payments were categorized appropriately in the December weekly cash reports.	2.60
01/08/20	SKL	Review and reconcile the latest One Stamford Realty transaction detail provided by J. Liceaga (TXP) and ensure the payments were tracked appropriately in the weekly cash report.	1.30
01/08/20	SKL	Prepare updates to the 01/03 week ending cash reporting summaries for Purdue and Rhodes.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/08/20	IA	Review Customer Programs report for November.	0.70
01/08/20	IA	Follow up with PJT and company on professional fees budget and year end accruals.	1.40
01/08/20	DS	Review of non-ADF royalties' structure for purposes of validating transactions for cash report	1.70
01/08/20	DS	Identify payments made to Customer Program Vendors from cash files	1.20
01/09/20	DS	Correspondence with S. LeMack (AlixPartners) re: specific vendor payment for purposes of cash reporting	0.50
01/09/20	DS	Review of Prime Clerk invoices for purposes of updating professional fees model	1.70
01/09/20	DS	Review and provide S. LeMack (AlixPartners) with comments on cash report	2.10
01/09/20	DS	Put together forecast-to-actual variance analysis for Rhodes for purposes of cash report	1.60
01/09/20	IA	Review updated actuals reporting for the week ended 12/20.	2.20
01/09/20	IA	Review updated actuals reporting for the week ended 12/27	2.30
01/09/20	IA	Review of legal payments in cash actuals for weeks ended 12/20, 12/27, and 1/03.	1.60
01/09/20	IA	Follow up on indemnity fee reimbursements status and actuals payments for weeks ended 12/20, 12/27, and 1/03.	1.40
01/09/20	SKL	Prepare and update deck for the weekly cash report (week ending 01/03/20) and circulate to the AlixPartners team for review.	2.70
01/09/20	SKL	Prepare list of outstanding questions re: IAC transactions and circulate to K. Darragh (Purdue) and J. Liceaga (TXP) for final review.	1.50
01/09/20	SKL	Prepare a new schedule for the weekly cash report, which	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		details weekly Restructuring related disbursements.	
01/10/20	SKL	Finalize updated weekly cash report and circulate to J. Lowne (Purdue) for review and sign-off.	2.40
01/10/20	SKL	Make additional updates to the Purdue and Rhodes IAC summaries within the weekly cash report.	2.00
01/10/20	SKL	Begin preparing the cash transaction activity information for the December Monthly Operating Report.	2.10
01/10/20	SKL	Update the summaries for the forecast-to-actuals section of the weekly cash report and distribute accordingly.	1.30
01/10/20	SKL	Begin updating the monthly bank account balances re: December Monthly Operating Report.	1.60
01/10/20	IA	Follow up on questions to TXP on IAC receipts.	0.60
01/10/20	IA	Follow up on professional fees end of year accruals and budget requested by the company.	1.30
01/10/20	IA	Review updated actuals reporting for the week ended 1/3.	1.70
01/10/20	IA	Update forecast to actuals variance explanations for week ended 01/03.	1.80
01/10/20	JD	Review and provide comments re: cash forecast to actual report	0.60
01/10/20	DS	Review cash report before sending out	0.50
01/10/20	DS	Update professional fees model	1.10
01/12/20	SKL	Finalize the monthly cash transaction activity re: Monthly Operating Report and send to J. Liceaga (TXP) for sign-off.	1.20
01/13/20	SKL	Review the 01/10/20 EastWest cash transaction detail and began categorizing accordingly for the weekly cash report.	2.10
01/13/20	SKL	Update the bank account balance and disbursement/credit detail re: December Monthly Operating Report	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/13/20	SKL	Review and reconcile the week ending 01/10/20 Paysource cash detail and categorized for the weekly cash report.	1.80
01/13/20	SKL	Review the week ending 01/10/20 IAC cash activity and prepared list of open items/questions to J. Liceaga (TXP) to provide further detail on.	1.30
01/13/20	IA	Review filed fee applications to update Purdue professional fees forecast and actuals reporting.	1.10
01/13/20	DS	Update professional fees model for fee applications on the docket	2.10
01/13/20	DS	Review retained professionals cash model to ensure accurate given payments made and fee applications filed	1.10
01/14/20	DS	Meeting with D. Samikkannu, and S. Lemack (both AlixPartners) to review cash forecast model	1.80
01/14/20	DS	Provide background on Aircastle account to S. Lemack (AlixPartners) for purposes of cash reporting	0.40
01/14/20	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss committees' IAC transaction request	0.20
01/14/20	IA	Meeting with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss committees' IAC transaction request	0.20
01/14/20	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss committees' IAC transaction request	0.20
01/14/20	SKL	Meeting with D. Samikkannu, J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss committees' IAC transaction request.	0.20
01/14/20	SKL	Meeting with D. Samikkannu, and S. Lemack (both AlixPartners) to review cash forecast model	1.80
01/14/20	SKL	Finalize updates to the bank account balance and cash activity re: December MOR and circulate accordingly.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/14/20	SKL	Update the December weekly cash reports with the latest investment activity provided by J. Liceaga (TXP) and roll-forward to week ending 01/10.	1.50
01/14/20	SKL	Review and reconcile the latest AP roll-forward and prepare updates for the cash-forecast accordingly.	1.30
01/14/20	SKL	Review and reconcile the latest AR roll-forward and prepare updates for the cash-forecast accordingly.	1.00
01/14/20	SKL	Prepare and finalize updates to the AR/AP section of the Rhodes 13-week cash forecast.	1.60
01/15/20	SKL	Review the latest Rhodes cash-forecast and update the underlying operating expense detail for the new 13-week time period.	2.40
01/15/20	SKL	Prepare and made updates to the customer rebate section of the update 13-week cash report.	2.10
01/15/20	SKL	Prepare updates to the IAC receipt/disbursement section re: Rhodes 13-week cash forecast.	2.00
01/15/20	SKL	Prepare and finalize updates to the Payroll/Employee benefit section of the Rhodes 13-week cash forecast.	2.40
01/16/20	SKL	Review the latest updates re: Purdue forecast-to-actuals and update the weekly cash report accordingly.	1.40
01/16/20	SKL	Begin preparing and reformatting an update Restructuring/Retained professional fee schedule per Davis Polk request.	1.50
01/16/20	SKL	Prepare final updates to the weekly cash report re: Purdue/Rhodes summaries, and circulate to the AlixPartners team for review.	2.10
01/16/20	IA	Update assumptions on operating expenses for 13-week Purdue cash forecast.	2.90
01/16/20	IA	Review updated bankruptcy and retained professional fees schedules and incorporate to Purdue cash forecast.	1.70
01/16/20	DS	Prepare Rhodes cash variance analysis for the 4 weeks	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		ended January 10	
01/16/20	DS	Review Rhodes budget for purposes of extending cash forecast	1.10
01/17/20	DS	Review draft cash forecast materials and provide comments to I. Arana and S. Lemack (both AlixPartners)	1.70
01/17/20	DS	Review draft cash report for updates made by S. Lemack (AlixPartners)	0.70
01/17/20	DS	Update customer rebates section of Rhodes forecast	2.40
01/17/20	DS	Review retained professionals cash forecast model	0.70
01/17/20	IA	Review company collections forecast and update 13-week sales and customer receipts forecast for Purdue.	2.80
01/17/20	IA	Update Purdue rebate forecast for updated 13-week cash flow forecast.	1.70
01/17/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.50
01/17/20	SKL	Reformat the Restructuring/Retained professional fee schedule and update the deck accordingly.	1.10
01/17/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off.	2.10
01/17/20	SKL	Prepare final updates to the weekly cash report based on J. Lowne's (Purdue) feedback and circulate accordingly.	0.60
01/17/20	SKL	Finalize Restructuring/Retained professional fee schedule and circulate to the Davis Polk team.	2.60
01/17/20	SKL	Update the weekly cash report deck re: forecast-to-actuals and circulate to the AlixPartners team for final review.	1.80
01/21/20	SKL	Review latest East West cash activity provided by J. Liceaga (TXP) and categorize for the weekly cash report.	2.10
01/21/20	SKL	Review latest IAC cash activity, provide updated list of action items/questions for J. Liceaga (TXP), and add to the weekly cash report.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/21/20	SKL	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Treasury Analyst (TXP Services) re: bank account history and specific payments made in prior week.	0.30
01/21/20	JD	Meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) to review draft cash forecast materials	0.50
01/21/20	JD	Review and provide comments on draft cash forecast presentation.	1.50
01/21/20	IA	Review and update Purdue rebate schedule based on latest payments.	1.30
01/21/20	IA	Review and incorporate updated professional fees schedule to Purdue model based on latest payments.	1.10
01/21/20	IA	Incorporate internal comments and update schedules to cash forecast overview presentation.	2.90
01/21/20	IA	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Treasury Analyst (TXP Services) re: bank account history and specific payments made in prior week.	0.30
01/21/20	IA	Meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) to review draft cash forecast materials	0.50
01/21/20	IA	Follow up on request from province to provide information on current and historical debtor bank accounts.	0.90
01/21/20	DS	Analysis of specific transactions for purposes of categorizing for cash report	2.20
01/21/20	DS	Make updates to cash forecast based on discussion with AlixPartners team	1.20
01/21/20	DS	Meeting with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Treasury Analyst (TXP Services) re: bank account history and specific payments made in prior week.	0.30
01/21/20	DS	Meeting with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners) to review draft cash forecast materials	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

01/22/20	DS	Draft detailed outline of cash forecast and send to Davis Polk and company counsel for approval	1.10
01/22/20	DS	Meeting with Purdue Treasurer re: business development projects to include in cash forecast	0.90
01/22/20	DS	Incorporate specific business development transactions into cash forecast	1.60
01/22/20	IA	Review actuals for legal payments including indemnity fees reporting.	2.40
01/22/20	IA	Final edits to cash forecast overview to incorporate management's comments.	1.60
01/22/20	IA	Follow up on and draft responses to questions from management on updated cash forecast.	1.80
01/22/20	SKL	Finalize review of latest investment activity and update the weekly cash report accordingly.	1.10
01/22/20	SKL	Update the cash forecasts with the latest cash actual information and prepare the variance report re: forecast to actuals.	1.50
01/22/20	SKL	Update the weekly cash report with the latest feedback provided by J. Liceaga (TXP) and update the summaries accordingly.	2.10
01/22/20	SKL	Finalize updated weekly cash reporting deck and circulate to AlixPartners team for final review.	2.30
01/22/20	SKL	Review latest Paysource cash activity and categorize for the weekly cash report.	1.30
01/23/20	SKL	Final updates to the weekly cash report and prepare for distribution and final sign-off.	0.80
01/24/20	IA	Review cash actuals report for the week ended 1/17.	0.80
01/24/20	IA	Update forecast to actuals analysis for the week ended 1/17.	1.60
01/27/20	IA	Review of Paysource payments for the week ended 01/24 to track legal expenses and large rebate payments for	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		cash reporting purposes.	
01/27/20	IA	Review company's updated Purdue collections report for the week ended 01/24	0.40
01/27/20	IA	Review cash transactions file for the week ended 01/24 to check against R&D and operating expenses forecast.	0.80
01/27/20	JD	Review listing of historical bank account information and correspondence with management re: same.	0.50
01/27/20	SKL	Review latest East West Transactions provided by J. Liceaga (TXP) and categorize for the weekly cash report.	2.30
01/28/20	SKL	Meeting to discuss weekly flash report with D. Fogel (Purdue), I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners).	0.50
01/28/20	SKL	Review and reconcile the latest Paysource cash transactions and categorize accordingly for the weekly cash report.	2.10
01/28/20	SKL	Review and reconcile the latest IAC cash activity and prepare list of action items and questions for J. Liceaga (TXP) and E. Nowakowski (Purdue) to provide updates on.	1.80
01/28/20	SKL	Finalize updates to the pre-petition IAC cash transaction summary.	1.30
01/28/20	SKL	Prepare updated Purdue and Rhodes IAC summaries based on the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue).	1.70
01/28/20	JD	Review upcoming professional fee payments.	0.30
01/28/20	IA	Meeting to discuss weekly flash report with D. Fogel (Purdue), I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners).	0.50
01/28/20	DS	Meeting to discuss weekly flash report with D. Fogel (Purdue), I. Arana, D. Samikkannu, and S. Lemack (all AlixPartners).	0.50
01/29/20	SKL	Finalize updates to the weekly cash report and prepare	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

		the deck for distribution.	
01/29/20	SKL	Update the Purdue and Rhodes forecast-to-actuals slides for the weekly cash report.	1.00
01/29/20	SKL	Review the latest fee applications filed to the docket and update the Retained Professional summary and forecast accordingly.	2.10
01/29/20	SKL	Review the latest fee applications filed to the docket and update the Restructuring Professional summary and forecast accordingly.	2.60
01/29/20	SKL	Reconcile the latest investment activity files provided by J. Liceaga (TXP) and update the weekly cash report accordingly.	1.20
01/30/20	SKL	Update the forecast-to-actuals slides based on the latest feedback provided for the weekly cash report.	1.10
01/30/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne and R. Aleali (both Purdue) for final-sign off.	1.20
01/30/20	SKL	Finalize updates to the Retained and Restructuring Professional forecasts based on the latest fee applications filed on the docket.	1.30
01/30/20	IA	Update Purdue cash actual variances to forecast.	1.70
01/30/20	IA	Review actuals report for the week ended 01/24.	1.40
01/30/20	JD	Review and provide comments on draft cash management report.	0.40
01/31/20	SKL	Finalize the weekly cash report updates and circulate to the Davis Polk team for final sign-off.	0.50
Total			756.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	217.20	440.00	95,568.00
Sam K Lemack	125.10	515.00	64,426.50
David Samikkannu	159.20	615.00	97,908.00
Isabel Arana de Uriarte	135.20	615.00	83,148.00
Isabel Arana de Uriarte	63.80	690.00	44,022.00
David Samikkannu	39.30	690.00	27,117.00
Ryan D Sublett	1.30	725.00	942.50
Jesse DelConte	10.40	945.00	9,828.00
Jesse DelConte	4.50	950.00	4,275.00
Total Hours & Fees	756.00		427,235.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
09/16/19	DS	Attend client Town Hall meeting.	1.20
09/18/19	MH	Attend meeting with the CFO regarding the formation of a creditors committee.	0.40
09/20/19	MH	Review additional vendors submitted by managers for Critical Vendor approval.	0.70
09/20/19	JD	Prepare for and attend kick off call with FTI, PJT and AlixPartners.	1.20
09/21/19	JD	Correspondence with AlixPartners team, DPW and PJT RE: diligence question list from FTI and work plan for pulling info together.	1.40
09/22/19	JD	Review materials related to FTI diligence requests.	0.70
09/23/19	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), CFO, Controller, and Treasurer re: FTI's initial diligence list	0.70
09/23/19	JD	Prepare for and participate in a call with a customer, E. Vonnegut (Davis Polk) and management RE: customer motion questions	0.50
09/23/19	IA	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), CFO, Controller, and Treasurer re: FTI's initial diligence list	0.70
09/23/19	MH	Prepare response to initial diligence list from ad hoc group.	2.40
09/23/19	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), CFO, Controller, and Treasurer re: FTI's initial diligence list	0.70
09/23/19	DS	Provide follow-up questions and requests to Rhodes Controller regarding data provided for counterparty analysis	0.70
09/23/19	ADD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), CFO, Controller, and Treasurer	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		re: FTI's initial diligence list	
09/25/19	ADD	Compile documents for FTI due diligence request.	2.90
09/25/19	ADD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items	0.40
09/25/19	DS	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items	0.40
09/25/19	NAS	Confirming accuracy of list of insiders to be provided to plaintiff advisor.	0.30
09/25/19	JD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items	0.40
09/25/19	JD	Discussions with PJT and Davis Polk RE: open FTI diligence items.	0.40
09/25/19	JD	Review latest items for FTI diligence	1.30
09/26/19	ADD	Compile and submit requested wage motion documents for review.	1.60
09/27/19	ADD	Set up Interlinks Live due diligence site and added members of FTI team.	2.30
09/27/19	DS	Call with FTI, PJT, J. DelConte, D. Samikkannu, I. Arana and M. Hartley (partial attendance) (all AlixPartners) to walk through first day motions and provide an update on diligence	1.80
09/27/19	JD	Call with FTI, PJT, J. DelConte, D. Samikkannu, I. Arana and M. Hartley (partial attendance) (all AlixPartners) to walk through first day motions and provide an update on diligence	1.80
09/27/19	JD	Conversations and correspondence with Davis Polk RE: open due diligence items	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
09/27/19	IA	Call with FTI, PJT, J. DelConte, D. Samikkannu, I. Arana and M. Hartley (partial attendance) (all AlixPartners) to walk through first day motions and provide an update on diligence	1.80
09/27/19	MH	Call with FTI, PJT, J. DelConte, D. Samikkannu, I. Arana and M. Hartley (partial attendance) (all AlixPartners) to walk through first day motions and provide an update on diligence	0.80
09/29/19	ADD	Review FTI due diligence status and provided update.	1.60
09/30/19	MH	Engage client support to respond to ad hoc advisors on the top 25 critical vendors.	0.40
09/30/19	JD	Review data related to FTI diligence. Review data provided by management in response to wage related questions. Review files prior to posting in the data room.	3.80
10/01/19	MH	Update answers to questions from the ad hoc advisors regarding the critical vendor motion.	2.30
10/02/19	MH	Call with J. DelConte, I. Arana, D. Samikkannu, M. Hartley (all AlixPartners), Akin Gump, Bayard and Province RE: second day issues list.	1.00
10/02/19	MH	Call with Rhodes management to review the request from the ad hoc professionals.	0.20
10/02/19	JD	Discussion with FTI RE: open diligence questions.	0.30
10/02/19	JD	Communication with Province and FTI RE: open diligence requests and timing for responses.	0.70
10/02/19	JD	Call with J. DelConte, I. Arana, D. Samikkannu, M. Hartley (all AlixPartners), Akin Gump, Bayard and Province RE: second day issues list.	1.00
10/02/19	IA	Call with J. DelConte, I. Arana, M. Hartley (all AlixPartners), Akin Gump, Bayard and Province RE: second day issues list.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/03/19	JD	Meeting with J. DelConte, D. Samikkannu (both AlixPartners) and FTI to discuss various customer programs, cash flows, and counter parties	1.00
10/03/19	JD	Prepare for and participate in a conversation with management RE: open diligence items.	1.50
10/03/19	MH	Meeting (partial) with UCC professionals to review second day hearing issues on motions.	0.80
10/04/19	JD	Call with FTI, TXP Services, D. Samikkannu, and J. DelConte (both AlixPartners) re: follow up insurance items and risk management	0.40
10/04/19	DS	Call with FTI, TXP Services, D. Samikkannu, and J. DelConte (both AlixPartners) re: follow up insurance items and risk management	0.40
10/05/19	JD	Call with J. DelConte, I. Arana (both AlixPartners), PJT, Davis Polk, Akin Gump, Province, Kramer Levin and FTI RE: open motion diligence questions	1.00
10/05/19	IA	Call with J. DelConte, I. Arana (both AlixPartners), PJT, Davis Polk, Akin Gump, Province, Kramer Levin and FTI RE: open motion diligence questions	1.00
10/06/19	JD	Correspondence with DPW, management and other advisors RE: open diligence items.	0.80
10/06/19	JD	Correspondence with management and the other advisors RE: open due diligence items	1.10
10/07/19	JD	Meeting with I. Arana, D. Samikkannu, J. DelConte (all AlixPartners) and management RE: open diligence requests.	0.50
10/07/19	JD	Meeting with I. Arana and J. DelConte (both AlixPartners) and management RE: open wage diligence questions.	0.80
10/07/19	JD	Review and respond to various UCC and Ad Hoc Committee wage motion diligence questions. Review information and analysis RE: same.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/07/19	JD	Correspondence with management and with Davis Polk RE: customer motion order reporting requirements from the UCC and Ad Hoc Committee. Conversations with management to determine what is doable.	0.90
10/07/19	JD	Respond to additional wage motion diligence questions from the UCC and Ad Hoc Committee.	0.60
10/07/19	IA	Meeting with I. Arana and J. DelConte (both AlixPartners) and management RE: open wage diligence questions.	0.80
10/07/19	IA	Meeting with I. Arana, D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners) and management RE: open diligence requests.	0.50
10/07/19	DS	Meeting with I. Arana, D. Samikkannu, J. DelConte, A. DePalma (all AlixPartners) and management RE: open diligence requests.	0.50
10/08/19	JD	Meeting with management RE: UCC information requests.	0.50
10/08/19	JD	Correspondence with management and Davis Polk RE: additional market access diligence questions.	0.70
10/08/19	JD	Prepare for and have catch up call with FTI RE: open diligence questions.	0.40
10/09/19	JD	Review latest diligence list from FTI. Compare status to latest internal tracker. Review items awaiting sign off against FTI list.	1.30
10/09/19	JD	Review correspondence with Davis Polk RE: providing customer agreements to committee advisors. Review certain relevant customer agreements.	0.60
10/13/19	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), PJT Partners, and UCC advisors (Province, Jefferies) re: introduction to business plan	1.40
10/13/19	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), PJT Partners and UCC advisors (Province, Jefferies) re: introduction to business plan	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/14/19	DS	Internal call with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) re: status of diligence items	1.10
10/14/19	DS	Call with D. Samikkannu, J. DelConte, and I. Arana (all AlixPartners), PJT and FTI RE: status of open diligence items.	1.00
10/14/19	DS	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: review of diligence items	0.60
10/14/19	ADD	Internal call with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) re: status of diligence items.	1.10
10/14/19	ADD	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma, and Davis Polk re: review of diligence items	0.60
10/14/19	JD	Review additional diligence questions from Province RE: indemnification spend, and ordinary course professional spend. Review materials provided to date and other information that we have received from management.	1.10
10/14/19	JD	Internal call with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) re: status of diligence items	1.10
10/14/19	JD	Call with D. Samikkannu, J. DelConte, A. DePalma, and I. Arana (all AlixPartners), PJT and FTI RE: status of open diligence items.	1.00
10/14/19	JD	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: review of diligence items	0.60
10/14/19	IA	Internal call with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) re: status of diligence items	1.10
10/14/19	IA	Call with D. Samikkannu, J. DelConte, A. DePalma, and I.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Arana (all AlixPartners), PJT and FTI RE: status of open diligence items.	
10/14/19	IA	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: review of diligence items	0.60
10/16/19	NAS	Analysis of procedures proposed by Unsecured Creditors Committee pertaining to critical vendors.	0.40
10/16/19	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), and PJT Partners re: diligence list sent by UCC financial advisors	0.30
10/16/19	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and PJT Partners re: diligence list sent by UCC financial advisors	0.30
10/16/19	JD	Correspondence with Davis Polk RE: UCC claims agent	0.40
10/16/19	JD	Conversation with Prime Clerk RE: UCC claims agent	0.40
10/17/19	JD	Review and provide comments to latest business plan due diligence tracker	0.50
10/17/19	JD	Prepare for and participate in a call with I. Arana, J. DelConte (both AlixPartners), FTI and Province RE: wage motion diligence questions	1.20
10/17/19	IA	Call with I. Arana, J. DelConte (both AlixPartners), FTI and Province RE: wage motion diligence questions	1.10
10/21/19	JD	Prepare UCC stipulation tracker. Review potential information sources for open diligence questions. Correspondence with team RE: open items.	1.70
10/23/19	JD	Finalize critical vendor analysis and draft email to the various committees.	0.80
10/24/19	JD	Correspondence with management and Davis Polk RE: open diligence questions and approval requests.	1.70
10/24/19	JD	Correspondence with management RE: UCC diligence	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		requests and ability to share materials with the committee	
10/24/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), PJT, Davis Polk, and Purdue GC to discuss due diligence procedures	1.30
10/24/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), PJT, Davis Polk, Purdue GC to discuss due diligence procedures	1.30
10/25/19	JD	Review open wage diligence questions and drafted responses.	0.80
10/25/19	JD	Prepare for and participate in a call with FTI, I. Arana, and J. DelConte (both AlixPartners).	1.20
10/25/19	IA	Call with J. DelConte, I Arana (both AlixPartners), and FTI to discuss wages diligence open items.	0.90
10/25/19	IA	Call with J. DelConte, I. Arana (both AlixPartners), and FTI to discuss wages diligence items.	0.90
10/28/19	JD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) to update diligence tracker	0.70
10/28/19	JD	Meeting with D. Samikkannu, J. DelConte, R. Sublett (all AlixPartners), management, Davis Polk, and PJT Partners re: preparation for UCC call on 10/30	0.70
10/28/19	JD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) to further review and refine diligence tracker	0.80
10/28/19	JD	Draft responses to open wage motion diligence questions	0.80
10/28/19	JD	Correspondence with DPW RE: IAC diligence process	0.60
10/28/19	DS	Meeting with D. Samikkannu, J. DelConte, R. Sublett (all AlixPartners), management, Davis Polk, and PJT Partners re: preparation for UCC call on 10/30	0.70
10/28/19	DS	Meeting with D. Samikkannu, J. DelConte, and A.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/28/19	DS	DePalma (all AlixPartners) to update diligence tracker	0.80
10/28/19	ADD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) to further review and refine diligence tracker	0.70
10/28/19	ADD	Meeting with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) to further review and refine diligence tracker	0.80
10/28/19	RDS	Review / update diligence tracker for committee diligence requests	0.70
10/28/19	RDS	Meeting with D. Samikkannu, J. DelConte, R. Sublett (all AlixPartners), management, Davis Polk, and PJT Partners re: preparation for UCC call on 10/30	0.70
10/29/19	ADD	Review adequate assurance calculation in preparation for call with G. Dusablon representing the City of Wilson	0.50
10/29/19	ADD	Call with G. Dusablon representing the City of Wilson re: additional adequate assurance	0.40
10/29/19	JD	Call with PJT and Davis Polk RE: IAC diligence process	0.50
10/29/19	JD	Correspondence with management RE: insurance diligence	0.50
10/29/19	JD	Update wage motion diligence list tracker	0.60
10/29/19	IA	Follow up on open items for wages diligence and update to notes and answers/comments in response to UCC and Adhoc wages requests.	1.90
10/29/19	NAS	Generate final individualized SOFA Part 2 Question 4 disclosures as requested by Sackler family counsel.	0.40
10/30/19	IA	Call with J. DelConte, I. Arana (both AlixPartners), and Province to review outstanding wages diligence items.	0.80
10/30/19	IA	Call with J. DelConte, I. Arana (both AlixPartners), and	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		FTI to discuss outstanding wages diligence items.	
10/30/19	MH	Attend first 30 minutes of call with committee advisors to review company business plan.	0.50
10/30/19	JD	Call with UCC and ad hoc committee advisors Jefferies, Province and FTI Consulting, as well as PJT and Davis Polk, J. Lowne, K. Darragh (both Purdue), J. DelConte and R. Sublett (both AlixPartners) re introduction to business plan and response to Jefferies question list	1.10
10/30/19	JD	Call with I. Arana, J DelConte (both AlixPartners), and Province to review outstanding wages diligence items	0.80
10/30/19	JD	Call with J. DelConte, I. Arana (both AlixPartners), and FTI to discuss outstanding wages diligence items.	0.50
10/30/19	RDS	Preparation for business plan diligence call and review of J. Lowne questions / responses	0.40
10/30/19	RDS	Call with UCC and ad hoc committee advisors Jefferies, Province and FTI Consulting, as well as PJT and Davis Polk, J. Lowne and K. Darragh (both Purdue), J. DelConte, and R. Sublett (both AlixPartners) re introduction to business plan and response to Jefferies question list	1.10
10/31/19	JD	Pre-meeting with Davis Polk, PJT, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners) prior to UCC meeting	1.00
10/31/19	JD	Initial meeting with the UCC, PJT, Davis Polk, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners)	4.10
10/31/19	JD	Correspondence with management, Wiggins and Dana and Davis Polk RE: diligence process	0.90
10/31/19	GJK	Pre-meeting with Davis Polk, PJT, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners) prior to UCC meeting	1.00
10/31/19	GJK	Initial meeting with the UCC, PJT, Davis Polk, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners)	4.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
10/31/19	LJD	Pre-meeting with Davis Polk, PJT, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners) prior to UCC meeting (partial attendance)	0.30
10/31/19	LJD	Prepare for and attend initial meeting with the UCC, PJT, Davis Polk, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners)	5.30
10/31/19	IA	Analysis of run rates by proposed OCP and retained firms in preparation for call with client and Davis Polk.	2.90
10/31/19	IA	Analysis of matters worked on and classification into tiers of proposed OCP and retained firms in preparation for call with client and Davis Polk.	2.20
11/01/19	IA	Call with management, Davis Polk, Akin Gump, Bayard, Kramer Levin, Brown Rudnick, I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion	0.80
11/01/19	IA	Call with management, Davis Polk and I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion and diligence questions	0.50
11/01/19	NAS	Provide Excel versions of underlying data for SOFA Part 2 Question 4 as requested by UCC financial advisor.	0.60
11/01/19	JD	Call with management, Davis Polk and I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion and diligence questions	0.50
11/01/19	JD	Call with management, Davis Polk, Akin Gump, Bayard, Kramer Levin, Brown Rudnick, I. Arana, and J. DelConte (both AlixPartners) re: ordinary course professional motion	0.80
11/04/19	JD	Call with D. Samikkannu, J. DelConte, G. Koch, A. DePalma (all AlixPartners), PJT Partners, and management re: R&D and pipeline diligence requests	0.50
11/04/19	JD	Review various diligence files prior to posting to the data	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		room.	
11/04/19	GJK	Call with D. Samikkannu, J. DelConte, G. Koch, A. DePalma (all AlixPartners), PJT Partners and management re: R&D and pipeline diligence requests	0.50
11/04/19	MH	Confirm status of all UCC requests.	0.90
11/04/19	MH	Prepare summary of additional Critical Vendors requested by UCC.	0.90
11/04/19	MH	Research coincidental names at the request of the UCC.	0.30
11/04/19	MH	Update UCC on questions regarding Schedules.	0.60
11/04/19	DS	Call with D. Samikkannu, J. DelConte, G. Koch, A. DePalma (all AlixPartners), PJT Partners and management re: R&D and pipeline diligence requests	0.50
11/04/19	ADD	Call with D. Samikkannu, J. DelConte, G. Koch, A. DePalma (all AlixPartners), PJT Partners and management re: R&D and pipeline diligence requests	0.50
11/05/19	DS	Call with Province re: customer report, cash reporting, and wages diligence items	0.20
11/05/19	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), and K. Kneuchtel (FTI) re: customer and wages diligence requests	0.30
11/05/19	MH	Prepare for call with UCC including research on possible large critical vendor payments.	0.70
11/05/19	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and M. Atkinson (Province) re: customer report, cash reporting, and wages diligence items	0.20
11/05/19	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and K. Kneuchtel (FTI) re: customer and wages diligence requests	0.30
11/06/19	IA	Conversation with FTI, Davis Polk, management, I. Arana, and J. DelConte (both AlixPartners) re: open wage motion	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		questions	
11/06/19	JD	Conversation with FTI, Davis Polk, management, I. Arana, and J. DelConte (both AlixPartners) re: open wage motion questions	1.00
11/06/19	JD	Call with FTI re: case update	0.30
11/08/19	JD	Catch up with FTI re: open diligence items	0.30
11/08/19	IA	Follow up on access permissions and user groups for project Windsor data room	1.20
11/09/19	JD	Call with Province, Akin Gump, Willis Towers Watson and Davis Polk re: WTW comp analysis	0.60
11/11/19	NAS	Create list of all payments made by Purdue to law firms for employee indemnification as requested by advisors to Unsecured Creditors Committee.	1.00
11/11/19	MH	Prepare for meeting with UCC professionals to review critical vendor status.	1.00
11/12/19	MH	Gather additional details on large clinical trial vendors to review with UCC professionals.	0.40
11/12/19	MH	Contact ad hoc professionals to review large clinical trial vendors for critical vendor status.	0.60
11/12/19	MH	Call with ad hoc professionals to review critical vendor status.	0.50
11/12/19	NAS	Review of available Purdue employee indemnification data to determine applicable items to provide to Unsecured Creditors Committee, as requested.	0.20
11/12/19	IA	Follow up on access and troubleshooting assistance for user groups for data room.	2.60
11/13/19	MH	Clarify process expectations with UCC professionals regarding critical vendor administration.	0.40
11/13/19	RDS	Call with advisors from Jefferies, Providence and PJT re EY relationship manager and various other EY partners on	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		the Mundi accounts / entities	
11/13/19	RDS	Discussion with J. Lowne, D. Darrah (both Purdue), R. Schnitzler (PJT) re next steps on business plan and diligence follow up items for committee	0.60
11/14/19	RDS	Partial participation in a conference call with S. Jameison (Mundipharma), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to discuss reporting structure and consolidation of Mundipharma entities.	1.50
11/14/19	ADD	IMS data call with management, D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners)	0.30
11/14/19	JD	IMS data call with management, D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners)	0.30
11/14/19	DS	IMS data call with management, D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners)	0.30
11/14/19	MH	Send data requests to support the October MOR.	0.40
11/15/19	MH	Attend call with UCC professionals to review critical vendor status.	0.50
11/15/19	MH	Prepare for call with UCC professionals on critical vendor status.	0.80
11/15/19	JD	Review latest diligence trackers from the various parties and draft diligence responses re: open items.	1.90
11/15/19	JD	Prepare for and participate in a call with FTI, Province, PJT Partners and management re: COGS/Manufacturing diligence	0.70
11/15/19	JD	Call with Davis Polk, Kramer Levin, Akin, Province, FTI, PJT, J. DelConte, and R. Sublett (both AlixPartners) re: Patents and LOE assumptions	0.80
11/15/19	RDS	Call with Davis Polk, Kramer Levin, Akin, Province, FTI, PJT, J. DelConte, and R. Sublett (both AlixPartners) re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Patents and LOE assumptions	
11/15/19	RDS	Project Windsor NC / COGS diligence call with PJT, AlixPartners, FTI, Jefferies, and Province advisors	0.50
11/18/19	RDS	Prepare for and participate in a call with management, PJT, Jefferies, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes business plan	1.60
11/18/19	RDS	Call with management, H. Ku, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio investment thesis.	0.30
11/18/19	RDS	Call with D. Fogel, R. Hamberlin, W. DiNicola (Rhodes) and advisors (PJT, Province, FTI, Jefferies) re Generics / Rhodes business	0.60
11/18/19	ADD	Meeting with J. DelConte, A.DePalma (both AlixPartners), and Controller re: FTI's business plan diligence request	0.70
11/18/19	JD	Prepare for and participate in a call with management, PJT, Jefferies, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes business plan	1.60
11/18/19	JD	Meeting with J. DelConte, A.DePalma (both AlixPartners), and Controller re: FTI's business plan diligence request	0.70
11/18/19	JD	Review OTC business plan materials in advance of OTC meeting with committee.	0.60
11/18/19	JD	Meeting with management, PJT, Jefferies, FTI and Province re: OTC Business	1.90
11/18/19	JD	Call with management, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio investment thesis.	0.30
11/18/19	MH	Prepare accounts payable release list.	1.20
11/18/19	MH	Review revised trade agreement language for large clinical trial vendor to ensure compliance with UCC expectations.	0.70
11/19/19	MH	Research payment history for critical vendor to resolve UCC objection to language in the trade agreement.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
11/19/19	MH	Prepare answers to vendor questions submitted by UCC professionals.	1.10
11/19/19	JD	Call with management, PJT Partners, Jefferies, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: R&D and Medical Affairs business plan.	1.60
11/19/19	RDS	Call with management, PJT Partners, Jefferies, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: R&D and Medical Affairs business plan.	1.60
11/20/19	JD	Meeting with management, PJT Partners, Jefferies, FTI and Province re: Branded P&L	1.60
11/20/19	JD	Correspondence and discussions with management, Davis Polk and PJT Partners re: sharing a UCC presentation with the AHC	0.80
11/25/19	JD	Call with Province re: wage negotiations.	0.30
11/25/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue Associate GC and DPW Litigation team re: material contracts production for due diligence requests	0.60
11/25/19	JD	Call with Province re: wage motion negotiation	0.20
11/25/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue Associate GC and DPW Litigation team re: material contracts production for due diligence requests	0.60
11/26/19	JD	Correspondence with Akin, Davis Polk and Province RE: LTRP summary file.	0.80
11/26/19	JD	Follow up call with PJT Partners, Province, FTI, Jefferies and management re: business plan follow up questions.	0.90
11/27/19	JD	Review previous correspondence with the PBGC and review materials provided to PBGC to date and materials prepared.	1.10
11/27/19	JD	Conference call with management, Davis Polk and PJT Partners re: PBGC questions.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
11/27/19	MH	Create new critical vendors status report for sharing with creditor professionals.	1.50
12/03/19	IA	Correspondence with management on DOJ requests related to current employee roster.	0.40
12/03/19	IA	Reconcile current employee roster with files provided through diligence process to committees	1.80
12/03/19	IA	Draft summary of current employee roster to be provided to DOJ.	0.90
12/05/19	NAS	Summary of C. Landau (Purdue) compensation data per request from State of Massachusetts via M. Huebner (Davis Polk).	1.40
12/09/19	JD	Review materials pull together to answer open questions re: CEO comp and correspondence with Davis Polk re: same.	0.80
12/10/19	JD	Correspondence and discussions with Davis Polk, PJT Partners and FTI re: confidentiality designation and FTI report to be shared with the AHC members and review request list of materials to be shared from FTI.	1.30
12/10/19	JD	Call with Davis Polk re: open diligence questions and process.	0.50
12/11/19	ADD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue and UCC/AHC Advisors re. Business Plan Questions	1.10
12/11/19	JD	Call with J. DelConte, A. DePalma (both AlixPartners), Purdue and UCC/AHC Advisors re. Business Plan Questions	1.10
12/11/19	JD	Call with management, PJT Partners and Davis Polk re: information sharing with the AHC members.	0.80
12/12/19	JD	Call with Davis Polk and management re: PBGC information request response.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
12/12/19	JD	Participate in an update call with PJT Partners, Davis Polk, management, Dechert, Skadden Arps and various shareholders and their representatives re: update call.	2.10
12/12/19	JD	Review open diligence questions. Correspondence with UCC advisors re: same.	0.60
12/12/19	NAS	Build category breakdown of payments to C. Landau (Purdue) over 90 days and 270 days prior to filing as requested by interested parties.	0.70
12/13/19	NAS	Build detailed summary of compensation received by C. Landau (Purdue) in year prior to bankruptcy filing as requested by counsel to UCC (Pillsbury).	0.80
12/13/19	NAS	Request insider payment data covering January 2018 through September 2018 from Purdue in order to respond to C. Landau (Purdue) compensation questions posed by counsel to UCC (Pillsbury).	0.60
12/15/19	NAS	Consolidate and build summary of C. Landau (Purdue) compensation data covering January 2018 through September 2018 received to date as requested by counsel to UCC (Pillsbury).	1.20
12/16/19	NAS	Build summary of pre-SOFA period payments to insiders as requested by advisors to UCC.	0.40
12/17/19	IA	Meeting with K. Tirabassi, K. Knechtel (both FTI), J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss outstanding questions re: Cash Forecast and Cash Actuals reports	0.70
12/17/19	JD	Meeting with K. Tirabassi, K. Knechtel (both FTI), J. DelConte, I. Arana, and S. Lemack (all AlixPartners) to discuss outstanding questions re: Cash Forecast and Cash Actuals reports	0.70
12/17/19	NAS	Build summaries of compensation for C. Landau (Purdue) by year paid and year earned for conversations with	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		advisors to UCC.	
12/17/19	MH	Prepare response to committee questions on certain 503(b)(9) payments.	0.70
12/17/19	SKL	Meeting with K. Tirabassi, K. Knechtel (both FTI), I. Arana, S. Lemack, and J. DelConte (all AlixPartners) to discuss outstanding questions re: Cash Forecast and Cash Actuals reports	0.70
12/18/19	MH	Prepare 503(b)(9) report for committee with specific invoice support.	0.50
12/18/19	MH	Prepare package of information to support a trade agreement with a large REMS consortium provider.	0.60
12/18/19	IA	Conference call with management, Province and I. Arana (AlixPartners) re: IT integration plan	0.70
12/18/19	JD	Conference call with management, Province and I. Arana (AlixPartners) re: IT integration plan	0.70
12/19/19	IA	Review of diligence items shared directly with committees to be posted to the data room.	0.80
12/20/19	MH	Research contracts for large REMS vendor to submit to the UCC professionals.	0.60
12/23/19	NAS	Revise detailed summary of C. Landau's (Purdue) compensation from 2018 through filing as requested by advisors to UCC.	0.90
12/30/19	JD	Prepare for and participate in a call with Province, Jefferies, FTI and PJT Partners re: BD opportunity and Purdue Canada transaction overviews.	0.60
01/02/20	JD	Correspondence with the committee advisors re: outstanding diligence questions and timing and subject of diligence call with management.	0.60
01/02/20	JD	Correspondence with management re: professional fee forecast diligence questions from the committee advisors.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
01/02/20	JD	Correspondence with management re: approval process for potential business opportunities.	0.40
01/03/20	JD	Call with R. Schnitzler (PJT), M. Atkinson (Province), K. Knechtel (FTI), L. Szlezinger (Jefferies), J. DelConte, R. Sublett and I. Arana (all AlixPartners) re: potential business opportunities.	0.80
01/03/20	JD	Call with K. Knechtel (FTI) re: follow up to previous call.	0.20
01/03/20	JD	Review list of open diligence questions, draft materials and responses to diligence questions and correspondence with committees re: same.	1.30
01/03/20	JD	Review existing materials re: charitable contributions per committee diligence request and review SOFA/SOAL charitable contribution information.	0.80
01/03/20	IA	Call with R. Schnitzler (PJT), M. Atkinson (Province), K. Knechtel (FTI), L. Szlezinger (Jefferies), J. DelConte, R. Sublett and I. Arana (all AlixPartners) re: potential business opportunities.	0.80
01/03/20	RDS	Call with R. Schnitzler (PJT), M. Atkinson (Province), K. Knechtel (FTI), L. Szlezinger (Jefferies), J. DelConte, R. Sublett and I. Arana (all AlixPartners) re: potential business opportunities.	0.80
01/06/20	DS	Call with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), and K. Knechtel (FTI) re: information requests and business plan timeline	0.30
01/06/20	IA	Call with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), and K. Knechtel (FTI) re: information requests and business plan timeline	0.30
01/06/20	JD	Call with D. Samikkannu, J. DelConte, I. Arana (all AlixPartners), and K. Knechtel (FTI) re: information requests and business plan timeline	0.30
01/07/20	JD	Correspondence with management re: charitable	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		contribution diligence questions.	
01/13/20	NAS	Consolidate and provide additional detail regarding C. Landau's (Purdue) compensation as requested by creditors.	1.10
01/14/20	NAS	Review summary of additional C. Landau (Purdue) compensation data requested by creditors.	0.30
01/15/20	MH	Attend call with counsel to present equity financial data to interested parties.	3.60
01/16/20	ADD	Organize and compile documentation for approval by Purdue AGC and Davis Polk	2.20
01/16/20	ADD	Research and respond to question from Davis Polk regarding interested party request.	0.70
01/17/20	ADD	Review complaints requested by the UCC for marginalia and other markings.	2.80
01/18/20	ADD	Review complaints requested by the UCC for marginalia and other markings.	2.80
01/20/20	ADD	Organize and compile documentation for approval by Purdue AGC and Davis Polk	2.30
01/20/20	JD	Review diligence follow up questions from Province and review latest status of requests.	0.60
01/20/20	JD	Correspondence with committee advisors re: OSR lease extension.	0.80
01/21/20	JD	Conversation with R. Aleali (Purdue), C. McMillian (Davis Polk), and T. Melvin (PJT) re: information sharing with the committee re: HRT.	0.90
01/21/20	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), M. Atkinson (Province), and K. Knechtel (FTI) re: OSF proposed lease.	0.60
01/21/20	ADD	Review of documents in data room for competitively sensitive and confidential information.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
01/21/20	ADD	Add Houlihan Lokey representatives to the data room.	0.30
01/21/20	ADD	Identify and prepare list of documents to be shared via the view only platform.	2.90
01/21/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.50
01/21/20	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), M. Atkinson (Province), and K. Knechtel (FTI) re: OSF proposed lease.	0.60
01/22/20	ADD	Review of documents in data room for competitively sensitive and confidential information.	2.90
01/22/20	ADD	Review of files modified since previous Davis Polk data room download.	2.40
01/22/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.60
01/22/20	NAS	Provide additional detail regarding C. Landau's (Purdue) to counsel in advance of 1/24 hearing.	1.90
01/23/20	JD	Review materials to prepare for call and participate in a call with D. Samikkannu, J. DelConte (both AlixPartners), T. Graulich (Davis Polk), M. Atkinson (Province), and S. Brauner (Akin Gump) re: proposed lease extension.	1.00
01/23/20	ADD	Organize and index files previously provided to Committee advisors in anticipation of signed protective order.	1.30
01/23/20	ADD	Call with C. McMillian and others (all Davis Polk) to discuss post-protective order diligence process.	0.60
01/23/20	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), T. Graulich (Davis Polk), M. Atkinson (Province), and S. Brauner (Akin Gump) re: proposed lease extension.	0.50
01/24/20	ADD	Organize and index files previously provided to Committee advisors in anticipation of signed protective	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		order.	
01/24/20	JD	Review status update on outstanding committee diligence requests.	0.60
01/27/20	IA	Meeting to discuss review and redaction process per Protective Order with D. Samikkannu, I. Arana, A. DePalma, and S. Lemack (all AlixPartners)	1.50
01/27/20	IA	Follow up on approvals for weekly sales by product reports for Rhodes and drafting communications to committees on updated reports.	1.30
01/27/20	IA	Review of debtor bank account data submitted by TXP in response to UCC request for current and closed debtor bank accounts going back to 2008.	1.20
01/27/20	IA	Follow up on approvals for report submitted by TXP showing debtor bank accounts in response to UCC request for current and closed debtor bank accounts going back to 2008.	0.70
01/27/20	IA	Follow up on FTI request for information on employees holding insider titles, going back to 2000.	0.30
01/27/20	SKL	Meeting to discuss review and redaction process per Protective Order with D. Samikkannu, I. Arana, A. DePalma, and S. Lemack (all AlixPartners).	1.50
01/27/20	SKL	Call with D. Samikkannu, A. DePalma, S. Lemack (all AlixPartners), and C. McMillian (Davis Polk) re: redaction process for Protective Order.	0.30
01/27/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.60
01/27/20	ADD	Meeting to discuss review and redaction process per Protective Order with D. Samikkannu, I. Arana, A. DePalma, and S. Lemack (all AlixPartners).	1.50
01/27/20	ADD	Call with D. Samikkannu, A. DePalma, S. Lemack (all AlixPartners) and C. McMillian (Davis Polk) re: redaction	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		process for Protective Order	
01/27/20	ADD	Research and respond to UCC requests for tax documentation.	1.80
01/27/20	ADD	Research entity history in response to UCC diligence request.	0.80
01/27/20	ADD	Review and redact of files for competitively sensitive and third-party confidential information.	1.70
01/27/20	DS	Call with D. Samikkannu, A. DePalma, S. Lemack (all AlixPartners), and C. McMillian (Davis Polk) re: redaction process for Protective Order	0.30
01/28/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.50
01/28/20	ADD	Update data room permissions to remove access to outside parties due to signed protective order.	0.70
01/28/20	ADD	Review and redact of files for competitively sensitive and third-party confidential information.	2.90
01/28/20	ADD	Review of file permissions for documents being processed by Davis Polk's eDiscovery team.	0.80
01/29/20	ADD	Review and compile files for AlixPartners eDiscovery team to upload into relativity.	2.60
01/29/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	1.20
01/29/20	ADD	Update summary of committee advisors at the request of counsel.	0.40
01/29/20	ADD	Review of insurance policies uploaded to the data room.	0.90
01/29/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.80
01/29/20	ADD	Review of file permissions for documents being processed by Davis Polk's eDiscovery team.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
01/29/20	ADD	Review and redact of files for competitively sensitive and third-party confidential information.	1.50
01/30/20	ADD	Review and redact files for competitively sensitive and third-party confidential information.	3.20
01/30/20	ADD	Manage data room access and add individuals and groups at the request of counsel.	0.80
01/30/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.50
01/30/20	ADD	Research IQVIA database to provide a summary to counsel.	0.60
01/30/20	JD	Prepare for and participate in a call with J. Turner (PJT), M. Diaz (FTI), and H. Schenk (Houlihan) re: meeting on Monday.	0.80
01/30/20	JD	Catch up call with M. Atkinson (Province) re: outstanding diligence.	0.20
01/31/20	JD	Call with PJT, Davis Polk, management, Akin Gump, Jefferies, Province, Kramer Levin, Brown Rudnick, Houlihan, FTI, J. DelConte, and I. Arana (both AlixPartners) re: auto injector agreement.	1.40
01/31/20	JD	Prepare for and participate in call with T. Pajolek (CBRE), J. Lowne (Purdue) and K. Knechtel (FTI) re: OSR lease.	0.60
01/31/20	IA	Call with PJT, Davis Polk, management, Akin Gump, Jefferies, Province, Kramer Levin, Brown Rudnick, Houlihan, FTI, J. DelConte, and I. Arana (both AlixPartners) re: auto injector agreement.	1.40
01/31/20	ADD	Review and redaction of files for competitively sensitive and third-party confidential information.	2.60
01/31/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bate stamping	2.40
01/31/20	ADD	Prepare for redaction of business development data call	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		with Purdue business development contact.	
		Total	312.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	0.70	440.00	308.00
Andrew D DePalma	18.10	480.00	8,688.00
Nate A Simon	11.20	480.00	5,376.00
Andrew D DePalma	66.40	515.00	34,196.00
Sam K Lemack	1.80	515.00	927.00
Nate A Simon	3.30	515.00	1,699.50
David Samikkannu	13.60	615.00	8,364.00
Isabel Arana de Uriarte	31.10	615.00	19,126.50
David Samikkannu	1.70	690.00	1,173.00
Isabel Arana de Uriarte	7.50	690.00	5,175.00
Ryan D Sublett	11.60	725.00	8,410.00
Ryan D Sublett	0.80	735.00	588.00
Gabe J Koch	5.60	830.00	4,648.00
Michael Hartley	25.30	830.00	20,999.00
Michael Hartley	3.60	840.00	3,024.00
Jesse DelConte	91.70	945.00	86,656.50
Jesse DelConte	9.00	950.00	12,350.00
Lisa Donahue	5.60	1,165.00	6,524.00
Total Hours & Fees	312.60		228,232.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/16/19	HK	Perform docket review for First Day relief analysis	0.70
09/16/19	HK	Review bank cash balances to update draft Schedules of Assets & Liabilities report.	0.70
09/16/19	HK	Research diligence requests for US Trustee regarding the Wages Motion.	1.70
09/16/19	HK	Research diligence requests for US Trustee regarding the Taxes Motion.	1.50
09/16/19	HK	Review Debtors' deposits and prepayments data for Schedules of Assets & Liabilities report.	1.20
09/16/19	HK	Review Debtors' fixed assets schedule for Schedule of Assets & Liabilities report.	1.30
09/16/19	SKL	Review the latest updates re: SOFA/Schedule litigation items and updated the SOFA/Schedule database accordingly.	2.40
09/16/19	SKL	Begin finalizing review of the 7/31 trial balance for the PPLP and Rhodes entities re: SOFA/Schedules.	2.10
09/17/19	SKL	Review the latest updates to the SOFA/Schedules database and put together updated list of outstanding items.	2.30
09/17/19	SKL	Review functionality of AP cutoff and processes and procedures.	0.80
09/17/19	SKL	Review the latest AP release list for pre/post-petition split.	0.90
09/17/19	SKL	Continue to update the SOFA/Schedules database with the latest analysis and feedback provided by K. Darragh (Purdue) re: 7/31 trial balance.	2.70
09/17/19	SKL	Finalize analysis of the fixed asset balances for PPLP entities re: SOFA/Schedule reporting.	2.30
09/17/19	HK	Gather data from the Debtors for the Schedules of Assets & Liabilities.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/17/19	HK	Gather data for the Debtors' Statement of Financial Affairs.	1.80
09/17/19	HK	Research follow-up requests from the U.S. Trustee's office on the Wages Motion.	0.40
09/17/19	HK	Research follow-up requests from the U.S. Trustee's office on the Taxes Motion.	0.30
09/17/19	HK	Begin reviewing Debtors' contracts database to develop Schedule G in the Schedules of Assets and Liabilities report.	2.10
09/17/19	HK	Analyze Debtors' intercompany liabilities for Chapter 11 reporting support.	2.70
09/17/19	HK	Draft Debtors' ownership and organizational structure for Chapter 11 reporting support.	0.90
09/18/19	HK	Prepare for and attend meeting with J. Lowne, E. Ruiz, K. Darragh (all Purdue), M. Hartley, H. Ku, and S. Lemack (all AlixPartners) for SOFAs and Schedules preparation.	0.60
09/18/19	HK	Review intercompany balances for Schedules of Assets & Liabilities.	0.60
09/18/19	SKL	Update the accounts payable section of the SOFA/Schedules database to include latest debtor to non-debtor intercompany receivable balances.	2.00
09/18/19	SKL	Put together updated action item list and requested updated financial information from the company re: SOFA/Schedules.	1.40
09/18/19	SKL	Prepare for and participated in SOFA/Schedule discussion with K. Darragh (Purdue) re: intercompany related assets.	0.70
09/18/19	SKL	Continue to review and make updates to the intercompany due to/from section of the SOFA/Schedules.	2.50
09/18/19	SKL	Prepare for and attend meeting with J. Lowne, E. Ruiz, K.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Darragh (all Purdue), M. Hartley, H. Ku, and S. Lemack (all AlixPartners) for SOFAs and Schedules preparation.	
09/18/19	SKL	Prepare for and participate in 8/31 trial balance meeting with K. Darragh (Purdue).	0.40
09/18/19	MH	Meeting with J. Lowne, E. Ruiz, K. Darragh (all Purdue), M. Hartley, H. Ku, and S. Lemack (all AlixPartners) for SOFAs and Schedules preparation.	0.60
09/18/19	MH	Review methodology for listing related party receivables.	0.40
09/18/19	MH	Attend meeting with the CFO to review the work plan to complete the Schedules.	0.60
09/18/19	NAS	SOFA Part 2 Question 1 preparation - internal coordination via email regarding as-of date for information and requesting necessary data from Purdue.	0.60
09/18/19	NAS	Consolidate and providing list of non-opioid litigation for incorporation in SOFAs and Schedules	0.10
09/18/19	JD	Correspondence with H. Ku (AlixPartners) and conversation with CFO RE: SOFA/SOAL go forward workplan.	0.70
09/18/19	JD	Prepare summary of first day hearing RE: changes to relief requested in the first day hearings	0.80
09/19/19	MH	Review proposed addition to Critical Vendor approved list.	0.80
09/19/19	MH	Attend call with Avrio management to discuss unique Chapter 11 issues with their vendor base.	0.90
09/19/19	MH	Research prepetition vs post-petition determination for marketing and advertising spend.	0.50
09/19/19	MH	Discuss with Plant management a vendor demanding prepaid terms to determine the best course of action.	0.30
09/19/19	MH	Prepare a release file for accounts payable.	1.20
09/19/19	MH	Update all approved vendors in the release files.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/19/19	MH	Update the CFO and Plant Manager on issues with a municipal utility provider.	0.40
09/19/19	MH	Research accounts payable anomalies to ensure compliance.	0.50
09/19/19	SKL	Finalize consolidation and review of the updated trial balance information re: SOFA/Schedules.	1.40
09/19/19	SKL	Begin updating the latest SOFA/Schedule workplan with the latest updates, notes, and outstanding items.	0.90
09/19/19	SKL	Begin updating the A-B input template for the SOFA/Schedule database with the latest updates re: 8/31 trial balance for SOFA/Schedules.	2.10
09/20/19	SKL	Put together updated action item list for the company re: SOFA/Schedules and reviewed the A/R Aging file for necessary updates.	2.30
09/20/19	SKL	Continue to compare and analyze the 8/31 trial balance with the 7/31 trial balance for notable variances.	2.60
09/20/19	SKL	Continue to review the 8/31 trial balance and began updating the SOFA/Schedule database with changes to the asset balances.	2.70
09/20/19	SKL	Analyze the latest Rhodes Entity trial balance and put together updated inquiry re: accumulated depreciation across fixed assets for SOFA/Schedule reporting.	1.10
09/20/19	JD	Discussion with D. Consola (DPW) RE: SOFA/SOALS. Research related to same.	0.70
09/20/19	JD	Review materials RE: investments question from the UST.	0.30
09/20/19	NAS	Consolidate and analyze insider payroll data over 1 year prior to filing per SOFA Part 2 Question 4	1.40
09/20/19	NAS	Consolidate and analyze insider T&E reimbursement data over past year for SOFA Part 2 Question 4	0.30
09/20/19	ADD	Review new SOFA and Schedules plan.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/22/19	ADD	Update SOFA and Schedules templates	1.20
09/23/19	ADD	Prepare data for inclusion in SOFA and Schedules.	1.80
09/23/19	ADD	Compile files for inclusion in data room for FTI due diligence request.	1.80
09/23/19	NAS	Find vendor codes relevant to insiders, search vendor codes in SAP, and consolidate activity from past 1 year in accounts payable for SOFA Part 2 Question 4.	0.80
09/23/19	NAS	Coordinate with T. Gilroy (TXP Services) and H. Benson (Purdue) regarding T&E and benefits payments for SOFA Part 2 Question 4	0.70
09/23/19	NAS	Review list of independent affiliated companies and transfer of value analysis to determine insider status for SOFA Part 2 Question 4.	0.70
09/23/19	JAD	Review current Schedule A/B progress to validate data prior to upload and identify missing information needed from client.	2.30
09/23/19	SKL	Review the latest trial balance information provided for the Rhodes Tech entities and consolidated with PPLP.	1.40
09/23/19	SKL	Prepare list of action items outstanding for the Rhodes Tech entities re: SOFA/Schedules.	1.60
09/23/19	MH	Respond to project comments from CFO on preparation of Schedules.	0.70
09/24/19	MH	Review methodology on insider payment data gathering.	0.40
09/24/19	MH	Meeting with M. Hartley and S. Lemack (both AlixPartners) to review status of Schedules preparation.	0.40
09/24/19	SKL	Meeting with M. Hartley and S. Lemack (both AlixPartners) to review status of Schedules preparation.	0.40
09/24/19	SKL	Continue to make updates to the SOFA/Schedule input table and database re: litigation matters.	2.40
09/24/19	SKL	Prepare for and participate in litigation meeting with W.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Chang to discuss outstanding liabilities.	
09/24/19	SKL	Prepare updates to the SOFA/Schedule status report per J. Lowne request.	1.90
09/24/19	SKL	Review the latest Rhodes Tech trial balance information and prepared updates to the SOFA/Schedule input template.	2.20
09/24/19	SKL	Prepare updated list of outstanding items to circulate to the Rhodes Tech and PPLP teams accordingly.	1.10
09/24/19	SKL	Continue to make updates to the SOFA/Schedule database re: debtor assets.	1.20
09/24/19	JAD	Comply and format data to be used in SOFA part 2.	2.90
09/24/19	NAS	Analyze intercompany account activity to determine best approach towards creating list of all intercompany cash disbursements.	0.60
09/24/19	NAS	Plan regarding remaining data sources needed to complete SOFA Part 2 Question 4.	0.90
09/24/19	NAS	Analyze benefits paid by Purdue for inclusion in SOFA Part 2 Question 4.	0.80
09/24/19	NAS	Draft detailed workplan and diligence list to ensure comprehensiveness of responses to SOFA Part 2 Question 4.	1.10
09/24/19	NAS	Consolidate lists of insiders across those designated by company, Sackler family members, Board members, and affiliated entities for SOFA Part 2 Question 4.	0.30
09/24/19	NAS	Consolidate list of all Board members for the past year and searching in SAP for any payments from Purdue Pharma Inc. to Board members for purposes of SOFA Part 2 Question 4.	1.20
09/24/19	NAS	Update insider project management workplan	0.40
09/24/19	NAS	Draft questions for restructuring counsel regarding which	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Purdue employees and Directors should be included in list of payments to insiders over the past year (SOFA Part 2 Question 4).	
09/24/19	NAS	Discussion with K. Darragh (Purdue) regarding timing and paying entities of T&E reimbursements.	0.20
09/24/19	ADD	Prepare data for inclusion in SOFA and Schedules.	2.10
09/24/19	ADD	Update data room organization for new files and add users per client request.	0.40
09/25/19	ADD	Meeting with client tax team to discuss accrued tax liabilities for SOFAa and Schedules.	0.70
09/25/19	ADD	Compile data for counsel information request.	1.70
09/25/19	REO	Discussion with N. Simon and R. Ochoa (both AlixPartners) re: Intercompany payments for inclusion in SOFA.	0.20
09/25/19	NAS	Research list of individuals who qualify as insiders but have resigned or have been terminated since 9/15/18 to be included in SOFA.	0.70
09/25/19	NAS	Analyze all payments to individuals serving on Purdue Pharma Inc.'s Board of Directors for purposes of SOFA.	0.30
09/25/19	NAS	Respond to question from Director of Finance and Accounting (TXP Services) regarding data requirements for SOFA.	0.20
09/25/19	NAS	Research cash-settled intercompany payments between independent affiliated companies and Purdue for inclusion in SOFA.	0.90
09/25/19	NAS	Research and email discussion with Controller (Purdue) regarding exact timing and paying entity of T&E reimbursements for purposes of SOFA.	0.50
09/25/19	NAS	Meeting with M. Hartley, N. Simon (both AlixPartners) and counsel to determine list of insiders for Schedules.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/25/19	NAS	Attended follow-up discussion with N. Simon and M. Hartley (both AlixPartners) to change work plan for insider payment report.	0.20
09/25/19	NAS	Call with R. Kennedy (TXP Services) regarding data requirements for intercompany payments over year prior to filing for inclusion in SOFA.	0.50
09/25/19	NAS	Discussion with N. Simon and R. Ochoa (both AlixPartners) re: Intercompany payments for inclusion in SOFA.	0.20
09/25/19	JAD	Comply and format data to be used in SOFA part 2.	2.90
09/25/19	JAD	Comply and format data to be used in Schedule AB Part 4.	1.10
09/25/19	JAD	Comply and format data to be used in Schedule AB Part 2.	1.70
09/25/19	JAD	Comply and format data to be used in Schedule AB Part 5.	1.60
09/25/19	SKL	Meeting with S. Lemack and M. Hartley (both AlixPartners) to update the status and reorganize the work.	0.80
09/25/19	SKL	Prepare updated status report re: SOFA/Schedule reporting.	2.30
09/25/19	SKL	Prepare updated SOFA/Schedule input file re: debtor assets.	2.20
09/25/19	MH	Meeting with S. Lemack and M. Hartley (both AlixPartners) to update the status and reorganize the work.	0.80
09/25/19	MH	Meeting with M. Hartley, N. Simon (both AlixPartners) and counsel to determine list of insiders for Schedules.	0.30
09/25/19	MH	Attended follow-up discussion with N. Simon and M. Hartley (both AlixPartners) to change work plan for	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		insider payment report.	
09/25/19	MH	Prepare for Schedules reviews with staff members.	0.70
09/26/19	SKL	Begin reviewing and validating the latest PPLP asset updates provided by K. Darragh re: SOFA/Schedules.	2.70
09/26/19	SKL	Begin reviewing and validating the latest Rhodes Pharma asset updates provided by R. Haberlin re: SOFA/Schedules.	2.40
09/26/19	SKL	Begin updating the fixed asset section of the SOFA/Schedule input template with the latest information provided by K. Darragh.	2.10
09/26/19	SKL	Begin updating the SOFA/Schedule input template with the latest fixed asset information provided from the 8/31 trial balance and from R. Haberlin.	2.00
09/26/19	JAD	Comply and format data to be used in Schedule AB Part 10.	2.40
09/26/19	JAD	Comply and format data to be used in SOFA part 2.	1.40
09/26/19	JAD	Meeting with W. DiNicola (Rhodes Tech) to discuss presentation of A/R in Schedule AB.	0.50
09/26/19	NAS	Correspondence with TXP Services Accounting Department regarding Directors' fees for purposes of SOFA	0.10
09/27/19	JAD	Compile and format data to be used in Schedule AB Part 10.	2.70
09/27/19	JAD	Compile and format data to be used in Schedule AB Part 5.	2.50
09/27/19	SKL	Begin reviewing and validating the latest Rhodes Tech asset updates provided by W. DiNicola re: SOFA/Schedules.	2.40
09/27/19	SKL	Prepare for and participate in Rhodes Tech trial balance discussion with W. DiNicola (Purdue).	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/27/19	SKL	Begin updating the A/R balances for all entities re: SOFA/Schedules.	2.30
09/27/19	SKL	Update the SOFA/Schedule input template with the Other Receivables piece of the A/R category.	1.30
09/27/19	SKL	Put together updated status report re: SOFA/Schedules and reviewed outstanding items.	1.50
09/27/19	MH	Review status of Schedule preparation.	0.60
09/27/19	MH	Create new tracker for Schedule preparation.	1.40
09/27/19	ADD	Review and updated SOFAs and Schedules status.	1.70
09/30/19	ADD	Review outstanding SOFA and Schedules items and submitted follow up requests to the client.	1.50
09/30/19	MH	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, and H. Ku (all AlixPartners) regarding SOFA and Schedules follow-up items from earlier discussion with J. Lowne (Purdue)	0.40
09/30/19	HK	Review vehicle and equipment lease data for Schedule of Assets & Liabilities.	0.80
09/30/19	HK	Review draft inputs to Statements of Financial Affairs reports.	1.40
09/30/19	HK	Review company data for supplemental Wages Declaration.	2.40
09/30/19	HK	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, and H. Ku (all AlixPartners) regarding SOFA and Schedules follow-up items from earlier discussion with J. Lowne (Purdue)	0.40
09/30/19	HK	Prepare for and attend SOFAs & Schedules discussion with J. Lowne, K. Darragh (both Purdue), H. Ku, and S. Lemack (all AlixPartners).	0.50
09/30/19	HK	Review intercompany contracts repository for Schedules of Assets and Liabilities report.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/30/19	HK	Review contracts database to update Schedule G to Schedule of Assets & Liabilities.	0.20
09/30/19	SKL	Prepare for and attend SOFAs & Schedules discussion with J. Lowne, K. Darragh (both Purdue), M. Hartley, H. Ku, and S. Lemack (all AlixPartners).	1.00
09/30/19	SKL	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, and H. Ku (all AlixPartners) regarding SOFA and Schedules follow-up items from earlier discussion with J. Lowne (Purdue)	0.40
09/30/19	SKL	Prepare updated SOFA/Schedule status report per feedback from J. Lowne meeting and circulated to the team for distribution.	1.90
09/30/19	SKL	Continue to update the SOFA/Schedule input file with the latest litigation information from R. Inz.	1.80
09/30/19	JAD	Compile and format data to be used in Schedule AB Part 5.	1.70
09/30/19	JAD	Compile and format data to be used in Schedule AB Part 10.	2.30
09/30/19	JAD	Review complete SOFA/Schedule workplan to determine status of data requests.	0.40
09/30/19	JAD	Compile and format data to be used in SOFA part 2.	2.70
09/30/19	JAD	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, and H. Ku (all AlixPartners) regarding SOFA and Schedules follow-up items from earlier discussion with J. Lowne (Purdue)	0.40
09/30/19	NAS	Update list of T&E payments to insiders per company guidance on debtor entity paying and payment date for purposes of SOFA Part 2 Question 4.	1.40
09/30/19	NAS	Analysis of address listings and one-off benefits for insiders for purposes of inclusion in SOFA Part 2 Question 4.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
09/30/19	NAS	Meeting with M. Hartley, N. Simon, J. Doherty, S. Lemack, and H. Ku (all AlixPartners) regarding SOFA and Schedules follow-up items from earlier discussion with J. Lowne (Purdue)	0.40
09/30/19	NAS	Incorporate revised T&E reimbursement data (both directly through payroll and through Amex) into response to SOFA Part 2 Question 4.	1.20
09/30/19	NAS	Review list of former employees who left over past year to determine if any qualify as insiders for inclusion in SOFA Part 2 Question 4 response.	0.70
09/30/19	NAS	Incorporate relationship to debtor for all insiders to be included in SOFA Part 2 Question 4.	0.30
09/30/19	NAS	Review of intercompany payment arrangement between TXP Services, Purdue Pharma Inc., and Purdue Pharma L.P. for A. Roncalli's (TXP Services) director fees.	0.70
09/30/19	NAS	Coordinate with restructuring counsel regarding insider/non-insider status of Purdue Pharma Inc. Board members for purposes of SOFA Part 2 Question 4.	0.30
09/30/19	JD	Review materials to provide to the UST.	0.70
09/30/19	JD	Review SOFA/SOAL update materials	0.60
10/01/19	JD	Review materials to provide to the UST to answer various questions	0.70
10/01/19	JAD	Compile and format data to be used in Schedule AB Part 10.	0.90
10/01/19	JAD	Follow up correspondence with various Purdue/Rhodes contacts for missing SOFA/Schedules deliverables.	0.60
10/01/19	JAD	Upload figures from various supporting schedules into Schedule AB upload template.	2.10
10/01/19	JAD	Compile and format data to be used in SOFA part 2.	0.40
10/01/19	NAS	Discussion with R. Aleali (Purdue) and K. McCarthy	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		(Purdue) regarding personal liability on corporate credit cards for company insiders.	
10/01/19	NAS	Track all outstanding data requests to ensure all insider payment information has been requested for purposes of SOFA Part 2 Question 4.	0.30
10/01/19	NAS	Discussion with C. Trompetta (TXP Services) regarding one-off benefits provided to insiders for purposes of SOFA Part 2 Question 4.	0.80
10/01/19	NAS	Review Amex/Purdue master services agreement to ensure joint company/individual liability on corporate credit cards for purposes of including Amex card payments in SOFA Part 2 Question 4.	0.40
10/01/19	NAS	Add payroll, T&E reimbursement, and accounts payable history for Purdue insider who resigned in May 2019 for purposes of SOFA Part 2 Question 4.	0.80
10/01/19	NAS	Investigate addresses listed in SAP for inclusion in list of payments to insiders (SOFA Part 2 Question 4).	0.40
10/01/19	NAS	Discussion with K. Lauren (Purdue) regarding benefits received by individuals designated as insiders for purposes of SOFA Part 2 Question 4.	0.50
10/01/19	SKL	Prepare for and participate in discussion with A. Green (Purdue) re: outstanding litigation.	0.50
10/01/19	SKL	Prepare updated breakdown and outstanding items list of all litigation issues re: SOFA/Schedules.	2.60
10/01/19	SKL	Finalize updates to the SOFA/Schedule input template re: PPLP assets.	1.60
10/01/19	SKL	Finalize updates to the SOFA/Schedule input template re: Rhodes assets.	1.40
10/01/19	SKL	Meeting with M. Hartley, S. Lemack, and H. Ku (all AlixPartners) to review status of Legal-items relating to the SOFAs & Schedules.	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/01/19	SKL	Finalize updates to the SOFA/Schedule workplan re: litigation and circulated to M. Hartley (AlixPartners) for distribution.	1.70
10/01/19	HK	Analyzed uncategorized agreements for Schedule of Assets & Liabilities draft report.	0.90
10/01/19	HK	Meeting with M. Hartley, S. Lemack, and H. Ku (all AlixPartners) to review status of Legal-items relating to the SOFAs & Schedules.	0.40
10/01/19	HK	Reviewed company partners, members, directors, and officer's information for Statements of Financial Affairs report.	2.20
10/01/19	HK	Analyze active intercompany and IAC agreements for Schedule of Assets & Liabilities report.	2.00
10/01/19	HK	Analyze active confidentiality and disclosure agreements for Schedule of Assets & Liabilities report.	1.10
10/01/19	HK	Analyze active Customer and Rebate agreements for Schedule of Assets & Liabilities report.	0.70
10/01/19	HK	Analyze active service and supply agreements for Schedule of Assets & Liabilities report.	2.20
10/01/19	MH	Meeting with S. Lemack, M. Hartley, and H. Ku (all AlixPartners) to review status of Legal-items relating to the SOFAs & Schedules.	0.40
10/01/19	ADD	Review data and update SOFA and schedules.	2.00
10/01/19	ADD	Update creditor matrix.	0.70
10/02/19	ADD	Update interested parties list.	0.40
10/02/19	ADD	Review data provided for SOFAs and schedules and make necessary updates.	2.30
10/02/19	HK	Gathered information for insurance-related terms in material contracts.	2.60
10/02/19	HK	Reviewed company partners, members, directors, and	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		officer's information for Statements of Financial Affairs report.	
10/02/19	HK	Updated company partners, members, directors, and officer's information for Statements of Financial Affairs report.	2.30
10/02/19	HK	Gathered information on vehicle and equipment leases for Schedules of Assets & Liabilities.	1.80
10/02/19	HK	Updated contracts data off of Company contracts database.	1.30
10/02/19	MH	Meeting to prepare for Schedules review with General Counsel, M. Hartley, S. Lemack, H. Ku, and N. Simon (all AlixPartners).	0.40
10/02/19	SKL	Meeting to prepare for Schedules review with General Counsel, M. Hartley, S. Lemack and N. Simon (all AlixPartners).	0.40
10/02/19	SKL	Prepare updated opioid litigation tracker re: SOFA/Schedules.	2.20
10/02/19	SKL	Prepare updates to the SOFA/Schedules workplan re: latest updates to the SOFA/Schedules database and circulated updated workplan to K. Darrugh, R. Haberlin, and W. DiNicola (all Purdue).	2.30
10/02/19	SKL	Update schedule E/F re: SOFA/Schedule non-opioid litigation.	1.60
10/02/19	SKL	Prepare updates to support the previously circulated workplan per W. DiNicola (Purdue) request.	1.00
10/02/19	SKL	Finalize updates to the SOFA/Schedules database re: prepaid assets.	1.20
10/02/19	SKL	Finalize updates to the workplan re: SOFA/Schedules per K. Darrugh (Purdue) request.	1.30
10/02/19	NAS	Review report of intercompany cash payments generated by R. Kennedy (TXP Services) for inclusion in SOFA Part 2	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Question 4.	
10/02/19	NAS	Meeting to prepare for Schedules review with General Counsel, M. Hartley, S. Lemack, H. Ku, and N. Simon (all AlixPartners).	0.40
10/02/19	NAS	Prepare summary documents of payments to insiders since filing for a subset of insiders meeting with Purdue General Counsel on 10/3.	2.00
10/02/19	NAS	Update SOFA Part 2 Question 4 response to include latest debtor relationships, addresses, and additional detail on payment categories.	0.60
10/02/19	NAS	Uploading SOFA Part 2 Question 4 to model in order to generate an example report for discussion in 10/3 meeting with M. Kesselman (Purdue).	0.80
10/02/19	NAS	Follow-up training call with Purdue Local Vendor Specialists regarding critical vendor review process.	0.60
10/02/19	NAS	Analysis of other benefits received by insiders outside of payroll, T&E, and accounts payable systems.	0.90
10/02/19	NAS	Discussion with T. Gilroy (Purdue) regarding classification of amounts reported in Purdue T&E system.	0.40
10/03/19	JD	Meeting with M. Kesselman, R. Aleale (both Purdue), C. Robertson (Davis Polk), B. Folse, M. Hartley, J. DelConte, N. Simon, S. Lemack, and H. Ku (all AlixPartners) to discuss SOFAs and Schedules disclosures related to legal matters.	1.00
10/03/19	JD	Meeting with J. Lowne, C. DeStefano, K. Laurel (all Purdue), C. Robertson (Davis Polk), J. DelConte and H. Ku (all AlixPartners) to discuss proposed edits to the Wages Supplement to the Jon Lowne Declaration. (Partial attendance)	1.00
10/03/19	NAS	Provide list of descriptions of payments to insiders included in SOFA Part 2 Question 4 as requested by M.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Kesselman (Purdue).	
10/03/19	NAS	Add additional T&E data to analysis of year prior to filing for SOFA Part 2 Question 4.	0.70
10/03/19	NAS	Meeting with B. Folse, M. Hartley, A. DePalma, N. Simon and S. Lemack (all AlixPartners) to do final transition review of accounts payable process (left meeting early).	0.30
10/03/19	NAS	Prepare for meeting with M. Kesselman (Purdue) and R. Aleali (Purdue) regarding progress on SOFAs and Schedules by drafting PowerPoint slides, reviewing content, and preparing sample documents.	1.40
10/03/19	NAS	Meeting with M. Kesselman, R. Aleale (both Purdue), C. Robertson (Davis Polk), B. Folse, M. Hartley, S. Lemack, N. Simon, and H. Ku (all AlixPartners) to discuss SOFAs and Schedules disclosures related to legal matters.	1.00
10/03/19	NAS	Discussion with B. Folse, M. Hartley, and N. Simon (all AlixPartners) regarding follow-up items from earlier meeting with M. Kesselman (Purdue) regarding progress on SOFAs and Schedules.	0.20
10/03/19	NAS	Phone call with K. Laurel (Purdue) regarding one-off benefits received by Purdue insiders and documenting findings for inclusion in SOFA Part 2 Question 4.	0.70
10/03/19	NAS	Discussion with T. Gilroy (TXP Services) regarding T&E data for additional Purdue employees and Board members.	0.40
10/03/19	JAD	Compile and format data to be used in SOFA part 2; change in methodology for isolating payments made by wire.	2.50
10/03/19	JAD	Meeting with R. Kennedy (Purdue) to confirm methodology for 90-day payment reporting.	0.70
10/03/19	JAD	Training session with S. Lemack and J. Doherty (both AlixPartners) to transition responsibilities for creating the	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		90-day payment schedule (SOFA 2).	
10/03/19	JAD	Compile and format data to be used in SOFA part 2; update for methodology on cutoff criteria.	1.40
10/03/19	IA	Meeting with C. DeStefano, L. Kusinski (both Purdue), I. Arana de Uriarte, and H. Ku (both AlixPartners) to review open items to the Wages Supplement to the Jon Lowne Declaration.	2.10
10/03/19	SKL	Review latest impairment breakdown re: SOFA/Schedules from Walter DiNicola's (Purdue) email and updated the SOFA/Schedule database accordingly.	1.40
10/03/19	SKL	Prepare updated list of action items and questions to Keith Darragh (Purdue) re: SOFA/Schedule A/R breakdowns.	1.00
10/03/19	SKL	Training session with J. Doherty and S. Lemack (both AlixPartners) to transition responsibilities for creating the 90-day payment schedule (SOFA 2).	0.60
10/03/19	SKL	Meeting with B. Folse, M. Hartley, A. DePalma, N. Simon, and S. Lemack (all AlixPartners) to do final transition review of accounts payable process.	0.70
10/03/19	SKL	Prepare updated status report re: SOFA/Schedules for B. Folse update.	1.10
10/03/19	MH	Meeting with M. Kesselman, R. Aleale (both Purdue), C. Robertson (Davis Polk), B. Folse, N. Simon, S. Lemack, M. Hartley, and H. Ku (all AlixPartners) to discuss SOFAs and Schedules disclosures related to legal matters.	1.00
10/03/19	HK	Meeting with M. Kesselman, R. Aleali (both Purdue), C. Robertson (Davis Polk), B. Folse, M. Hartley, N. Simon, H. Ku and S. Lemack (all AlixPartners) to discuss SOFAs and Schedules disclosures related to legal matters.	1.00
10/03/19	HK	Updates to legal matters in the draft SOFAs & Schedules report.	1.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/03/19	HK	Gather information on Company's GPO and Distributor agreements for Insurance requirement information.	1.10
10/03/19	HK	Meeting with J. Lowne, C. DeStefano, K. Laurel (Purdue), C. Robertson (Davis Polk), J. DelConte, H. Ku, and I. Arana de Uriarte (all AlixPartners) to discuss proposed edits to the Wages Supplement to the Jon Lowne Declaration.	1.00
10/03/19	HK	Research requests from the U.S. Trustee's office on Jon Lowne Declaration	1.00
10/03/19	HK	Meeting with C. DeStefano, L. Kusinski (both Purdue), I. Arana de Uriarte, and H. Ku (both AlixPartners) to review open items to the Wages Supplement to the Jon Lowne Declaration.	2.10
10/03/19	HK	Run attrition rate analysis for J. Lowne Declaration update.	2.40
10/03/19	HK	Run diligence for U.S. Trustee office's request regarding J. Lowne Declaration's draft Wage Supplement.	2.70
10/03/19	MH	Discussion with B. Folse, M. Hartley, and N. Simon (all AlixPartners) regarding follow-up items from earlier meeting with M. Kesselman (Purdue) regarding progress on SOFAs and Schedules.	0.20
10/03/19	MH	Meeting with B. Folse, A. DePalma, N. Simon, M. Hartley, and S. Lemack (all AlixPartners) to do final transition review of accounts payable process.	0.70
10/03/19	MH	Meeting with B. Folse, A. DePalma, and M. Hartley (all AlixPartners) to review status of Statements and Schedules preparation.	0.60
10/03/19	MH	Meeting with B. Folse and M. Hartley (both AlixPartners) to transition status of Statements and Schedules preparation.	1.40
10/03/19	MH	Meeting with B. Folse and M. Hartley (both AlixPartners),	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		to transition status of contract listing preparation.	
10/03/19	MH	Meeting with B. Folse and M. Hartley (both AlixPartners) to determine implementation plan of new contract tracking process.	0.40
10/03/19	MH	Meeting with B. Folse and M. Hartley (both AlixPartners) to discuss contract issues with licenses and settlement agreements.	0.30
10/03/19	BF	Review detailed insider payment information in preparation for meeting with GC.	0.80
10/03/19	BF	Meeting with M. Kesselman, R. Aleale (both Purdue), C. Robertson (Davis Polk), B. Folse, M. Hartley, J. DelConte, N. Simon and H. Ku (all AlixPartners) to discuss SOFAs and Schedules disclosures related to legal matters.	1.00
10/03/19	BF	Debrief from meeting with GC on legal matters and follow ups with staff.	0.80
10/03/19	BF	Detailed review of SOFA and Schedules work plan and output in preparation for meetings with staff.	1.50
10/03/19	BF	Discussion with B. Folse, M. Hartley, and N. Simon (all AlixPartners) regarding follow-up items from earlier meeting with M. Kesselman (Purdue) regarding progress on SOFAs and Schedules.	0.20
10/03/19	BF	Meeting with B. Folse, M. Hartley, A. DePalma, N. Simon, and S. Lemack (all AlixPartners) to do final transition review of accounts payable process.	0.70
10/03/19	BF	Meeting with B. Folse, M. Hartley, and A. DePalma (all AlixPartners) to review status of Statements and Schedules preparation.	0.60
10/03/19	BF	Meeting with B. Folse and M. Hartley (both AlixPartners), to transition status of contract listing preparation.	0.50
10/03/19	BF	Meeting with B. Folse, and M. Hartley (both AlixPartners) to transition status of Statements and Schedules	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		preparation.	
10/03/19	BF	Meeting with B. Folse, and M. Hartley (both AlixPartners) to discuss contract issues with licenses and settlement agreements.	0.30
10/03/19	BF	Review of legal noticing and disclosure issues related to contracts and SOFAs.	0.40
10/03/19	BF	Meeting with B. Folse, and M. Hartley (both AlixPartners) to determine implementation plan of new contract tracking process.	0.40
10/03/19	ADD	Meeting with B. Folse, A. DePalma, and M. Hartley (all AlixPartners), to review status of Statements and Schedules preparation.	0.60
10/03/19	ADD	Meeting with B. Folse, M. Hartley, N. Simon, A. DePalma, and S. Lemack (all AlixPartners) to do final transition review of accounts payable process.	0.70
10/03/19	REO	Research SAP database: Intercompany cash settlements SOFAs	2.30
10/04/19	HK	Discussion with K. McCarthy on potential contract terminations or rejections for Treyburn facility.	0.50
10/04/19	HK	Updates to GPO and Distributor agreements for Insurance provision review.	1.20
10/04/19	HK	Support U.S. Trustee office's information requests for Wages Supplement to Jon Lowne Declaration.	1.60
10/04/19	HK	Revise draft SOFAs and Schedules report with updates to transaction history.	2.10
10/04/19	SKL	Finalize review of all fixed-asset listings and ensured the SOFA/Schedules database was updated accordingly.	2.70
10/04/19	SKL	Finalize review of outstanding items re: SOFA/Schedule workplan and prepared updates to the workplan accordingly.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/04/19	SKL	Finalize review of the AP Cutoff process and procedures and ran updated AP distribution report.	2.90
10/04/19	SKL	Prepare updates to the non-opioid litigation tracker and updated the SOFA/Schedule database accordingly.	1.20
10/04/19	IA	Gathering of support documents on wages and benefits to be shared with US trustee.	1.80
10/04/19	JAD	Compile and format data to be used in Schedule AB Part 10 and update for Rhodes licenses.	1.70
10/04/19	JAD	Compile and format data to be used in SOFA part 2.	1.30
10/04/19	NAS	Follow-up items regarding payments to insiders (SOFA Part 2 Question 4) from meeting with M. Kesselman (Purdue) and R. Aleali (Purdue).	0.30
10/07/19	NAS	Analysis of payments to insiders over the past year for purposes of SOFA Part 2 Question 4.	0.50
10/07/19	NAS	Analysis of long-term incentive payments over the past year to individuals who were insiders in years past.	0.60
10/07/19	NAS	Review of intercompany cash payment report provided by TXP Services to ensure report is comprehensive for purposes of insider payments in SOFA Part 2 Question 4.	1.10
10/07/19	NAS	Conversation with R. Aleali regarding time window and data requirements for payments to insiders (SOFA Part 2 Question 4).	0.20
10/07/19	NAS	Discussion with N. Simon, A. DePalma, and S. Robertson (all AlixPartners) regarding intercompany cash payment report provided by TXP Services.	0.20
10/07/19	NAS	Adding payments to Directors to analysis of T&E reimbursements for purposes of SOFA Part 2 Question 4.	0.90
10/07/19	SKL	Prepare updates to the SOFA/Schedule workplan re: PPLP items and circulated updated report to K. Darragh (Purdue).	2.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/07/19	SKL	Prepare for and participate in discussion with Herb Baer (Prime Clerk) re: Opioid litigation.	0.80
10/07/19	SKL	Update the SOFA/Schedule database with the latest information re: Opioid litigation following today's call with Prime Clerk.	1.50
10/07/19	SKL	Finalize updates to the SOFA/Schedule workplan following K. Darragh, R. Haberlin, and W. DiNicola (all Purdue) signoff and updated the tracker accordingly.	2.20
10/07/19	SKL	Review the latest trade agreement tracker and Open AP tracker and prepared updated release lists re: daily AP releases.	1.80
10/07/19	HK	Update draft Statements of Financial Affairs with revised charitable contributions data.	1.50
10/07/19	HK	Update draft Schedules of Assets & Liabilities with updated employee compensation data.	1.80
10/07/19	HK	Gather equipment lease copies to extract data for Schedules of Assets & Liabilities.	2.30
10/07/19	HK	Prepare for and attend discussion with R. Aleali (Purdue) on former Directors and Officers data .	0.80
10/07/19	HK	Review employee address data for notice of commencement requirements.	0.20
10/07/19	HK	Review prior audited financial report data for Statements of Financial Affairs information.	1.40
10/07/19	HK	Review certain contracts with critical vendors for termination clause examples.	0.60
10/07/19	HK	Review of accounts for self-settled or spendthrift trusts as described under the Statement of Financial Affairs report.	0.70
10/07/19	ADD	Discussion with N. Simon, A. DePalma, and S. Robertson (all AlixPartners) regarding intercompany cash payment report provided by TXP Services.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/07/19	SR	Discussion with N. Simon, A. DePalma, and S. Robertson (all AlixPartners) regarding intercompany cash payment report prepared by TXP Services	0.20
10/08/19	ADD	Meeting with J. Lowne, K. Darragh (both Pharma), B. Folse, H. Ku, S. Lemack, and A. DePalma (all AlixPartners) on SOFAs and Schedules data request sign-off status.	0.50
10/08/19	ADD	Teleconference with controller (Purdue), C. Robertson (Davis Polk), B. Folse, A. DePalma, and H. Ku (all AlixPartners) on payment status of trade agreements and payments to be made under the Critical Vendor Motion.	0.20
10/08/19	DS	Start process of trying out July GAAP disbursements data to actuals cash reporting data (bank basis) for purposes of reporting disbursements as part of bankruptcy requirements	1.40
10/08/19	HK	Generate draft Schedule G reports for the contracts review process.	0.80
10/08/19	HK	Meeting with J. Lowne, K. Darragh (both Purdue), B. Folse, S. Lemack, H. Ku, and A. DePalma (all AlixPartners) on SOFAs and Schedules data sign-off status.	0.50
10/08/19	HK	Teleconference with K. Darragh (Purdue), C. Robertson (Davis Polk), B. Folse, H. Ku, and A. DePalma (all AlixPartners) on payment status of trade agreements and payments to be made under the Critical Vendor Motion.	0.20
10/08/19	HK	Review and updated equipment lease data for Schedule E/F to the Schedules of Assets and Liabilities.	1.60
10/08/19	HK	Revise draft Global Notes to the Statements of Financial Affairs.	1.80
10/08/19	HK	Revise draft Global Notes to the Schedules of Assets & Liabilities.	2.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/08/19	HK	Revise SOFAs & Schedules workplan summary with refreshed amounts.	2.10
10/08/19	SKL	Review the latest trade agreement tracker and Open AP tracker and prepared updated release lists re: daily AP releases.	1.70
10/08/19	SKL	Meeting with J. Lowne, K. Darragh (both Pharma), B. Folse, H. Ku, S. Lemack, and A. DePalma (all AlixPartners) on SOFAs and Schedules data request sign-off status.	0.50
10/08/19	SKL	Prepare updated non-opioid litigation summary and detail report.	1.70
10/08/19	SKL	Prepare updated opioid litigation summary and detail report.	1.20
10/08/19	BF	Review draft SOFA and Schedules output.	2.80
10/08/19	BF	Conference call with B. Folse, N. Simon (both AlixPartners), C. Robertson (Davis Polk), and creditor's counsel regarding pre-/post-petition status of amounts owed and requested changes to critical vendor order.	0.40
10/08/19	BF	Teleconference with K. Darragh (Purdue), C. Robertson (Davis Polk), B. Folse, H. Ku, and A. DePalma (all AlixPartners) on payment status of trade agreements and payments to be made under the Critical Vendor Motion.	0.20
10/08/19	BF	Meeting with J. Lowne, K. Darragh (both Pharma), B. Folse, H. Ku, S. Lemack, and A. DePalma (all AlixPartners) on SOFAs and Schedules data request sign-off status.	0.50
10/08/19	NAS	Conference call with B. Folse, N. Simon (both AlixPartners), C. Robertson (Davis Polk), and creditor's counsel regarding pre-/post-petition status of amounts owed and requested changes to critical vendor order.	0.40
10/08/19	NAS	Analysis of Sackler family indemnification payments	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		incurred by Purdue for purposes of inclusion in SOFA Part 2 Question 4.	
10/08/19	NAS	Draft consolidated list of open items for insider payments for purposes of SOFA Part 2 Question 4.	0.70
10/08/19	NAS	Meeting with J. DelConte, and N. Simon (both AlixPartners) to discuss approach towards addressing insider payments open items for purposes of SOFA Part 2 Question 4.	0.30
10/08/19	NAS	Analyze lists of former employees receiving various long-term payments and indemnification provided by Purdue to ensure all appropriate former insiders are included in SOFA Part 2 Question 4.	1.20
10/08/19	JD	Meeting with N. Simon and J. DelConte (both AlixPartners) to discuss approach towards addressing insider payments open items for purposes of SOFA Part 2 Question 4.	0.30
10/09/19	JD	Call with B. Folse, J. DelConte, A. DePalma (all AlixPartners), UST and Davis Polk re: First Purdue Pharma MOR submission	0.20
10/09/19	JD	Meeting with B. Folse, N. Simon, J. DelConte (all AlixPartners), J. Lowne, R. Aleali, and K. Laurel (all Purdue) to provide update on analysis of payments to insiders over the year prior to filing.	1.40
10/09/19	NAS	Coordination with C. MacDonald (Purdue) and updates to analysis of payments related to indemnification for purposes of SOFA Part 2 Question 4.	0.90
10/09/19	NAS	Prepare materials and discussion points for meeting with J. Lowne, R. Aleali, and K. Laurel (all Purdue) regarding update on analysis of payments made to insiders over the year prior to filing.	1.20
10/09/19	NAS	Meeting with B. Folse, J. DelConte, N. Simon (all AlixPartners), J. Lowne, R. Aleali, and K. Laurel (all	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/09/19	NAS	Purdue) to provide update on analysis of payments to insiders over the year prior to filing.	0.20
10/09/19	NAS	Correspondence with D. Shell (Rhodes) regarding benefits received by insiders outside of standard payment processes for purposes of SOFA Part 2 Question 4.	0.70
10/09/19	IA	Revisions to listing of payments made to insiders over the year prior to filing following additional information provided by Purdue on ancillary benefits to insiders.	1.40
10/09/19	IA	Follow up on and update of SOFA 17 on 401k, pension plan.	1.70
10/09/19	IA	Draft SOFA 11 for payments to restructuring professionals.	0.40
10/09/19	BF	Follow up on information on closed accounts to be reported on schedules.	2.10
10/09/19	BF	Meeting with B. Folse, J. DelConte, N. Simon (all AlixPartners), J. Lowne, R. Aleali, and K. Laurel (all Purdue) to provide update on analysis of payments to insiders over the year prior to filing.	0.20
10/09/19	SKL	Call with B. Folse, J. DelConte, and A. DePalma (all AlixPartners) with UST and DP re: First Purdue Pharma MOR submission	1.80
10/09/19	HK	Review the latest trade agreement tracker and Open AP tracker and prepared updated release lists re: daily AP releases.	1.30
10/09/19	HK	Review prepayments and deposits data for Chapter 11 reporting.	2.40
10/09/19	HK	Revise draft Global Notes to SOFAs and Schedule.	0.80
10/09/19	HK	Review Ordinary Course Professional procedures in response to Company's question.	2.70
10/09/19	HK	Review updated Ariba data for contracts review process.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/09/19	HK	Revise inputs to the SOFAs & Schedules with refreshed data.	2.10
10/09/19	DS	Prepare analysis showing follow up items between TXP's disbursement reports and Alix's cash reporting (for purposes of UST reporting)	1.90
10/09/19	ADD	Call with B. Folse, J. DelConte, and A. DePalma (all AlixPartners) with UST and DP re: First Purdue Pharma MOR submission	0.20
10/09/19	ADD	Compile and review SOFA and schedules data to prepare update.	0.80
10/10/19	ADD	Update SOFAs and Schedules templates and uploaded data to reporting model.	2.70
10/10/19	DS	Meeting with TXP (Disbursements) re: comments on TXP disbursements listing	0.50
10/10/19	DS	Review TXP (Disbursements) updated July report and reconciliation of GAAP cash disbursements, net of voids/reversals, and provide comments	1.70
10/10/19	DS	Draft agenda detailing specifics of meeting with TXP (Disbursements) re: UST reporting	1.10
10/10/19	SKL	Review the latest trade agreement tracker and Open AP tracker and prepared updated release lists re: daily AP releases.	1.20
10/10/19	SKL	Continue to finalize updates to the SOFA/Schedules database re: asset balances.	2.80
10/10/19	SKL	Finalize review of schedule A-B print outs and breakdowns re: SOFA/Schedules.	2.20
10/10/19	HK	Prepare for and attend meeting with K. McCarthy, C. Ricarte (both Purdue), W. Chang, and A. Green (both TXP) on insurance provisions for key relationships.	1.20
10/10/19	HK	Gather agreements for Company's insurance provision	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		review.	
10/10/19	HK	Review historical transactions identified as outside the ordinary course of business for the draft Statement of Financial Affairs.	2.70
10/10/19	HK	Generate draft Schedules of Assets and Liabilities for review process.	2.80
10/10/19	HK	Generate draft Statements of Financial Affairs report for review process.	0.90
10/10/19	BF	Review draft reports for SOFAs and schedules and comment.	1.50
10/10/19	NAS	Requesting from Purdue/Rhodes/TXP and tracking follow-ups items from insider payment discussion on 10/9.	1.20
10/11/19	HK	Update draft contracts data for Schedules of Assets and Liabilities.	2.10
10/11/19	HK	Research and update transaction data to be reported in the Statements of Financial Affairs.	2.10
10/11/19	HK	Review copies of draft SOFAs and Schedules reports.	2.40
10/11/19	SKL	Review the latest trade agreement tracker and Open AP tracker and prepared updated release lists re: daily AP releases.	1.70
10/12/19	HK	Review unsecured claims data for Schedules of Assets & Liabilities draft report.	1.60
10/12/19	BF	Review draft SOFA and Schedules	2.40
10/13/19	HK	Review copies of draft SOFAs and Schedules reports.	1.30
10/13/19	HK	Update draft financial data for Schedules of Assets and Liabilities.	2.90
10/13/19	NAS	Review comments to latest draft of SOFAs and schedules and implementing necessary changes.	0.20
10/13/19	NAS	Incorporate tax preparation services provided by Purdue	0.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/14/19	NAS	to certain insiders in response to SOFA Part 2 Question 4. Analysis of paying entity and timing of payment for foreign tax preparation services provided to specific insiders.	0.20
10/14/19	NAS	Revisions to internal insider payments presentation following comments from R. Aleali (Purdue) and J. Lowne (Purdue).	0.10
10/14/19	NAS	Review list of titles for former Purdue employees provided by HR to ensure that all insiders are included in SOFA Part 2 Question 4 response.	0.70
10/14/19	NAS	Analysis of additional fringe benefit information provided by payroll for inclusion in response to SOFA Part 2 Question 4.	0.50
10/14/19	NAS	Update internal status of all outstanding ancillary benefits received by insiders for purposes of tracking progress of SOFA Part 2 Question 4.	0.60
10/14/19	NAS	Analysis of indemnification payment data provided by Purdue and inclusion in response to SOFA Part 2 Question 4.	0.60
10/14/19	NAS	Analysis of historical lists of prior directors and officers for Rhodes entities to identify insiders as defined by SOFA Part 2 Question 4.	1.10
10/14/19	HK	Revise transaction data for the draft Statements of Financial Affairs.	1.10
10/14/19	HK	Meeting with D. Warren (Purdue) to discuss HR metrics for board presentation.	0.50
10/14/19	HK	Generate and review draft SOFA and Schedule report.	1.70
10/14/19	HK	Analyze patent and trademark data for Schedules of Assets & Liabilities report.	1.80
10/14/19	HK	Meeting with J. Lowne, C. Ricarte, K. McCarthy (all Purdue), W. Chang, and A. Green (both TXP) on	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		insurance provisions to material agreements.	
10/14/19	HK	Review material agreements for insurance provision information.	1.20
10/14/19	HK	Meeting with J. Lowne, K. Darragh (both Purdue), Rhodes executives, H. Ku, and S. Lemack (both AlixPartners) on SOFAs and Schedules review process.	0.30
10/14/19	HK	Review professional retainer balances for Schedules of Assets & Liabilities report.	2.30
10/14/19	SKL	Meeting with J. Lowne, K. Darragh (both Purdue), Rhodes executives, H. Ku, and S. Lemack (both AlixPartners) on SOFAs and Schedules review process.	0.30
10/15/19	SKL	Meeting with J. Lowne, K. Darragh (both Purdue), B. Folse, H. Ku, and S. Lemack (all AlixPartners) to discuss comments to draft SOFAs and Schedules report.	1.30
10/15/19	SKL	Begin reviewing latest Davis Polk opioid-litigation tracker and updating the SOFA/Schedules accordingly.	2.30
10/15/19	SKL	Cross referenced the latest Davis Polk opioid-litigation tracker with the Prime Clerk file to begin updating the debtor information.	1.40
10/15/19	SKL	Put together updates and action items following the J. Lowne (Purdue) meeting re: SOFA/Schedules.	1.30
10/15/19	HK	Review agreements and relationships for which financial statements were provided.	0.90
10/15/19	HK	Review SOFAs & Schedules draft reports to prepare for company meeting.	1.80
10/15/19	HK	Analyze company records on off-premise storage facilities for Statements of Financial Affairs.	2.60
10/15/19	HK	Meeting with J. Lowne, K. Darragh (both Purdue), B. Folse, H. Ku, and S. Lemack (all AlixPartners) to discuss comments to draft SOFAs and Schedules report.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/15/19	HK	Meeting with D. Warren (Purdue) on HR metrics for Board presentation.	0.50
10/15/19	HK	Review open legal items related to SOFAs and Schedules draft report.	0.20
10/15/19	HK	Meeting with R. Aleali (Purdue), B. Folse, J. DelConte, H. Ku, and N. Simon (all AlixPartners) to discuss current status of insider payments analysis and history of Board members for Purdue and Rhodes.	1.10
10/15/19	HK	Meeting with R. Aleali (Purdue) to discuss D&O history.	0.20
10/15/19	HK	Review legal entity information sheets for former directors and officers schedule.	1.40
10/15/19	BF	Prepare for and attend meeting with J. Lowne, K. Darragh (both Purdue), B. Folse, H. Ku, and S. Lemack (all AlixPartners) to discuss comments to draft SOFAs and Schedules report.	1.50
10/15/19	BF	Meeting with R. Aleali (Purdue), B. Folse, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to discuss current status of insider payments analysis and history of Board members for Purdue and Rhodes	1.10
10/15/19	ED	Draft disclosures re additional parties received.	4.00
10/15/19	NAS	Follow up with S. Epperlein Battikha (Purdue) regarding relocation expenses paid by Purdue for certain insiders for inclusion in SOFA Part 2 Question 4.	0.50
10/15/19	NAS	Consolidate status of insider list and corresponding data points for individuals who have control over debtor for purposes of SOFA Part 2 Question 4.	0.70
10/15/19	NAS	Consolidate status of insider list and corresponding data points for former insiders, Sackler family members, Board members, and independent affiliated companies for purposes of SOFA Part 2 Question 4.	0.40
10/15/19	NAS	Documenting all ancillary benefits received by insiders	0.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		following discussions with Purdue employees.	
10/15/19	NAS	Meeting with R. Aleali (Purdue), B. Folse, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to discuss current status of insider payments analysis and history of Board members for Purdue and Rhodes.	1.10
10/15/19	NAS	Update to analysis of insider payments over year prior to filing to include additional ancillary benefits.	0.60
10/15/19	NAS	Create comprehensive list of individuals to be included in SOFA Part 2 Question 4 following discussion with R. Aleali (Purdue).	0.70
10/15/19	NAS	Coordination with restructuring counsel regarding benefit payments made to specific insider and prior research on ancillary benefits conducted by Davis Polk.	1.20
10/15/19	DS	Meeting with financial analyst (PPLP) re: Customer Programs reporting	0.30
10/15/19	DS	Draft email to AlixPartners team outlining disbursements reporting process for UST	0.40
10/15/19	JD	Meeting with R. Aleali (Purdue), B. Folse, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to discuss current status of insider payments analysis and history of Board members for Purdue and Rhodes (left early).	0.60
10/16/19	DS	Meeting with D. Samikkannu (AlixPartners) and TXP Services re: September disbursements report for UST reporting	0.30
10/16/19	DS	Correspondence with TXP re: September disbursements report	0.40
10/16/19	DS	Review of September disbursements report wires	1.30
10/16/19	DS	Review of September disbursements report non-Paysource transactions	1.90
10/16/19	DS	Draft request list to financial analyst (PPLP) for customer	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		programs monthly reporting	
10/16/19	DS	Draft request list to financial analyst (PPLP) for customer programs monthly reporting (rebates, returns, vendors)	1.20
10/16/19	ADD	Update SOFA and Schedules model	1.40
10/16/19	ADD	Compile and review documentation for provided for due diligence requests	2.40
10/16/19	NAS	Correspondence with S. Epperlein Battikha (Purdue) regarding relocation benefits for purposes of inclusion in SOFA Part 2 Question 4.	0.20
10/16/19	NAS	Follow-up discussions with R. Aleali and C. MacDonald (both Purdue) regarding indemnity payments on behalf of insiders over past year.	0.90
10/16/19	NAS	Researching housing benefits provided to insiders to ensure SOFA Part 2 Question 4 disclosures are comprehensive.	1.00
10/16/19	NAS	Meeting with C. MacDonald (Purdue) to discuss indemnification payments made on behalf of insiders during year prior to filing.	1.00
10/16/19	NAS	Meeting with J. Beck-Sechow (TXP) to discuss how non-cash benefits are treated in employee payroll data.	0.60
10/16/19	NAS	Revise payroll analysis to exclude non-cash gross-ups following conversation with J. Beck-Sechow (TXP).	0.20
10/16/19	NAS	Review taxable benefit figures to be included in response to SOFA Part 2 Question 4.	0.30
10/16/19	NAS	Review of amounts reported as taxable benefits on insider W-2s in order to identify all fringe benefits.	0.90
10/16/19	NAS	Updates to analysis of indemnification payments following discussion with C. MacDonald (Purdue).	0.30
10/16/19	NAS	Correspondence with R. Aleali (Purdue) regarding updates to indemnification and ancillary benefit analyses.	0.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/16/19	NAS	Analysis of transaction between Purdue/Imbrium and external vendor for corporate fleet vehicles.	1.10
10/16/19	NAS	Analyze payroll data provided by company to determine how non-cash benefits are treated in order to assess what potential adjustments need to be made for SOFA Part 2 Question 4.	0.80
10/16/19	ED	Draft disclosures re additional parties received.	7.00
10/16/19	BF	Review of detailed schedules and SOFAs exhibits and comment.	2.60
10/16/19	HK	Gather data for insurance provisions to material agreements.	0.40
10/16/19	HK	Review updated directors' and officers' lists for Statements of Financial Affairs.	0.40
10/16/19	HK	Meeting with D. Warren (Purdue) on presentation of HR metrics for Board presentation.	0.20
10/16/19	HK	Research grants and charitable contributions data for Statements of Financial Affairs.	2.10
10/16/19	HK	Update business investments data for Schedules of Assets and Liabilities.	1.80
10/16/19	HK	Update prepayments data for Schedules of Assets and Liabilities.	0.40
10/16/19	HK	Update real property assets schedule for Schedules of Assets & Liabilities.	0.30
10/16/19	HK	Update investment accounts detail for Schedules of Assets and Liabilities.	0.30
10/16/19	HK	Revise draft Global Notes to SOFAs and Schedules.	1.10
10/16/19	HK	Update Debtors' inventory detail for Schedules of Assets and Liabilities.	2.30
10/16/19	SKL	Prepare for and participate in opioid litigation tracking discussion with H. Baer (Prime Clerk).	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/17/19	HK	Discussion with D. Levy-Lewis (Purdue) to update Gifts data for Statements of Financial Affairs.	0.20
10/17/19	HK	Meeting with K. Darragh (Purdue) on gross and non-business revenue analysis.	0.50
10/17/19	HK	Updates to SOFAs and Schedules database for draft reports.	0.80
10/17/19	HK	Review gross and non-business revenue data for summary requested by Company.	2.50
10/17/19	HK	Update SOFAs and Schedules database with footnotes.	1.20
10/17/19	HK	Review detail of inventory held on third party premises for the Statements of Financial Affairs.	0.90
10/17/19	HK	Review non-business revenue detail for Statements of Financial Affairs.	1.20
10/17/19	HK	Revise Global Notes to SOFAs and Schedules report.	1.30
10/17/19	HK	Review SOFAs and Schedules data for potentially newsworthy data per the Company's request.	2.10
10/17/19	BF	Review drafts of insider exhibits and respond to questions.	1.60
10/17/19	ED	Draft disclosures re additional parties received.	6.00
10/17/19	NAS	Revisions to payroll data included in response to SOFA Part 2 Question 4 to incorporate information on fringe benefit tax gross-ups.	0.60
10/17/19	NAS	Track data received to date, identify remaining open items, and request remaining data for full list of potential insiders for purposes of SOFA Part 2 Question 4.	1.00
10/17/19	NAS	Meeting with K. Darragh (Purdue) to discuss payment processes for corporate apartments occupied by insiders to be included in SOFA Part 2 Question 4.	0.60
10/17/19	NAS	Update payroll data for response to SOFA Part 2 Question 4 to include former insiders who received payment over	1.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		year prior to filing.	
10/17/19	NAS	Update T&E analysis for expanded list of insiders to be included in SOFA Part 2 Question 4.	0.50
10/17/19	NAS	Search comprehensive insider list in accounts payable to determine payments from year prior to filing and requesting confirmation from H. Benson (Purdue).	1.60
10/17/19	DS	Draft request list for customer programs reporting and send to Rhodes Controller	1.60
10/18/19	NAS	Analysis of payroll data (including fringe benefits) to ensure all payments to insiders over year prior to filing are captured.	1.20
10/18/19	NAS	Updates to Travel & Expense data for insiders included in response to SOFA Part 2 Question 4.	0.30
10/18/19	NAS	Updates to payments through accounts payable to insiders over year prior to filing for response to SOFA Part 2 Question 4.	0.70
10/18/19	NAS	Updates to summary of indemnification payments made on behalf of insiders in year prior to filing for inclusion in response to SOFA Part 2 Question 4.	0.90
10/18/19	NAS	Analyze payments made to Directors through accounts payable and intercompany process over year prior to filing for inclusion in SOFA Part 2 Question 4.	1.00
10/18/19	NAS	Analysis of foreign tax preparation services provided by Purdue to insiders during year prior to filing for inclusion in response to SOFA Part 2 Question 4.	0.90
10/18/19	NAS	Draft supplemental disclosures relating to payments to groups of insiders for response to SOFA Part 2 Question 4.	0.80
10/18/19	NAS	Meeting with D. Cabral (TXP) to discuss treatment of fringe benefits in payroll system.	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/18/19	NAS	Implement changes to payroll information for insiders over the past year following meeting with D. Cabral (Purdue).	1.00
10/18/19	NAS	Upload insider payments data to SOFAs and Schedules model to generate copies for review.	0.70
10/18/19	NAS	Revise response to SOFA Part 2 Question 4 per comments from B. Folse (AlixPartners).	0.30
10/18/19	NAS	Create summary of insider payment data over year prior to filing to restructuring counsel (Davis Polk and Wardwell) for review.	1.50
10/18/19	NAS	Draft email to restructuring counsel (Davis Polk and Wardwell) outlining insider benefits identified for review.	0.40
10/18/19	ED	Draft disclosures re additional parties received.	3.50
10/18/19	HK	Revise intangible assets data to Schedules of Assets and Liabilities per Company's update.	0.20
10/18/19	HK	Draft revised SOFAs and Schedules reports for Debtors' Finance review.	2.60
10/18/19	HK	Draft summary of potentially newsworthy items in SOFAs and Schedules disclosures.	2.90
10/18/19	HK	Revise executory contracts and unexpired lease data for Schedules of Assets and Liabilities report.	2.10
10/19/19	HK	Compile "newsworthy" SOFAs and Schedules data per the Debtors' request.	1.80
10/19/19	BF	Review revised exhibits to SOFAs and Schedules and correspondence with client and team.	1.80
10/19/19	NAS	Reconciling differences amongst calculation methodologies for value of fringe benefits in data sources provided by Purdue.	0.60
10/19/19	NAS	Draft summary of payments received by Board members for review by R. Aleali (Purdue).	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/19/19	NAS	Draft summary of fringe benefits and how data is treated in various company sources for review by AlixPartners team.	1.40
10/19/19	NAS	Correspondence with restructuring counsel (Davis Polk & Wardwell) to ensure alignment in calculation methodology for value of fringe benefits received by insiders.	0.30
10/19/19	DS	Identify intercompany transfers in GAAP disbursements report	1.30
10/19/19	DS	Allocate disbursements to Purdue Pharmaceuticals L.P. and Purdue Pharma Manufacturing L.P.	0.90
10/19/19	DS	Prepare reconciliation (GAAP-to-banks) for 9/15 - 9/30 time period	1.50
10/19/19	DS	Prepare reconciliation (GAAP-to-banks) for month of September	1.30
10/20/19	NAS	Revisions to amounts included and descriptions applied to director fees listed in payments to insider over year prior to filing.	0.80
10/20/19	NAS	Review of summary for other benefits received by insiders prepared by restructuring counsel (Davis Polk and Wardwell).	0.70
10/20/19	NAS	Discussion with L. Tullo (TXP) regarding payment of PPI Director fees and revising SOFA Part 2 Question 4 response accordingly.	0.90
10/20/19	NAS	Draft individual summaries of disclosures for payments made to PPI Directors for review by R. Aleali (Purdue).	1.10
10/20/19	NAS	Confirm list of former Rhodes Directors included in response to SOFA Part 2 Question 4 with R. Aleali (Purdue).	0.30
10/20/19	HK	Review Debtors' directors' and officers' detail for Statements of Financial Affairs reporting.	2.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/20/19	HK	Update draft Statements of Financial Affairs data per updates from the Company.	2.10
10/21/19	HK	Meeting with R. Aleali (Purdue), M. Hartley, J. DelConte, H. Ku, and N. Simon (all AlixPartners) on disclosures related to employee personal data.	0.70
10/21/19	HK	Updates to the Schedules of Assets and Liabilities data per Debtors' revised data.	1.40
10/21/19	HK	Updates to the Statements of Financial Affairs data per Debtors' revised data.	1.90
10/21/19	HK	Analyze non-business revenue data for Statements of Financial Affairs.	1.90
10/21/19	HK	Meeting with J. Lowne (Purdue) on SOFAs and Schedules status update review.	0.30
10/21/19	HK	Meeting with R. Aleali (Purdue) to discuss legal-related SOFAs and Schedules data.	0.90
10/21/19	HK	Call with I. Arana, J. DelConte (both AlixPartners), and Teneo RE: SOFA/SOAL	0.50
10/21/19	HK	Meeting with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), B. Folse, J. DelConte, H. Ku, M. Hartley and N. Simon (all AlixPartners) to discuss insider disclosures that will be made in SOFA.	1.00
10/21/19	MH	Review proposed summary of insider payments to present to General Counsel.	0.80
10/21/19	MH	Meeting with N. Simon and M. Hartley (both AlixPartners) to review presentation for 10/26 management meeting.	0.30
10/21/19	MH	Meeting with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), B. Folse, J. DelConte, H. Ku, M. Hartley and N. Simon (all AlixPartners) to discuss insider disclosures that will be made in SOFA.	1.00
10/21/19	MH	Meeting with R. Aleali (Purdue), J. DelConte, H. Ku, M.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Hartley, and N. Simon (all AlixPartners) to discuss remaining open items for SOFA insider disclosures.	
10/21/19	MH	Discuss with counsel how to display certain business transactions with confidentiality agreements.	0.60
10/21/19	MH	Research technical options to adjust the display of insider payments to more accurately reflect correct categories.	0.50
10/21/19	NAS	Revise indemnification payment data included in response to SOFA Part 2 Question 4 following updates from C. MacDonald (Purdue).	0.20
10/21/19	NAS	Revise benefit calculations included in response to SOFA Part 2 Question 4 to portray cost incurred by Purdue.	0.90
10/21/19	NAS	Discussion with R. Aleali (Purdue) to prepare for 10/21 meeting with Purdue Executive Team regarding insider disclosures in SOFA.	0.20
10/21/19	NAS	Incorporate fleet vehicle benefit data provided by company into response to SOFA Part 2 Question 4.	0.50
10/21/19	NAS	Incorporate corporate housing benefit data provided by Purdue into response to SOFA Part 2 Question 4.	0.30
10/21/19	NAS	Generate draft response to SOFA Part 2 Question 4 for 10/27 meeting with Purdue management team.	0.40
10/21/19	NAS	Create detailed presentation regarding SOFA insider disclosures for meeting with Purdue management.	1.80
10/21/19	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to review presentation for 10/26 management meeting.	0.30
10/21/19	NAS	Revise insider disclosure presentation for management meeting following feedback from M. Hartley (AlixPartners).	0.70
10/21/19	NAS	Meeting with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), B. Folse, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to discuss insider	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		disclosures that will be made in SOFA.	
10/21/19	NAS	Create consolidated list of remaining open items for response to SOFA Part 2 Question 4 in order to ensure all outstanding requests are met.	0.30
10/21/19	NAS	Create draft of overview deck for 10/22 conversation with full group of Purdue operational insiders regarding SOFA Part 2 Question 4 disclosures.	1.10
10/21/19	NAS	Meeting with R. Aleali (Purdue), M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to discuss remaining open items for SOFA insider disclosures.	0.70
10/21/19	IA	Call with I. Arana, J. DelConte (both AlixPartners), and Teneo RE: SOFA/SOAL	0.50
10/21/19	DS	Assemble UST disbursements reporting for 9/16 - 9/30 period	1.60
10/21/19	DS	Review disbursements reporting for completeness and accuracy	1.80
10/21/19	DS	Calculate UST fees for disbursements report	0.80
10/21/19	JD	Call with I. Arana, J. DelConte (both AlixPartners), and Teneo RE: SOFA/SOAL	0.50
10/21/19	JD	Meeting with C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. DelConte, H. Ku, M. Hartley and N. Simon (all AlixPartners) to discuss insider disclosures that will be made in SOFA.	1.00
10/21/19	JD	Meeting with R. Aleali (Purdue), M. Hartley, J. DelConte, H. Ku, and N. Simon (all AlixPartners) to discuss remaining open items for SOFA insider disclosures.	0.70
10/21/19	JD	Outstanding review items and customer contracts disclosure process discussion with management	0.50
10/22/19	JD	Meeting with all current Purdue insiders, M. Hartley, N. Simon, J. DelConte, and H. Ku (all AlixPartners) to review disclosures to be made in response to SOFA Part 2	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Question 4.	
10/22/19	JD	Review SOFA/SOAL insider disclosures. Provide comments RE: same.	0.90
10/22/19	DS	Draft email to operations manager re: vendor data needed for Customer Programs report	0.50
10/22/19	DS	Draft request to cost analyst re: specific vendor for Customer Programs report	0.30
10/22/19	DS	Update UST disbursements report based on comments from management	0.70
10/22/19	DS	Draft email to financial analyst (PPLP) re: Customer Programs report specific data requirements	0.40
10/22/19	ADD	Prepare model to update schedule F and reclass payables in a net debit position	2.30
10/22/19	NAS	Prepare individual compensation summaries included in SOFA Part 2 Question 4 for review by current operational insiders.	1.30
10/22/19	NAS	Incorporate revisions from R. Aleali (Purdue) to presentation materials for 10/22 meeting with current Purdue operational insiders.	1.10
10/22/19	NAS	Meeting with all current Purdue insiders, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review disclosures to be made in response to SOFA Part 2 Question 4.	0.60
10/22/19	NAS	Discussion with R. Aleali (Purdue) regarding SOFA Part 2 Question 4 disclosure presentation to be provided to Purdue Pharma Inc. Board of Directors.	0.10
10/22/19	NAS	Review SOFA Part 2 Question 4 presentation format of in recent Chapter 11 cases.	0.10
10/22/19	NAS	Revise response to SOFA Part 2 Question 4 following Purdue executive team meeting on 10/21.	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/22/19	NAS	Review investigation of payments to independent associated companies by AlixPartners team for inclusion in SOFA Part 2 Question 4 response where applicable.	1.60
10/22/19	NAS	Review listing prepared by Purdue of cash payments to independent affiliated companies for overlapping entries with AlixPartners investigation and inclusion in SOFA Part 2 Question 4 response where applicable.	1.80
10/22/19	NAS	Incorporate payments to independent associated companies over year prior to filing into response to SOFA Part 2 Question 4.	1.20
10/22/19	MH	Meeting with all current Purdue insiders, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review disclosures to be made in response to SOFA Part 2 Question 4.	0.60
10/22/19	MH	Meeting with all current Purdue insiders, Respond to client questions regarding the scope of disclosures on insider payments.	0.60
10/22/19	MH	Review current status of all SOFA/SOAL preparation lines.	1.70
10/22/19	HK	Update gifts data to the Statements of Financial Affairs.	1.70
10/22/19	HK	Revise the draft Global Notes to the SOFAs and Schedules reports.	0.80
10/22/19	HK	Review Debtors' directors' and officers' documents for Statements of Financial Affairs disclosures.	1.70
10/22/19	HK	Update organizational structure reporting for SOFAs and Schedules.	1.30
10/22/19	HK	Update potential tax authority claim data for Schedule E/F of the Schedules of Assets and Liabilities.	1.40
10/22/19	HK	Review Debtors' detail for requests by Teneo.	1.30
10/22/19	HK	Update the SOFAs and Schedules work plan to coordinate team revisions.	0.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/22/19	HK	Meeting with all current Purdue insiders, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review disclosures to be made in response to SOFA Part 2 Question 4.	0.60
10/23/19	HK	Review Rhodes' Debtors diligence responses for outstanding SOFAs and Schedules requests.	0.50
10/23/19	HK	Update closed financial account detail for Statements of Financial Affairs.	0.20
10/23/19	HK	Create Debtors' inventory schedule summary per J. Lowne's (Purdue) request.	1.90
10/23/19	HK	Gather final version SOFAs and Schedules detail for J. Lowne's (Purdue) sign-off.	2.10
10/23/19	HK	Review sample of contractual agreements for insurance requirements.	2.90
10/23/19	HK	Review Debtors' litigation draft detail for Schedules of Assets and Liabilities.	1.50
10/23/19	HK	Update Debtors' listed business purpose detail to Statements of Financial Affairs.	0.90
10/23/19	HK	Revise specific footnotes to Accounts Receivables footnote to Schedules of Assets and Liabilities.	0.40
10/23/19	HK	Review correspondences from taxing authorities on potential tax claims for Schedule E/F to Schedules of Assets and Liabilities.	0.60
10/23/19	FOS	Meeting with N. Simon and F. Silva (both AlixPartners) to review intercompany payment activity included in SOFA Part 2 Question 4.	0.70
10/23/19	SKL	Prepare updated reconciliation of A/R intercompany balances to confirm amounts are accurately reflected on the SOFA/Schedules.	2.40
10/23/19	SKL	Continue to finalize the review and analysis on the opioid	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		litigation tracker.	
10/23/19	SKL	Update the SOFA/Schedule database with the latest review/analysis of the Prime Clerk opioid litigation tracker.	2.10
10/23/19	SKL	Review latest updates re: 90-day payments outside of SAP and updated the database accordingly.	1.70
10/23/19	SKL	Review the latest AP payments and payables file and prepared the updated releases for today's distribution.	1.10
10/23/19	SKL	Prepare and review updated formatting of the 90-day payments re: SOFA/Schedules.	1.50
10/23/19	MH	Review all global and schedule specific notes included in SOFA/SOAL draft.	1.10
10/23/19	MH	Reconcile three sources of payments to IACs to finalize the listing of insider payments.	2.60
10/23/19	BF	Review of revisions to SOFAs and Schedules and UST distributions report.	2.60
10/23/19	NAS	Consolidate list of open items regarding SOFA Part 2 Question 4 disclosure to ensure all deadlines are met.	0.10
10/23/19	NAS	Meeting with F. Silva and N. Simon (both AlixPartners) to review intercompany payment activity included in SOFA Part 2 Question 4.	0.70
10/23/19	NAS	Review intercompany payments included in response to SOFA Part 2 Question 4 for accuracy.	2.30
10/23/19	NAS	Format and upload intercompany payment data into model for response to SOFA Part 2 Question 4.	0.80
10/23/19	NAS	Revise descriptions of intercompany payments included in response to SOFA Part 2 Question 4 following comments from Purdue.	0.30
10/23/19	NAS	Reconcile lists of intercompany payments across sources provided by Purdue to ensure accuracy of disclosure in	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		SOFA Part 2 Question 4.	
10/23/19	NAS	Draft presentation and working documents for Board review of insider disclosures in SOFA Part 2 Question 4.	1.60
10/23/19	NAS	Generate new draft of response to SOFA Part 2 Question 4 for review by AlixPartners, Purdue, and Davis Polk & Wardwell.	1.40
10/23/19	NAS	Revise insider payments summary materials for Board of Directors following comments by Purdue and AlixPartners.	0.40
10/23/19	NAS	Reviewing final presentation on insider payments disclosures to be provided to Board of Directors for accuracy.	0.70
10/23/19	ADD	Prepare model for updated schedule F data.	2.20
10/23/19	DS	Draft email to financial analyst (PPLP) re: prompt pay discounts and co-pay reduction rebates	2.30
10/23/19	DS	Compile final UST disbursements report for submission	0.90
10/23/19	DS	Categorize rebate spend from 9/16 to 9/30 for purposes of Customer Programs report	0.50
10/23/19	DS	Call with controller (Rhodes) re: Customer Programs report deliverables	0.50
10/23/19	JD	Review updated SOFA/SOAL insider disclosures and associated presentations.	0.70
10/23/19	JD	Prepare analysis and draft email to send to company legal for review prior to sending to the Board detailing potential areas of sensitivity included in the SOFA/SOAL disclosures.	2.40
10/23/19	JD	Review IAC payment descriptions and open items.	0.40
10/24/19	JD	Correspondence with Davis Polk and management RE: insider disclosures in the SOFA/SOALS	1.30
10/24/19	ADD	Update schedule F model	2.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/24/19	NAS	Revise relocation data included in response to SOFA Part 2 Question 4 to reflect actual cost incurred by Purdue and incorporate changes into model.	1.40
10/24/19	NAS	Research specific intercompany transaction in company's books and records to confirm that it wasn't a cash payment and therefore should not be included in response to SOFA Part 2 Question 4.	0.20
10/24/19	NAS	Revise compensation category for specific insider payments to correct misclassification by Purdue.	0.30
10/24/19	NAS	Generate draft of latest version of response to SOFA Part 2 Question 4 for external counsel review.	0.80
10/24/19	NAS	Generate draft response to SOFA Part 2 Question 4 for review by J. Lowne (Purdue).	0.40
10/24/19	NAS	Research qualitative data (including legal entity names and addresses) for independent associated companies to be included in SOFA Part 2 Question 4 disclosure.	1.50
10/24/19	NAS	Correspondence with R. Kennedy (Purdue) regarding different sources used by company in generating list of intercompany payment history.	0.20
10/24/19	NAS	Review data for fleet vehicles used by insiders to ensure SOFA Part 2 Question 4 disclosures are comprehensive.	0.10
10/24/19	NAS	Generate draft reports of SOFA Part 2 Question 4 disclosures for review by Purdue Pharma Inc. Board of Directors.	0.90
10/24/19	NAS	Revise descriptions of intercompany payments following feedback by K. Darragh (Purdue).	0.70
10/24/19	NAS	Correspondence with D. Consola (Davis Polk & Wardwell) regarding restructuring counsel comments on response to SOFA Part 2 Question 4.	0.70
10/24/19	NAS	Revise response to SOFA Part 2 Question 4 following comments from Davis Polk & Wardwell.	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/24/19	NAS	Modify format of SOFA Part 2 Question 4 response in model to ensure presentation format is correct.	0.30
10/24/19	NAS	Revise draft response to SOFA Part 2 Question 4 to be provided to Board of Directors following comments from Davis Polk & Wardwell.	0.70
10/24/19	BF	Detailed review of draft SOFAs and Schedules	3.40
10/24/19	MH	Review proposals for alternative presentations of relocation payments in the SOFA.	0.40
10/24/19	MH	Review updates to SOFA and SOAL drafts.	0.80
10/24/19	SKL	Review the latest AP payments and payables file and prepared the updated releases for today's distribution.	1.20
10/24/19	SKL	Prepare updated vendor analysis for the company to review.	1.40
10/24/19	SKL	Begin review of printed SOFA/Schedules to confirm accuracy and format is consistent.	1.60
10/24/19	SKL	Finalize Schedule E/F (litigation) and circulate latest printout to the AlixPartners team to review.	2.30
10/24/19	HK	Review Debtors' 90-day transactions to Insiders for the drafted Statements of Financial Affairs.	1.60
10/24/19	HK	Update noticing data for the contracts database for Schedule G to the Schedules of Assets and Liabilities.	1.40
10/24/19	HK	Revise SOFAs and Schedules data per CFO J. Lowne's (Purdue) comments.	1.40
10/24/19	HK	Review sample of contractual agreements for insurance provisions.	2.80
10/24/19	HK	Update Debtors' contracts and noticing database with business development agreements.	2.30
10/24/19	HK	Update Debtors' contracts and noticing databased with settlement agreement detail.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/25/19	HK	Review Debtors' business development agreements and updated contracts database.	2.70
10/25/19	HK	Review Debtors' collaboration agreements to update contracts database.	2.20
10/25/19	HK	Update charitable contribution data for Statements of Financial Affairs.	1.10
10/25/19	HK	Update Debtors' revenue detail for Statements of Financial Affairs.	2.80
10/25/19	HK	Generate and review revised draft SOFAs and Schedules.	3.30
10/25/19	SKL	Review the Insider/IAC 90-day payment information provided by N. Simon (AlixPartners) and began to incorporate into the 90-day payment SOFA.	2.90
10/25/19	SKL	Finalize review and reconciliation of the Insider/IAC 90-day payment information provided by N. Simon (AlixPartners) and review the latest 90-day payment printout re: SOFA/Schedules.	2.70
10/25/19	SKL	Review the latest AP payments and payables file and prepare the updated releases for today's distribution.	1.00
10/25/19	SKL	Prepare updated critical vendor breakdown based on the latest AP and vendor agreement information provided.	2.10
10/25/19	SKL	Finalize updates to the opioid litigation piece of the SOFA/Schedules.	2.40
10/25/19	MH	Review proposed SOFA 2 draft.	0.80
10/25/19	MH	Review proposed SOAL F draft.	0.70
10/25/19	MH	Develop plan for final preparation and review of SOFA and SOAL for the work team.	0.90
10/25/19	BF	Review of Global Notes and Revised Schedule F and 90-day payments.	2.50
10/25/19	NAS	Research fleet vehicle expenses (pre-program termination) for insiders and add to response to SOFA	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Part 2 Question 4.	
10/25/19	NAS	Research monthly corporate apartment cost for insiders and add to SOFA Part 2 Question 4 response.	1.40
10/25/19	NAS	Correspondence with restructuring counsel regarding revisions to insider payments disclosure in SOFA Part 2 Question 4.	0.20
10/25/19	NAS	Finalize descriptions of intercompany payments included in SOFA Part 2 Question 4 following guidance from W. DiNicola (Rhodes).	0.90
10/25/19	NAS	Revise indemnification payments listed in response to SOFA Part 2 Question 4 to reflect comments from Davis Polk & Wardwell.	0.30
10/25/19	NAS	Incorporate revisions to insider payment disclosures in SOFA Part 2 Question 4 following review by Davis Polk & Wardwell.	0.40
10/25/19	NAS	Isolate payments to insiders over 90 days prior to bankruptcy for inclusion in SOFA Part 2 Question 3 response.	0.70
10/25/19	NAS	Generate new draft SOFA Part 2 Question 4 response after removing payments from last 90 days (included in Question 3 response).	0.60
10/25/19	NAS	Generate individual insider disclosure reports to be provided to former Rhodes Board members.	0.90
10/25/19	ADD	Update schedule F model to prepare SOFA and Schedule templates.	2.90
10/25/19	ADD	Transaction research for SOFA and Schedules	2.50
10/25/19	ADD	Create schedule F templates for upload into SOFA and Schedules model	1.20
10/26/19	ADD	Research transaction for SOFA and Schedule filing.	1.70
10/26/19	ADD	Create summary spreadsheet of schedule F data for SOFA	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		and Schedule review.	
10/26/19	ADD	Review and document schedule F model.	2.60
10/26/19	NAS	Create individual insider disclosures to share with former members of relevant Rhodes Boards of Directors.	0.40
10/26/19	NAS	Research housing data provided by Purdue payroll for particular insider to ensure accuracy of SOFA Part 2 Question 4 disclosure.	0.20
10/26/19	MH	Review drafts of SOFA and SOAL reports.	2.80
10/26/19	HK	Revisions to the SOFAs and Schedule detail per Debtors' comments.	2.40
10/27/19	HK	Update the SOFAs and Schedules data per Debtors' comments.	3.30
10/27/19	SKL	Additional updates to the 90-day payments re: Insiders on the SOFA/Schedules.	2.10
10/27/19	MH	Review drafts of SOFA and SOAL reports.	2.90
10/27/19	NAS	Create revised individual insider disclosures to be shared with specific former Purdue employees.	0.60
10/27/19	ADD	Document and distribute schedule F model procedures to AlixPartners team	0.70
10/28/19	DS	Call with D. Consla (Davis Polk) re: Customer Programs report	0.20
10/28/19	JD	Meeting with management, H. Ku, and J. DelConte (both AlixPartners) RE: SOFA disclosures	1.00
10/28/19	JD	Review list of material agreements RE: SOFA/SOAL filing	0.70
10/28/19	JD	Review correspondence with management RE: IAC disclosure descriptions	0.50
10/28/19	JD	Review Sackler insider disclosures	0.50
10/28/19	NAS	Correspondence with H. Benson (Purdue) regarding housing benefits received by insider to ensure disclosures	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		in SOFA Part 2 Question 4 are accurate.	
10/28/19	NAS	Revise response to SOFA Part 2 Question 4 following comments from Davis Polk & Wardwell.	1.30
10/28/19	NAS	Research specific transactions and update descriptions of payments to entities considered to be insiders accordingly following feedback from J. Lowne (Purdue).	1.40
10/28/19	NAS	Draft list of remaining open items for response to SOFA Part 2 Question 4 to ensure all data is incorporated by end of day.	0.50
10/28/19	NAS	Revise relocation and housing data included in response to SOFA Part 2 Question 4 for specific insider following feedback from H. Benson (Purdue).	0.70
10/28/19	NAS	Correspondence with A. Dunton (former Purdue employee) regarding his disclosures included in SOFA Part 2 Question 4 response.	0.40
10/28/19	NAS	Reclassify payment to M. Timney (former Purdue employee) listed in response to SOFA Part 2 Question 4 after review of his separation agreement.	0.20
10/28/19	NAS	Meeting with K. Darragh (Purdue) to discuss remaining questions on payments to entities considered to be insiders for purposes of SOFA Part 2 Question 4 disclosures.	0.60
10/28/19	NAS	Revise descriptions included in SOFA Part 2 Question 4 response of payments to entities considered to be insiders following discussion with K. Darragh (Purdue).	0.70
10/28/19	NAS	Upload data to SOFA model following all prior updates over course of day and review for accuracy.	1.40
10/28/19	NAS	Note entities below \$6,825 threshold and remove from SOFA Part 2 Question 4 response per form's instructions.	0.30
10/28/19	NAS	Review of reimbursement of royalty payment made in error to ensure payment is cash settled and thus should	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		be included in SOFA Part 2 Question 4 disclosure.	
10/28/19	NAS	Draft individual Sackler family SOFA Part 2 Question 4 disclosures for review by family counsel (Millbank).	0.60
10/28/19	MH	Review updated SOFA 4 listings.	2.10
10/28/19	MH	Review responses on reconciliation of insider payments between Accounts Payable and TXP reports.	0.50
10/28/19	MH	Research correct entity name for license payment to related party to ensure no additional payments.	1.40
10/28/19	MH	Review drafts of SOFA and SOAL reports.	3.10
10/28/19	BF	Detailed review of SOFAs and Schedules	3.60
10/28/19	SKL	Review the latest SOFA/Schedule printouts and provide commentary accordingly.	2.30
10/28/19	SKL	Finalize reconciliation of 90-day payment source info vs. the information received re: insider/IAC payments.	2.30
10/28/19	SKL	Prepare updated critical vendor breakdown for the company to review.	1.20
10/28/19	SKL	Review the latest AP payments and payables file and prepare the updated releases for today's distribution.	1.20
10/28/19	HK	Prepare for meeting with CFO J. Lowne and Controller K. Darragh (both Purdue) on final sign-off to SOFAs and Schedules detail.	0.60
10/28/19	HK	Meeting with management, H. Ku, and J. DelConte (both AlixPartners) RE: SOFA disclosures.	1.00
10/28/19	HK	Review Purdue Pharma Inc management agreements for Debtors' contracts database.	1.20
10/28/19	HK	Update Debtors' intercompany matrix for Schedules of Assets and Liabilities detail.	0.20
10/28/19	HK	Update Schedule E/F non-priority data with open and closed prepetition trade payables detail.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/28/19	HK	Review final draft SOFAs and Schedules reports.	2.80
10/28/19	HK	Revise drafted Global Notes with additional comments from Davis Polk and the Debtors.	1.90
10/28/19	HK	Review non-business revenue detail per CFO J. Lowne's (Purdue) request.	0.70
10/28/19	HK	Generate final draft reports for the SOFAs and Schedules for filing.	1.50
10/29/19	HK	Meeting with J. Lowne, K. Darragh (both Purdue), S. Lemack, N. Simon, H. Ku, and J. DelConte (all AlixPartners) to review payments to entities disclosed in SOFA Part 2 Question 4 response.	0.50
10/29/19	HK	Review final draft Schedules of Assets and Liabilities for filing.	2.40
10/29/19	HK	Review final draft Statements of Financial Affairs for filing with Court.	2.80
10/29/19	HK	Gather SOFAs and Schedules detail in Excel per request from committees' advisors.	0.90
10/29/19	HK	Review taxing authorities' letters regarding claim estimates.	0.60
10/29/19	HK	Update Insider payments data inputs for Statements of Financial Affairs.	0.40
10/29/19	HK	Revise Schedule E/F non-priority claim data with updated trade payables information.	0.20
10/29/19	HK	Incorporate revisions to the final SOFAs and Schedules per comments from Davis Polk.	1.10
10/29/19	SKL	Review the latest AP payments and payables file and prepare the updated releases for today's distribution.	1.10
10/29/19	SKL	Meeting with J. Lowne, K. Darragh (both Purdue), H. Ku, N. Simon, S. Lemack, and J. DelConte (all AlixPartners) to review payments to entities disclosed in SOFA Part 2	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		Question 4 response.	
10/29/19	SKL	Prepare updated breakdown of the critical vendor notification tracker and distribute to the client to review.	2.40
10/29/19	SKL	Finalize updates to Schedule E/F (litigation) re: SOFA/Schedules.	2.60
10/29/19	SKL	Finalize updates to SOFA 7 re: SOFA/Schedules.	2.10
10/29/19	SKL	Finalize review of asset balances re: SOFA/Schedules and sign off accordingly.	1.20
10/29/19	BF	Review of final SOFAs and Schedules and signoff.	2.40
10/29/19	MH	Review drafts of SOFA and SOAL reports.	2.40
10/29/19	MH	Conduct final review of all SOFA and SOAL reports.	3.00
10/29/19	NAS	Meeting with J. Lowne, K. Darragh (both Purdue), S. Lemack, H. Ku, N. Simon, and J. DelConte (all AlixPartners) to review payments to entities disclosed in SOFA Part 2 Question 4 response.	0.50
10/29/19	NAS	Finalize descriptions for payments to entities listed in SOFA Part 2 Question 4 response following review by J. Lowne and K. Darragh (both Purdue).	0.60
10/29/19	NAS	Incorporate revisions to SOFA Part 2 Question 4 response into full SOFAs and Schedules model.	0.40
10/29/19	NAS	Review prior to filing of final draft of SOFA Part 2 Question 4 response for accuracy.	1.40
10/29/19	NAS	Remove non-insider individual from list of indemnity payments included in response to SOFA Part 2 Question 4.	0.20
10/29/19	NAS	Review of data for individuals listed in response to Purdue Pharma L.P. SOFA Part 2 Question 4 for accuracy.	1.80
10/29/19	NAS	Review of data for entities listed in response to Purdue Pharma L.P. SOFA Part 2 Question 4 for accuracy.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/29/19	JD	Meeting with J. Lowne, K. Darragh (both Purdue), S. Lemack, H. Ku, N. Simon, and J. DelConte (all AlixPartners) to review payments to entities disclosed in SOFA Part 2 Question 4 response.	0.50
10/29/19	DS	Review Cumberland data for purposes of Customer Programs report	0.70
10/29/19	DS	Incorporate state data for Medicaid / Medicare into Customer Programs report	1.80
10/29/19	DS	Reconcile payments in Customer Programs report with cash actuals report	1.10
10/29/19	ADD	Update SOFA and Schedules schedule F .	1.20
10/30/19	DS	Call with D. Consla (Davis Polk) re: draft Customer Programs report	0.20
10/30/19	DS	Draft overview to Customer Programs report outlining key items	1.10
10/30/19	DS	Prepare summary outline of Customer Programs items categorized by (1) non-cash credits and chargebacks processed, (2) customer program payments, and (3) payments to customer program vendors	0.80
10/30/19	DS	Draft outline summarizing Customer Programs report for Davis Polk review	0.60
10/30/19	DS	Assemble prompt pay discounts by counterparty schedule	0.70
10/30/19	DS	Assemble sales returns / credits by counterparty schedule	0.60
10/30/19	DS	Assemble wholesaler chargebacks by counterparty schedule	0.50
10/30/19	DS	Assemble fee for service credits by counterparty schedule	0.30
10/30/19	DS	Assemble private insurance program rebates by counterparty schedule	0.40
10/30/19	DS	Assemble Medicaid rebates by counterparty schedule	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
10/30/19	DS	Assemble Medicare part D rebates by counterparty schedule	0.20
10/30/19	NAS	Create individualized SOFA Part 2 Question 4 disclosures as requested by counsel for one former insider.	0.20
10/30/19	NAS	Provide additional detail regarding insider compensation as requested by restructuring counsel (Davis Polk & Wardwell).	0.50
10/30/19	MH	Direct staff to create electronic versions of SOFA and SOAL reports for committees and noticing agent.	0.70
10/30/19	MH	Answer questions from counsel on the tax listings in the Schedules.	0.20
10/30/19	SKL	Finalize updates to the critical vendor notification tracker and provide to the company to sign-off accordingly.	2.10
10/30/19	SKL	Refresh the critical vendor and vendor management tracker with the latest information provided by the company re: latest vendor agreements.	1.80
10/30/19	SKL	Review the latest AP payments and payables file and prepare the updated releases for today's distribution.	1.00
10/30/19	HK	Gather filed SOFAs and Schedules detail in Excel per communication advisor Teneo's request for data.	1.10
10/30/19	HK	Research and provide detail to Davis Polk on press-related questions regarding the SOFAs and Schedules disclosures.	2.90
10/30/19	HK	Provide detail on reported attrition and employment-related issues to Human Resources.	0.30
10/31/19	HK	Research SOFAs and Schedules-related requests on filed amounts per Davis Polk.	1.40
10/31/19	HK	Research and provide detail for diligence requests by committees' professionals.	2.70
10/31/19	SKL	Prepare updated critical vendor status report for the	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		company to review and sign-off on before distribution to Davis Polk.	
10/31/19	SKL	Review the latest AP payments and payables file and prepare the updated releases for today's distribution.	1.70
10/31/19	SKL	Prepare updated summary report and detailed vendor notification tracker and prepare distribution to the Paul Weiss team.	2.60
10/31/19	SKL	Prepare updated 90-day payment breakdown per UCC/AHC request.	2.10
10/31/19	SKL	Reconcile the critical vendor cap analysis between the last two weeks to determine differences in vendor balances.	1.70
10/31/19	JD	Correspondence with management and the UST RE: questions on cash balances	0.40
11/01/19	DS	Draft answers to Head of Customer Programs (PPLP) in response to her comments to Customer Programs Monthly Report	1.10
11/01/19	DS	Analyze information from TXP Accounts Receivable analyst re: Purdue RDC credits for purposes of Customer Programs Monthly Report	0.40
11/01/19	HK	Review SOFAs & Schedules filed data to be responsive to Committees' requests.	3.40
11/01/19	MH	Prepare response to questions from committee professionals on indemnity expenses in the insider payment list.	0.30
11/04/19	HK	Review Debtors' legal settlement payment receipt detail.	1.30
11/04/19	HK	Review diligence documents to respond to UCC requests.	2.70
11/04/19	HK	Review Debtors' vendor detail to provide to UCC per diligence request.	1.20
11/04/19	HK	Review non-bankruptcy professional payments per UCC diligence request.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/05/19	HK	Attend part of 341 Meeting	0.90
11/05/19	HK	Prepare for SOFAs & Schedules discussion at 341 Meeting.	2.40
11/05/19	HK	Review follow-up requests to SOFAs & Schedules questions at 341 Meeting.	2.70
11/05/19	MH	Call with D. Samikkannu and M. Hartley (both AlixPartners) call re: October MOR reporting process	0.30
11/05/19	MH	Research reported error in the Schedules and confirm report is incorrect.	0.80
11/05/19	MH	Prepare summary of third quarter UST fees due and coordinate payment with the UST and the company.	0.70
11/05/19	JD	Pre-meeting with management and Davis Polk re: 341 meeting	1.50
11/05/19	JD	Participate in 341 meeting	0.80
11/05/19	DS	Call with D. Samikkannu and M. Hartley (both AlixPartners) re: October MOR reporting process	0.30
11/05/19	ADD	Review SOFA and Schedules (schedule F) support and schedules filed on Prime Clerk site in response to an inquiry.	0.80
11/06/19	HK	Review contracts data in preparation for contracts assumption discussion.	1.40
11/06/19	HK	Review documents to provide to UCC per diligence requests.	3.20
11/06/19	MH	Prepare list of charities associated with the Sackler family and reconcile with prior analysis work.	0.80
11/06/19	SKL	Review latest status and analysis of Critical Vendor payments and tracking towards vendor payment cap.	1.00
11/07/19	HK	Review documents to provide to UCC per diligence requests.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/07/19	HK	Review preference period payments per Counsel's request.	1.20
11/07/19	HK	Review contracts data in preparation for contracts assumption discussion.	3.40
11/07/19	JD	Review latest parties in interest list and review correspondence from Davis Polk re: same.	0.50
11/08/19	HK	Review documents to provide to UCC per diligence requests.	1.30
11/08/19	MH	Coordinate with accounts payable to ensure payment of UST fees.	0.40
11/11/19	HK	Reconciliation of vendor claim amounts and prepetition open trade payables.	2.90
11/11/19	HK	Gather diligence documents for upload to the Intralinks data site for UCC.	0.40
11/11/19	HK	Review vendor payments detail for vendor categorization data for UCC diligence request.	0.40
11/11/19	HK	Review contractual relationships with vendors paid under motion.	0.90
11/12/19	HK	Review vendor payments detail for vendor categorization data for UCC diligence request.	2.70
11/12/19	HK	Gather diligence documents for upload to the Intralinks data site for UCC.	0.90
11/12/19	HK	Review Debtors' trust agreement data for UCC diligence request.	1.80
11/12/19	HK	Reconciliation of vendor claim amounts and prepetition open trade payables.	2.40
11/12/19	JD	Review additional details re: 90-day payments in response to UCC/AHC committee questions	0.60
11/13/19	HK	Reconciliation of vendor claim amounts and prepetition open trade payables.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/13/19	HK	Review Debtors' trust agreement data for UCC diligence request.	0.80
11/13/19	HK	Gather diligence documents for upload to the Intralinks data site for UCC.	2.40
11/13/19	HK	Review vendor payments detail for vendor categorization data for UCC diligence request.	1.40
11/13/19	HK	Prepare and review the latest Critical Vendor Breakdown and Analysis with S. Lemack and H. Ku (both AlixPartners).	0.50
11/13/19	HK	Review Critical Vendor Payment and Tracking Process with S. Lemack, H. Ku and M. Hartley (all AlixPartners).	1.30
11/13/19	MH	Review Critical Vendor Payment and Tracking Process with S. Lemack, H. Ku, and M. Hartley (all AlixPartners)	1.30
11/13/19	MH	Confirm all requirements for the Monthly Operating Report as agreed with the United States Trustee.	0.60
11/13/19	MH	Develop project plan to create new MOR package template.	1.20
11/13/19	MH	Send data requests to support the October MOR.	0.50
11/13/19	SKL	Review Critical Vendor Payment and Tracking Process with H. Ku, S. Lemack and M. Hartley (all AlixPartners).	1.30
11/13/19	SKL	Prepare and review the latest Critical Vendor Breakdown and Analysis with H. Ku and S. Lemack (both AlixPartners).	1.10
11/13/19	NAS	Discussion with C. MacDonald (Purdue) to clarify list of individuals for whom indemnity payment data is required for Monthly Operating Report.	0.20
11/13/19	NAS	Draft list of data requirements for insider payments portion of monthly operating report.	0.90
11/13/19	NAS	Submit required data requests to complete insider payments portion of Monthly Operating Report.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/14/19	NAS	Correspondence with K. Darragh (Purdue) and H. Benson (Purdue) regarding required insider payment data points for Monthly Operating Report.	0.20
11/14/19	HK	Review prepetition invoices to be paid under motion.	2.70
11/14/19	HK	Review contractual relationships with vendors paid under motion.	1.80
11/14/19	HK	Review vendors' pending trade agreements for disclosure to UCC.	1.50
11/15/19	HK	Review prepetition trade payables to be paid under motion.	1.10
11/15/19	HK	Update vendor trade agreement tracker for Account Payable hold process.	0.70
11/15/19	SKL	Finalize review and update to the latest critical vendor breakdown and tracker.	1.40
11/15/19	NAS	Analyze insider payment data provided by Purdue for purposes of Monthly Operating Report to ensure all required information is captured.	1.40
11/15/19	NAS	Consolidate insider payment data provided by Purdue into Monthly Operating Report model and review for accuracy.	1.80
11/15/19	DS	Tie-out bank balances to cash activity in cash actuals reporting model for MOR purposes	2.30
11/15/19	DS	Incorporate comments by I. Arana (AlixPartners) into cash report	0.40
11/18/19	DS	Review cash and short-term investments account and match with cash reporting listing to ensure completeness for MOR	1.90
11/18/19	NAS	Update insider payment section of Monthly Operating Report following revisions to data received from Purdue.	0.70
11/18/19	NAS	Revise listing of IAC payments in insider payments section of Monthly Operating Report following discussions	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		with K. Darragh (Purdue).	
11/18/19	NAS	Search vendor codes for insiders and incorporate relevant transactions in insider payments section of Monthly Operating Report.	0.90
11/18/19	NAS	Check all figures included in insider payments section of Monthly Operating Report for accuracy.	1.80
11/18/19	NAS	Confirmation with Purdue and TXP of select insider payments included in latest draft of Monthly Operating Report following internal Alix team review.	0.40
11/18/19	SKL	Review latest feedback re: Vendor Management and prepare updates accordingly.	0.60
11/18/19	HK	Review Critical Vendor Payment and Tracking Process	1.30
11/18/19	HK	Gather diligence documents for upload to the Intralinks data site for UCC.	3.10
11/18/19	HK	Review vendor payments detail for vendor categorization data for UCC diligence request.	1.20
11/18/19	HK	Review prepetition transactions for vendor categorization per UCC request.	2.60
11/18/19	MH	Prepare answers to vendor questions submitted by UCC professionals.	0.30
11/18/19	MH	Prepare cash data for October MOR.	1.60
11/18/19	MH	Finalize October MOR template.	2.30
11/19/19	MH	Prepare financial data for October MOR.	2.30
11/19/19	MH	Prepare insider data for October MOR	1.70
11/19/19	MH	Prepare professional payment data for October MOR.	0.30
11/19/19	MH	Create first draft of October MOR for management review.	1.80
11/19/19	HK	Review Critical Vendor Payment and Tracking Process	1.40
11/19/19	HK	Reconciliation of vendor claim amounts and prepetition open trade payables.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/19/19	NAS	Revisions to insider payments section of Monthly Operating Report following AlixPartners and Purdue review.	0.80
11/19/19	NAS	Revise T&E data included in insider payments section of Monthly Operating Report to reflect disbursement date as opposed to expense report approval date.	1.90
11/19/19	NAS	Review of latest draft of Monthly Operating Report for accuracy ahead of 11/20 filing.	1.80
11/19/19	DS	Update summary page to monthly Customer Programs report	1.20
11/19/19	DS	Review draft MOR report and send comments	1.50
11/20/19	JD	Review previous cash tracking files and correspondence re: quarterly UST fee payment.	0.30
11/20/19	NAS	Review of final Monthly Operating Report for accuracy prior to submission.	0.60
11/20/19	HK	Update critical vendor payments analysis for company discussion.	2.80
11/20/19	HK	Update critical vendor summary for UCC reporting.	0.70
11/20/19	HK	Review additional adequate assurance requests pursuant to the Utilities Motion.	0.40
11/20/19	HK	Review draft trade agreements under the Vendor Motion.	1.20
11/20/19	HK	Review accounts payable tracking under the First Day Motions.	2.30
11/20/19	SKL	Provide updates re: Critical Vendor inquiries.	0.50
11/20/19	MH	Update the October MOR to reflect updates and revisions from reviewers.	1.80
11/20/19	MH	Create final October MOR for filing.	1.40
11/21/19	HK	Review reconciliation of vendor invoices paid under First Day Motions.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/21/19	HK	Review accounts payable tracking under the First Day Motions.	1.90
11/21/19	HK	Update critical vendor payments analysis for company discussion.	1.40
11/21/19	HK	Meeting on payments under Vendor Motion including J. Lowne, E. Ruiz, Sanil Daniel (all Purdue)	0.50
11/22/19	HK	Update critical vendor payments analysis for company discussion.	1.80
11/22/19	HK	Review accounts payable tracking under the First Day Motions.	2.70
11/22/19	SKL	Prepare updates to the latest Critical Vendor inquiries.	0.80
11/25/19	HK	Update vendor payments summary for UCC reporting.	1.30
11/25/19	HK	Review draft trade agreements under the Vendor Motion.	3.20
11/25/19	HK	Discussion with D. Ebere (Rhodes Pharma) on vendor trade agreement statuses.	0.30
11/25/19	HK	Update critical vendor payments analysis for company discussion.	2.70
11/26/19	HK	Update critical vendor payments analysis for company discussion.	3.10
11/26/19	HK	Review draft trade agreements under the Vendor Motion.	2.40
11/27/19	HK	Update vendor payments summary for UCC reporting.	1.70
11/27/19	HK	Update critical vendor payments analysis for company discussion.	1.50
11/27/19	HK	Review draft trade agreements under the Vendor Motion.	1.30
11/29/19	HK	Review accounts payable tracking under the First Day Motions.	2.20
11/29/19	HK	Review draft trade agreements under the Vendor Motion.	2.20
11/29/19	HK	Update critical vendor summary for UCC reporting.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/29/19	HK	Update critical vendor payments analysis for company discussion.	2.10
12/03/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	1.30
12/03/19	HK	Update vendor payments tracker with revised Accounts Payable data for internal discussion.	0.70
12/04/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	2.70
12/04/19	HK	Review draft trade agreements under the Vendor Motion.	1.60
12/04/19	SKL	Review the SOFA/Schedule filings and provide update re: patents per request.	0.70
12/05/19	HK	Update critical vendor payments tracker with revised Accounts Payable data.	1.50
12/06/19	HK	Review of pre-petition invoices to confirm payments paid under Motion.	1.40
12/09/19	HK	Update status tracking documents for vendor trade agreements	0.70
12/09/19	MH	Prepare new Monthly Operating Report template for November.	0.80
12/09/19	MH	Distribute work plan for November Monthly Operating Report.	0.30
12/09/19	MH	Update retained professionals release list to reflect new retention orders.	0.70
12/09/19	MH	Build new professional payment tracking system.	2.20
12/10/19	HK	Update tracking documents for Critical Vendor payments under motion	0.90
12/10/19	JD	Discussion with management re: additional accounting reserves and review latest MOR re: incorporating updated numbers into the upcoming filing.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
12/11/19	HK	Update tracking documents for Critical Vendor payments under motion	1.30
12/11/19	IF	Review cash transfers of Value Report for redactions	4.20
12/11/19	IF	Review cash transfers of Value Report for redactions.	4.20
12/11/19	HK	Update tracking documents for Critical Vendor payments under motion	0.20
12/11/19	HK	Update status tracking documents for vendor trade agreements	0.50
12/11/19	NAS	Review insider T&E and housing payment data provided by Purdue/TXP Services for purposes of November 2019 Monthly Operating Report.	0.50
12/11/19	NAS	Request payroll, benefit, and one-off insider payment sources from Purdue/TXP for purposes of November 2019 Monthly Operating Report.	0.40
12/12/19	NAS	Request updated insider payment data for purposes of November 2019 Monthly Operating Report and consolidate data received to date.	1.00
12/12/19	HK	Update status tracking documents for vendor trade agreements	1.40
12/13/19	HK	Update tracking documents for Critical Vendor payments under motion	1.20
12/16/19	HK	Update status tracking documents for vendor trade agreements	1.60
12/16/19	HK	Update tracking documents for Critical Vendor payments under motion	1.40
12/16/19	NAS	Consolidate data sources and build model for insider payments section of November 2019 Monthly Operating Report.	1.80
12/16/19	NAS	Check all figures listed in initial draft of insider payments section for November 2019 Monthly Operating Report.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
12/16/19	NAS	Further analysis of annual fair market value computation for vehicles used by C. Landau and M. Kesselman (both Purdue) as listed in company payroll reports.	0.50
12/17/19	NAS	Proof insider payments section of November 2019 Monthly Operating Report and revise where necessary.	1.70
12/17/19	NAS	Discussion with M. Hartley and N. Simon (both AlixPartners) regarding remaining open items for insider payments section of November 2019 Monthly Operating Report.	0.30
12/17/19	HK	Update status tracking documents for vendor trade agreements	1.40
12/17/19	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding (all Purdue), D. Fogel (Rhodes), H. Ku, and M. Hartley (both AlixPartners) on critical vendor management issues.	0.40
12/17/19	MH	Review submitted data for inclusion in the November Monthly Operating Report.	2.20
12/17/19	MH	Discussion with N. Simon and M. Hartley (both AlixPartners) regarding remaining open items for insider payments section of November 2019 Monthly Operating Report.	0.30
12/18/19	MH	Prepare initial draft of the November Monthly Operating Report.	2.80
12/18/19	HK	Update status tracking documents for vendor trade agreements	1.30
12/18/19	HK	Update tracking documents for Critical Vendor payments under motion	1.80
12/19/19	HK	Update tracking documents for Critical Vendor payments under motion	1.60
12/19/19	HK	Update status tracking documents for vendor trade agreements	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
12/19/19	MH	Finalize edits to the November Monthly Operating Report.	2.40
12/19/19	JD	Review and provide comments re: draft November MOR.	0.70
12/20/19	MH	Create and submit final November Monthly Operating Report for filing.	0.80
12/20/19	HK	Update status tracking documents for vendor trade agreements	0.50
12/20/19	NAS	Review of final November 2019 Monthly Operating Report for accuracy.	0.60
12/23/19	HK	Update status tracking documents for vendor trade agreements	1.10
12/23/19	HK	Update tracking documents for Critical Vendor payments under motion	1.30
12/24/19	HK	Update status tracking documents for vendor trade agreements	1.80
12/26/19	HK	Update status tracking documents for vendor trade agreements	0.80
12/26/19	HK	Update tracking documents for Critical Vendor payments under motion	1.80
12/26/19	HK	Review IAC diligence materials for COGS reduction initiatives	1.40
12/27/19	HK	Update tracking documents for Critical Vendor payments under motion	0.40
12/27/19	HK	Update status tracking documents for vendor trade agreements	1.40
12/30/19	HK	Update status tracking documents for vendor trade agreements	1.80
12/30/19	HK	Update tracking documents for Critical Vendor payments under motion	1.80
12/31/19	HK	Update status tracking documents for vendor trade	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		agreements	
01/02/20	HK	Update status tracking documents for vendor trade agreements	1.30
01/07/20	NAS	Request and receive partial December 2019 MOR insider payments and plan submission timetable.	0.10
01/08/20	HK	Update status tracking documents for vendor trade agreements	2.10
01/09/20	HK	Update status tracking documents for vendor trade agreements	1.30
01/10/20	HK	Update status tracking documents for vendor trade agreements	2.10
01/10/20	MH	Update professional payments for December MOR.	1.30
01/10/20	MH	Update Monthly Operating Report template for December.	0.70
01/10/20	NAS	Review data provided by Purdue regarding insider payments section of MOR and ask follow-up questions.	0.20
01/13/20	HK	Update status tracking documents for vendor trade agreements	2.50
01/13/20	DS	Review MOR disbursements allocation for completeness and accuracy	1.90
01/13/20	DS	Review supporting MOR schedules to ensure accuracy	1.40
01/13/20	DS	Prepare data and support schedules for S. Lemack (AlixPartners) re: calculation of U.S. Trustee fees	0.80
01/14/20	HK	Update status tracking documents for vendor trade agreements	0.40
01/14/20	HK	Review trading region budget presentations to update draft business overview	2.30
01/14/20	HK	Review non-trading cost center reference materials to update Mundipharma business overview documents.	1.70
01/14/20	JD	Review cash details for December MOR, review against	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		previous months and review Q4 US Trustee fee calculation.	
01/15/20	HK	Review non-trading cost center reference materials to update Mundipharma business overview documents.	2.20
01/15/20	HK	Review trading region budget presentations to update draft business overview	2.80
01/15/20	HK	Update status tracking documents for vendor trade agreements	1.20
01/16/20	HK	Update status tracking documents for vendor trade agreements	1.40
01/16/20	HK	Update sales analysis by region and therapeutic are per PJT request.	2.80
01/16/20	MH	Prepare summaries of cash and bank activity for Monthly Operating Report.	0.80
01/17/20	MH	Update legal expenses for the December Monthly Operating Report.	0.30
01/17/20	HK	Update status tracking documents for vendor trade agreements	1.50
01/21/20	HK	Update status tracking documents for vendor trade agreements	0.80
01/21/20	DS	Follow up with Rhodes controller re: data needed for Customer Programs report	0.30
01/21/20	DS	Follow up with Finance manager (Purdue) re: data needed for Customer Programs report	0.30
01/22/20	HK	Update status tracking documents for vendor trade agreements	0.90
01/23/20	HK	Review public litigation data disclosures for possible creditor due diligence request.	0.20
01/24/20	HK	Update status tracking documents for vendor trade agreements	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
01/27/20	HK	Update status tracking documents for vendor trade agreements	0.40
01/27/20	NAS	Update and consolidate all insider payment reports for December 2019 Monthly Operating Report.	2.60
01/27/20	DS	Correspondence with AlixPartners Operations team re: assistance with redaction process	0.30
01/28/20	NAS	Revise insider payments section of December 2019 Monthly Operating Report and review for accuracy.	1.10
01/29/20	NAS	Finalize insider payments section of December 2019 MOR.	0.20
01/29/20	DS	Review U.S. Trustee data supporting quarterly fee	0.40
01/30/20	NAS	Final review and submission of insider payments section of December 2019 Monthly Operating Report.	0.80
01/31/20	MH	Complete the December Monthly Operating Report (except for financial statements).	2.20
Total			1,168.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Edward DuHalde	20.50	360.00	7,380.00
Roy Ellis Ochoa	2.50	385.00	962.50
Sam K Lemack	206.80	440.00	90,992.00
Hart Ku	410.20	440.00	180,488.00
Andrew D DePalma	50.80	480.00	24,384.00
Nate A Simon	171.10	480.00	82,128.00
Julie A Doherty	41.70	480.00	20,016.00
Hart Ku	28.10	515.00	14,471.50
Nate A Simon	5.00	515.00	2,575.00
David Samikkannu	49.40	615.00	30,381.00
Isabel Arana de Uriarte	7.90	615.00	4,858.50
Fernando O Silva	0.70	615.00	430.50
David Samikkannu	5.40	690.00	3,726.00
Isaac Fisboin	8.40	775.00	6,510.00
Michael Hartley	84.80	830.00	70,384.00
Scott Robertson	0.20	830.00	166.00
Michael Hartley	5.30	840.00	4,452.00
Jesse DelConte	26.90	945.00	25,420.50
Jesse DelConte	0.70	950.00	665.00
Barry Folse	41.80	1,080.00	45,144.00
Total Hours & Fees	1,168.20		615,534.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/16/19	NAS	Attend Purdue employee town hall to ensure vendor communication strategy is aligned with information provided to employees	1.00
09/16/19	NAS	Search company's books and records to obtain corrected contact information for specific vendors and ensure all information is up-to-date.	0.50
09/16/19	NAS	Coordinate with D. McGuire and J. Carlisle (both Purdue) to respond to vendor requests, determine status of amounts owed (pre- or post-petition), and escalate any necessary approvals to corporate.	1.40
09/16/19	NAS	Led Chapter 11 vendor management training session along with J. Carlisle and D. McGuire (both Purdue) for Finance and Procurement employees who are in regular contact with vendors.	2.00
09/16/19	NAS	Meeting with D. McGuire and J. Carlisle (both Purdue) to discuss timing of bankruptcy training information distributed to Purdue employees in contact with vendors.	0.30
09/16/19	NAS	Review latest available information regarding prepetition amounts outstanding to inform vendor communication strategy and contact priority.	0.50
09/16/19	NAS	Consolidate relevant first day motions and providing summary for Associate Director of Finance in order for Associate Director of Finance to provide most up-to-date information to vendors.	0.40
09/16/19	NAS	Lead training call alongside with D. McGuire and J. Carlisle (both Purdue) for procurement specialists at Purdue Treyburn manufacturing facility to explain Chapter 11 vendor procedures and provide plan to handle any vendor inquiries to Treyburn facility regarding prepetition amounts owed.	0.30
09/16/19	JAD	Conduct training for client 'Local Specialists' on process	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for interacting with vendors after the filing.	
09/16/19	JAD	Address Rhodes questions regarding trade agreements and business development partner relationships.	1.50
09/16/19	JAD	Answer Rhodes vendor specific questions from Local Specialists making proactive outbound calls.	2.90
09/16/19	JAD	Attend Rhodes Local Specialists meeting to determine Rhodes specific outreach and documentation strategy.	0.50
09/16/19	JAD	Answer Rhodes technical bankruptcy questions regarding pre- vs. post-petition, purpose of various motions, etc.	2.70
09/16/19	IA	Review of business plan materials in preparation for putting together diligence support documents.	0.80
09/16/19	JD	Conversations with Associate General Counsel RE: open vendor communications and issues	0.80
09/16/19	JD	Attend employee town hall meeting with all employees	1.00
09/16/19	DS	Call with T. Melvin (PJT) re: commentary around business plan	0.30
09/16/19	DS	Correspondence with Assistant General Counsel R. Aleali (Purdue) re: business plan commentary	0.30
09/16/19	DS	Review of employee historical count data	0.90
09/16/19	DS	Address Davis Polk's inquiries re: customer breakout and cash vs. non-cash rebates/chargebacks	1.70
09/17/19	DS	Review of existing materials to incorporate into business plan package	1.90
09/17/19	JAD	Address Rhodes questions regarding trade agreement templates and modifications.	2.80
09/17/19	JAD	Answer Rhodes technical bankruptcy questions regarding pre- vs. post-petition, purpose of various motions, etc.	2.70
09/17/19	NAS	Assist J. Carlisle (Purdue) and his employees at Purdue Wilson facility with vendor communication strategies and	1.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		any payment questions posed by vendors.	
09/17/19	NAS	Escalate shutoff notice provided by internet provider to ensure continuation of service pursuant to Utilities motion filed 9/16.	0.50
09/17/19	NAS	Telephone call with A. Hart and J. Carlisle (both Purdue) to address vendor-specific strategy questions.	0.50
09/17/19	NAS	Resolve technical issue regarding access to vendor communication tracking database for Purdue Wilson Finance/Procurement employee.	0.20
09/17/19	NAS	Investigation into which vendors qualify for payment of prepetition amounts owed under "Clinical Trial Vendors" classification in Critical Vendors motion filed 9/16.	0.30
09/18/19	NAS	Meeting with J. Carlisle (Purdue) regarding ability to pay prepetition state taxes and licensing fees under Taxes motion filed 9/16.	0.10
09/18/19	NAS	Discussion with J. Carlisle (Purdue) regarding pre- or post-petition status of obligations for goods in transit, continued use of procurement cards, and necessity of trade agreements for vendors with no prepetition amount owed.	0.50
09/18/19	NAS	Assist Purdue Finance/Procurement employees at Wilson facility with responses to vendor inquiries including determination of prepetition amounts owed listed on trade agreement, authorized signatories for trade agreements, and additional detail on internal prepetition invoice payment process.	1.10
09/18/19	NAS	Assist J. Carlisle (Purdue) and member of his team in direct contact with vendor with negotiating post-petition payment terms for an IT vendor.	0.20
09/18/19	NAS	Discussion with J. Carlisle (Purdue) regarding noticing for utilities, negotiation strategy for vendors not owed any prepetition amounts but are requesting accelerated	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		terms, and timing of prepayments for postpetition obligations.	
09/18/19	JAD	Create tracking document to review status of critical vendor communication and prepetition liability release.	2.30
09/18/19	JAD	Review contracts of proposed vendors to determine whether those vendors qualify for payment under the critical vendor motion.	2.60
09/18/19	JAD	Address Rhodes questions regarding trade agreement templates and modifications.	1.60
09/18/19	JAD	Answer Rhodes technical bankruptcy questions regarding pre- vs. post-petition, purpose of various motions, etc.	0.50
09/18/19	IA	Follow up on motions and orders for distribution to company.	1.30
09/18/19	IA	Review vendor communications and provided comments on status of motions and upcoming hearings.	1.70
09/18/19	IA	Review and updated year to date legal spend information to show shareholder versus other indemnification spend by firm, for review by PJT.	2.40
09/18/19	IA	Review of OCP motion, current firms based on spend and potential cap analysis.	1.90
09/18/19	DS	Correspondence with J. DelConte (AlixPartners) re: business plan format provided to PBGC	0.20
09/18/19	DS	Review previous business plan materials to identify which data to include in revised business plan package	2.20
09/18/19	DS	Create business plan tracker to organize source data and files already in existence	2.20
09/18/19	DS	Review business plan model provided by PJT	1.30
09/18/19	DS	Correspondence with PJT re: existing business plan materials and requesting support files as applicable	0.40
09/19/19	ADD	Update due diligence status for review	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/19/19	ADD	Download and distribute accounts payable file. (afternoon refresh)	0.80
09/19/19	ADD	Call with VDR provider customer support.	0.60
09/19/19	ADD	Set up VDR file structure and uploaded initial due diligence items.	2.40
09/19/19	ADD	Develop VDR approval work flows.	1.30
09/19/19	ADD	Review sample of accounts payable invoices to check for correct coding.	2.10
09/19/19	IA	Follow up on OCP process and tiers for different firms based on run rates.	2.70
09/19/19	IA	Follow up on list of closed accounts for reporting on SOFAs and schedules	0.40
09/19/19	IA	Review YTD payments to OCPs and process for go-forward payments.	2.10
09/19/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.80
09/19/19	JAD	Address Rhodes questions regarding trade agreement templates and modifications.	1.70
09/19/19	JAD	Review contracts of proposed vendors to determine whether those vendors qualify for payment under the critical vendor motion.	0.90
09/19/19	JAD	Answer Rhodes technical bankruptcy questions regarding pre- vs. post-petition, purpose of various motions, etc.	1.90
09/19/19	NAS	Assist J. Carlisle's (Purdue) team of Purdue employees responsible for contact with vendors with vendor questions regarding continuation of services and payment of prepetition amounts. Vendors include utility providers and those deemed critical to operations.	0.80
09/19/19	JD	Correspondence with AlixPartners team and PJT RE: diligence process and preliminary diligence materials.	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/20/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.60
09/20/19	JAD	Review proposed vendors to determine whether those vendors qualify for payment under the critical vendor motion.	1.40
09/20/19	JAD	Address Rhodes questions regarding trade agreement templates and modifications.	0.70
09/20/19	JAD	Review submitted and signed trade agreements for critical vendors.	1.10
09/20/19	IA	Follow up on indemnity payment diligence requests and review of existing backup information.	2.40
09/20/19	IA	Follow up on legal vendor payments and critical vendor process.	1.80
09/20/19	IA	Drafting of OCP notes and process outline for discussion with legal team.	3.20
09/20/19	ADD	Send out email requests for due diligence items.	0.40
09/20/19	ADD	Download and distribute update accounts payable invoice listing and historical payments.	0.90
09/20/19	ADD	Review and organize diligence items.	0.60
09/20/19	ADD	Create historical critical vendor spend schedules.	1.40
09/20/19	ADD	Review open / cleared accounts payable and researched potential exceptions	1.70
09/21/19	ADD	Address comments for file uploaded to VDR.	0.70
09/21/19	ADD	Prepare financial schedules and organize data in anticipation of due diligence requests.	2.30
09/21/19	ADD	Update file provided by client to conform with diligence requirements.	2.20
09/21/19	ADD	Update log of information shared by client to external parties	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/21/19	IA	Review of initial diligence list from FTI.	0.80
09/21/19	IA	Review and provide edit suggestions to files in preparation for uploading to data room for diligence.	2.60
09/22/19	ADD	Update log of information provided to client to external parties.	1.50
09/22/19	ADD	Submit request to for outstanding data.	0.40
09/22/19	ADD	Address virtual data room comments.	2.20
09/23/19	ADD	Research accounts payable to identify potential conflicts.	1.30
09/23/19	ADD	Submit approval request for due diligence request	0.60
09/23/19	ADD	Meeting with I. Arana, A. DePalma (both AlixPartners), and HR Team re: FTI's initial diligence list	0.80
09/23/19	ADD	Meeting with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) to review items to be uploaded to data room and provide status updates on open items.	1.60
09/23/19	ADD	Extract open and cleared AP from SAP and provided file to the team.	0.40
09/23/19	ADD	Research potential sources of data for counsel request.	0.80
09/23/19	DS	Compile backup for Project Gale sale and provide sale proceeds number to PJT	0.20
09/23/19	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners) to review items to be uploaded to data room and provide status updates on open items	1.60
09/23/19	IA	Meeting with I. Arana, A.DePalma (both AlixPartners), and HR Team re: FTI's initial diligence list.	0.80
09/23/19	IA	Meeting with D. Samikkannu, J. DelConte, I. Arana, and A. DePalma (all AlixPartners) to review items to be uploaded to data room and provide status updates on open items	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/23/19	IA	Update to account balances summary as of filing date to be posted in response to diligence questions.	0.40
09/23/19	IA	Follow up on cash management motion diligence requests.	2.50
09/23/19	JAD	Meeting with K. Darragh (Purdue), J. Doherty, and S. Lemack (both AlixPartners) to discuss presentation of A/R in Schedule AB.	0.50
09/23/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.10
09/23/19	JAD	Review submitted and signed trade agreements for critical vendors.	0.40
09/23/19	JD	Correspondence with E. Vonnegut (Davis Polk) and management RE: PBGC premium payments	0.40
09/23/19	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners) to review items to be uploaded to data room and provide status updates on open items	1.60
09/23/19	JD	Review materials that could be responsive to FTI data requests	2.20
09/23/19	JD	Review customer ADA	0.40
09/23/19	JD	Review DOL audit letters and discussion with management RE: same.	0.80
09/23/19	JD	Calls with CFO RE: open business issues	0.50
09/23/19	SKL	Prepare for and attend meeting with K. Darragh (Purdue), J. Doherty, and S. Lemack (both AlixPartners) to discuss presentation of A/R in Schedule AB.	0.70
09/24/19	JD	Review isosceles captive cell insurance agreement	0.50
09/24/19	JD	Correspondence with management and Davis Polk RE: certain wage payments and reimbursements	0.60
09/24/19	JD	Review information related to insurance submissions and provide comments RE: same.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/24/19	JD	Review details of wage motion bonus details	0.40
09/24/19	JD	Prepare for and participate in a call with Davis Polk and management RE: wage motion and go forward program implementation.	0.70
09/24/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.90
09/24/19	JAD	Review submitted and signed trade agreements for critical vendors.	2.70
09/24/19	IA	Review and source documents and drafting of summaries of Treyburn Severance and Retention for diligence purposes.	2.30
09/24/19	IA	Updated information for SOFA and schedules related to cash management and bank accounts	1.50
09/24/19	IA	Review of Purdue and Rhodes org charts.	0.40
09/24/19	IA	Meeting with A. DePalma, I. Arana (both AlixPartners) and C. Ricarte (Purdue) to discuss available information produced for discovery and centralization for go-forward diligence process.	0.50
09/24/19	IA	Call with HR (Purdue), Davis Polk, I. Arana, and D. Samikkannu (both AlixPartners) re: compensation programs.	0.90
09/24/19	IA	Follow up on diligence requests on indemnity payments to employees.	1.70
09/24/19	IA	Follow up with client on diligence requests from Davis Polk re: wages and benefits.	1.20
09/24/19	DS	Meeting with TXP re: insurance data requested by Willis Towers Watson and insurance diligence items from FTI	0.40
09/24/19	DS	Call with Controller (Rhodes) re: rebates	0.20
09/24/19	DS	Call with HR (Purdue), Davis Polk, I. Arana, and D. Samikkannu (both AlixPartners) re: compensation	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		programs	
09/24/19	DS	Work on counterparty model - incorporating data received from both Rhodes and PPLP	3.50
09/24/19	DS	Review and updated Rhodes customer discount data for counterparty analysis	1.80
09/24/19	ADD	Prepare files for upload to data room for FTI due diligence request	3.20
09/24/19	ADD	Due diligence and information request discussion with assistant GC.	0.40
09/24/19	ADD	Meeting with A. DePalma, I. Arana (both AlixPartners) and C. Ricarte (Purdue) to discuss available information produced for discovery and centralization for go-forward diligence process.	0.50
09/24/19	ADD	Discuss due diligence request with controller.	0.60
09/24/19	ADD	Download and distribute accounts payable data.	0.40
09/25/19	ADD	Add data room users and updated permissions per counsel request.	0.30
09/25/19	ADD	Request approval from client and counsel for documents prior to inclusion in data room.	0.80
09/25/19	ADD	Review classification of invoices submitted for payment.	1.60
09/25/19	ADD	Compile and distribute accounts payable data to team.	1.30
09/25/19	DS	Review files to provide N. Simon (AlixPartners) with data re: voluntary employee terminations	0.60
09/25/19	DS	Finish assembling business plan draft section for consumer health business and provide to J. DelConte for review	2.60
09/25/19	IA	Follow up on market access program diligence requests. Review of sales bonus amounts paid historically by employee.	3.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/25/19	IA	Follow up on diligence requests related to severance in employee compensation benchmarking.	0.60
09/25/19	IA	Review of 2015-2019 earnings reports showing payments by employee and summarizing of historical plan payments in response to diligence requests.	3.90
09/25/19	IA	Update of Purdue Severance and Treyburn severance detail to be uploaded to the data room for diligence purposes.	1.40
09/25/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	0.80
09/25/19	JAD	Comply and format data to be used in Schedule AB Part 10.	1.30
09/26/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.80
09/26/19	IA	Review of initial batch of financial files to be uploaded to the data room for diligence purposes.	2.40
09/26/19	IA	Draft of Non-Executive retention schedule to be shared for diligence purposes.	1.70
09/26/19	IA	Review and reconciliation of active employee roster amounts with projected benefit payments under different programs. Drafting of redacted summary to be shared with external parties for diligence purposes.	3.30
09/26/19	JAD	Create summary statistics to be used in Rhodes and Purdue vendor review committee meetings.	0.70
09/26/19	JD	Correspondence with PJT and AlixPartners RE: diligence update and review latest materials.	0.70
09/26/19	JD	Call with D. Samikkannu, J. DeConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items approvals	0.30
09/26/19	DS	Work on organizing PPLP section of business plan	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		materials	
09/26/19	DS	Call with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items approvals	0.30
09/26/19	DS	Review 2018 sales allocation by customer and product to compare with updated numbers	0.80
09/26/19	DS	Correspondence with financial analyst re: customers in sales listing	0.30
09/26/19	ADD	Configure data room to add ad hoc committee's consultants.	1.50
09/26/19	ADD	Review accounts payable to report amounts paid authorized by motion.	0.80
09/26/19	ADD	Call with D. Samikkannu, J. DelConte, and A. DePalma (all AlixPartners) re: status of FTI diligence items approvals.	0.30
09/26/19	ADD	Compile and upload files to the Interlinks VDR for ad hoc committee FA review.	2.80
09/27/19	ADD	Download and distribute accounts payable file.	0.50
09/27/19	ADD	Upload data to Live Intralinks VDR.	1.10
09/27/19	DS	Provide guidance to management re: payments/credits to a customer based on applicable 1st Day document	0.30
09/27/19	JD	Call with Controller RE: treatment of prepetition severance accruals	0.60
09/27/19	JD	Review intercompany matrix and associated analysis and correspondence with Controller RE: same.	1.10
09/27/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.10
09/27/19	IA	Follow up on opening of data room to external parties and managing of access to individuals.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/27/19	IA	Call with J. Lowne (Purdue) to review files to be uploaded to data room.	0.50
09/27/19	IA	Follow up on wages diligence requests from Davis Polk to include details by employee by program and sourcing of plan documents.	3.80
09/27/19	IA	Follow up on UBS request for debtor EINs to track down accounts per court notification.	1.10
09/27/19	IA	Review of historical earnings reports to summarize benefit payments by employee and analysis of categorization to tie to known existing programs.	1.70
09/27/19	LJD	Review and respond to correspondence	0.80
09/28/19	LJD	Prepare for and attend call with M. Cyganowski	0.30
09/28/19	LJD	Prepare update email to the team RE: call with M. Cyganowski	0.40
09/29/19	JD	Review latest diligence material update	0.70
09/30/19	JD	Meeting with H. Ku, J. DelConte, and A. DePalma (all AlixPartners) re: Intercompany transactions review with controller	0.80
09/30/19	JD	Call with DPW, PJT, I. Arana, D. Samikkannu, A. DePalma, and J. DelConte (all AlixPartners) RE: outstanding FTI diligence	0.80
09/30/19	JD	Update calls and meeting with CFO RE: various open business items and decisions	0.60
09/30/19	JD	Review historical OCP spend information	1.10
09/30/19	IA	Call with DPW, PJT, I. Arana, D. Samikkannu, A. DePalma, and J. DelConte (all AlixPartners) RE: outstanding FTI diligence	0.80
09/30/19	IA	Review of active employee dataset and target benefit payments.	2.40
09/30/19	IA	Draft file on LTRP payments to retirees in response to	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence requests,	
09/30/19	IA	Update and upload of sign-on and Treyburn severance support files in response to diligence requests.	2.60
09/30/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	1.80
09/30/19	NAS	Transition responsibilities for vendor management and accounts payable processes for Vice President (AlixPartners) leaving engagement at end of week.	0.50
09/30/19	MH	Send note to Rhodes management advising them to notify counsel of any new business development arrangements under consideration.	0.30
09/30/19	HK	Meeting with H. Ku, J. DelConte, and A. DePalma (all AlixPartners) re: Intercompany transactions review with controller	0.80
09/30/19	DS	Meeting with financial analyst re: specifics of Medicare / Medicaid cash flows, as well as commercial rebates	0.40
09/30/19	DS	Call with DPW, PJT, I. Arana, D. Samikkannu, A. DePalma, and J. DelConte (all AlixPartners) RE: outstanding FTI diligence	0.80
09/30/19	ADD	Meeting with H. Ku, J. DelConte, and A. DePalma (all AlixPartners) re: Intercompany transactions review with controller	0.80
09/30/19	ADD	Review outstanding diligence items and updated tracker.	1.60
09/30/19	ADD	Identify and organize customer agreements for FTI diligence request.	0.40
09/30/19	ADD	Call with DPW, PJT, I. Arana, D. Samikkannu, A. DePalma, and J. DelConte (all AlixPartners) RE: outstanding FTI diligence	0.80
09/30/19	ADD	Download and distribute accounts payable data to team	0.60
09/30/19	ADD	Compile and upload files to the Interlinks VDR for ad hoc	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		committee FA review.	
10/01/19	ADD	Compile and submit due diligence requests for approval	1.80
10/01/19	ADD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and management (PPLP, Rhodes) re: new round of FTI diligence items.	0.90
10/01/19	ADD	Compile and distribute accounts payable data.	0.40
10/01/19	ADD	Compile and upload files to virtual data room for due diligence.	2.20
10/01/19	ADD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), Davis Polk, and PJT Partners re: status of FTI diligence requests	0.30
10/01/19	ADD	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and FTI re: status of deliverables and schedule of future requests.	1.00
10/01/19	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), Davis Polk and PJT Partners re: status of FTI diligence requests	0.30
10/01/19	DS	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and FTI re: status of deliverables and schedule of future requests	1.00
10/01/19	DS	Review PJT's updates to business plan summary deck	1.90
10/01/19	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and management (PPLP, Rhodes) re: new round of FTI diligence items	0.90
10/01/19	DS	Correspondence with TXP Services Manager re: captive insurance policy documentation	0.20
10/01/19	JAD	Coordinate access to client email, SharePoint, and other documentation to transition vendor management responsibilities to N. Simon and A. DePalma (both AlixPartners).	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/01/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.10
10/01/19	NAS	Transition of vendor management responsibilities and coordination with Wilson employees regarding vendor payment and trade agreement questions.	0.40
10/01/19	IA	Follow up on severance payments open items for diligence requests.	0.50
10/01/19	IA	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), Davis Polk and PJT Partners re: status of FTI diligence requests	0.30
10/01/19	IA	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and FTI re: status of deliverables and schedule of future requests	1.00
10/01/19	IA	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and management (PPLP, Rhodes) re: new round of FTI diligence items	0.90
10/01/19	IA	Review of historical benefit payment information for Purdue and Rhodes, drafting of summaries for diligence purposes.	3.70
10/01/19	IA	Discussion and follow up with management on review of benefit payment amounts by program for last three years in response to diligence questions.	2.20
10/01/19	IA	Drafting of diligence request file on future wages and benefits payments by employee.	2.40
10/01/19	JD	Finish initial historical and future wage analysis	2.30
10/01/19	JD	Conversations with CFO about various open items	0.80
10/01/19	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), Davis Polk and PJT Partners re: status of FTI diligence requests	0.30
10/01/19	JD	Call with D. Samikkannu, J. DelConte, I. Arana, A.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DePalma (all AlixPartners), and FTI re: status of deliverables and schedule of future requests	
10/01/19	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and management (PPLP, Rhodes) re: new round of FTI diligence items	0.90
10/01/19	JD	Review various wage motion diligence items	1.40
10/02/19	JD	Prepare for and participate in call RE: commercial team contract update	0.60
10/02/19	JD	Review final person by person go forward compensation file to share with advisors.	0.80
10/02/19	JD	Review and comment on latest business plan presentation to share with advisors. Review summaries against business plan files.	1.60
10/02/19	JD	Review diligence materials collected and created by the team prior to uploading for client and legal review.	2.80
10/02/19	NAS	Discussion with J. Doherty, N. Simon, and A. DePalma (all AlixPartners) regarding follow-ups from local specialist training call.	0.20
10/02/19	IA	Review of wages and benefits program documents provided by management in response to diligence questions.	2.20
10/02/19	IA	Follow up and drafting of summaries of future severance payments in response to requests from Davis Polk.	1.60
10/02/19	SJC	Meeting with S. Canniff, M. Hartley, and A. DePalma (all AlixPartners) re: walkthrough of AP controls payment process.	0.90
10/02/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	0.40
10/02/19	JAD	Discussion with M. Hartley, N. Simon, J. Doherty and A. DePalma (all AlixPartners) regarding follow-ups from local	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		specialist training call.	
10/02/19	JAD	Meeting with D. Foegel (Rhodes) et al. for Rhodes Vendor Review Committee; discuss status of vendor outreach progress, current vendor issues, and strategic priorities for immediate future.	0.80
10/02/19	JAD	Meeting with E. Ruiz (Purdue) et al. (Purdue Vendor Management team) to discuss contract review strategy for critical vendors and changes to SharePoint tracker to improve transparency of vendor review.	0.50
10/02/19	JAD	Compile and format data to be used in SOFA part 2; change in methodology for isolating payments made by wire.	2.20
10/02/19	MH	Meeting with S. Canniff, A. DePalma, and M. Hartley (all AlixPartners) re: walkthrough of AP controls payment process.	0.90
10/02/19	DS	Compare insurance policy documents received with list of in-force policies	2.20
10/02/19	DS	Review of backup files to business plan update	1.30
10/02/19	DS	Further review of PJT's business plan updates - providing list of changes to J. DelConte (AlixPartners)	2.60
10/02/19	DS	Review list of insurance policies in-force	0.80
10/02/19	ADD	Compile and submit files for approval to distribute to committee's advisors.	1.60
10/02/19	ADD	Compile and upload files to virtual data room for due diligence.	2.80
10/02/19	ADD	Meeting with S. Canniff, M. Hartley, and A. DePalma (all AlixPartners) re: walkthrough of AP controls payment process.	0.90
10/02/19	ADD	Discussion with M. Hartley, N. Simon, A. DePalma, and J. Doherty (all AlixPartners) regarding follow-ups from local	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		specialist training call.	
10/03/19	ADD	Training session with N. Simon, A. DePalma, and J. Doherty (all AlixPartners) to transition responsibilities for critical vendor trade agreement tracking.	0.30
10/03/19	ADD	Download and distribute SAP extract.	0.30
10/03/19	ADD	Meeting with Purdue controller to discuss intracompany agreements	1.10
10/03/19	ADD	Compile and upload files to virtual data room for due diligence.	2.50
10/03/19	DS	Put together an active employee analysis by tier to compare correspondence between salary and incentive compensation	1.30
10/03/19	DS	Add slides to comprehensive business plan package for PPLP - Pipeline Overview	2.80
10/03/19	DS	Add slides to comprehensive business plan package for PPLP - Pipeline Financial Plan Details	2.70
10/03/19	DS	Add specific charts to comprehensive business plan package for Adhansia	0.80
10/03/19	DS	Add specific charts to comprehensive business plan package for EDO	0.90
10/03/19	DS	Add specific charts to comprehensive business plan package for Spinethera	0.70
10/03/19	LJD	Prepare for and attend board update call	1.20
10/03/19	JAD	Update tracking document to review status of critical vendor communication and prepetition liability release.	2.80
10/03/19	JAD	Training session with N. Simon, J. Doherty and A. DePalma (all AlixPartners) to transition responsibilities for critical vendor trade agreement tracking.	0.30
10/03/19	NAS	Training session with A. DePalma, N. Simon and J. Doherty (all AlixPartners) to transition responsibilities for	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		critical vendor trade agreement tracking.	
10/03/19	NAS	Review critical vendor trade agreement tracking files and instructions.	0.70
10/03/19	NAS	Correspondence with Purdue vendor management committee regarding approval process for critical vendor payments.	0.70
10/03/19	IA	Review of headcount information and terminations received from client for attrition analysis.	0.60
10/03/19	IA	Preparation of file showing insider payments in response to diligence requests,	1.30
10/03/19	JD	Prepare for and attend PPI Board	1.10
10/03/19	JD	Review and discuss 2019 corporate scorecard with management	0.40
10/03/19	JD	Correspondence with management RE: open wage motion diligence items. Review latest FTI diligence lists and materials collected to date to be responsive.	1.40
10/03/19	JD	Correspondence with management RE: insurance policies	0.30
10/03/19	JD	Review various IAC agreements prior to posting to answer advisor diligence requests	0.70
10/03/19	JD	Discussion and correspondence with management RE: LTRP and AIP performance to date	0.50
10/03/19	JD	Review critical vendor details	0.40
10/03/19	JD	Review pipeline details file prepared in connection with outstanding diligence requests	1.10
10/04/19	JD	Review materials provided by management to be responsive to open wage motion diligence questions	2.60
10/04/19	JD	Review LTRP breakdown. Analyze payment by grant year.	1.90
10/04/19	JD	Work on analysis of indemnitee payments to date prior to	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		the filing.	
10/04/19	IA	Follow up on questions regarding headcount, titles, and number of employees entitled to payments under each of the benefit programs.	3.30
10/04/19	NAS	Preparation for trade agreement tracking training session and distributing approved trade agreement list for AP release.	0.30
10/04/19	NAS	Training session with J. Doherty and N. Simon (both AlixPartners) regarding vendor trade agreement tracking and AP release process.	0.50
10/04/19	JAD	Training session with N. Simon and J. Doherty (both AlixPartners) regarding vendor trade agreement tracking and AP release process.	0.50
10/04/19	DS	Create analysis of potential Ordinary Course Professionals - utilizing Team Connect data	2.40
10/04/19	ADD	Download and distribute open and cleared accounts payable.	0.40
10/04/19	ADD	Compile and upload documentation to virtual data room.	2.70
10/04/19	ADD	Compile and submit files for approval to distribute to committee financial advisors	1.20
10/05/19	DS	Revise OCP analysis based on information received from legal analyst (PPLP)	0.90
10/05/19	IA	Draft of schedule showing historical benefit payments and number of employees in response to request by FTI.	1.30
10/05/19	IA	Follow up on diligence requests and wages and benefits documents for review by Davis Polk.	3.30
10/05/19	IA	Review of Rhodes AIP and LTRP metrics documents and responses from management.	1.20
10/05/19	JD	Pull together responses to various wage motion diligence requests.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/05/19	JD	Finalize indemnitee tracker analysis in response to diligence questions.	1.10
10/05/19	JD	Review OCP analysis for motion caps	0.60
10/06/19	JD	Review and prepare responses to open diligence questions for company and DPW review.	2.40
10/06/19	IA	Review and analysis of future and historical benefit payments by employee in response to Davis Polk requests to support supplementary wages filings.	2.40
10/06/19	IA	Preparation of file showing historical and future payments to current and former employees to be shared with FTI.	2.60
10/06/19	IA	Gathering of wage support documents and analyses to be shared with US Trustee.	1.40
10/06/19	IA	Analysis of current headcount to be split by functions, manufacturing v. non-manufacturing, and top payouts by salary ranges in response to request from Davis Polk.	2.80
10/06/19	ADD	Review and upload items to the virtual data room.	0.80
10/07/19	ADD	Research vendor inquiry to identify spend history and open invoices.	1.10
10/07/19	ADD	Add committee advisor to the virtual data room	0.40
10/07/19	ADD	Request approval to upload due diligence documents.	0.70
10/07/19	ADD	Compile and update SOFA and schedules data.	2.80
10/07/19	ADD	Review and update due diligence request status.	1.40
10/07/19	DS	Compile list of IAC transactions in the last 2 months for purposes of estimating run-rate	2.20
10/07/19	DS	Review materials for comprehensive business plan package relating to PPLP subsidiaries	1.80
10/07/19	REO	Meeting with N. Simon, E. Ellis Ochoa, and H. Ku (all AlixPartners) to discuss trade agreement tracking and documentation process.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/07/19	IA	Follow up on diligence requests related to market access program payments and calculations.	2.10
10/07/19	IA	Follow up and review of documents related to FTI diligence requests on top payouts and job descriptions.	1.50
10/07/19	IA	Update of legal fees YTD spend analysis for PJT to show MDL specific spend.	1.80
10/07/19	IA	Update of individual market access participant scorecards to show redacted pages.	1.70
10/07/19	IA	Follow up on Davis Polk information requests in support of ongoing conversations with stakeholders regarding benefit programs.	2.30
10/07/19	NAS	Review of vendor trade agreement types and existing documentation to prepare for meeting with H. Ku and R. Ellis Ochoa (both AlixPartners).	0.80
10/07/19	NAS	Meeting with H. Ku, N. Simon and R. Ellis Ochoa (all AlixPartners) to discuss trade agreement tracking and documentation process.	0.50
10/07/19	NAS	Updates to tracking file of critical vendors who have signed trade agreements for purposes of releasing prepetition amounts owed.	1.00
10/07/19	NAS	Prioritize trade agreements to review for key terms as part of critical vendor reporting.	0.40
10/07/19	NAS	Correspondence with Purdue vendor approval committee regarding trade agreements with critical vendors.	0.20
10/07/19	NAS	Ensure vendors that are deemed critical and have signed trade agreements are correctly released in accounts payable for prepetition amounts owed.	0.60
10/07/19	NAS	Establish access to Purdue's contract database for purposes of analyzing existing trade agreements.	0.10
10/07/19	JD	Correspondence with AlixPartners and with Davis Polk RE:	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		value transfer report and information sharing with the various committees on IAC payments.	
10/07/19	JD	Correspondence with management and Davis Polk RE: go forward product litigation and plan to retain counsel.	0.30
10/07/19	JD	Create forecasted fee estimate for AlixPartners for September so that management can accrue an accurate amount on the books for Q3.	0.70
10/07/19	JD	Discussion with Davis Polk RE: vendor reclamation letter.	0.40
10/07/19	JD	Correspondence with Davis Polk RE: market access program. Review data RE: potential go forward payments.	0.80
10/07/19	JD	Review data RE: Treyburn retention and severance payments.	0.40
10/07/19	JD	Correspondence with Davis Polk RE: cash management motion and IAC receipt/payment details. Review historical details to estimate potential go forward caps.	1.10
10/07/19	HK	Meeting with N. Simon, H. Ku, and R. Ellis Ochoa (all AlixPartners) to discuss trade agreement tracking and documentation process.	0.50
10/08/19	JD	Review latest diligence trackers to review progress. Review relevant materials out for review to be responsive to outstanding requests.	1.50
10/08/19	NAS	Update critical vendor trade agreement tracking file and database in order to begin release process for approved prepetition amounts owed.	1.10
10/08/19	NAS	Coordination with Purdue vendor management committee regarding critical vendor approval process and payments.	0.80
10/08/19	NAS	Analyze invoices for a critical vendor to determine pre-/post-petition status and support approval process for prepetition amounts owed.	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/08/19	DS	Meeting with D. Samikkannu, and A. DePalma (both AlixPartners) to review diligence items	1.30
10/08/19	DS	Review of Amex related payments pulled by TXP Accounts Payable Supervisor to share with Amex program coordinator (PPLP)	0.70
10/08/19	DS	Correspondence with TXP Services manager re: cyber liability policy	0.30
10/08/19	DS	Meeting with TXP Services Manager re: Amex payments made	0.20
10/08/19	DS	Meeting with TXP Accounts Payable Supervisor re: Amex payments detailed data	0.30
10/08/19	ADD	Request approval to upload due diligence documents.	0.40
10/08/19	ADD	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to review diligence items	1.30
10/08/19	ADD	Research vendor inquiry regarding outstanding invoices.	1.30
10/08/19	ADD	Research legal vendor invoice question.	0.80
10/08/19	ADD	Analyze ordinary course professionals spend data.	2.10
10/08/19	ADD	Identify and research missing ordinary course professionals spend data.	1.40
10/08/19	ADD	Review and compile due diligence request for upload to the virtual data room.	1.70
10/09/19	ADD	Research vendor inquiry related to difference in pre/post-petition invoice amounts.	1.30
10/09/19	ADD	Compile diligence responses and upload to virtual data room.	2.80
10/09/19	ADD	Analyze intercompany balances to prepare schedule for due diligence request.	2.60
10/09/19	REO	Review of Ariba download prepared by engagement SVP re: tracking of "published" vendor contracts.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/09/19	DS	Draft response to Controller (PPLP) question re: handling of prepetition invoice re: a potential ordinary course professional	0.40
10/09/19	DS	Correspondence with Amex program leader (PPLP) re: general strategy on identifying Amex payments	0.20
10/09/19	DS	Assemble business plans materials for Rhodes (operations, projections, pipeline)	2.70
10/09/19	DS	Put together returns credits analysis for Purdue for June to August 2019 timeframe	1.30
10/09/19	DS	Put together returns reserve analysis for Purdue as of Petition Date	1.10
10/09/19	DS	Put together returns reserve analysis for Rhodes as of Petition Date	0.90
10/09/19	DS	Put together returns credits analysis for Rhodes for June to August 2019 timeframe	1.20
10/09/19	NAS	Updates to tracking document for executed trade agreements with critical vendors for purposes of payment release for prepetition amounts owed.	0.60
10/09/19	NAS	Research invoices and resolving discrepancy between amount claimed by critical vendor and amounts previously paid and listed as postpetition by Purdue.	0.90
10/09/19	NAS	Review of special postpetition payment arrangement proposed by critical vendor for business appropriateness and compliance requirements.	0.70
10/09/19	NAS	Discussion with Rhodes vendor management team regarding revisions to trade agreement requested by critical vendor.	0.60
10/09/19	NAS	Prioritization of vendors requiring further review of existing service agreements and contracts.	1.00
10/09/19	IA	Follow up on and review wages motion diligence	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		documents including job descriptions for certain employees.	
10/09/19	JD	Review 2019 forecasted legal fee spend and updated thoughts on forecast. Discuss with management in advance of Board meeting next week.	0.80
10/09/19	JD	Correspondence with management RE: Rhodes indemnification costs	0.50
10/09/19	JD	Correspondence and conversations with management RE: wage motion messaging plan	0.80
10/10/19	NAS	Updates to tracking document for executed trade agreements with critical vendors for purposes of payment release for prepetition amounts owed.	0.70
10/10/19	NAS	Conference call with K. McCarthy, P. Strassburger, M. Kroese (all Purdue), D. Ebere, J. Doyle (both Rhodes) and representatives from critical vendor regarding prepetition amounts owed and trade agreement.	0.50
10/10/19	NAS	Call with K. McCarthy (Purdue) regarding follow-up items from trade agreement discussion with critical vendor.	0.10
10/10/19	NAS	Correspondence with restructuring counsel regarding executed critical vendor trade agreements and amounts paid to-date.	0.30
10/10/19	NAS	Correspondence with Purdue local vendor specialists regarding continuation of utilities service per Utilities motion.	0.40
10/10/19	NAS	Response to Rhodes vendor inquiry regarding additional detail behind critical vendor order and prepetition amounts owed.	0.30
10/10/19	NAS	Meeting with N. Somon and R. Ellis-Ochoa (both AlixPartners) to discuss prioritization of trade agreement reviews.	0.30
10/10/19	NAS	Correspondence with Purdue vendor management	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		committee regarding prepetition amounts owed to critical vendors.	
10/10/19	DS	Call with T. Melvin (PJT) re: business plan materials	0.30
10/10/19	DS	Correspondence with Controller (PPLP) re: timing and rationale behind Rhodes returns reserve analysis and corresponding sources	0.40
10/10/19	DS	Meeting with D. Samikkannu (AlixPartners), TXP Services (Manager and Accounts Payable Supervisor), and Amex program lead (PPLP) to discuss Amex disbursements	0.60
10/10/19	DS	Update business plan tracker, detailing sources of various materials included in business plan package, to send to PJT Partners	0.50
10/10/19	DS	Prepare business plan materials package, including detailed commentary on project plan and strategy going forward, to send to PJT Partners	0.90
10/10/19	DS	Assemble Data basics data to identify Amex payments and send to TXP for review	1.60
10/10/19	REO	Meeting with N. Simon and R. Ellis Ochoa (both AlixPartners) to discuss prioritization of trade agreement reviews.	0.30
10/10/19	REO	Review of prioritization tracker delivered by engagement VP re: priority and status of vendors.	1.30
10/10/19	ADD	Summarize customer motion responses for upload to virtual data room.	1.40
10/10/19	ADD	Review due diligence requests status and follow up with outstanding items.	1.30
10/10/19	ADD	Meeting to discuss intercompany accounts with Purdue controllers.	1.00
10/10/19	ADD	Respond to utility vendor inquiry.	0.30
10/11/19	ADD	Compile and upload due diligence documents to virtual	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		data room.	
10/11/19	ADD	Submit approval request for permission to release to files creditor committee advisors.	0.90
10/11/19	DS	Assemble analysis of Amex payments made prior to filing and send to Davis Polk	1.40
10/11/19	NAS	Review of two critical vendor trade agreements in advance of discussion with J. Doyle and E. Ruta (both Rhodes).	0.50
10/11/19	NAS	Call with J. Doyle and E. Ruta (both Rhodes) to respond to questions from two critical vendors regarding their respective trade agreements.	0.50
10/11/19	NAS	Correspondence with Purdue vendor management committee regarding vendors covered under critical vendor order, wage order, and customer order.	1.10
10/11/19	NAS	Updates to tracking document for executed trade agreements with critical vendors for purposes of payment release for prepetition amounts owed.	0.40
10/11/19	NAS	Correspondence with J. Gibbs (Rhodes) regarding timing of payments to critical vendor who signed trade agreement.	0.30
10/11/19	NAS	Correspondence with utilities provider covered under utilities order to ensure services are not inadvertently disconnected.	0.40
10/11/19	NAS	Review critical vendor and executory contract assumption/rejection/assignment strategy.	0.20
10/12/19	ADD	Review due diligence status and document items outstanding.	2.60
10/12/19	ADD	Follow up with outstanding request.	1.50
10/13/19	ADD	Compile and upload documentation to virtual data room	2.70
10/13/19	ADD	Follow up on outstanding due diligence requests.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/14/19	ADD	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and TXP Services personnel re: FTI's additional insurance due diligence requests	0.60
10/14/19	ADD	Compile and upload files to virtual data room	2.80
10/14/19	ADD	Research tax distribution transaction.	0.90
10/14/19	ADD	Review documentation provided for due diligence requests.	2.40
10/14/19	ADD	Update interested parties list.	1.40
10/14/19	ADD	Trade agreement procedures review with N. Simon and A. DePalma (both AlixPartners)	0.50
10/14/19	REO	Review of Ariba for Vendor management and tracking per discussions with Engagement VP.	2.30
10/14/19	REO	Edit Vendor Tracker for latest agreements within Ariba re: agreement clauses and rights.	2.50
10/14/19	REO	Consolidation of Ariba contact IDs re: Prime Clerk data request.	1.30
10/14/19	DS	Meeting with D. Samikkannu, A. DePalma (both AlixPartners), and TXP Services personnel re: FTI's additional insurance due diligence requests	0.60
10/14/19	DS	Communication with N. Simon (AlixPartners) re: classification of rebates on front-end of payment processing	0.30
10/14/19	DS	Correspondence with Rebates Manager (PPLP) re: processing rebates on front-end	0.40
10/14/19	DS	Communication with AlixPartners payment team (N. Simon, S. Lemack, and H. Ku) re: ability to pay a particular vendor	0.70
10/14/19	DS	Draft email outlining specific language in Wages Motion supporting specific payment	0.80
10/14/19	NAS	Communication with H. Benson (Purdue) regarding	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		processes to split invoices between prepetition and postpetition.	
10/14/19	NAS	Correspondence with Purdue vendor management committee regarding payments for prepetition amounts owed to critical vendors and processes around postpetition payments.	1.10
10/14/19	NAS	Updates to tracking document for executed trade agreements with critical vendors for purposes of payment release for prepetition amounts owed.	0.10
10/14/19	NAS	Communication regarding prepetition/postpetition split of invoices covered under Customer Programs order.	0.50
10/14/19	NAS	Trade agreement procedures review with A. DePalma and N. Simon (both AlixPartners).	0.50
10/14/19	NAS	Correspondence with E. Ruiz (Purdue) regarding precise meaning of language in critical vendor order.	0.20
10/14/19	NAS	Find solution for specific vendor unable to generate pro-forma invoice but still requiring prepayment.	0.70
10/14/19	NAS	Correspondence with utility to ensure postpetition amounts are paid and utility abides by Utilities order preventing disconnection.	0.20
10/14/19	NAS	Correspondence with Purdue/Rhodes vendor management committee regarding prepetition amounts owed to agency providing temporary employee services.	0.50
10/14/19	IA	Update of headcount by function file for review by Davis Polk in response to diligence questions.	0.80
10/14/19	IA	Update of OCP run rate file for review by legal operations in response to diligence questions.	0.50
10/14/19	IA	Create summary of future LTRP payments to former employees for review by finance team.	1.80
10/14/19	IA	Discussion with C. MacDonald (Purdue) on open diligence	0.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		requests related to legal spend.	
10/14/19	JD	Review materials RE: future sublease	0.40
10/14/19	JD	Correspondence with management RE: critical vendor and trade agreement discussions.	0.30
10/14/19	JD	Review schedule of future LTRP retiree payments against detailed back up info.	0.50
10/15/19	NAS	Correspondence regarding Purdue's assumption/rejection decision for executory contract with critical vendor.	0.40
10/15/19	IA	Call with J. Lowne (Purdue) and Prime Clerk to discuss updated restructuring fee projections for 2020.	0.50
10/15/19	NAS	Correspondence with B. Folse, M. Hartley, N. Simon (all AlixPartners), H. Benson (Purdue), and critical vendor regarding payment terms for postpetition services.	0.40
10/15/19	NAS	Updates to tracking document for executed trade agreements with critical vendors for purposes of payment release for prepetition amounts owed.	0.80
10/15/19	IA	Review of diligence lists and trackers submitted by UCC and Adhoc advisors for diligence purposes.	1.40
10/15/19	DS	Meeting with D. Samikkannu, and J. DelConte (both AlixPartners) re: Customer Programs payment process	0.40
10/15/19	JD	Meeting with management RE: updated professional fee forecast for 2019 and 2020.	1.00
10/15/19	JD	Review materials RE: LTRP and AIP calculations. Correspondence with DPW RE: same	1.10
10/15/19	JD	Review historical professional fee budgets. Correspondence with PJT, management and DPW RE: same.	0.70
10/15/19	JD	Correspondence with management RE: ordinary course professionals. Review exhibit to OCP motion.	0.30
10/15/19	JD	Review and compare latest Prime Clerk budgets.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Discussion with Prime Clerk, management and I. Arana RE: same.	
10/15/19	JD	Meeting with D. Samikkannu, and J. DelConte (both AlixPartners) re: Customer Programs payment process	0.40
10/15/19	REO	Review of Ariba system re: Vendor contracts matched to the vendor tracker.	2.70
10/15/19	REO	Review of Ariba system: vendor contracts not matched to the vendor tracker.	2.10
10/15/19	REO	Edit Vendor tracker re: agreements found in Ariba matching codes/name in vendor tracker.	1.90
10/15/19	REO	Edit Vendor tracker re: agreements found in Ariba not matching codes/name in vendor tracker.	1.40
10/15/19	ADD	Updated spend model to determine vendor inclusion in the interested parties list.	2.70
10/15/19	ADD	Update executed critical vendor tracker and release file	0.70
10/16/19	ADD	Research entity name for interested parties list at direction of counsel.	1.80
10/16/19	ADD	Review new trade agreements and update trade agreement tracker.	0.70
10/16/19	ADD	Request approval to upload diligence items to the data room.	1.30
10/16/19	ADD	Compile and upload data to virtual data room.	1.80
10/16/19	JD	Prepare for and participate in a meeting with management RE: bankruptcy cost assumptions	0.60
10/16/19	JD	Review OCP spend summary and forecast go forward	0.90
10/16/19	JD	Call with PJT RE: professional fee run rate	0.50
10/16/19	JD	Prepare for and participate in a meeting with management, PJT, J. DelConte, and I. Arana (both AlixPartners) RE: 2020 professional fee forecast	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/16/19	DS	Review terminated employee's data	0.80
10/16/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.40
10/16/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.70
10/16/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.00
10/16/19	IA	Meeting with management, PJT, J. DelConte, and I. Arana (both AlixPartners) RE: 2020 professional fee forecast	1.20
10/16/19	IA	Follow up on wages and benefits diligence items from UCC and Ad-hoc advisors	2.30
10/16/19	NAS	Correspondence with E. Ruiz (Purdue) regarding changes to critical vendor trade agreement process.	0.20
10/16/19	NAS	Purdue critical vendor management committee meeting with S. Daniel, K. McCarthy, E. Ruiz, and J. Lowne (all Purdue).	0.80
10/16/19	NAS	Resolve discrepancy between amount listed in trade agreement by critical vendor and amount listed for vendor in open accounts payable.	0.30
10/16/19	LJD	Prepare for and attend call with PJT	0.40
10/17/19	LJD	Prepare for and attend board meeting	4.50
10/17/19	NAS	Draft message to Purdue vendor contacts regarding critical vendor process in order to clarify procedures on tracking trade agreements and treatment of critical vendors who haven't yet received trade agreements.	0.40
10/17/19	NAS	Correspondence with A. Hart and E. Ruiz (both Purdue) regarding whether or not a particular vendor qualifies as critical.	0.20
10/17/19	NAS	Analyze open accounts payable and corresponding release	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		codes to resolve why critical vendor with signed trade agreement hadn't been paid to date.	
10/17/19	NAS	Design revised vendor management process and prioritization of trade agreements for remaining critical vendors who have not yet signed an agreement.	0.50
10/17/19	NAS	Resolve critical vendor payment inquiry received by Prime Clerk.	0.20
10/17/19	NAS	Prepare for trade agreement prioritization meeting with Purdue Vendor Management Committee.	0.80
10/17/19	NAS	Draft and send follow up email to Purdue vendor contacts regarding go-forward processes for tracking critical vendor trade agreements.	0.20
10/17/19	IA	Follow up on approvals of diligence files under review by company and Davis Polk.	1.20
10/17/19	IA	Review with G. Issa (Purdue) of legal firm billing post-petition items and indemnity firms.	0.50
10/17/19	IA	Drafting of historical detail files in response to diligence questions on wages.	3.40
10/17/19	IA	Review of submitted information on year to date performance and quarterly financials and drafting/editing of summaries in response to diligence questions.	2.20
10/17/19	IA	Review of diligence lists and trackers submitted by UCC and Adhoc advisors for diligence purposes.	1.60
10/17/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.20
10/17/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	3.10
10/17/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/17/19	DS	Prepare for and participate in a call with management, B. Folse, J. DelConte, S. Lemack, N. Simon, and D. Samikkannu (all AlixPartners) RE: critical vendor process going forward.	1.10
10/17/19	DS	Correspondence with financial analyst (PPLP) re: prompt pay discounts data	0.40
10/17/19	ADD	Upload schedule F data into SOFA and Schedules model	2.10
10/17/19	ADD	Update UCC due diligence tracker	0.70
10/17/19	ADD	Review new trade agreements and update tracker.	0.80
10/17/19	ADD	Create model for SOFA and Schedules trade payable data.	2.60
10/17/19	ADD	Compile and review files provided in response to diligence requests.	2.40
10/18/19	ADD	Compile and review data for upload to virtual data room.	2.80
10/18/19	ADD	Update vendor agreement tracker.	0.80
10/18/19	ADD	Request approval to upload information to the data room.	1.10
10/18/19	ADD	Follow up with outstanding diligence items.	1.20
10/18/19	ADD	Update due diligence tracker	1.50
10/18/19	ADD	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), CFO and Controller re: FTI diligence items status	0.30
10/18/19	ADD	Call with A. DePalma and I. Arana (both AlixPartners) to review status of open diligence items in preparation with review with client finance team.	0.40
10/18/19	DS	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), CFO and Controller re: FTI diligence items status	0.30
10/18/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/18/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.40
10/18/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.00
10/18/19	IA	Call with A. DePalma and I. Arana (both AlixPartners) to review status of open diligence items in preparation with review with client finance team,	0.40
10/18/19	IA	Call with Davis Polk, K. Laurel, and C. DeStefano (both Purdue) to walk through open questions on wages and benefits programs.	1.10
10/18/19	IA	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), CFO and Controller re: FTI diligence items status	0.30
10/18/19	IA	Call with R. Aleali (Purdue) to review comments to job descriptions requested by FTI.	0.60
10/18/19	IA	Review of wages and benefits programs documents and backup for calculations in preparation for wages discussion with client and Davis Polk.	1.80
10/18/19	IA	Review of year to date separations information for Purdue and Rhodes, in response to diligence requests.	0.40
10/18/19	IA	Review of details on further employees and follow up on open items for diligence purposes.	1.60
10/18/19	NAS	Provide update to S. Lemack (AlixPartners) regarding critical vendor strategy conversation on 10/17.	0.20
10/18/19	LJD	Review presentations for management team and comment	0.80
10/18/19	LJD	Discuss staffing for business plan team and potential approach and kickoff meeting	0.40
10/19/19	LJD	Work on staffing for additional workstreams	0.40
10/19/19	LJD	Review and discuss SOFA disclosures	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/19/19	NAS	Correspondence with Purdue vendor contact team regarding question related to foreign vendors.	0.10
10/20/19	ADD	Research vendor payments history.	0.80
10/20/19	ADD	Compile and upload files to data room.	1.60
10/21/19	ADD	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), C. Robertson, and D. Consola (both Davis Polk) re: diligence items for review and customer agreements	0.30
10/21/19	ADD	Format diligence documentation for upload to data room.	3.00
10/21/19	ADD	Compile and review files provided in response to diligence requests.	2.70
10/21/19	ADD	Review and update due diligence tracker.	1.80
10/21/19	ADD	Follow up with due diligence items	0.80
10/21/19	ADD	Meeting with A. DePalma and M. Hartley (both AlixPartners) to review general status and priorities.	0.40
10/21/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.00
10/21/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.50
10/21/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	3.00
10/21/19	DS	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), C. Robertson, and D. Consola (both Davis Polk) re: diligence items for review and customer agreements	0.30
10/21/19	JD	Call with management and PJT RE: business plan	0.50
10/21/19	JD	Review latest business plan diligence tracker. Correspondence with PJT RE: same.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/21/19	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss new critical vendor process and remaining open items for insider payments SOFA disclosure.	0.50
10/21/19	NAS	Responding to inquiries from Purdue Vendor Management Committee regarding treatment of foreign creditors.	0.30
10/21/19	IA	Call with D. Samikkannu, A. DePalma, I. Arana (all AlixPartners), C. Robertson, and D. Consola (both Davis Polk) re: diligence items for review and customer agreements	0.30
10/21/19	IA	Review and update of job descriptions and other wages diligence files.	3.10
10/21/19	IA	Follow up on internal company and Davis Polk approvals on wages and OCP diligence items.	1.70
10/21/19	IA	Review and formatting of Rhodes year to date September financials to be published in response to diligence requests.	1.90
10/21/19	MH	Meeting with N. Simon and M. Hartley (both AlixPartners) to discuss new critical vendor process and remaining open items for insider payments SOFA disclosure.	0.50
10/21/19	MH	Research proposed payment to determine qualification under the Wage order.	0.40
10/21/19	MH	Meeting with assistant general counsel to review options to provide general education to key staff members regarding Chapter 11 requirements.	0.40
10/21/19	MH	Meeting with A. DePalma and M. Hartley (both AlixPartners) to review general status and priorities.	0.40
10/22/19	MH	Research source of German individuals receiving bankruptcy notices.	0.40
10/22/19	MH	Discussion with J. DelConte, N. Simon, M. Hartley, and S. Lemack (all AlixPartners) regarding critical vendor reporting process requested by unsecured creditors	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		committee.	
10/22/19	MH	Meeting with H. Ku and M. Hartley (both AlixPartners) to review general status and priorities.	0.40
10/22/19	MH	Clarify with client management future expectations regarding contract assumptions.	0.60
10/22/19	SKL	Prepare for and participate in meeting with K. McCarthy, E. Ruiz, S. Daniel (all Purdue), N. Simon, and S. Lemack (both AlixPartners) to discuss new unsecured creditors committee critical vendor reporting requirements.	1.10
10/22/19	SKL	Discussion with M. Hartley, J. DelConte, S. Lemack, and N. Simon (all AlixPartners) regarding critical vendor reporting process requested by unsecured creditors committee.	0.20
10/22/19	HK	Meeting with H. Ku and M. Hartley (both AlixPartners) to review general status and priorities.	0.40
10/22/19	IA	Meeting with D. Samikkannu, J. DelConte, R. Sublett, A. DePalma, and I. Arana (all AlixPartners), PJT Partners, and CFO and Controller (PPLP) re: business plan	0.80
10/22/19	IA	Follow up on open diligence items on wages.	3.30
10/22/19	IA	Review of East West source files and update of cash reporting model for the week ended 10/18.	3.60
10/22/19	IA	Call with D. Samikkannu, J. DelConte, S. Robertson, A. DePalma, I. Arana (all AlixPartners), and Davis Polk re: various diligence requests and process	1.10
10/22/19	NAS	Discussion with M. Hartley, J. DelConte, N. Simon, and S. Lemack (all AlixPartners) regarding critical vendor reporting process requested by unsecured creditors committee.	0.20
10/22/19	NAS	Analysis of new unsecured creditors committee trade agreement process prior to call with UCC's advisors.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/22/19	NAS	Respond to questions from Purdue Vendor Management Committee regarding critical vendor process.	0.10
10/22/19	NAS	Lead local vendor specialist training session to provide an update on critical vendor process and launch new unsecured creditors committee reporting process.	0.80
10/22/19	NAS	Meeting with K. McCarthy, E. Ruiz, S. Daniel (all Purdue), N. Simon, and S. Lemack (both AlixPartners) to discuss new unsecured creditors committee critical vendor reporting requirements.	0.50
10/22/19	JD	Discussion with R. Sublett and J. DelConte (both AlixPartners) RE: business plan process and timeline	0.70
10/22/19	JD	Meeting with D. Samikkannu, J. DelConte, I. Arana, R. Sublett, A. DePalma (all AlixPartners), PJT Partners and CFO and Controller (PPLP) re: business plan	0.80
10/22/19	JD	Discussion with M. Hartley, N. Simon, J. DelConte, and S. Lemack (all AlixPartners) regarding critical vendor reporting process requested by unsecured creditors committee.	0.20
10/22/19	JD	Call with D. Samikkannu, J. DelConte, S. Robertson, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: various diligence requests and process	1.10
10/22/19	JD	Review PHI analysis to potentially share with the committee	1.10
10/22/19	JD	Review AG decks for potential sharing with committee advisors	0.70
10/22/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.80
10/22/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.50
10/22/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		contract analysis.	
10/22/19	DS	Review Rhodes Pharma sales report and send to A. DePalma (AlixPartners) to post for review	0.40
10/22/19	DS	Draft request to cost analyst re: specific vendor for Customer Programs report	1.80
10/22/19	DS	Review diligence list for business plan support	1.40
10/22/19	DS	Review vendor chargebacks data by category received	0.80
10/22/19	DS	Draft email with follow up requests re: vendor chargebacks data received	0.30
10/22/19	DS	Call with D. Samikkannu, J. DelConte, S. Robertson, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: various diligence requests and process	1.10
10/22/19	DS	Meeting with D. Samikkannu, J. DelConte, I. Arana, R. Sublett, A. DePalma (all AlixPartners), PJT Partners and CFO and Controller (PPLP) re: business plan	0.80
10/22/19	ADD	Prepare files for upload into data room.	2.30
10/22/19	ADD	Submit data requests from the committee to the client.	0.80
10/22/19	ADD	Review documentation provided by client in response to committee request.	2.20
10/22/19	ADD	Respond to diligence requests from the client.	0.30
10/22/19	ADD	Review trade agreements submitted by client.	0.40
10/22/19	ADD	Consolidated request list submitted by the creditor committees.	1.40
10/22/19	ADD	Call with D. Samikkannu, J. DelConte, S. Robertson, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: various diligence requests and process	1.10
10/22/19	ADD	Meeting with D. Samikkannu, J. DelConte, I. Arana, R. Sublett, A. DePalma (all AlixPartners), PJT Partners and CFO and Controller (PPLP) re: business plan	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/22/19	ADD	Manage data room access adjusting permissions and granting access.	0.70
10/22/19	SR	Call with D. Samikkannu, J. DelConte, S. Robertson, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: various diligence requests and process	1.10
10/22/19	RDS	Discussion with R. Sublett and J. DelConte (both AlixPartners) RE: business plan process and timeline	0.70
10/22/19	RDS	Meeting with D. Samikkannu, J. DelConte, I. Arana, R. Sublett, A. DePalma (all AlixPartners), PJT Partners and CFO and Controller (PPLP) re: business plan	0.80
10/23/19	ADD	Update diligence trackers.	1.10
10/23/19	ADD	Request approval for diligence items.	0.30
10/23/19	ADD	Format diligence documentation for upload to data room	2.30
10/23/19	ADD	Follow up with due diligence items	1.20
10/23/19	ADD	Compile and review files provided in response to diligence requests.	2.60
10/23/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	1.60
10/23/19	DS	Review specific vendor data sent by cost analyst (PPLP)	0.70
10/23/19	DS	Meeting with Treasurer (PPLP) re: R&D materials	0.60
10/23/19	DS	Review vendor chargebacks by wholesaler report	0.60
10/23/19	DS	Draft email to financial analyst (PPLP) re: prompt pay discounts and co-pay reduction rebates	0.30
10/23/19	DS	Draft question re: Tricare rebate to financial analyst (PPLP)	0.30
10/23/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.90
10/23/19	REO	Review of Vendor Contracts re: Contract terms and	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		conditions.	
10/23/19	JD	Put together business plan timeline and workplan	1.60
10/23/19	JD	Conversation with PJT RE: PHI diligence items	0.60
10/23/19	JD	Review comments to the business plan timeline.	0.30
10/23/19	JD	Review updated business plan diligence lists. Review correspondence from PJT RE: same.	0.80
10/23/19	JD	Review analysis of lease damages claims for OSR wrap lease	0.50
10/23/19	IA	Review of 90 days of IAC transaction descriptions in response to diligence requests.	1.70
10/23/19	IA	Follow up on open wages diligence items including job descriptions and payments to retirees.	4.20
10/23/19	IA	Follow up on SOFAs and schedules requests on information related to indemnification agreements	2.30
10/23/19	MH	Prepare summary of Critical Vendor status including options for management to manage the total amount to be paid.	0.80
10/23/19	LJD	Review and discuss business plan timeline	0.60
10/24/19	MH	Analyze proposed status change to invoice from North Carolina vendor from prepetition to post petition.	0.30
10/24/19	MH	Evaluate relevant agreements to assume for supplier and licensor.	0.40
10/24/19	MH	Review proposal for adequate assurance from North Carolina utility.	0.20
10/24/19	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners), H. Benson (TXP accounts payable) to discuss SOFA & Schedules	0.30
10/24/19	IA	Review of third party and business partner indemnification agreements submitted for review	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		regarding SOFAS and schedules.	
10/24/19	IA	Follow up on internal approvals for wages related diligence items.	1.10
10/24/19	IA	Follow up on differences between wages motion benefit program amounts and updated source files shared in data room per FTI's diligence request.	1.40
10/24/19	IA	Review third party indemnification information and followed up on agreements with Purdue legal team.	1.10
10/24/19	IA	Review and edit of wages diligence files submitted in response to diligence requests, and submission for approvals to Davis Polk and client.	3.00
10/24/19	IA	Meeting with management, Davis Polk, I. Arana, and J. DelConte (both AlixPartners) RE: LTRP and AIP metrics.	0.60
10/24/19	JD	Meeting with management, Davis Polk, I. Arana, and J. DelConte (both AlixPartners) RE: LTRP and AIP metrics	0.60
10/24/19	JD	Meeting with management RE: open diligence	0.50
10/24/19	JD	Call with management RE: open model issues	0.50
10/24/19	JD	Call with J. Lowne, K. Darragh, H. Shih (all PPLP), J. DelConte, R. Sublett (both AlixPartners) T. Melvin, G. Sim, J. Turner (all PJT) re consolidated model roll ups	0.60
10/24/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.40
10/24/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.50
10/24/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.10
10/24/19	DS	Review R&D pipeline materials provided by Treasurer (PPLP)	2.10
10/24/19	DS	Correspondence with T. Melvin (PJT Partners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		distribution and R&D pipeline materials	
10/24/19	DS	Call with CFO (PPLP) and PJT Partners re: consolidated model behind business plan	0.50
10/24/19	DS	Review distribution list for business plan summary and draft email response to PJT	0.30
10/24/19	DS	Review prompt pay discounts data sent by financial analyst (PPLP)	0.80
10/24/19	DS	Review assembled business plan materials and send to PJT to discuss	0.40
10/24/19	ADD	Meeting with S. Lemac, A. DePlama (both AlixPartners), and H.Benson (TXP accounts payable) to discuss SOFA & Schedules	0.30
10/24/19	ADD	Research conflict list entry at request of DPW	1.20
10/24/19	ADD	Compile and review files provided in response to diligence requests.	2.90
10/24/19	RDS	Call with J. Lowne, K. Darragh, H. Shih (all PPLP), J. DelConte, R. Sublett (both AlixPartners), T. Melvin, G. Sim, and J. Turner (all PJT) re consolidated model roll ups	0.60
10/25/19	ADD	Vendor inquiry research.	1.80
10/25/19	ADD	Respond to data room questions.	0.40
10/25/19	ADD	Add users to data room at the request of counsel.	0.50
10/25/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	1.70
10/25/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.20
10/25/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	1.50
10/25/19	JD	Review preliminary business plans from management.	2.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/25/19	JD	Catch up call on process go forward with L. Donahue and J. DelConte (both AlixPartners)	0.50
10/25/19	IA	Review of updated twelve months spend file for proposed OCP and retained firms.	2.80
10/25/19	IA	Follow up on wages diligence open items.	2.30
10/25/19	IA	Call with client to discuss diligence request for individual performance metrics and historical factors.	0.60
10/25/19	MH	Research prepetition receivable from related entity to determine resolution.	0.60
10/25/19	MH	Call with procurement manager to discuss issues with key suppliers.	0.60
10/25/19	LJD	Catch up call on process go forward with L. Donahue and J. DelConte (both AlixPartners)	0.60
10/26/19	IA	Follow up on open items on wages diligence list.	1.20
10/26/19	JD	Correspondence with M. Hartley and B. Folse (both AlixPartners) and management RE: board emails.	0.50
10/28/19	JD	Review draft business plan materials provided in advance of business plan meetings	1.60
10/28/19	JD	Meeting with J. Lowne, D. Fogel, J. Carlisle (all Purdue), J. Turner (PJT), J. DelConte and R. Sublett (both AlixPartners) re impact of market dislocation in generic opioids market	1.00
10/28/19	DS	Call with Controller (Rhodes) re: fee for service data	0.30
10/28/19	DS	Draft questions to North Carolina plant manager re: Emerson expenses incurred post-petition	0.40
10/28/19	DS	Review Q3 commercial rebate by customer file for Rhodes	1.30
10/28/19	DS	Inquire with financial analyst (PPLP) re: co-pay reduction rebate payments made in September post-petition	0.30
10/28/19	DS	Analyze per-unit rebates for Rhodes in conjunction with	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		gross-to-net historical analysis	
10/28/19	DS	Correspondence with Controller (Rhodes) re: gross-to-net classifications	0.50
10/28/19	DS	Quantify fee-for-service credits processed in post-petition September period	1.40
10/28/19	ADD	Call with Purdue Associate GC to discuss diligence request	0.30
10/28/19	ADD	Format diligence documentation for upload to data room	2.60
10/28/19	ADD	Update SOFA and Schedules schedule F	1.70
10/28/19	ADD	Compile and review files provided in response to diligence requests.	2.30
10/28/19	ADD	Follow up with client contact regarding due diligence items.	1.00
10/28/19	RDS	Meeting with J. Lowne, D. Fogel, J. Carlisle (all Purdue), J. Turner (PJT), R. Sublett, and J. DelConte (both AlixPartners) re impact of market dislocation in generic opioids market	1.00
10/28/19	RDS	Assemble financial and market summary for generic opioid business within Rhodes	1.80
10/28/19	RDS	Modeling of Rhodes opioid increases	1.70
10/28/19	IA	Update of historical LTRP grants by employee file showing the split of projected 2020 payment and outstanding grants by year.	2.90
10/28/19	IA	Follow up on outstanding wages diligence items in response to updated UCC and Adhoc lists.	2.60
10/28/19	IA	Follow up on historical AIP objectives and results for Purdue and Rhodes with management and review of submitted materials in response to diligence requests.	1.90
10/29/19	IA	Follow up with management and review of requested job descriptions and other wages diligence items in response to committee diligence requests.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/29/19	IA	Call with D. Samikkannu, J. DelConte, A. DePalma, I Arana (all AlixPartners), and Davis Polk re: diligence process and document production	0.80
10/29/19	NAS	Correspondence with Purdue vendor management committee regarding new critical vendor approval/payment process.	0.60
10/29/19	NAS	Meeting to discuss ongoing critical vendor approval/payment process with M. Hartley, S. Lemack, N. Simon (all AlixPartners), E. Ruiz, J. Lowne, K. McCarthy, S. Daniel, and L. Harding (all Purdue).	0.60
10/29/19	LJD	Prepare for and participate in a call with Davis Polk, PJT, management, Dechert, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners) RE: Thursday meeting with the UCC	1.00
10/29/19	MH	Meeting to discuss ongoing critical vendor approval/payment process with S. Lemack, N. Simon, M. Hartley (all AlixPartners), E. Ruiz, J. Lowne, K. McCarthy, S. Daniel, and L. Harding (all Purdue).	0.60
10/29/19	GJK	Call with Davis Polk, PJT, management, Dechert, L. Donahue, G. Koch, and J. DelConte (all AlixPartners) RE: Thursday meeting with the UCC	0.50
10/29/19	SKL	Meeting to discuss ongoing critical vendor approval/payment process with M. Hartley, S. Lemack, N. Simon (all AlixPartners), E. Ruiz, J. Lowne, K. McCarthy, S. Daniel, and L. Harding (all Purdue).	0.60
10/29/19	ADD	Call with D. Samikkannu, A. DePalma (both AlixPartners), and controller (Rhodes) re: gross-to-net reconciliation with historical financials	0.20
10/29/19	ADD	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: diligence process and document production	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/29/19	ADD	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to update diligence tracker for completion dates and data room references	0.40
10/29/19	ADD	Request approval to upload information to the data room.	1.10
10/29/19	ADD	Compile and review files provided in response to diligence requests.	2.90
10/29/19	ADD	Format diligence documentation for upload to data room.	2.80
10/29/19	RDS	Assemble slides articulating thin margins in generic opioid business within Rhodes	1.70
10/29/19	RDS	Alter slides regarding pricing pressures in generic opioid business within Rhodes Pharma	0.40
10/29/19	RDS	Review end to end Rhodes generic opioid model to prepare for call with D. Fogel (Rhodes)	0.60
10/29/19	RDS	Call with D. Fogel & J. Carlisle (Rhodes/Purdue) to discuss generic opioid market opportunity presentation materials	1.10
10/29/19	RDS	Further amendments to Rhodes generic vertical opioid presentation to reflect D. Fogel (Rhodes) comments	1.70
10/29/19	RDS	Discussion with J. DelConte and R. Sublett (both AlixPartners) regarding Rhodes standard cost allocation methodology as it pertains to vertical generic opioid analysis	0.20
10/29/19	RDS	Review and comment on J. Lowne comments ahead of 10/30 call with UCC advisors	0.60
10/29/19	JD	Review PBGC materials to provide to Department of Labor	0.40
10/29/19	JD	Review promotional materials for Adhansia. Correspondence with management RE: same.	1.10
10/29/19	JD	Prepare for and participate in a call with Davis Polk, PJT, management, Dechert, L. Donahue, B. Folse, G. Koch, and J. DelConte (all AlixPartners) RE: Thursday meeting with the UCC	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/29/19	JD	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: diligence process and document production	0.80
10/29/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	3.00
10/29/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.40
10/29/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.70
10/29/19	DS	Call with D. Samikkannu, A. DePalma (both AlixPartners), and controller (Rhodes) re: gross-to-net reconciliation with historical financials	0.20
10/29/19	DS	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to update diligence tracker for completion dates and data room references	0.40
10/29/19	DS	Review revised Rhodes profit share/royalty schedule for cash forecasting purposes	0.80
10/29/19	DS	Call with D. Samikkannu, J. DelConte, I. Arana, A. DePalma (all AlixPartners), and Davis Polk re: diligence process and document production	0.80
10/30/19	DS	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) to review and update of combined UCC / Ad Hoc diligence tracker	1.80
10/30/19	DS	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), and Davis Polk to approve outstanding diligence items	0.30
10/30/19	DS	Review PJT's business plan Excel and consolidated diligence tracker	0.90
10/30/19	DS	Draft summary outline of workstreams to G. Koch (AlixPartners) encompassing the following topics: IACs,	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan, cash reporting, public health initiative, Mundi transaction process	
10/30/19	DS	Assemble MDL related documents for purposes of compiling IAC / Intercompany documents	0.50
10/30/19	DS	Correspondence with G. Koch (AlixPartners) re: DOJ investigation, Medicare/Medicaid	0.30
10/30/19	REO	Meeting with N. Simon and R. Ellis Ochoa (both AlixPartners) to discuss analysis of existing Purdue/Rhodes vendor agreements.	0.30
10/30/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.70
10/30/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.40
10/30/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	3.00
10/30/19	JD	Call with management RE: department of labor requests	0.30
10/30/19	JD	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski, C. Mazzi (all Purdue), various other Purdue management team members, J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, Medical Affairs	0.60
10/30/19	JD	Call with Davis Polk RE: open diligence items	0.50
10/30/19	JD	Call with PJT, Davis Polk, management, R. Sublett, and J. DelConte (both AlixPartners) RE: UCC presentation materials.	1.00
10/30/19	JD	Review board materials and minutes RE: compensation decisions	0.70
10/30/19	JD	Review updated budget iterations RE: medical affairs and consumer health	1.30
10/30/19	JD	Analyze historical attrition rates for the UCC presentation	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/30/19	ADD	Meeting with D. Samikkannu and A. DePalma (both AlixPartners) review and update of combined UCC / Ad Hoc diligence tracker	1.80
10/30/19	ADD	Pick up thumb drive Wiggin and Dana LLP	0.60
10/30/19	ADD	Call with D. Samikkannu, I. Arana, A. DePalma (all AlixPartners), and Davis Polk to approve outstanding diligence items	0.30
10/30/19	ADD	Download insurance documents from read smith share site.	1.20
10/30/19	ADD	Research vendor inquiry.	0.50
10/30/19	ADD	Compile and submit diligence requests to Purdue client contacts	1.60
10/30/19	ADD	Request approval to upload information to the data room.	0.80
10/30/19	ADD	Compile and review files provided in response to diligence requests.	2.30
10/30/19	ADD	Format diligence documentation for upload to data room	2.70
10/30/19	RDS	Review latest LE June Long Term Plan and make notes for PJT	1.40
10/30/19	RDS	Meeting with C. Landau, J. Lowne, K. Darragh, M. Kwarcinski, C. Mazzi (all Purdue), various other Purdue management team members, J. DelConte, and R. Sublett (both AlixPartners) re 2020 budget, Medical Affairs	0.60
10/30/19	RDS	Call with PJT, Davis Polk, management, R. Sublett, and J. DelConte (both AlixPartners) RE: UCC presentation materials.	1.00
10/30/19	MH	Attend call with vendor to review reasons why they do not qualify for critical vendor motion and review future options.	0.80
10/30/19	MH	Meeting with assistant general counsel and sourcing manager to review best course of action with vendor	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		holding security deposit.	
10/30/19	MH	Call with representatives from communications advisor to explain disclosure practices of vendor payments.	0.30
10/30/19	LJD	Review correspondence and reply	0.40
10/30/19	LJD	Review and discuss info for UCC meeting	0.50
10/30/19	NAS	Review new critical vendor trade agreements and ensure tracking document reflects all those provided to Unsecured Creditors Committee for review.	0.80
10/30/19	NAS	Meeting with R. Ellis-Ochoa and N. Simon (both AlixPartners) to discuss analysis of existing Purdue/Rhodes vendor agreements.	0.30
10/30/19	IA	Review of pension plan documents to be gathered and sent to client in response to audit request.	0.80
10/30/19	IA	Update of year to date separations to overall historical and future benefits and wages payments by employee file in response to diligence request.	0.70
10/30/19	IA	Follow up on open items related to insider compensation in response to diligence requests.	0.60
10/30/19	IA	Update of AIP and LTRP year to date progress summary to be posted in response to diligence requests.	0.30
10/30/19	IA	Call with D. Samikkannu, A. DePalma, I. Arana (all AlixPartners), and Davis Polk to approve outstanding diligence items	0.30
10/30/19	IA	Review of Purdue employee sample individual performance information in response to diligence requests.	1.30
10/30/19	IA	Correspondence with client and review of submitted job descriptions in response to wages diligence.	2.10
10/30/19	IA	Review of UCC meeting materials related to employee attrition as requested by client.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/30/19	IA	Correspondence with client and analysis of source data to update historical and year to date attrition analysis.	2.90
10/31/19	IA	Review and update of nine job descriptions to be posted in response to diligence questions on wages.	2.80
10/31/19	IA	Review of UCC meeting presentation materials.	1.30
10/31/19	NAS	Correspondence with Purdue vendor management committee regarding payment status for critical vendors.	0.60
10/31/19	NAS	Correspondence with R. Ellis-Ochoa (AlixPartners) regarding analysis of existing vendor contracts.	0.10
10/31/19	MH	Advise client on eligibility of prepetition liability relative to the Customer order.	0.30
10/31/19	RDS	Review updated presentation materials ahead of 10am UCC meeting	0.60
10/31/19	RDS	Outline for operating model alterations - Purdue commercial products end to end, operating expenses	1.20
10/31/19	RDS	Outline for operating model alterations - Purdue pipeline products	0.30
10/31/19	RDS	Prepare RT third party volume and price information for meeting with J. Lowne (Purdue)	0.80
10/31/19	RDS	Meeting with K. Darragh (Purdue) re NC cost structure and standard cost methodology	0.70
10/31/19	RDS	Review of Rhodes analysis on opioid price and volume elasticity	0.30
10/31/19	ADD	Format diligence documentation for upload to data room	2.20
10/31/19	ADD	Upload files to virtual data room	1.40
10/31/19	ADD	Request approval to upload information to the data room.	0.60
10/31/19	ADD	Add individuals to data room	0.40
10/31/19	ADD	Compile and submit diligence requests to Purdue client contacts	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
10/31/19	ADD	Call with Rhodes CFO to discuss diligence items	0.50
10/31/19	ADD	Compile and review files provided in response to diligence requests.	2.20
10/31/19	JD	Participate in Compensation Committee Board meeting	0.70
10/31/19	JD	Review latest draft working excel model to share with the various committees	1.00
10/31/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.40
10/31/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	3.30
10/31/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.50
11/01/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	3.10
11/01/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	3.30
11/01/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.00
11/01/19	DS	Update lease damage analysis model to include net effects of sublease rental income (update model for all sublessee floors to incorporate into damages calculation)	1.40
11/01/19	DS	Draft outline of responses to PJT re: business plan and R&D related diligence requests	1.30
11/01/19	ADD	Add individuals to data room	0.50
11/01/19	ADD	Discussion with Intralinks technical support	0.60
11/01/19	ADD	Review vendors receiving distributions	1.30
11/01/19	ADD	Respond to data room information request.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/01/19	ADD	Format diligence documentation for upload to data room	2.90
11/01/19	ADD	Compile and review files provided in response to diligence requests.	1.80
11/01/19	RDS	Discussion re NC overhead absorption with J. DelConte and R. Sublett (both AlixPartners)	0.50
11/01/19	RDS	Review Evercore IAC valuation analysis	0.80
11/01/19	RDS	Call with J. Lowne, M. Sisoda, N. Davis, D. Fogel (all Purdue/Rhodes), T. Melvin (PJT), J. DelConte, and R. Sublett (both AlixPartners) re Rhodes business development opportunity.	0.90
11/01/19	RDS	Call with D. Fogel, D. Lundie (both Purdue/Rhodes), J. DelConte, and R. Sublett (both AlixPartners) re Rhodes 2020 Budget overview	1.30
11/01/19	RDS	Lay out Rhodes / North Carolina overhead absorption for marginal contribution analysis	0.30
11/01/19	RDS	Prepare presentation on North Carolina Fixed Overhead absorption - discrete data points to plot continuous function	1.30
11/01/19	LJD	Call with PJT regarding bi-weekly update calls and agenda requirements	0.50
11/01/19	JD	Partial participation in the initial diligence call with Mundipharma, FTI, Province, PJT, G. Koch and J. DelConte (both AlixPartners)	2.00
11/01/19	JD	Call with J. Lowne, M. Sisoda, N. Davis, D. Fogel (all Purdue/Rhodes), T. Melvin (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes business development opportunity.	0.90
11/01/19	JD	Call with D. Fogel, D. Lundie (both Purdue/Rhodes), J. DelConte, and R. Sublett (both AlixPartners) re Rhodes 2020 Budget overview	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/01/19	JD	Review ordinary course professional analysis and potential cap breakdowns.	0.70
11/01/19	JD	Review latest sublease and One Stamford Forum draft Board presentation. Provide comments re: same.	0.80
11/01/19	JD	Review Evercore IAC diligence presentation	0.80
11/01/19	JD	Discussion re NC overhead absorption with J. DelConte and R. Sublett (both AlixPartners)	0.50
11/02/19	ADD	Troubleshoot client file sharing issues for documentation needed for diligence requests.	0.60
11/04/19	ADD	Update diligence tracker.	0.80
11/04/19	ADD	Prepare and format files provided in response to diligence requests for upload to data room.	1.50
11/04/19	ADD	Add individuals from Creditor Committees' advisors to data room	0.30
11/04/19	ADD	Review files provided by Purdue and Rhodes in response to diligence requests.	1.40
11/04/19	ADD	Request approval to upload files provided in response to diligence requests to the data room.	0.70
11/04/19	ADD	Research Intralinks capabilities to develop a diligence tracking process with Davis Polk	2.10
11/04/19	ADD	Submit request to the client to have TPA executed for Akin Gump to access IMS data.	0.20
11/04/19	DS	Create subtenant income by floor analysis leveraging model outputs	1.80
11/04/19	DS	Incorporate floor 2 into lease damage analysis model	1.60
11/04/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	2.60
11/04/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/04/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.50
11/04/19	RDS	Fix overhead and variable cost contribution analysis for Rhodes products	1.30
11/04/19	RDS	Phone call with D. Fogel (Purdue/Rhodes) to discuss vertical generic opioid presentation	0.50
11/04/19	RDS	Meeting with D. Lundie, D. Fogel, J. Lowne, R Shamblan, V. Mancinelli and other management (Purdue / Rhodes) T. Melvin (PJT), J. DelConte, and R. Sublett (both AlixPartners) re RALP (RT & RP) 2020 budget review	1.20
11/04/19	RDS	Financial justification of NC and RT overhead - analysis of vertical opioid product volumes against standard cost absorption	0.90
11/04/19	RDS	Deconstruct 2020 long term plan for generic business - insight on low volume, high margin focus	0.40
11/04/19	RDS	Review final 2020 Rhodes and North Carolina Budget, analysis of variable cost assumptions	1.70
11/04/19	RDS	Prepare slides to discuss North Carolina cost structure with J. Carlisle (Purdue) and send to him	0.50
11/04/19	JD	Meeting with D. Lundie, D. Fogel, J. Lowne, R Shamblan, V. Mancinelli and other management (Purdue / Rhodes) T. Melvin (PJT), J. DelConte, R. Sublett (both AlixPartners) re RALP (RT & RP) 2020 budget review	1.20
11/04/19	JD	Review the latest Rhodes and Wilson budget presentation to be reviewed with management.	1.10
11/04/19	JD	Review latest presentation related to LTRP and AIP metrics.	0.70
11/04/19	JD	Correspondence with management RE: insider disclosures	0.40
11/04/19	JD	Review LTS agreements and correspondence re: open	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		prepetition amounts owed and contract assumption.	
11/04/19	MH	Review status and results of critical vendor contract analysis.	1.30
11/04/19	MH	Respond to vendor inquiry on status as utility or not.	0.40
11/04/19	MH	Discuss with counsel status of a marketing vendor seeking critical vendor status.	0.50
11/04/19	MH	Provide update to marketing vendor on critical vendor request.	0.30
11/04/19	MH	Review with legal department the process for moving legal invoices from the review system to SAP to ensure proper controls.	0.40
11/05/19	MH	Call with company counsel on large development partner concerning prepetition amounts.	0.40
11/05/19	MH	Reconcile open balances for large license partner to isolate balances across three contracts.	2.90
11/05/19	MH	Call with clinical trial manager regarding large vendors with open prepetition balances.	0.40
11/05/19	MH	Prepare for call with clinical trial manager.	0.70
11/05/19	MH	Call with sourcing manager to discuss possible critical vendor treatment for a vendor.	0.40
11/05/19	LJD	Weekly Advisor Call with T. Coleman, J. Turner, T. Melvin, etc. (PJT), M. Huebner, T. Graulich, etc. (Davis Polk), L. Donahue, J. DelConte, R. Sublett, G. Koch, B. Folse, D. Samikkannu, and I. Arana (all AlixPartners) re case status updates	0.70
11/05/19	LJD	Review latest case update materials	0.30
11/05/19	LJD	Call with K. Buckfire regarding board meetings	0.50
11/05/19	LJD	Review and comment for staffing purposes the forward timeline	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/05/19	JD	Review proposed Board questions for next week's board meeting. Draft proposed responses re: same.	1.20
11/05/19	JD	Review various files re: diligence questions on business performance	0.60
11/05/19	JD	Correspondence with management re: open critical vendor payments and trade agreements.	0.70
11/05/19	IA	Follow up with client on firm names and descriptions for OCP list proposal	1.70
11/05/19	IA	Follow up on open diligence requests on wages.	1.60
11/05/19	IA	Update of job descriptions requested by committees and follow up on approvals from client and Davis Polk	2.80
11/05/19	RDS	Isolate investment and earnings ROI within Avrio 2020 budget / 5-year plan	1.30
11/05/19	RDS	Impact on Rhodes Technology from Oxy APAP and other low margin products	2.10
11/05/19	RDS	Analyze Avrio data to understand investment that has been made in S&P and R&D over the past two years against current expected budget	0.60
11/05/19	RDS	Review and correct D. Fogel (Purdue / Rhodes) slide on Vertical Generic Opioid contribution and margin	1.10
11/05/19	RDS	Call with D. Fogel (Purdue/Rhodes) re marginal vertically integrated generic products with low ASP. Standard cost absorption	0.80
11/05/19	RDS	Aggregate headcount and expenses by various departments from 2020 budget	2.10
11/05/19	RDS	Turn slides for D. Fogel (Purdue/Rhodes) on Volume impacts in core generics for C. Landau / J. Lowne	0.40
11/05/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/05/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.10
11/05/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	3.40
11/05/19	DS	Update gross damages calculation section of Board deck	1.10
11/05/19	DS	Update net damages calculation section of Board deck	0.90
11/05/19	DS	Add slide on subtenant income and effects on net damages calculation	1.30
11/05/19	DS	Update Kokino data in lease damages model for potential extension	1.80
11/05/19	DS	Working session with Treasurer (PPLP) re: edits to lease considerations deck and model	0.20
11/05/19	DS	Make adjustments to Charter in lease damages model	0.60
11/05/19	DS	Outline changes made and send email to CFO and Treasurer	0.50
11/05/19	DS	Update Board materials for CBRE historical data obtained from Treasurer	0.60
11/05/19	DS	Revise lease damages model for 9th and 10th floor estimated rent payments	1.10
11/05/19	DS	Update model for ROCKIT and CBRE extension and rent assumptions	1.30
11/05/19	DS	Update damages chart based on comments from CFO	0.50
11/05/19	DS	Update Kokino data in lease damages model for potential extension	0.70
11/05/19	JD	Review various materials provided by management to be responsive to open business diligence questions.	0.70
11/05/19	ADD	Prepare and format files received in response to diligence requests for upload to data room.	2.40
11/05/19	ADD	Respond to data room issue with corrupt file.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/05/19	ADD	Review outstanding prepetition accounts payable.	1.10
11/05/19	ADD	Request approval to upload files submitted in response to diligence request to the data room.	0.50
11/05/19	ADD	Review files submitted in response to diligence requests.	2.10
11/06/19	RDS	Call with J. Turner and R. Schnitzler (both PJT) re run-off model for PPLP	0.20
11/06/19	RDS	Aggregate 2020 PLP Budget to discuss run off model considerations	1.30
11/06/19	RDS	Review of updated generic opioid cost structure	1.40
11/06/19	RDS	Model runoff scenario - Purdue G&A	0.70
11/06/19	RDS	Model runoff scenario - Purdue Med Affairs	0.60
11/06/19	RDS	Model runoff scenario - Rhodes Pharma	1.20
11/06/19	RDS	Meeting with J. Lowne (Purdue) to discuss generic opioid market slides for the board	0.60
11/06/19	RDS	Call with D. Fogel (Purdue / Rhodes) re Rhodes Tech volumes if MKT were to exit the Opioid API business	0.20
11/06/19	ADD	Update prepetition accounts payable analysis for Purdue controller	1.70
11/06/19	ADD	Research and respond to Davis Polk data room / Intralinks questions.	0.60
11/06/19	ADD	Request approval to upload diligence requests to data room.	0.40
11/06/19	ADD	Evaluate potential additions to interested parties list at request of counsel.	2.10
11/06/19	ADD	Update trade agreement review tracker.	1.10
11/06/19	JD	Conversations with management re: critical vendor process	0.60
11/06/19	JD	Review proposed Board questions RE: emergence plan go forward	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/06/19	JD	Call with J. Lowne (Purdue), J. DelConte, G. Koch (both AlixPartners) and PJT to walkthrough responses to board questions	0.70
11/06/19	DS	Correspondence with Controller (Rhodes) re: Amex payments	1.40
11/06/19	DS	Correspondence with Controller (Rhodes) re: Amex payments	0.00
11/06/19	DS	Compare Amex data obtained from TXP with that per SOFAs/SOALS	1.40
11/06/19	DS	Call with J. DelConte, D. Samikkannu (both AlixPartners), CFO and Treasurer re: comments to lease analysis deck	0.20
11/06/19	DS	Update lease damages model for further refined assumptions for 9th and 10th floor	1.20
11/06/19	DS	Update gross damages calculation analysis based on further comments from CFO.	1.10
11/06/19	DS	Update net damages calculation analysis based on further comments from CFO	1.30
11/06/19	DS	Update net damages calculation analysis based on further comments from CFO	1.60
11/06/19	DS	Draft and send email to CFO and Treasurer outlining changes made to Board presentation on lease damages analysis	0.50
11/06/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	1.40
11/06/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	2.00
11/06/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	2.30
11/06/19	IA	Review of 2020 LTRP payment performance grants by	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		year as per employee	
11/06/19	LJD	Review agenda for adhoc meeting and comment	0.50
11/06/19	MH	Continue preparation for call with UCC on critical vendor payments.	0.90
11/06/19	MH	Call with the UCC advisors on administration of the critical vendor order.	0.70
11/06/19	MH	Participate in Critical Vendor update meeting re: vendor cap with S. Lemack and M. Hartley (both AlixPartners).	1.00
11/06/19	MH	Prepare for call with clinical trial manager to review two large vendors.	0.80
11/06/19	MH	Follow up call with clinical trial manager regarding large vendors with open prepetition balances.	0.60
11/06/19	MH	Respond to Rhodes management on ability to engage consultant on market study.	0.70
11/06/19	MH	Research inclusion of preference waivers in the trade agreements prepared to date.	1.10
11/06/19	MH	Research status of proposed trade agreements to determine if the drafts provided are near final or still in negotiation.	0.60
11/06/19	MH	Prepare response to UCC advisors on issues raised in earlier call.	0.80
11/06/19	GJK	Call with J. Lowne (Purdue), J. DelConte, G. Koch (both AlixPartners) and PJT to walkthrough responses to board questions	0.70
11/06/19	SKL	Participate in Critical Vendor update meeting re: vendor cap with M. Hartley and S. Lemack (both AlixPartners).	1.00
11/07/19	SKL	Prepare for and participate in a meeting with management, M. Hartley, B. Folse, J. DelConte and S. Lemack (all AlixPartners) re: critical vendor process	1.00
11/07/19	MH	Prepare for and participate in a meeting with	1.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management, M. Hartley, B. Folse, J. DelConte and S. Lemack (all AlixPartners) re: critical vendor process	
11/07/19	MH	Prepare for call with client on critical vendor status.	1.40
11/07/19	MH	Call with R. Ellis Ochoa and M. Hartley (both AlixPartners) to discuss transition of contract analysis project.	0.30
11/07/19	MH	Review status files from contract analysis project in advance of status call with analyst.	0.70
11/07/19	MH	Review revised critical vendor tracking statistics in preparation of client review.	1.20
11/07/19	MH	Create revised critical vendor summary to reflect the analysis requests from the CFO.	1.20
11/07/19	MH	Create the accounts payable release file.	0.40
11/07/19	MH	Perform initial research on legal invoices for firms in the retention process.	0.50
11/07/19	MH	Reconcile accounts payable for a vendor requesting critical vendor status.	0.80
11/07/19	LJD	Review and comment on strategy deck	0.80
11/07/19	BF	Prepare for and participate in a meeting with management, M. Hartley, B. Folse, J. DelConte and S. Lemack (all AlixPartners) re: critical vendor process	1.00
11/07/19	DS	Provide Davis Polk with SOFA details behind Amex payments	0.60
11/07/19	JD	Review asset monetization presentation prepared by PJT	0.70
11/07/19	JD	Review correspondence re: Sackler family diligence process	0.40
11/07/19	JD	Review and comment on updated analysis re: critical vendors	0.90
11/07/19	JD	Prepare for and participate in a meeting with management, M. Hartley, B. Folse, J. DelConte and S.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/07/19	JD	Lemack (all AlixPartners) re: critical vendor process	
11/07/19	JD	Conversation with management, J. DelConte, and R. Sublett (both AlixPartners) re: strategic planning process go forward.	1.70
11/07/19	JD	Review details on people who have left the company since filing and analysis of bonus amounts owed.	0.50
11/07/19	JD	Prepare analysis of Alix fees through 2020 for draft board materials.	1.10
11/07/19	ADD	Develop plan to remove watermark security feature from Intralinks.	0.30
11/07/19	RDS	Call with D. Fogel (Purdue) re Rhodes Technology API economics if Mallinckrodt exits	0.40
11/07/19	RDS	Board slide preparation for API volume disintermediation scenario	0.50
11/07/19	RDS	Conversation with management, J. DelConte, and R. Sublett (both AlixPartners) re: strategic planning process go forward.	1.70
11/07/19	RDS	Review of Hydrocodone APAP SKUs at Rhodes Pharma and overlap with Mallinckrodt	0.70
11/07/19	RDS	Correspondence with C. Landau, D. Lundie, J. Lowne (Purdue) regarding API opportunity	0.60
11/07/19	RDS	Review PJT Asset Monetization Discussion Materials as provided by J. Turner	1.20
11/07/19	RDS	Rhodes Technology API analysis changes - Hydrocodone & Rhodes Pharma overlap	1.60
11/07/19	ADD	Request approval from Davis Polk to upload files to the data room.	0.40
11/07/19	ADD	Evaluate potential additions to interested parties list at request of counsel.	1.80
11/07/19	ADD	Added individuals from Creditor Committees' advisors to	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		data room	
11/07/19	REO	Call with R. Ellis Ochoa and M. Hartley (both AlixPartners) to discuss transition of contract analysis project.	0.30
11/08/19	ADD	Trouble shoot data room access issue at request of counsel.	1.40
11/08/19	ADD	Upload documents to the data room and update permissions.	0.70
11/08/19	RDS	Changes to messaging in board slides regarding Rhodes Pharma / Tech market disruption Scenario	1.40
11/08/19	RDS	Call with D. Fogel and J. Lowne (Purdue) to finalize Rhodes disruption slides for board	0.20
11/08/19	RDS	Build our strategic options board deck to bridge to analysis framework	0.70
11/08/19	JD	Participate in meeting with PJT, Davis Polk, L. Donahue, G. Koch, J. DelConte (all AlixPartners), management, David Sackler, Milbank, Debevoise, FTI, Kramer Levin, Otterbourg, Brown Rudnick, Gilbert and the Ad Hoc Committee	5.30
11/08/19	JD	Post-meeting debrief with PJT, Davis Polk, L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: next steps	0.50
11/08/19	JD	Review and comment on critical vendor email to management.	0.40
11/08/19	LJD	Review and discuss board presentation slides	0.80
11/08/19	LJD	Prepare for and participate in meeting with PJT, Davis Polk, L. Donahue, G. Koch, J. DelConte (all AlixPartners), management, David Sackler, Milbank, Debevoise, FTI, Kramer Levin, Otterbourg, Brown Rudnick, Gilbert and the Ad Hoc Committee	5.50
11/08/19	LJD	Review and discuss cash report	0.60
11/08/19	LJD	Post-meeting debrief with PJT, Davis Polk, L. Donahue, J.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DelConte and G. Koch (all AlixPartners) re: next steps	
11/08/19	MH	Participate in critical vendor update meeting with S. Lemack and M. Hartley (both AlixPartners)	0.50
11/08/19	MH	Research invoices related to new critical vendor request to determine accurate payment status.	0.40
11/08/19	MH	Identify all invoices paid related to legal fees to determine status of controls related to retention.	0.90
11/08/19	MH	Prepare memo to CFO on options to manage critical vendor payment cap.	0.60
11/08/19	GJK	Participate in meeting with PJT, Davis Polk, L. Donahue, G. Koch, J. DelConte (all AlixPartners), management, David Sackler, Milbank, Debevoise, FTI, Kramer Levin, Otterbourg, Brown Rudnick, Gilbert and the Ad Hoc Committee	4.50
11/08/19	SKL	Participate in critical vendor update meeting with M. Hartley and S. Lemack (both AlixPartners).	0.50
11/08/19	IA	Follow up on attrition calculations and presentation with client.	0.70
11/09/19	JD	Review Willis Towers Watson comp analysis	0.50
11/09/19	ADD	Collaborate with Davis Polk to prepare data room and download data room contents.	1.10
11/09/19	ADD	Research and respond to Davis Polk data room questions.	0.40
11/09/19	ADD	Upload files to data room.	0.30
11/10/19	JD	Correspondence with management re: latest fee budget and Monday board presentation	0.30
11/10/19	JD	Correspondence with Davis Polk re: access to information for the non-consenting states committee advisors	0.60
11/10/19	LJD	Review advance documents for board meeting	0.90
11/10/19	LJD	Review advance staffing and budget proposal for	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners team for 2020	
11/11/19	LJD	Prepare for and attend board meeting	6.00
11/11/19	LJD	Strategy discussion with PJT and management regarding revised business plan and products offered	0.70
11/11/19	MH	Respond to questions from client about foreign vendor treatment.	0.30
11/11/19	MH	Call with supply chain manager about negotiations with a vendor for partial payment of open amounts.	0.40
11/11/19	MH	Prepare accounts payable reconciliation for large clinical trial vendor.	1.10
11/11/19	MH	Research apparent duplicate invoices from international patch supplier to resolve prepetition balance.	0.60
11/11/19	MH	Prepare accounts payable reconciliation for second large clinical trial vendor.	0.90
11/11/19	SKL	Meeting with M. Hartley, S. Lemack, and N. Simon (all AlixPartners) to discuss critical vendor trade agreement review and tracking processes.	0.30
11/11/19	SKL	Training session for accounts payable release process and critical vendor tracking with N. Simon, S. Lemack, and M. Hartley (all AlixPartners).	1.30
11/11/19	HK	Review Debtors' business plan presentations for forecasting.	2.10
11/11/19	MH	Meeting with N. Simon, M. Hartlery, and S. Lemack (all AlixPartners) to discuss critical vendor trade agreement review and tracking processes.	0.30
11/11/19	MH	Training session for accounts payable release process and critical vendor tracking with N. Simon, M. Hartley, and S. Lemack (all AlixPartners).	1.30
11/11/19	MH	Prepare accounts payable release list.	0.40
11/11/19	JD	Participate in person at board meeting	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/11/19	JD	Participate by phone at board meeting	1.80
11/11/19	NAS	Correspondence with Purdue vendor contacts regarding latest status of critical vendor trade agreements.	0.60
11/11/19	NAS	Review list of trade agreements provided to advisors for Unsecured Creditors Committee during week of November 4th.	0.70
11/11/19	NAS	Reconciliation of prepetition amounts claimed by two critical vendors to amounts listed for those vendors in Purdue's accounts payable system.	0.60
11/11/19	NAS	Implement new guidelines from advisors to Unsecured Creditors Committee regarding review period and approval requirements for critical vendor trade agreements.	0.90
11/11/19	NAS	Meeting with M. Hartley, N. Simon, and S. Lemack (all AlixPartners) to discuss critical vendor trade agreement review and tracking processes.	0.30
11/11/19	NAS	Training session for accounts payable release process and critical vendor tracking with M. Hartley, N. Simon, and S. Lemack (all AlixPartners).	1.30
11/11/19	JD	Review materials in preparation for Board meeting	0.80
11/11/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	1.30
11/11/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	1.50
11/11/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	1.20
11/11/19	DS	Review PPLP's financial data to assess consolidating financials accuracy	1.30
11/11/19	DS	Draft email to B. Folse (AlixPartners) re: workstream	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		summary	
11/11/19	DS	Correspondence with Controller (Rhodes) re: new iContracts/Medicaid process	0.40
11/11/19	ADD	Review documentation provided in response to diligence requests.	2.40
11/11/19	ADD	Research and respond to Davis Polk data room questions.	0.90
11/11/19	ADD	Prepare and format files for upload to the data room	3.10
11/11/19	ADD	Meeting with Controller (PPLP) re: consolidating financial statements	0.30
11/11/19	ADD	Update and circulate interested parties list.	1.20
11/11/19	ADD	Update and review data room permissions.	0.30
11/11/19	RDS	Call with D. McGuire and J. Carlisle (both Purdue) re virializing cost structure in Wilson post-Treyburn	0.30
11/11/19	RDS	Review Avrio S&IOP deck review and analysis for implications from Avrio underperformance	0.90
11/12/19	RDS	Review of IAC business connectivity and diligence	0.30
11/12/19	RDS	Correspondence with J. Lowne (Purdue) regarding Avrio capital spending plan	0.50
11/12/19	RDS	Meeting with management, J. DelConte, and R. Sublett (both AlixPartners) re: business plan update process	1.10
11/12/19	RDS	Meeting with management, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes business plan scenarios	0.50
11/12/19	ADD	Prepare and format files for upload to the data room	2.70
11/12/19	ADD	Follow up with City of Wilson counsel regarding request for additional adequate assurance.	0.40
11/12/19	ADD	Request approval to upload files received in response to diligence requests to the data room	0.50
11/12/19	ADD	Upload documents to internal data room for Davis Polk review.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/12/19	ADD	Review documentation provided in response to diligence requests.	1.40
11/12/19	ADD	Spoke with Intralinks customer support to troubleshoot data room issue.	0.40
11/12/19	REO	Review of Vendor Contracts re: Contract terms and conditions.	1.50
11/12/19	REO	Review of Ariba database re: analysis of existing contracts that match the shared vendor list.	1.00
11/12/19	REO	Edit contract database file re: terms, conditions and outstanding items identified through Ariba search and contract analysis.	0.50
11/12/19	JD	Meeting with management, J. DelConte, and R. Sublett (both AlixPartners) re: business plan update process	1.10
11/12/19	JD	Meeting with management, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes business plan scenarios	0.50
11/12/19	JD	Final review of business plan process slide to share with management	0.40
11/12/19	JD	Review Mundipharma Europe overview presentation	1.20
11/12/19	JD	Correspondence with Davis Polk re: professional eyes-only designations	0.50
11/12/19	JD	Review and revise latest professional fee forecasts given updated work streams	1.70
11/12/19	NAS	Draft list of remaining independent associated company diligence questions following conference calls with A. Martinez (Mundipharma Europe) and R. Singh (Mundipharma LAM).	0.70
11/12/19	NAS	Prepare for and follow up for Mundipharma calls	0.70
11/12/19	NAS	Call with A. Martinez (Mundipharma), G. Koch, N. Simon (both AlixPartners), Norton Rose, UCC and Adhoc advisors re Mundipharma Europe operations	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/12/19	NAS	Review of budget materials for Mundipharma Europe in order to better understand recent trends and business drivers for purposes of independent affiliated company diligence.	1.00
11/12/19	NAS	Review of budget materials for Mundipharma LAM region (Asia/Pacific, Latin America, and Africa) in order to better understand recent trends and business drivers for purposes of independent affiliated company diligence.	0.70
11/12/19	NAS	Create detailed list of open requests and questions for purposes of independent associated company diligence.	1.10
11/12/19	NAS	Meeting with N. Simon and G. Koch (both AlixPartners) re Mundipharma diligence planning	1.00
11/12/19	NAS	Call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), Norton Rose, UCC and Ad Hoc advisors re Mundipharma LAM operations	1.20
11/12/19	NAS	Meeting with N. Simon and G. Koch (both AlixPartners) re Mundipharma diligence planning	0.00
11/12/19	NAS	Create draft of independent associated company workplan for review by company's investment banker (PJT Partners).	0.80
11/12/19	MH	Call with clinical trial manager to review negotiation status of large trial vendors.	0.50
11/12/19	MH	Prepare for call with clinical trial manager.	1.10
11/12/19	MH	Meeting with R. Ellis-Ochoa, H. Ku and M. Hartley (all AlixPartners) to review transition materials for contract analysis.	0.40
11/12/19	MH	Prepare talking points for vendor negotiation contacts regarding critical vendor status.	0.70
11/12/19	MH	Research issue with invoice release program to determine why certain invoices do not release as expected.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/12/19	MH	Prepare status summary notes for all hand's status call.	0.40
11/12/19	MH	Prepare accounts payable release list.	0.40
11/12/19	MH	Correct programming to release process to correct invoices not releasing.	1.30
11/12/19	MH	Review complaint from marketing vendor regarding possible legal action.	0.90
11/12/19	HK	Review Debtors' business plan presentations for forecasting.	1.70
11/12/19	HK	Meeting with H. Ku and M. Hartley (all AlixPartners) to review transition materials for contract analysis.	0.40
11/12/19	GJK	Meeting with N. Simon and G. Koch (both AlixPartners) re Mundipharma diligence planning	1.00
11/12/19	GJK	Call with A. Martinez (Mundipharma), G. Koch, N. Simon (both AlixPartners), Norton Rose, UCC and Adhoc advisors re Mundipharma Europe operations	2.10
11/13/19	GJK	Call with EY, Province, Jefferies, FTI, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to discuss EY workstreams for IAC	1.20
11/13/19	GJK	Call with PJT, N. Simon and G. Koch (both AlixPartners) to discuss IAC diligence workstreams	0.30
11/13/19	LJD	Review documents	0.50
11/13/19	HK	Review Debtors' business plan presentations for forecasting.	1.70
11/13/19	MH	Prepare for meeting to review the entire Trade Agreement process.	0.70
11/13/19	MH	Meeting with supply chain manager to review invoices of large clinical trial vendor.	0.60
11/13/19	MH	Meeting with vendor to discuss trade agreement.	0.70
11/13/19	MH	Prepare accounts payable release list.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/13/19	MH	Review list of accounts payable discrepancies compared to proposed trade agreements.	1.10
11/13/19	NAS	Call with EY, Province, Jefferies, FTI, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to discuss EY workstreams for IAC	1.20
11/13/19	NAS	Call with PJT, N. Simon and G. Koch (both AlixPartners) to discuss IAC diligence workstreams	0.30
11/13/19	JD	Prepare for and attend call with EY, Province, Jefferies, FTI, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to discuss EY workstreams for IAC	1.60
11/13/19	JD	Meeting with PJT, management, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: finance overview	1.30
11/13/19	JD	Review and provide comments on updated professional fee forecast	0.80
11/13/19	JD	Review question list from the UCC and Ad Hoc committees re: business plan overview presentations	0.50
11/13/19	RDS	Avrio product level business review, preliminary NPV and valuation analysis	1.30
11/13/19	ADD	Troubleshoot permissions issues in Intralinks.	0.40
11/13/19	ADD	Update and provide new data locations at the request of UCC counsel.	1.60
11/13/19	ADD	Request approval from internal Purdue/Rhodes counsel and David Polk to upload files to the data room.	0.60
11/13/19	ADD	Upload requests to the data room	0.40
11/13/19	ADD	Prepare documentation for upload to the data room.	3.10
11/13/19	ADD	Update trade agreement tracker.	0.70
11/13/19	RDS	Meeting with PJT, management, FTI, Province, J. DelConte, and R. Sublett (both AlixPartners) re: finance overview	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/14/19	RDS	Call with D. McGuire, J. Carlisle (Purdue), R. Sublett and K. McCafferty (both AlixPartners) re. Wilson cost scenarios and analysis	1.00
11/14/19	RDS	Correspondence with K. McCafferty (AlixPartners) re North Carolina cost structure and Purdue situation update since June (KM rolled off and is coming back to project)	0.50
11/14/19	RDS	Due diligence conference call with D. Pidduck (Purdue), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to understand business drivers and recent performance trends.	1.20
11/14/19	RDS	Review oncology pipeline NPV analysis	1.70
11/14/19	RDS	Review ADHA Business lines - generic, branded, financial and R&D analysis	2.40
11/14/19	RDS	Conversation with PJT Partners, J. DelConte, and R. Sublett (both AlixPartners) re: business plan process going forward and pipeline forecasts	0.50
11/14/19	RDS	Treyburn equipment installation analysis - shift structure and stepwise cost glide path	1.10
11/14/19	ADD	Upload files received to fulfill diligence request in the data room.	2.10
11/14/19	ADD	Follow up with outstanding diligence request.	0.70
11/14/19	ADD	Prepare documentation for upload to the data room.	2.80
11/14/19	KM	Call with D. McGuire, J. Carlisle (Purdue), R. Sublett and K. McCafferty (both AlixPartners) re. Wilson cost scenarios and analysis	1.00
11/14/19	JD	Coordination call with B. Folse, J. DelConte and L. Donahue (both AlixPartners) regarding case management and staffing workstreams.	0.50
11/14/19	JD	Conversation with PJT Partners, J. DelConte, and R.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Sublett (both AlixPartners) re: business plan process going forward and pipeline forecasts	
11/14/19	JD	Update analysis of total time spent on the investigation to date	1.90
11/14/19	JD	Review vendor agreement in relation to open invoice questions	0.50
11/14/19	DS	Correspondence with Davis Polk re: insurance collateral analysis	0.40
11/14/19	DS	Create analysis in response to M. Atkinson (Province) re: questions re: insurance collateral	1.60
11/14/19	DS	Draft email outlining answers to M. Atkinson (Province) questions re: insurance collateral	0.60
11/14/19	NAS	Conference call with S. Jameison (Mundipharma), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to discuss reporting structure and consolidation of Mundipharma entities.	2.30
11/14/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: financial reporting structure of Mundipharma network of companies following call with S. Jamieson (Mundipharma).	0.20
11/14/19	NAS	Due diligence conference call with D. Pidduck (Purdue), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to understand business drivers and recent performance trends.	1.20
11/14/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: key takeaways and next steps following Purdue Canada diligence call.	0.40
11/14/19	NAS	Correspondence with Purdue vendor management committee regarding vendors who have not yet received	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		trade agreements.	
11/14/19	NAS	Update master Mundipharma diligence list to incorporate all items received and questions answered during week of November 11th.	1.40
11/14/19	NAS	Draft key takeaways and outstanding questions regarding Mundipharma diligence for weekly Alix team coordination call.	0.70
11/14/19	IA	Review and follow up with HR on attrition, headcount and termination assumptions pre and post filing.	1.40
11/14/19	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle (all Purdue), D. Fogel (Rhodes), H. Ku, and M. Hartley (both AlixPartners) on vendor management process.	0.80
11/14/19	MH	Prepare presentation for client managers on current critical vendor status.	1.70
11/14/19	MH	Review current forecast for critical vendor budget.	0.80
11/14/19	MH	Prepare accounts payable release list.	0.30
11/14/19	MH	Prepare proposed language for a modified trade agreement regarding waiver of claims.	0.50
11/14/19	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle (all Purdue), D. Fogel (Rhodes), H. Ku, and M. Hartley (both AlixPartners) on vendor management process.	0.80
11/14/19	HK	Review Avrio Health business plan model.	1.60
11/14/19	HK	Review sales forecast data by SKU for Avrio Health.	1.20
11/14/19	LJD	Prepare for and attend update call with advisors	0.60
11/14/19	LJD	Work on staffing	0.50
11/14/19	LJD	Coordination call with B. Folse, J. DelConte and L. Donahue (both AlixPartners) regarding case management and staffing workstreams.	0.50
11/14/19	BF	Coordination call with B. Folse, J. DelConte and L. Donahue (both AlixPartners) regarding case management	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and staffing workstreams.	
11/14/19	GJK	Conference call with S. Jameison (Mundipharma), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to discuss reporting structure and consolidation of Mundipharma entities.	2.30
11/14/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: financial reporting structure of Mundipharma network of companies following call with S. Jamieson (Mundipharma).	0.20
11/14/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: key takeaways and next steps following Purdue Canada diligence call.	0.40
11/14/19	GJK	Due diligence conference call with D. Pidduck (Purdue), G. Koch, N. Simon, R. Sublett (all AlixPartners), PJT Partners, and advisors to Unsecured Creditors Committee and Ad-Hoc Committee to understand business drivers and recent performance trends.	1.20
11/15/19	GJK	IAC Tax meeting with KPMG, UCC, Ad Hoc, PJT, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to understand tax implications for various Mundipharma entity sale structures.	2.10
11/15/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: key takeaways and follow-up items after Mundipharma tax meeting.	0.20
11/15/19	LJD	Prepare for and attend call with J. Dubel (Purdue)	0.30
11/15/19	MH	Review large foreign vendor with Rhodes CFO to determine correct petition status.	0.70
11/15/19	MH	Research employment vendor to determine qualification for wage motion treatment.	0.40
11/15/19	MH	Prepare summary of open prepetition payables for CFO.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/15/19	MH	Research discrepancies in critical vendor report for unpaid amounts.	0.70
11/15/19	MH	Research correct treatment of three related vendor accounts to ensure accurate motion status.	0.70
11/15/19	NAS	IAC Tax meeting with KPMG, UCC, Ad Hoc, PJT, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to understand tax implications for various Mundipharma entity sale structures.	2.10
11/15/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: key takeaways and follow-up items after Mundipharma tax meeting.	0.20
11/15/19	NAS	Draft comprehensive list of follow-up items after Mundipharma tax meeting.	0.60
11/15/19	DS	Create side-by-side comparison of insurance collateral (original funding vs. interest earned)	1.20
11/15/19	JD	Call with D. Lundie, D. Fogel, C. Mazzi, J. Lowne (Purdue / Rhodes), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re Rhodes quality and manufacturing cost consolidation workplan	0.80
11/15/19	JD	Conversation with PJT re: pipeline forecast and monetization opportunities	0.50
11/15/19	JD	Call with management and PJT Partners re: potential monetization opportunities	0.40
11/15/19	JD	Partial participation in IAC Tax meeting with KPMG, UCC, Ad Hoc, PJT, N. Simon, J. DelConte, and G. Koch (all AlixPartners) to understand tax implications for various Mundipharma entity sale structures.	1.10
11/15/19	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) regarding case update and next steps with Rhodes cost consolidation exercise.	0.40
11/15/19	KM	Call with D. Lundie, D. Fogel, C. Mazzi, J. Lowne (Purdue	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		/ Rhodes), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re Rhodes quality and manufacturing cost consolidation workplan	
11/15/19	RDS	Call with D. Lundie, D. Fogel, C. Mazzi, J. Lowne (Purdue / Rhodes), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: Rhodes quality and manufacturing cost consolidation workplan	0.80
11/15/19	RDS	Review latest Rhodes cost initiatives	0.30
11/15/19	RDS	Project Windsor Tax Advisor Meeting with L. Schreyer and L. Kelly, all professionals for UCC and Ad Hoc	1.00
11/15/19	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) regarding case update and next steps with Rhodes cost consolidation exercise.	0.40
11/15/19	ADD	Prepare and format files for upload to data room	2.60
11/15/19	ADD	Review entities receiving distributions in preparation for diligence requests.	1.80
11/15/19	ADD	Request documentation for creditor due diligence.	2.30
11/15/19	ADD	Upload documentation to internal data room for DPW review.	0.80
11/15/19	ADD	Call with Rhodes CFO to discuss diligence request.	0.20
11/17/19	ADD	Compile documentation submitted as responses to diligence request for review and approval to upload to the data room.	1.20
11/17/19	ADD	Review board materials and extract business plan, forecasts, budgets, etc.	2.20
11/17/19	JD	Develop strategic alternatives decision tree and future business plan steps	1.40
11/17/19	JD	Conversation with management re: OTC business plan	0.30
11/18/19	JD	Call with management, PJT, J. DelConte, and R. Sublett (both AlixPartners) re: pipeline strategy in updated	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan.	
11/18/19	JD	Update analysis re: Avrio investment thesis	1.10
11/18/19	JD	Discussion with management, PJT Partners, J. DelConte and R. Sublett (all AlixPartners) re: Avrio investment plan.	0.50
11/18/19	JD	Prepare analysis incorporating initial hypothesis for business plan path forward for various cost centers and products for management review.	0.90
11/18/19	DS	Update and compare insurance collateral analysis with historical transactions in investments reports	1.40
11/18/19	DS	Review draft weekly gross-to-net report for PPLP	0.80
11/18/19	DS	Revise insurance collateral analysis to include original funded amounts and current balances plus interest	1.80
11/18/19	DS	Correspondence with TXP Manager re: Lumbermens deposit classification	0.30
11/18/19	DS	Draft detailed summary to Province re: nuances of insurance collateral, mapping to applicable policies	2.20
11/18/19	DS	Meeting with TXP Manager to review insurance collateral balances per Investments summaries and bank documentation	0.80
11/18/19	DS	Correspondence with A. Kramer (Reed Smith) re: backup documentation for insurance collateral	0.30
11/18/19	DS	Incorporate TXP Manager's edits to insurance collateral analysis	0.60
11/18/19	ADD	Review data room permissions check that users have the correct access.	0.30
11/18/19	ADD	Compile and review files provided in response to diligence requests.	2.70
11/18/19	ADD	Review and update diligence request tracker.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/18/19	ADD	Request approval from client to upload files to the data room.	0.60
11/18/19	KM	Discussion with D. Fogel, R. Hamberlin, W. DiNicola (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re headcount consolidation at RALP	1.10
11/18/19	KM	Discussion with D. Fogel (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Tech R&D pipeline	0.60
11/18/19	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes 2020 budget updates - discuss R&D	1.00
11/18/19	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Org structure	0.30
11/18/19	KM	Analysis re: Rhodes Tech headcount and reporting	0.70
11/18/19	KM	Analysis re: Rhodes Pharma headcount and reporting	0.90
11/18/19	KM	Analysis re: Rhodes Pharma R&D portfolio	1.30
11/18/19	RDS	Avrio model update following meeting with J. Lowne	0.50
11/18/19	RDS	Construction of Rhodes Tech comparative cost structure model - lowest cost scenario	0.50
11/18/19	RDS	Avrio comparative valuation analysis (DCF)	1.70
11/18/19	RDS	Discussion with D. Fogel, R. Hamberlin, W. DiNicola (Rhodes) and K. McCafferty, R. Sublett (both AlixPartners), re headcount consolidation at RALP	1.10
11/18/19	RDS	Discussion with D. Fogel (Rhodes) K. McCafferty, R. Sublett (both AlixPartners) re Rhodes Tech R&D pipeline	0.60
11/18/19	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Org structure	0.30
11/18/19	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes 2020 budget updates - discuss R&D	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/18/19	RDS	Discussion with management, PJT Partners, J. DelConte, H. Ku and R. Sublett (all AlixPartners) re: Avrio investment plan.	0.50
11/18/19	RDS	Rhodes headcount data analysis - department level rationalization	0.60
11/18/19	RDS	Call with management, PJT, J. DelConte, and R. Sublett (both AlixPartners) re: pipeline strategy in updated business plan.	0.50
11/18/19	RDS	Discussion with D. Fogel (Rhodes) on data requests for cost structure scenarios	0.40
11/18/19	NAS	Review of Mundipharma valuation analysis performed by Evercore in 2017 to understand investment banker's view of value proposition offered by company and business drivers.	2.30
11/18/19	MH	Call with clinical trial manager to discuss latest status if two large vendor negotiations.	0.50
11/18/19	MH	Prepare for call with clinical trial manager.	0.60
11/18/19	MH	Prepare list of new prepetition invoices qualifying for critical vendor status to initiate secondary review.	0.40
11/18/19	MH	Update accounts payable reconciliation for large clinical trial vendor.	0.50
11/18/19	MH	Prepare accounts payable release list.	0.40
11/19/19	MH	Prepare accounts payable release list.	0.40
11/19/19	HK	Revise assumptions to the Avrio Business Plan for internal review.	2.10
11/19/19	HK	Reconcile employee compensation detail with business plan forecasts for internal discussion.	1.40
11/19/19	NAS	Review current status of IAC diligence to update weekly workplan.	0.30
11/19/19	NAS	Analysis of IAC valuation performed by Evercore (2018)	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and providing key takeaways and follow-up questions to Alix team.	
11/19/19	NAS	Update diligence request tracking notes for IACs to ensure all requests are on track to be met.	0.80
11/19/19	NAS	Compare actual performance of IACs to projections presented to Board of Directors in order to assess reliability of projections and changes in business outlook.	0.90
11/19/19	NAS	Evaluate trading multiples for various IAC business lines used in Evercore valuation (2018) relative to industry trading multiples today and assess whether or not assumptions are appropriate.	0.40
11/19/19	RDS	Analysis of Rhodes Tech scenarios ahead of meeting with Randy to discuss variablizing cost structure	1.00
11/19/19	RDS	Meeting with D. Shell, D. Fogel (both Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re reporting structure for Rhodes entities	1.10
11/19/19	RDS	Review Strategic Options and lay out scenarios for Rhodes Tech and Rhodes Pharma	0.70
11/19/19	RDS	Work with org charts for NC positions and work into spans/levels analysis for organization	2.10
11/19/19	RDS	Discussion with W. DiNicola, D. Fogel (both Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Technology staffing schedule	0.70
11/19/19	RDS	Discussion of Rhodes Tech operating structure	0.30
11/19/19	RDS	Rhodes headcount and reporting structure data gathering and analysis	0.90
11/19/19	RDS	Review Rhodes Pharma pipeline ahead of meeting with management	1.20
11/19/19	RDS	Meeting with N. Davis, D. Fogel, V. Mancinelli, K. Kolar (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re pipeline progress and cost allocation	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		down to the ending pipeline	
11/19/19	KM	Meeting with D. Shell, D. Fogel (both Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re reporting structure for Rhodes entities	1.10
11/19/19	KM	Analysis re: RT headcount and reporting	1.50
11/19/19	KM	Analysis re: RP headcount and reporting	1.20
11/19/19	KM	Meeting with R.Shamblin (Rhodes) re: RT production labor, campaigning strategy, quota management and inventory limits	2.40
11/19/19	KM	Work with org charts for NC positions and work into spans/levels analysis for organization	0.60
11/19/19	KM	Meeting with N. Davis, D. Fogel, V. Mancinelli, K. Kolar (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re pipeline progress and cost allocation down to the ending pipeline	1.10
11/19/19	KM	Discussion with W. DiNicola, D. Fogel (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Technology staffing schedule	0.70
11/19/19	ADD	Review and prepare files provided for diligence requests for upload to data room.	2.90
11/19/19	ADD	Review outstanding diligence request and update diligence request tracker.	2.40
11/19/19	ADD	Request approval from client to upload documents to the data room.	0.60
11/19/19	ADD	Review and follow up on diligence requests.	1.70
11/19/19	DS	Meeting with TXP Manager re: insurance collateral schedule review	0.30
11/19/19	DS	Reconcile the latest files re: October bank balances and meeting with TXP Manager, S. Lemack, and D. Samikkannu (all AlixPartners) to review	0.80



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/19/19	DS	Make revisions to insurance collateral analysis based on comments from assistant general counsel	0.40
11/19/19	DS	Review further revisions to insurance collateral analysis made by TXP Manager	0.50
11/19/19	DS	Review PPLP's historical rebate spend categorized by financial analyst	1.40
11/19/19	DS	Draft summary outline to send to Province re: changes to insurance collateral analysis	0.70
11/19/19	DS	Update Customer Programs report for details surrounding IFF payments and certain chargeback processing vendors	1.20
11/19/19	JD	Call with management and PJT re: OTC business plan	0.50
11/19/19	JD	Review R&D pipeline diligence materials and latest business plan. Review Medical Affairs projections and recent actuals.	0.80
11/19/19	JD	Prepare summary breakdown of LTRP payments between VP and above and below VP	1.40
11/20/19	JD	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: wage motion proposal	0.30
11/20/19	JD	Review and update presentation re: wage motion	1.10
11/20/19	JD	Update Avrio investment thesis analysis	1.30
11/20/19	JD	Call with J. Lowne (Purdue), J. DelConte, R. Sublett (both AlixPartners), R. Schnitzler, T. Melvin (both PJT) re Avrio business plan and valuation update	0.60
11/20/19	JD	Prepare analysis of previous company scorecards by opioid / non-opioid measures	0.70
11/20/19	DS	Correspondence with PPLP analyst re: Avrio vendor's October transactions	0.40
11/20/19	DS	Review cash actuals detail to compile co-pay reduction rebate payments for the month of October	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/20/19	DS	Review co-pay reduction rebates detail with PPLP financial analyst	0.50
11/20/19	DS	Review detail provided by Wilson Controller re: vendor payment details for October	0.40
11/20/19	DS	Incorporate data received from GPO/Chargeback PPLP analyst for purposes of October Customer Programs report	1.10
11/20/19	DS	Review Rhodes Cash discounts data provided by Rhodes controller and provide follow up questions	1.40
11/20/19	DS	Analyze Rhodes data for Coverage Gap payments	1.20
11/20/19	DS	Put together analysis comparing accrued vs. paid rebates detail for Rhodes and send to Rhodes controller	1.80
11/20/19	DS	Incorporate Rhodes wholesaler chargeback data into Customer Programs model	0.80
11/20/19	ADD	Compile and review files provided in response to diligence requests.	2.30
11/20/19	ADD	Review and update diligence request tracker.	1.20
11/20/19	ADD	Compile collaboration agreements for upload to data room.	1.20
11/20/19	ADD	Prepare and format presentation for upload to the data room.	0.80
11/20/19	ADD	Compile documentation provided directly to the to the UCC/AHC.	1.80
11/20/19	KM	Work to build spans of control analysis for North Carolina operations	1.20
11/20/19	KM	Work to build Rhodes Tech production volume sensitivity	0.90
11/20/19	KM	Work with R. Sublett and K. McCafferty (both AlixPartners) to clean up org charts for NC positions and work into spans/levels analysis for organization	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/20/19	KM	Work with R. Sublett and K. McCafferty (both AlixPartners) to clean headcount data for headcount analysis and interpret departments to AlixPartners methodology	1.70
11/20/19	KM	Work with R. Sublett and K. McCafferty (both AlixPartners) to reformat RALP headcount data into presentation format for D. Lundie (Purdue) meeting	0.60
11/20/19	KM	Meeting with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re RALP structural scenarios and cost consolidation efforts	2.60
11/20/19	KM	Call with D. McGuire, J. Carlisle (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re staffing models for variabilizine Wilson cost structure and headcount impacts	1.10
11/20/19	KM	Discussion re Rhodes Tech API manufacturing structure with R. Sublett and K. McCafferty (both AlixPartners)	0.70
11/20/19	RDS	Work with R. Sublett and K. McCafferty (both AlixPartners) to clean up org charts for NC positions and work into spans/levels analysis for organization	1.50
11/20/19	RDS	Call with J. Lowne (Purdue), J. DelConte, R. Sublett (both AlixPartners), R. Schnitzler, and T. Melvin (both PJT) re Avrio business plan and valuation update	0.60
11/20/19	RDS	Prepare SKU and basket (distributor) level analysis of Rhodes vertically integrated opioid products	0.30
11/20/19	RDS	Work with R. Sublett and K. McCafferty (both AlixPartners) to clean headcount data for headcount analysis and interpret departments to AlixPartners methodology	1.70
11/20/19	RDS	Work with R. Sublett and K. McCafferty (both AlixPartners) to reformat RALP headcount data into presentation format for D. Lundie (Purdue) meeting	0.60
11/20/19	RDS	Meeting with D. Lundie (Purdue), K. McCafferty, and R.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Sublett (both AlixPartners) re RALP structural scenarios and cost consolidation efforts	
11/20/19	RDS	Call with D. McGuire, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re staffing models for variabilizine Wilson cost structure and headcount impacts	1.10
11/20/19	RDS	Modeling of the RALP cost structure at a high level	0.30
11/20/19	RDS	Discussion re Rhodes Tech API manufacturing structure with R. Sublett and K. McCafferty (both AlixPartners)	0.70
11/20/19	IA	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: wage motion proposal	0.30
11/20/19	NAS	Research Mundipharma China diligence materials following 11/20 investigation article published by Associated Press.	1.50
11/20/19	NAS	Draft additional diligence questions for Mundipharma China following 11/22 Associated Press report.	0.30
11/20/19	NAS	Review of Mundipharma LAM region budgets to assess changes in growth strategy over time.	0.70
11/20/19	NAS	Draft discussion topics and questions for alignment call with advisors involved in IAC diligence from Province, FTI, and AlixPartners.	1.10
11/20/19	NAS	Conference call with IAC diligence advisors to various parties (Unsecured Creditors Committee, Ad-Hoc Committee), G. Koch, N. Simon, and M. Hartley (all AlixPartners) to discuss preliminary conclusions from IAC diligence.	0.60
11/20/19	NAS	Discussion with G. Koch, N. Simon, and M. Hartley (all AlixPartners) regarding key takeaways and action items following alignment call with UCC and Ad-Hoc Committee advisors.	0.50
11/20/19	NAS	Review of settlement framework term sheet filed on	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		docket to determine exact definition of net proceeds and treatment of taxes and expenses.	
11/20/19	NAS	Conference call with Norton Rose, DLA Piper, Mundipharma, Legal and Financial Advisors to UCC and Ad-Hoc Committee, G. Koch, N. Simon, and M. Hartley (all AlixPartners) to discuss Associated Press report on sales practices at Mundipharma China and ongoing DLA Piper investigation into allegations.	0.50
11/20/19	NAS	Draft notes on definitions of included in settlement framework term sheet and build model translating IAC sale price to ultimate proceeds for distribution to AlixPartners IAC diligence team.	0.70
11/20/19	HK	Draft risk sensitivity content for Avrio business plan presentation.	1.90
11/20/19	MH	Conference call with Norton Rose, DLA Piper, Mundipharma, Legal and Financial Advisors to UCC and Ad-Hoc Committee, G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss Associated Press report on sales practices at Mundipharma China and ongoing DLA Piper investigation into allegations.	0.50
11/20/19	MH	Discussion with G. Koch, N. Simon, and M. Hartley (all AlixPartners) regarding key takeaways and action items following alignment call with UCC and Ad-Hoc Committee advisors.	0.50
11/20/19	MH	Conference call with IAC diligence advisors to various parties (Unsecured Creditors Committee, Ad-Hoc Committee), G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss preliminary conclusions from IAC diligence.	0.60
11/20/19	MH	Review all vendor related correspondence to update the critical vendor status reports.	2.80
11/20/19	MH	Prepare accounts payable release list.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/20/19	MH	Review latest trade agreement tracking report and share with management for an update.	1.10
11/20/19	GJK	Conference call with Norton Rose, DLA Piper, Mundipharma, Legal and Financial Advisors to UCC and Ad-Hoc Committee, G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss Associated Press report on sales practices at Mundipharma China and ongoing DLA Piper investigation into allegations.	0.50
11/20/19	GJK	Conference call with IAC diligence advisors to various parties (Unsecured Creditors Committee, Ad-Hoc Committee), G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss preliminary conclusions from IAC diligence.	0.60
11/20/19	GJK	Discussion with G. Koch, N. Simon, and M. Hartley (all AlixPartners) regarding key takeaways and action items following alignment call with UCC and Ad-Hoc Committee advisors.	0.50
11/21/19	GJK	Catch up call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence	0.40
11/21/19	MH	Meeting with client management to review status of critical vendor motion.	1.10
11/21/19	MH	Prepare for critical vendor update to management.	2.20
11/21/19	MH	Attend call with other professionals to discuss upcoming disclosure meeting.	0.70
11/21/19	MH	Research correct treatment of certain recruiting vendors relative to motion status.	0.40
11/21/19	MH	Initiate deletion process of approved critical vendors to prevent overpayment.	0.80
11/21/19	MH	Prepare accounts payable release list.	0.40
11/21/19	LJD	Prepare for and attend coordination call with advisors and company personnel	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/21/19	LJD	Review presentation from PJT regarding asset monetization	0.80
11/21/19	HK	Review employee compensation to support business plan analysis.	1.40
11/21/19	NAS	Review of Mundipharma LAM region 2017 budget materials submitted to Board of Directors to assess evolution of growth strategy over time.	1.80
11/21/19	NAS	Review of 2018 Mundipharma China compliance presentation submitted to Board of Directors and drafting key takeaways for G. Koch and M. Hartley (both AlixPartners).	0.40
11/21/19	IA	Draft and edit summary of proposed benefit program payouts versus expected amounts, broken out by insiders, non-insiders, former employees and employee levels, for review with client and DPW.	3.10
11/21/19	NAS	Review of Mundipharma LAM region 2018 budget materials submitted to Board of Directors to assess evolution of growth strategy over time.	2.00
11/21/19	RDS	Discuss Strategic Options scenarios with R. Sublett and K. McCafferty (both AlixPartners) re Rhodes Tech operating scenarios in conjunction with Rhodes Pharma pipeline	1.00
11/21/19	RDS	Call with J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re Strategic Operating Scenarios	0.30
11/21/19	RDS	Call with D. Fogel (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re schedule for next week and SKU / customer level data for Rhodes Pharma	0.30
11/21/19	RDS	Org structure analysis - Avrio diligence work plan assembly	0.80
11/21/19	RDS	Update decision matrix for Strategic Planning Process -RT and RP products based upon latest thinking	1.20
11/21/19	RDS	Correspondence with D. Lundie (Purdue) and G. Koch	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners) re IAC diligence intro	
11/21/19	RDS	Discussion with K. McCafferty and R. Sublett (both AlixPartners) re headcount planning for quality organization ahead of J. Northington (Purdue) call	0.40
11/21/19	RDS	Call with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: quality org structure	1.00
11/21/19	RDS	Meeting with D. McGuire and J. Carlisle (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: NC Treyburn to Wilson headcount	0.70
11/21/19	RDS	Model framework for Strategic Options 2 and 3 - Rhodes Tech relevance	1.20
11/21/19	KM	Analysis re: Purdue NC ops quality organization analysis	1.40
11/21/19	KM	Analysis re: Purdue NC ops quality organization benchmarks and spans of control	1.60
11/21/19	KM	Analysis re: Rhodes spans of control analysis	1.70
11/21/19	KM	Analysis re: Integration of Rhodes compensation and headcount data	0.90
11/21/19	KM	Call with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: quality org structure	1.00
11/21/19	KM	Meeting with D. McGuire and J. Carlisle (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: NC Treyburn to Wilson headcount	0.70
11/21/19	KM	Meeting with D. McGuire and J. Carlisle (Purdue) re: impact of manufacturing for Purdue Canada	0.20
11/21/19	KM	Discussion with R. Sublett and K. McCafferty (both AlixPartners) re: headcount planning for quality organization ahead of J. Northington (Purdue) call	0.40
11/21/19	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re Strategic Operating Scenarios	0.30
11/21/19	KM	Discuss Strategic Options scenarios with R. Sublett and K.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/21/19	KM	McCafferty (both AlixPartners) re Rhodes Tech operating scenarios in conjunction with Rhodes Pharma pipeline	0.30
11/21/19	ADD	Call with D. Fogel (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re schedule for next week and SKU / customer level data for Rhodes Pharma	0.90
11/21/19	ADD	Work to resolve data room issue at the request of a user.	2.80
11/21/19	ADD	Review and follow up on outstanding diligence request.	2.80
11/21/19	ADD	Compile and prepare files for upload to data room.	0.30
11/21/19	ADD	Add users to the data room.	0.50
11/21/19	ADD	Request approval from client to upload files to the data room.	1.30
11/21/19	DS	Upload board materials to internal data room for Davis Polk review.	0.80
11/21/19	DS	Investigate discrepancy between investments summary report and cash actuals reporting	0.50
11/21/19	DS	Meeting with PPLP analyst to review data for October Customer Programs report	0.60
11/21/19	DS	Revise Co-Pay Reduction rebate detailed listing to review with PPLP analyst	1.10
11/21/19	JD	Update Customer Programs model for further updates to savings cards details provided by PPLP analyst	0.60
11/21/19	JD	Call with FTI, Jefferies, Province, PJT Partners and management re: business plan model questions	0.30
11/21/19	JD	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re Strategic Operating Scenarios	0.90
11/21/19	JD	Review latest sale vs keep analysis prior to sharing externally	0.30
11/21/19	JD	Provide comments on company pipeline review strategic plan	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/21/19	JD	Catch up call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence	0.40
11/21/19	JD	Review presentation re: insourcing Canada production	0.60
11/22/19	JD	Finalize Avrio investment thesis slides to provide to management	1.40
11/22/19	JD	Review PHI materials. Participate in call with FTI, Province, Jefferies, PJT Partners and management RE: PHI projections.	1.20
11/22/19	ADD	Call with Rhodes Tech accountant to discuss diligence request.	0.20
11/22/19	ADD	Review outstanding diligence requests.	0.80
11/22/19	KM	Analysis re. Aggregation of NC headcount and compensation data.	2.10
11/22/19	KM	Analysis re. NC headcount benchmarking - quality deep dive.	1.60
11/22/19	RDS	North Carolina high level capacity modeling for strategic options analysis	0.60
11/22/19	RDS	Review Avrio funding / valuation presentation and update for C. Landau, J. Lowne (Purdue)	0.60
11/22/19	RDS	Correspondence with R. Haberman (Rhodes) re Rhodes Pharma headcount and span analysis	0.30
11/22/19	RDS	Analyze Avrio SP and marketing plans to determine ROI by product line	0.80
11/22/19	RDS	Call with advisors: PJT, Province, Jefferies FTI and company representatives re Public Health Initiatives	0.80
11/22/19	RDS	Review Rhodes headcount cost cutting exercise and general business planning work plan timing	0.50
11/22/19	NAS	Review of notes and materials provided by M. Hartley (AlixPartners) from meeting between UCC, Ad-Hoc Committee, accompanying advisors, and Sackler family	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		counsel.	
11/22/19	NAS	Coordination with G. Koch (AlixPartners) regarding IAC diligence workstream priorities.	0.10
11/22/19	NAS	Review of 2019 Mundipharma LAM Budget materials sent to Board of Directors in order to assess current growth strategy.	2.00
11/22/19	NAS	Draft summary of key takeaways and next steps from review of Mundipharma LAM budget materials from 2017 through 2019.	0.80
11/23/19	RDS	Continue strategic option analysis and correspondence with C. Mazzi (Purdue)	0.50
11/23/19	ADD	Identify files uploaded to the data room since initial download.	1.30
11/23/19	JD	Correspondence with L. Donahue (AlixPartners) and PJT Partners RE: audit recommendation.	0.60
11/23/19	JD	Update LTRP / AIP Summary sheet for distribution to UCC.	0.90
11/23/19	JD	Correspondence with management, Davis Polk and UCC advisors RE: wage motion negotiations.	0.70
11/24/19	JD	Call with management, Davis Polk, J. DelConte, and I. Arana (both AlixPartners) re: wage motion negotiations.	0.80
11/24/19	JD	Review and update analysis for latest UCC counter re: wage motion.	1.50
11/24/19	JD	Review and edit draft response to UCC RE: wage motion negotiations.	0.60
11/24/19	ADD	Assist Davis Polk eDiscovery team with data room download.	2.10
11/24/19	ADD	Work with Intralinks technical support to resolve issues with data room settings and file download.	1.60
11/24/19	RDS	Review Strategic Options update from C. Mazzi	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/24/19	IA	Prepare for and attend call with management, Davis Polk, J. DelConte, and I. Arana (both AlixPartners) re: wage motion negotiations.	1.00
11/25/19	NAS	Ensure recent critical vendor documentation requests are being processed by appropriate parties.	0.10
11/25/19	NAS	Draft key takeaways from analysis of historical LAM budgets in advance of call with G. Koch and M. Hartley (both AlixPartners).	0.50
11/25/19	NAS	Conference call with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to discuss key conclusions from meeting with Sackler family counsel and analysis of historical LAM budgets.	0.80
11/25/19	NAS	Review new IAC diligence documents from November 2019 Mundipharma Board meeting provided by Norton Rose.	0.90
11/25/19	NAS	Draft updated summary of where workstream stands, what new questions have arisen, and how that correlates to IAC workplan for discussion with G. Koch (AlixPartners).	2.00
11/25/19	NAS	Review list of existing follow-up questions for Mundipharma diligence and add new questions where applicable.	0.70
11/25/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding where IAC diligence currently stands, what new questions have arisen, and how that correlates to workplan.	0.70
11/25/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding goals for week of 11/25 and broader workstream objectives.	0.30
11/25/19	GJK	Conference call with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss key conclusions from meeting	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		with Sackler family counsel and analysis of historical LAM budgets.	
11/25/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) regarding where IAC diligence currently stands, what new questions have arisen, and how that correlates to workplan	0.70
11/25/19	GJK	Review of new IAC materials posted to data room - Arnaud slides; global finance slides	3.00
11/25/19	GJK	Prepare for R&D and internal calls; including R&D budget and Europe and LAM budget books	2.70
11/25/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) regarding goals for week of 11/25 and broader workstream objectives.	0.30
11/25/19	MH	Conference call with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss key conclusions from meeting with Sackler family counsel and analysis of historical LAM budgets.	0.80
11/25/19	MH	Prepare accounts payable release list.	0.40
11/25/19	MH	Evaluate new clinical trial vendor invoices for petition status.	0.70
11/25/19	MH	Redesign the information flow process for trade agreement finalization.	0.60
11/25/19	MH	Research consulting vendor to confirm status relative to the Wage motion.	0.40
11/25/19	MH	Review proposed language changes to trade agreement.	0.30
11/25/19	MH	Research specific invoices referred by client to determine release and payment status.	1.30
11/25/19	RDS	Discussion of RP net-to-gross analysis with D. Fogel and P. Pradith (both Rhodes)	0.70
11/25/19	RDS	Rhodes Pharma Generic Opioid Net-to-Gross analysis -	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Bup Trans AG and Dilaudid AG	
11/25/19	RDS	Meeting with D. Fogel (Rhodes) to discuss Dilaudid AG standard cost data	0.30
11/25/19	RDS	Review updated 2020 Budget for Rhodes Tech / Rhodes Pharma	1.20
11/25/19	RDS	Discussion with D. Fogel re Net to Gross SKU-level analysis	0.40
11/25/19	RDS	Rhodes Pharma Generic Opioid Net-to-Gross analysis - Oxy APAP and Oxy IR	1.40
11/25/19	RDS	Rhodes Pharma Generic Opioid Net-to-Gross analysis - Hydro APAP & MSER	1.70
11/25/19	RDS	Analysis of SKU level data for Rhodes Net-to-Gross	1.50
11/25/19	ADD	Compile and upload documents to the data room for Davis Polk's review.	1.20
11/25/19	ADD	Format and prepare files provided in response to diligence request for upload to the data room.	0.90
11/25/19	KM	Analysis re. headcount for RT and RP	0.80
11/25/19	JD	Review and edit latest counter proposal summary sheet. Correspondence with Davis Polk and management re: same.	2.20
11/25/19	JD	Review and edit analysis of LTRP by employee by performance year to provide to the UCC. Correspondence with Davis Polk, Akin and Province re: same.	1.90
11/25/19	JD	Review October board report to create monthly flash report for AHC and UCC.	0.80
11/25/19	JD	Review and provide comments re: insider comp summary. Correspondence with Davis Polk re: same.	1.10
11/25/19	DS	Research IAC entities in response to diligence questions from FTI Consulting	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/25/19	DS	Correspondence with F. Silva (AlixPartners) re: products subject to royalties	0.40
11/25/19	RDS	Rhodes pipeline and BD review and correspondence with M. Sisodia (Rhodes)	0.30
11/26/19	RDS	Analysis of Net-to-Gross ahead of B. TheBeau (Rhodes)	0.60
11/26/19	RDS	Meeting with B. TheBeau, D. Fogel (both Rhodes) R. Sublett, and K. McCafferty (both AlixPartners) re customer level pricing and aggregation	1.00
11/26/19	RDS	Meeting with A. Nadeau, D. Fogel, R. Shamblan (all Rhodes) R. Sublett, and K. McCafferty (both AlixPartners) re Materials management organization in Rhodes, RI plant	0.70
11/26/19	RDS	Meeting with J. Stymiest, D. Fogel, R. Shamblan (all Rhodes), R. Sublett, and K. McCafferty (both AlixPartners) re Rhodes Technology research and development group	1.10
11/26/19	RDS	Meeting with A. Soma, D. Fogel, R. Shamblan (all Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Technology operations functions	1.50
11/26/19	RDS	Analysis of Rhodes Tech cost structure and scenario analysis	0.60
11/26/19	RDS	Call with advisors K. McCafferty, R. Sublett (both AlixPartners) (Jefferies, PJT, AlixPartners, FTI, Province) and K. Darragh, J. Carlisle, D. Fogel (all Purdue) re standard costs in manufacturing operations	0.50
11/26/19	RDS	Review market for API manufacturing re Rhodes Tech partnership opportunity -	0.50
11/26/19	RDS	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re third party partnership opportunities for API manufacture	0.80
11/26/19	RDS	Catch up call with R. Sublett and J. DelConte (all AlixPartners) re: business plan work stream progress and	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		go forward plan.	
11/26/19	RDS	Call with M. Sisodia (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re BD and product pipeline NPV	1.00
11/26/19	RDS	Call with J. Lowne (Rhodes), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re Purdue SG&A expense scenario planning (commercial, pipeline implications)	0.50
11/26/19	RDS	Discuss Oxy APAP Net-to-Gross wholesaler add-backs with D. Fogel (Rhodes)	0.20
11/26/19	RDS	Work with R. Sublett and K. McCafferty (both AlixPartners) to develop initial modeling scenarios and shell of a presentation for C. Landeau (Purdue)	1.00
11/26/19	JD	Correspondence with Davis Polk and management re: final wage motion counter proposal	1.00
11/26/19	JD	Catch up call with K. McCafferty, R. Sublett and J. DelConte (all AlixPartners) re: business plan work stream progress and go forward plan.	0.50
11/26/19	JD	Correspondence with R. Sublett and K. McCafferty (both AlixPartners) re: go forward meeting planning.	0.40
11/26/19	JD	Call with J. Lowne (Rhodes), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re Purdue SG&A expense scenario planning (commercial, pipeline implications)	0.50
11/26/19	JD	Review write up of recommendation re: 2018 and 2019 audit and correspondence with PJT Partners and management re: same.	0.70
11/26/19	JD	Prepare analysis to create final offer re: wage motion	1.30
11/26/19	KM	Analyze 2019 production schedule re. Rhodes Technologies API production	1.20
11/26/19	KM	Analyze crewing model and options re. Rhodes Technologies API production	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/26/19	KM	Call with advisors K. McCafferty, R. Sublett (both AlixPartners) (Jefferies, PJT, AlixPartners, FTI, Province) and K. Darragh, J. Carlisle, D. Fogel (all Purdue) re standard costs in manufacturing operations	0.50
11/26/19	KM	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re third party partnership opportunities for API manufacture	0.80
11/26/19	KM	Call with M. Sisodia (Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re BD and product pipeline NPV	1.00
11/26/19	KM	Call with J. Lowne (Rhodes), R. Sublett, J. DelConte, and K. McCafferty (all AlixPartners) re Purdue SG&A expense scenario planning (commercial, pipeline implications)	0.50
11/26/19	KM	Work with R. Sublett and K. McCafferty (both AlixPartners) to develop initial modeling scenarios and shell of a presentation for C. Landeau (Purdue)	1.00
11/26/19	KM	Meeting with B. TheBeau, D. Fogel (both Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re customer level pricing and aggregation	1.00
11/26/19	KM	Meeting with A. Nadeau, D. Fogel, R. Shamblan (all Rhodes) R. Sublett, and K. McCafferty (both AlixPartners) re Materials management organization in Rhodes, RI plant	0.70
11/26/19	KM	Meeting with J. Stymiest, D. Fogel, R. Shamblan (all Rhodes), R. Sublett, and K. McCafferty (both AlixPartners) re Rhodes Technology research and development group	1.10
11/26/19	KM	Meeting with A. Soma, D. Fogel, R. Shamblan (all Rhodes), K. McCafferty, and R. Sublett (both AlixPartners) re Rhodes Technology operations functions	1.50
11/26/19	ADD	Reconcile Davis Polk's list of new files since last download with AlixPartners' list of new files.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/26/19	ADD	Prepare files for upload to the data room.	1.30
11/26/19	MH	Prepare accounts payable release list.	0.40
11/26/19	MH	Prepare list of new prepetition invoices for research.	0.60
11/26/19	MH	Eliminate OCP accounts from hold routine based on determination that they do not qualify as professionals.	0.60
11/26/19	MH	Call with supply chain manager to review clinical trial vendor invoices.	0.50
11/26/19	MH	Attend call with Mundipharma management to review recent steps to improve financial performance.	1.50
11/26/19	GJK	Review and update latest IAC Diligence tracker	0.70
11/26/19	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss initial reactions to conversations with B. Kudlek (Mundipharma Tech Ops) and C. Mazzi (Purdue) as well as topics discussed on weekly debtor advisor call.	0.30
11/26/19	GJK	Follow up notes to PJT and AlixPartners	0.70
11/26/19	GJK	Call with B. Kudlek (Mundipharma Tech Ops), G. Koch, N. Simon (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to better understand role of Tech Ops in overall Mundipharma network.	2.00
11/26/19	GJK	Call with C. Mazzi (Purdue) N. Simon, and G. Koch (both AlixPartners) regarding Christian's experiences at Mundipharma.	0.60
11/26/19	GJK	Call with D Lundie (Purdue), N. Simon, and G. Koch (both AlixPartners) to discuss view on IAC operations	1.10
11/26/19	GJK	Call with N. Simon and G. Koch (both AlixPartners) to discuss D Lundie Call and next steps	0.70
11/26/19	NAS	Call with B. Kudlek (Mundipharma Tech Ops), G. Koch, N. Simon (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to better understand role of Tech Ops in overall Mundipharma network.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/26/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss initial reactions to conversations with B. Kudlek (Mundipharma Tech Ops) and C. Mazzi (Purdue) as well as topics discussed on weekly debtor advisor call.	0.30
11/26/19	NAS	Discussion with Ian McClatchey (Norton Rose) and advisors to UCC and Ad-Hoc Committee regarding current status of all diligence requests.	0.90
11/26/19	NAS	Call with C. Mazzi (Purdue) N. Simon, and G. Koch (both AlixPartners) regarding Christian's experiences at Mundipharma (joined late).	0.40
11/26/19	NAS	Consolidate notes from 11/26 calls with B. Kudlek (Mundipharma Tech Ops), I. McClatchey (Norton Rose), and C. Mazzi (Purdue).	0.20
11/26/19	NAS	Review of 2019 Mundipharma budget materials presented to Board of Directors in November 2019 to understand business outlook and projections.	1.50
11/26/19	NAS	Call with D Lundie (Purdue), N. Simon, and G. Koch (both AlixPartners) to discuss view on IAC operations	1.10
11/26/19	NAS	Call with N. Simon and G. Koch (both AlixPartners) to discuss D Lundie Call and next steps	0.90
11/26/19	NAS	Research prior performance and press coverage of Mundipharma China to assess compliance practices.	0.30
11/27/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss overall diligence approach and key takeaways from 11/26 call with D. Lundie (Purdue).	0.90
11/27/19	NAS	Call with G. Koch, N. Simon, and M. Hartley (all AlixPartners) regarding key takeaways following 11/26 call with D. Lundie (Purdue).	0.40
11/27/19	NAS	Consolidate notes and draft summary email for AlixPartners, PJT, and Davis Polk regarding 11/26 conversation with D. Lundie (Purdue).	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/27/19	NAS	Review compliance report authored by DLA Piper regarding Mundipharma LAM and note key follow up questions.	0.90
11/27/19	NAS	Call with G. Koch, and N. Simon (both AlixPartners) to review summary for Alix/PJT/Davis Polk and align on current IAC diligence priorities.	0.50
11/27/19	GJK	Call with G. Koch, and N. Simon (both AlixPartners) to review summary for Alix/PJT/Davis Polk and align on current IAC diligence priorities.	0.50
11/27/19	GJK	Call with G. Koch, N. Simon, and M. Hartley (all AlixPartners) regarding key takeaways following 11/26 call with D. Lundie (Purdue).	0.40
11/27/19	GJK	LAM document review from Nov Board Meeting	2.50
11/27/19	GJK	Document review - Canada, Commercial, Finance from Nov Board	1.20
11/27/19	GJK	IAC workplan and next steps discussion	0.70
11/27/19	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss overall diligence approach and key takeaways from 11/26 call with D. Lundie (Purdue).	0.90
11/27/19	GJK	Review DLP Piper Report, notes from N. Simon, and create follow up notes/questions	2.50
11/27/19	BF	IAC discussions with staff.	0.70
11/27/19	MH	Call with G. Koch, M. Hartley, and N. Simon (all AlixPartners) regarding key takeaways following 11/26 call with D. Lundie (Purdue).	0.40
11/27/19	MH	Create analysis of remaining critical vendors to identify paths to resolving the budget gap.	2.20
11/27/19	MH	Research invoices not releasing for payment to determine cause.	0.70
11/27/19	MH	Research benefits provider invoices not releasing for	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		payment.	
11/27/19	ADD	Compile and prepare file for upload to data room.	1.80
11/27/19	ADD	Review and reconcile Purdue's internal distribution analysis.	1.30
11/27/19	ADD	Upload files to the data room.	0.40
11/27/19	ADD	Reconcile Davis Polk's list of new files since last download with AlixPartners' list of new files.	3.10
11/27/19	KM	Assemble scenario summary slide for J. Lowne (Purdue) with R. Sublett (AlixPartners)	1.10
11/27/19	KM	Call with D. Fogel (Purdue) R. Sublett, and K. McCafferty (both AlixPartners) re One-pager on RALP cost structure	0.60
11/27/19	JD	Review and provide comments re: draft board slide on business plan process	0.40
11/27/19	RDS	Assemble scenario summary slide for J. Lowne (Purdue) with K. McCafferty (AlixPartners)	1.10
11/27/19	RDS	Call with D. Fogel (Purdue) R. Sublett, and K. McCafferty (both AlixPartners) re One-pager on RALP cost structure	0.60
11/29/19	DGP	Research M&A deals for Alcaliber, Cambrex, Mallinckrodt, Noramco, Teva, Aurobindo, Hima, Endo	1.60
11/29/19	DGP	Research press clippings for Alcaliber, Cambrex, Mallinckrodt, Noramco, Teva, Aurobindo, Hikma and Endo	4.80
11/30/19	ADD	Create distribution reconciliation file.	3.20
12/01/19	JD	Review high-level preliminary G&A 5-year plan	0.40
12/01/19	JD	Review initial draft Purdue Canada CMO proposal presentation from PJT	0.50
12/01/19	GJK	Strawman Outline for Due Diligence Deck for IAC	1.00
12/01/19	GJK	Notes on Canada budget from Nov 2019 Board Meeting	1.00
12/01/19	GJK	Notes on Europe Budget from Nov 2019 Board Meeting	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/01/19	GJK	Notes on LAM Budget from Nov 2019 Board Meeting	1.50
12/01/19	GJK	Notes on overall budget from Nov 2019 Board Meeting	1.00
12/02/19	GJK	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key take away.	1.50
12/02/19	GJK	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	GJK	IAC project coordination, including follow up activities (info request lists, diligence workstreams)	1.00
12/02/19	GJK	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	GJK	Mundi financial comparison with Evercore financials	2.10
12/02/19	LJD	Review and comment on PJT presentation regarding insourcing options	0.90
12/02/19	LJD	Call with B. Folse, L. Donahue, and J. DelConte (all AlixPartners) re: go forward work streams.	0.50
12/02/19	MH	Meeting with CFO to review critical vendor status and develop plan to finish the project.	0.40
12/02/19	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) to discuss vendor payment management efforts.	0.50
12/02/19	MH	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	MH	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key takeaways.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/02/19	MH	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	MH	Update release lists with new trade agreement activity.	0.70
12/02/19	MH	Develop analysis process to evaluate paid critical vendor invoices for petition status.	0.40
12/02/19	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) to discuss vendor payment management efforts.	0.50
12/02/19	JD	Review long term business plan details re: G&A forecast and discuss same with management.	0.70
12/02/19	JD	Review updated draft October flash report to post for various creditor advisors. Provide comments re: same.	1.20
12/02/19	JD	Correspondence with Davis Polk and Willis Towers Watson re: outstanding wage questions prior to the hearing on Wednesday.	0.70
12/02/19	JD	Review analysis of various compensation packages and outstanding compensation programs for the company. Provide updated figures to Davis Polk for the hearing.	0.90
12/02/19	JD	Review latest draft Board deck re: 2020 budget. Provide comments re: same.	2.00
12/02/19	JD	Review analysis of and correspondence re: attrition estimates.	0.50
12/02/19	NAS	Track executed trade agreements submitted by critical vendors to ensure payment is made for pre-petition amounts owed.	0.50
12/02/19	NAS	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to review November 2019 Mundipharma budget materials presented to Board of Directors and discuss key takeaways.	1.50
12/02/19	NAS	Review current draft of IAC diligence summary and	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		proposed report structure in advance of meeting with G. Koch and M. Hartley (both AlixPartners).	
12/02/19	NAS	Compile questions related to IAC diligence that have been submitted to Norton Rose/Mundipharma and note which have been addressed within IAC diligence tracking document.	1.60
12/02/19	NAS	Meeting with G. Koch, N. Simon, and M. Hartley (all AlixPartners) to prepare accounts payable release list.	0.50
12/02/19	NAS	Meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to discuss outline for Mundipharma diligence report.	1.00
12/02/19	ADD	Update interested parties list.	1.40
12/02/19	ADD	Download and compile vendor spend and outstanding invoice data.	1.10
12/02/19	KM	Review and research background information re. API marketplace competitors and market share	1.20
12/02/19	KM	Review and research background information re. API marketplace deals and transactions.	0.90
12/02/19	KM	Call with D.Fogel, R. Shamblen, J. Freidrichsen (all Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: API market competition, growth opportunities, and partnership opportunities	1.60
12/02/19	KM	Review API market analysis for discussion with D.Fogel, R. Shamblen, J. Freidrichsen (all Rhodes)	0.90
12/02/19	KM	Prepare API market analysis for key Rhodes APIs	1.60
12/02/19	KM	Prepare personnel restructuring analysis and review presentation	1.90
12/02/19	KM	Call with R. Sublett, and K. McCafferty (both AlixPartners) re API market workstreams	0.20
12/02/19	DS	Correspondence with Controller (Rhodes) re: follow-up	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		items for October Customer Programs monthly report	
12/02/19	DS	Review draft October monthly flash report and send to J. DelConte (AlixPartners) for approval before sending to management for review	0.90
12/02/19	DS	Draft email with calculation of discounts/big 3 discounts to be reviewed by Controller (Rhodes)	0.30
12/02/19	DS	Draft outline to Controller (PPLP) re: significant items in monthly flash report and seeking feedback	0.70
12/02/19	DS	Review cash discounts data sent by Controller (Rhodes), incorporate into analysis, and include in draft Customer Programs report	1.40
12/02/19	DS	Review Coverage Gap data sent by Controller (Rhodes) and incorporate into draft Customer Programs report	0.80
12/02/19	DS	Review Q3 commercial rebates data sent by Controller (Rhodes) and reconcile with items identified in AlixPartners' cash reporting process	1.70
12/02/19	RDS	API market research.	1.70
12/02/19	RDS	Prepare for API call with J. Fredrickson (Purdue) - review market dynamics and previous production volumes	1.20
12/02/19	RDS	Call with D. Fogel, R. Shamblen, J. Freidrichsen (all Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: API market competition, growth opportunities, and partnership opportunities	1.60
12/02/19	RDS	Call with R. Sublett, and K. McCafferty (both AlixPartners) re API market workstreams	0.20
12/03/19	RDS	Correspondence with Rhodes Tech management to chase deliverables	0.30
12/03/19	RDS	Presentation slides - low scenario strategic layout	1.50
12/03/19	RDS	Meeting with D. Igo (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re group dynamics in the	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		tech transfer function	
12/03/19	RDS	Meeting with J. Northington (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re quality organization - spans and layers of control under various scenario analysis	2.10
12/03/19	RDS	Slide creation for quality org structure	0.40
12/03/19	RDS	Conversation with J. Carlisle (Purdue) re board meeting update and NC cost scenarios	0.20
12/03/19	RDS	Quality organization value mapping	0.60
12/03/19	DS	Draft email to general counsel outlining key items and seeking approval to post monthly flash report	0.40
12/03/19	DS	Correspondence with C. Robertson (Davis Polk) re: approval for monthly flash report	0.30
12/03/19	DS	Revise October monthly flash report based on comments received from C. Robertson	0.50
12/03/19	DS	Call with Controller (Rhodes) re: commercial rebates classification for purposes of October Customer Programs report	0.40
12/03/19	DS	Draft outline to CFO (Purdue) describing contents of October monthly flash report and key items to note	1.20
12/03/19	DS	Correspondence with Controller (PPLP) re: monthly flash report process going forward	0.30
12/03/19	DS	Correspondence with Analyst (PPLP) re: GPO fees disbursements in October	0.30
12/03/19	DS	Review commercial rebates supporting detail provided by financial analyst (Rhodes)	1.70
12/03/19	DS	Provide follow up questions to Controller and financial analyst (Rhodes) re: commercial rebates supporting detail	0.70
12/03/19	KM	Meeting with D. Igo (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re group dynamics in the tech	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transfer function	
12/03/19	KM	Meeting with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re quality organization - spans and layers of control under various scenario analysis	2.10
12/03/19	KM	Discussion with D. McGuire (Purdue) re: Wilson site visit logistics	0.30
12/03/19	KM	Analysis re: Quality function headcount for Wilson, RT and RP in preparation for discussion with J. Northington (Purdue)	1.40
12/03/19	ADD	Draft response to diligence request in preparation for discussion with counsel.	1.30
12/03/19	ADD	Compile and prepare files for upload to the data room.	2.90
12/03/19	ADD	Submit approval requests to upload files submitted in response to diligence requests to data room.	1.30
12/03/19	ADD	Review board materials and compile financial presentations for upload to data room	1.60
12/03/19	NAS	Revise IAC diligence tracker to incorporate latest requests, documents received, interviews held, and questions outstanding.	1.40
12/03/19	NAS	Review materials related to Mundipharma China compliance in advance of call with DLA Piper.	0.40
12/03/19	NAS	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	1.00
12/03/19	NAS	Call with P. Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to provide an overview of Mundipharma IT systems and capabilities.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/03/19	NAS	Follow-up discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from compliance call with DLA Piper and Mundipharma IT Services overview.	0.50
12/03/19	NAS	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams.	1.20
12/03/19	NAS	Research into global opioid prescription trends to assess projections made by Mundipharma management to Board of Directors.	0.60
12/03/19	NAS	Analyze Mundipharma legal entity descriptions and product flow maps provided by Norton Rose to understand both functional and legal structure of Mundipharma network of companies.	1.70
12/03/19	IA	Prepare file showing agreed LTRP payments by employee for VPs and above as request by HR.	1.60
12/03/19	JD	Correspondence with management re: outstanding and accrued professional fees.	0.70
12/03/19	JD	Review analysis of updated employee roster in response to DOJ request.	0.50
12/03/19	JD	Review supplemental Donahue declaration	0.20
12/03/19	JD	Review documentation created in response to DOJ diligence request list. Provide comments re: same.	0.60
12/03/19	JD	Review and provide comments re: latest cash flow forecast and year end cash estimates.	1.30
12/03/19	JD	Coordination and planning of work streams re: business planning.	0.40
12/03/19	JD	Review outstanding diligence request lists from PJT Partners re: UCC and ACH business plan diligence. Review certain items up for approval to be responsive to	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		said requests.	
12/03/19	HK	Attend meetings with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/03/19	HK	Discussion with M. Hartley and H. Ku (both AlixPartners) on vendor trade agreement statuses.	0.30
12/03/19	HK	Review and update IAC diligence status.	0.80
12/03/19	HK	Review diligence documents to analyze cost savings opportunities identified in board budget presentations.	3.20
12/03/19	HK	Update plan on due diligence research coordination.	1.00
12/03/19	HK	Review budget documents of independent affiliated companies.	3.50
12/03/19	MH	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	1.00
12/03/19	MH	Call with Philippe Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to provide an overview of Mundipharma IT systems and capabilities. (partial attendance)	0.50
12/03/19	MH	Attend meetings with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/03/19	MH	Prepare analysis of possible additional 503(b)(9) qualifying invoices for research.	1.90
12/03/19	MH	Create new deletion script to stop additional payments to settled critical vendors.	0.80
12/03/19	MH	Research legal vendor not releasing from accounts	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		payable.	
12/03/19	MH	Prepare accounts payable release list.	0.70
12/03/19	MH	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams.	1.20
12/03/19	MH	Develop new project plan outline for IAC analysis.	1.20
12/03/19	MH	Discussion with M. Hartley and H. Ku (both AlixPartners) on vendor trade agreement statuses.	0.30
12/03/19	GJK	IAC diligence info request updates - what information has been provided	0.50
12/03/19	GJK	Follow-up call with R. Chesley, G. Rodgers (both DLA Piper), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to address questions on Mundipharma compliance investigation memo.	1.00
12/03/19	GJK	Call with P. Mazas (Mundipharma), G. Koch, M. Hartley, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to provide an overview of Mundipharma IT systems and capabilities.	1.20
12/03/19	GJK	Follow-up discussion with G. Koch and N. Simon (both AlixPartners) regarding key takeaways from compliance call with DLA Piper and Mundipharma IT Services overview.	0.50
12/03/19	GJK	IAC diligence team coordination meeting with G. Koch, M. Hartley, and N. Simon (all AlixPartners) to ensure alignment on priorities and to determine allocation of workstreams. (partial attendance)	0.50
12/03/19	GJK	Financial analysis - high level P&L analysis based on available Mundi information	2.80
12/03/19	GJK	Financial analysis - DCF impact of revised projections	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/03/19	GJK	Project coordination, including follow ups with other advisors (Provence, FTI, Jefferies)	1.20
12/04/19	GJK	Review and comparison of Canada budget books	1.90
12/04/19	GJK	Updates to DCF projections	2.50
12/04/19	GJK	Adjustments to DCF based on risks related to LAM performance and Celltrion assets	2.40
12/04/19	GJK	Work session with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of OpEx reduction projections presented by Mundipharma management to Board of Directors in November 2019.	1.50
12/04/19	GJK	Review of cost reduction activities developed by H Ku (AlixPartners)	0.50
12/04/19	GJK	Review of org structure and strawman updates by N. Simon (AlixPartners)	0.50
12/04/19	GJK	Mundi strawman development	2.20
12/04/19	GJK	Internal discussion with G. Koch and N. Simon (both AlixPartners) regarding proper discount rate and terminal growth rate assumptions to be included in DCF analysis of Mundipharma.	0.50
12/04/19	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) regarding workstream priorities and deliverables for 12/5 meeting.	0.70
12/04/19	GJK	Discussion with G. Koch, N. Simon (both AlixPartners), R. Schnitzler, T. Melvin, and J. Turner (all PJT Partners) regarding assumptions used in prior Evercore analysis of Mundipharma valuation.	0.30
12/04/19	LJD	Prepared for board meeting on 12/5	0.60
12/04/19	GJK	IAC diligence team alignment meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	
12/04/19	MH	IAC diligence team alignment meeting with G. Koch, N. Simon, M. Hartley, and H. Ku (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90
12/04/19	MH	Meeting with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00
12/04/19	MH	Call with North Carolina vendor contact to review petition status of new invoice from contract manufacturer.	0.50
12/04/19	MH	Prepare accounts payable release list.	0.40
12/04/19	MH	Research CMO vendor invoice not releasing for payment.	0.40
12/04/19	MH	Complete the project outline for analysis of IAC value.	2.60
12/04/19	MH	Create analysis of new pre-petition invoices to prediction of remaining invoices that may be produced.	1.40
12/04/19	MH	Research split invoice incorrectly marked as pre-petition.	0.40
12/04/19	HK	Work session with G. Koch, H. Ku, and N. Simon (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of OpEx reduction projections presented by Mundipharma management to Board of Directors in November 2019.	1.50
12/04/19	HK	Review operating expense summaries in IAC due diligence materials.	1.60
12/04/19	HK	Meeting with H. Ku and N. Simon (all AlixPartners) on OpEx savings included in November 2019 Mundipharma budget materials in order to quantify overall opportunity	0.60
12/04/19	HK	Meeting with E. Ruiz (Purdue), various company vendor specialists, H. Ku, and M. Hartley (both AlixPartners) on vendor trade agreement statuses.	1.00



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/04/19	HK	IAC diligence team alignment meeting with G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90
12/04/19	JD	Review CEO compensation arrangements. Discussion re: next steps in negotiations.	0.70
12/04/19	IA	Correspondence with Davis Polk on customer agreements.	0.40
12/04/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) regarding workstream priorities and deliverables for 12/5 meeting.	0.70
12/04/19	NAS	Provide overview to H. Ku (AlixPartners) of OpEx savings included in November 2019 Mundipharma budget materials in order to quantify overall opportunity.	0.60
12/04/19	NAS	Update IAC diligence tracker to reflect latest questions submitted to and documents received from Norton Rose, interviews held with Mundipharma employees, and key takeaways.	1.90
12/04/19	NAS	Discussion with G. Koch, N. Simon (both AlixPartners), R. Schnitzler, T. Melvin, and J. Turner (all PJT Partners) regarding assumptions used in prior Evercore analysis of Mundipharma valuation.	0.30
12/04/19	NAS	IAC diligence team alignment meeting with G. Koch, M. Hartley, N. Simon and H. Ku (all AlixPartners) to review workplan, report outline, and key deliverables in advance of 12/5 update with B. Folse (AlixPartners).	0.90
12/04/19	NAS	Equity cost of capital analysis for Mundipharma through trading comparable.	1.10
12/04/19	NAS	Work session with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review revisions to diligence tracker, draft of proposed diligence report outline, and summary of OpEx reduction projections presented by Mundipharma	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management to Board of Directors in November 2019.	
12/04/19	NAS	Draft legal and functional Mundipharma organization notes for update materials in advance of 12/5 meeting with B. Folse (AlixPartners).	1.00
12/04/19	NAS	Review all diligence overview materials for accuracy and completeness in advance of 12/5 update meeting with B. Folse (AlixPartners).	0.80
12/04/19	NAS	Revise Mundipharma DCF analysis to incorporate revisions to assumed discount rates.	0.40
12/04/19	NAS	Internal discussion with G. Koch and N. Simon (both AlixPartners) regarding proper discount rate and terminal growth rate assumptions to be included in DCF analysis of Mundipharma.	0.50
12/04/19	ADD	Compile and format files supplied in response to diligence requests.	2.90
12/04/19	ADD	Review and update data room permissions.	0.40
12/04/19	ADD	Review diligence request and requested outstanding items.	2.20
12/04/19	ADD	Request permission to upload files to the data room.	1.30
12/04/19	ADD	Upload files submitted in response to diligence requests to data room.	1.10
12/04/19	KM	Meeting with J. Northington (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re quality headcount scenarios for Avrio, development pipeline and various reporting structures	0.60
12/04/19	KM	Meeting with D. McGuire, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re. staffing for various, production volume scenarios (partial attendance)	1.10
12/04/19	KM	Review Wilson manufacturing productivity monthly and	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		YTD dashboard and reports	
12/04/19	KM	Prepare Wilson Quality organization spans of control analysis for discussion with J. Northington (Purdue)	0.90
12/04/19	KM	Meeting with B. Addicks (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re supply chain and packaging development functions	1.10
12/04/19	DS	Correspondence with financial analyst (Rhodes) re: Medicaid and Industrial Funding Fee payments	0.30
12/04/19	DS	Update October Customer Program report with Medicaid and Industrial Funding fee payment data	0.70
12/04/19	DS	Update October Customer Program report for Medicaid by state data obtained from financial analyst (PPLP), i.e. detail behind Cumberland funding's	2.10
12/04/19	DS	Update October Customer Program report for Medicaid by state data obtained from financial analyst (PPLP), i.e. detail behind iContracts funding's	1.70
12/04/19	DS	Follow up with general counsel re: approval process for monthly flash report	0.40
12/04/19	DS	Send draft October Customer Programs report to management and general counsel for review, outlining key items and supporting data	0.50
12/04/19	DS	Draft email to C. Robertson (Davis Polk) seeking final approval for draft monthly flash report	0.20
12/04/19	DS	Further refine iContracts by state allocation based on additional detail provided by Controller (Rhodes)	1.30
12/04/19	RDS	Meeting with B. Addicks (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re supply chain and packaging development functions	1.10
12/04/19	RDS	Conversation with J. Northington (Purdue), R. Sublett, and K. McCafferty (both AlixPartners) re quality headcount scenarios for Avrio, development pipeline and	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		various reporting structures	
12/04/19	RDS	Layout quality organization heads and identify individuals for various scenarios	0.50
12/04/19	RDS	Prepare follow ups for B. Addicks (Purdue) meeting	0.30
12/04/19	RDS	Meeting with D. McGuire, J. Carlisle (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re. staffing for various, production volume scenarios	1.80
12/04/19	RDS	Call with D. Fogel (Purdue/Rhodes) to discuss IAC royalties and production volumes / functions in the US organization - both Purdue and Rhodes	0.50
12/04/19	RDS	Call with C. Chomiak (Purdue/Avrio) re scheduling and business planning timelines	0.30
12/04/19	RDS	Prepare email for follow ups to J. Freidrichson (Purdue/Rhodes)	0.50
12/04/19	RDS	Allocation of historical failure to supply events for Rhodes Generic supplier-level variable contribution analysis	1.10
12/05/19	RDS	Prepare thoughts on API market response strategy	0.70
12/05/19	RDS	Prepare presentation materials for Rhodes generic opioids by customer	0.20
12/05/19	RDS	Rhodes pipeline NPV analysis - R&D group headcount allocation	0.70
12/05/19	RDS	Preparation of time / expense allocation document and correspondence with W. Addicks (Purdue) re the same	0.40
12/05/19	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re API go forward path and board meeting download	0.50
12/05/19	RDS	Review Wilson, NC plant operating metrics - tablet production, quality, exceptions, investigations, etc.	0.60
12/05/19	RDS	Review IQVIA / IMS API market data	0.70
12/05/19	RDS	Call with D. Lundie (Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes operations	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		opportunities and forward-looking scenarios	
12/05/19	DS	Call with Controller (Rhodes) re: final review of Customer Programs report	0.40
12/05/19	DS	Correspondence with C. Robertson (Davis Polk) re: approval for October Customer Programs report	0.30
12/05/19	DS	Provide analysis and commentary to FTI re: customer rebates timing and drivers	1.10
12/05/19	KM	Call with D. Lundie (Rhodes) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes operations opportunities and forward-looking scenarios	1.20
12/05/19	KM	Prepare overview for discussion with D. Lundie (Rhodes) re. Rhodes operations opportunities and forward-looking scenarios	0.30
12/05/19	ADD	Review and update data room permissions.	0.40
12/05/19	ADD	Call with Rhodes general counsel regarding diligence request.	0.30
12/05/19	ADD	Compile and format files supplied in response to diligence requests.	3.10
12/05/19	ADD	Request approval to upload diligence requests.	0.60
12/05/19	ADD	Review diligence request and requested outstanding items.	2.20
12/05/19	ADD	Assist data room user with technical support issue.	0.70
12/05/19	NAS	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	NAS	Update IAC diligence tracker to reflect most recent documents provided by Mundipharma/Norton Rose and set up organization process for internal AlixPartners	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		analyses.	
12/05/19	NAS	Coordinate all IAC diligence management meetings for 12/6 and week of 12/9, as well as corresponding updates to diligence tracker.	0.70
12/05/19	NAS	Final review of IAC diligence update materials prior to meeting with B. Folse (AlixPartners).	0.40
12/05/19	NAS	Pre-update call walk-through of IAC diligence materials with G. Koch, N. Simon and H. Ku (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	JD	Review final board materials prior to board meeting	0.50
12/05/19	JD	Participate in PPI board meeting	5.80
12/05/19	JD	Catch up with R. Sublett and J. DelConte (both AlixPartners) re: business plan work stream and potential partnership opportunities	0.50
12/05/19	JD	Review analysis re: CEO compensation	0.70
12/05/19	HK	Update risk analysis for budget materials in due diligence database.	1.90
12/05/19	HK	Review operating expense summaries in IAC due diligence materials.	1.00
12/05/19	HK	Pre-update call walk-through of IAC diligence materials with G. Koch, H. Ku, and N. Simon (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	HK	Discussion with M. Hartley and H. Ku (both AlixPartners) on changes to the critical vendor tracking process.	0.40
12/05/19	HK	Conference call with B. Folse, G. Koch, M. Hartley, H. Ku and N. Simon (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	MH	Conference call with B. Folse, G. Koch, N. Simon, M.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Hartley, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	
12/05/19	MH	Research and correct legal related vendors not being released from accounts payable.	0.70
12/05/19	MH	Discussion with H. Ku and M. Hartley (both AlixPartners) on changes to the critical vendor tracking process.	0.40
12/05/19	MH	Prepare accounts payable release list.	0.40
12/05/19	MH	Prepare additional accounts payable release list and reconcile all changes.	0.60
12/05/19	MH	Research new pre-petition invoice from food services provider that carries an old date.	0.30
12/05/19	LJD	Prepare for and attend board meeting	5.50
12/05/19	BF	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	GJK	Pre-update call walk-through of IAC diligence materials with G. Koch, N. Simon, and H. Ku (all AlixPartners) to ensure accuracy and comprehensiveness.	0.90
12/05/19	GJK	Mundi strawman updates	1.20
12/05/19	GJK	Conference call with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to review IAC diligence status, proposed report outline, management interviews to-date, preliminary assessments of value/risk, organizational structure, and go-forward priorities.	1.80
12/05/19	GJK	Follow up on Europe budget development	1.00
12/06/19	GJK	Call with I. McClatchy (Norton Rose) to discuss diligence,	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		including meeting with European management	
12/06/19	GJK	Call with J. Theurillat (MN Consulting), G. Koch, N. Simon, M. Hartley (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss evolution of his role at Mundipharma and key business trends.	1.60
12/06/19	GJK	Prepare update on discussions with I. McClatchy (Norton Rose) and J. Theurillat (MN Consulting)	0.40
12/06/19	GJK	Follow up discussions with N. Simon and G. Koch (both AlixPartners) on J Theurillat (MN Consulting) call and LAM	0.90
12/06/19	GJK	Review of European budget changes over time, key drugs	2.40
12/06/19	GJK	Project coordination activities and planning	2.00
12/06/19	LJD	Update call with J. Dubel (Board Member).	0.50
12/06/19	MH	Attend part of call with client management on status of critical vendor payments.	0.20
12/06/19	MH	Analyze additional invoices for treatment as 503(b)(9).	0.40
12/06/19	MH	Review the latest critical vendor status report to assess the final payment capacity.	0.90
12/06/19	MH	Attend call with supply chain manager to discuss deposit payments to a vendor.	0.30
12/06/19	HK	Meeting with J. Lowne, E. Ruiz (both Purdue), and various company specialists, on vendor trade agreement status updates.	0.30
12/06/19	HK	Attend call for advisors to interview J. Theurillat (MN Consulting).	1.00
12/06/19	HK	Update critical vendor payment summaries for internal discussion with company.	2.70
12/06/19	HK	Review due diligence documents on budget details for European independent affiliated companies.	1.80
12/06/19	NAS	Update diligence tracking document to reflect latest	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		interviews held, requests made, and documents received.	
12/06/19	NAS	Call with J. Theurillat (MN Consulting), G. Koch, N. Simon, M. Hartley (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss evolution of his role at Mundipharma and key business trends.	1.60
12/06/19	NAS	Conference call for UCC Stipulation Presentation regarding Sackler family finances (partial).	0.80
12/06/19	NAS	Consolidate IAC diligence notes and create list of follow-up questions after conference call with J. Theurillat (MN Consulting).	0.40
12/06/19	NAS	Follow up discussions with N. Simon and G. Koch (both AlixPartners) on J Theurillat (MN Consulting) call and LAM	0.90
12/06/19	NAS	Analysis of Mundipharma LAM budget materials from 2017 to present to assess performance trends and changes in projections.	1.50
12/06/19	IA	Review CEO compensation details received from company for 2018-2019 YTD period,	3.40
12/06/19	ADD	Call with Purdue CFO, Purdue Associate General Counsel, Purdue Controller, and Skadden to discuss DOJ financial requests.	0.40
12/06/19	ADD	Compile and format files supplied in response to diligence requests.	2.80
12/06/19	ADD	Research diligence request at direction of counsel.	1.50
12/06/19	DS	Follow up with general counsel re: approval of October Customer Programs report	0.30
12/06/19	RDS	API Market construction	0.70
12/06/19	RDS	Call with J. Friederichsen (Purdue/Rhodes) re API volumes and general market landscape	0.90
12/06/19	RDS	Prepare for IT staffing call (NC/RT/RP)	0.40
12/06/19	RDS	Call with H. Ghnaimeh (Purdue) re IT headcount and	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transformation plans	
12/06/19	RDS	Purdue and RALP IT infrastructure org structure construction	0.60
12/06/19	RDS	Review working plan by A. Soma (Purdue) for staffing / crewing levels	1.30
12/07/19	NAS	Analysis of Mundipharma LAM budget materials from 2017 to present to assess performance trends and changes in projections.	1.70
12/07/19	JD	Review of intercompany receivables/payables	0.50
12/08/19	HK	Review IAC diligence materials for OPEX reduction initiatives	2.40
12/08/19	HK	Review IAC diligence materials for COGS reduction initiatives	1.40
12/08/19	RDS	Review updated budget projections and provide commentary	0.80
12/08/19	ADD	Respond to inquiry from Davis Polk regarding available documentation.	0.30
12/09/19	ADD	Request permission to upload files to the data room.	0.80
12/09/19	ADD	Draft responses to diligence inquiry for Davis Polk.	1.80
12/09/19	ADD	Compile and format files supplied in response to diligence requests.	2.90
12/09/19	ADD	Review and update data room permissions.	0.50
12/09/19	ADD	Review November month-end open pre-petition accounts payable.	1.20
12/09/19	ADD	Review diligence request and requested outstanding items.	2.20
12/09/19	KM	Analysis preparation re. Rhodes indirect labor spans and layers	0.90
12/09/19	KM	Report preparation re. strategic alliances and API industry	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		activity	
12/09/19	KM	Analysis update re. Wilson manufacturing quality roles and responsibilities	2.30
12/09/19	KM	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	KM	Analysis preparation re. Rhodes Tech staffing operations models to support various production levels	1.90
12/09/19	KM	Prepare for and attend call with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re headcount in distribution and supply chain (NC)	1.00
12/09/19	KM	Analysis preparation re. Rhodes Tech staffing operations models to support various production levels	1.90
12/09/19	KM	Analysis preparation re. Rhodes resource allocations by project	1.30
12/09/19	DS	Outline key items of Customer Programs report to AlixPartners team for purposes of executing report in coming weeks	0.90
12/09/19	DS	Review of draft weekly sales reports prepared by management in response to Province's data requests	0.40
12/09/19	DS	Compile support files from October's data request for Customer Programs report for Rhodes and send along with request list to controller (Rhodes)	0.50
12/09/19	DS	Compile support files from October's data request for Customer Programs report for PPLP and send along with request list to financial analyst (PPLP)	0.70
12/09/19	JD	Review correspondence re: business plan diligence requests.	0.60
12/09/19	JD	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	JD	Review materials re: cognition patent transaction.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Review future business plan.	
12/09/19	JD	Catch up conversation with management re: business planning work stream	0.60
12/09/19	JD	Correspondence with Province re: open diligence requests. Discussions with management re: open data requests and review latest materials provided.	1.20
12/09/19	RDS	Review NC production spans of control	0.80
12/09/19	RDS	Meeting with K. Darragh (Purdue) re royalty structure allocation from Mundi IACs and PAD group headcount detail	0.60
12/09/19	RDS	Review RT Materials Management headcount	0.60
12/09/19	RDS	Rhodes Technology headcount allocation and classification methodologies	0.30
12/09/19	RDS	Call with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re headcount in distribution and supply chain (NC)	0.50
12/09/19	RDS	Wilson red/yellow/pink scenario model alterations	0.80
12/09/19	RDS	Call with J. Stymiest (Purdue/Rhodes) re RT R&D man-hour allocation exercise	0.20
12/09/19	RDS	Review A. Soma (Purdue / Rhodes) provided shift schedules	0.70
12/09/19	RDS	Rhodes product pipeline analysis with failure to supply one-time charges	1.30
12/09/19	RDS	Review Avrio marketing and product launch documents	1.10
12/09/19	RDS	Correspondence with B. Evans, D. Fogel (both Purdue) re scheduling calls for the week	0.20
12/09/19	RDS	Make wages motion impacts to compensation analysis	0.80
12/09/19	RDS	Review quality spans of control (NC & RALP)	0.40
12/09/19	RDS	RP R&D Allocation per K. Kolar (Purdue) notes.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/09/19	RDS	Meeting with management, K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: business plan process	0.60
12/09/19	HK	Review IAC diligence materials for COGS reduction initiatives	1.50
12/09/19	HK	Attend advisor call with Neil Trueman (Mundipharma Chief International Intellectual Property Counsel).	1.10
12/09/19	HK	Review IAC diligence materials for Global IT OPEX reduction initiatives	1.60
12/09/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.50
12/09/19	HK	Review historical royalty's data to support draft Business Plan	0.80
12/09/19	HK	Review IAC diligence materials for Europe region requests	1.40
12/09/19	HK	Calls with H. Ku and G. Koch (both AlixPartners) to discuss Mundi cost reduction initiatives	0.80
12/09/19	MH	Prepare accounts payable release list.	0.40
12/09/19	GJK	Call with N. Trueman (Mundi IP) and Advisors for overview of Mundipharma IP program	2.00
12/09/19	GJK	Calls with H. Ku and G. Koch (both AlixPartners) to discuss Mundi cost reduction initiatives	0.80
12/09/19	GJK	Review of LAM 2020 OB	2.50
12/09/19	GJK	Project coordination activities including weekly activities list, priorities for Mundi diligence for week	2.00
12/09/19	IA	Review of retention payment calculations and correspondence with management on calculated payments to specific employees.	0.30
12/09/19	IA	Follow up on OCPs and process for payment.	0.60
12/09/19	IA	Review of summary of CEO compensation timeline and details prepared by Davis Polk.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/09/19	IA	Follow up with company on open items in CEO timeline summary, put together for diligence purposes.	1.40
12/09/19	IA	Review of private jet travel payment history and timing of payments.	0.60
12/09/19	IA	Correspondence and meeting with management to discuss CEO taxable benefit payments and timeline of agreements.	0.70
12/09/19	IA	Review of updated rebates forecast received from TXP and incorporation into forecast model for inclusion in cash forecast for Purdue.	2.80
12/09/19	IA	Review of information received on payment to CEO for personal travel.	1.10
12/09/19	IA	Drafting of summary of private travel and other benefits as requested by Davis Polk.	1.80
12/10/19	NAS	Finish reviewing 2019 Mundipharma LAM budget materials and provide key takeaways to IAC diligence team.	1.90
12/10/19	NAS	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	NAS	Introductory conference call with investment banker for Mundipharma entities (Deutsche Bank), G. Koch, N. Simon (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss timetable and initial views on business.	0.60
12/10/19	NAS	Provide overview to AlixPartners IAC diligence team regarding content and data room location of relevant Mundipharma Board presentations.	0.30
12/10/19	NAS	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss approach towards building global Mundipharma business plan and align on current responsibilities.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/10/19	NAS	Incorporate Europe sales and margin build into preliminary draft of Mundipharma due diligence model.	2.50
12/10/19	GJK	Introductory conference call with investment banker for Mundipharma entities (Deutsche Bank), N. Simon and G. Koch (both AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss timetable and initial views on business	0.60
12/10/19	GJK	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	GJK	Call with B. Folse and G. Koch (both AlixPartners) to discuss staffing needs and Mundi diligence	0.20
12/10/19	GJK	Updates to Mundi weekly analysis	2.80
12/10/19	GJK	Review and revise LAM 2018-2020 budget review	1.50
12/10/19	GJK	Review and revise Europe 2018-2020 budget review	1.00
12/10/19	GJK	Updates and revisions to Canada 2018-2020 budget review	1.50
12/10/19	GJK	Mundi financial model	0.50
12/10/19	GJK	Finalize Mundi weekly update	0.50
12/10/19	GJK	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss approach towards building global Mundipharma business plan and align on current responsibilities.	1.10
12/10/19	BF	Call with B. Folse and G. Koch (both AlixPartners) to discuss staffing needs and Mundi diligence	0.20
12/10/19	LJD	Work on staffing for IAC support	0.30
12/10/19	BF	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	MH	Update trade agreement tracking for new activity.	1.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/10/19	MH	Meeting with supply chain manager to discuss deposit agreement with vendor.	0.40
12/10/19	MH	Perform initial review of available financial data to study IAC cash flows.	2.60
12/10/19	MH	Research Trade Agreement settlements for three different agreements with a large vendor.	1.30
12/10/19	MH	Meeting with H. Ku and M. Hartley (both AlixPartners) to finalize transition of Critical Vendor management.	0.40
12/10/19	MH	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	MH	Build new critical vendor reporting tools.	1.20
12/10/19	MH	Prepare accounts payable release list.	0.40
12/10/19	MH	Attend Debtor's advisors call.	0.90
12/10/19	HK	Review historical royalty's data to support draft Business Plan	1.30
12/10/19	HK	Meeting with IAC diligence team including B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to align on current priorities.	0.30
12/10/19	HK	Review IAC diligence materials for Europe region requests	2.80
12/10/19	HK	Meeting with M. Hartley and H. Ku (both AlixPartners) to finalize transition of Critical Vendor management.	0.40
12/10/19	HK	Biz Ops - Review IAC diligence materials for LAM region requests	0.60
12/10/19	HK	Review IAC diligence materials for Intellectual Property Department requests	1.30
12/10/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.50
12/10/19	RDS	Presentation of Rhode variable contribution per dose,	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		prepare slides	
12/10/19	RDS	Assemble slide deck shell for update meeting	1.00
12/10/19	RDS	Slide preparation - Rhodes commercial product average sale price and value mapping analysis	1.80
12/10/19	RDS	Slide preparation - Rhodes tech r&d cost allocation and rationalization	1.10
12/10/19	RDS	Slide preparation - Rhodes tech direct / indirect labor span of control and ratio analysis	1.60
12/10/19	RDS	Slide preparation - Rhodes pipeline NPV analysis	0.90
12/10/19	RDS	Slide preparation - Rhodes & Wilson pharm tech allocation	1.40
12/10/19	RDS	Slide preparation - North Carolina product development allocation	1.20
12/10/19	RDS	Slide preparation - North Carolina quality organization span of control analysis	1.00
12/10/19	RDS	North Carolina - based budget vs low base cost allocation	0.70
12/10/19	RDS	Revise presentation flow - update total Rhodes graphs to reflect products outside of the vertical generic opioids	0.60
12/10/19	RDS	Slide preparation - Rhodes commercial product overview	0.80
12/10/19	JD	Review materials re: OSR lease and Purdue Canada manufacturing agreement.	0.50
12/10/19	JD	Participate in Special Committee Board meeting	0.80
12/10/19	JD	Review update materials re: IAC diligence progress	0.90
12/10/19	JD	Review summary presentation to be presented to management re: status update on business plan process.	0.80
12/10/19	JD	Run analysis re: potential severance obligations	0.70
12/10/19	JD	Correspondence with management and Davis Polk re: new retention program and discussion with Province re: same. Review materials on IT separation and retention program.	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/10/19	KM	Report preparation re. Rhodes Tech direct labor staffing structure options	1.10
12/10/19	KM	Report preparation re. Wilson operations direct labor staffing structure options	2.20
12/10/19	KM	Report preparation re. Wilson indirect labor potential savings	1.90
12/10/19	KM	Report preparation re. Rhodes indirect labor potential savings	1.30
12/10/19	KM	Report preparation re. Rhodes Tech indirect labor potential savings	0.80
12/10/19	KM	Report preparation re. Wilson manufacturing quality organizations spans and support structure	1.00
12/10/19	KM	Report preparation re. Rhodes R&D pipeline NPV and project timing	1.00
12/10/19	KM	Report preparation re. product and customer profitability	1.50
12/10/19	KM	Report preparation re. general document structure	2.10
12/10/19	KM	Report preparation re. partnership opportunities for RALP	0.70
12/10/19	KM	Advisor call with PJT re: case update	0.50
12/10/19	KM	Prepare Rhodes and North Carolina personnel baseline presentation slides re: project update	1.50
12/10/19	ADD	Prepare November month-end open pre-petition accounts payable update.	3.10
12/10/19	ADD	Review and update data room permissions.	0.80
12/10/19	ADD	Compile and format files supplied in response to diligence requests.	2.30
12/11/19	ADD	Review and update data room permissions.	1.00
12/11/19	ADD	Request permission to upload files to the data room.	1.50
12/11/19	ADD	Compile and format files supplied in response to diligence requests.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/11/19	KM	Report preparation re. R&D cost reduction opportunity summary	1.40
12/11/19	KM	Analysis re. Rhodes Tech indirect labor sensitivity analysis	2.10
12/11/19	KM	Report preparation re. Rhodes Tech R&D portfolio NPV and project timing analyses	1.20
12/11/19	KM	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	KM	Report revisions re. RALP Business Planning and Cost Assessment	1.20
12/11/19	KM	Report review with D. Lundie (Rhodes), M. McCafferty and R. Sublett (both AlixPartners) re. RALP Business Planning and Cost Assessment	1.50
12/11/19	KM	Report revisions re. RALP Business Planning and Cost Assessment	0.20
12/11/19	KM	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	RDS	Rhodes NPV alterations based upon R&D department headcount expenses	0.70
12/11/19	RDS	Opioid API market update commentary and slide creation	2.10
12/11/19	RDS	Report review with D. Lundie (Rhodes), M. McCafferty and R. Sublett (both AlixPartners) re. RALP Business Planning and Cost Assessment	1.50
12/11/19	RDS	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	RDS	Slide construction - Wilson cost structure under various cost structures, circular nature of generic opioid price considerations	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/11/19	RDS	Slide construction - API manufacturing landscape and partnership opportunities	0.80
12/11/19	RDS	Slide construction - Rhodes Technology R&D headcount allocation under PHI scenario	0.90
12/11/19	RDS	Slide construction - API partnership opportunities SWAT analysis	0.40
12/11/19	RDS	Slide creation - Rhodes Technology crewing model in direct labor	1.10
12/11/19	RDS	Slide construction - Rhodes Technology indirect : direct labor ratio analysis and sensitivity analysis	0.80
12/11/19	RDS	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	HK	Review IAC diligence materials for Global IT OPEX reduction initiatives	0.70
12/11/19	HK	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, H. Ku, and N. Simon (all AlixPartners).	0.80
12/11/19	HK	Draft Rhodes' Opioid Market Dynamics slides to support Business Plan meetings	1.60
12/11/19	HK	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.40
12/11/19	MH	Reconcile changes to vendor balance at the request of the UCC.	0.40
12/11/19	MH	Prepare accounts payable release list.	0.40
12/11/19	MH	Review historical financial data for Canadian IAC.	2.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/11/19	MH	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, J. DelConte, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	MH	Weekly internal IAC diligence team update Reconcile all trade agreement activity with notification tracker.	1.90
12/11/19	MH	Reconcile all trade agreement activity with Intralinks activity tracker.	2.10
12/11/19	MH	Build new critical vendor reporting tools.	0.90
12/11/19	LJD	Prepare for and attend call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.20
12/11/19	BF	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	BF	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) following initial viewing of Mundipharma vendor due diligence report authored by EY	0.30
12/11/19	GJK	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	GJK	Visit to Norton Rose to review EY Vendor Due Diligence draft; follow up email/calls	1.50
12/11/19	GJK	Project management of Mundi cash flow work stream and overall project; follow up on diligence management	1.50
12/11/19	NAS	Incorporate Mundipharma LAM sales and gross margin	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		data derived from various Board/budget presentations into Mundipharma business plan model.	
12/11/19	NAS	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	NAS	Draft key takeaways and project status points in advance of broader AlixPartners engagement team call scheduled for 12/13.	1.50
12/11/19	NAS	Incorporate Mundipharma Canada sales and gross margin data derived from multiple Board/budget presentations into Mundipharma business plan model.	0.90
12/11/19	NAS	Update Mundipharma diligence tracker to reflect latest meetings held (including key takeaways) and documents received.	0.70
12/11/19	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) following initial viewing of Mundipharma vendor due diligence report authored by EY.	0.30
12/11/19	NAS	Review new Mundipharma diligence files uploaded to data room, including 2019 midyear review presentation made by Mundipharma CFO (A. Breabout).	0.80
12/11/19	IA	Review of available information on IT employees and requested details from HR management team.	0.70
12/11/19	IA	Draft summary of requested wages and benefit payment details for 9 employees involved in IT transition project.	0.40
12/11/19	IA	Correspondence with management and counsel for review and approval of IT transition diligence request responses and detailed files.	0.80
12/11/19	IA	Draft email to finance management team for overview of updated cash forecast and assumptions.	0.70
12/11/19	IA	Review of filed fee applications, detailed fees and expense	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		amounts, to update retained professional's payment forecast.	
12/11/19	IA	Update of retained professional's payment forecast to reflect filed fee applications.	1.20
12/11/19	IA	Update of restructuring advisors' fees forecast based on filed fee applications.	1.90
12/11/19	IA	Update Purdue cash flow forecast model to incorporate edits to professional fees forecast.	2.30
12/11/19	IA	Correspondence with management regarding submitted diligence requests on additional retention program and review of submitted support data.	1.80
12/11/19	JD	Weekly internal IAC diligence team update call to discuss new findings and process status with B. Folse, G. Koch, M. Hartley, J. DelConte, N. Simon, and H. Ku (all AlixPartners).	0.80
12/11/19	JD	Call with L. Donahue, B. Folse, K. McCafferty, J. DelConte and R. Sublett (all AlixPartners) re: business plan analysis progress.	1.00
12/11/19	JD	Review and comment on final business plan presentation prior to meeting with management.	1.70
12/11/19	JD	Meeting with K. McCafferty, J. DelConte, H. Ku, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, and D. Fogel (Purdue) re presentation on RALP cost structure modeling	1.50
12/11/19	JD	Review materials re: IT IAC transition work stream	0.60
12/12/19	JD	Review latest update on critical vendor status and vendor payment positions.	0.60
12/12/19	JD	Pull together additional information re: wage diligence questions.	0.80
12/12/19	JD	Review final package of retention plan diligence answers prior to providing for the UCC advisors.	0.70



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/12/19	JD	Review business plan presentation to determine potential high-level summary details to share with management.	1.30
12/12/19	IA	Follow up on payment of Canadian counsel fees as approved by the court.	0.60
12/12/19	IA	Review of existing materials on IT Capabilities split project.	1.30
12/12/19	IA	Drafting of summary of IT capabilities project to be shared with the UCC as part of retention program diligence.	1.80
12/12/19	IA	Correspondence with management regarding professional fees forecast included in cash forecast.	1.20
12/12/19	IA	Edits to Purdue and Rhodes 13-week cash forecast to incorporate management's comments.	2.60
12/12/19	IA	Review of comments received from management on cash forecast and follow up of open items on rebates and IAC transactions.	1.60
12/12/19	IA	Follow up on questions received on CEO compensation as part of committee diligence requests.	0.30
12/12/19	IA	Follow up on IT transition diligence question items received.	1.70
12/12/19	NAS	Update IAC diligence tracker to reflect latest documents received, interviews conducted, and key conclusions drawn.	0.70
12/12/19	NAS	Incorporate Mundipharma LAM regional operating expense figures in overall Mundipharma business plan model.	1.30
12/12/19	NAS	Incorporate Mundipharma Europe regional operating expense figures in overall Mundipharma business plan model.	0.70
12/12/19	NAS	Incorporate Mundipharma Canada regional operating	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		expense figures in overall Mundipharma business plan model.	
12/12/19	GJK	Update Mundi update document and provide to PJT	0.80
12/12/19	LJD	Participate in a call with management, Davis Polk, PJT and AlixPartners re: status update and ongoing work streams.	0.50
12/12/19	LJD	Review and discuss October bill and fee app	0.30
12/12/19	MH	Reconcile all trade agreement activity with email responses from vendor management team.	2.40
12/12/19	MH	Add additional functionality to critical vendor reporting process.	2.60
12/12/19	MH	Attend Debtor professionals call with client management.	0.70
12/12/19	MH	Attend meeting with accounts payable team to coordinate year end payment cutoff activity.	0.90
12/12/19	MH	Prepare accounts payable release list.	0.40
12/12/19	HK	Review IAC diligence materials for COGS reduction initiatives	2.60
12/12/19	HK	Review IAC diligence materials for OPEX reduction initiatives	1.30
12/12/19	HK	Review IAC diligence materials for Europe region requests	1.70
12/12/19	RDS	Slide construction - Rhodes cost structure under various volume scenarios, quality spans of control and value mapping	1.80
12/12/19	RDS	Preparation of API landscape slides	0.80
12/12/19	RDS	Slide construction - Rhodes Technology R&D headcount allocation under PHI scenario	0.90
12/12/19	KM	Prepare and document RALP operations scenario summary for discussion with D. Lundie (Rhodes)	1.40
12/12/19	KM	Review feedback from J. Lowne (Purdue) re. RALP	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business planning and cost reduction assessment	
12/12/19	KM	Prepare analysis for J. Northington (Purdue) re: RT/RP quality organization options	1.10
12/12/19	KM	Meeting with J. Northington (Purdue) re: RT/RP quality organization options	1.60
12/12/19	KM	Prepare analysis for H. Ghnaimeh (Purdue) re: RELP IT organization structure and costs	0.60
12/12/19	KM	Meeting with H. Ghnaimeh (Purdue) re: RELP IT organization structure and costs	1.30
12/12/19	KM	Prepare analysis in support of Business Planning and Cost Reduction Assessment presentation to Purdue Management team	1.20
12/12/19	ADD	Call with Davis Polk to discuss redacting board materials for upload to data room.	0.30
12/12/19	ADD	Call with Davis Polk to discuss response to diligence request.	0.30
12/12/19	ADD	Compile and format files supplied in response to diligence requests.	3.30
12/12/19	ADD	Review new and outstanding diligence request.	1.90
12/13/19	ADD	Prepare for status update meeting.	0.70
12/13/19	ADD	Call with Skadden and Purdue GC to discuss real estate documentation request.	0.20
12/13/19	ADD	Compile documentation diligence items requested by the UCC/AHC.	2.70
12/13/19	ADD	Upload documentation for diligence requests to the data room.	1.70
12/13/19	ADD	Submit requests for outstanding diligence items.	1.60
12/13/19	KM	Discussion with D. Lundie (Rhodes) re. RALP Business Planning and Cost Reduction project next steps	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/13/19	KM	Prepare program approach slides for presentation to C. Landau (Purdue) re. RALP Business Planning and Cost Reduction project next steps	2.20
12/13/19	KM	Analysis re. RALP partnership opportunities	0.70
12/13/19	KM	Discussion with J. DelConte and M. McCafferty (both AlixPartners) re. RALP Business Strategy and Cost Reduction project	0.20
12/13/19	MH	Update trade agreement tracker with new activity.	0.40
12/13/19	MH	Review Sackler related family due diligence information.	1.80
12/13/19	MH	Prepare for team update call.	0.30
12/13/19	NAS	Update IAC diligence tracker to reflect latest documents received, interviews conducted, and key conclusions drawn.	0.40
12/13/19	IA	Follow up on approvals for IT transition overview presentation, to be shared with the UCC.	0.40
12/13/19	IA	Edit and format Purdue weekly sales by product report, and request of approvals for posting to data room.	1.10
12/13/19	IA	Follow up on questions from management on OCP payment forecast.	1.30
12/13/19	IA	Review benefit amounts per employee as approved by the court in preparation for next week's payments to hourly employees.	2.10
12/13/19	JD	Review latest weekly sales analysis and provide comments. Compare to latest budget and forecast files.	0.60
12/13/19	JD	Conversation with management re: conversations with operational leadership and scenario analysis.	0.50
12/13/19	JD	Discussion with J. DelConte and M. McCafferty (both AlixPartners) re. RALP Business Strategy and Cost Reduction project	0.20
12/15/19	JD	Review draft slides for management presentation.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/15/19	LJD	Review and comment on business plan deck	1.50
12/16/19	LJD	Review info regarding Purdue disclosures and discuss internally and with risk team	0.90
12/16/19	GJK	Call with N. Simon and G. Koch (both AlixPartners) to review current status of Mundipharma business plan model.	0.30
12/16/19	GJK	Call with H. Ku and G. Koch (both AlixPartners) to review diligence information management	0.30
12/16/19	MH	Research vendor payments in response to questions from vendor contacts.	1.10
12/16/19	MH	Update professional firm hold list to release invoices.	0.50
12/16/19	MH	Prepare accounts payable release list.	0.60
12/16/19	MH	Advise client on proper treatment of a pre-petition credit.	0.30
12/16/19	MH	Review new list of pre-petition items to support month end accounting for liabilities subject to compromise.	0.40
12/16/19	HK	Review IAC diligence materials for Europe region requests	2.40
12/16/19	HK	Call with H. Ku and G. Koch (both AlixPartners) to review diligence information management	0.30
12/16/19	HK	Update Due Diligence / information request tracker with uploads to data site.	1.30
12/16/19	JD	Review weekly sales by product against business plan prior to posting.	0.50
12/16/19	JD	Review OSR lease materials prior to call.	0.40
12/16/19	JD	Call with Davis Polk and management re: go forward leasing options.	0.50
12/16/19	JD	Meeting with management and K. McCafferty (AlixPartners) re: business plan scenario analysis and next steps.	1.50
12/16/19	JD	Review business plan presentation and business plan	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		scenario analyses.	
12/16/19	JD	Research public benefit corporations and potential compensation structures.	0.70
12/16/19	IA	Follow up on review and approvals for weekly sales by product reports.	0.60
12/16/19	NAS	Review and summarize key takeaways from new Associated Press article on Mundipharma and Nyxoid for purposes of IAC diligence.	0.60
12/16/19	NAS	Review Mundipharma business plan model in advance of meeting with G. Koch (AlixPartners).	0.40
12/16/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review current status of Mundipharma business plan model.	0.30
12/16/19	NAS	Incorporate business development-related operating expense projections into Mundipharma business plan model.	0.80
12/16/19	NAS	Incorporate research and development-related operating expense projections into Mundipharma business plan model.	1.40
12/16/19	KM	Report modifications re: decision framework RALP Business Planning and Cost Assessment	1.10
12/16/19	KM	Report modifications re: end-to-end variable contribution for RALP Business Planning and Cost Assessment	1.30
12/16/19	KM	Report modifications re: financial impact summary for RALP Business Planning and Cost Assessment	0.70
12/16/19	KM	Meeting with management and K. McCafferty (AlixPartners) re: business plan scenario analysis and next steps.	1.50
12/16/19	KM	Analysis re: Rhodes R&D project valuation for RALP business plan	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/16/19	KM	Analysis revision re: Non-site supply chain organization structure options	0.70
12/16/19	KM	Report preparation re: agenda and plan for RALP leadership workshop on Jan. 7-8	0.90
12/16/19	ADD	Request assistance with error received when updated file.	0.30
12/16/19	ADD	Update and distribute vendor master.	0.40
12/16/19	ADD	Compile data to generate monthly outstanding accounts payable not covered by motion report.	2.60
12/16/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.70
12/16/19	ADD	Compile and review files submitted in response to UCC/AHC diligence request.	2.80
12/16/19	ADD	Request approval to upload documents to the data room.	0.60
12/17/19	ADD	Request and compile documentation from Purdue and Rhodes to respond to UCC diligence request.	2.20
12/17/19	ADD	Update monthly account payable report per comments from Purdue Controller.	1.70
12/17/19	ADD	Create monthly outstanding accounts payable not covered by motion report.	2.30
12/17/19	ADD	Review monthly accounts payable report with Purdue Controller.	0.40
12/17/19	ADD	Format and prepare files submitted in response to diligence request for upload to the data room.	1.50
12/17/19	KM	Discussion with D. Lundie (Rhodes) re: RELP leadership workshop agenda and participants	0.30
12/17/19	KM	Discussion with D. Fogel (Rhodes) re: cost allocation approach for RP product portfolio	0.70
12/17/19	KM	Analysis re: allocation of non-labor resources to RP product pipeline	1.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/17/19	KM	Preliminary analysis re: cost allocation approach for regulatory affairs resources to RP pipeline product portfolio	1.70
12/17/19	KM	Preliminary analysis re: cost allocation approach for quality resources to RP pipeline product portfolio	1.70
12/17/19	KM	Preliminary analysis re: cost allocation approach for tech ops resources to RP pipeline product portfolio	1.10
12/17/19	KM	Document preparation re: Approach for RALP leadership workshop Jan7-8 2020	2.10
12/17/19	JD	Additional research into public benefit corporations and compensation structures.	1.00
12/17/19	JD	Correspondence with management re: accounts receivable write off	0.60
12/17/19	JD	Review materials re: Novo Nordisk as a public benefit corp.	0.50
12/17/19	JD	Review latest materials re: Rhodes BD opportunity	0.60
12/17/19	JD	Meeting with management re: public benefit corporation organizational objectives and go forward process for setting corporate scorecard.	0.50
12/17/19	JD	Participate in conference call with PJT Partners and management re: asset monetization materials.	0.70
12/17/19	NAS	Incorporate Technical Operations (supply chain)-related operating and capital expense projections into Mundipharma business plan model.	1.40
12/17/19	NAS	Incorporate information technology-related operating and capital expense projections into Mundipharma business plan model.	1.60
12/17/19	NAS	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	HK	Update Due Diligence / information request tracker with	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		uploads to data site.	
12/17/19	HK	Review IAC diligence materials for Europe region requests	2.30
12/17/19	HK	Meeting with M. Hartley and H. Ku (both AlixPartners) to discuss Company follow-ups from vendor management status update.	0.10
12/17/19	HK	Meeting with G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	MH	Attend debtor advisor call.	0.60
12/17/19	MH	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	MH	Meeting with supply chain manager to review vendor payment issues.	0.50
12/17/19	MH	Prepare accounts payable release list.	0.40
12/17/19	MH	Meeting with H. Ku and M. Hartley (both AlixPartners) to discuss Company follow-ups from vendor management status update.	0.10
12/17/19	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding (all Purdue), D. Fogel (Rhodes), M. Hartley, and H. Ku (both AlixPartners) on critical vendor management issues.	0.40
12/17/19	MH	Update critical vendor status report with new activity.	0.60
12/17/19	MH	Meeting with plant manager to discuss possible resolution path for polynox supplier.	0.70
12/17/19	GJK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to discuss IAC diligence request status.	0.40
12/17/19	LJD	Call with A. Preiss of Akin regarding disclosures	0.40
12/17/19	LJD	Call with PJT regarding disclosures and general update	0.30
12/18/19	MH	Update critical vendor status report with new activity.	0.50
12/18/19	MH	Prepare accounts payable release list.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/18/19	MH	Research vendor payments in response to questions from vendor contacts.	1.30
12/18/19	MH	Develop procedures for processing partial payments to support negotiated trade agreement amounts.	0.90
12/18/19	HK	Review IAC diligence materials for Europe region requests	2.40
12/18/19	HK	Update Due Diligence / information request tracker with uploads to data site.	2.50
12/18/19	NAS	Revise net revenue and gross margin calculations in Mundipharma business plan model to align with reporting format used by company.	0.90
12/18/19	NAS	Finalize addition of Technical Operations (supply chain)-related operating and capital expense projections into Mundipharma business plan model.	1.30
12/18/19	NAS	Revise consolidation piece of Mundipharma business plan model to tie to individual region budgets and add ability to include 2017 historical financials when provided.	1.60
12/18/19	NAS	Review of initial draft of Mundipharma business plan model to identify key takeaways and any variances relative to prior analyses.	0.80
12/18/19	IA	Review and reconciliation of updated retention payment tracker by employee to approved amounts.	1.80
12/18/19	IA	Correspondence and follow up with client on approvals of sales by product reports to be posted to the data room.	0.60
12/18/19	IA	Prepare for IT Transition overview call with Province and management and review of shared materials and submitted questions.	1.20
12/18/19	IA	Review of submitted Purdue and Rhodes customer programs data for monthly customer report.	2.80
12/18/19	KM	Document preparation re: Purpose and Goals for RALP leadership workshop Jan7-8 2020	2.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/18/19	KM	Preliminary analysis re: cost allocation approach for tech ops resources to RP pipeline product portfolio	0.90
12/18/19	KM	Preliminary analysis re: cost allocation approach for quality resources to RP pipeline product portfolio	1.60
12/18/19	KM	Preliminary analysis re: cost allocation approach for regulatory affairs resources to RP pipeline product portfolio	1.30
12/18/19	KM	Analysis re: allocation of non-labor resources to RP product pipeline	1.50
12/18/19	KM	Call with M.Sisodia (Rhodes) re. NPV calculation approach for RP pipeline	0.90
12/18/19	ADD	Request approval to upload documents to the data room.	0.90
12/18/19	ADD	Request and compile documentation from Purdue and Rhodes to respond to UCC diligence request.	2.20
12/18/19	ADD	Research document production history at request of DPW.	0.40
12/18/19	JD	Review IT integration materials prior to call.	0.70
12/18/19	JD	Call with management and Davis Polk re: future lease options.	0.50
12/18/19	JD	Correspondence with management and Davis Polk re: PRALP and PPI partnership agreements. Review existing organizational documents.	0.90
12/18/19	JD	Conversations with management re: retention issues and go forward staffing plans.	0.60
12/18/19	JD	Review existing operational update presentations from management. Correspondence with management re: updated slides and potential other operational trackers.	1.20
12/18/19	JD	Review materials to be responsive to outstanding DOJ diligence requests.	0.70
12/18/19	JD	Review correspondence with management re: Rhodes BD deal approval process. Review internal materials re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		same.	
12/18/19	JD	Review historic business plan board presentations in response to outstanding diligence requests.	1.00
12/19/19	JD	Participate in discussion with PJT Partners and management re: Cognition deal.	0.80
12/19/19	JD	Participate in discussion with Davis Polk and PJT Partners re: approval process for Rhodes BD deals.	0.50
12/19/19	JD	Call with Davis Polk, Skadden, J. DelConte and A. DePalma (both AlixPartners) re: DOJ requests.	0.60
12/19/19	JD	Review materials collected to be responsive to various business plan diligence requests from committee advisors.	1.20
12/19/19	JD	Review draft lease proposal to share with OSR.	0.40
12/19/19	ADD	Compile and format files submitted in response to UCC/AHC diligence request.	3.00
12/19/19	ADD	Request approval to upload documents to the data room.	0.70
12/19/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.40
12/19/19	ADD	Call with Davis Polk, Skadden, J. DelConte and A. DePalma (both AlixPartners) re: DOJ requests.	0.60
12/19/19	ADD	Compile documentation submitted to the UCC outside of the data room for review by Davis Polk.	1.30
12/19/19	KM	Call with M.Sisodia, D. Fogel (both Rhodes) and J. Carlisle (Purdue) re. NPV calculation approach for RP pipeline	0.70
12/19/19	KM	Call with K. Kolar (Rhodes) re. allocation of regulatory affairs, quality, and tech ops resources to the RP pipeline products	0.90
12/19/19	KM	Call with D. Fogel (Rhodes) re. RP pipeline products	0.40
12/19/19	KM	Analysis re: cost of quality labor to the RP product	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		pipeline	
12/19/19	KM	Analysis re: cost of tech ops labor to the RP product pipeline	1.30
12/19/19	KM	Analysis re: cost of regulatory affairs labor to the RP product pipeline	1.50
12/19/19	KM	Document preparation re: cost of RP product pipeline	1.50
12/19/19	IA	Review of actual rebates and comparison to customer rebates information received from Purdue and Rhodes.	1.80
12/19/19	IA	Review of updated monthly November flash report to be posted to the data room.	1.30
12/19/19	NAS	Resolve question regarding beneficiaries of indemnification payments and incorporate answer in November 2019 Monthly Operating Report.	1.90
12/19/19	NAS	Review initial draft of Mundipharma Vendor Due Diligence report authored by EY.	0.30
12/19/19	NAS	Review latest draft of November 2019 Monthly Operating Report for accuracy.	0.80
12/19/19	HK	Update Due Diligence / information request tracker with uploads to data site.	0.60
12/19/19	HK	Update analysis of historical royalty's data to support draft Business Plan	1.80
12/19/19	HK	Review IAC diligence materials for Europe region requests	2.50
12/19/19	MH	Update critical vendor status report with new activity.	0.50
12/19/19	MH	Prepare accounts payable release list.	0.40
12/20/19	MH	Prepare second accounts payable release list to resolve issues from AP manager.	0.50
12/20/19	MH	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/20/19	MH	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, N. Simon, M. Hartley, H. Ku (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	MH	Update critical vendor status report with new activity.	0.50
12/20/19	MH	Prepare accounts payable release list.	0.40
12/20/19	MH	Call with company and vendor counsel to review trade agreement options with polynox supplier.	0.60
12/20/19	BF	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	GJK	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	GJK	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, N. Simon, H. Ku (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	HK	Call with B. Sheehan, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, H. Ku, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	HK	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, H. Ku, and N. Simon (all AlixPartners).	0.60
12/20/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.80
12/20/19	HK	Update Due Diligence / information request tracker with	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		uploads to data site.	
12/20/19	NAS	Mundipharma diligence initial impressions and workstream update with B. Folse, G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners).	0.60
12/20/19	NAS	Review Volume 1 of Project Malta Vendor Due Diligence Report prepared by EY.	1.90
12/20/19	NAS	Call with B. Sheeha, J. Leighton-Scott (both Mundipharma), G. Koch, M. Hartley, H. Ku, N. Simon (all AlixPartners), and advisors to UCC and Ad-Hoc Committee to discuss Mundipharma Research & Development and Medical Affairs/regulatory operations.	1.80
12/20/19	JD	Prepare updated analysis of Dr. Landau's compensation over 2018 and 2019 time periods. Prepare correspondence to send to Davis Polk re: same.	1.50
12/20/19	JD	Review draft E&Y R&D report re: IACs.	0.60
12/20/19	JD	Review monthly and weekly NPA data for diligence requests.	0.40
12/20/19	JD	Review potential Rhodes BD deal re: HSR approvals.	0.70
12/20/19	JD	Correspondence with management and PJT Partners re: IMS data requests from FTI	0.30
12/20/19	JD	Review previous deal approval memo re: HSR value thresholds.	0.40
12/20/19	KM	Document preparation re: cost of RP product pipeline	1.10
12/20/19	KM	Document preparation re: RALP leadership workshop	2.30
12/20/19	ADD	Redact documents in preparation for distribution to the UCC/AHC.	2.30
12/20/19	ADD	Request approval to upload documents to the data room.	0.70
12/20/19	ADD	Upload documentation submitted in response to diligence requests to the data room.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/20/19	ADD	Prepare for weekly update call.	0.30
12/22/19	JD	Update Dr. Landau compensation analysis. Correspondence with Davis Polk and Willis Towers Watson re: same.	0.70
12/22/19	JD	Review draft Purdue branded business plan materials prior to meeting with management tomorrow.	1.00
12/23/19	JD	Meeting with management, PJT Partners, J. DelConte and K. McCafferty (both AlixPartners) re: Purdue branded long-term business plan.	1.20
12/23/19	JD	Review draft Purdue branded business plan materials prior to meeting.	0.50
12/23/19	JD	Meeting with management re: lease counterproposal from OSR and potential counter. Discussion with Davis Polk and CBRE re: same.	1.10
12/23/19	JD	Review materials re: open Province diligence questions, review cash flow forecast professional fee summary and correspondence with management re: same and review various business plan diligence items.	0.80
12/23/19	JD	Update analysis re: Dr. Landau compensation for 2018 and 2019.	1.70
12/23/19	JD	Prepare correspondence for Davis Polk to send to the non-consenting states re: Dr. Landau compensation.	1.00
12/23/19	NAS	Call with G. Koch and N. Simon (both AlixPartners) to align on priorities for week of 12/23 and discuss key takeaways from 12/19 meeting with tax advisors.	0.50
12/23/19	NAS	Review Europe Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	0.70
12/23/19	NAS	Review Business and Transaction Overview section of Volume 1 of EY Mundipharma Vendor Due Diligence Report.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/23/19	NAS	Review Key Transaction Considerations section of Volume 1 of EY Mundipharma Vendor Due Diligence Report.	2.70
12/23/19	NAS	Review appendices related to EBITDA adjustments and net debt calculations included in Volume 1 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/23/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	1.30
12/23/19	HK	Review IAC diligence materials for Global TechOps OPEX reduction initiatives	1.80
12/23/19	GJK	Call with G. Koch and N. Simon (both AlixPartners) to align on priorities for week of 12/23 and discuss key takeaways from 12/19 meeting with tax advisors.	0.50
12/23/19	MH	Research vendor payment questions referred by client staff.	0.80
12/23/19	MH	Resolve discrepancies between legal invoices referred by legal operations for payment against the release list.	1.10
12/23/19	GJK	Review and notes on VDD Phase 1 workbook	2.50
12/23/19	ADD	Upload documentation submitted in response to diligence request to data room	0.60
12/23/19	ADD	Work with Intralinks (data room) technical support to resolve access issue.	0.30
12/23/19	ADD	Request approval to upload files to data room to satisfy diligence requests.	0.70
12/23/19	ADD	Review and format documentation submitted in response to diligence requests for upload to data room.	2.60
12/23/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (agenda, objective and goals)	1.90
12/23/19	KM	Meeting with management, PJT Partners, J. DelConte and K. McCafferty (both AlixPartners) re: Purdue branded long-term business plan.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/24/19	MH	Create release file for accounts payable, including final resolution of legal discrepancies.	1.20
12/24/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.10
12/24/19	NAS	Review Europe Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.60
12/24/19	NAS	Provide summary of Mundipharma Australia settlement article to IAC diligence team.	0.20
12/24/19	NAS	Review LAM Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/25/19	NAS	Review LAM Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	0.30
12/25/19	NAS	Review Canada Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.20
12/25/19	GJK	Review and notes on E&Y Vendor Due Diligence Phase 1 report (~30 pages)	3.20
12/26/19	MH	Create release file for accounts payable.	0.80
12/26/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.10
12/26/19	NAS	Review Canada BerHol Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.40
12/26/19	NAS	Review Switzerland and Mundipharma IT Services Quality of Earnings sections of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/26/19	NAS	Review Technical Operations Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	2.60
12/26/19	NAS	Review Research and Development Quality of Earnings section of Volume 2 of EY Mundipharma Vendor Due	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Diligence Report.	
12/26/19	NAS	Review Quality of Net Assets section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/26/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (agenda, objective and goals)	1.50
12/26/19	KM	Document creation re: RALP leadership workshop Jan 7-8 (case for evaluation)	1.70
12/27/19	NAS	Review Quality of Net Assets section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.50
12/27/19	NAS	Review Quality of Cash Flow section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	1.10
12/27/19	NAS	Review Quality of Financial Information section of Volume 2 of EY Mundipharma Vendor Due Diligence Report.	2.30
12/27/19	NAS	Broad overview of Volume 3 of EY Mundipharma Vendor Due Diligence report.	0.70
12/27/19	JD	Review materials re: Rhodes BD deal and insourcing opportunity. Correspondence with management and PJT Partners re: same.	0.80
12/27/19	JD	Review IT separation agreement materials. Correspondence with management re: same.	0.60
12/27/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.70
12/27/19	HK	Review IAC diligence materials for Global IT OPEX reduction initiatives	1.70
12/27/19	GJK	Review and notes on VDD Overview section	2.50
12/27/19	GJK	Workbook 1 Review and Notes: Adjusted EBITDA	3.00
12/27/19	GJK	Finalize VDD Workbook 1 Review and Notes	3.00
12/28/19	GJK	VDD Workbook 2 and 3 review - begin review/notes	1.50
12/28/19	JD	Correspondence with Davis Polk and PJT Partners re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transaction overviews.	
12/29/19	JD	Review transaction overview presentations to send to committee advisors. Correspondence with committee advisors re: setting up a call to provide	1.10
12/29/19	JD	Finalize IT separation docs to post to the data room for committee advisors.	0.30
12/29/19	NAS	Review Europe IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	1.50
12/29/19	NAS	Review LAM IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	0.50
12/29/19	GJK	VDD Volume 2 Review and Notes	2.30
12/30/19	GJK	Review and notes of Vol 2 of VDD	2.00
12/30/19	GJK	Review and notes of Volume 2 of VDD	3.00
12/30/19	MH	Update vendor tracking files for trade agreement activity during holiday week.	1.70
12/30/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.40
12/30/19	NAS	Review LAM IACs section of Volume 3 of EY Mundipharma Vendor Due Diligence Report.	1.50
12/30/19	JD	Correspondence with Davis Polk re: business development partner and committee communications	0.70
12/30/19	JD	Correspondence with Davis Polk and management re: ownership agreements	0.40
12/30/19	JD	Review ownership documents to be responsive to UCC requests.	0.50
12/30/19	ADD	Review of files in data room for potential redactions as part of the designation process.	3.20
12/30/19	ADD	Compile and review documentation to complete UCC diligence requests.	2.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
12/30/19	ADD	Update designation review tracker.	0.80
12/31/19	ADD	Review of files in data room for potential redactions as part of the designation process.	2.80
12/31/19	ADD	Compile and upload documentation to data room	0.90
12/31/19	ADD	Update designation review tracker.	0.60
12/31/19	RDS	Analysis of margin profile for third-party RP products	0.80
12/31/19	RDS	Prepare slide for budget scenarios of third-party RP volumes	0.40
12/31/19	HK	Review draft advisor business overview of Mundipharma proposed transaction.	2.30
12/31/19	GJK	Review and notes of Vol 2 of VDD	3.00
12/31/19	GJK	VDD Volume 3 Review and Notes	3.00
01/02/20	GJK	Coordination call with G. Koch and N. Simon (both AlixPartners), J. Turner (PJT), M. Diaz (FTI), M. Atkinson (Province) and L. Szlezinger (Jefferies) in advance of Mundipharma Europe diligence meetings.	0.40
01/02/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to briefly discuss initial impressions from EY Mundipharma VDD report, next steps following review of report, and discussion topics for 1/4 AlixPartners internal update call	0.30
01/02/20	GJK	Work on Mundipharma diligence planning for week ahead	2.50
01/02/20	MH	Prepare status summary for team status call.	0.30
01/02/20	MH	Create release file for accounts payable.	0.80
01/02/20	JD	Special committee board meeting re: potential opportunities.	1.20
01/02/20	JD	Review materials re: potential business development opportunity prior to Board call.	0.90
01/02/20	JD	Correspondence with Davis Polk re: diligence materials and potential redactions.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/02/20	JD	Correspondence with management re: committee advisor review of potential business opportunities and review and summarize outstanding questions and potential answers.	0.80
01/02/20	JD	Review updated professional fee forecast from PJT and discussion with T. Melvin (PJT) re: same.	0.50
01/02/20	JD	Review business development agreement to potentially provide to the committee advisors as diligence.	0.40
01/02/20	JD	Review various IAC diligence materials prior to call re: London diligence trip.	0.50
01/02/20	NAS	Review correspondence with advisors to debtor (AlixPartners, PJT), Ad-Hoc Committee (FTI), and UCC (Province, Jefferies) regarding most efficient approach to Mundipharma diligence meetings in London.	0.10
01/02/20	NAS	Coordination call with G. Koch and N. Simon (both AlixPartners), J. Turner (PJT), M. Diaz (FTI), M. Atkinson (Province) and L. Szlezinger (Jefferies) in advance of Mundipharma Europe diligence meetings.	0.40
01/02/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to briefly discuss initial impressions from EY Mundipharma VDD report, next steps following review of report, and discussion topics for 1/4 AlixPartners internal update call.	0.30
01/02/20	IA	Review of updated retention payments tracker from HR.	0.40
01/02/20	IA	Follow up on weekly sales by product reports for Purdue and Rhodes, as requested by the committees.	1.10
01/02/20	ADD	Review of files in data room for potential redactions as part of the designation process.	2.60
01/02/20	ADD	Upload files submitted in response to diligence requests to the data room	1.20
01/02/20	KM	Review and amend presenter notes re: Rhodes management presentation to the Board	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/03/20	KM	Discussion with D. Lundie (Purdue) re: RELP leadership workshop objectives Jan 7-8	0.70
01/03/20	KM	Document preparation re: RALP cost savings scenarios for leadership workshop	1.80
01/03/20	KM	Document preparation re: RALP leadership workshop participants and approach	0.30
01/03/20	KM	Discussion with K. McCafferty and R. Sublett (both AlixPartners) re: RALP leadership team workshop Jan. 7-8	0.90
01/03/20	KM	Call with advisors re: business opportunity diligence questions	0.80
01/03/20	ADD	Request approval to upload files submitted in response to diligence requests to the data room.	0.50
01/03/20	ADD	Review of files in data room for potential redactions as part of the designation process.	2.90
01/03/20	ADD	Compile and review documentation to complete UCC diligence requests.	2.60
01/03/20	ADD	Upload files submitted in response to diligence requests to the data room	0.40
01/03/20	ADD	Review and research new UCC diligence requests.	1.50
01/03/20	RDS	Edit business plan overview slides for next week	0.20
01/03/20	RDS	Discussion with K. McCafferty and R. Sublett (both AlixPartners) re: RALP leadership team workshop Jan. 7-8	0.90
01/03/20	RDS	Prepare detailed bridge slides for unit economics analysis of Rhodes products on the fringe of profitability	1.60
01/03/20	RDS	Review Avrio business planning document and side-by-side forecasting documents from old and new head of finance	1.30
01/03/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) re: Mundipharma business plan modeling	0.90



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/03/20	NAS	Revise Mundipharma UK business plan strawman following discussion with G. Koch (AlixPartners) and share template with H. Ku (AlixPartners) to expand to other countries and regions.	1.40
01/03/20	NAS	Calls with I. McClatchy (Norton Rose), M. Diaz (FTI), G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: planning for Mundipharma mgmt. team interviews	0.50
01/03/20	NAS	Implement initial Mundipharma business plan modeling strategy through contribution for historical and projected UK financials.	1.20
01/03/20	NAS	Review 12/30 Associated Press article regarding illicit opioid sales in China and provide summary to AlixPartners IAC diligence team.	0.40
01/03/20	NAS	Call with I. McClatchy (Norton Rose), M. Atkinson (Province), L. Szlezinger (Jefferies), M. Diaz (FTI), G. Koch, and N. Simon (both AlixPartners) re: Mundipharma mgmt. team meetings and information for prep	0.90
01/03/20	NAS	Review data categories included in EY Mundipharma Vendor Due Diligence report and devise initial strategy for Mundipharma business plan model.	2.20
01/03/20	NAS	Review diligence meeting agenda and data request list drafted by FTI in advance of meetings with management in Europe week of 1/13.	0.30
01/03/20	NAS	Review individual country Mundipharma budget materials to determine what information is available to support projection methodology.	0.30
01/03/20	JD	Calls with I. McClatchy (Norton Rose), M. Diaz (FTI), G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: planning for Mundipharma mgmt. team interviews	0.50
01/03/20	JD	Pre-call with J. Lowne and others (Purdue) prior to diligence call with committee advisors.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/03/20	JD	Call with R. Brown (Purdue) and T. Melvin (PJT) re: professional fee forecast.	0.50
01/03/20	JD	Review forecasted professional fee details.	0.40
01/03/20	JD	Conversation with R. Brown (Purdue) re: professional fee forecast details.	0.30
01/03/20	JD	Correspondence with management re: potential business opportunity and approval process.	0.80
01/03/20	MH	Create release file for accounts payable.	0.70
01/03/20	GJK	Follow ups/prep for Mundipharma mgmt. team meetings, including review of diligence items, questions/info requests from FTI, analytic points for model to cover (eg. category vs product, opioid v non)	2.00
01/03/20	GJK	Calls with I. McClatchy (Norton Rose), M. Diaz (FTI), G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: planning for Mundipharma mgmt. team interviews	0.50
01/03/20	GJK	Call with I. McClatchy (Norton Rose), M. Atkinson (Province), L. Szlezinger (Jefferies), M. Diaz (FTI), G. Koch, and N. Simon (both AlixPartners) re: Mundipharma mgmt. team meetings and information for prep	0.90
01/03/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) re: Mundipharma business plan modeling	0.90
01/03/20	GJK	Review VDD and Mundipharma P&L projections for model prep and follow up	2.50
01/03/20	HK	Update due diligence information tracker with review of data site.	1.80
01/03/20	HK	Review European IAC financial modeling from draft Vendor Due Diligence report.	1.10
01/04/20	GJK	Call/webex with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review inputs for business plan/model	0.60
01/04/20	NAS	Call/webex with G. Koch (AlixPartners) to review inputs	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for business plan/model	
01/04/20	RDS	Correspondence with D. Fogel (Purdue) re: Rhodes budget presentation and incorporation of materials	0.50
01/05/20	RDS	Review of Avrio long term plan - innovation pipeline and retailer-level compilation	1.30
01/05/20	GJK	Question/categories for Mundipharma analytics, including review of previous board books for potential information ask for budget book data	1.00
01/05/20	HK	Review European IAC financial modeling from draft Vendor Due Diligence report.	2.70
01/06/20	HK	Conference call with R. Schnitzler, J. Turner, T. Melvin (all PJT), G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review revised Mundipharma diligence workplan.	0.50
01/06/20	SKL	Prepare for and participate in meeting to review the latest information and updates re: November Customer Programs report with D. Samikkannu and S. Lemack (both AlixPartners).	1.10
01/06/20	HK	Conference call with B. Folse, G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to provide update on current Mundipharma diligence status and walk through revised workplan.	0.80
01/06/20	HK	Review business plan presentations prepared for Avrio business plan meeting	0.80
01/06/20	HK	Update IAC diligence workplan with updated information request tracker	0.90
01/06/20	HK	Update Mundipharma's regional models with responses with draft Quality of Earnings reports.	1.20
01/06/20	GJK	Updates to work plan and project management coordination	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/06/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) to align on questions asked to S. Jamieson (Management Revisions) and approach for Mundipharma business plan model.	0.40
01/06/20	GJK	Conference call with G. Koch, N. Simon (both AlixPartners), M. Atkinson (Province), and M. Diaz (FTI) re: in-person diligence meeting agenda (for week of 1/13) and materials to be prepared in advance by company.	0.50
01/06/20	GJK	Coordination call with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), M. Atkinson (Province), and M. Diaz (FTI) in advance of diligence meetings during the week of 1/13.	0.90
01/06/20	GJK	Update to Mundipharma project management work plan; project coordination calls with M. Diaz (FTI) and I. McClatchy (Norton Rose)	2.80
01/06/20	GJK	Conference call with B. Folse, G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to provide update on current Mundipharma diligence status and walk through revised workplan.	0.80
01/06/20	GJK	Conference call with R. Schnitzler, J. Turner, T. Melvin (all PJT), G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review revised Mundipharma diligence workplan.	0.50
01/06/20	BF	Conference call with B. Folse, G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to provide update on current Mundipharma diligence status and walk through revised workplan.	0.80
01/06/20	LJD	Review MNC IAC presentation and discuss	0.80
01/06/20	GJK	Conversation with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/06/20	MH	Respond to vendor inquiries submitted by client.	2.20
01/06/20	MH	Prepare accounts payable release file.	0.70
01/06/20	MH	Respond to general counsel of questions regarding public availability of legal invoices.	0.30
01/06/20	MH	Update the critical vendor status report.	1.30
01/06/20	MH	Review the latest IAC work plan.	0.40
01/06/20	NAS	Prepare for IAC diligence call with S. Jamieson (Management Revisions).	0.30
01/06/20	NAS	Coordination call with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), M. Atkinson (Province), and M. Diaz (FTI) in advance of diligence meetings during the week of 1/13.	0.90
01/06/20	NAS	Conference call with G. Koch, N. Simon (both AlixPartners), M. Atkinson (Province), and M. Diaz (FTI) re: in-person diligence meeting agenda (for week of 1/13) and materials to be prepared in advance by company.	0.50
01/06/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) to align on questions asked to S. Jamieson (Management Revisions) and approach for Mundipharma business plan model.	0.40
01/06/20	NAS	Enter LAM region historical data from EY Mundipharma Vendor Due Diligence report into business plan model and build initial projections.	2.90
01/06/20	NAS	Review and edit latest draft of Mundipharma workplan/key question list in advance of calls with B. Folse (AlixPartners) and PJT team.	0.40
01/06/20	NAS	Review Mundipharma compliance presentation prepared by DLA Piper in advance of 1/8 meeting.	0.40
01/06/20	NAS	Conference call with B. Folse, G. Koch, J. DelConte, N.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Simon, and H. Ku (all AlixPartners) to provide update on current Mundipharma diligence status and walk through revised workplan.	
01/06/20	NAS	Conference call with R. Schnitzler, J. Turner, T. Melvin (all PJT), G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review revised Mundipharma diligence workplan.	0.50
01/06/20	NAS	Enter Canada region historical data from EY Mundipharma Vendor Due Diligence report into business plan model and build initial projections.	0.40
01/06/20	IA	Call with J. DelConte, I Arana (both AlixPartners), and D. Sims (Willis Tower Watson) to discuss 2020 objectives.	0.40
01/06/20	IA	Follow up with Davis Polk and HR on potential claims by retirees for LTRP payments.	1.10
01/06/20	JD	Correspondence with management and committee advisors re: potential transaction.	0.70
01/06/20	JD	Review DLA presentation re: IAC compliance and review supporting documentation materials.	2.30
01/06/20	JD	Conference call with B. Folse, G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to provide update on current Mundipharma diligence status and walk through revised workplan.	0.80
01/06/20	JD	Conference call with R. Schnitzler, J. Turner, T. Melvin (all PJT), G. Koch, J. DelConte, N. Simon, and H. Ku (all AlixPartners) to review revised Mundipharma diligence workplan.	0.50
01/06/20	JD	Conversation with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.30
01/06/20	JD	Review latest draft license agreement re: proposed business development opportunity.	0.70
01/06/20	JD	Call with J. DelConte, I Arana (both AlixPartners), and D.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/06/20	RDS	Sims (Willis Tower Watson) to discuss 2020 objectives.	
01/06/20	RDS	Call with D. Lundie (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re. RALP leadership workshop document and agenda	1.30
01/06/20	RDS	Create slide for 7 category revenue and gross profit projection for RALP entity	0.70
01/06/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re budget slides for workshop presentation	0.40
01/06/20	RDS	Create slides for headcount analysis to dictate spans of control and functional expertise inside of Rhodes Pharma and Rhodes Tech	1.40
01/06/20	RDS	Create slide for Strengths, weaknesses of the RALP entities to leverage for external strategic partnerships	1.10
01/06/20	RDS	Create slides for Rhodes budgeting exercise: cost structure by functional area and expense type	1.20
01/06/20	RDS	Create slides for workshop session on pipeline slippage for both Rhodes Tech and Rhodes Pharma	0.80
01/06/20	RDS	Create slides and R&D headcount allocation by project - NC PAD	0.50
01/06/20	RDS	Create slides and R&D headcount allocation by project - RT	0.50
01/06/20	RDS	Create slides and R&D headcount allocation by project - Rhodes Pharma w/ regulatory, quality and tech ops overlay	0.80
01/06/20	RDS	Construct slides and NC standard cost allocation down to conversion cost per tablet	1.00
01/06/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: budget slides for workshop presentation	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/06/20	KM	Prepare RALP leadership workshop document re: scenario description and planning	2.10
01/06/20	KM	Prepare RALP leadership workshop document re: proposed structure for integrated quality organization - Rhodes movement	1.80
01/06/20	KM	Prepare RALP leadership workshop document re: proposed structure for integrated quality organization - Wilson movement	2.20
01/06/20	KM	Prepare RALP leadership workshop document re: Rhodes Pharma pipeline and resources required analysis	2.00
01/06/20	KM	Call with D. Lundie (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: RALP leadership workshop document and agenda	1.30
01/06/20	ADD	Compile and upload documentation in response to diligence requests to the data room.	2.90
01/06/20	ADD	Request approval to upload documentation submitted in response to the diligence request to the data room.	0.60
01/06/20	ADD	Review available support for grant/charitable contributions and data in SAP.	1.40
01/06/20	ADD	Work with Purdue grants/charitable contribution team to understand available supporting documentation.	0.90
01/06/20	DS	Prepare for and participate in meeting to review the latest information and updates re: November Customer Programs report with D. Samikkannu, and S. Lemack (both AlixPartners)	1.10
01/06/20	DS	Review November chargebacks by wholesaler data for purposes of reconciling for Customer Programs report	1.30
01/06/20	DS	Request GPO November fee data from Rebate Manager (Purdue)	0.20
01/07/20	DS	Compile and review all potential Rhodes Customer	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Programs payments and ensure categorizations are accuracy and list complete	
01/07/20	DS	Correspondence with Rhodes Pharma Controller and Analyst re: review of Customer Programs classifications	0.40
01/07/20	DS	Review Deloitte GPO fees detail and compile follow up questions for Rebate Manager (Purdue)	1.40
01/07/20	DS	Review of specific Medicare Part D payment and correspondence with financial analyst (Purdue) on categorization	1.60
01/07/20	DS	Meeting with D. Samikkannu, S. LeMack (both AlixPartners), and financial analyst (Purdue) re: open items for November Customer Programs report	0.40
01/07/20	KM	Prepare RALP leadership workshop document re: messaging and presentation consistency	2.10
01/07/20	KM	Prepare RALP leadership workshop document re: financial valuation edits and changes	1.00
01/07/20	KM	Attend RALP Executive Leadership session Day 1 with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblan, D. McGuire etc. (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	6.50
01/07/20	KM	Prepare RALP leadership workshop document re: format and agenda changes for Day 2	1.00
01/07/20	KM	Prepare RALP leadership workshop document re: additional headcount reduction and product pipeline analyses	1.90
01/07/20	RDS	Construct slides for management workshop and Rhodes Pharma pipeline cost allocation	0.70
01/07/20	RDS	Construct slides for management workshop and NC per dose budget communication	0.50
01/07/20	RDS	Attend RALP Executive Leadership session Day 1 with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblan, D. McGuire	6.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		etc. (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	
01/07/20	RDS	Construct slides for management workshop - Rhodes Tech pipeline cost allocation	0.80
01/07/20	RDS	Construct slides for management workshop - Rhodes Tech headcount, direct labor makeup	0.60
01/07/20	RDS	Construct slides for management workshop - Rhodes Tech indirect labor headcount organization	0.80
01/07/20	RDS	Construct slides for management workshop - Rhodes Tech, Rhodes Pharma and NC quality organization	0.90
01/07/20	RDS	Construct slides for management workshop - scenario overview slide	0.30
01/07/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), and C. Robertson (Davis Polk) to discuss 2020 objectives and scorecard process.	0.50
01/07/20	JD	Meeting with E. Vonnegut, D. Consola and C. Robertson (all Davis Polk), J. DelConte, and I. Arana (both AlixPartners) re: 2020 corporate objectives and 2020 bonus program.	0.50
01/07/20	JD	Review and provide comments re: key documents and meetings on IAC diligence process.	1.50
01/07/20	JD	Review weekly IMS report per diligence ask.	0.30
01/07/20	JD	Review responses to Canada insourcing questions from committee advisors.	0.50
01/07/20	JD	Review draft business development opportunity financial analysis.	1.30
01/07/20	JD	Conversations and correspondence with C. Robertson (Davis Polk) and with M. Atkinson (Province) and K. Knechtel (FTI) re: information sharing protocol with committee members re: potential business opportunity.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/07/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), and C. Robertson (Davis Polk) to discuss 2020 objectives and scorecard process.	0.50
01/07/20	IA	Meeting with E. Vonnegut, D. Consla and C. Robertson (all Davis Polk), J. DelConte, and I. Arana (both AlixPartners) re: 2020 corporate objectives and 2020 bonus program.	0.50
01/07/20	NAS	Determine best approach towards roll-up/consolidation of individual country projections for Mundipharma business plan model.	0.80
01/07/20	NAS	Meeting with G. Koch and N. Simon (both AlixPartners) to coordinate Mundipharma Europe meetings scheduled for week of 1/13 and discuss approach towards Mundipharma business plan model.	0.40
01/07/20	NAS	Conference call with G. Koch, N. Simon (both AlixPartners), I. McClatchey (Norton Rose), J. Turner, R. Schnitzler (both PJT), J. Crockett (Province) and B. Bromberg (FTI) to prepare for Mundipharma Europe diligence meetings during week of 1/13.	0.40
01/07/20	NAS	Create roll-up/consolidation tabs for Mundipharma LAM and Canada business plan model for purposes of IAC diligence.	1.10
01/07/20	NAS	Create summary of historical sales, growth rates, and product mix across Mundipharma companies in order to prepare for 1/13 Mundipharma Europe management meetings.	0.90
01/07/20	NAS	Revise Mundipharma business plan model to include checks relative to figures included in EY Mundipharma Vendor Due Diligence report.	0.60
01/07/20	NAS	Search for and resolve source of discrepancy between prior draft of Mundipharma business plan model and figures included in EY Mundipharma Vendor Due Diligence	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		report.	
01/07/20	NAS	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review components of Mundipharma budget materials that could be used for business plan model projections and to review current draft of Mundipharma business plan model.	0.80
01/07/20	NAS	Create roll-up/consolidation tabs for Mundipharma Europe business plan model for purposes of IAC diligence.	2.10
01/07/20	MH	Prepare new status report of critical vendor for client review.	1.20
01/07/20	MH	Attend vendor status review with client.	0.70
01/07/20	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding, D. Fogel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) on critical vendor management issues.	0.40
01/07/20	MH	Reconcile approved legal vendors with OCP tracking and Monthly Operating Report.	1.60
01/07/20	MH	Review process to effect partial accounts payable payments.	0.80
01/07/20	MH	Prepare accounts payable release file.	0.60
01/07/20	GJK	Review of DLA Piper compliance report and create quick stats on size of analgesic sales in China and ANZ	1.00
01/07/20	GJK	Diligence coordination, including communication with other advisors and planning for Mundipharma management team interviews	1.50
01/07/20	GJK	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review components of Mundipharma budget materials that could be used for business plan model projections and to review current draft of Mundipharma business plan model.	0.80
01/07/20	GJK	Conference call with G. Koch, N. Simon (both AlixPartners), I. McClatchey (Norton Rose), J. Turner, R.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Schnitzler (both PJT), J. Crockett (Province) and B. Bromberg (FTI) to prepare for Mundipharma Europe diligence meetings during week of 1/13.	
01/07/20	GJK	Meeting with G. Koch and N. Simon (both AlixPartners) to coordinate Mundipharma Europe meetings scheduled for week of 1/13 and discuss approach towards Mundipharma business plan model.	0.40
01/07/20	GJK	Walk through of budget book detail for forecasting with G. Koch and H. Ku (both AlixPartners)	0.60
01/07/20	GJK	Review of DLA Piper Compliance back-up materials	2.50
01/07/20	GJK	Review of VDD volumes and thematic questions for modeling/follow up meetings	1.00
01/07/20	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, L. Harding, D. Fogel (all Purdue), H. Ku, and M. Hartley (both AlixPartners) on critical vendor management issues.	0.40
01/07/20	HK	Meeting with G. Koch, H. Ku, and N. Simon (all AlixPartners) to review components of Mundipharma budget materials that could be used for business plan model projections and to review current draft of Mundipharma business plan model.	0.80
01/07/20	HK	Review updates to Avrio business plans received from company.	1.90
01/07/20	HK	Review certain LAM budget books by country to update forecast model.	2.20
01/07/20	HK	Review certain Canada budget books to update forecast model.	0.90
01/07/20	HK	Review certain Europe budget books by country to update forecast model.	1.30
01/07/20	HK	Walk through of budget book detail for forecasting with G. Koch and H. Ku (both AlixPartners)	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/07/20	SKL	Meeting with D. Samikkannu, S. Lemack (both AlixPartners), and financial analyst (Purdue) re: open items for November Customer Programs report.	0.40
01/08/20	HK	Review China budget and board presentation to update OPEX assumptions.	1.60
01/08/20	HK	Review risk assessment on LAM budget presentations.	2.10
01/08/20	GJK	Board book review (2018) and board decisions review (2014 to 2017) re: decisions related to opioid promotion	1.50
01/08/20	GJK	China and ANZ analysis related to opioid promotion, including review of key documents for Canada, China and ANZ	2.50
01/08/20	GJK	Meeting with DLA Piper, UCC committee advisors, AHC committee advisors, G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: IAC compliance activities and DLA work to date.	2.00
01/08/20	GJK	Prepare for DLA Piper compliance meeting	0.50
01/08/20	GJK	Review and feedback on analysis related to Mundipharma base case model	2.00
01/08/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: Europe diligence meetings (following call with other advisors) and DLA Piper Mundipharma compliance meetings.	0.20
01/08/20	GJK	Phone call with G. Koch and N. Simon (both AlixPartners) to discuss key take away from Mundipharma compliance meeting with DLA Piper.	0.20
01/08/20	GJK	Europe diligence meeting coordination call with G. Koch, N. Simon (both AlixPartners), I. McClatchey (Norton Rose), J. Turner (PJT), J. Crockett (Province), P. Topper (Jefferies) and B. Bromberg (FTI).	0.50
01/08/20	MH	Prepare accounts payable release file.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/08/20	MH	Prepare second accounts payable release file at request of AP manager.	0.40
01/08/20	NAS	Research impact of opioid promotion and subsequent correspondence with G. Koch, N. Simon, and H. Ku (all AlixPartners) regarding initial observations.	0.60
01/08/20	NAS	Revise Mundipharma business plan model to include joint ventures and intercompany eliminations.	1.40
01/08/20	NAS	Phone call with G. Koch and N. Simon (both AlixPartners) to discuss key take away from Mundipharma compliance meeting with DLA Piper.	0.20
01/08/20	NAS	Revise Mundipharma business plan model to include corporate functions.	1.00
01/08/20	NAS	Europe diligence meeting coordination call with G. Koch, N. Simon (both AlixPartners), I. McClatchey (Norton Rose), J. Turner (PJT), J. Crockett (Province), P. Topper (Jefferies) and B. Bromberg (FTI).	0.50
01/08/20	NAS	Incorporate adjustments to roll-up pages of Mundipharma business plan model in order to tie to figures included in EY Mundipharma Vendor Due Diligence report.	0.30
01/08/20	NAS	Create consolidated financial roll-up tab in Mundipharma business plan model and check relative to figures included in EY Mundipharma Vendor Due Diligence report.	1.10
01/08/20	NAS	Partial attendance (via phone) meeting with DLA Piper, UCC committee advisors, AHC committee advisors, G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: IAC compliance activities and DLA work to date.	1.10
01/08/20	NAS	Incorporate adjustments to Mundipharma business plan model to call out and compensate for data discrepancies/omissions in latest draft of EY Vendor Due Diligence report.	1.90
01/08/20	NAS	Provide summary and latest draft of Mundipharma	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan model to G. Koch and H. Ku (both AlixPartners).	
01/08/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: Europe diligence meetings (following call with other advisors) and DLA Piper Mundipharma compliance meetings.	0.20
01/08/20	IA	Meeting with E. Vonnegut and D. Consla (Davis Polk), K. Laurel and J. Lowne (both Purdue), J. DelConte, and I. Arana (both AlixPartners) re: 2020 corporate objectives and 2020 incentive compensation program.	1.40
01/08/20	IA	Review proposed updated 2020 corporate objectives scorecard.	0.90
01/08/20	JD	Participate in Board special committee meeting.	0.80
01/08/20	JD	Meeting with E. Vonnegut and D. Consla (Davis Polk), K. Laurel and J. Lowne (both Purdue), J. DelConte, and I. Arana (both AlixPartners) re: 2020 corporate objectives and 2020 incentive compensation program.	1.40
01/08/20	JD	Meeting with DLA Piper, UCC committee advisors, AHC committee advisors, G. Koch, J. DelConte, and N. Simon (all AlixPartners) re: IAC compliance activities and DLA work to date.	2.00
01/08/20	JD	Conversation with J. Lowne (Purdue) and R. Schnitzler (PJT) re: Rhodes business plan update.	0.50
01/08/20	JD	Review of data room files to identify confidential and competitively sensitive information with A. DePalma and J. DelConte (both AlixPartners)	1.20
01/08/20	JD	Review data room files re: confidentiality and protective order designations.	1.50
01/08/20	JD	Correspondence and conversations with C. Robertson, C. McMillian and K. Benedict (all Davis Polk) re: sharing information with AHC and UCC committee members on	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		potential business opportunity.	
01/08/20	JD	Review set of potential 2020 corporate objectives.	0.40
01/08/20	JD	Review draft PPI / PRA partnership agreement.	0.50
01/08/20	JD	Review correspondence re: IAC diligence and compliance issues.	0.40
01/08/20	RDS	Meeting with D. Lundie, J. Lowne, B. Weingarten, P. Mederios (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP leadership workshop findings	1.30
01/08/20	RDS	Attend RALP Executive Leadership session Day 2 with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblan, D. McGuire etc. (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	6.00
01/08/20	RDS	Prepare slides and summary scenario slides for J. Lowne (Purdue) meeting	1.10
01/08/20	RDS	Prepare for meetings with Rhodes Pharma business development projects.	0.40
01/08/20	RDS	Prepare slides and update Rhodes Pharma pipeline metrics including outside spend analysis	0.80
01/08/20	KM	Attend RALP Executive Leadership session Day 2 with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblan, D. McGuire etc. (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	6.00
01/08/20	KM	Meeting with D. Lundie (Purdue) re: RALP leadership workshop Day 2 agenda and meeting cadence planning	0.70
01/08/20	KM	Prepare RALP leadership workshop document re: Day 2 document edits and changes	0.80
01/08/20	KM	Prepare RALP leadership workshop document re: changes to scenario planning and valuation from the workshop	1.00
01/08/20	KM	Meeting with D. Lundie, J. Lowne, B. Weingarten, P. Mederios (all Purdue), J. DelConte, K. McCafferty, and R.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Sublett (all AlixPartners) re. RALP leadership workshop findings	
01/08/20	KM	Analysis preparation re: Rhodes Tech and Rhodes Pharma site visits on Jan 9 2020	0.40
01/08/20	ADD	Review of data room files to identify confidential and competitively sensitive information with A. DePalma and J. DelConte (both AlixPartners)	1.20
01/08/20	DS	Create footnotes for following schedules in November Customer Programs report: Medicaid Rebates, Medicare Part D rebates, GPO Fee Payments	0.70
01/08/20	DS	Review of Deloitte fees for GPO chargeback processing	0.50
01/08/20	DS	Compile outline of key items for November Customer Programs report and send to management for review	0.80
01/08/20	DS	Update for November Customer Programs report for edit requested by head of rebates (Purdue)	1.10
01/08/20	DS	Assemble an entity breakout of amounts in draft November Customer Programs report to aid in management's review	0.90
01/08/20	DS	Redact specific counterparty names for November Customer Programs report (and replace with generic references), creating an index to keep generic references internally consistent between multiple schedules in the report	2.80
01/08/20	DS	Prepare Customer Programs Reporting Summary for report	0.60
01/09/20	DS	Draft email to management with key consideration points for redacted version of November Customer Programs report	0.80
01/09/20	DS	Correspondence with C. Robertson and C. McMillian (both Davis Polk) re: redaction of November Customer Programs report in context of impending protective order	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/09/20	KM	Analysis preparation re: Rhodes Tech and Rhodes Pharma headcount breakdown	1.20
01/09/20	KM	Analysis review and augmentation with R. Shamblen, D. Fogel, W. DiNicola, D. Shell (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech headcount	1.60
01/09/20	KM	Meeting with D. Shell, R. Shamblan, D. Fogel, W. DiNicola, A. Soma (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Tech organization structure reconciliation	1.50
01/09/20	KM	Meeting with D. Shell, R. Shamblan, D. Fogel, W. DiNicola (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech direct labor and staffing model	1.70
01/09/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: finance impacts to the budget	1.60
01/09/20	KM	Analysis review and augmentation with V. Mancinelli, D. Fogel, W. DiNicola, D. Shell (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma product pipeline and supporting headcount	2.10
01/09/20	RDS	Discussion with J. DelConte and R. Sublett (both AlixPartners) re: Rhodes business plan model	0.20
01/09/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: finance impacts to the budget	1.60
01/09/20	RDS	Prepare org charts and presentation slides for discussions with Rhodes management on cost reductions	0.40
01/09/20	RDS	Call with D. Lundie (Purdue) re: supply partnership agreement modeling	0.10
01/09/20	RDS	Analysis review and augmentation with V. Mancinelli, D.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/09/20	RDS	Fogel, W. DiNicola, D. Shell (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma product pipeline and supporting headcount	1.50
01/09/20	RDS	Meeting with D. Shell, R. Shamblan, D. Fogel, W. DiNicola, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech organization structure reconciliation	1.60
01/09/20	RDS	Analysis review and augmentation with R. Shamblan, D. Fogel, W. DiNicola, D. Shell (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech headcount	1.70
01/09/20	RDS	Meeting with D. Shell, R. Shamblan, D. Fogel, W. DiNicola (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech direct labor and staffing model	0.50
01/09/20	RDS	Discussion with R. Haberman (Purdue) re: Rhodes Pharma budgeting requirements	0.50
01/09/20	JD	Review audit memo prepared by the company re: PPI receivable	0.40
01/09/20	JD	Correspondence with management and Davis Polk re: settlement payments.	0.20
01/09/20	JD	Discussion with J. DelConte and R. Sublett (both AlixPartners) re: Rhodes business plan model	1.20
01/09/20	NAS	Review and comment on draft materials pulled together in response to open committee diligence questions.	0.90
01/09/20	NAS	Correspondence with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) and research into Mundipharma opioid promotion.	1.10
01/09/20	NAS	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		analyses.	
01/09/20	NAS	Review Mundipharma China compliance materials prepared by DLA Piper and correspondence with UCC and Ad-Hoc Committee advisors regarding follow-ups.	0.80
01/09/20	NAS	Review list of questions to be submitted to EY regarding Mundipharma Vendor Due Diligence report and add questions where necessary.	0.50
01/09/20	NAS	Revise Mundipharma business plan model in order to add additional scenario analyses and refine assumptions.	2.40
01/09/20	NAS	Draft Mundipharma diligence talking points in advance of 1/10 AlixPartners engagement team update call.	0.50
01/09/20	MH	Prepare for and participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson (both Davis Polk), M. Hartley, L. Donahue, G. Koch, J. DelConte (all AlixPartners), J. Lowne, and M. Kesselman (both Purdue) re: case update and go forward plan.	0.60
01/09/20	MH	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	1.10
01/09/20	MH	Meeting with legal operations to develop tracking of payments to Ordinary Course Professional firms.	1.30
01/09/20	MH	Run new reconciliation of critical vendor tracking with all source documents.	1.40
01/09/20	MH	Prepare accounts payable release file.	0.60
01/09/20	GJK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	1.10
01/09/20	GJK	DLA Piper compliance items follow up, including feedback from other financial advisors	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/09/20	GJK	Mundipharma balance sheet and cash flow review	1.00
01/09/20	GJK	Project coordination, and workstream updates	1.00
01/09/20	LJD	Prepare for and participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson (both Davis Polk), M. Hartley, L. Donahue, G. Koch, J. DelConte (all AlixPartners), J. Lowne, and M. Kesselman (both Purdue) re: case update and go forward plan.	0.60
01/09/20	HK	Review risk assessment on LAM budget presentations.	1.90
01/09/20	HK	Update to running list of questions for EY on draft Quality of Earnings reports.	1.80
01/09/20	HK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	1.10
01/09/20	HK	Update draft Mundipharma business overview summary.	0.60
01/10/20	HK	Update draft Mundipharma business overview summary.	2.30
01/10/20	HK	Update Mundipharma due diligence request tracker with documents reviewed in Norton Rose data site.	1.40
01/10/20	GJK	Meeting with G. Koch and M. Hartley (both AlixPartners) to review status of IAC diligence and determine work priorities going forward.	0.50
01/10/20	GJK	London trip document/background preparation	2.00
01/10/20	GJK	Materials review/preparation for Mundipharma meetings	2.70
01/10/20	MH	Build initial test model of tracking for Ordinary Course Professionals.	2.90
01/10/20	MH	Review new invoices for settled Critical Vendors to determine proper treatment.	0.70
01/10/20	MH	Meeting with G. Koch and M. Hartley (both AlixPartners) to review status of IAC diligence and determine work priorities going forward.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/10/20	MH	Reconcile all legal firms in OCP tracking with legal operations.	0.90
01/10/20	MH	Respond to critical vendor question regarding application of deposits to pre-petition invoices.	0.30
01/10/20	NAS	Review new Mundipharma materials posted in data room in preparation for Mundipharma Europe management meetings starting 1/13.	1.80
01/10/20	IA	Review updated retention tracker reflecting latest separations.	0.40
01/10/20	JD	Call with V. Mancinelli, D. Fogel, K. Kolar, R. Haberlin, (all Purdue), K. McCafferty, J. DelConte, and R. Sublett (both AlixPartners) re Rhodes Pharma pipeline prioritization methodology and practical next steps (partial attendance)	0.80
01/10/20	JD	Review correspondence re: review of open accounting question	0.70
01/10/20	JD	Review and comment on draft list of IAC follow ups following DLA Piper meeting.	0.40
01/10/20	JD	Discussion with R. Schnitzler (PJT) re: pushing committee advisors forward on potential business development deal.	0.30
01/10/20	JD	Review updated draft professional fee forecast for 2020.	0.70
01/10/20	RDS	Review Avrio budget documents	0.70
01/10/20	RDS	Call with V. Mancinelli, D. Fogel, K. Kolar, R. Haberlin, (all Purdue), K. McCafferty, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline prioritization methodology and practical next steps	1.90
01/10/20	RDS	Call with D. Fogel (Purdue) re R&D cost savings in Rhodes Pharma	0.30
01/10/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: back pocket AG business plan model for Rhodes	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/10/20	RDS	Aggregate Rhodes headcount and cost reduction plan and slide creation and discussion.	0.50
01/10/20	RDS	Call with V. Mancinelli, D. Fogel, M. Sisodia, etc. (all Purdue) re: Levorphenol and Mixed Amphetamine Salts development modeling discussion	1.00
01/10/20	KM	Call with V. Mancinelli, D. Fogel, K. Kolar, R. Haberin, (all Purdue), K. McCafferty, J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline prioritization methodology and practical next steps (partial attendance)	1.20
01/10/20	KM	Analysis re: Rhodes product pipeline prioritization and valuation	0.80
01/10/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: back pocket AG business plan model for Rhodes (partial attendance)	0.30
01/10/20	ADD	Prepare for team update call.	0.70
01/10/20	ADD	Review supporting documentation for charitable contributions provided in response to diligence request.	3.10
01/10/20	ADD	Compile and upload documentation in response to diligence requests to the data room.	2.70
01/10/20	ADD	Request approval to upload documentation submitted in response to diligence requests to the data room.	0.80
01/12/20	RDS	Review Wilson 2020 Objectives	0.40
01/12/20	NAS	Review Mundipharma Europe diligence materials in advance of management meetings.	0.60
01/12/20	HK	Update Mundipharma due diligence request tracker with documents reviewed in Norton Rose data site.	1.30
01/13/20	HK	Update Mundipharma due diligence request tracker with documents reviewed in Norton Rose data site.	2.10
01/13/20	HK	Update draft Mundipharma business overview summary.	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/13/20	MH	Call with A. DePalma and M. Hartley (both AlixPartners) to discuss diligence request for charitable payments.	0.30
01/13/20	MH	Review status of IAC diligence and determine work priorities going forward.	0.50
01/13/20	MH	Create accounts payable release files.	0.40
01/13/20	MH	Reconcile all vendor activity with tracking and control systems.	1.80
01/13/20	GJK	Mundipharma Europe diligence meeting with B. Lea (Mundipharma General Counsel), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/13/20	GJK	Mundipharma Europe diligence meeting with S. Lopez (Mundipharma GM Switzerland and Austria), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/13/20	GJK	Mundipharma Europe diligence meeting with P. Mazas (Mundipharma Information Technology), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.50
01/13/20	GJK	Mundipharma Europe diligence meeting with N. Trueman (Mundipharma Intellectual Property), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.50
01/13/20	GJK	Prepare notes related to Mundipharma Monday meetings	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/13/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners), M. Diaz, and B. Bromberg (both FTI) re: key take aways from 1/13 Mundipharma Europe management meetings and current outlook on diligence process.	0.50
01/13/20	NAS	Review of Mundipharma IT and Legal/Compliance materials in advance of 1/13 management meetings.	0.40
01/13/20	NAS	Mundipharma Europe diligence meeting with B. Lea (Mundipharma General Counsel), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/13/20	NAS	Mundipharma Europe diligence meeting with S. Lopez (Mundipharma GM Switzerland and Austria), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/13/20	NAS	Mundipharma Europe diligence meeting with P. Mazas (Mundipharma Information Technology), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.50
01/13/20	NAS	Mundipharma Europe diligence meeting with N. Trueman (Mundipharma Intellectual Property), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.50
01/13/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners), M. Diaz, and B. Bromberg (both FTI) regarding key take	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/13/20	IA	aways from 1/13 Mundipharma Europe management meetings and current outlook on diligence process.	1.90
01/13/20	IA	Review of legal payments since filing in cash actuals report and follow up with company on reporting requirements against OCP caps.	2.70
01/13/20	IA	Follow up on diligence requests on CEO compensation in preparation to file second wages reply.	0.40
01/13/20	IA	Follow up on updated Purdue weekly sales report.	0.90
01/13/20	IA	Draft updated report and follow up on approvals for post-filing separations report to be shared with the committees.	1.30
01/13/20	IA	Follow up on end of year accruals for AdHoc and UCC advisors as requested by the company.	1.60
01/13/20	JD	Review report 1b, review comments from management and discuss same with management.	0.50
01/13/20	JD	Review various PHI agreements that could be shared with the UCC.	0.90
01/13/20	JD	Review various insurance documents pulled together to share with the UCC. Review recently posted insurance materials.	0.20
01/13/20	JD	Review updated post-filing separations report.	1.40
01/13/20	JD	Review summary list and actual personal injury complaints pulled together to share with the UCC. Correspondence with Davis Polk re: same.	0.80
01/13/20	RDS	Meeting with D. McGuire and J. Carlisle (both Purdue) re: budget implementation for the week	0.70
01/13/20	RDS	Meeting with J. Carlisle (Purdue) re: unit dose contribution figures	1.00
01/13/20	RDS	End to end Rhodes Pharma gross profit analysis -Oxy APAP	



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/13/20	RDS	Call with Rhodes and NC finance organization re: weekly timelines and objectives	0.60
01/13/20	RDS	Analysis review and augmentation with R. Shamblen, D. Fogel, W. DiNicola, D. Shell, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech direct labor staffing models	2.00
01/13/20	RDS	Rhodes Pharma pipeline discussion with K. Kolar and D. Ebere (both Purdue)	2.00
01/13/20	RDS	Prepare Avrio historical budgeting reconciliation report	0.40
01/13/20	RDS	Analysis of North Carolina supply chain	0.30
01/13/20	RDS	Rhodes tech pipeline slide creation	0.50
01/13/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.50
01/13/20	RDS	Day recap call with D. Lundi (Purdue) re: Budget targets	0.60
01/13/20	ADD	Call with A. DePalma, and M. Hartley (both AlixPartners) to discuss diligence request for charitable payments	0.30
01/13/20	KM	Meeting with K. Kolar and D. Ebere (both Purdue) re: Rhodes Pharma pipeline discussion	2.30
01/13/20	KM	Meeting with W. DiNicola and D. Fogel (both Purdue) re: Rhodes Technologies opportunities	1.30
01/13/20	KM	Meeting with K. Kolar and D. Fogel (both Purdue) re: Rhodes Pharma pipeline financial analysis	1.70
01/13/20	ADD	Review supporting documentation for charitable contributions provided in response to diligence request.	2.60
01/13/20	ADD	Request approval to upload documentation provided in response to diligence requests to the data room.	0.60
01/13/20	ADD	Compile and upload documentation in response to diligence requests to the data room.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/13/20	ADD	Review data room files for potential redactions under new protective order.	1.40
01/13/20	KM	Analysis preparation re: Rhodes Tech and Rhodes Pharma site visit on Jan 13 2020	1.50
01/13/20	KM	Analysis review and augmentation with R. Shamblen, D. Fogel, W. DiNicola, D. Shell, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech direct labor staffing models	2.00
01/13/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.50
01/13/20	DS	Draft list of outstanding items for December Customer Programs report for Rhodes	0.50
01/13/20	DS	Draft list of outstanding items for December Customer Programs report for Purdue	0.70
01/13/20	DS	Prepare list of requests for Rebates Manager (Purdue) for December Customer Programs report	0.30
01/14/20	DS	Working session with D. Samikkannu, I. Arana, S. Lemack, and A. DePalma (all AlixPartners) to discuss committees' IAC data request	0.30
01/14/20	DS	Review of data sources and reports to evaluate whether possible to provide historical IAC receipts as requested by committee advisors	2.20
01/14/20	DS	Review of OSF lease presentations and documents to gain background for presentation to committees	1.60
01/14/20	DS	Review of IAC entities listing provided by EY	0.30
01/14/20	DS	Compose list of questions for Treasurer (Purdue) re: OSR draft deck	0.80
01/14/20	DS	Put together slides for draft OSR materials, updating	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		analyses as appropriate	
01/14/20	KM	Call with D. Fogel, R. Haberin, K. Kolar, D. Eber (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline headcount allocation	2.00
01/14/20	KM	Call with D. Fogel, R. Haberin, K. Kolar, D. Eber (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline	1.00
01/14/20	KM	Analysis with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline resource allocation model	1.50
01/14/20	KM	Meeting with J. Northington (Purdue) re: Quality organization structure	2.80
01/14/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.80
01/14/20	KM	Discussion with D. Lundie (Purdue) re: RALP operating opportunities	0.20
01/14/20	KM	Document preparation re: RALP operating opportunities for discussion with C. Landau	2.10
01/14/20	ADD	Working session with D. Samikkannu, I. Arana, S. Lemack, and A. DePalma (all AlixPartners) to discuss committees' IAC data request.	0.30
01/14/20	ADD	Review documentation for upload to the data room for any outside markings or writing/analysis at the direction of Davis Polk.	2.80
01/14/20	ADD	Add individuals to the data room and adjusted data room permissions.	0.70
01/14/20	ADD	Review of files in data room for potential redactions as part of the designation process.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/14/20	ADD	Compile and upload documentation to data room.	2.40
01/14/20	RDS	Update volume communication between Rhodes Tech, Rhodes Pharma and NC staff to coordinate budget procedures	0.80
01/14/20	RDS	Review of Rhodes Technology standard cost and idle capacity modeling	1.30
01/14/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.80
01/14/20	RDS	Call with D. Fogel, R. Haberin, K. Kolar, D. Eber (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline headcount allocation	2.00
01/14/20	RDS	Nalmefene API sourcing decision making process - review Purdue material and model ROI from proposed strategy	0.50
01/14/20	RDS	Call with D. Fogel, R. Haberin, K. Kolar, D. Eber (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline	1.00
01/14/20	RDS	Meeting with D. Lundie (Purdue) in partnership strategy to derisk manufacturing	1.00
01/14/20	RDS	Analysis with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline resource allocation model	1.50
01/14/20	RDS	Analysis of Nalmefene API sourcing	0.80
01/14/20	RDS	Meeting with J. Northington (Purdue) re: quality organization function in various volume scenarios and with systems improvements	1.80
01/14/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/14/20	JD	Finish initial review of report 1b.	1.70
01/14/20	JD	Correspondence with PJT re: UCC and AHC IAC related diligence requests.	0.50
01/14/20	JD	Review previous iterations of OSR board presentations to pull together outline of committee presentation on potential new lease with OSR.	1.30
01/14/20	JD	Review draft 2020 corporate objectives scorecard. Correspondence with management and Davis Polk re: same.	0.70
01/14/20	JD	Review update on Rhodes business planning process. Review updated work plan and progress to date.	0.60
01/14/20	IA	Follow up on additional information requests and updating of actual spend in support of upcoming hearing on CEO comp.	2.20
01/14/20	IA	Follow up and update professional fees forecast and actuals accruals based on budgets received from committee advisors.	1.50
01/14/20	IA	Review updated January MCO rebate forecast for Purdue prepared by the company.	1.30
01/14/20	IA	Review CEO T&E information for 2018-2019 summaries provided to committees.	1.10
01/14/20	IA	Reconcile Purdue commercial rebate payments to be paid through third party vendor to funding requests and company forecast to update timing assumptions in Purdue 13-week cash forecast model.	2.20
01/14/20	IA	Review of historical information collected on IAC receipts through cash actuals tracking process in response to committees' requests.	1.70
01/14/20	IA	Working session with D. Samikkannu, I. Arana, S. Lemack, and A. DePalma (all AlixPartners) to discuss committees' IAC data request	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/14/20	NAS	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to review legal entity level, country level, and consolidated P&Ls.	3.00
01/14/20	NAS	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to review entrepreneur/limited risk distributor transfer pricing structure.	2.00
01/14/20	NAS	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to discuss remaining questions on Mundipharma P&Ls.	2.00
01/14/20	NAS	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to review bank balance summary of Mundipharma cash positions.	2.00
01/14/20	GJK	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province,	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Jefferies) to review bank balance summary of Mundipharma cash positions.	
01/14/20	GJK	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to review legal entity level, country level, and consolidated P&Ls.	3.00
01/14/20	GJK	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to discuss remaining questions on Mundipharma P&Ls.	2.00
01/14/20	GJK	Mundipharma Europe diligence meeting with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) to review entrepreneur/limited risk distributor transfer pricing structure.	2.00
01/14/20	GJK	Prepare notes and coordination re: Tuesday Mundipharma meetings	0.50
01/14/20	LJD	Prepare for and attend update call with DPW	0.40
01/14/20	MH	Meeting with M. Hartley and H. Ku (both AlixPartners) to prepare presentation overview for Mundipharma businesses.	0.50
01/14/20	MH	Coordinate with accounts payable to effect partial payment of a vendor.	0.40
01/14/20	MH	Review draft of Malta summary presentation.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/14/20	MH	Follow up with vendor contacts on aged trade agreements to update critical vendor estimates.	1.70
01/14/20	MH	Create release files for accounts payable including manual releases of specific invoices.	0.80
01/14/20	HK	Meeting with M. Hartley and H. Ku (both AlixPartners) to prepare presentation overview for Mundipharma businesses.	0.50
01/14/20	SKL	Working session with D. Samikkannu, I. Arana, S. Lemack, and A. DePalma (all AlixPartners) to discuss committees' IAC data request	0.30
01/14/20	HK	Update draft Mundipharma business overview summary.	2.20
01/15/20	HK	Update draft Mundipharma business overview summary.	2.40
01/15/20	MH	Reconcile accounts payable for transportation vendor to ensure accurate estimates for critical vendor.	0.70
01/15/20	MH	Review Malta strawman financial summary presentation.	0.90
01/15/20	MH	Update critical vendor tracking report.	1.20
01/15/20	MH	Create accounts payable release file.	0.40
01/15/20	MH	Create two additional accounts payable releases upon special requests.	0.60
01/15/20	GJK	Mundipharma Europe diligence meeting with F. Bongenaar (Mundipharma GM Netherlands and Belgium), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.50
01/15/20	GJK	Mundipharma Europe diligence meeting with D. Bell (Mundipharma Head of Quality), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province,	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Jefferies).	
01/15/20	GJK	Mundipharma Europe diligence meeting with S. Cremascoli (Mundipharma GM Italy), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/15/20	GJK	Mundipharma Europe diligence meeting with J. Alvarado (Mundipharma GM Spain), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/15/20	GJK	Call with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), R. Schnitzler, M. Diaz, and B. Bromberg (all FTI) to address additional follow-up questions re: Mundipharma Europe P&Ls provided.	0.50
01/15/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) regarding next steps in Mundipharma diligence process following Europe management meetings.	0.40
01/15/20	NAS	Mundipharma Europe diligence meeting with F. Bongenaar (Mundipharma GM Netherlands and Belgium), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.50
01/15/20	NAS	Mundipharma Europe diligence meeting with D. Bell (Mundipharma Head of Quality), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI,	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/15/20	NAS	Houlihan Lokey), and advisors to UCC (Province, Jefferies). Discussion with G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) regarding next steps in Mundipharma diligence process following Europe management meetings.	0.40
01/15/20	NAS	Mundipharma Europe diligence meeting with J. Alvarado (Mundipharma GM Spain), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/15/20	NAS	Mundipharma Europe diligence meeting with S. Cremascoli (Mundipharma GM Italy), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/15/20	NAS	Call with S. Jamieson (Management Revisions), G. Koch, N. Simon (both AlixPartners), R. Schnitzler, M. Diaz, and B. Bromberg (all FTI) to address additional follow-up questions re: Mundipharma Europe P&Ls provided.	0.50
01/15/20	NAS	Consolidate key take aways and follow-up items from Mundipharma Europe management meetings on 1/13 through 1/15.	0.40
01/15/20	IA	Review of weekly sales by product reporting for Purdue	0.70
01/15/20	IA	Follow up on request from UCC to provide historical information for employees who have held insider titles.	1.60
01/15/20	IA	Meeting with C. Destefano (Purdue) and her team to discuss VP compensation and 2019 AIP payment	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		calculations.	
01/15/20	IA	Update LTRP payments by employee calculation to reflect estimated factor for Purdue, to be used by management for end of year accruals.	1.30
01/15/20	IA	Follow up on professional fees 2020 budget and end of year accruals requested by the company from committee advisors.	0.60
01/15/20	IA	Follow up on additional information requests and updating of actual spend in support of upcoming hearing on CEO comp.	2.70
01/15/20	JD	Prepare for and participate in call re: planning work streams for PBC conversion with T. Melvin (PJT), R. Aleali (Purdue), C. Robertson, E. Diggs and others (all Davis Polk).	1.00
01/15/20	JD	Review initial draft OSR deck. Provide comments re: same.	1.30
01/15/20	JD	Correspondence with PJT and Davis Polk re: professional fee actuals for 2019 and forecast for 2020.	0.50
01/15/20	JD	Review draft Rhodes scorecard and Rhodes business plan objectives.	0.60
01/15/20	JD	Review comments from management on report.	0.60
01/15/20	RDS	Call with D. Fogel, R. Haberin, K. Kolar, D. Ebere (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline	1.50
01/15/20	RDS	Review internal Rhodes Pharma R&D allocation mode	0.20
01/15/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	0.90
01/15/20	RDS	Meeting with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: supply chain org structure	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		efficiencies	
01/15/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.50
01/15/20	RDS	Slide sketching for C. Landau presentation Monday and strategy inversion.	0.50
01/15/20	RDS	Analysis of Rhodes Pharma run rate R&D spend and impact of project rationalization output	1.40
01/15/20	RDS	Slide creation: strategic pillars and exogenous market conditions for RALP	0.70
01/15/20	RDS	Slide creation: Rhodes Pharma pipeline rationalization	0.70
01/15/20	RDS	Review Rhodes strategic positioning presentation and management shakeup strategy	0.50
01/15/20	RDS	Meeting with D. Lundie (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy	0.50
01/15/20	KM	Call with D. Fogel, W. DiNicola, R. Haberlin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.50
01/15/20	KM	Meeting with B. Evans (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: supply chain org structure efficiencies	0.50
01/15/20	KM	Meeting with D. Lundie (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy	0.50
01/15/20	KM	Perform analysis re: integrated RALP Quality synergies	1.50
01/15/20	KM	Meeting with J. Northington (Purdue) re: Quality organization structure	0.80
01/15/20	KM	Perform analysis re: updating and reprioritizing Rhodes Pharma pipeline NPV	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/15/20	KM	Document creation re: RALP strategies and FCF opportunities for presentation to C. Landau	2.10
01/15/20	KM	Perform analysis re: Rhodes Pharma pipeline NPV	1.50
01/15/20	KM	Call with D. Fogel, R. Haberin, K. Kolar, D. Ebere (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma pipeline	1.50
01/15/20	ADD	Add individuals to the data room at request of Davis Polk.	0.40
01/15/20	ADD	Review documentation for upload to the data room for any outside markings or writing/analysis at the direction of Davis Polk.	2.10
01/15/20	ADD	Upload documentation responsive to diligence requests to the data room.	1.10
01/15/20	ADD	Compile and format files in response to diligence request for upload to the data room.	3.10
01/15/20	DS	Meeting with Treasurer (Purdue) re: comments on OSF draft materials	0.40
01/15/20	DS	Review and edit draft OSF materials	1.10
01/15/20	DS	Update Treasurer's model for OSF draft materials	1.40
01/15/20	DS	Revise slides based on discussion with Treasurer (Purdue)	1.20
01/15/20	DS	Draft comprehensive list of key issues and open items based on revisions made to OSF deck	1.70
01/15/20	DS	Draft email to CFO (Purdue) of key items in OSF deck	0.50
01/15/20	DS	Review and update OSF materials for data received by Treasurer (Purdue)	1.40
01/16/20	DS	Incorporate CFO's comments into OSF lease materials	2.10
01/16/20	DS	Call with Imbrium analyst re: cash flow calculations in OSF lease materials	0.30
01/16/20	DS	Update prepaid rent and rent return in cash flow schedule in OSF lease materials	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/16/20	DS	Revise illustrative term length in cash flow comparative analysis in OSF lease materials	0.80
01/16/20	DS	Update comments in cash flow comparative slide in OSF lease materials	1.40
01/16/20	DS	Correspondence with C. Robertson (Davis Polk) re: OSF lease materials	0.40
01/16/20	ADD	Compile and format files in response to diligence request for upload to the data room.	2.70
01/16/20	KM	Review of slides for CEO presentation and correspondence to keep projects on target to build additional data into said slides with K. McCafferty and R. Sublett (both AlixPartners)	0.50
01/16/20	KM	Call with K. McCafferty, R. Sublett, L. Donahue, J. DelConte (all AlixPartners), and D. Fogel (Purdue) re: Rhodes Pharma R&D project level spend	0.70
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): shift in strategy for gx business	0.50
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): Rhodes Pharma pipeline cut methodology	1.00
01/16/20	KM	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency with K. McCafferty and R. Sublett (both AlixPartners)	1.30
01/16/20	KM	Discuss cost reduction strategy and AlixPartners role in creating implementation plan with K. McCafferty and R. Sublett (both AlixPartners)	0.40
01/16/20	KM	Update call with K. McCafferty, R. Sublett (both AlixPartners), and D. Fogel (Purdue) on presentation status ahead of meeting	1.00
01/16/20	KM	Meeting with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel, D. Lundie, J. Giordano (all	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue) re: presentation materials for Monday CEO presentation	
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): Rhodes technology pipeline	0.70
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): partnership strategy shift	0.40
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): generic industry dynamics and the impact on Rhodes	1.10
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): summary of strategic and tactical changes and process of decision making	1.30
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP impacts on the Purdue business strategy and cash flow	0.50
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP headcount charts - function aggregation, spans of control, Direct: Indirect	1.10
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP financial makeup commentary and bridges	0.70
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): elimination of negative gross profit products	1.00
01/16/20	KM	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): quarterly transformation implementation plan in broad strokes	1.20
01/16/20	RDS	Review of slides for CEO presentation and correspondence to keep projects on target to build additional data into said slides with K. McCafferty and R. Sublett (both AlixPartners)	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/16/20	RDS	Call with K. McCafferty, R. Sublett, L. Donahue, J. DelConte (all AlixPartners), and D. Fogel (Purdue) re: Rhodes Pharma R&D project level spend	0.70
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): shift in strategy for gx business	0.50
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): Rhodes Pharma pipeline cut methodology	1.00
01/16/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency with K. McCafferty and R. Sublett (both AlixPartners)	1.30
01/16/20	RDS	Discuss cost reduction strategy and AlixPartners role in creating implementation plan with K. McCafferty and R. Sublett (both AlixPartners)	0.40
01/16/20	RDS	Update call with K. McCafferty, R. Sublett (both AlixPartners), and D. Fogel (Purdue) on presentation status ahead of	1.00
01/16/20	RDS	Meeting with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel, D. Lundie, J. Giordano (all Purdue) re: presentation materials for Monday CEO presentation	1.80
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): Rhodes technology pipeline	0.70
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): partnership strategy shift	0.40
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): generic industry dynamics and the impact on Rhodes	1.10
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): summary of strategic and tactical changes and process of decision making	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP impacts on the Purdue business strategy and cash flow	0.50
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP headcount charts - function aggregation, spans of control, Direct: Indirect	1.10
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): RALP financial makeup commentary and bridges	0.70
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): elimination of negative gross profit products	1.00
01/16/20	RDS	Slide creation with K. McCafferty and R. Sublett (both AlixPartners): quarterly transformation implementation plan in broad strokes	1.20
01/16/20	JD	Call with K. McCafferty, R. Sublett, L. Donahue, J. DelConte (all AlixPartners), and D. Fogel (Purdue) re: Rhodes Pharma R&D project level spend	0.70
01/16/20	JD	Review and comment on latest list of historical insider employees.	0.40
01/16/20	JD	Review and comment on tax diligence request. Discuss same with Davis Polk.	0.90
01/16/20	JD	Correspondence with management re: professional fee accruals.	0.30
01/16/20	JD	Review employee communication from management.	0.30
01/16/20	JD	Review and comment on the latest update to the OSR lease presentation to share with the committee and review historical board presentations.	1.20
01/16/20	JD	Participate in weekly update call with L. Donahue, B. Folse, J. DelConte, M. Hartley (all AlixPartners), PJT, Davis Polk, and management.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/16/20	JD	Review and comment on the latest wage motion reply.	0.90
01/16/20	IA	Follow up on requests from Davis Polk related to CEO compensation data to corroborate numbers provided by objecting states.	2.60
01/16/20	IA	Review of insider compensation agreement with committees and upcoming payments for AIP bonuses.	0.40
01/16/20	IA	Prepare summary of wages and benefit payments to be included in Rhodes and Purdue 13-week cash forecast.	2.30
01/16/20	NAS	Tour of Mundipharma Bard manufacturing facility and quality control operation with G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/16/20	NAS	Mundipharma Europe diligence meeting with B. Kudlek, G. Rosetti (both Mundipharma Technical Operations), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.10
01/16/20	NAS	Mundipharma Europe diligence meeting with H. Day, W. Johnson (both Napp UK), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/16/20	NAS	Mundipharma Europe diligence meeting with A. Fogstrup (Mundipharma GM Germany), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/16/20	NAS	Correspondence with M. Hartley, G. Koch, N. Simon, and H. Ku (all AlixPartners) regarding Mundipharma opioid sales projections.	0.20
01/16/20	GJK	Tour of Mundipharma Bard manufacturing facility and quality control operation with G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/16/20	GJK	Mundipharma Europe diligence meeting with B. Kudlek, G. Rosetti (both Mundipharma Technical Operations), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.10
01/16/20	GJK	Mundipharma Europe diligence meeting with A. Fogstrup (Mundipharma GM Germany), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.70
01/16/20	GJK	Mundipharma Europe diligence meeting with H. Day, W. Johnson (both Napp UK), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	1.80
01/16/20	LJD	Participate in weekly update call with L. Donahue, B. Folse, J. DelConte, M. Hartley (all AlixPartners), PJT, Davis Polk, and management.	0.50
01/16/20	LJD	Call with K. McCafferty, R. Sublett, L. Donahue, J. DelConte (all AlixPartners), and D. Fogel (Purdue) re:	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Rhodes Pharma R&D project level spend	
01/16/20	BF	Participate in weekly update call with L. Donahue, B. Folse, J. DelConte, M. Hartley (all AlixPartners), PJT, Davis Polk, and management.	0.40
01/16/20	MH	Participate in weekly update call with L. Donahue, B. Folse, J. DelConte, M. Hartley (all AlixPartners), PJT, Davis Polk, and management.	0.50
01/16/20	MH	Reconcile accounts payable balances for remaining critical vendor candidates.	1.70
01/16/20	MH	Assist in preparation of a free cash flow summary of analgesics in the international business.	1.00
01/16/20	MH	Update legal vendor release files to reconcile with latest Ordinary Course Professional status.	0.50
01/16/20	HK	Update draft Mundipharma business overview summary.	2.40
01/17/20	HK	Update draft Mundipharma business overview summary.	2.90
01/17/20	HK	Update draft Mundipharma products overview summary.	2.10
01/17/20	MH	Review all vendor due diligence files for Malta project.	1.10
01/17/20	LJD	Review scorecard tied to budget assumptions and discuss	0.70
01/17/20	GJK	Mundipharma Europe diligence meeting with C. Surridge (Mundipharma SVP Business and Strategy), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/17/20	GJK	Mundipharma Europe diligence meeting with F. Bernard (Mundipharma GM France), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) and follow-up discussion with Alberto Martinez	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(CEO, Mundipharma Europe).	
01/17/20	GJK	Wrap up meeting with A. Martinez (Mundipharma)	0.50
01/17/20	GJK	Meeting with I. McClatchy (Norton Rose) and G. Parks (Huron) and advisors on next steps in diligence process	0.50
01/17/20	GJK	Mundipharma Europe diligence meeting with A. Martinez (CEO, Mundipharma Europe), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/17/20	NAS	Consolidate follow-ups and key takeaways from Mundipharma Europe management meetings from 1/16 and 1/17.	0.20
01/17/20	NAS	Mundipharma Europe diligence meeting with A. Martinez (CEO, Mundipharma Europe), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/17/20	NAS	Mundipharma Europe diligence meeting with C. Surridge (Mundipharma SVP Business and Strategy), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies).	2.00
01/17/20	NAS	Mundipharma Europe diligence meeting with F. Bernard (Mundipharma GM France), G. Koch, N. Simon (both AlixPartners), PJT, advisors to Mundipharma (Norton Rose, Huron), advisors to Ad-Hoc Committee (FTI, Houlihan Lokey), and advisors to UCC (Province, Jefferies) and follow-up discussion with Alberto Martinez (CEO, Mundipharma Europe).	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/17/20	IA	Review updated 2019 AIP payment by employee calculations and sample spreadsheets prepared by the company.	2.10
01/17/20	JD	Review draft report 1b and management comments on same.	1.60
01/17/20	JD	Review and provide comments on professional fee run rate schedule.	0.50
01/17/20	JD	Review and provide comments on the latest Rhodes business plan presentation to share with management on Monday.	1.00
01/17/20	RDS	Review and make comments to RALP transformation presentation	0.20
01/17/20	RDS	Review flip charts from RELT planning session and incorporate into presentation.	0.30
01/17/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	1.00
01/17/20	RDS	Slide creation: partnership detail	0.70
01/17/20	RDS	Slide creation: financial summary slides	0.60
01/17/20	RDS	Processing slide edits: generic market disruption	1.00
01/17/20	RDS	Call with D. Lundie, J. Giordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy presentation for C. Landau (Purdue)	1.90
01/17/20	RDS	Presentation edits with K. McCafferty and S. Sublett (both AlixPartners) to streamline messaging for Monday	2.60
01/17/20	KM	Document creation and editing re: RALP strategies and FCF opportunities for presentation to C. Landau (Purdue)	1.10
01/17/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue) re: coordinating reporting approach to account for scenario and synergy savings	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/17/20	KM	Presentation edits with K. McCafferty and S. Sublett (both AlixPartners) to streamline messaging for Monday	2.60
01/17/20	KM	Document creation and editing re: customer and product profitability	1.70
01/17/20	KM	Call with D. Lundie, J. Giordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy presentation for C. Landau (Purdue)	1.90
01/17/20	ADD	Update data room users' permissions at the request of Davis Polk.	0.70
01/17/20	ADD	Compile documentation to satisfy internal information request.	0.30
01/17/20	ADD	Request approval from the client to upload documentation submitted in response to diligence request to the data room.	0.60
01/17/20	ADD	Compile and format files submitted in response to diligence request for upload to the data room.	3.10
01/17/20	DS	Provide supporting details of negotiated prepaid rent for contemplated OSF lease	0.50
01/17/20	DS	Review professional fees summary and provide comments to S. Lemack (AlixPartners)	0.90
01/17/20	DS	Correspondence with C. Robertson (Davis Polk) re: follow up items on OSF lease materials	0.20
01/18/20	DS	Update draft OSF lease materials for comments received from Davis Polk	1.40
01/18/20	KM	Document creation and editing re: RALP strategies and FCF opportunities for presentation to C. Landau (Purdue)	2.30
01/18/20	RDS	Correspondence with D. Fogel and D. Lundie (both Purdue) re: presentation for C. Landau (Purdue)	0.90
01/18/20	RDS	Call with D. Fogel (Purdue) re: cost reduction scorecard and finance repercussions	1.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/18/20	RDS	Discussion of fixed and variable components of spend inside RALP with D. Fogel, R. Haberin, W. DiNicola (all Purdue)	1.30
01/18/20	RDS	Call with D. Fogel (Purdue) re: D. Lundie (Purdue) changes to Monday presentation materials.	0.30
01/19/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy presentation for C. Landau (Purdue) on Jan 20	1.50
01/19/20	RDS	Update Monday presentation in advance of pre-read with J. Lowne (Purdue)	0.50
01/19/20	RDS	Call with J. Lowne (Purdue) pre-read on Monday presentation to Craig	0.40
01/19/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP operations strategy presentation for C. Landau (Purdue) on Jan 20	1.50
01/19/20	LJD	Review and discuss draft business plan presentation for management review	1.40
01/20/20	LJD	Call with PJT to discuss proposal from outsider and update on call with DP	0.80
01/20/20	MH	Update call with G. Koch, and M. Hartley (both AlixPartners) on Mundipharma Europe diligence and next steps	1.00
01/20/20	MH	Review critical vendor request from legal staff for legal records vendor.	0.60
01/20/20	MH	Reconcile all partial payments to ensure completeness and accuracy.	0.40
01/20/20	MH	Create accounts payable release file.	0.90
01/20/20	GJK	Update call with G. Koch, and M. Hartley (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) on Mundipharma Europe diligence and next steps	
01/20/20	GJK	Call with G. Koch, and N. Simon (both AlixPartners) to plan for Mundipharma diligence activities for week ahead and debrief on post-London diligence updates.	0.30
01/20/20	GJK	Review of provided financials (COGS and Adjusted COGS) and potential revisions to model	2.00
01/20/20	GJK	Review of available LAM information from VDD	2.50
01/20/20	GJK	Draft of next steps in workplan	1.50
01/20/20	JD	RALP 2020 Budget presentation with C. Landau, D. Lundie, J. Lowne, D. Weingarten, D. McGuire, J. Giordanno, P. Medeiros, D. Fogel (all Purdue), K. McCafferty, J. DelConte and R. Sublett (all AlixPartners)	1.40
01/20/20	JD	Review charitable contribution documentation to provide to the committee advisors.	0.40
01/20/20	JD	Review and comment on final draft slides on Rhodes business plan prior to meeting with management.	0.60
01/20/20	JD	Follow up meeting with management after Rhodes business plan meeting.	1.20
01/20/20	JD	Review diligence questions from committee re: various IMS data pulls and correspondence with management re: same.	0.50
01/20/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to plan for Mundipharma diligence activities for week ahead and debrief on post-London diligence updates.	0.30
01/20/20	KM	Final edits and document prep re: RALP strategies and FCF opportunities for presentation to C. Landau (Purdue)	1.00
01/20/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/20/20	KM	account for scenario and synergy savings RALP 2020 Budget presentation with C. Landau, D. Lundie, J. Lowne, D. Weingarten, D. McGuire, J. Giordanno, P. Medeiros, D. Fogel (all Purdue), K. McCafferty, J. DelConte and R. Sublett (all AlixPartners)	1.40
01/20/20	KM	Meeting with D. Lundie (Purdue), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: next steps and go forward plan for RALP turnaround	1.40
01/20/20	KM	Preparation of RALP implementation plan	1.90
01/20/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: savings reconciliation for RALP improvement opportunities	1.40
01/20/20	ADD	Compile and format files submitted in response to diligence request for upload to the data room.	2.60
01/20/20	DS	Update OSF lease materials for comments received from CFO	0.40
01/20/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: savings reconciliation for RALP improvement opportunities	1.40
01/20/20	RDS	Prepare notes for further analysis ahead of board meeting next week	0.60
01/20/20	RDS	Slide creation: Appendix slide on Gx opioid pain ASP trends	0.50
01/20/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	0.50
01/20/20	RDS	RALP 2020 Budget presentation with C. Landau, D. Lundie, J. Lowne, D. Weingarten, D. McGuire, J. Giordanno, P. Medeiros, D. Fogel (all Purdue), K.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, J. DelConte and R. Sublett (all AlixPartners)	
01/20/20	RDS	Meeting with D. Lundie (Purdue), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: next steps and go forward plan for RALP turnaround	1.40
01/20/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.50
01/20/20	RDS	Reconcile NC / Rhodes Tech / Rhodes Pharma headcount to current latest staffing	1.00
01/20/20	RDS	Research & development analysis for return on investment calculations - slide update	1.40
01/21/20	RDS	Meeting with D. Lundie, J. Giordanno, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP Board presentation document structure	1.40
01/21/20	RDS	Review presentation messaging - storyboard changes due to feedback from CEO / CFO presentation on 1/20	0.70
01/21/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	1.20
01/21/20	RDS	Slide creation: messaging on critical patient care against generic drug pricing and margins	0.50
01/21/20	RDS	Meeting with D. Lundie, J. Giordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: review of latest draft of RALP presentation to Purdue Board	1.80
01/21/20	RDS	Slide creation - continuum of care underlines all our decisions around pricing and volume for generic opioids	1.20
01/21/20	RDS	Call with D. Fogel (Purdue) re: updated financials slide for board presentation	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/21/20	RDS	Re-storyboard strategy shift for board presentation	1.40
01/21/20	RDS	Slide creation - timeline of milestones for RALP transformation	1.00
01/21/20	RDS	Slide creation - opening narrative for market and internal ramifications of the PBC	1.30
01/21/20	RDS	Slide creation - bridge to cumulative cash flow savings from transformation plan	1.20
01/21/20	RDS	Presentation edits - variable costs above revenue requires new approach with fiscal responsibility	1.40
01/21/20	RDS	Scorecard review with Rhodes finance team	0.60
01/21/20	KM	Analysis re: aggregated RALP headcount	1.00
01/21/20	KM	Meeting with D. Lundie, J. Giordanno, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP Board presentation document structure	1.40
01/21/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	1.20
01/21/20	KM	Document editing and planning re: RALP presentation to Purdue Board	0.90
01/21/20	KM	Update financial analysis and reporting re: RALP presentation to Purdue Board	0.90
01/21/20	KM	Document report creation re: Patient Care POV for inclusion in RALP presentation to Purdue Board	1.60
01/21/20	KM	Meeting with D. Lundie, J. Giordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: review of latest draft of RALP presentation to Purdue Board	1.80
01/21/20	KM	Document report editing re: Patient Care POV for inclusion in RALP presentation to Purdue Board	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/21/20	KM	Document report creation re: Purdue FCF required to fund RALP - for RALP presentation to Purdue Board	1.40
01/21/20	KM	Document report creation re: impact of PBC on RALP strategy for presentation to Purdue Board	1.50
01/21/20	KM	Document update re: add latest financial information in RALP presentation to Purdue Board	1.40
01/21/20	NAS	Consolidate all data provided by Purdue for insider payments section of December 2019 Monthly Operating Report.	1.50
01/21/20	NAS	Prepare notes and review initial draft of business overview slides in advance of Mundipharma diligence team touch-base.	0.50
01/21/20	NAS	Discussion with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) re: key takeaways from Mundipharma Europe management meetings during week of Jan 13th, initial draft of business overview section for diligence report, and priorities for week of Jan 21st.	1.00
01/21/20	NAS	Incorporate data provided by S. Jamieson (Management Revisions) into product and country-level sales build of Mundipharma business plan model.	1.70
01/21/20	NAS	Incorporate product-level cost information for Europe provided by S. Jamieson (Management Revisions) into Mundipharma business plan model.	2.60
01/21/20	IA	Follow up on requests for updated budgets from professional advisors.	1.40
01/21/20	JD	Review various lease comp data from management prior to call with committee advisors.	0.60
01/21/20	JD	Review draft materials to provide to the committees re: outstanding complaints	0.80
01/21/20	GJK	Discussion with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) re: key takeaways from Mundipharma	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Europe management meetings during week of Jan 13th, initial draft of business overview section for diligence report, and priorities for week of Jan 21st.	
01/21/20	GJK	Call with I. McClatchy (Norton Rose) and diligence follow up	0.50
01/21/20	GJK	European product and P&L review	2.50
01/21/20	MH	Discussion with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) re: key takeaways from Mundipharma Europe management meetings during week of Jan 13th, initial draft of business overview section for diligence report, and priorities for week of Jan 21st.	1.00
01/21/20	MH	Meeting with H. Benson (TXP), W. Sielert (Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss possible changes to the Accounts Payable controls process.	0.50
01/21/20	MH	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, K. McCarthy (all Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss management of pre-petition payments against the Vendor Motion cap.	0.40
01/21/20	MH	Reconcile all trade agreement activity with accounts payable control system.	0.80
01/21/20	MH	Review detail of Ordinary Course Professional invoices to integrate into the OCP control system.	1.20
01/21/20	MH	Determine proper course of action for legal services payments later determined to be associated with indemnified legal matters.	0.50
01/21/20	MH	Research pre-petition invoice that was not released to determine cause and correction.	0.40
01/21/20	MH	Determine cause of unpaid pre-petition amounts for vendors with completed Trade Agreements.	1.60
01/21/20	MH	Create accounts payable release file.	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/21/20	HK	Discussion with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) re: key takeaways from Mundipharma Europe management meetings during week of Jan 13th, initial draft of business overview section for diligence report, and priorities for week of Jan 21st.	1.00
01/21/20	HK	Meeting with H. Benson (TXP), W. Sielert (Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss possible changes to the Accounts Payable controls process.	0.50
01/21/20	HK	Meeting with J. Lowne, E. Ruiz, S. Daniel, J. Carlisle, K. McCarthy (all Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss management of pre-petition payments against the Vendor Motion cap	0.40
01/21/20	HK	Update Mundipharma due diligence request tracker with documents reviewed in Norton Rose data site.	1.30
01/21/20	HK	Update draft Mundipharma business overview summary.	2.70
01/21/20	HK	Follow-up review of AP processes discussed in meeting with W. Sielert (Purdue) and H. Benson (TXP)	1.20
01/22/20	HK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest version of the Mundipharma business overview presentation.	1.10
01/22/20	HK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	0.60
01/22/20	HK	Update Mundipharma due diligence request tracker with documents reviewed in Norton Rose data site.	2.70
01/22/20	HK	Update draft Mundipharma business overview summary.	2.40
01/22/20	MH	Create revised financial analysis of historical financial results of IAC.	2.10
01/22/20	MH	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest version of the	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma business overview presentation.	
01/22/20	MH	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	0.60
01/22/20	MH	Research vendor payment questions from vendor contacts.	0.70
01/22/20	MH	Create new critical vendor status report for management distribution.	0.60
01/22/20	MH	Create accounts payable release file.	0.60
01/22/20	GJK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	0.60
01/22/20	GJK	Update and planning of workstreams for Mundipharma based on UK Trip	2.00
01/22/20	GJK	Outline for status update on key findings from UK and P&L profitability	2.00
01/22/20	GJK	Status update deck, feedback and comments on draft	2.40
01/22/20	GJK	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest version of the Mundipharma business overview presentation.	1.10
01/22/20	GJK	Meeting with G. Koch and N. Simon (both AlixPartners) to determine best approach for initial version of Mundipharma business plan model	0.60
01/22/20	JD	Review draft diligence request responses re: open lease extension diligence requests.	0.70
01/22/20	JD	Review and provide comments on draft corporate scorecard for 2020 company objectives.	1.10
01/22/20	JD	Review and provide comments on draft Avrio board	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		presentation. Correspondence with management and PJT re: same.	
01/22/20	IA	Follow up and review of weekly sales reporting.	0.70
01/22/20	IA	Review and update of voluntary resignations report based on information received from HR team.	0.40
01/22/20	NAS	Meeting with G. Koch and N. Simon (both AlixPartners) to determine best approach for initial version of Mundipharma business plan model	0.60
01/22/20	NAS	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest version of the Mundipharma business overview presentation (joined late).	0.60
01/22/20	NAS	Revise product-level sales build incorporated in Mundipharma business plan model.	0.90
01/22/20	NAS	Build consolidated product/region-level P&L through gross margin for Mundipharma business plan model.	2.40
01/22/20	NAS	Meeting with G. Koch, M. Hartley, N. Simon, and H. Ku (all AlixPartners) to walk through latest iteration of Mundipharma business plan model and discuss scenario analyses.	0.60
01/22/20	KM	Analysis update re: profit contribution for Rhodes Pharma oxy-APA and oxy-IR	0.90
01/22/20	KM	Document update re: in RALP presentation to Purdue Board	1.70
01/22/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.30
01/22/20	KM	Analysis re: integrated RALP YE 2019 headcount reconciliation	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/22/20	KM	IAC transformation plan and implication on RALP	0.40
01/22/20	KM	Detailed aggregated RALP headcount analysis and reconciliation	2.00
01/22/20	KM	Meeting with D. Lundie, J. Diordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Review of latest draft of RALP presentation to Purdue Board	1.70
01/22/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP savings scorecard changes and issues	0.30
01/22/20	KM	Rework headcount analysis slides	1.10
01/22/20	KM	Rework introductory slides per D. Lundie (Purdue)	1.00
01/22/20	KM	Slide creation re: preliminary implementation timeline for Rhodes cost reduction program	1.80
01/22/20	ADD	Calculate pre-petition invoices not covered by motion for December month end and update vendor invoice breakout.	2.70
01/22/20	DS	Analyze GPO fees funding data for Q4 2019	0.70
01/22/20	RDS	Slide creation - update variable contribution model to articulate savings from eliminating unprofitable products	1.20
01/22/20	RDS	Slide creation - AG only model	0.30
01/22/20	RDS	Slide creation - headcount reconciliation to transformation budget	0.40
01/22/20	RDS	Background analytics for board presentation on volume reductions	0.90
01/22/20	RDS	Slide edits - update presentation for latest scorecard information	1.30
01/22/20	RDS	IAC update and implications on Rhodes transformation plan	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/22/20	RDS	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	0.50
01/22/20	RDS	Revise opening toolkit slide to reflect commentary from D. Lundie (Purdue) on the importance of partnership to API	1.50
01/22/20	RDS	Meeting with D. Lundie, J. Diordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Review of latest draft of RALP presentation to Purdue Board	1.70
01/22/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: RALP savings scorecard changes and issues	0.30
01/22/20	RDS	Rework introductory slides per commentary from D. Lundie (Purdue)	1.00
01/22/20	RDS	Update financials throughout the presentation per latest scorecard from D. Fogel (Purdue)	1.30
01/22/20	RDS	Reconcile language throughout bird deck	0.20
01/22/20	RDS	Slide construction - gant chart for implementation plan in presentation	0.40
01/22/20	RDS	Slide construction - financial projections impacted by one-time NWC changes and forecasting methodology	0.80
01/22/20	RDS	Slide creation - final bridge depicting financial impact of transformative change plan	0.70
01/22/20	RDS	Final review of presentation materials before sharing with team	0.50
01/22/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin, N. Davis, J. Carlisle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: coordinating reporting approach to account for scenario and synergy savings	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/23/20	RDS	Turn comments from J. Lowne (Purdue) to board presentation	0.50
01/23/20	RDS	Review updated board presentation and provide comments	0.30
01/23/20	RDS	Meeting with D. Lundie, J. Diordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: review of latest draft of RALP presentation to Purdue Board	0.60
01/23/20	KM	Slide creation re: Rhodes integrated headcount	1.70
01/23/20	KM	Call with D. Fogel, W. DiNicola, R. Haberin, N. Davis, J. Carlisle (all Purdue) re: coordinating reporting approach to account for scenario and synergy savings	0.70
01/23/20	KM	Slide creation re: Rhodes financial bridges and associated commentary	1.30
01/23/20	KM	Meeting with D. Lundie, J. Diordano, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: review of latest draft of RALP presentation to Purdue Board	0.60
01/23/20	KM	Slide creation re: quarterly transformation implementation plan in broad strokes	1.30
01/23/20	KM	Slide creation re: Rhodes free cash flow summary	1.10
01/23/20	KM	Slide creation re: strategic and tactical changes and process of decision making	0.90
01/23/20	NAS	Correspondence with G. Koch, N. Simon, and M. Hartley (all AlixPartners) re: questions raised on weekly debtor advisor call and implications for Mundipharma business plan model.	0.20
01/23/20	JD	Review diligence request questions from Analysis Group and list of documents available to us.	0.80
01/23/20	GJK	Call with J. Turner (PJT) re: Mundipharma diligence	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/23/20	LJD	Update call with Davis Polk regarding additional options for consultants and next steps	0.40
01/23/20	LJD	Call with R. Aeli (Purdue) re: staffing, upcoming board meetings	0.60
01/23/20	GJK	Update Mundipharma diligence and project workstreams	2.00
01/23/20	MH	Create accounts payable release file.	0.70
01/23/20	MH	Reconcile all trade agreement activity with accounts payable control system.	1.10
01/24/20	MH	Create accounts payable release file.	0.60
01/24/20	GJK	Call with S. Jamieson (Management Revisions), G. Parks (Huron), I. McClatchy (Norton Rose), and advisors to discuss due diligence requests	0.60
01/24/20	GJK	Likely upside review prioritization for analysis	0.50
01/24/20	LJD	Review and discuss tax implications deck	0.80
01/24/20	LJD	Review notes from advisor call	0.50
01/24/20	HK	Review IAC due diligence documents uploaded to the Norton Rose data site to update information tracker.	1.80
01/24/20	HK	Update draft Mundipharma business overview summary.	2.10
01/24/20	NAS	Call with S. Jamieson (Management Revisions), G. Parks (Huron), I. McClatchy (Norton Rose), and advisors to discuss due diligence requests	0.60
01/24/20	KM	Review of project management tracker accounting for volume savings, headcount savings, project savings and ultimately synergies driven from efficiency	1.20
01/24/20	KM	Slide creation: re: Rhodes partnership detail	0.70
01/24/20	KM	Slide creation re: financial summary slides	0.60
01/24/20	KM	Document edits re: Rhodes generic market disruption	1.00
01/24/20	KM	Call with D. Lundie, D. Fogel (both Purdue) re: changes to presentation and updated messaging for CEO next week	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/24/20	KM	Presentation edits re: Rhodes Board presentation for Jan. 30	1.60
01/24/20	RDS	Call with D. Lundie, R. Shamblan, V. Mancinelli (all Purdue) to present current iteration of board deck and solicit feedback	1.30
01/24/20	RDS	PowerPoint presentation edits and comments from Rhodes leadership team	1.70
01/24/20	RDS	Call with T. Melvin (PJT) re: Rhodes board deck comments and key settlement implications	0.30
01/24/20	RDS	Review Avrio board presentation and prepare questions and comments	1.40
01/24/20	RDS	Call with D. Fogel (Purdue) to review PJT comments to the board presentation	1.20
01/24/20	RDS	Slide creation - Low ABUK impact on the cost structure of providing generic oxycodone products	1.10
01/25/20	RDS	Review consolidated Purdue financial plan ahead of board meeting.	0.70
01/25/20	JD	Review business plan forecast presentation and provide comments re: same.	1.10
01/25/20	LJD	Review and discuss documents from Kramer Levin - RSA, etc.	1.50
01/26/20	GJK	Review of diligence status update/feedback	1.00
01/26/20	JD	Correspondence with management re: business plan forecast presentation.	0.60
01/26/20	JD	Correspondence with Province re: open diligence requests.	0.40
01/26/20	RDS	Correspondence with D. Fogel (Purdue) re: backup materials for headcount attribution within R&D function	0.20
01/26/20	RDS	Correspondence with D. Fogel (Purdue) re Rhodes Pharma pipeline rationalization metrics	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/27/20	RDS	Review legal and other Purdue comments to Rhodes budget presentation	0.80
01/27/20	RDS	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re next steps to get to board presentation	0.80
01/27/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re edits to the presentation	0.70
01/27/20	RDS	Process edits to RHODES board presentation	1.10
01/27/20	RDS	Meeting with J. DelConte, K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) to discuss follow-up questions on the updated Avrio business plan	0.70
01/27/20	RDS	Review latest Avrio presentation and prepare comments for AlixPartners analysis	1.80
01/27/20	RDS	Process edits to board presentation - backup slide for AG-only model	0.90
01/27/20	KM	Meeting with J. DelConte, K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) to discuss follow-up questions on the updated Avrio business plan	0.70
01/27/20	KM	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re next steps to get to board presentation	0.80
01/27/20	KM	Implementation plan development and milestone planning re: Rhodes management presentation to the board	1.40
01/27/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re edits to the presentation	0.70
01/27/20	KM	Implementation plan and sequencing re: Rhodes proposed strategic plan implementation	1.30
01/27/20	KM	Slide development re: Rhodes Oxy-IR standard cost profile	1.60
01/27/20	KM	Slide edits for strategic partnerships re: Rhodes	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management presentation to the Board	
01/27/20	KM	Deck messaging and flow edits re: Rhodes management presentation to the Board	0.70
01/27/20	DS	Update prompt pay discount section of Customer Programs model	1.40
01/27/20	DS	Track Rhodes cash rebates per cash model and compare to client data	2.20
01/27/20	DS	Update vendor chargeback data in Customer Programs model based on data received from client	1.60
01/27/20	DS	Review documents provide by Purdue Treasurer re: floorplan of 9th and 10th floors for purposes of extending OSF lease	1.20
01/27/20	DS	Meeting with Purdue Financial Manager re: Customer Programs data and sales report	0.30
01/27/20	JD	Correspondence with management re: business development deals.	0.40
01/27/20	JD	Meeting with J. DelConte, K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) to discuss follow-up questions on the updated Avrio business plan	0.70
01/27/20	JD	Correspondence with management re: OTC business plan and review updated materials and responses from management.	1.20
01/27/20	JD	Correspondence with management re: tax diligence requests.	0.40
01/27/20	JD	Review weekly sales data and correspondence with management and Davis Polk re: same.	0.50
01/27/20	JD	Review updates related to IAC diligence and updated diligence requests.	0.70
01/27/20	JD	Review Debtor follow up diligence requests for DLA Piper re: IAC work.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/27/20	JD	Review information re: charitable contribution diligence requests.	1.10
01/27/20	NAS	Conversation with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: comments from B. Folse (AlixPartners) on Mundipharma diligence update presentation.	0.50
01/27/20	NAS	Review draft outline for Mundipharma diligence update presentation, EY Vendor Due Diligence follow-up question list, and topics for discussion with A. Breabout (Mundipharma).	0.50
01/27/20	NAS	Review latest Mundipharma business plan model for potential slides to use in Mundipharma diligence update presentation.	0.30
01/27/20	NAS	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss status of Mundipharma diligence update slides.	0.60
01/27/20	NAS	Create first draft of Mundipharma diligence update presentation.	2.20
01/27/20	IA	Follow up on request for operating dashboard from North Carolina for Monthly operating report.	0.80
01/27/20	IA	Review of operating dashboard samples received from North Carolina for monthly operating report.	1.40
01/27/20	GJK	Conversation with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: comments from B. Folse (AlixPartners) on Mundipharma diligence update presentation.	0.50
01/27/20	GJK	Call with G. Koch and B. Folse (both AlixPartners) to walk through Mundipharma diligence status update, received feedback, planning	1.00
01/27/20	GJK	Mundipharma diligence update and coordination, including review of agenda items proposed for call with A. Breabout (Mundipharma), communication with advisors	1.90
01/27/20	GJK	Analysis of Mundipharma product performance in Europe, extrapolation for LAM	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/27/20	GJK	Meeting with G. Koch and N. Simon (both AlixPartners) to discuss status of Mundipharma diligence update slides.	0.60
01/27/20	LJD	Pre-read material for board meeting on Thursday 1/30	2.50
01/27/20	BF	Call with G. Koch and B. Folse (both AlixPartners) to walk through Mundipharma diligence status update, received feedback, planning	1.00
01/27/20	MH	Create the accounts payable release file.	0.80
01/27/20	HK	Meeting with J. DelConte, K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) to discuss follow-up questions on the updated Avrio business plan	0.70
01/27/20	HK	Conversation with G. Koch, N. Simon, and H. Ku (all AlixPartners) re: comments from B. Folse (AlixPartners) on Mundipharma diligence update presentation.	0.50
01/27/20	HK	Draft Mundipharma introduction to Due Diligence Update presentation	1.30
01/27/20	HK	Revise IAC Due Diligence update with various comments from PJT and AlixPartners.	2.30
01/27/20	HK	Review updates to Mundipharma due diligence data site	2.40
01/27/20	HK	Update draft Due Diligence Update presentation with business background materials.	1.60
01/28/20	HK	Draft status update presentation to Avrio business plan review process.	2.50
01/28/20	HK	Meeting with G. Koch and H. Ku (both AlixPartners) to review business overview and gating items discussion in draft diligence update presentation	1.50
01/28/20	HK	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review PJT comments to draft interim diligence update	0.80
01/28/20	HK	Meeting with G. Koch, N. Simon, J. DelConte, and H. Ku (all AlixPartners) to review current draft of Mundipharma	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence update presentation	
01/28/20	HK	Update draft Due Diligence Update report with updated financial information.	2.80
01/28/20	HK	Update draft Due Diligence Update presentation with business background materials.	2.20
01/28/20	SKL	Call with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Rhodes CFO re: monthly operating metrics.	0.30
01/28/20	MH	Reconcile all vendor activity with critical vendor report.	1.80
01/28/20	MH	Review updated IAC status report.	0.70
01/28/20	MH	Review December report of insider payments and update comments.	0.60
01/28/20	MH	Create the accounts payable release file.	0.70
01/28/20	MH	Call with G. Koch, and M. Hartley (both AlixPartners) to discuss diligence process and status update deck	0.50
01/28/20	LJD	Internal correspondence and phone check-in with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: status of board presentation and presenters	0.60
01/28/20	LJD	Review decks for Thursday board meeting	1.50
01/28/20	GJK	Call with I. McClatchey (Norton Rose) to discuss diligence process, next steps for LAM, follow up items, call with A. Breabout (Mundipharma)	1.50
01/28/20	GJK	Meeting with G. Koch and H. Ku (both AlixPartners) to review business overview and gating items discussion in draft diligence update presentation	1.50
01/28/20	GJK	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review PJT comments to draft interim diligence update.	0.80
01/28/20	GJK	Draft notes to Diligence advisors (incl Huron) following	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		call with Norton Rose, and call with advisors to discuss process, including LAM trip	
01/28/20	GJK	Call with G. Koch, and M. Hartley (both AlixPartners) to discuss diligence process and status update deck	0.50
01/28/20	GJK	Review of diligence status update materials and drafts, including feedback to N. Simon and H. Ku (both AlixPartners)	2.50
01/28/20	GJK	Meeting with G. Koch, N. Simon, J. DelConte, and H. Ku (all AlixPartners) to review current draft of Mundipharma diligence update presentation	1.00
01/28/20	IA	Call with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Rhodes CFO re: monthly operating metrics	0.30
01/28/20	IA	Follow up with Davis Polk on employees with insider titles request from UCC.	0.50
01/28/20	IA	Review of materials sent by Norton Rose with information on employees with insider titles in response to request from UCC.	1.80
01/28/20	IA	Review filed fee applications and affidavits to adjust legal and restructuring fees forecast.	1.60
01/28/20	IA	Follow up with Davis Polk on company's request for updated AdHoc estimates.	0.70
01/28/20	IA	Review foreign IAc receipts summary drafted in response to committee's request.	1.70
01/28/20	NAS	Review comments provided by PJT regarding Mundipharma diligence update presentation.	0.50
01/28/20	NAS	Add product-level Selling & Promotion and Medical Affairs costs to Mundipharma business plan model.	0.70
01/28/20	NAS	Revise Mundipharma diligence update presentation following comments from B. Folse (AlixPartners) and J.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Turner (PJT).	
01/28/20	NAS	Meeting with G. Koch, N. Simon, J. DelConte, and H. Ku (all AlixPartners) to review current draft of Mundipharma diligence update presentation.	1.00
01/28/20	NAS	Conference call with Mundipharma diligence working group (Norton Rose, Huron, AlixPartners, PJT, FTI, Houlihan Lokey, Province, Jefferies) to review open diligence items and plan for in-person meetings in Singapore.	0.90
01/28/20	NAS	Revise Mundipharma diligence update slides following meeting with G. Koch and H. Ku (both AlixPartners).	1.20
01/28/20	NAS	Meeting with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review PJT comments to draft interim diligence update.	0.80
01/28/20	JD	Meeting with G. Koch, N. Simon, J. DelConte, and H. Ku (all AlixPartners) to review current draft of Mundipharma diligence update presentation.	1.00
01/28/20	JD	Review and provide comments on analysis of headcount and square footage in OSR.	0.50
01/28/20	JD	Internal correspondence and phone check-in with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: status of board presentation and presenters	0.60
01/28/20	JD	Review and provide comments draft Rhodes business planning presentation for Thursday's board meeting.	1.40
01/28/20	JD	Review and provide comments on draft auto injector motion and declaration.	1.30
01/28/20	JD	Review and provide comments on pre-reads for the board meeting on Thursday.	1.60
01/28/20	JD	Review potential avenues for review and redaction of current diligence information.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/28/20	DS	Review and format foreign IAC receipts model to put into a presentation	1.70
01/28/20	DS	Put together deck describing scope and including schedules of IAC receipts since March 2019	1.90
01/28/20	DS	Analyze employee headcount data provided by Purdue CFO	1.10
01/28/20	DS	Put together analysis by department for employees in Stamford to provide context of space needs in corporate office	3.40
01/28/20	DS	Call with D. Samikkannu, I. Arana, S. Lemack (all AlixPartners), and Rhodes CFO re: monthly operating metrics	0.30
01/28/20	KM	Slide development with D. Lundie (Purdue) re: conclusion wrap up slide for Rhodes management presentation to the Board meeting	1.50
01/28/20	KM	Management presentation (board meeting) dry run with D. Lundie, D. Fogel (both Purdue) K. McCafferty, and R. Sublett (both AlixPartners)	1.70
01/28/20	KM	Develop slide by slide talking points re: Rhodes management presentation to the Board	2.30
01/28/20	KM	Slide development re: appendix conclusions for Rhodes management presentation to the board meeting	0.40
01/28/20	KM	Slide deck edits from dry run #1 re: Rhodes management presentation to the board meeting	1.40
01/28/20	KM	Internal correspondence and phone check-in with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: status of board presentation and presenters	0.60
01/28/20	KM	Call with D. Fogel (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: presentation backup and logistics	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/28/20	KM	Prepare backup slide commentary re: Rhodes management presentation to the Board	0.70
01/28/20	KM	Call with D. Fogel (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: backup analysis for partnership and pricing sensitivity	0.40
01/28/20	KM	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: implementation plan and human capital management	0.50
01/28/20	ADD	Review lease documentation for economic terms.	0.60
01/28/20	RDS	Slide creation of conclusion wrap up slide with commentary from D. Lundie (Purdue)	1.50
01/28/20	RDS	Prepare commentary for backup slides to board presentation	0.70
01/28/20	RDS	Call with D. Fogel (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: backup analysis for partnership and pricing sensitivity	0.40
01/28/20	RDS	Call with D. Lundie (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: implementation plan and human capital management	0.50
01/28/20	RDS	Call with D. Fogel (Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: presentation backup and logistics	0.10
01/28/20	RDS	Management presentation (board meeting) dry run with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	1.70
01/28/20	RDS	Write management presentation talking points	2.30
01/28/20	RDS	Slide creation of appendix conclusions update	0.40
01/28/20	RDS	Edits to board management presentation after dry run #1	1.40
01/28/20	RDS	Internal correspondence and phone check-in with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) re: status of board presentation and	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		presenters	
01/29/20	RDS	Review management presentation and made amendments to presenter notes	0.70
01/29/20	RDS	Correspondence with D. Fogel (Purdue) re: CPP break even analysis	0.20
01/29/20	RDS	Work stream planning with K. McCafferty and R. Sublett (both AlixPartners) for Rhodes restructuring planning and implementation	0.70
01/29/20	RDS	Discussion with K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) re: Avrio presentation review	1.00
01/29/20	RDS	Amendments to presentation notes per D. Lundie (Purdue) comments	1.10
01/29/20	RDS	Organizational change planning with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners)	1.00
01/29/20	RDS	Lay out work plan for CPP, Rhodes Tech R&D, Rhodes Pharma R&D, strategic partnership and workforce restructuring work streams	2.60
01/29/20	KM	Review and amend presenter notes re: Rhodes management presentation to the Board	0.70
01/29/20	KM	Discussion with D. Fogel (Purdue) re: CPP break even analysis	0.20
01/29/20	KM	Work stream planning with K. McCafferty and R. Sublett (both AlixPartners) for Rhodes restructuring planning and implementation	0.70
01/29/20	KM	Discussion with K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) re: Avrio presentation review	1.00
01/29/20	KM	Amend presentation notes per D. Lundie (Purdue) re: Rhodes management presentation to the Board	1.10
01/29/20	KM	Organizational change planning with D. Fogel (Purdue) K. McCafferty, and R. Sublett (both AlixPartners)	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/29/20	KM	Create work plan for CPP, Rhodes Tech R&D, Rhodes Pharma R&D, Strategic Partnership and workforce restructuring re: Rhodes implementation	2.60
01/29/20	DS	Draft outline of my understanding of subordination rights for various Purdue sublessees and send to Davis Polk for review	1.00
01/29/20	DS	Call with T. Pajolek (CBRE), J. Crockett (Province), J. Lowne (Purdue), J. DelConte, and D. Samikkannu (both AlixPartners) re: lease extension process.	0.40
01/29/20	DS	Correspondence with Purdue general counsel requesting approval for headcount data report	0.20
01/29/20	DS	Discussion with C. Robertson (Davis Polk) re: headcount data	0.30
01/29/20	JD	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: auto injector development agreement.	0.80
01/29/20	JD	Call with T. Pajolek (CBRE), J. Crockett (Province), J. Lowne (Purdue), J. DelConte, and D. Samikkannu (both AlixPartners) re: lease extension process.	0.40
01/29/20	JD	Review and comment on draft board materials re: auto injector development agreement.	0.80
01/29/20	JD	Correspondence with management and PJT re: preparation of materials to share with the committee advisors on the auto injector development agreement and prepare and edit draft materials re: same.	1.60
01/29/20	JD	Review updated IMS data before sharing with committee advisors.	0.40
01/29/20	JD	Review potential redaction options for diligence materials.	0.30
01/29/20	JD	Conversation with G. Koch and J. DelConte (both AlixPartners) re: report timing	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/29/20	JD	Catch up conversation with Associate General Counsel re: next day's board meeting.	0.40
01/29/20	JD	Review final board decks prior to the board meeting tomorrow.	1.80
01/29/20	NAS	Revise Mundipharma diligence update slides following additional feedback from G. Koch (AlixPartners).	2.20
01/29/20	NAS	Discussion of Mundipharma diligence update deck, and review and updates with G. Koch, N. Simon, and H. Ku (all AlixPartners)	2.50
01/29/20	NAS	Revise Mundipharma diligence update presentation following morning meeting with G. Koch and H. Ku (both AlixPartners).	1.10
01/29/20	NAS	Revise Mundipharma diligence update presentation following afternoon meeting with G. Koch and H. Ku (both AlixPartners).	0.70
01/29/20	NAS	Final walk through of Mundipharma Diligence Update draft with G, Koch, N. Simon, and H. Ku (all AlixPartners)	0.50
01/29/20	IA	Reconciliation of materials sent by Norton Rose with information on employees with insider titles in response to HR provided information in response to request from committees.	2.10
01/29/20	IA	Review of auto injector existing materials to put together package to be shared with committees.	1.30
01/29/20	IA	Incorporate requested edits and follow up on approvals of materials to be shared with committees on auto injector agreement.	3.20
01/29/20	IA	Meeting with management, J. DelConte, and I. Arana (both AlixPartners) re: auto injector development agreement.	0.80
01/29/20	IA	Review of wages agreement to provide feedback on timing and approval of upcoming benefit payments.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/29/20	IA	Discussion with C. Destefano (Purdue) to discuss timing and approval of upcoming benefit payments as well as final 2019 scorecards.	0.20
01/29/20	IA	Follow up on AdHoc advisors budget requested by company.	0.40
01/29/20	GJK	Calls with I. McClatchy (Norton Rose) re: diligence discussion with Mundipharma CFO and LAM diligence trip, and follow up notes and brief to team	1.50
01/29/20	GJK	Call with M. Diaz and B. Bromberg (both FTI) on Asia trip, Arnaud and report timing, and follow up call with J. Turner (PJT).	0.70
01/29/20	GJK	Final walk through of Mundipharma Diligence Update draft with G. Koch, N. Simon, and H. Ku (all AlixPartners)	0.50
01/29/20	GJK	Edits to draft of Mundipharma Diligence Update deck, sent to AlixPartners and PJT professionals for final review	1.20
01/29/20	GJK	Discussion of Mundipharma diligence update deck, and review and updates with G. Koch, N. Simon, and H. Ku (all AlixPartners)	2.50
01/29/20	GJK	Conversation with G. Koch and J. DelConte (both AlixPartners) re: report timing	0.30
01/29/20	LJD	Review revised board deck information	1.10
01/29/20	MH	Answer client questions regarding pre-petition invoices.	0.70
01/29/20	MH	Create the accounts payable release file.	0.80
01/29/20	HK	Discussion with K. McCafferty, R. Sublett, and H. Ku (all AlixPartners) re: Avrio presentation review	1.00
01/29/20	HK	Discussion of Mundipharma diligence update deck, and review and updates with G. Koch, N. Simon, and H. Ku (all AlixPartners)	2.50
01/29/20	HK	Final walk through of Mundipharma Diligence Update draft with G. Koch, N. Simon, and H. Ku (all AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/29/20	HK	Update status update presentation to Avrio business plan review process.	2.70
01/29/20	HK	Update draft Due Diligence Update report with updated financial information.	1.40
01/29/20	HK	Update draft Due Diligence Update presentation with business background materials.	2.20
01/30/20	HK	Call with N. Simon and H. Ku (both AlixPartners) to discuss data sources used in Mundipharma diligence update presentation	0.50
01/30/20	HK	Diligence update analysis and questions walk through with G. Koch and H. Ku (both AlixPartners)	1.00
01/30/20	HK	Update draft Due Diligence Update report with updated financial information.	1.80
01/30/20	HK	Update status update presentation to Avrio business plan review process.	2.50
01/30/20	HK	Review EY draft Quality of Earnings report to validate historical assumptions in Due Diligence Update presentation.	2.90
01/30/20	HK	Review partial Mundipharma financial model to validate forecasted estimates.	2.40
01/30/20	MH	Respond to client questions regarding possible trade agreement with a vendor.	0.70
01/30/20	MH	Update the accounts payable control system to release law firms approved by the Special Committee for indemnification payments.	1.90
01/30/20	MH	Research an invoice to determine petition status and possible motion eligibility.	0.70
01/30/20	MH	Create the accounts payable release file.	1.20
01/30/20	LJD	Prepare for board meeting	0.80
01/30/20	LJD	Attend board meeting with L. Donahue and J. DelConte	6.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both AlixPartners)	
01/30/20	GJK	Updates, edits and revisions to Mundipharma diligence update deck, follow up emails and discussion with G. Koch and H. Ku (both AlixPartners)	2.50
01/30/20	GJK	Call with I. McClatchey (Norton Rose) re: Singapore trip and follow up with advisors	0.30
01/30/20	GJK	Diligence coordination and next steps for Mundipharma	0.50
01/30/20	GJK	Diligence update analysis and questions walk through with G. Koch and H. Ku (both AlixPartners)	1.00
01/30/20	IA	Prepare for and attend meeting with J. Lowne, E. Ruiz and others (all Purdue) to discuss upcoming diligence call with the committees for nalmafene auto injector.	2.40
01/30/20	IA	Review and reconciliation of AIP payment amounts included in compensation committee presentation.	1.40
01/30/20	IA	Follow up and coordination of call with company, UCC and Ad Hoc advisors to discuss nalmafene auto injector project.	1.80
01/30/20	IA	Review job descriptions submitted through diligence process in response to request from legal department.	0.40
01/30/20	IA	Meeting with E. Ruiz and others (all Purdue) to discuss updated auto injector financials file from company showing market assumptions and additional requested details.	0.40
01/30/20	IA	Review submitted auto injector financials file from company, showing variances to earlier version of PHI initiative presented to committees and other requested details.	1.20
01/30/20	NAS	Call with N. Simon and H. Ku (both AlixPartners) to discuss data sources used in Mundipharma diligence update presentation.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/30/20	NAS	Create directional bridge of EBIT discrepancies across data sources provided as part of Mundipharma diligence.	0.50
01/30/20	JD	Attend board meeting with L. Donahue and J. DelConte (both AlixPartners)	6.70
01/30/20	JD	Review draft board materials for the meeting with the AHC on Monday.	0.80
01/30/20	JD	Correspondence with PJT, Davis Polk and management re: auto injector diligence questions and prepare responses to additional diligence requests.	0.90
01/30/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio next steps	0.20
01/30/20	JD	Call with J. Lowne (Purdue), J. DelConte, R. Sublett (both AlixPartners), and R. Schnitzler (PJT) re: Avrio business plan KPIs	0.40
01/30/20	DS	Review Purdue rebates schedule for purposes of incorporating into Customer Programs report	0.80
01/30/20	DS	Follow up with Purdue financial analyst re: classification of specific Managed Care rebate	0.40
01/30/20	DS	Put together schedule for Purdue rebates among various categories	1.70
01/30/20	DS	Analyze Rhodes data and put rebates schedule together in Customer Programs model	1.50
01/30/20	DS	Review GPO data for December Customer Programs report	0.50
01/30/20	KM	Pre-Board discussion on restructuring plan for Rhodes business with K. McCafferty and R. Sublett (both AlixPartners)	0.80
01/30/20	KM	Discuss implementation plan with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes strategic plan	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/30/20	KM	Prepare management presentation with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: communication of approved budget to Rhodes leadership team	1.20
01/30/20	KM	Key milestone development and planning re: Rhodes strategic plan implementation	1.30
01/30/20	KM	Board presentation of Rhodes business plan with K. McCafferty and R. Sublett (both AlixPartners)	1.10
01/30/20	KM	Board presentation of Avrio business plan with K. McCafferty and R. Sublett (both AlixPartners)	1.00
01/30/20	KM	Implementation plan refinement re: Rhodes strategic plan	0.60
01/30/20	KM	Discussion with C. Comiack (Purdue), K. McCafferty and R. Sublett (both AlixPartners) re: next steps and date follow up for the board meeting	0.40
01/30/20	RDS	Pre-Board discussion on restructuring plan for Rhodes business with K. McCafferty and R. Sublett (both AlixPartners)	0.80
01/30/20	RDS	Board Presentation of Rhodes business plan with K. McCafferty and R. Sublett (both AlixPartners)	1.10
01/30/20	RDS	Board Presentation of Avrio business plan with K. McCafferty and R. Sublett (both AlixPartners)	1.00
01/30/20	RDS	Discussion with C. Comiack (Purdue), K. McCafferty and R. Sublett (both AlixPartners) re: next steps and date follow up for the board meeting	0.40
01/30/20	RDS	Continue to refine implementation plan for Rhodes transformation	1.00
01/30/20	RDS	Discuss implementation plan with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes strategic plan	1.00
01/30/20	RDS	Correspondence regarding Avrio budget impact analysis	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/30/20	RDS	Prepare management presentation with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: communication of approved budget to Rhodes leadership team	1.20
01/30/20	RDS	Call with J. Lowne (Purdue), J. DelConte, R. Sublett (both AlixPartners), and R. Schnitzler (PJT) re: Avrio business plan KPIs	0.40
01/30/20	RDS	Assemble reflections on business plan and other conclusions into Avrio AlixPartners slide presentation	1.20
01/30/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio next steps	0.20
01/31/20	RDS	Correspondence with Rhodes team about presentation materials for today's meeting.	0.30
01/31/20	RDS	Edits to Rhodes management budget approval presentation	1.70
01/31/20	RDS	Call with J. Tran (Purdue) to discuss board-level financial metrics	0.40
01/31/20	RDS	Call with J. Lowne, C. Chomiack, J. Tran (all Purdue), J. DelConte, D. Sammikkannu, and R. Sublett (all AlixPartners) to discuss next steps for Avrio business planning review.	0.50
01/31/20	RDS	Call with D. Lundie and D. Fogel (Rhodes) to download budget approval and feedback from the board of directors	1.10
01/31/20	RDS	Review and update on other matters of the case.	0.30
01/31/20	RDS	Call with D. Samikkannu, R. Sublett, and I. Arana (all AlixPartners) re: Avrio business plan follow ups	0.30
01/31/20	RDS	Call with D. Fogel (Purdue) to discuss management communication on KPI dashboard	0.20
01/31/20	RDS	Review Avrio business plan and assemble notes for meeting next week with CEO/CFO.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/31/20	RDS	Review November analysis of Avrio cash flow savings to invest and grow scenarios	0.40
01/31/20	KM	Implementation development and planning re: Rhodes strategic plan implementation	1.30
01/31/20	DS	Call with J. Lowne, C. Chomiack, J. Tran (all Purdue), J. DelConte, D. Sammikkanu, and R. Sublett (all AlixPartners) to discuss next steps for Avrio business planning review.	0.50
01/31/20	DS	Call with D. Samikkannu, R. Sublett, and I. Arana (all AlixPartners) re: Avrio business plan follow ups	0.30
01/31/20	DS	Correspondence with I. Arana (AlixPartners) re: financial board materials for Rhodes and Purdue	0.20
01/31/20	DS	Compile rebate related data from weekly cash models for days in December for Purdue for purposes of reconciling with accounting data	2.20
01/31/20	DS	Compile rebate related data from weekly cash models for days in December for Rhodes for purposes of reconciling with accounting data	2.10
01/31/20	JD	Call with C. Robertson (Davis Polk) and J. Turner (PJT) re: preparation for auto injector call.	0.30
01/31/20	JD	Call with J. Lowne, C. Chomiack, J. Tran (all Purdue), J. DelConte, D. Sammikkanu, and R. Sublett (all AlixPartners) to discuss next steps for Avrio business planning review.	0.50
01/31/20	JD	Review follow up diligence responses following earlier call on the auto injector development agreement.	0.50
01/31/20	JD	Review materials provided re: auto injector agreement for potential redactions and correspondence with management re: same.	0.80
01/31/20	JD	Review additional diligence requests from the various committees against materials collected to date and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		correspondence with PJT re: same.	
01/31/20	JD	Review existing PHI information provided to date and associated analyses and compare against updated PHI forecast for the auto injector development costs.	1.50
01/31/20	NAS	Prepare for discussion with G. Koch and H. Ku (both AlixPartners) regarding Mundipharma data sources used in model and diligence update presentation.	0.40
01/31/20	NAS	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review data sources and figures included in Mundipharma diligence update presentation.	0.60
01/31/20	NAS	Final revisions to Mundipharma diligence update presentation following discussion and walk through with G. Koch and H. Ku (both AlixPartners).	1.50
01/31/20	NAS	Call with A. Breabout (Mundipharma), G. Koch, N. Simon, H. Ku (all AlixPartners), Advisors to Debtor, Ad-Hoc Committee, and Unsecured Creditors Committee.	1.00
01/31/20	NAS	Full review of near final draft of Mundipharma diligence update presentation.	2.40
01/31/20	NAS	Final walk through of Mundipharma diligence update presentation with G. Koch, N. Simon, and H. Ku (all AlixPartners).	1.40
01/31/20	IA	Call with D. Samikkannu, R. Sublett, and I. Arana (all AlixPartners) re: Avrio business plan follow ups	0.30
01/31/20	IA	Review of latest retention trackers and additional program participant amounts.	1.10
01/31/20	GJK	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review data sources and figures included in Mundipharma diligence update presentation	0.60
01/31/20	GJK	Calls with I. McClatchey (Norton Rose), B. Bromberg (FTI) and coordination activities to prep for call with Mundipharma CFO	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
01/31/20	GJK	Call with A. Breabout (Mundipharma), G. Koch, N. Simon, H. Ku (all AlixPartners), Advisors to Debtor, Ad-Hoc Committee, and Unsecured Creditors Committee	1.00
01/31/20	GJK	Review of uploaded Mundipharma documents (general overview of postings)	2.50
01/31/20	GJK	Final walk through of Mundipharma diligence update presentation with G. Koch, N. Simon, and H. Ku (all AlixPartners)	1.40
01/31/20	GJK	Review of uploaded LAM region documents for Mundipharma	1.60
01/31/20	LJD	Review correspondence	0.50
01/31/20	MH	Attend call with A. Breabout (Mundipharma) to review operational results.	1.00
01/31/20	HK	Update draft Due Diligence Update presentation with business background materials.	1.90
01/31/20	HK	Update draft Due Diligence Update report with updated financial information.	1.20
01/31/20	HK	Review updates to Mundipharma due diligence data site	1.10
01/31/20	HK	Call with G. Koch, N. Simon, and H. Ku (all AlixPartners) to review data sources and figures included in Mundipharma diligence update presentation	0.60
01/31/20	HK	Call with A. Breabout (Mundipharma), G. Koch, N. Simon, H. Ku (all AlixPartners), Advisors to Debtor, Ad-Hoc Committee, and Unsecured Creditors Committee	1.00
01/31/20	HK	Final walk through of Mundipharma diligence update presentation with G. Koch, N. Simon, and H. Ku (all AlixPartners)	1.40
Total			<u>3,602.20</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	134.60	385.00	51,821.00
Sam K Lemack	7.00	440.00	3,080.00
Hart Ku	120.20	440.00	52,888.00
Dirk G Pfannenschmidt	6.40	450.00	2,880.00
Andrew D DePalma	450.20	480.00	216,096.00
Julie A Doherty	63.30	480.00	30,384.00
Nate A Simon	212.50	480.00	102,000.00
Andrew D DePalma	62.20	515.00	32,033.00
Hart Ku	115.40	515.00	59,431.00
Sam K Lemack	2.10	515.00	1,081.50
Nate A Simon	122.20	515.00	62,933.00
David Samikkannu	188.20	615.00	115,743.00
Isabel Arana de Uriarte	274.20	615.00	168,633.00
Sam J Canniff	0.90	615.00	553.50
Isabel Arana de Uriarte	67.90	690.00	46,851.00
David Samikkannu	71.00	690.00	48,990.00
Ryan D Sublett	201.50	725.00	146,087.50
Ryan D Sublett	195.30	735.00	143,545.50
Gabe J Koch	145.50	830.00	120,765.00
Scott Robertson	1.10	830.00	913.00
Michael Hartley	159.40	830.00	132,302.00
Michael Hartley	69.30	840.00	58,212.00
Gabe J Koch	143.80	840.00	120,792.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Kevin M McCafferty	163.40	895.00	146,243.00
Jesse DelConte	252.50	945.00	238,612.50
Kevin M McCafferty	190.10	950.00	180,595.00
Jesse DelConte	99.40	950.00	94,430.00
Barry Folse	6.90	1,080.00	7,452.00
Barry Folse	2.20	1,090.00	2,398.00
Lisa Donahue	50.10	1,165.00	58,366.50
Lisa Donahue	23.40	1,195.00	27,963.00
Total Hours & Fees	3,602.20		2,474,075.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
11/21/19	MH	Research terms of new equity owner non-disclosure agreement relative to other work streams.	0.40
11/22/19	MH	Attend meeting with professionals to initiate disclosures from the equity holders.	2.50
11/22/19	MH	Prepare meeting summary of equity holder disclosure meeting.	1.40
11/22/19	MH	Prepare for meeting with equity holders on disclosures.	1.00
12/06/19	MH	Attend portion of disclosure call with equity counsel to present arguments in the litigation.	3.10
Total			8.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Michael Hartley	8.40	830.00	6,972.00
Total Hours & Fees	8.40		6,972.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
09/17/19	JD	Review of potential contract for rejection. Correspondence with Controller and CFO RE: same.	0.40
10/02/19	JD	Correspondence with management and Prime Clerk RE: contract review.	0.40
10/07/19	DS	Correspondence with Avrio management team re: status of Emerson agreements for purposes of posting to the data room	0.20
10/07/19	DS	Correspondence with A. DePalma (AlixPartners) re: confidentiality provisions re: Customer Programs agreements	0.20
10/08/19	DS	Compile relevant Emerson agreements for posting to data room	0.40
10/09/19	DS	Communication with Davis Polk re: customer agreements contract provisions	0.20
10/09/19	DS	Compile links to data room for key customer contracts to prioritize review of specific provisions to send to Davis Polk	1.10
10/15/19	DS	Review D. Consla (Davis Polk) analysis of contracts pertaining to customer programs	0.80
10/18/19	DS	Call with D. Consla (Davis Polk) re: provisions in customer contracts	0.30
10/18/19	DS	Review Davis Polk's initial commentary on customer agreements in preparation for call with Davis Polk	0.80
10/22/19	DS	Draft email to Davis Polk re: locating material agreements	0.30
10/23/19	DS	Review and update lease damage analysis and draft summary of thoughts for Davis Polk	1.80
10/24/19	DS	Assemble lease documents to send to R. Collura (AlixPartners)	0.30
10/25/19	JD	Review and provide executory contracts for SOFA/SOALs.	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
10/25/19	JD	Call with Davis Polk and management RE: OSR wrap lease and leasing go forward	0.70
10/25/19	JD	Review latest rejection damage analysis and review potential sublease income.	0.40
10/29/19	DS	Obtain exhibits to One Stamford Forum lease	0.40
11/04/19	DS	Meeting with D. Samikkannu and J. DelConte (both AlixPartners) to review lease damages calculation and analysis	0.30
11/04/19	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: lease damage analysis methodology, cash report, marketing materials for diligence	0.30
11/04/19	DS	Review OSR lease document	1.30
11/04/19	DS	Review exhibits to OSR lease document	0.80
11/04/19	JD	Meeting with D. Samikkannu and J. DelConte (both AlixPartners) to review lease damages calculation and analysis	0.30
11/04/19	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: lease damage analysis methodology, cash report, marketing materials for diligence	0.30
11/05/19	JD	Review updated presentation on potential sub lease options and rent/leases go forward, review contract damages calculation and provide comments.	0.80
11/05/19	DS	Meeting with J. DelConte, D. Samikkannu (both AlixPartners), CFO and Treasurer (PPLP) re: lease considerations deck	0.70
11/05/19	JD	Meeting with J. DelConte, D. Samikkannu (both AlixPartners), CFO and Treasurer (PPLP) re: lease considerations deck	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
11/06/19	JD	Call with J. DelConte, D. Samikkannu (both AlixPartners), CFO and Treasurer re: comments to lease analysis deck	0.20
12/06/19	DS	Obtain and send PRA and TXP subleases to A. DePalma (AlixPartners)	0.40
12/07/19	JD	Correspondence with management re: contract rejection	0.30
12/15/19	JD	Correspondence with management and Davis Polk re: lease rejection and extension issues	0.20
12/26/19	JD	Correspondence with Davis Polk re: lease rejection / assumption process	0.50
12/27/19	JD	Correspondence with management and Davis Polk re: lease rejection / assumption	0.20
12/27/19	JD	Correspondence with management re: professional fee payments	0.20
12/31/19	JD	Correspondence with management re: OSR lease go forward process	0.50
01/02/20	JD	Review vendor agreement for potential rejection.	0.30
01/04/20	JD	Review draft OSR lease materials for discussion with the special committee.	0.50
01/05/20	JD	Review management correspondence re: OSR lease	0.40
01/08/20	JD	Correspondence with management and Davis Polk re: potential contract rejection.	0.50
01/14/20	JD	Meeting with D. Samikkannu, and J. DelConte (both AlixPartners) to review approach to BoD slides on specific cost analysis	0.30
01/14/20	DS	Meeting with D. Samikkannu, and J. DelConte (both AlixPartners) to review approach to BoD slides on specific cost analysis	0.30
01/17/20	JD	Review OSR lease materials in advance of sending them to the committee advisors.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
01/18/20	JD	Review and provide comments on draft OSR lease presentation and correspondence with management re: same.	1.30
01/20/20	JD	Review and provide comments on final draft OSR presentation.	0.40
01/22/20	JD	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: OSF lease extension data requests by UCC advisors	0.20
01/22/20	DS	Call with D. Samikkannu, J. DelConte (both AlixPartners), and C. Robertson (Davis Polk) re: OSF lease extension data requests by UCC advisors	0.20
01/22/20	DS	Review two subtenant leases with Purdue and draft summary analysis of implications of lease extension to send to Davis Polk	1.30
01/27/20	JD	Review historical IAC contracts re: API supply agreements.	0.50
01/27/20	JD	Review Rhodes executory contract for potential rejection.	0.30
01/28/20	JD	Meeting with D. Samikkannu, J. DelConte (both AlixPartners), J. Crockett (Province), and J. Lowne (Purdue) re: lease extension.	0.30
01/28/20	JD	Review historical OSR lease summaries and correspondence in preparation for committee call.	0.80
01/28/20	DS	Meeting with D. Samikkannu, J. DelConte (both AlixPartners), J. Crockett (Province), and J. Lowne (Purdue) re: lease extension.	0.30
01/29/20	DS	Review in detail Hillside, Brookside, Kokino subleases	2.10
01/29/20	DS	Review in detail the Consent, Subordination, Nondisturbance and Attornment Agreement for Charter, Aircastle, Deutsch	2.40
01/29/20	DS	Draft outline of my understanding of subordination rights	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
		for various Purdue sublessees and send to Davis Polk for review	
01/29/20	JD	Review subordination agreements for subtenants at OSR.	0.70
Total			<u><u>33.30</u></u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
David Samikkannu	10.60	615.00	6,519.00
David Samikkannu	8.70	690.00	6,003.00
Jesse DelConte	6.70	945.00	6,331.50
Jesse DelConte	7.30	950.00	6,935.00
Total Hours & Fees	33.30		25,788.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
01/06/20	JD	Review details of claims filed to date from Prime Clerk.	0.50
Total			<u>0.50</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	0.50	950.00	475.00
Total Hours & Fees	0.50		475.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
09/16/19	DS	Discussion with TXP re: CDA for insurance process	0.40
09/16/19	DS	Correspondence with Willis Towers Watson re: insurance diligence process	0.20
09/17/19	DS	Correspondence with W. Chang (TXP) and Assistant General Counsel R. Aleali (Purdue)re: counterparty's edits to CDA (insurance)	0.20
09/17/19	JD	Review and edit final declaration to be filed with the preliminary injunction motion	1.50
09/17/19	JD	Review backup materials created in support of my declaration	0.70
09/24/19	DS	Collection and transmission of data to Willis Towers Watson related to potential new insurance coverage	0.70
09/25/19	JD	Deposition preparation at Davis Polk	5.70
09/25/19	JD	Review my declaration in preparation for deposition	0.70
09/26/19	JD	Prepare for and attend deposition	7.20
10/09/19	JD	Review declaration and support materials provided in support of the preliminary injunction.	0.70
10/09/19	JD	Review preliminary injunction objections and Debtor original preliminary injunction and reply brief in advance of Friday's hearing.	2.30
10/10/19	JD	Review my declaration, the preliminary injunction, objections and the reply brief in advance of tomorrow's hearing.	2.80
10/10/19	JD	Prep for tomorrow's hearing with Davis Polk.	0.60
11/06/19	JD	Preparation for court hearing re: preliminary injunction	1.00
11/27/19	JD	Review DLA Piper IAC memo	0.80
01/15/20	JD	Attend family wealth disclosure meeting.	3.50
01/15/20	JD	Prepare for family wealth disclosure meeting.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
01/21/20	DS	Prepare backup support (for internal purposes) for lease materials	2.40
01/21/20	DS	Correspondence with C. Robertson (Davis Polk) re: lease extension materials for advisors	0.40
01/22/20	DS	Correspondence with OSR re: square foot analysis for One Stamford Forum	0.20
01/22/20	DS	Review of floorplan analysis schedules received from Purdue Treasurer, to use as backup support for lease extension documents	0.80
01/30/20	PM	Windsor: Create five Relativity users.	0.30
01/30/20	KG	Load and image exception documents in LAW, overlay images into Relativity, and run OCR and index for search/retrieval.	0.80
01/30/20	KG	Stage data for processing, process data for loading to Relativity, export and import data into Relativity, and image documents for redactions.	1.10
01/30/20	JWG	Create the Windsor Review workspace based on the Global Template (Mindseye) v14 with standard groups/permissions from the template, and also create the System Admin - Windsor group and add the initial access users.	0.20
01/30/20	JKL	Intaking new data and case setup in Relativity.	1.40
Total			37.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Paraskevas Moisakis	0.30	250.00	75.00
John W Girgis	0.20	295.00	59.00
David Samikkannu	1.50	615.00	922.50
Kristina Galbraith	1.90	645.00	1,225.50
David Samikkannu	3.80	690.00	2,622.00
Jesse DelConte	24.00	945.00	22,680.00
Jay K Lynn	1.40	950.00	1,330.00
Jesse DelConte	4.50	950.00	4,275.00
Total Hours & Fees	37.60		33,189.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
09/16/19	ESK	Continue to revise and prepare retention pleadings and disclosures	1.90
09/17/19	ESK	Review and revised retention pleadings	0.30
09/24/19	MH	Review changes to AlixPartners billing with client to ensure electronic processing will not be affected.	0.40
10/03/19	LCV	Emails with K&E and Legal re: parties-in-interest.	0.10
10/09/19	JD	Review latest AlixPartners retention documents.	0.60
10/15/19	LCV	Review and respond to updated parties-in-interest list received from Davis Polk.	0.20
10/15/19	JD	Review and provide existing ELs to Davis Polk for retention application.	0.30
10/16/19	LCV	Review and respond to emails re: updated retention documents from Davis Polk.	0.20
10/16/19	LCV	Revise retention documents.	0.40
10/16/19	LCV	Review and respond to additional updates to parties-in-interest list received from Davis Polk.	0.20
10/22/19	LCV	Review revised retention documents.	0.20
10/22/19	ESK	Revise and finalize retention pleadings for submission to UST	1.50
10/23/19	LCV	Research disclosure of certain related entities.	0.30
10/23/19	LCV	Emails re: retention documents and certain disclosures.	0.20
10/23/19	JD	Review and provide comments RE: retention documents	0.70
10/24/19	LCV	Review revised retention documents.	0.20
10/30/19	LCV	Call with E. Kardos, L. Verry, K. Sundt, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	0.30
10/30/19	LCV	Review UST's comments/concerns with retention documents.	0.20
10/30/19	LCV	Prepare summary/responses to UST's	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
		comments/concerns with retention documents.	
10/30/19	LCV	Email J. DelConte (AlixPartners) re: UST's comments re: retention documents.	0.10
10/30/19	ESK	Prepare for and attend call with E. Kardos, L. Verry, K. Sundt, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	1.00
10/30/19	TB	Call with E. Kardos, L. Verry, K. Sundt, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	0.30
10/30/19	KAS	Call with E. Kardos, L. Verry, K. Sundt, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	0.30
10/31/19	TB	Call with E. Kardos, L. Verry, K. Sundt and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	0.30
10/31/19	LCV	Call with E. Kardos and L. Verry (both AlixPartners) re: Pillowtex analysis per UST.	0.40
10/31/19	LCV	Call with E. Kardos, L. Verry, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST.	0.30
10/31/19	LCV	Review various documents for Pillowtex analysis.	0.50
10/31/19	ESK	Call with L. Verry, K. Sundt, B. Kardos, and T. Brewer (all AlixPartners) re: Pillowtex analysis per UST	0.30
10/31/19	ESK	Review Pillowtex analysis for UST	0.80
10/31/19	ESK	Review and finalize response to UST re: retention questions	0.50
10/31/19	ESK	Continue to address UST questions	0.80
10/31/19	ESK	Call with L. Verry and B. Kardos (both AlixPartners) re: Pillowtex analysis per UST.	0.40
11/01/19	LCV	Emails re: response to UST re: retention documents.	0.10
11/04/19	LCV	Emails with E. Kardos and K. Sundt (both AlixPartners) re: finalizing retention documents.	0.20
11/05/19	LCV	Provide exhibits to D. Consla (DavisPolk) re: retention	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
		documents.	
11/05/19	KAS	Update retention pleadings and circulate for internal signoff.	0.20
11/05/19	KAS	Send final retention pleadings to D. Consila (Davis Polk) for filing.	0.20
11/08/19	KAS	Review and edit draft firmwide email regarding potential relationship disclosures.	1.20
11/12/19	KAS	Review and edit firmwide email.	2.10
11/13/19	ESK	Review disclosure items in response to All Firm	0.50
11/13/19	LCV	Provide information to E. Kardos (AlixPartners) re: retention terms and conditions.	0.40
11/14/19	KAS	Review updated parties in interest received from D. Consila (DPW) and circulate to run through conflicts check.	0.20
11/14/19	KAS	Correspondence to D. Consila (DPW) regarding updated parties in interest categories.	0.20
11/15/19	ESK	Review and analyze disclosure matters in response to All Firm	1.50
11/15/19	KM	Manufacturing/COGS Meeting/Call - Purdue manufacturing (D. McGuire, J. Carlisle), J. Lowne (Purdue), advisors (Province, FTI, Jeffries)	0.80
11/19/19	ESK	Communicated with R. Collura and J. DelConte (both AlixPartners) re: filling of report and redactions	0.50
11/19/19	KAS	Internal correspondence regarding firm wide email responses and potential connections.	0.30
11/20/19	KM	Dec. 4-5 North Carolina plant visit coordination	0.80
11/21/19	KM	Review of proposed PHI scenario 3 for 2020 Strategic plan	0.80
11/21/19	ESK	Review email and orders re: compensation guidelines	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
11/21/19	ESK	Review and revise NDA requested by counsel	0.50
11/22/19	LCV	Retrieve retention order from docket and circulate.	0.10
11/22/19	KAS	Update supplemental declaration.	0.20
11/22/19	KAS	Update supplemental declaration of L. Donahue.	0.40
11/23/19	KAS	Circulate updated supplemental declaration to L. Donahue for approval.	0.20
11/26/19	ESK	Review order re retainer and other matters	0.30
12/02/19	LCV	Work on Supplemental Declaration.	0.50
12/03/19	LCV	Draft supplemental declaration of L. Donahue.	0.70
12/09/19	LCV	Prepare supplemental declaration re: rate increase notice.	0.40
12/17/19	LCV	Draft communication re: rate increases.	0.40
12/17/19	LCV	Draft supplemental declaration of J. DelConte (AlixPartners) re: information barrier program.	1.10
12/17/19	LCV	Emails with E. Kardos, L. Verry, and N. Andrews (all AlixPartners) re: supplemental declaration.	0.20
12/18/19	LCV	Revise supplemental affidavit.	0.30
12/19/19	LCV	Finalize supplemental declaration of L. Donahue re: rate changes and send for filing.	0.40
Total			33.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Tammy Brewer	0.60	430.00	258.00
Kaitlyn A Sundt	5.50	490.00	2,695.00
Laurie C Verry	10.20	490.00	4,998.00
Elizabeth S Kardos	12.30	685.00	8,425.50
Michael Hartley	0.40	830.00	332.00
Kevin M McCafferty	2.40	895.00	2,148.00
Jesse DelConte	1.60	945.00	1,512.00
Total Hours & Fees	33.00		20,368.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
09/25/19	KMD	Preparation of professional fees for September 2019.	1.50
09/30/19	KMD	Preparation of professional fees for September 2019	1.10
10/02/19	KMD	Preparation of professional fees for September 2019	0.50
10/09/19	KMD	Preparation of professional fees for September 2019	2.50
10/09/19	TB	Review court docket	0.20
10/10/19	KMD	Preparation of professional fees for September 2019	2.40
10/11/19	KMD	Preparation of professional fees for September 2019	0.90
10/14/19	KMD	Preparation of professional fees for October 2019	0.80
10/16/19	KMD	Preparation of professional fees for October 2019	0.50
10/17/19	KMD	Preparation of professional fees for October 2019	0.90
10/21/19	KMD	Preparation of professional fees for October 2019	2.50
10/23/19	KMD	Preparation of professional fees for September 2019	1.50
10/24/19	KMD	Preparation of professional fees for September 2019	2.00
10/31/19	TB	Prepare Pillowtex analysis for UST.	1.80
11/04/19	JD	Review initial September fee application	0.60
11/06/19	KMD	Preparation of professional fees for September 2019	1.50
11/07/19	KMD	Preparation of professional fees for October 2019	1.70
11/08/19	KMD	Preparation of professional fees for October 2019	2.50
11/14/19	KMD	Preparation of professional fees for October 2019	2.00
11/15/19	KMD	Preparation of professional fees for October 2019	4.70
11/18/19	KMD	Preparation of professional fees for October 2019	2.40
11/21/19	KMD	Preparation of professional fees for November 2019	0.50
11/21/19	LCV	Review compensation and expense reimbursement order.	0.10
11/22/19	JD	Review preliminary October invoice	1.80
11/23/19	TB	Review court docket for pertinent date and deadlines.	0.20
11/23/19	TB	Prepare September 2019 monthly fee statement with	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		supporting exhibits and schedules.	
11/25/19	TB	Prepare September 2019 monthly fee statement with supporting exhibits and schedules.	2.20
11/25/19	KMD	Preparation of professional fees for October 2019	1.00
11/25/19	KAS	Review monthly fee statement.	0.30
11/25/19	JD	Call with E. Kardos, L. Verry and J. DelConte (all AlixPartners) re: expense guidelines	0.20
11/25/19	LCV	Call with E. Kardos, L. Verry, and J. DelConte (all AlixPartners) re: expense guidelines.	0.20
11/25/19	LCV	Review district expense guidelines.	0.30
11/25/19	ESK	Call with E. Kardos, L. Verry, and J. DelConte (all AlixPartners) re: expense guidelines.	0.20
11/26/19	JD	Review and provide comments on the September fee application and the October draft invoice.	1.00
11/30/19	TB	Prepare September 2019 monthly fee statement with supporting exhibits and schedules.	1.30
12/02/19	TB	Prepare fee application for September 2019.	0.80
12/02/19	KAS	Respond to J. DelConte (AlixPartners) regarding offset of retainer.	0.30
12/02/19	JD	Review and finalize September fee statement.	0.60
12/06/19	TB	Review court docket.	0.20
12/06/19	TB	Review interim compensation order for pertinent dates and deadlines.	0.30
12/09/19	KMD	Preparation of professional fees for November 2019	3.90
12/10/19	KMD	Preparation of professional fees for November 2019	3.30
12/11/19	KMD	Preparation of professional fees for November 2019	5.00
12/12/19	TB	Preparation of October monthly fee statement and supporting exhibits.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
12/12/19	JD	Review and comment on draft October fee application.	0.70
12/17/19	TB	Review court docket.	0.20
12/17/19	KMD	Preparation of professional fees for November 2019	1.90
12/20/19	TB	Review court docket.	0.20
01/03/20	JD	Review draft November fee application and invoice from accounting.	0.50
01/07/20	JD	Review draft November fee application and invoice.	0.90
01/10/20	JD	Finalize and send around November invoice and draft November fee application.	0.50
01/10/20	TB	Preparation of fee statement and fee application for November 2019.	2.40
01/13/20	KAS	Review second monthly fee statement.	0.20
01/14/20	TB	Prepare monthly fee statement for November 2019.	0.80
01/14/20	JD	Review and comment on updated fee statement.	0.30
01/15/20	TB	Prepare monthly fee statement for November 2019	0.80
01/16/20	KMD	Preparation of professional fees for December 2019	2.80
01/17/20	KMD	Preparation of professional fees for December 2019	3.00
01/17/20	KMD	Continued preparation of professional fees for December 2019	3.20
01/18/20	KMD	Preparation of professional fees for December 2019	2.80
01/28/20	KMD	Preparation of professional fees for January 2020	1.40
01/30/20	KMD	Preparation of professional fees for January 2020	1.90
Total			90.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Kiera M Davids	47.50	400.00	19,000.00
Kiera M Davids	15.10	415.00	6,266.50
Tammy Brewer	14.90	430.00	6,407.00
Tammy Brewer	4.00	450.00	1,800.00
Laurie C Verry	0.60	490.00	294.00
Kaitlyn A Sundt	0.60	490.00	294.00
Kaitlyn A Sundt	0.20	510.00	102.00
Elizabeth S Kardos	0.20	685.00	137.00
Jesse DelConte	4.90	945.00	4,630.50
Jesse DelConte	2.20	950.00	2,090.00
Total Hours & Fees	90.20		41,021.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
09/17/19	MH	Listen to key motions for first day hearings.	1.80
09/17/19	JD	Prepare for and attend court hearing	4.20
09/17/19	RC	Dial in to the First Day hearing.	2.50
09/17/19	JAD	Participate in audio-cast of first day motion hearing.	3.00
09/17/19	SR	Attend first day hearing by dial in	3.60
10/10/19	RC	Dial in to second day hearings.	2.50
10/10/19	JD	Prepare for and participate in court hearing.	4.40
10/11/19	JD	Prepare for and attend the preliminary injunction hearing.	7.20
10/11/19	RC	Dial into preliminary injunction hearing.	2.10
10/11/19	RC	Continue to dial into preliminary injunction hearing.	2.20
10/11/19	RC	Continue dialing into preliminary injunction hearing.	0.90
11/04/19	DS	Gather data for Davis Polk for purposes of preliminary injunction hearing	1.60
11/05/19	RDS	Direct attribution of volume/pricing impact to Rhodes from a hypothetical Mallinckrodt exit from the generic opioid space - Oxycodone and Hydrocodone	0.60
11/06/19	JD	Attend court hearing on preliminary injunction extension	2.00
11/06/19	RDS	Dial into 11/6/19 hearing re Preliminary Injunction	0.60
11/06/19	RDS	Direct attribution of volume/pricing impact to Rhodes from a hypothetical Mallinckrodt exit from the generic opioid space	2.10
11/06/19	RC	Dial into preliminary injunction court hearing.	2.00
11/19/19	KM	Dial into phone call hearing: OCP and retention applications among others	0.50
11/19/19	JD	Preparation for court hearing.	1.20
11/19/19	JD	Attend omnibus court hearing.	4.20
11/19/19	RDS	Dial into phone call hearing: OCP and retention	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
		applications among others	
12/04/19	RDS	Dial into court hearings	1.10
12/04/19	JD	Preparation for court hearing on the wage motion.	0.80
12/04/19	JD	Attend court hearing.	3.60
12/05/19	RDS	Update analysis of Rhodes generic opioid SKU-level customer analysis	1.70
12/19/19	JD	Participate in court hearing.	1.60
12/19/19	RC	Dial into portion of court hearing related to Ernst & Young's retention and discussions around the AlixPartners cash transfers of value report.	1.30
Total			59.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Julie A Doherty	3.00	480.00	1,440.00
David Samikkannu	1.60	615.00	984.00
Ryan D Sublett	6.60	725.00	4,785.00
Scott Robertson	3.60	830.00	2,988.00
Michael Hartley	1.80	830.00	1,494.00
Kevin M McCafferty	0.50	895.00	447.50
Jesse DelConte	29.20	945.00	27,594.00
Richard Collura	13.50	1,080.00	14,580.00
Total Hours & Fees	59.80		54,312.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/16/19	RC	Review and analysis of cash distributions in response to requests from Davis Polk.	2.10
09/16/19	RC	Review draft transfer of value report and update information based on comments provided by Davis Polk.	2.30
09/16/19	RC	Review information related to responses to discovery requests by Rhode Island DA.	2.10
09/16/19	RC	Call with M. Clarens and J. Kiechel (both Davis Polk) to discuss Rhode Island discovery requests and additional work to perform regarding cash distributions.	0.50
09/16/19	RC	Review and analysis of fringe benefit data and update information in the draft transfer of value report.	0.80
09/16/19	RC	Review recent articles and research related party information in response to requests from Davis Polk.	0.70
09/16/19	NAS	Consolidate all raw data used in transfer of value analysis and providing it for the State of Rhode Island (through Restructuring Counsel) as requested by the State of Rhode Island	2.20
09/16/19	SJC	Distribution testing review	1.00
09/16/19	SJC	Review of flow of funds schedules.	1.20
09/16/19	SJC	Flow of funds analysis.	2.30
09/16/19	SJC	Analysis of distributions.	2.50
09/16/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	2.20
09/16/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	1.60
09/16/19	FOS	Review updated draft report slides and emails re: Ex-US royalties paid to PALP.	0.40
09/16/19	FOS	Analyze inter-company account settlement files re: shared services charges between PPLP and Rhodes entities.	4.80
09/16/19	FOS	Update draft transfer of value presentation re: shared	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		services charges between PPLP and Rhodes entities.	
09/16/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.40
09/16/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.10
09/16/19	KS	Review transactions in SAP and analyzed the inter-company charge.	0.80
09/16/19	KS	Review transactions in SAP and analyzed the inter-company charge.	1.40
09/16/19	KS	Draft the report slides regarding transfer pricing	1.40
09/16/19	REO	Review of data request reply from company re: intercompany account activity.	0.40
09/16/19	REO	Verification of data request reply by company in SAP re: intercompany account activity.	1.60
09/16/19	REO	Update slides for transfer pricing deck re: non-cash transfers of equity.	1.10
09/16/19	REO	Review of SAP system for transfer pricing support re: foreign cash settlements.	1.40
09/16/19	REO	Update transfer pricing deck slides re: updated foreign cash settlement support.	2.50
09/16/19	REO	Review of updated transfer pricing slides re: QC performed by engagement VP.	0.50
09/16/19	REO	Edit transfer pricing deck re: Implemented/followed up on changes suggested by engagement VP's QC.	0.70
09/16/19	JDH	QC Review of the flow of funds report.	5.70
09/16/19	SR	Read media reports of PPLP filing	1.00
09/17/19	SR	Amend Rhode Island data request, changes and proofing	0.50
09/17/19	SR	Discuss additional entities identified in court filings, search of named insureds	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/17/19	JDH	Analysis of payroll in order to update the flow of funds report.	2.20
09/17/19	JDH	Analysis of fringe benefits received from the company.	2.90
09/17/19	REO	Review of updated transfer pricing slides re: QC performed by engagement VP.	0.60
09/17/19	REO	Edit transfer pricing deck re: Implement/follow up on changes suggested by VP's QC.	1.00
09/17/19	KS	Draft the report slides regarding transfer pricing	1.50
09/17/19	KS	Review transactions in SAP and analyzed the inter-company charge.	2.60
09/17/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.80
09/17/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	1.80
09/17/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	1.70
09/17/19	LD	Review status of analysis	0.80
09/17/19	SJC	Distributions analysis; agreeing distributions to SAP.	2.10
09/17/19	SJC	Review PPT for consistency/to underlying schedules.	1.30
09/17/19	SJC	Vendor to distribution analysis.	1.90
09/17/19	SJC	Review of compensation and legal expenses in PowerPoint.	2.70
09/17/19	SJC	Review of distribution testing file.	2.00
09/17/19	NAS	Revisions to fringe benefit tables included in transfer of value presentation per updates provided on 9/18.	1.10
09/17/19	NAS	In-person meeting with B. Piacenza (TXP Services) to discuss whether or not vehicle maintenance charges were reimbursed by specific Purdue employees per investigation report (attended via telephone and dropped off call early).	0.40
09/17/19	NAS	Internal AlixPartners discussion (via email) regarding	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		expense reimbursement practices between PPLP, TXP Services Inc, and Sackler family members.	
09/17/19	NAS	Drafting detailed methodology notes for restructuring and litigation counsel regarding data analyzed and calculations performed to quantify value of fringe benefits received by specific Purdue employees and any related reimbursements.	1.10
09/17/19	RC	Review first day declaration and informational brief.	1.60
09/17/19	RC	Prepare responses to Rhode Island's discovery requests.	2.30
09/17/19	RC	Prepare summary of transfers of value information in response to requests from Davis Polk.	2.70
09/18/19	RC	Call with R. Collura, N. Simon (both AlixPartners), M. Clarens and E. Kim (both Davis Polk) to discuss response to Rhode Island's discovery requests.	0.60
09/18/19	RC	Review and update transfer of value analysis.	2.30
09/18/19	RC	Review and update schedules included in the transfer of value report.	2.40
09/18/19	RC	Gather information in response to discovery requests by Rhode Island.	1.60
09/18/19	RC	Prepare summary of transfer of value categories and provide to Davis Polk.	2.10
09/18/19	NAS	Revise overview tables of fringe benefits received by specific Purdue employees to incorporate latest information on reimbursements for amounts invoiced.	0.50
09/18/19	NAS	Quality check tables relating to fringe benefits received by specific Purdue employees that were provided in investigation report.	1.40
09/18/19	NAS	Call with R. Collura, N. Simon (both AlixPartners), M. Clarens and E. Kim (both Davis Polk) to discuss response to Rhode Island's discovery requests.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/18/19	SJC	Bank statement analysis and review of updated PowerPoint.	2.70
09/18/19	SJC	Sending flow of funds PowerPoint to team members.	0.30
09/18/19	SJC	Review of PowerPoint sent back from Design Team.	1.20
09/18/19	SJC	Adding new distributions/flows to the PowerPoint.	2.90
09/18/19	SJC	Making changes and updating PowerPoint per feedback from team.	0.90
09/18/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	2.30
09/18/19	MFR	Discuss status update on analysis and presentation draft with F. Silva and M. Rule (both AlixPartners).	0.20
09/18/19	KS	Review transactions in SAP and analyzed the inter-company charge.	2.40
09/18/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.90
09/18/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.70
09/18/19	KS	Perform the QC for the report slides regarding transfer pricing.	0.80
09/18/19	KS	Draft the report slides regarding transfer pricing	1.50
09/18/19	FOS	Discuss status update on analysis and presentation draft with F. Silva and M. Rule (both AlixPartners).	0.20
09/18/19	FOS	Compose email to AlixPartners re: draft presentation quality control responsibilities and tasks.	0.40
09/18/19	FOS	Update quality control status tracker re: draft transfer of value presentation.	0.40
09/18/19	FOS	Analyze inter-company account settlement files re: shared services charges between PPLP and Rhodes entities.	3.80
09/18/19	FOS	Update draft transfer of value presentation re: shared	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		services charges between PPLP and Rhodes entities.	
09/18/19	REO	Review latest deck for consistency with latest analyses/SAP support re: non-cash transfers.	2.30
09/18/19	REO	Update transfer pricing deck re: non-cash transfer slides (1/2).	1.60
09/18/19	REO	Review of transfer pricing deck for quality control re: slides prepared by engagement VP.	2.90
09/18/19	JDH	Perform analysis of travel and expenses submitted to the company on behalf of the Sackler family members.	1.40
09/18/19	JDH	Perform analysis of fringe benefits provided by the company.	1.10
09/18/19	JDH	Perform analysis of reimbursements submitted to the company on behalf of the Sackler family members.	2.10
09/18/19	JDH	Update flow of funds report based on additional analysis of travel and expenses, fringe benefits and other reimbursements.	3.60
09/18/19	SR	Meeting with K. Darragh re: intercompany accounts receivable between PRA and PPI	0.30
09/18/19	SR	Obtain updated ex-US loan excel schedule from K. Darragh, forward to R. Collura	0.20
09/18/19	SR	Read media coverage forwarded to email	1.00
09/19/19	SR	Respond to email request from E. Kim (Davis Polk) for additional information on schedule of loans to ex-us IAC prepared by K. Darragh (Purdue). Communication with K. Daragh to connect with E. Kim, follow up call with E. Kim.	0.50
09/19/19	JDH	Revise distribution flow of funds in the flow of funds report.	3.70
09/19/19	REO	Update transfer pricing deck re: non-cash transfer slides (2/2).	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/19/19	REO	Edit transfer pricing deck re: reconciliation of intercompany cash settlements.	0.80
09/19/19	REO	Review latest deck for consistency with latest analyses/SAP support re: cash transfers.	3.20
09/19/19	REO	Update slides for transfer pricing deck re: updated figures and SAP support for cash transfers.	2.20
09/19/19	FOS	Review draft transfers of value presentation re: quality control and updates.	3.60
09/19/19	KS	Draft the report slides regarding transfer pricing	2.10
09/19/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.50
09/19/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	2.10
09/19/19	SJC	Flow of funds bank statement analysis.	0.70
09/19/19	SJC	Analysis of flow of funds distributions.	2.70
09/19/19	SJC	SAP pull of transactions for flow of funds PowerPoint.	2.80
09/19/19	SJC	Writing instructions to send to Design Team.	0.70
09/19/19	SJC	Flow of funds PowerPoint review.	1.10
09/19/19	NAS	Review and accuracy check of revised T&E tables included in investigation report.	0.20
09/19/19	NAS	Revisions to entity classification key in flow of funds diagrams incorporated in investigation report.	0.30
09/19/19	RC	Review and incorporate comments regarding transfer of value analysis.	2.10
09/19/19	RC	Review discovery responses to Rhode Island requests.	0.60
09/19/19	RC	Update date transfer of value exhibits.	1.70
09/19/19	RC	Review and respond to emails from Davis Polk regarding Rhode Island discovery requests.	0.10
09/20/19	RC	Review and analysis of transfer of value categories and	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		update exhibits.	
09/20/19	RC	Review and update responses to DOJ requests.	2.40
09/20/19	RC	Review and comment of flow of funds distribution analysis.	1.80
09/20/19	NAS	Review response to data request summarizing of fringe benefits received by specific Purdue employees/owners for accuracy and completeness.	0.10
09/20/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	2.20
09/20/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	1.80
09/20/19	MFR	Discuss status on analysis and presentation draft with F. Silva and M. Rule (both AlixPartners).	0.10
09/20/19	KS	Update the report slides regarding transfer pricing.	1.70
09/20/19	KS	Draft the report slides regarding transfer pricing.	1.20
09/20/19	KS	Draft the report slides regarding transfer pricing	1.20
09/20/19	KS	Draft the report slides regarding transfer pricing	2.60
09/20/19	KS	Draft the report slides regarding transfer pricing	1.40
09/20/19	FOS	Discuss status on analysis and presentation draft with F. Silva and M. Rule (both AlixPartners).	0.10
09/20/19	FOS	Compose emails to AlixPartners re: licensing agreement between PPLP and Rhodes Pharma.	0.40
09/20/19	FOS	Analysis of SAP entries re: licensing agreement between PPLP and Rhodes Pharma	0.80
09/20/19	FOS	Review and update draft presentation slides re: R&D services provided to PPLP by IACs.	1.90
09/20/19	FOS	Review and Compose response to email from AlixPartners re: R&D services provided to PPLP by IACs.	0.40
09/20/19	FOS	Review and update draft presentation slides re: rent paid to Terramar by PPLP.	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/20/19	FOS	Review and update draft presentation slides re: royalties paid by PPLP to PRA for Betadine and Senokot.	0.40
09/20/19	FOS	Review and update draft presentation slides re: loan repayment to PPLP by ERG Realty.	0.40
09/20/19	FOS	Review and update draft presentation slides re: payments from Mundipharma to Purdue for finished products.	0.30
09/20/19	FOS	Review and update draft presentation slides re: royalties paid to PPLP by foreign IACs on various products.	1.00
09/20/19	FOS	Review and update draft presentation slides re: various non-cash transfers of value between PPLP and PRA.	0.50
09/20/19	FOS	Edit draft presentation slides re: general quality control and review.	1.40
09/20/19	REO	Review of transfer pricing deck for quality control re: slides prepared by engagement VP.	3.50
09/20/19	REO	Review of transfer pricing deck shared documentation support re: Box.	1.70
09/20/19	REO	Edit transfer pricing deck re: updated summary slides.	1.40
09/20/19	JDH	Revise the flow of funds report.	3.60
09/20/19	SR	Amend DOJ presentation for cell phones and distributions	1.50
09/22/19	MFR	Edits to Executive Summary of draft transfer pricing report.	1.80
09/23/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	2.10
09/23/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	2.70
09/23/19	FOS	Compose emails to R. Haberlin (Rhodes) re: licensing agreement between PPLP and Rhodes Pharma.	0.40
09/23/19	FOS	Compose emails to AlixPartners re: draft transfers of value presentation edits.	0.50
09/23/19	FOS	Edit draft presentation slides re: general quality control and review.	7.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/23/19	KS	Update the report slides regarding transfer pricing.	2.90
09/23/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.60
09/23/19	KS	Review transactions in SAP and analyzed the inter-company charge.	2.10
09/23/19	KS	Perform the QC for the report slides regarding transfer pricing.	0.80
09/23/19	SJC	Flow of funds bank statement analysis.	2.80
09/23/19	SJC	Adding new distributions/flows to the PowerPoint.	2.30
09/23/19	SJC	Review PowerPoint for consistency/to underlying schedules.	2.90
09/23/19	RC	Review responses to DOJ requests and incorporate comments.	2.40
09/23/19	RC	Review distributions flow of funds analysis and provide comments.	2.30
09/23/19	RC	Review and update transfer of value analysis.	1.80
09/23/19	RC	Review and respond to questions from Davis Polk regarding distribution information.	0.20
09/23/19	RC	Review and update information prepared in response to DOJ requests.	1.30
09/23/19	NAS	Expand analysis of T&E payments made through accounts payable to 2019 for inclusion in plaintiff data request and investigation report.	0.40
09/23/19	NAS	Update transfer of value tables requested by plaintiffs and checking for accuracy.	1.70
09/23/19	NAS	Internal coordination on DOJ and Rhode Island data requests to ensure comprehensiveness	0.20
09/23/19	NAS	Revise transfer of value investigation report.	0.30
09/23/19	SR	Review DOJ file for accuracy	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/23/19	SR	Review 2009 distributions file for accuracy	0.50
09/23/19	SR	Trace tax distributions from PPLP through PRA to PPI	2.50
09/23/19	JDH	Update distribution flows in the flow of funds report.	4.20
09/23/19	REO	Review documentation for SAP and all other support re: Box folder.	2.20
09/23/19	REO	Review data request response by company re: Intercompany settlement and supporting agreements.	2.50
09/23/19	REO	Edit transfer pricing deck re: updated information from the company supporting the intercompany settlement to cash.	1.60
09/23/19	REO	Research in SAP re: royalty amounts incurred in 2017 per conversation with engagement MD.	1.00
09/24/19	REO	Edit transfer pricing deck re: updated data from company on intercompany settlements.	1.50
09/24/19	REO	Review of slides for quality control re: slides prepared by engagement VP for Purdue.	2.50
09/24/19	REO	Edit transfer pricing deck for quality control re: slides prepared by engagement SVP.	3.30
09/24/19	REO	Review of transfer pricing deck for quality control re: SAP screenshots and accounting slides.	1.70
09/24/19	JDH	Update flow of funds report through September 23.	5.40
09/24/19	JDH	Update flow of funds deck - pensions.	0.80
09/24/19	JDH	Meeting with R. Piacenza (One Stamford Realty) regarding fringe benefits.	1.30
09/24/19	ADD	Meeting with N. Simon, A. DePalma and C.S. Robertson (all AlixPartners) to discuss method for quantifying intercompany cash flows	0.30
09/24/19	SR	Meeting with N. Simon, A. DePalma and C.S. Robertson (all AlixPartners) to discuss method for quantifying	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany cash flows	
09/24/19	SR	Prepare abstract of audited statement of cash flows	1.00
09/24/19	SR	Reconcile distributions from PPLP to PPI via PRA 2008-20017 to establish total PPI distributions, all intercompany activity between PRA and PPI, intercompany receivable from PRA to PPI	7.00
09/24/19	RC	Review and update expense reimbursement analysis	2.10
09/24/19	RC	Review and update fringe benefit analysis.	1.70
09/24/19	RC	Review and update cash distributions analysis.	2.20
09/24/19	RC	Review and update the transfer of value report.	2.00
09/24/19	SJC	Updating PowerPoint for additional distributions.	2.90
09/24/19	SJC	Analysis of vendors receiving distributions	2.70
09/24/19	SJC	Review underlying schedules to PowerPoint.	1.10
09/24/19	SJC	Review PowerPoint for both numerical and grammatical consistency.	1.30
09/24/19	NAS	Meeting with N. Simon, A. DePalma and C.S. Robertson (all AlixPartners) to discuss method for quantifying intercompany cash flows	0.30
09/24/19	NAS	Confirm benefit end dates for responses to plaintiff questions.	0.50
09/24/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.30
09/24/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.60
09/24/19	KS	Update the report slides regarding transfer pricing.	1.40
09/24/19	KS	Update the report slides regarding transfer pricing.	1.20
09/24/19	KS	Review transactions in SAP and analyzed the inter-company charge.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/24/19	FOS	Review status of draft transfer of value presentation.	0.20
09/24/19	FOS	Update summary schedules re: draft transfer of value presentation.	2.20
09/24/19	FOS	Edit draft presentation slides re: general quality control and review.	2.60
09/24/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	2.50
09/24/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	2.30
09/25/19	MFR	Review of Exhibit 1 of draft transfer pricing report.	2.40
09/25/19	MFR	Edits to Exhibit 1 of draft transfer pricing report.	2.60
09/25/19	MFR	Review of Appendix 1 to draft transfer pricing report.	2.80
09/25/19	MFR	Edits to Appendix 1 to draft transfer pricing report.	2.30
09/25/19	LD	Review status of analysis	0.90
09/25/19	MFR	Discuss draft presentation quality control and staffing with F. Silva and M. Rule (both AlixPartners).	0.20
09/25/19	MH	Prepare for Schedules reviews with staff members.	0.60
09/25/19	KS	Review transactions in SAP and analyzed the inter-company charge.	2.10
09/25/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.60
09/25/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.30
09/25/19	KS	Update the report slides regarding transfer pricing.	2.10
09/25/19	FOS	Review payments to/from IACs RE: SOFA/SOAL preparation.	0.20
09/25/19	FOS	Review of draft transfer of value presentation re: quality control of non-cash distributions to PRA.	3.00
09/25/19	FOS	Discuss draft presentation quality control and staffing with F. Silva and M. Rule (both AlixPartners).	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/25/19	FOS	Compose emails to AlixPartners re: quality control of draft presentation deck.	0.20
09/25/19	SJC	Review PowerPoint for both numerical and grammatical consistency.	2.50
09/25/19	SJC	Editing for comments and questions on flow of funds PowerPoint.	2.70
09/25/19	SJC	Charitable contributions review.	2.80
09/25/19	RC	Call with S. Robertson, R. Collura (both AlixPartners) and J. Kiechel (Davis Polk) to discuss status of transfer of value report and additional work streams.	0.60
09/25/19	RC	Review and update transfer of value analysis draft report and provide to Davis Polk.	2.70
09/25/19	RC	Prepare additional updates to the transfer of value analysis report based on comments from Davis Polk.	1.50
09/25/19	RC	Call with J. Kiechel (Davis Polk) to discuss the transfer of value analysis.	0.20
09/25/19	RC	Update schedules for DOJ based on comments from Skadden.	0.80
09/25/19	RC	Review and update various schedules supporting the transfer of value analysis.	1.70
09/25/19	RC	Review and update flow of funds distributions analysis.	0.60
09/25/19	SR	Add description of non-cash distributions to DOJ/Skadden information request	0.40
09/25/19	SR	Meeting with K. Darragh (Purdue) re PPI intercompany receivable from PRA, discuss details of sliver distributions and movement among companies 208, 416 and 301	1.50
09/25/19	SR	Call with S. Robertson, R. Collura (both AlixPartners) and J. Kiechel (Davis Polk) to discuss status of transfer of value report and additional work streams.	0.60
09/25/19	SR	Emails and call to K. Darragh (Purdue Controller) re PPI	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany receivable	
09/25/19	REO	Review of updated transfer pricing deck re: new intercompany analyses for previously QC'd sections prepared by engagement VP and SVP.	3.50
09/25/19	REO	Review of follow-ups by engagement SVP re: cash transfers and SAP support.	3.60
09/25/19	REO	Review of comments and suggested edits re: engagement SVP and VP QC.	1.60
09/25/19	REO	Verify proper documentation and support for transfer pricing deck re: SAP and Box.	1.50
09/26/19	REO	Correct non cash transfer slides re: Accounting and organization of slides.	1.90
09/26/19	REO	Consolidate all agreements mentioned within the transfer pricing deck for TRS engagement team.	1.70
09/26/19	REO	Review transfer pricing deck for universal consistency re: Cash Transfers - G/L account and company account codes.	3.50
09/26/19	REO	Edit transfer pricing deck re: Appendix 1 for updated G/L account codes and company codes.	2.30
09/26/19	REO	Meeting with F. Silva and R. Ochoa (both AlixPartners) re: Review of non-cash transfers and relevant SAP support.	0.50
09/26/19	JDH	Collection of supporting documentation for the flow of funds report.	3.90
09/26/19	JDH	Update the flow of funds report based on comments from R. Collura (AlixPartners).	4.30
09/26/19	ADD	Prepare for transfer of value presentation review session.	1.20
09/26/19	ADD	Analyze transaction for value transfer presentation.	1.70
09/26/19	SR	Meeting with J. Lowne, K. Darraugh (both PPLP) , J. Kiecheal (Davis Polk, by phone), M. Hartley, R. Collura (both AlixPartners) and S. Robertson (AlixPartners, by	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		phone) to discuss distribution analysis.	
09/26/19	SR	Follow up on comments made in 4 PM conference call specifically changes to wording in detailed reconciliation of distributions to audit reports, clarification of distribution amounts and payees	1.70
09/26/19	SR	Confirm Millsaw distribution as shown in transfer of value report	0.50
09/26/19	RC	Prepare updates to responses to requests from the DOJ.	2.60
09/26/19	RC	Prepare responses to Skadden regarding responses to DOJ requests.	0.60
09/26/19	RC	Call with J. Kiechel (Davis Polk) to discuss transfer of value analysis.	0.50
09/26/19	RC	Call with J. Kiechel (Davis Polk) to discuss comments related to the transfer of value analysis report.	0.70
09/26/19	RC	Research and respond to questions from Davis Polk regarding distributions.	0.50
09/26/19	RC	Meeting with J. Lowne (PPLP), J. Kiechel (Davis Polk, by phone), M. Hartley and R. Collura (both AlixPartners) to review draft of transfer of value analysis.	1.10
09/26/19	RC	Meeting with J. Lowne, K. Darraugh (both PPLP), J. Kiecheal (Davis Polk, by phone), M. Hartley, R. Collura (both AlixPartners) and S. Robertson (AlixPartners, by phone) to discuss distribution analysis.	1.30
09/26/19	RC	Meeting with K. Darraugh (PPLP) to discuss distribution analysis.	0.60
09/26/19	RC	Review and update flow of funds analysis.	2.10
09/26/19	RC	Review and update exhibits to the transfer of value report.	1.70
09/26/19	RC	Review and update transfer of value analysis.	2.10
09/26/19	SJC	Review and update of PowerPoint and underlying support.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/26/19	NAS	Consolidate latest versions of fringe benefit overview tables for inclusion in investigation report and communication with interested parties.	0.20
09/26/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.50
09/26/19	KS	Update the report slides regarding transfer pricing.	2.00
09/26/19	KS	Review transactions in SAP and analyzed the inter-company charge.	1.20
09/26/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.80
09/26/19	FOS	Perform quality control review on Draft presentation re: Non-cash transfers of value.	4.40
09/26/19	FOS	Prepare materials for AlixPartners re: support for transfers of value between debtors and non-debtors 2017 to present.	2.60
09/26/19	FOS	Discuss deliverables for FTI request on payments between debtor and non-debtor entities with F. Silva and M. Rule (both AlixPartners).	0.50
09/26/19	FOS	Meeting with F. Silva and R. Ochoa (both AlixPartners) re: Review of non-cash transfers and relevant SAP support.	0.50
09/26/19	KS	Update the report slides regarding transfer pricing.	0.70
09/26/19	MH	Prepare for forensic report review with the CFO.	0.80
09/26/19	MH	Meeting with J. Lowne (PPLP), J. Kiechel (Davis Polk, by phone), M. Hartley and R. Collura (both AlixPartners) to review draft of transfer of value analysis.	1.10
09/26/19	MH	Meeting with J. Lowne, K. Darraugh (both PPLP), J. Kiecheal (Davis Polk, by phone), M. Hartley, R. Collura (both AlixPartners) and S. Robertson (AlixPartners, by phone) to discuss distribution analysis.	1.30
09/26/19	MFR	Discuss deliverables for FTI request on payments between	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		debtor and non-debtor entities with F. Silva and M. Rule (both AlixPartners).	
09/26/19	MFR	Edits to Executive Summary of draft transfer pricing report.	2.10
09/26/19	MFR	Review of Executive Summary of draft transfer pricing report.	2.70
09/26/19	MFR	Review of Exhibit 2 of draft transfer pricing report.	2.20
09/26/19	MFR	Edits to Exhibit 2 of draft transfer pricing report.	2.10
09/27/19	MFR	Edits to Exhibit 2 of draft transfer pricing report.	1.80
09/27/19	MFR	Review of Exhibit 2 of draft transfer pricing report.	2.60
09/27/19	MFR	Review of Appendix 2 to draft transfer pricing report.	2.40
09/27/19	LD	Review investigation deck	2.30
09/27/19	RC	Review and update flow of funds analysis charts.	2.30
09/27/19	RC	Call with J. Kiechel (Davis Polk) regarding DOJ requests.	0.20
09/27/19	RC	Review and update responses to requests from Skadden Arps related to DOJ requests.	0.80
09/27/19	RC	Call with M. Florence (Skadden Arps) to discuss responses to DOJ requests.	0.10
09/27/19	RC	Research requests from Davis Polk regarding cash distributions.	0.80
09/27/19	RC	Review and update draft transfer of value analysis.	2.30
09/27/19	RC	Update responses to DOJ requests and provide to Skadden Arps and Davis Polk.	0.30
09/27/19	RC	Update transfer of value analysis.	1.10
09/27/19	RC	Review supporting documents and prepare updates to the flow of funds analysis.	1.40
09/27/19	SR	Review internal classification of each transaction traced in the transfer of value deck for consistency with	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		presentation	
09/27/19	SR	Respond and review to questions of general ledger activity regarding intercompany transfers between Rhodes and PPLP	0.50
09/27/19	SR	Respond to email and reply to Skadden inquiry regarding flow of funds from PPLP to PRA	0.20
09/27/19	SR	Respond to emails and responses re: intercompany transfers between Rhodes and PPLP	1.00
09/27/19	JDH	Create additional flow of funds charts for the flow of funds report.	4.70
09/27/19	JDH	Update flow of funds report to include updated travel and expense information.	1.30
09/27/19	JDH	Revisions to flow of funds charts within the report.	2.10
09/27/19	REO	Review transfer pricing deck for universal consistency re: Non-Cash Transfers - G/L account codes and company account codes.	3.40
09/27/19	REO	Edit transfer pricing deck re: Appendix 1 for updated G/L account codes and company codes	2.80
09/27/19	REO	Review full transfer pricing deck re: profit center codes, cost center codes and all other codes shown in SAP screenshots.	2.10
09/27/19	REO	Edit transfer pricing deck re: Appendix 1 for profit center codes, cost center codes and all other codes shown in SAP screenshots.	1.00
09/28/19	SR	Respond to questions regarding classification of distributions to Beacon and Rosebay included in ex-US distributions	2.00
09/28/19	RC	Review and update transfer of value analysis report based on comments from Purdue and Davis Polk.	2.30
09/28/19	RC	Research and respond to questions from Davis Polk and	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Purdue related to distributions analysis.	
09/28/19	RC	Review and update transfer of value analysis based on additional comments from Davis Polk and Purdue.	1.40
09/28/19	MFR	Review of Executive Summary of draft transfer pricing report.	1.50
09/29/19	RC	Review and respond to questions from J. Lowne (Purdue) regarding the transfer of value analysis.	0.50
09/29/19	NAS	Provide supporting documentation to answer questions regarding intercompany agreements listed in investigation report.	0.10
09/30/19	NAS	Coordinating with Associate Director at One Stamford Realty to obtain supporting documentation that addresses questions regarding intercompany agreements listed in investigation report.	0.70
09/30/19	SJC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) re: value transfer presentation review	0.30
09/30/19	SJC	Follow-up on compensation and AP.	1.80
09/30/19	SJC	Schedule and review flow of funds.	4.00
09/30/19	SJC	Review distribution analysis.	2.00
09/30/19	RC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) re: value transfer presentation review	0.30
09/30/19	RC	Review and update transfer of value analysis based on additional work performed.	2.70
09/30/19	RC	Review corporate organization charts and related information in order to update information included in the transfer of value report.	1.30
09/30/19	RC	Prepare emails to PPLP regarding documentation related to the transfer of value analysis.	0.20
09/30/19	RC	Review and update exhibits to the transfer of value report.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/30/19	MFR	Edits to Appendix 2 to draft transfer pricing report.	2.70
09/30/19	MFR	Review of Exhibit 1 to draft transfer pricing report.	1.80
09/30/19	MFR	Edits to Exhibit 1 of the draft transfer pricing report.	2.20
09/30/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.40
09/30/19	KS	Update the report slides regarding transfer pricing.	1.50
09/30/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.80
09/30/19	KS	Update the report slides regarding transfer pricing.	1.60
09/30/19	FOS	Perform quality control review on Draft presentation re: Non-cash transfers of value.	3.80
09/30/19	FOS	Draft update email re: transfers of value report drafting and workflow status.	0.20
09/30/19	FOS	Edits to draft presentation re: Non-cash transfers of value.	3.90
09/30/19	SR	Research and confirm status of distributions as ex-US vs US partner	2.00
09/30/19	REO	Research of SAP system re: request by engagement SVP for new accounting support of non-cash transfers.	2.40
09/30/19	REO	Edit transfer pricing deck re: updated SAP support and incorporation of comments by engagements SVP.	3.10
09/30/19	REO	Update Box folder re: new SAP support and back-up excel files for transfer pricing deck.	0.80
09/30/19	REO	Review of new slides for transfer pricing deck re: suggested comments and edits from SVP on non-cash transfer	1.50
09/30/19	ADD	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) re: value transfer presentation review	0.30
09/30/19	ADD	Review value transfer presentation in preparation for	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		submission to DOJ.	
09/30/19	ADD	Receive and document approvals for due diligence items uploaded to the virtual data room	0.90
09/30/19	LH	QC of Transfer of Value Analysis	3.10
09/30/19	LH	Review and comment on Transfer of Value Analysis	2.20
10/01/19	LH	Additional QC	1.50
10/01/19	REO	Review of transfer pricing slides re: slides prepared by the leading engagement SVP for edits suggested as part of the quality control process.	1.30
10/01/19	REO	Edit transfer pricing deck re: update slides per comments from engagement SVP as part of the quality control process.	1.80
10/01/19	REO	Research in SAP re: updated documentation of SAP entries for transfer pricing slides.	1.40
10/01/19	REO	Review transfer pricing deck accounting slides re: Verification of entities involved cash and non-cash transfers and their respective positions within Purdue's ownership structure.	2.50
10/01/19	JDH	Update flow of funds report through September 30, 2019.	1.20
10/01/19	SR	Create summary table of distributions for inclusion in transfer of value deck	1.00
10/01/19	KS	Review transactions in SAP and analyze the inter-company charge.	2.90
10/01/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.50
10/01/19	KS	Update the report slides regarding transfer pricing.	2.80
10/01/19	FOS	Edit draft intercompany transfer of value presentation re: quality control findings.	7.80
10/01/19	MFR	Revisions to Exhibit 1A of the transfer pricing report.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/01/19	MFR	Revisions to Exhibit 1B of the transfer pricing report.	1.30
10/01/19	MFR	Revisions to Exhibit 1C of the transfer pricing report.	1.20
10/01/19	MFR	Review of Exhibit 1A of transfer pricing report and supporting documentation and analyses.	2.60
10/01/19	MFR	Review of Exhibit 1B of transfer pricing report and supporting documentation and analyses.	2.40
10/01/19	MFR	Review of Exhibit 1C of transfer pricing report and supporting documentation and analyses.	2.10
10/01/19	MH	Attend call with R. Collura and M. Hartley (both AlixPartners) to review updates to the forensic report.	0.50
10/01/19	MH	Review request to extend the forensic report to 9/30 to determine work plan to complete.	0.60
10/01/19	MH	Research historical reimbursement of shared telecom costs at company headquarters for forensic report.	0.90
10/01/19	RC	Review and analysis of transfer of value support and update related report exhibits.	2.20
10/01/19	RC	Attend call with R. Collura and M. Hartley (both AlixPartners) to review updates to the forensic report.	0.50
10/01/19	RC	Meeting with J. Dubel (Special Committee), C. Duggan and J. Kiechel (both Davis Polk) to discuss transfer of value analysis.	2.00
10/01/19	RC	Update the transfer of value report.	1.70
10/01/19	RC	Continue updating transfer of value analysis report.	2.40
10/01/19	RC	Review additional transfer of value analysis and update report.	2.10
10/01/19	NAS	Update summary of fringe benefits received for investigation report through 9/30/19.	0.30
10/01/19	NAS	Analysis of arrangement between PPLP, TXP Services, and Pharmaceutical Research Associates regarding bill for	1.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		usage of certain landlines.	
10/02/19	SJC	Downloading supporting distributions documents from SAP.	2.40
10/02/19	SJC	Review and edit of distributions file.	2.60
10/02/19	SJC	Analysis and testing of distributions.	3.00
10/02/19	RC	Review and analysis of cash transfers and update relevant section of draft report.	2.70
10/02/19	RC	Update transfer of value report and related exhibits.	2.20
10/02/19	RC	Review analysis related to transfer of value categories and prepare updates to the report.	1.60
10/02/19	RC	Review corporate organization charts and updates report appendix.	0.70
10/02/19	RC	Review and update the flow of funds and tracing analysis included in draft report.	1.40
10/02/19	NAS	Revise investigation report per comments from restructuring counsel.	0.40
10/02/19	MH	Review legal and pension expenses in the forensic report.	0.60
10/02/19	MH	Draft new language to describe future pension benefits in the forensic report.	0.30
10/02/19	MFR	Review of Exhibit 1D of transfer pricing report and supporting documentation and analyses.	2.40
10/02/19	MFR	Review of Exhibit 1E of transfer pricing report and supporting documentation and analyses.	1.90
10/02/19	MFR	Review of Exhibit 1F of transfer pricing report and supporting documentation and analyses.	2.10
10/02/19	MFR	Revisions to Exhibit 1D of the transfer pricing report.	1.00
10/02/19	MFR	Revisions to Exhibit 1E of the transfer pricing report.	0.70
10/02/19	MFR	Revisions to Exhibit 1F of the transfer pricing report.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/02/19	MFR	Conference call with F. Silva, M. Rule, K. Shibuya, and R. Ellis Ochoa (all AlixPartners) re: intercompany transfers of value workstream update discussion.	0.40
10/02/19	FOS	Edit draft intercompany transfer of value presentation re: quality control findings.	5.60
10/02/19	FOS	Conference Call with M. Rule, F. Silva, K. Shibuya, and R. Ellis Ochoa (all AlixPartners) re: intercompany transfers of value workstream update discussion.	0.40
10/02/19	KS	Conference Call with M. Rule, F. Silva, K. Shibuya, and R. Ellis Ochoa (all AlixPartners) re: intercompany transfers of value workstream update discussion.	0.40
10/02/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.30
10/02/19	KS	Update the report slides regarding transfer pricing.	2.70
10/02/19	KS	Review transactions in SAP and analyze the inter-company charge.	2.70
10/02/19	SR	Review wording change from "distribution" to "transfers" to capture distributions reclassified as loans.	0.50
10/02/19	SR	Update PPI accounts payable analysis through the end of September 2019. Import additional AP data and amend table by payee.	0.70
10/02/19	SR	Enter and sort AP data for PPI 2019 YTD	1.20
10/02/19	JDH	Update travel and expense reporting through September 30, 2019.	2.10
10/02/19	JDH	Update accounts payable reporting through September 30, 2019.	1.80
10/02/19	JDH	Analyze Purdue Pharma Inc. Distributions.	4.30
10/02/19	REO	Edit transfer pricing deck re: updated slides per comments from leading engagement SVP.	2.50
10/02/19	REO	Edit excel support file for transfer pricing deck re: ensure	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		data consistency between slides and excel sheets.	
10/02/19	REO	Update Box files re: upload newly updated excel supports files for transfer pricing deck	0.90
10/02/19	REO	Research SAP database re: continue to research SAP codes and abbreviations for appendix.	1.30
10/02/19	ADD	Research Purdue Pharma Inc. account activity.	1.40
10/02/19	LH	Additional QC	2.30
10/02/19	LH	Continue QC	1.80
10/02/19	REO	Conference Call with M. Rule, F. Silva, R. Ochoa and K. Shibuya (all AlixPartners) re: intercompany transfers of value workstream update discussion.	0.40
10/03/19	LH	Continue QC	2.10
10/03/19	LH	Continue QC	1.60
10/03/19	ADD	Update distribution schedules for value transfer presentation.	2.90
10/03/19	ADD	Analyze transaction using Purdue's SAP accounting system.	1.50
10/03/19	ADD	Update value transfer presentation slides.	1.20
10/03/19	REO	Review of transfer pricing deck re: review of updated information for non-cash transfer as per comments from engagement Director.	3.80
10/03/19	REO	Research Sap database re: historical review of non-cash transfers as per comments from engagement Director.	1.00
10/03/19	REO	Research SAP Database re: additional SAP codes and abbreviations as per comments from engagement Director.	1.60
10/03/19	JDH	Create flow of funds for Purdue Pharma Inc. distributions.	3.60
10/03/19	JDH	Discussion with Tracy Gilroy (Purdue) regarding the timing of Databasics go-live.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/03/19	JDH	Revise flow of funds report to reflect accurate periods of T&E reimbursement systems.	3.10
10/03/19	SR	Edit transfer of value deck on call with R. Collura (AlixPartners). Changes to language in distributions, discussion of loans vs. distributions, distinction of \$35 million tax transfer in 2017 etc.	1.00
10/03/19	SR	Reconcile payee names on Exhibit C to payee names shown in the flow of funds chart	0.40
10/03/19	SR	Identify payee for PPI dividend in 2012	0.50
10/03/19	SR	Work with A. DePalma (AlixPartners) to amend items found in AP, modify tables and transfer of value report to reflect update	2.10
10/03/19	SR	Read media reports, J&J settlements and J&J assertion of judges \$107 million error, statements by AGs in opposition to settlement	0.50
10/03/19	SR	Review file of intercompany disbursements prepared by R. Kennedy (Purdue) for SOFA. Compare to file of intercompany activity by month through 2018, compare to description of entity in MDL deck	1.50
10/03/19	SR	Edits to flow of funds deck prepared by J. Hecht (AlixPartners)	0.80
10/03/19	SR	Respond to R. Collura (AlixPartners) inquiries regarding language in transfer of value deck around AP queries and procedures	1.20
10/03/19	KS	Review transactions in SAP and analyze the inter-company charge.	0.80
10/03/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.60
10/03/19	KS	Update the report slides regarding transfer pricing.	1.60
10/03/19	KS	Perform the QC for the report slides regarding transfer	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		pricing.	
10/03/19	KS	Update the report slides regarding transfer pricing.	1.90
10/03/19	FOS	Edit draft intercompany transfer of value presentation re: quality control findings.	6.40
10/03/19	FOS	Review transfers of value presentation draft status and schedule of intercompany payments.	0.40
10/03/19	FOS	Reconcile schedule of intercompany payments re: transfers of value draft presentation.	1.20
10/03/19	BSC	Draft email to explain bank statement reconciliation work performed and results thereof	0.40
10/03/19	MFR	Revisions to Exhibit 1G of the transfer pricing report.	1.10
10/03/19	MFR	Revisions to Exhibit 1H of the transfer pricing report.	0.80
10/03/19	MFR	Revisions to Exhibit 1I of the transfer pricing report.	1.20
10/03/19	MFR	Review of Exhibit 1G of transfer pricing report and supporting documentation and analyses.	1.80
10/03/19	MFR	Review of Exhibit 1H of transfer pricing report and supporting documentation and analyses.	2.20
10/03/19	MFR	Review of Exhibit 1I of transfer pricing report and supporting documentation and analyses.	1.90
10/03/19	RC	Incorporate comments from Davis Polk related to the transfer of value analysis.	2.20
10/03/19	RC	Update draft report and related exhibits.	2.70
10/03/19	RC	Review distributions flow of funds analysis and support documentation.	1.70
10/03/19	RC	Review and update cash transfers of value tables and exhibits.	2.20
10/03/19	RC	Review benefit payments analysis and update transfer of value report.	1.60
10/03/19	RC	Review and analysis of support documentation and	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		update transfer of value report.	
10/03/19	RC	Update draft transfer of value report and incorporate comments from Davis Polk.	1.10
10/03/19	NAS	Revisions to investigation report per comments from restructuring counsel.	0.30
10/04/19	NAS	Clarify point in investigation report regarding employees of Purdue Pharma Inc. and incorporating revisions per comments from restructuring counsel.	0.80
10/04/19	RC	Review and prepare updates to draft report in response to requests from the DOJ.	2.20
10/04/19	RC	Continue to work on draft report in response to requests from DOJ.	1.90
10/04/19	RC	Call with J. Kiechel (Davis Polk) to discuss draft of the transfer of value report.	0.20
10/04/19	RC	Review and analysis of PPI's cash disbursements.	1.30
10/04/19	RC	Follow-up call with J. Kiechel (Davis Polk) to discuss comments related to the transfer of value report.	0.10
10/04/19	RC	Review and update transfer of value report based on comments from Davis Polk.	1.40
10/04/19	RC	Prepare draft transfer of value report and send to Skadden and Davis Polk in response to requests from DOJ.	1.00
10/04/19	MFR	Review of Exhibit 1J of transfer pricing report and supporting documentation and analyses.	2.60
10/04/19	MFR	Review of Exhibit 1K of transfer pricing report and supporting documentation and analyses.	2.10
10/04/19	MFR	Review of Exhibit 1L of transfer pricing report and supporting documentation and analyses.	2.20
10/04/19	MFR	Revisions to Exhibit 1J of the transfer pricing report.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/04/19	MFR	Revisions to Exhibit 1K of the transfer pricing report.	1.40
10/04/19	MFR	Revisions to Exhibit 1L of the transfer pricing report.	1.20
10/04/19	MFR	Discussion with F. Silva and M. Rule (both AlixPartners) re: intercompany general ledger analysis.	0.20
10/04/19	MH	Advise investigation team lead on accuracy of various statements relative to the relationship between Purdue and TXP Services.	0.40
10/04/19	FOS	Discussion with F. Silva and M. Rule (both AlixPartners) re: intercompany general ledger accounts analysis.	0.20
10/04/19	FOS	Compose email to R. Kennedy (TXP Services) re: intercompany transfers analysis.	0.30
10/04/19	FOS	Review intercompany transfers schedule re: reconciliation to draft transfers of value presentation.	3.50
10/04/19	FOS	Reconcile intercompany general ledger account activity re: draft presentation on transfers of value.	3.70
10/04/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.60
10/04/19	KS	Review transactions in SAP and analyze the inter-company charge.	2.50
10/04/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.10
10/04/19	KS	Update the report slides regarding transfer pricing.	1.90
10/04/19	SR	Review edits to report sent to Davis Polk overnight including \$35 million tax distribution 12/17, Rhodes classification of tax vs non-tax distribution, charitable contributions made by PPI on behalf of the Sackler family, background on changes to items found in AP.	2.10
10/04/19	SR	Tie out authorizations and wire instructions for all PPI charitable payments	2.10
10/04/19	SR	Draft PPI deck	4.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/04/19	SR	Read media reports, specifically figure of \$12-\$13 billion in distributions to Sacklers, UCC activity	0.50
10/04/19	JDH	Create and update flows of funds for PPI report.	2.30
10/04/19	REO	Research SAP database re: continued to review intercompany cash payments for SOFAs.	1.50
10/04/19	REO	Review of transfer pricing deck re: slide edits and comments by engagement leading SVP.	1.70
10/04/19	REO	Edit transfer pricing deck re: updated slides per comments from engagement leading SVP.	2.00
10/04/19	REO	Update SAP documentation re: Box folders.	1.10
10/04/19	ADD	Research transactions for value transfer presentation.	1.60
10/04/19	ADD	Review data provided for SOFAs and schedules.	1.70
10/05/19	MFR	Revisions to Exhibit 1M of the transfer pricing report.	0.80
10/05/19	MFR	Revisions to Exhibit 1N of the transfer pricing report.	1.20
10/05/19	MFR	Review of Exhibit 1M of transfer pricing report and supporting documentation and analyses.	2.20
10/05/19	MFR	Review of Exhibit 1N of transfer pricing report and supporting documentation and analyses.	2.50
10/06/19	MFR	Review of Exhibit 1O of transfer pricing report and supporting documentation and analyses.	2.60
10/06/19	MFR	Review of Exhibit 1P of transfer pricing report and supporting documentation and analyses.	3.70
10/06/19	MFR	Revisions to Exhibit 1O of the transfer pricing report.	0.90
10/06/19	MFR	Revisions to Exhibit 1P of the transfer pricing report.	2.20
10/06/19	RC	Review and respond to questions from Davis Polk regarding distributions.	2.40
10/06/19	RC	Prepare responses to questions from Davis Polk regarding distributions.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/06/19	RC	Call with M. Huebner (Davis Polk) to discuss distributions analysis.	0.20
10/06/19	SR	Respond to M. Heubner (Davis Polk) emails regarding distributions and timing of distributions. Produce new schedules for selected time periods	3.00
10/07/19	SR	Create table of charitable contribution by date and payee for PPI	0.60
10/07/19	SR	Update PPI deck for charitable contributions, transmit to S. Canniff, and A. DePalma (both AlixPartners) with instructions for additional items to add to report	1.10
10/07/19	SR	Call with R. Collura and S. Robertson (both AlixPartners) to discuss cash and non-cash distributions.	0.50
10/07/19	SR	Call with R. Collura, and S. Robertson (both AlixPartners) updating requests for clarification from M. Heubner (Davis Polk) received earlier in the day as additional information is received from Purdue.	0.20
10/07/19	SR	Vet schedules and files supplied by Purdue in response to Davis Polk inquires	0.60
10/07/19	SR	Read media reports	0.20
10/07/19	REO	Review of updated SAP codes re: company-delivered explanations of code definitions and proper usage.	0.60
10/07/19	REO	Edit Transfer Pricing Deck re: updated SAP codes and definitions within Appendix per communications with the company.	1.70
10/07/19	REO	Review of Transfer Pricing Deck re: consistency of universal formatting edits for slides and tables.	2.30
10/07/19	REO	Edit Transfer Pricing Deck re: Consistent universal formatting for slides and tables.	1.00
10/07/19	JDH	Analysis of distributions per company organizational structure.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/07/19	JDH	Analysis of Rhodes distributions per company organization charts.	0.60
10/07/19	RC	Review and analysis of information related to distributions.	1.70
10/07/19	RC	Research questions from Davis Polk related to distributions and prepare responses.	1.50
10/07/19	RC	Review and analysis of distributions made by PPLP.	0.80
10/07/19	RC	Review and analysis of information related to the non-tax and tax distributions.	0.80
10/07/19	RC	Call with R. Collura and S. Robertson (both AlixPartners) to discuss cash and non-cash distributions.	0.50
10/07/19	RC	Call with R. Collura and S. Robertson (both AlixPartners) to discuss information related to PPI's disbursements.	0.20
10/07/19	RC	Call with J. Kiechel (Davis Polk) to discuss information related to cash and non-cash distributions.	0.30
10/07/19	RC	Call with K. Darraugh (PPLP) to discuss information related to Dilaudid and MS Contin distribution.	0.20
10/07/19	RC	Review and analysis of distributions made by Rhodes.	0.80
10/07/19	RC	Review and analysis of PPLP's financial statements and respond to questions from Davis Polk.	1.20
10/07/19	SJC	Review and update of distributions testing file.	1.50
10/07/19	MFR	Revisions to Exhibit 2A of the transfer pricing report.	1.10
10/07/19	MFR	Revisions to Exhibit 2B of the transfer pricing report.	0.20
10/07/19	MFR	Revisions to Exhibit 3A of the transfer pricing report.	0.80
10/07/19	MFR	Review of Exhibit 2A of transfer pricing report and supporting documentation and analyses.	2.60
10/07/19	MFR	Review of Exhibit 2B of transfer pricing report and supporting documentation and analyses.	1.40
10/07/19	MFR	Review of Exhibit 3A of transfer pricing report and	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		supporting documentation and analyses.	
10/07/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft presentation and quality control.	0.20
10/07/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft presentation and quality control.	0.20
10/07/19	FOS	Compose email to M. Rule re: MS Contin and Dilaudid transfer to Rhodes Pharma.	0.10
10/07/19	FOS	Review presentation deck re: transfer of MS Contin and Dilaudid to Rhodes Pharma.	0.20
10/07/19	FOS	Analyze intercompany general ledger accounts re: reconciliation of transfers of value versus other activity.	4.20
10/07/19	FOS	Compose email to M. Rule (AlixPartners) re: intercompany general ledger account activity.	0.30
10/07/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.50
10/07/19	KS	Update the report slides regarding transfer pricing.	2.80
10/07/19	KS	Review transactions in SAP and analyze the inter-company charge.	1.60
10/07/19	KS	Perform the QC for the report slides regarding transfer pricing.	1.20
10/08/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.30
10/08/19	KS	Update the report slides regarding transfer pricing.	2.40
10/08/19	KS	Perform the QC for the report slides regarding transfer pricing.	2.50
10/08/19	KS	Update the report slides regarding transfer pricing.	0.90
10/08/19	FOS	Review intercompany general ledger account activity.	0.40
10/08/19	FOS	Compose email to K. Shibuya (AlixPartners) re: quality control of draft report.	0.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/08/19	FOS	Compose email to R. Kennedy (TXP Services) re: Intercompany payments discussion.	0.10
10/08/19	FOS	Review draft transfers of value report re: quality control.	0.30
10/08/19	FOS	Draft slides for transfers of value report re: intercompany general ledger account activity.	6.60
10/08/19	MFR	Review of Exhibit 3B of transfer pricing report and supporting documentation and analyses.	2.40
10/08/19	MFR	Review of Exhibit 3C of transfer pricing report and supporting documentation and analyses.	2.10
10/08/19	MFR	Review of Exhibit 3D of transfer pricing report and supporting documentation and analyses.	1.90
10/08/19	MFR	Revisions to Exhibit 3B of the transfer pricing report.	1.10
10/08/19	MFR	Revisions to Exhibit 3C of the transfer pricing report.	1.30
10/08/19	MFR	Revisions to Exhibit 3D of the transfer pricing report.	1.20
10/08/19	SJC	PPI charitable contributions testing.	2.90
10/08/19	SJC	PPI charitable contributions review and analysis.	2.20
10/08/19	SJC	PPI management fees analysis.	2.00
10/08/19	SJC	Updating and editing PPI PowerPoint.	1.40
10/08/19	RC	Review and analysis of transactions with PRA L.P. and non-cash distributions and respond to questions from Davis Polk.	2.80
10/08/19	RC	Call with K. Darragh (Purdue) to discuss transactions with PRA L.P.	0.60
10/08/19	RC	Call with K. Wolfgang, Z. Kaufman and V. Obasaju (all Davis Polk) to discuss transactions with PRA L.P.	0.40
10/08/19	RC	Call with J. Kiechel (Davis Polk) to discuss transactions with PRA L.P. and non-cash distributions.	0.30
10/08/19	RC	Review and analysis of information related to non-cash distributions.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/08/19	RC	Review and analysis of documents related to US Partner and Ex-US distributions.	1.70
10/08/19	RC	Review draft stipulation order with the UCC.	0.20
10/08/19	JDH	Reviewing Rhodes distributions flow of funds analysis.	3.60
10/08/19	REO	Follow up on outstanding request from the company re: outstanding SAP reference codes.	1.00
10/08/19	REO	Review of Transfer Pricing Deck re: quality control process for slides originally assigned to lead engagement SVP.	2.40
10/08/19	REO	Edit Transfer Pricing Deck re: suggested changes and edits to slides originally prepared by engagement SVP.	0.80
10/08/19	REO	Update SAP Transfer Deck re: intercompany analysis for Terramar transfers past June 2018.	2.50
10/08/19	REO	Review SAP Database re: updated support for the Terramar intercompany transfer.	1.60
10/09/19	REO	Review of Transfer Pricing Deck re: quality control process for additional slides originally assigned to engagement lead SVP.	2.20
10/09/19	REO	Edit Transfer Pricing Deck re: suggested changes and edits for the additional slides originally assigned to the Engagement lead SVP.	1.50
10/09/19	REO	Review of Transfer Pricing Deck re: final review of personally-prepared cash transfer slides and suggested changes/edits by engagement SVPs.	1.70
10/09/19	ADD	Review outstanding diligence status and update diligence tracker	1.60
10/09/19	RC	Review documentation related the cash transfers of value analysis.	1.10
10/09/19	RC	Review and analysis of information related to tax distributions.	1.30



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/09/19	RC	Review and analysis of documents related to US and Ex-US cash distributions.	1.60
10/09/19	SJC	Analysis of fees paid to management of PPI.	1.70
10/09/19	SJC	Downloading supporting documents for PPI PowerPoint from SAP.	2.20
10/09/19	SJC	Updating and editing PPI PowerPoint.	1.10
10/09/19	SJC	PPI charitable contributions review and analysis.	3.00
10/09/19	MFR	Revisions to Exhibit 3E of the transfer pricing report.	0.90
10/09/19	MFR	Revisions to Exhibit 3F of the transfer pricing report.	1.10
10/09/19	MFR	Revisions to Exhibit 4A of the transfer pricing report.	0.80
10/09/19	MFR	Review of Exhibit 3E of transfer pricing report and supporting documentation and analyses.	2.20
10/09/19	MFR	Review of Exhibit 3F of transfer pricing report and supporting documentation and analyses.	2.30
10/09/19	MFR	Review of Exhibit 4A of transfer pricing report and supporting documentation and analyses.	2.10
10/09/19	LD	Reviewed project status	1.10
10/09/19	FOS	Compose email to M. Rule (AlixPartners) re: SAP support for payments from PPLP to TXP.	0.30
10/09/19	FOS	Draft slides for transfers of value report re: intercompany general ledger account activity.	6.80
10/10/19	MFR	Review of Exhibit 4B of transfer pricing report and supporting documentation and analyses.	1.80
10/10/19	MFR	Review of Exhibit 4C of transfer pricing report and supporting documentation and analyses.	2.30
10/10/19	MFR	Revisions to Exhibit 4B of the transfer pricing report.	1.20
10/10/19	MFR	Revisions to Exhibit 4C of the transfer pricing report.	1.10
10/10/19	RC	Review analysis of reinvestment transactions.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/10/19	RC	Review and analysis of SAP documentation related to distributions.	1.60
10/10/19	RC	Review draft cash transfer of value analysis.	1.40
10/10/19	RC	Respond to questions from Davis Polk related to distributions.	0.10
10/10/19	RC	Review documentation related to Rhodes's tax distributions.	0.20
10/10/19	RC	Review documentation in SAP related to the cash transfers of value report.	1.20
10/10/19	ADD	Review contribution analysis testing for transfer of value report.	1.20
10/10/19	ADD	Update and provide payments made under motion statistics.	0.80
10/10/19	REO	Review of Transfer pricing deck re: self-review of non-cash transfer for quality control purposes.	1.40
10/10/19	REO	Review of Box re: accurate and complete support for all documents, tables and screenshots for the non-cash transfers.	0.80
10/10/19	REO	Review of transfer pricing deck re: self-review of appendix 1 for consistency with updated slides.	1.60
10/10/19	REO	Review of Intercompany transactions re: preparation for meeting with engagement Director on slide accounting and SAP support.	1.00
10/10/19	JDH	Review of PPI distribution analysis.	2.60
10/11/19	JDH	Preparing flow of funds narratives and slides.	4.30
10/11/19	REO	Updated review of Intercompany Transfers.	1.10
10/11/19	REO	Research SAP Database re: Post-meeting request from engagement Director for additional SAP support of transfers settled to cash.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/11/19	REO	Edit Transfer Pricing Deck re: updated SAP support for transfers settled to cash.	0.90
10/11/19	REO	Review of Transfer Pricing Deck re: accounting for non-cash transfer per comments from Engagement Director.	1.00
10/11/19	REO	Reconcile supporting documents delivered by the company with SAP data re: non cash transfers.	2.70
10/11/19	RC	Review and analysis of supporting documentation related to the cash transfers of value analysis.	2.10
10/11/19	RC	Review and analysis of documents related to loans.	0.70
10/11/19	MFR	Revisions to Exhibit 4D of the transfer pricing report.	1.40
10/11/19	MFR	Revisions to Exhibit 4E of the transfer pricing report.	1.20
10/11/19	MFR	Revisions to Exhibit 4F of the transfer pricing report.	1.50
10/11/19	MFR	Review of Exhibit 4D of transfer pricing report and supporting documentation and analyses.	2.00
10/11/19	MFR	Review of Exhibit 4E of transfer pricing report and supporting documentation and analyses.	3.20
10/11/19	MFR	Review of Exhibit 4F of transfer pricing report and supporting documentation and analyses.	2.80
10/11/19	FOS	Review payments to Purdue Pharma Tech Inc.	0.20
10/11/19	FOS	Analyze intercompany payments and settlements re: Purdue Pharma Tech Inc.	3.60
10/11/19	FOS	Review documents re: Bard and MacFarlan Smith agreement and Purdue Pharma Tech Inc. security services agreement.	0.40
10/11/19	FOS	Compose email to Fred Selck (Bates White) re: Bard and MacFarlan Smith agreement and Purdue Pharma Tech Inc. security services agreement.	0.20
10/12/19	FOS	Quality review of draft transfers of value report.	0.30
10/12/19	MFR	Review of Exhibit 4G of transfer pricing report and	2.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		supporting documentation and analyses.	
10/12/19	MFR	Review of Exhibit 4H of transfer pricing report and supporting documentation and analyses.	1.20
10/12/19	MFR	Revisions to Exhibit 4G of the transfer pricing report.	1.10
10/12/19	MFR	Revisions to Exhibit 4H of the transfer pricing report.	0.50
10/13/19	MFR	Revisions to Exhibit 4I of the transfer pricing report.	1.50
10/13/19	MFR	Revisions to Exhibit 4J of the transfer pricing report.	0.40
10/13/19	MFR	Review of Exhibit 4I of transfer pricing report and supporting documentation and analyses.	2.20
10/13/19	MFR	Review of Exhibit 4J of transfer pricing report and supporting documentation and analyses.	1.10
10/13/19	RC	Review and respond to questions from counsel related to the cash transfers of value report.	2.20
10/13/19	RC	Update the cash transfers of value report based on requests from counsel.	1.70
10/13/19	RC	Prepare email correspondence to internal team requesting information related to the cash transfer of value report and incorporate responses into draft report.	0.30
10/13/19	RC	Prepare responses to counsel's questions and comments related to the cash transfer of value report.	1.30
10/13/19	NAS	Research additional detail on sublease agreement for 9th floor of One Stamford Forum and providing summary to investigation team.	0.40
10/14/19	SJC	Contribution analysis.	2.50
10/14/19	SJC	Call with R. Collura, S. Canniff, and A. DePalma (all AlixPartners) re: Tax Distributions review and additional distribution testing methodology discussion	0.90
10/14/19	RC	Prepare questions for TXP Services regarding Tax Distributions.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/14/19	RC	Review and analysis of distribution reconciliations and related supporting documents.	2.70
10/14/19	RC	Review analysis related to Purdue Pharma Inc.	1.60
10/14/19	RC	Call with R. Collura, S. Canniff, and A. DePalma (all AlixPartners) to discuss additional work to perform related to cash distributions.	0.90
10/14/19	RC	Review and analysis of tax distributions.	1.50
10/14/19	RC	Call with J. Kiechel (Davis Polk) to discuss cash transfer of value report.	0.30
10/14/19	RC	Review draft cash transfers of value report and identify information for redaction.	0.80
10/14/19	MFR	Revisions to Appendix 1 of transfer pricing report.	0.80
10/14/19	MFR	Revisions to Appendix 2 of transfer pricing report.	0.50
10/14/19	MFR	Revisions to Appendix 3 of transfer pricing report.	0.40
10/14/19	MFR	Revisions to Appendix 4 of transfer pricing report.	0.30
10/14/19	MFR	Revisions to Executive Summary of the transfer pricing report.	2.80
10/14/19	LD	Reviewed project status	1.00
10/14/19	MFR	Conference call with F. Silva, M. Rule, and R. Ellis Ochoa (all AlixPartners) re: status update on draft report on transfers of value.	0.20
10/14/19	FOS	Conference call with M. Rule, F. Silva, and R. Ellis Ochoa (all AlixPartners) re: status update on draft report on transfers of value	0.20
10/14/19	FOS	Compose email to D. Fogel and W. DiNicola (all Rhodes Tech) re: written agreement between Bard and MacFarlan Smith.	0.10
10/14/19	FOS	Compose email to R. Kennedy (TXP Services) re: discussion on cash transfers between debtor and non-	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		debtor entities.	
10/14/19	FOS	Compose email to K. Shibuya (AlixPartners) re: proposed edits to draft Intercompany and Non-Cash Transfers Analysis.	0.40
10/14/19	FOS	Compose email to F. Selck (Bates White) re: written agreement between Bard and MacFarlan Smith.	0.20
10/14/19	FOS	Analyze general ledger activity re: accounts receivable for Rhodes Tech sales of Active Pharmaceutical Ingredients.	7.00
10/14/19	KS	Update the Intercompany and Non-Cash Transfers Report	2.40
10/14/19	KS	Update the Intercompany and Non-Cash Transfers Report	2.60
10/14/19	KS	Update the Intercompany and Non-Cash Transfers Report	1.80
10/14/19	REO	Conference call with M. Rule, R. Ellis Ochoa and F. Silva (all AlixPartners) re: status update on draft report on transfers of value.	0.20
10/14/19	ADD	Call with R. Collura, S. Canniff, and A. DePalma (all AlixPartners) re: Tax Distributions review and additional distribution testing methodology discussion	0.90
10/15/19	ADD	Research tax distribution transaction.	2.20
10/15/19	ADD	Research and download supporting documentation for invoice.	0.40
10/15/19	ADD	Review interested parties list and evaluate for potential omissions.	2.60
10/15/19	ADD	Update interested parties list.	1.80
10/15/19	LH	Assist with finalizing presentation for distribution	1.20
10/15/19	LH	Call with R. Collura and L. Hill (both AlixPartners) to discuss redactions of information in the transfer of value report.	0.50
10/15/19	KS	Update the Intercompany and Non-Cash Transfers Report	2.50
10/15/19	KS	Update the Intercompany and Non-Cash Transfers Report	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/15/19	KS	Update the Intercompany and Non-Cash Transfers Report	2.90
10/15/19	FOS	Conference call with R. Kennedy (TXP Services, Inc.), M. Rule, and F. Silva (both AlixPartners) re: Intercompany cash transfers between debtor and non-debtor companies.	0.50
10/15/19	FOS	Review draft Intercompany and non-cash transfers report re: quality control of edits made.	0.40
10/15/19	FOS	Analyze general ledger activity re: accounts receivable for Rhodes Tech sales of Active Pharmaceutical Ingredients.	2.30
10/15/19	FOS	Compose email to M. Rule (AlixPartners) re: analysis of activity in accounts receivable for Rhodes Tech.	0.20
10/15/19	FOS	Compose email to E. Kim, M. Clarens, J. Kiechel, N. Williams (all Davis Polk) re: updated draft of Intercompany and Non-Cash Transfers Report.	0.10
10/15/19	FOS	Compose email to K. Shibuya (AlixPartners) re: edits to draft Intercompany and Non-Cash Transfers Report.	0.20
10/15/19	FOS	Compose email to M. Rule (AlixPartners) re: analysis of intercompany general ledger accounts for shared services charges.	0.30
10/15/19	FOS	Analyze intercompany general ledger accounts re: shared services charges from Purdue Pharma LP.	4.20
10/15/19	MFR	Conference call with R. Kennedy (TXP Services, Inc.), M. Rule, and F. Silva (both AlixPartners) re: Intercompany cash transfers between debtor and non-debtor companies.	0.50
10/15/19	LD	Reviewed status of analysis	0.50
10/15/19	RC	Call with J. Kiechel (Davis Polk) to discuss redaction of information in the cash transfers of value report.	0.20
10/15/19	RC	Review information from TXP Service related to Tax Distributions.	0.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/15/19	RC	Review and update the draft cash transfers of value report based on comments from counsel.	2.20
10/15/19	RC	Review report for redacted information.	1.20
10/15/19	RC	Review and analysis of support documentation related to tax distributions.	2.40
10/15/19	RC	Review and analysis of cash distributions data.	0.80
10/15/19	RC	Call with R. Collura and L. Hill (both AlixPartners) to discuss redactions of information in the transfer of value report.	0.50
10/15/19	SJC	Review of supporting bank statements and aggregation for FTI and DOJ.	3.00
10/15/19	SJC	Review of supporting documents for Cash Transfer of Value report and adding related watermarks.	2.00
10/15/19	SJC	Review of supporting legal documents and aggregation for FTI and DOJ.	3.00
10/15/19	NAS	Revise investigation report per comments from restructuring counsel.	0.90
10/15/19	NAS	Redact identifiable bank account information in investigation report prior to distribution.	0.20
10/16/19	SJC	Follow up for details of 2000-2004 distributions.	1.50
10/16/19	SJC	Analysis of 2000-2004 distributions support.	3.00
10/16/19	SJC	Analysis of supporting documentation in SAP for 2000-2004 distributions.	2.90
10/16/19	SJC	Aggregation of all distributions for the period 2000-2008 and analysis.	1.70
10/16/19	SJC	Analysis of supporting documentation in SAP for 2005-2008 distributions.	2.90
10/16/19	RC	Review and update draft cash transfers of value report and related exhibits.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/16/19	RC	Review and analysis of support documentation related to flow of funds schedules.	2.10
10/16/19	RC	Call with J. Kiechel (Davis Polk) to discovery additional work to perform for the Special Committee.	0.50
10/16/19	RC	Draft outline of next steps to perform based on discussions with Davis Polk and communicate information to the team.	0.70
10/16/19	RC	Prepare tasks to perform for additional work streams requested by Davis Polk for the Special Committee.	0.40
10/16/19	RC	Review schedules supporting the October 2018 MDL Presentation related to distributions.	1.50
10/16/19	RC	Update draft cash transfers of value report and provide to Davis Polk.	0.90
10/16/19	KS	Update the report slides regarding transfer pricing.	2.40
10/16/19	KS	Update the report slides regarding transfer pricing.	1.60
10/16/19	JDH	Coordinating system access with client IT department.	3.20
10/16/19	JDH	Distribution testing planning.	1.40
10/17/19	JDH	Meeting with TXP Tax department.	1.10
10/17/19	JDH	Distribution Matrix development and information gathering.	1.90
10/17/19	REO	Review of intercompany transfers re: prepared detailed summary for Director in preparation of call with counsel.	1.50
10/17/19	REO	Conference call with M. Rule and R. Ellis Ochoa (both AlixPartners) re: Preparatory review of intercompany transfers for conference call with Davis Polk	0.20
10/17/19	REO	Conference call with M. Rule and R. Ellis Ochoa (both AlixPartners) and Davis Polk re: Intercompany transfers discussion.	0.50
10/17/19	MFR	Conference call with R. Ellis Ochoa and M. Rule (both	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners) re: preparatory review of intercompany transfers for conference call with Davis Polk.	
10/17/19	MFR	Preparation for conference call with Davis Polk re: intercompany transfers.	0.60
10/17/19	MFR	Conference call with E. Kim, N. Williams (both Davis Polk), R. Ellis Ochoa, and M. Rule (both AlixPartners) regarding intercompany Transfers.	0.50
10/17/19	MFR	Review of PJT presentation regarding MSER transfer.	0.60
10/17/19	RC	Review and analysis of cash distributions and related support documentation.	1.70
10/17/19	RC	Update draft cash transfer of value report based on comments from Davis Polk.	2.80
10/17/19	RC	Communicate with internal team regarding additional work streams.	0.20
10/17/19	RC	Review and analysis of tax distributions.	1.30
10/17/19	RC	Review and update draft cash transfers of value report and send to Davis Polk.	2.20
10/17/19	SJC	Summary of distributions for the period 2000-2008 and analysis.	1.50
10/17/19	SJC	Review and analysis of distributions from PPLP for the period of 2005-2008.	3.00
10/21/19	SJC	Constructing 2000-2004 distribution detail.	4.00
10/21/19	SJC	Redact names from org chart.	2.00
10/21/19	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: report status and edits.	0.20
10/21/19	MFR	Review the status of the intercompany account's analysis.	1.60
10/21/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: report status and edits.	0.20
10/21/19	FOS	Edit intercompany transfers of value report re: quality	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		review process.	
10/21/19	FOS	Review general ledger intercompany accounts re: analysis of account activity.	5.10
10/21/19	REO	Edit transfer pricing deck re: Updated slide on intercompany transfer and shared with engagement lead SVP.	1.20
10/21/19	SR	Read media reports re: grant of injunction, MDL negotiations, comments by dissenting AGs	1.00
10/21/19	SR	Read two weeks of emails received while out of country	0.60
10/21/19	SR	Save and read updated transfer of valuation report and related distribution report (as of 10/17)	0.50
10/21/19	SR	Download audit reports 2003-2007	0.20
10/21/19	SR	Communication with A. Depalma, S. Robertson, and S. Caniff (all AlixPartners) as to time required to extend distribution analysis to cover 2003-2007	0.30
10/21/19	SR	Rebuild distributions files to include 5 years 2003-2007	1.50
10/21/19	SR	Print 5 years of audit reports, PPI presentation deck	0.40
10/21/19	SR	Read PPI presentation deck	0.50
10/22/19	SR	Review Davis Polk request for additional testing of distributions for years 2000 to 2007 to determine scope, staffing and timing issues	0.50
10/22/19	SR	Review status and timing of additional distribution analysis	0.50
10/22/19	SR	Redact statements of equity from audited financial statements for years 2000 to 2007	1.10
10/22/19	SR	Summarize details for all distributions (gross and net) and reconcile to MDL and audits for 2000 to 2007	3.50
10/22/19	SR	Receive 2000-2004 details for distributions (totals in workbook but no detail for those years). Review for gross	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		v. net presentation	
10/22/19	SR	Summarize sliver distributions to PPI 2008-2017	1.20
10/22/19	REO	Review of transfer pricing deck support re: final review of updated SAP support within Box.	0.70
10/22/19	FOS	Edit intercompany transfer of value report re: quality control review.	2.40
10/22/19	FOS	Review general ledger intercompany accounts re: analysis of account activity.	4.70
10/22/19	FOS	Compose emails to N. Simon (AlixPartners) re: draft intercompany transfers of value report and supporting documentation.	0.40
10/22/19	MFR	Review the status of the intercompany account's analysis.	1.30
10/22/19	SJC	Review of PPI charitable contributions and underlying support.	2.10
10/22/19	SJC	Review of PPI management fees received and analysis of underlying support.	2.10
10/22/19	SJC	Analysis of PPI PowerPoint and edits.	3.00
10/22/19	RC	Call with M. Clarens (Davis Polk) to discuss case status and additional work to perform related to transfers of value.	0.40
10/22/19	RC	Review analysis of information related to Purdue Pharma Inc.	1.60
10/22/19	RC	Review and comment on draft of analysis related to Purdue Pharma Inc.	2.30
10/22/19	RC	Review and analysis of PPLP distributions schedules.	0.40
10/22/19	RC	Review and update tracking template related to Tax Distributions.	2.20
10/22/19	RC	Meeting with R. Aleali (PPLP) to discuss status of draft report.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/22/19	RC	Review and analysis of Purdue Pharma Inc.'s cash disbursements.	1.10
10/23/19	RC	Review PRA sublease agreement.	0.50
10/23/19	RC	Update transfer of value analysis related to Purdue Pharma Inc.	2.30
10/23/19	RC	Review and analysis of SAP documentation related to Purdue Pharma Inc.	1.60
10/23/19	RC	Review and analysis of financial and accounting records related to Purdue Pharma Inc.	1.80
10/23/19	RC	Prepare for call with E. Mahony (TXP/PRA).	0.20
10/23/19	RC	Review and update tax distribution tracking template.	0.70
10/23/19	RC	Review supporting schedules related to the cash distributions analysis.	1.40
10/23/19	SJC	Contributions analysis and follow up questions.	1.70
10/23/19	SJC	Analysis of vendor payments.	2.40
10/23/19	SJC	PPI and PPLP charitable contributions analysis.	1.80
10/23/19	SJC	Review of contributions from PHLP to PPLP.	2.10
10/23/19	MFR	Review the status of the intercompany account's analysis.	1.20
10/23/19	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: results of intercompany general ledger account analysis and report status.	0.30
10/23/19	MH	Call with E. Mahony (TXP/PRA) to discuss PRA sublease agreement.	0.60
10/23/19	MH	Prepare for call to discuss sublease agreements.	0.40
10/23/19	FOS	Phone call with M. Rule and F. Silva (both AlixPartners) re: results of intercompany general ledger account analysis and report status.	0.30
10/23/19	FOS	Review general ledger intercompany accounts re: analysis of account activity.	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/23/19	JDH	Tax Martrix development.	1.20
10/23/19	ADD	Compile supporting documentation for investigation report	0.50
10/23/19	SR	Update and edit PPI distributions file, separate cash and non-cash distributions	1.00
10/23/19	SR	Research SVC joint venture (sales of Dranibonol) to support SOFA and schedules	0.50
10/23/19	SR	Update PPI management fee schedule to condense to a single table, update PPI charitable contributions table to summarize by payee, transmit to R. Collura	2.00
10/23/19	SR	Update PPLP distributions table to PPI to break out non-cash from cash items, transmit to R. Collura	0.50
10/23/19	SR	Update PPI contributions, ran PPLP contributions	0.50
10/23/19	SR	Tracing sliver distributions from Internal PPLP workbook to PPI account analysis for years 2008 - 2018	1.20
10/23/19	SR	Draft PPI summary deck	1.20
10/24/19	SR	Respond to inquiries re: internal v external reporting in distribution analysis source documentation	0.50
10/24/19	SR	PPI ownership structure and summary report	0.50
10/24/19	SR	Read media reports	0.50
10/24/19	JDH	Tax distribution matrix development.	2.10
10/24/19	REO	Edit transfer pricing support files re: edited and consolidated transfer pricing support files for breakdown of historical activity for past 18 months per request from TRS VP.	2.50
10/24/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of intercompany general ledger review and intercompany payments.	0.20
10/24/19	FOS	Compose email to R. Kennedy (TXP Services Inc.) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Intercompany payments between debtor and non-debtor entities.	
10/24/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	6.50
10/24/19	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: status of intercompany general ledger review and intercompany payments.	0.20
10/24/19	SJC	PPI and PPLP charitable contribution analysis and organizational chart review.	2.60
10/24/19	RC	Call with M. Clarens and E. Kim (Davis Polk) to discuss responses to requests from the DOJ.	0.40
10/24/19	RC	Review cash transfers of value report and identify support documentation in preparation for call with Davis Polk.	0.60
10/24/19	RC	Review and analysis of financial information related to Purdue Pharma Inc.	1.40
10/24/19	RC	Review PRA LP sublease and rent payment information.	0.50
10/24/19	RC	Review organizational charts for PPLP and Rhodes.	0.30
10/24/19	RC	Compile information and provide to Davis Polk in response to requests from the DOJ,	1.30
10/24/19	RC	Review and analysis of PPLP's internal distributions workbook.	1.50
10/24/19	RC	Review bank statement tracing analysis.	1.20
10/24/19	RC	Review SAP vendor information and testing work on distributions.	1.10
10/25/19	RC	Review information related to the lease with One Stamford Realty and sublease with PRA LP.	2.40
10/25/19	RC	Review and update Purdue Pharma Inc. analysis and identify additional follow-up work to perform.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/25/19	FOS	Compose email to M. Rule (AlixPartners) re: analysis of cash payments from PPLP to non-debtor entities.	0.20
10/25/19	FOS	Compose email to R. Kennedy (TXP Services Inc.) re: follow-up on meeting request.	0.10
10/25/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	3.50
10/25/19	FOS	Review general ledger intercompany accounts re: analysis of account activity.	1.50
10/25/19	JDH	Documentation of flow-of-funds and corporate organization.	1.40
10/25/19	SR	Read OSF lease with PPLP, OSF renewal with PPLP, PPLP lease with PRA	2.10
10/25/19	SR	Update PPI summary presentation	0.70
10/28/19	JDH	Compile documentation to respond to request from DOJ	5.30
10/28/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: update on review of intercompany payments and intercompany general ledger accounts.	0.30
10/28/19	FOS	Compose email to J. DelConte and N. Simon (both AlixPartners) re: payments to IACs.	0.20
10/28/19	FOS	Compose emails to M. Rule (AlixPartners) re: IAC payments and shared services charges from TXP Services Inc.	0.10
10/28/19	FOS	Compose email to N. Simon (AlixPartners) re: intercompany payment for Avrio Health.	0.10
10/28/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	6.30
10/28/19	MFR	Call with F. Silva and M. Rule (both AlixPartners) re: update on review of intercompany payments and	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany general ledger accounts.	
10/28/19	MFR	Review of draft report and general ledger analysis.	2.80
10/28/19	MFR	Review and analysis of supporting documents for general ledger analysis.	2.40
10/28/19	MFR	Review of documentation supporting report draft.	2.90
10/28/19	RC	Review and provide comments on the reinvestment/tax refund analysis.	1.70
10/28/19	RC	Review and provide comments on the SAP vendor payments analysis.	1.80
10/28/19	RC	Review cash transfers of value report and identifying source documentation.	0.80
10/28/19	RC	Review bank statement tracing analysis and setup team on organizing documents in response to requests from the DOJ.	1.20
10/28/19	RC	Call with M. Clarens (Davis Polk) to discuss discovery requests.	0.30
10/28/19	RC	Review internal cash distributions workbooks.	0.80
10/28/19	RC	Review supporting documentation related to cash transfer of value categories.	1.40
10/28/19	SJC	Organizing bank statements for DOJ request.	2.70
10/28/19	SJC	Uploading and organizing bank statements for DOJ request.	1.50
10/29/19	SJC	Call with R. Collura, S. Robertson, S. Canniff and J. Hecht (all AlixPartners), Davis Polk, Province and Akin Gump to discuss cash transfers of value report.	0.70
10/29/19	SJC	Summarize and organize bank statements per requests.	1.80
10/29/19	SJC	Analysis of contributions to PPLP.	2.70
10/29/19	SJC	Bank statement analysis.	2.20
10/29/19	SJC	Analysis of open and closed accounts payable.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/29/19	RC	Review and analysis of office rent expenses.	1.10
10/29/19	RC	Review bank statement tracing analysis and identify relevant source documents in response to requests from the DOJ.	1.60
10/29/19	RC	Review and update Purdue Pharma Inc. analysis.	1.70
10/29/19	RC	Call with R. Collura, S. Robertson, S. Canniff and J. Hecht (all AlixPartners), Davis Polk, Province and Akin Gump to discuss cash transfers of value report.	0.70
10/29/19	RC	Review documents related to Purdue Pharma Inc. analysis.	0.80
10/29/19	RC	Review and organize supporting documentation in response to requests from the UCC's professionals.	1.70
10/29/19	MFR	Review of intercompany accounts analyses.	2.60
10/29/19	MFR	Revisions to draft report.	2.50
10/29/19	MFR	Revisions to draft exhibits.	3.10
10/29/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	4.60
10/29/19	FOS	Review general ledger intercompany accounts re: analysis of account activity.	1.90
10/29/19	BSC	Compile bank statement supporting documentation for cash tracing exercise.	1.00
10/29/19	JDH	Review of company bank statements.	3.40
10/29/19	SR	Call with R. Collura, S. Robertson and S. Canniff (all AlixPartners), Davis Polk, Province and Akin Gump to discuss cash transfers of value report.	0.70
10/29/19	SR	Read media reports (additional ad-hoc committee)	0.10
10/29/19	SR	Review value of office space provided to family, planning and timing of meetings and calls	0.50



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/29/19	SR	Emails to attempt to schedule meeting with K. Darragh (Purdue) and Bob Piacenza (OSR) regarding provision of office space and accounting for office space to family	0.30
10/29/19	SR	Create 10-year file for rent expense for Tresser Blvd property, reconcile to GL detail.	1.90
10/29/19	SR	Update lease extracts for 2006, 2021 and PRA subleases	0.70
10/29/19	SR	Inquiries to R Piacenza (Purdue) and K. Darragh (Purdue) re: circumstances of providing office space to family members and recording of leasing costs.	0.40
10/29/19	SR	Obtain exhibits to 2021 PPLP lease renewal for 201 Tresser add to extracts	0.50
10/30/19	SR	Postponed meeting with R. Piacenza (OSR) re: Stamford office lease	0.20
10/30/19	SR	Meeting with R. Piacenza (OSR) regarding Stamford office lease, provision of space to Sackler family	0.50
10/30/19	SR	Build tables to value provision of office space to Sackler family members	0.50
10/30/19	SR	Follow up with R. Kennedy re: Operations Statements, J. Beck re: admins for family members	0.30
10/30/19	SR	Draft report for discussion purposes re: Sackler family offices	4.00
10/30/19	SR	Clear review notes and update PPI report	1.50
10/30/19	SR	Retracing individual PPLP distributions to PPI GL	0.70
10/30/19	SR	Analysis of value of office rent	0.30
10/30/19	JDH	Call with counsel and committee financial advisors.	0.70
10/30/19	JDH	Review of supporting documentation related to distributions.	4.80
10/30/19	JDH	Review of fringe benefits analysis.	2.60
10/30/19	FOS	Review intercompany payments and general ledger	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		accounts.	
10/30/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	3.90
10/30/19	MFR	Revisions to draft report exhibits.	2.40
10/30/19	MFR	Revisions to draft executive summary.	2.70
10/30/19	MFR	Review of supporting documentation to draft report.	2.60
10/30/19	MFR	Call with M. Rule and R. Collura (both AlixPartners) to discuss status if intercompany report and related next steps.	0.50
10/30/19	LD	Reviewed presentation	1.20
10/30/19	RC	Call with M. Clarens (Davis Polk) to discuss protocol for producing documents to the committees' professionals.	0.30
10/30/19	RC	Continue to compile support documents in response to requests from the UCC's professionals and setup team to perform related QC.	2.30
10/30/19	RC	Review and update analysis related to Purdue Pharma Inc.	2.20
10/30/19	RC	Call with M. Rule and R. Collura (both AlixPartners) to discuss status if intercompany report and related next steps.	0.50
10/30/19	RC	Provide additional comments related to Purdue Pharma Inc. analysis.	1.10
10/30/19	RC	Compile support documents in response to requests from the UCC's professionals.	1.60
10/30/19	NAS	Provide update to investigation team on all payments to associated entities that were disclosed in SOFA Part 2 Question 4 response and historical list of Purdue Pharma Inc. Directors.	0.60
10/30/19	NAS	Provide source data from transfer of value investigation to	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		J. Hecht (AlixPartners).	
10/31/19	NAS	Review Sackler family disclosures included in SOFAs and provide summary to AlixPartners investigation team.	0.30
10/31/19	RC	Review support documentation related to the cash transfers of value report.	2.20
10/31/19	RC	Review transactions included in the SOFAs and Schedules.	1.30
10/31/19	RC	Review and provide comments to the Purdue Pharma Inc. analysis.	0.80
10/31/19	RC	Review and analysis of legal indemnification costs.	0.50
10/31/19	RC	Compile and review additional documents requested by the UCC's advisors.	0.80
10/31/19	RC	Review vendor payment analysis.	1.00
10/31/19	SJC	Review compensation, legal, and pension support to PowerPoint and uploading supporting documentation.	1.80
10/31/19	SJC	Vendor distribution analysis.	1.10
10/31/19	SJC	Review and upload of flow of funds bank statements.	1.30
10/31/19	MFR	Review intercompany payments and general ledger accounts.	0.10
10/31/19	MFR	Review and analysis of intercompany accounts analyses.	2.90
10/31/19	MFR	Review and analysis of supporting documentation to draft report exhibits.	2.80
10/31/19	MFR	Revisions to draft report and corresponding exhibits.	2.20
10/31/19	MH	Create summary of charitable organizations affiliated with the Sackler family.	0.60
10/31/19	FOS	Review support for list of payments from PPLP to other non-debtor entities re: preparation for SOFA and Schedules filing.	2.00
10/31/19	JDH	Compile supporting documentation for counsel.	4.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
10/31/19	JDH	Review of source documentation provided by Purdue related to fringe benefits.	3.10
10/31/19	ADD	Update distribution entity list	0.60
10/31/19	ADD	Research vendor categorizations.	1.20
11/01/19	JDH	Compile supporting bank statement documentation for counsel	3.10
11/01/19	JDH	Compile information in response to committee request.	2.80
11/01/19	SR	Review adjusting items at PPI, update tables and report	2.00
11/01/19	FOS	Review of intercompany general ledger account activity in SAP re: shared services charges between debtor and non-debtor entities.	4.00
11/01/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1C.	2.70
11/01/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1D.	2.90
11/01/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1E.	3.10
11/01/19	SJC	Analysis of PPI reversed management fees.	1.30
11/01/19	SJC	Review of underlying documents to reports.	0.70
11/01/19	SJC	Prepare documents for the committee's professionals.	2.80
11/01/19	SJC	Prepare documents for the DOJ.	2.00
11/01/19	RC	Review documents compiled in response to the DOJ's requests and provide documents to Davis Polk.	2.20
11/01/19	RC	Call with M. Greenblatt, K. Knechtel, N. Costaldo and P. Kyviakidis (all FTI) to discuss the cash transfers of value report.	0.80
11/01/19	RC	Coordinate with team to organize additional support documents to provide to the UCC and ad hoc committee's professionals.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/01/19	RC	Reconcile SOFA and Schedules to support documentation for the cash transfer of value report.	1.20
11/01/19	RC	Review information related SAP vendor payment analysis.	1.10
11/04/19	RC	Call with M. Clarens (Davis Polk) to discuss information requests from the UCC and ad hoc committee's professionals.	0.20
11/04/19	RC	Coordinate and supervise staff with respect to gathering information in response to request by the committees' professionals.	0.30
11/04/19	RC	Provide next steps to team based on discussions with Davis Polk.	0.20
11/04/19	RC	Review and provide comments related to the summary of vendor analysis testing.	1.20
11/04/19	RC	Review and provide comments to the summary of testing related to reinvestments and tax refunds received.	0.90
11/04/19	SJC	Open and cleared accounts payable report runs and analysis.	2.70
11/04/19	SJC	Analysis of payroll and compensation data.	2.90
11/04/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1F.	2.60
11/04/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status update on tasks and staffing.	0.20
11/04/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status update on tasks and staffing.	0.20
11/04/19	FOS	Compose email to R. Ellis Ochoa (AlixPartners) re: communications with non-debtor entities' employees.	0.10
11/04/19	FOS	Review of intercompany general ledger account activity in SAP re: shared services charges between debtor and non-debtor entities.	4.70
11/04/19	JDH	Compile supporting bank documentation for various	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		committees.	
11/04/19	JDH	Compile supporting documentation for various committees related to family T&E.	3.30
11/04/19	ADD	Follow up regarding office space usage by PPLP and PRA at One Stamford.	0.30
11/05/19	ADD	Upload to the data room investigation report support and permissioned files.	0.80
11/05/19	ADD	Discussion and working session with S. Canniff and A. DePalma (both AlixPartners) to document testing procedures and determine next steps	2.20
11/05/19	JDH	Compile supporting documentation for various committees relate to family T&E.	3.60
11/05/19	JDH	Compile supporting bank documentation for various committees.	3.70
11/05/19	SR	Review updated PPI report, recheck equity GL accounts to confirm no additional dividends paid, clear review notes	0.50
11/05/19	SR	Follow up with S. Canniff (AlixPartners) re: earnings of admins assigned to family members, follow up with I. Arana (AlixPartners) re: fringe benefit calculation used for budget purposes, and adjust model to reflect fixed dollar amount used for fringe benefits.	0.50
11/05/19	FOS	Review of intercompany general ledger account activity in SAP re: shared services charges between debtor and non-debtor entities.	4.90
11/05/19	MH	Prepare list of charities associated with the Sackler family and reconcile with prior analysis work.	0.80
11/05/19	SJC	Intro and review of Intralinks.	0.90
11/05/19	SJC	Analysis and review of accounts payable.	3.40
11/05/19	SJC	Analysis review and documentation.	1.60
11/05/19	SJC	Discussion and working session with S. Canniff, and A.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		DePalma (both AlixPartners) to document testing procedures and determine next steps.	
11/05/19	RC	Update Purdue Pharma Inc analysis and provide comments to team.	2.70
11/05/19	RC	Call with Margarita Claren (Davis Polk) to discuss responses to requests for documents made by the UCC's advisors.	0.20
11/05/19	RC	Correspond with Margarita Claren (Davis Polk) regarding responses to the DOJ's requests for documents.	0.10
11/05/19	RC	Review and finalize documents to be uploaded into the data room for professionals' eyes only.	2.10
11/05/19	RC	Prepare additional updates to the Purdue Pharma Inc. analysis.	1.20
11/05/19	RC	Review accounting and financial documents related to Purdue Pharma Inc.	1.40
11/06/19	RC	Call with M. Clarens (Davis Polk) to discuss request for additional information related to the Cash Transfers of Value report.	0.20
11/06/19	RC	Follow-up call with M. Clarens (Davis Polk) to discuss additional cash transfers of value information.	0.20
11/06/19	RC	Prepare analysis related to cash transfers based on requests from Davis Polk.	1.10
11/06/19	RC	Review and analysis of Purdue's internal distributions workbook and setup team on documenting procedures performed.	1.70
11/06/19	RC	Review and analysis of vendor disbursements and setup team on documenting procedures performed.	0.80
11/06/19	RC	Review additional supporting documentation related to the Cash Transfers of Value report in response to requests from the committees' professionals.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/06/19	RC	Correspond with Davis Polk regarding requests for information from TXP Services and PRA L.P.	0.10
11/06/19	SJC	Accounts payable review and analysis.	2.80
11/06/19	SJC	Analysis of open accounts payable	0.30
11/06/19	SJC	Open/cleared accounts payable analysis.	0.40
11/06/19	SJC	Distribution review and analysis.	2.80
11/06/19	FOS	Compose email to R. Ellis Ochoa (AlixPartners) re: assistance on review of intercompany general ledger accounts for shared services charges.	0.30
11/06/19	FOS	Review of intercompany general ledger account activity in SAP re: shared services charges between debtor and non-debtor entities.	3.80
11/06/19	SR	Perform analysis and reconciliation of External Reporting and Internal Reporting columns in Purdue internal workbook	8.00
11/06/19	JDH	Compile supporting documentation for various committees related to family T&E.	2.90
11/06/19	REO	Review of Intercompany accounts re: Shared Services.	2.50
11/07/19	REO	Review of Intercompany accounts in SAP re: Identifiable Shared Services.	1.20
11/07/19	REO	Review of Intercompany accounts in SAP re: Unidentifiable Shared Services.	1.50
11/07/19	REO	Edit Shared Services tracker re: Categorization of all relevant entries.	2.80
11/07/19	REO	Review of intercompany transfers re: quality control of previous categorizations by engagement lead SVP.	2.00
11/07/19	REO	Conference call with F. Silva, and R. Ochoa (both AlixPartners) re: review of Intercompany Shared Services Workstream.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/07/19	DS	Call with M. Clarens, K. Benedict, D. Rubin (all Davis Polk), R. Collura, J. DelConte, S. Robertson, and D. Samikkannu (all AlixPartners) to discuss information requests from PRA LP and TXP.	0.50
11/07/19	SR	Call with M. Clarens, K. Benedict, D. Rubin (all Davis Polk), R. Collura, J. DelConte, S. Robertson, and D. Samikkannu (all AlixPartners) to discuss information requests from PRA LP and TXP.	0.50
11/07/19	SR	Continue to work on reconciliation of Internal and External reporting in the Purdue internal workbook. Reconcile to Transfer of Value Deck	5.10
11/07/19	FOS	Compose emails to R. Ellis Ochoa (AlixPartners) re: discussion regarding intercompany shared services charges.	0.10
11/07/19	FOS	Conference call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: review of Intercompany Shared Services workstream.	0.40
11/07/19	FOS	Review of intercompany general ledger account activity in SAP re: shared services charges between debtor and non-debtor entities.	3.80
11/07/19	SJC	Respond to follow up questions and review of outstanding requests.	1.10
11/07/19	SJC	Open accounts payable analysis.	0.70
11/07/19	RC	Dial into portion of call with M. Clarens, K. Benedict, D. Rubin (all Davis Polk), R. Collura, S. Robertson, and D. Samikkannu (all AlixPartners) to discuss information requests from PRA LP and TXP.	0.20
11/07/19	RC	Call with M. Clarens (Davis Polk) to discuss protocols for communication with TXP Services.	0.10
11/07/19	RC	Communicate with team regarding information requests for TXP Services.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/07/19	RC	Provide initial set of documents to Wiggin and Dana in response to the DOJ's requests	0.50
11/07/19	RC	Review and analysis of reinvestment information.	1.80
11/07/19	RC	Review and analysis of tax distributions.	1.60
11/07/19	RC	Provide documents in response to the DOJ's requests to Purdue for further production.	0.10
11/08/19	RC	Review PPI financial information and update related analysis.	2.60
11/08/19	RC	Review and update data requests for TXP Services.	0.50
11/08/19	RC	Call with S. Robertson and R. Collura (both AlixPartners) to discuss PPI analysis and additional requests for TXP and PRA.	0.60
11/08/19	SJC	Accounts payable review and analysis.	3.00
11/08/19	SJC	Distributions review and analysis.	1.50
11/08/19	SR	Emails with K. Darragh (Purdue) re: 2019 Corporate reorganization and PPI as new general partner.	0.50
11/08/19	SR	Prepare data request for TXP employees	0.50
11/08/19	SR	Call with S. Robertson and R. Collura (both AlixPartners) to discuss PPI analysis and additional requests for TXP and PRA.	0.60
11/08/19	REO	Review of Intercompany accounts in SAP re: Identifiable Shared Services.	2.10
11/08/19	REO	Review of Intercompany accounts in SAP re: Unidentifiable Shared Services.	1.70
11/08/19	REO	Edit Shared Services tracker re: Categorization of all relevant entries.	2.20
11/08/19	REO	Review of intercompany transfers re: quality control of previous categorizations by engagement lead SVP.	2.60
11/08/19	JDH	Review of bank statement analysis.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/11/19	JDH	Analysis of non-reimbursed T&E items.	3.10
11/11/19	REO	Review of Intercompany accounts re: Shared Services.	2.00
11/11/19	REO	Review of intercompany transfers re: quality control of previous categorizations by engagement lead SVP.	1.10
11/11/19	REO	Edit Shared Services tracker re: Categorization of all relevant entries.	1.50
11/11/19	REO	Review of Intercompany accounts in SAP re: Unidentifiable Shared Services.	0.60
11/11/19	REO	Review of Intercompany accounts in SAP re: Identifiable Shared Services.	1.00
11/11/19	SJC	Review of distributions file to accounts payable transactions.	2.80
11/11/19	SJC	Review of AP entries to distributions file.	3.20
11/11/19	RC	Prepare list of questions and outstanding information requests for TXP Services and One Stamford Realty.	1.50
11/11/19	RC	Review lease agreement and related amendments between Purdue and One Stamford.	0.50
11/11/19	RC	Review and analysis of accounting information related to contributions.	1.40
11/11/19	RC	Prepare updated analysis of Purdue Pharma Inc.	1.60
11/11/19	RC	Review tax distribution flow of funds and prepare related questions for TXP Services.	0.80
11/11/19	RC	Review Province's tracker of documents provided.	0.10
11/11/19	RC	Review additional support documentation in response to UCC's requests for information.	1.70
11/11/19	FOS	Review Intercompany Shared Services workstream update	0.20
11/11/19	FOS	Edit draft presentation re: intercompany and non-cash transfers report.	0.40



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/11/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1G.	3.20
11/11/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 1L.	2.60
11/11/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 3A.	3.00
11/12/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 3B.	2.80
11/12/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 3E.	2.90
11/12/19	MFR	Review of intercompany analyses and supporting documents - Exhibit 3F.	3.20
11/12/19	FOS	Compose email to R. Ellis Ochoa (AlixPartners) re: analysis of intercompany general ledger accounts.	0.20
11/12/19	FOS	Edit draft presentation re: intercompany and non-cash transfers report.	0.80
11/12/19	FOS	Review draft intercompany and non-cash transfers deck and intercompany shared services charges.	0.20
11/12/19	FOS	Review latest Intercompany Shared Services workstream update.	0.20
11/12/19	RC	Update list of questions and data requests for TXP Services.	1.00
11/12/19	RC	Review internal distributions workbook and update analysis of Purdue Pharma Inc.	1.60
11/12/19	RC	Review and comment on analysis of cash disbursements.	1.70
11/12/19	RC	Review limited partnership agreements and management fee information.	1.60
11/12/19	RC	Update tax distributions flow of funds template.	1.10
11/12/19	SJC	Review of distribution testing.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/12/19	REO	Review of Intercompany accounts in SAP re: Identifiable Shared Services.	1.00
11/12/19	REO	Review of Intercompany accounts in SAP re: Unidentifiable Shared Services.	0.90
11/12/19	REO	Edit Shared Services tracker re: Categorization of all relevant entries.	1.50
11/12/19	REO	Review of intercompany transfers re: quality control of previous categorizations by engagement lead SVP.	1.10
11/12/19	REO	Review of Intercompany accounts re: Shared Services.	1.00
11/12/19	JDH	Documentation of cash transactions to bank statements.	3.10
11/12/19	JDH	Research charitable contributions made by family members and trusts.	0.70
11/12/19	ADD	Review distribution completeness testing.	1.20
11/12/19	ADD	Research and identify potential affiliated charities in the Purdue vendor list	2.20
11/12/19	ADD	Prepare schedule of payments made to affiliated charities	0.70
11/13/19	ADD	Meeting with R. Collura, S. Canniff, J. Hecht and A. DePalma (all AlixPartners) to discuss investigation status updates.	1.30
11/13/19	ADD	Working session with S. Canniff and A. DePalma (both AlixPartners) re: review of distribution analysis	2.70
11/13/19	JDH	Analysis of reimbursed and non-reimbursed T&E expenses incurred by company on behalf of family members.	2.90
11/13/19	JDH	Analysis of reimbursed and non-reimbursed T&E expenses incurred by company on behalf of family members.	1.70
11/13/19	JDH	Meeting with R. Collura, S. Canniff, J. Hecht and A. DePalma (all AlixPartners) to discuss investigation status updates.	1.30
11/13/19	JDH	Research charitable contributions made by family	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		members and trusts.	
11/13/19	SJC	Meeting with R. Collura. S. Canniff, J.Hecht and A. DePalma (all AlixPartners) to discuss investigation status updates.	1.30
11/13/19	SJC	Working session with S. Canniff and A. DePalma (both AlixPartners) re: review of distribution analysis.	2.70
11/13/19	SJC	Analysis of charitable contributions.	0.90
11/13/19	SJC	Analysis of compensation data.	2.50
11/13/19	SJC	Analysis of distribution detail and supporting documents.	1.40
11/13/19	RC	Identify outstanding work streams and assign team members to tasks.	0.40
11/13/19	RC	Meeting with R. Collura. S. Canniff, J.Hecht and A. DePalma (all AlixPartners) to discuss investigation status updates.	1.30
11/13/19	RC	Prepare for and call with M. Clarens (Davis Polk) to discuss ongoing work streams and investigation status update.	0.60
11/13/19	RC	Review T&E reimbursement data and provide comments to team.	0.50
11/13/19	RC	Review Purdue Pharma Inc.'s distributions received analysis and provide comments to team.	1.30
11/13/19	RC	Research information related to affiliated entities.	0.80
11/13/19	RC	Update status of ongoing investigation work streams.	0.30
11/13/19	RC	Call with M. Greenblatt (FTI) to discuss information requests.	0.10
11/13/19	RC	Review communication from Province regarding status of information requests.	0.20
11/13/19	RC	Review and analysis of PPI and PPLP cash disbursements information.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/13/19	RC	Review additional documents to produce in response to requests from the DOJ and UCC's advisors.	0.70
11/13/19	RC	Communication with Davis Polk and AlixPartners teams regarding process for requests for information from TXP Services.	0.10
11/13/19	FOS	Review and update draft intercompany and non-cash transfers deck.	0.20
11/13/19	FOS	Draft slides for intercompany and non-cash transfers report re: shared service charges to/from Purdue Pharma LP.	1.50
11/13/19	MH	Prepare summary of all past research on Purdue legal spend related to the equity owners.	0.80
11/13/19	FOS	Analyze intercompany general ledger account activity re: shared services charges to/from Purdue Pharma LP.	6.00
11/13/19	MFR	Review of Box drive for transfer pricing workpapers.	2.60
11/13/19	MFR	Revisions to transfer pricing report - executive summary.	2.90
11/13/19	MFR	Revisions to transfer pricing report - appendices.	3.30
11/14/19	MFR	Revisions to transfer pricing report - appendices.	2.80
11/14/19	MFR	Revisions to transfer pricing report - Exhibit 1N.	3.30
11/14/19	MFR	Revisions to transfer pricing report - executive summary.	3.10
11/14/19	MFR	Conference call with F. Silva, M. Rule (both AlixPartners) and M. Clarens (Davis Polk) regarding comments on the report draft.	1.10
11/14/19	FOS	Conference call with F. Silva, M. Rule (both AlixPartners) and M. Clarens (Davis Polk) regarding comments on the report draft.	1.10
11/14/19	FOS	Create update of call with Davis Polk Wardwell and comments on draft intercompany and non-cash transfers report.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/14/19	FOS	Analysis of intercompany general ledger accounts re: shared services charges to/from Purdue Pharma LP.	3.20
11/14/19	FOS	Draft slides for intercompany and non-cash transfers report re: shared service charges to/from Purdue Pharma LP.	0.80
11/14/19	FOS	Edit draft presentation re: intercompany and non-cash transfers report.	2.80
11/14/19	SJC	Review of compensation data.	2.70
11/14/19	SJC	Review of distributions analysis.	3.00
11/14/19	RC	Review T&E reimbursement data and prepare information for UCC advisors and the DOJ.	0.80
11/14/19	RC	Review PRA promissory note information and prepare information for UCC's advisors and the DOJ.	0.50
11/14/19	RC	Review and update Purdue Pharma Inc analysis and provide to counsel for review.	2.60
11/14/19	RC	Review and analysis of Purdue Pharma Inc's financial information.	2.00
11/14/19	RC	Review cash transfers of value report and related support documentation.	1.20
11/14/19	RC	Review bank statement tracing analysis.	1.30
11/14/19	SJC	Working session with S. Canniff and A. DePalma (both AlixPartners) re: review of distribution analysis .	1.60
11/14/19	JDH	Research of foundations established or controlled by family members.	3.20
11/14/19	JDH	Research of foundations established or controlled by family members.	3.80
11/14/19	JDH	Review of travel and entertainment expenses.	1.10
11/14/19	ADD	Working session with S. Canniff and A. DePalma (both AlixPartners) re: review of distribution analysis.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/15/19	JDH	Research on family foundations.	2.40
11/15/19	REO	Review of Intercompany Transfers re: Data request from engagement lead SVP.	0.50
11/15/19	RC	Review and analysis of Purdue Pharma Inc.'s accounting records and update report information.	1.80
11/15/19	RC	Review support documentation related to the cash tracing analysis.	1.30
11/15/19	RC	Review and update PPI financial analysis.	1.10
11/15/19	FOS	Edit draft presentation re: intercompany and non-cash transfers report.	9.20
11/15/19	MFR	Revisions to non-cash transfer of value draft report - edits to executive summary.	2.80
11/15/19	MFR	Revisions to non-cash transfer of value draft report - edits to Exhibit 1.	3.20
11/15/19	MFR	Revisions to non-cash transfer of value draft report - edits to Exhibit 2.	2.10
11/16/19	MFR	Revisions to non-cash transfer of value draft report - edits to Exhibit 3.	3.30
11/16/19	FOS	Edit draft presentation re: intercompany and non-cash transfers report.	3.90
11/16/19	FOS	Compose email to R. Ellis Ochoa (AlixPartners) re: accounting for royalty payments from Ex-U.S. IACs.	0.10
11/17/19	MFR	Revisions to non-cash transfer of value draft report - edits to Exhibit 4.	3.00
11/18/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of exhibit 1 and source documents.	2.80
11/18/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of exhibit 2 and source documents.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/18/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of exhibit 3 and source documents.	3.10
11/18/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of exhibit 4 and source documents.	2.90
11/18/19	FOS	Compose email to M. Clarens (David Polk) re: draft intercompany and non-cash transfers report.	0.20
11/18/19	FOS	Analyze intercompany general ledger accounts re: shared services charges to/from Purdue Pharma LP.	3.80
11/18/19	FOS	Edits draft report re: intercompany and non-cash transfers.	1.40
11/18/19	FOS	Edit draft intercompany and non-cash transfers report.	0.20
11/18/19	RC	Call with D. Samikkannu, R. Collura, A. DePalma (all AlixPartners), R. Hoff (Wiggin and Dana) and Davis Polk re: DOJ production	0.30
11/18/19	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss PPI analysis and related support documentation.	0.50
11/18/19	RC	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: review Province value transfer diligence request	1.00
11/18/19	RC	Call with M. Clarens (Davis Polk) to discuss Province's diligence requests, questions for TXP and PPI analysis.	0.30
11/18/19	RC	Review internal distributions analysis and reconcile information to cash transfers of value report.	1.30
11/18/19	RC	Review supporting documents related to Purdue Pharma Inc analysis.	1.40
11/18/19	RC	Review Purdue's distributions to Purdue Pharma Inc. and related support documentation.	0.90
11/18/19	RC	Review testing on cash distribution analysis.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/18/19	SJC	Review of Province request.	0.50
11/18/19	SJC	Compensation data analysis.	1.70
11/18/19	SJC	Distribution review.	3.00
11/18/19	SJC	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: review Province value transfer diligence request	1.00
11/18/19	DS	Call with D. Samikkannu, R. Collura, A. DePalma (all AlixPartners), R. Hoff (Wiggin and Dana) and Davis Polk re: DOJ production	0.30
11/18/19	JDH	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: review Province value transfer diligence request	1.00
11/18/19	JDH	Research of charitable organizations that received donations.	2.10
11/18/19	ADD	Work with Davis Polk to resolve issue with Intralinks data room.	0.80
11/18/19	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss PPI analysis and related support documentation.	0.50
11/18/19	ADD	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: review Province value transfer diligence request	1.00
11/18/19	ADD	Call with D. Samikkannu, R. Collura, A. DePalma (all AlixPartners), R. Hoff (Wiggin and Dana) and Davis Polk re: DOJ production	0.30
11/19/19	ADD	Review and analyze distribution transaction	1.50
11/19/19	JDH	Preparation of travel and expense analysis for counsel.	2.20
11/19/19	RC	Dial into Purdue Pharma Omnibus court hearing.	2.00
11/19/19	FOS	Analyze intercompany general ledger accounts re: shared services charges to/from Purdue Pharma LP.	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/19/19	SJC	Attend hearing.	2.50
11/19/19	SJC	Review and analysis of distributions.	2.90
11/19/19	SJC	Review of Province request.	0.70
11/19/19	SJC	Review of compensation data.	2.10
11/19/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of executive summary and source documents.	3.30
11/19/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of intercompany analyses.	3.10
11/19/19	MFR	Preparation for meeting with John Dubel (Purdue) regarding draft report - review of royalty payments and source documents.	2.20
11/20/19	MFR	Preparation for and meeting with John Dubel (Purdue), F. Silva, M. Rule (both AlixPartners) and M. Clarens (Davis Polk) regarding comments on draft report.	3.00
11/20/19	MFR	Revisions to transfer pricing report - Executive Summary.	2.90
11/20/19	MFR	Discussion with M. Rule and F. Silva (both AlixPartners) re: intercompany and non-cash transfers of value report draft.	0.50
11/20/19	SJC	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: investigation status update.	1.50
11/20/19	FOS	Discussion with M. Rule and F. Silva (both AlixPartners) re: intercompany and non-cash transfers of value report draft.	0.50
11/20/19	FOS	Meeting with John Dubel (Purdue), F. Silva, M. Rule (both AlixPartners) and M. Clarens (Davis Polk) regarding comments on draft report.	2.00
11/20/19	FOS	Update analyses of transactions with IACs to activity as of petition date re: intercompany and non-cash transfers draft report.	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/20/19	RC	Review and provide comments related to research performed on charitable organizations.	1.20
11/20/19	RC	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: investigation status update	1.50
11/20/19	RC	Review and analysis of support documents for cash transfers of value report in response to questions from the UCC's financial advisors.	1.20
11/20/19	RC	Review outstanding requests from Davis Polk and identify next steps.	0.70
11/20/19	SJC	Compensation summary and review.	0.90
11/20/19	SJC	Call with IT for new Citrix password.	0.40
11/20/19	JDH	Meeting with S. Canniff, R. Collura, A. DePalma, J. Hecht (all AlixPartners) re: investigation status update	1.50
11/20/19	JDH	Analysis of Baker foundation.	2.70
11/20/19	ADD	Meeting with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: investigation status update	1.50
11/21/19	JDH	Analysis of cash transfers made from Purdue to foundations.	4.20
11/21/19	REO	Review of Intercompany Entries: LCD entries within intercompany activity.	1.20
11/21/19	REO	Research updated SAP data re: company activity between June 2019 and September 2019.	2.50
11/21/19	REO	Update transfer pricing analysis re: breakdown of intercompany transactions with mark-ups up to September 15, 2019.	1.40
11/21/19	REO	Update Transfer Pricing Analysis: Intercompany transfers for royalty amounts up to 9/15/2019.	2.30
11/21/19	REO	Research update data SAP: update royalty activity.	1.00
11/21/19	RC	Review cash activity and respond to questions from	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Province.	
11/21/19	RC	Review and provide comments related to the documentation of cash distributions testing.	1.20
11/21/19	RC	Review and provide comments to research related to charitable contributions.	0.60
11/21/19	RC	Review and provide comments regarding vendor payments analysis.	0.50
11/21/19	FOS	Compose emails to K. Shibuya and R. Ellis Ochoa (both AlixPartners) re: updating analyses of intercompany transfers to petition date for draft intercompany and non-cash transfers report.	0.50
11/21/19	FOS	Compose emails to M. Clarens and E. Kim (both Davis Polk) re: accounting for transfers of royalties between PALP and PPLP.	0.20
11/21/19	FOS	Compose emails to M. Clarens and E. Kim (both Davis Polk) re: access to documentation and support for draft intercompany and non-cash transfers report.	0.20
11/21/19	FOS	Update analyses of transactions with IACs to activity as of petition date re: intercompany and non-cash transfers draft report.	6.40
11/21/19	FOS	Conference call with M. Clarens, E. Kim (both Davis Polk) re: Intercompany/Non-Cash Transfers Report	0.50
11/21/19	MFR	Revisions to transfer pricing report - Exhibit 1N.	3.20
11/21/19	MFR	Review of intercompany analyses.	2.80
11/21/19	MFR	Review and edits to transfer pricing report appendices.	2.60
11/22/19	MFR	Review and edits to transfer pricing report.	3.30
11/22/19	FOS	Edit draft intercompany and non-cash transfers report re: updates to report for data as of petition date.	1.40
11/22/19	FOS	Update analyses of transactions with IACs to activity as of petition date re: intercompany and non-cash transfers	4.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		draft report.	
11/22/19	FOS	Call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: status update of intercompany activity review.	0.30
11/22/19	RC	Identify additional work to be performed related to the analysis of Purdue Pharma Inc.	0.70
11/22/19	RC	Review and provide comments related to accounts payable vendor testing.	1.10
11/22/19	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests from Province and PPI analysis.	0.60
11/22/19	RC	Review and analysis accounting information related to PPI.	1.30
11/22/19	RC	Review informational materials provided by counsel to the family members.	1.50
11/22/19	RC	Review cash transfers of value report for potential redactions.	0.30
11/22/19	REO	Research updated SAP data re: company activity between June 2019 and September 2019.	2.10
11/22/19	REO	Update transfer pricing analysis re: breakdown of intercompany transactions for sales to foreign entities.	2.50
11/22/19	REO	Call with F. Silva and R. Ochoa (both AlixPartners) re: status update of intercompany activity review.	0.30
11/22/19	REO	Review (initial) of intercompany activity re: foreign oxycontin intercompany activity.	1.10
11/22/19	JDH	Analysis of family foundation tax returns.	3.20
11/22/19	ADD	Download and compile accounting data in preparation for diligence request.	1.90
11/22/19	ADD	Review distribution accounting in preparation request.	2.20
11/22/19	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests from Province and PPI analysis.	0.60



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/25/19	ADD	Compile general ledger data and other support in preparation for meeting with UCC's advisors.	1.70
11/25/19	JDH	Review and analysis of family trusts and IACs.	4.30
11/25/19	REO	Review (preliminary) of YTD updated foreign sales file shared by company.	0.50
11/25/19	REO	Review of SAP database re: Updated Intercompany activity.	2.10
11/25/19	REO	Edit Transfer Pricing Deck re: Update intercompany activity and cash settlements.	2.50
11/25/19	RC	Review and analysis of information provided by the family members and setup team on next steps.	1.20
11/25/19	RC	Review information related to charitable organizations and provide comments to team.	1.00
11/25/19	RC	Review and analysis of accounting information related to PPI's intercompany accounts.	1.40
11/25/19	RC	Review and analysis of accounting information related to PPI's payments to charitable organizations.	1.50
11/25/19	RC	Review and analysis of accounting information related to PPI's management fee income.	1.20
11/25/19	RC	Review and analysis of information related to PPI's distributions received from Purdue and PRA LP.	1.30
11/25/19	RC	Review and updated PPI analysis.	0.90
11/25/19	FOS	Compose email to W. DiNicola (Rhodes Tech) re: outstanding request on sales summaries.	0.10
11/25/19	FOS	Edit draft report re: intercompany and non-cash transfers.	3.80
11/25/19	KS	Update the report slides regarding transfer pricing.	2.50
11/25/19	KS	Update the report slides re transfer pricing	2.80
11/25/19	SJC	Analysis of supporting documents for PPI charitable	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		contributions.	
11/25/19	SJC	Documentation of distributions procedures for review of completeness.	1.70
11/25/19	SJC	Review and documentation of documents received related to trust and entity structures.	3.60
11/26/19	SJC	Call with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: Sackler family trusts/entities list creation.	0.30
11/26/19	SJC	Analysis of documents received related to Sackler family trusts/entities.	2.30
11/26/19	SJC	Documentation and analysis of Sackler family trusts/entities.	3.00
11/26/19	KS	Update the report slides regarding transfer pricing.	1.70
11/26/19	KS	Update the report slides regarding transfer pricing.	2.80
11/26/19	FOS	Compose email to D. Samikkannu (AlixPartners) re: IAC descriptions and royalties paid by IACs to Purdue.	0.30
11/26/19	FOS	Edit draft report re: intercompany and non-cash transfers.	1.80
11/26/19	MH	Prepare list of payments to medical center to support analysis of overlap with equity owner charities.	0.80
11/26/19	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: distributions testing strategy for UCC request.	0.80
11/26/19	RC	Call with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: Sackler family trusts/entities list creation.	0.30
11/26/19	RC	Review Sackler family trusts/entities list creation.	0.30
11/26/19	RC	Call with R. Collura, A. DePalma (both AlixPartners), Province, and Akin Gump re: distributions sampling and testing process.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/26/19	RC	Call with R. Collura, A. DePalma (both AlixPartners), and K. Darraugh (Purdue) to discuss PPI analysis.	0.70
11/26/19	RC	Prepare updates to PPI related analysis.	1.50
11/26/19	RC	Review distributions workbook and update PPI analysis.	1.60
11/26/19	RC	Review PPI intercompany account activity.	1.10
11/26/19	RC	Review draft template of family related entity names.	0.40
11/26/19	RC	Review updated research related to charities.	0.50
11/26/19	REO	Research Updated intercompany balances for foreign sales by entity in SAP.	1.80
11/26/19	REO	Edit Transfer Pricing Deck for updated transaction data for foreign sales by entity.	1.10
11/26/19	JDH	Call with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: Sackler family trusts/entities list creation	0.30
11/26/19	JDH	Review and analysis of family trusts and IACs.	5.70
11/26/19	ADD	Review distribution accounting and developed testing strategies for the UCC committee.	2.60
11/26/19	ADD	Call with R. Collura, A. DePalma (both AlixPartners), Province and Akin Gump re: distributions sampling and testing process	0.80
11/26/19	ADD	Call with R. Collura, A. DePalma (both AlixPartners), and K. Darraugh (Purdue) to discuss PPI analysis.	0.70
11/26/19	ADD	Call with S. Canniff, R. Collura, A. DePalma, and J. Hecht (all AlixPartners) re: Sackler family trusts/entities list creation	0.30
11/26/19	ADD	Call with R. Collura, and A. DePalma (both AlixPartners) re: distributions testing strategy for UCC request	0.80
11/27/19	ADD	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/27/19	JDH	Review of family trusts and IACs.	3.10
11/27/19	RC	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity.	0.70
11/27/19	RC	Review and analysis of distribution activity in connection with updating Purdue Pharam Inc. analysis.	1.60
11/27/19	RC	Review and analysis payments to charities and provide comments to team.	0.70
11/27/19	RC	Review and provide comments to template for list of Sackler related entities.	0.80
11/27/19	RC	Review and analysis of distribution information included in the audited financial statements.	0.70
12/02/19	RC	Review SAP system documentation related to transfers of value analysis.	1.20
12/02/19	RC	Review and update list of investigation team's weekly activities and related progress.	0.50
12/02/19	RC	Review articles and other public information related to Sackler family related charities.	1.00
12/02/19	RC	Review and analysis of Purdue transfers of value analysis.	2.30
12/02/19	RC	Update and provide comments related to Purdue analysis and communicate with K. Darruagh (Purdue) regarding follow-up requests for information.	1.60
12/02/19	RC	Review historical changes to Purdue's corporate organizational charts.	0.70
12/02/19	RC	Prepare status of additional work streams for internal discussion.	0.50
12/02/19	SJC	Analysis of Mortimer family trusts/entities.	3.00
12/02/19	SJC	Documentation of Mortimer family trusts/entities.	3.00
12/02/19	SJC	Review of Mortimer family trusts/entities.	2.10
12/02/19	FOS	Edit and update draft report re: intercompany and non-	6.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		cash transfers.	
12/02/19	JDH	Research donations made by family members to various institutions.	2.80
12/02/19	JDH	Analysis of entities owned/controlled by family members.	3.70
12/02/19	ADD	Review and update distributions presentation.	2.10
12/03/19	ADD	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity and presentation update	0.90
12/03/19	JDH	Analysis of entities owned/controlled by family members.	4.70
12/03/19	JDH	Research donations made by family members to various institutions.	2.20
12/03/19	FOS	Review latest intercompany and non-cash transfers report.	0.20
12/03/19	FOS	Edit and update draft report re: intercompany and non-cash transfers.	5.30
12/03/19	SJC	Review distributions payments and related SAP entries.	2.90
12/03/19	SJC	Analysis of Mortimer family trusts/entities.	3.00
12/03/19	SJC	Review of Mortimer family trusts/entities.	2.20
12/03/19	RC	Review and analysis of PPLP's audited financial statements.	1.30
12/03/19	RC	Review financial documents produced in connection with the Rhode Island litigation.	1.20
12/03/19	RC	Review discovery requests and related responses related to distributions or entity ownership structures.	1.30
12/03/19	RC	Call with R. Collura, and A. DePalma (both AlixPartners) re: PPI distribution activity and presentation update	0.90
12/03/19	RC	Review Purdue 's internal financial statements.	1.10
12/03/19	RC	Review support documentation related to the cash transfers of value report.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/03/19	RC	Review information related to ownership structure of PPLP and other related entities.	0.70
12/04/19	RC	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/04/19	RC	Review PPI general ledger activity related to cash disbursements.	1.30
12/04/19	RC	Call with M. Clarens (Davis Polk) to discuss status of various work streams and next steps.	0.80
12/04/19	RC	Review and analysis of financial information for PPLP and PPI.	1.30
12/04/19	RC	Review PPI's intercompany activity and related documentation.	0.60
12/04/19	RC	Prepare list of additional work streams and status of each.	0.40
12/04/19	RC	Review PPI's investment account activity.	1.00
12/04/19	RC	Review information related to ownership changes in organization structure.	0.60
12/04/19	SJC	Review of payments for charitable contributions.	3.00
12/04/19	SJC	Document payments for charitable contributions.	1.70
12/04/19	SJC	Review of distribution supporting documents.	2.00
12/04/19	SJC	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/04/19	JDH	Research donations made by family members to various institutions.	1.90
12/04/19	JDH	Analysis of entities owned/controlled by family members.	3.30
12/04/19	ADD	Call with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) re: investigation status update	1.00
12/05/19	ADD	Call with A. DePalma, R. Collura, (both AlixPartners) and K. Darraugh (Purdue) to discuss Purdue 's distributions and financial information.	1.20



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/05/19	ADD	Assist with download and formatting of distribution support documentation.	0.60
12/05/19	JDH	Analysis of entities owned/controlled by family members.	4.20
12/05/19	SJC	Review of documents for charitable contributions.	1.80
12/05/19	SJC	Aggregating and reviewing distributions follow up questions.	3.00
12/05/19	RC	Call with A. DePalma, R. Collura, (both AlixPartners) and K. Darraugh (Purdue) to discuss Purdue's distributions and financial information.	1.20
12/05/19	RC	Review summary of information related to charitable organizations.	1.00
12/05/19	RC	Review summary of information related to Sackler family-controlled entities.	1.60
12/05/19	RC	Review support documentation related to distribution testing.	1.70
12/05/19	RC	Review and analysis of documentation related to PPLP distributions.	1.30
12/06/19	RC	Review and analysis of Purdue's financial statements and cash disbursements.	1.80
12/06/19	RC	Review accounting documentation related to Purdue's cash disbursements.	1.30
12/06/19	RC	Review information related to payments to not-for-profit organizations.	1.00
12/06/19	SJC	Draft email for distribution follow up questions, reviewing follow up questions, and reviewing documents for distribution follow up questions.	2.20
12/06/19	FOS	Review documents provided by counsel re: intercompany and non-cash transfers report.	0.60
12/06/19	FOS	Review intercompany and non-cash transfers report.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/06/19	FOS	Compose emails to W. DiNicola (Rhodes Tech) re: intercompany settlement files between Rhodes and PPLP.	0.20
12/06/19	JDH	Research additional IACs and other entities controlled by family members.	3.40
12/09/19	JDH	Analysis of RS family entities and trusts.	4.60
12/09/19	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss responses to the DOJ's requests for information related to the cash transfers of value report.	0.40
12/09/19	FOS	Edit and review draft report re: intercompany and non-cash transfers.	4.00
12/09/19	FOS	Prepare update on status of intercompany and non-cash transfers report draft.	0.20
12/09/19	SJC	Review information provided by the Sackler Family and create a comprehensive list of all referenced entities for Mortimer side.	3.00
12/09/19	SJC	Review information provided by the Sackler Family and create a comprehensive list of all referenced entities for Raymond side.	1.50
12/09/19	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss responses to the DOJ's requests for information related to the cash transfers of value report.	0.40
12/09/19	RC	Prepare email communication to Davis Polk regarding status of work streams.	0.30
12/09/19	RC	Review and analysis of accounting information provided by the debtors regarding Purdue	2.00
12/09/19	RC	Prepare updates to summary of investigation related work streams.	0.10
12/09/19	RC	Review requests from PRA LP and communicate with Davis Polk.	0.20
12/09/19	RC	Review information requests for TXP.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/09/19	RC	Prepare email to team regarding accounting information related to Purdue	0.20
12/09/19	RC	Review accounting documentation related to Purdue's cash disbursements.	1.70
12/09/19	RC	Review support documentation compiled for cash transfers of value report.	1.90
12/10/19	RC	Prepare for and call with E. Kim and A. Whisenant (both Davis Polk) to discuss the cash transfers of value report.	0.60
12/10/19	RC	Review questions and comments from Davis Polk related to cash transfers of value report.	1.70
12/10/19	RC	Review information in cash report for redactions.	2.00
12/10/19	RC	Prepare open items list related to requests for TXP and PRA LP.	0.80
12/10/19	RC	Review support documentation related to cash transfers of value report.	1.50
12/10/19	RC	Review and analysis of intercompany schedules prepared by the Debtors.	1.40
12/10/19	SJC	Create and analyze trust information in order to create a comprehensive list of all referenced entities for Mortimer side.	3.00
12/10/19	SJC	Review comprehensive list of all referenced entities for Mortimer side created.	2.60
12/10/19	SJC	Review comprehensive list of all referenced entities for Raymond side created (trusts).	2.40
12/10/19	MFR	Revisions to Report 1B (non-cash report).	2.20
12/10/19	ADD	Review cash value of transfer presentation and compared data tables to prior versions.	2.40
12/10/19	JDH	Analysis of RS family entities and trusts.	3.90
12/11/19	JDH	Analysis of RS family entities and trusts.	3.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/11/19	JDH	Review of MS family entities database.	3.80
12/11/19	ADD	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck	0.80
12/11/19	MFR	Revisions to Report 1B (non-cash report).	2.10
12/11/19	IF	Call with I. Fisboin and R. Collura (both AlixPartners) to discuss potential redactions to the cash report.	0.40
12/11/19	SJC	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck.	0.80
12/11/19	SJC	Review of edits to Cash Transfers of Value Report.	1.20
12/11/19	SJC	Review of family trust data - Raymond-side and related edits.	3.00
12/11/19	SJC	Edits to family trust data - Mortimer side.	3.00
12/11/19	RC	Call with R. Collura, A. DePalma, S.Canniff (all AlixPartners), and DPW litigation team re: cash value transfer deck.	0.80
12/11/19	RC	Call with I. Fisboin and R. Collura (both AlixPartners) to discuss to potential redactions to the cash report.	0.40
12/11/19	RC	Review information in cash report for potential redactions.	1.70
12/11/19	RC	Review comments from Davis Polk and update cash transfers of value report.	2.50
12/11/19	RC	Review and update schedules and tables in the cash transfer of value report.	2.10
12/11/19	RC	Review supporting documentation related to the cash distributions section of the cash report.	1.50
12/12/19	RC	Call with M. Clarens, E. Kim and A. Whisenant (all Davis Polk) to discuss cash transfers of value report and potential redactions.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/12/19	RC	Call with M. Clarens (Davis Polk) to discuss potential redactions to cash report.	0.10
12/12/19	RC	Review potential redactions to cash report.	0.20
12/12/19	RC	Coordinate with team on reviewing updated information in cash transfers of value report.	0.60
12/12/19	RC	Review and update cash report and provide to Davis Polk.	2.40
12/12/19	RC	Review and update tables and schedules in cash report.	1.80
12/12/19	RC	Review cash report and related support documents for potential redactions.	1.70
12/12/19	RC	Call with E. Kim (Davis Polk) to discuss the cash report.	0.10
12/12/19	RC	Review and prepare responses to questions from Davis Polk regarding the cash transfer of value report.	0.70
12/12/19	RC	Call with M. Clarens (Davis Polk) to discuss cash transfers of value report.	0.20
12/12/19	SJC	Review of Family Trust data - Raymond Side.	2.70
12/12/19	SJC	Review of edits to Cash Transfers of Value Report.	1.70
12/12/19	NAS	Edits to investigation report in preparation for docket release.	0.90
12/12/19	MFR	Revisions to Report 1B (non-cash report).	2.60
12/12/19	ADD	Review latest versions of cash value transfer draft prior to submission.	2.60
12/12/19	JDH	Review of MS family entities database.	4.20
12/13/19	JDH	Review of MS family entities database.	4.30
12/13/19	MFR	Revisions to Report 1B (non-cash report).	2.30
12/13/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/13/19	MH	Call with M. Hartley and R. Collura (both AlixPartners) to discuss Sackler family related due diligence.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/13/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/13/19	FOS	Draft intercompany and non-cash transfers report re: intercompany shared services charges.	1.10
12/13/19	RC	Call with M. Hartley and R. Collura (both AlixPartners) to discuss Sackler family related due diligence.	0.30
12/13/19	RC	Review and update questions for TXP Services and related support documentation.	2.30
12/13/19	RC	Review partnership related documents.	1.10
12/16/19	RC	Review redacted version of cash transfers of value report.	1.30
12/16/19	RC	Call with M. Clarens (Davis Polk) to discuss case status and recent developments.	0.10
12/16/19	RC	Communicate with team regarding redacted cash transfers of value report.	0.20
12/16/19	RC	Review various articles related to the cash transfers of value report.	0.70
12/16/19	RC	Continue review of redacted cash transfers of value report.	0.80
12/16/19	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/16/19	FOS	Compose emails to M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
12/16/19	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft of intercompany and non-cash transfers report.	0.20
12/16/19	MFR	Revisions to Report 1B (non-cash report).	3.10
12/16/19	JDH	Review of family entity database	4.40
12/17/19	JDH	Revising family entity database.	4.60
12/17/19	MFR	Revisions to Report 1B (non-cash report).	3.10
12/17/19	RC	Communicate with Purdue controller regarding	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		distribution support documentation.	
12/18/19	RC	Review status of intercompany and non-cash distributions work streams.	0.50
12/18/19	RC	Review bank statements and SAP detail in response to questions from the UCC's advisors.	2.10
12/18/19	RC	Review and respond to email communication related to partnership agreements and organizational structure.	0.20
12/18/19	RC	Call with M. Clarens regarding case update and status of work streams.	0.10
12/18/19	RC	Review and comment on distributions analysis support documentation.	1.80
12/18/19	RC	Review and analysis of transactions with US and Ex-US partners.	1.30
12/18/19	SJC	Review and edits to Mortimer and Raymond family trust information.	2.70
12/18/19	JDH	Family entity data base revisions.	4.10
12/18/19	ADD	Compile files requested by the UCC to support Transfer of Value report diligence.	2.30
12/19/19	ADD	Research distribution transactions and compile supporting material in response to diligence request.	1.50
12/19/19	JDH	Review of Family entity database.	4.30
12/19/19	RC	Review intercompany analysis and non-cash transfers of value.	0.50
12/19/19	RC	Review and research information requests made by the Committee's advisors.	0.70
12/19/19	RC	Prepare email to Davis Polk regarding additional document requests from the UCC.	0.40
12/19/19	SJC	Review and edits to Mortimer family trust information.	3.00
12/19/19	SJC	Attend hearing,	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
12/19/19	SJC	Review of follow up information received.	1.50
12/20/19	MFR	Preparation for and conference call with E. Kim (Davis Polk) regarding revisions to Report 1B (non-cash report).	2.40
12/20/19	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss documentation related to distribution analysis.	0.80
12/20/19	RC	Call with M. Clarens (Davis Polk) to discuss requests from the Committee's advisors.	0.20
12/20/19	RC	Review documentation related to payments analysis.	2.10
12/20/19	SJC	Review and edits to Mortimer family trust information.	2.60
12/20/19	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss documentation related to distribution analysis.	0.80
12/20/19	ADD	Research distribution transactions and compile supporting material in response to diligence request.	2.20
12/22/19	ADD	Review and analysis of payments made from debtor entities.	2.30
12/22/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.80
12/23/19	ADD	Review and analysis of payments made from debtor entities.	2.30
12/23/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.30
12/23/19	MFR	Revisions to Report 1B (non-cash report).	2.70
12/24/19	MFR	Revisions to Report 1B (non-cash report).	2.40
12/24/19	ADD	Review and analysis of payments made from debtor entities.	3.20
12/24/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.50
12/26/19	MFR	Revisions to Report 1B (non-cash report).	2.90
12/26/19	RC	Review support documentation related to payments to	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		IACs and taxing authorities.	
12/27/19	RC	Review presentation of defenses prepared by counsel to the Raymond Sackler Family.	2.30
12/27/19	MFR	Revisions to Report 1B (non-cash report).	2.10
12/30/19	MFR	Revisions to Report 1B (non-cash report).	2.80
12/30/19	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.60
01/02/20	ADD	Review and research of payments made by Purdue entities.	2.30
01/03/20	ADD	Review of documentation compiled in response to transfer of value report diligence request.	1.70
01/06/20	ADD	Discussion and working session with S. Canniff and A. DePalma (both AlixPartners) to document distributions and determine next steps	2.30
01/06/20	RC	Review and comment on supporting documentation related to vendor payments analysis.	2.20
01/06/20	RC	Review information gathered in response to requests from the UCC's advisors.	2.10
01/06/20	RC	Review partnership agreements and organizational charts.	0.80
01/06/20	RC	Review presentations from Sackler family counsel regarding IACs and trust structures.	1.60
01/06/20	RC	Additional review of charts diagraming family trust and IAC structures.	1.40
01/06/20	SJC	Discussion and working session with S. Canniff and A. DePalma (both AlixPartners) to document distributions and determine next steps	2.30
01/07/20	SJC	Review of documents in anticipation of meeting with FTI.	1.10
01/07/20	SJC	Follow-up meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review supporting documentation related to payments made by Debtor	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		entities.	
01/07/20	SJC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review payments made to IACs and taxing authorities and related support documentation.	2.80
01/07/20	SJC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review payments made by debtor entities.	1.40
01/07/20	SJC	Call with R. Collura, A. DePalma, S. Canniff, J. Hecht (all AlixPartners), and M. Greenblatt (FTI) re: cash transfer of value report testing strategy	0.70
01/07/20	RC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review and analysis payments made by debtor entities.	1.40
01/07/20	RC	Follow-up meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review supporting documentation related to payments made by Debtor entities.	2.10
01/07/20	RC	Call with R. Collura, A. DePalma, S. Canniff, J. Hecht (all AlixPartners), and M. Greenblatt (FTI) re: cash transfer of value report testing strategy	0.70
01/07/20	RC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review payments made to IACs and taxing authorities and related support documentation.	2.80
01/07/20	RC	Review and compile documentation and respond to requests from UCC's advisors.	0.40
01/07/20	RC	Review and analysis of cash payments by debtor entities.	0.80
01/07/20	FOS	Compose email to E. Kim (Davis Polk) re: Oxycontin license agreements.	0.20
01/07/20	ADD	Review and analyzed distribution transactions in for diligence requests.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
01/07/20	ADD	Follow-up meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review supporting documentation related to payments made by Debtor entities.	2.10
01/07/20	ADD	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review payments made to IACs and taxing authorities and related support documentation.	2.80
01/07/20	ADD	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to review payments made by debtor entities	1.40
01/07/20	ADD	Call with R. Collura, A. DePalma, S. Canniff, J. Hecht (all AlixPartners), and M. Greenblatt (FTI) re: cash transfer of value report testing strategy	0.70
01/07/20	JDH	Continue integration of family entity database.	1.20
01/07/20	JDH	Call with R. Collura, A. DePalma, S. Canniff, J. Hecht (all AlixPartners), and M. Greenblatt (FTI) re: cash transfer of value report testing strategy	0.70
01/07/20	JDH	Integration of family entity database.	3.00
01/07/20	JDH	Review of cash distribution report	2.20
01/08/20	JDH	Integration of family entity database.	3.80
01/08/20	JDH	Testing of distributions made from Purdue.	3.60
01/08/20	ADD	Research and analyze financial statements to better understand the recording of distributions transactions.	2.00
01/08/20	ADD	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to analyze payments in anticipation of diligence request	2.80
01/08/20	ADD	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to discuss distribution support	2.00
01/08/20	ADD	Discussion with R. Collura, N. Simon, S. Canniff, and A. DePalma (all AlixPartners) regarding Mundipharma investment made by other IAC for purposes of	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners distribution analysis.	
01/08/20	RC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to analyze payments in anticipation of diligence request .	2.80
01/08/20	RC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to discuss distribution support.	2.00
01/08/20	RC	Review and analysis of flow of funds related to tax distribution in preparation for call with TXP's counsel.	0.80
01/08/20	RC	Review and update information requests for TXP Services.	0.30
01/08/20	RC	Review payments by debtor entities and related supporting documentation.	0.80
01/08/20	RC	Review audited financial statements for information regarding related party payments.	1.00
01/08/20	RC	Discussion with R. Collura, N. Simon, S. Canniff, and A. DePalma (all AlixPartners) regarding Mundipharma investment made by other IAC for purposes of AlixPartners distribution analysis.	0.30
01/08/20	SJC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to discuss distribution support.	2.00
01/08/20	SJC	Analysis of payments related to diligence request.	1.40
01/08/20	SJC	Meeting with R. Collura, A. DePalma, and S. Canniff (all AlixPartners) to analyze payments in anticipation of diligence request .	2.80
01/08/20	SJC	Discussion with R. Collura, N. Simon, S. Canniff, and A. DePalma (all AlixPartners) regarding Mundipharma investment made by other IAC for purposes of AlixPartners distribution analysis.	0.30
01/08/20	NAS	Discussion with R. Collura, N. Simon, S. Canniff, and A. DePalma (all AlixPartners) regarding Mundipharma investment made by other IAC for purposes of	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners distribution analysis.	
01/09/20	SJC	Review and update of documents per discussion and meetings 1/7 and 1/8.	2.10
01/09/20	SJC	Call with F. Silva, A. DePalma, and S. Canniff (all AlixPartners) to discuss value transfer report methodology.	0.30
01/09/20	SJC	Working session with A. DePalma and S. Canniff (both AlixPartners) working session to analyze payments made from Purdue entities.	1.70
01/09/20	RC	Review documents and prepare for call with counsel for TXP and PRA LP.	0.70
01/09/20	RC	Call with R. Collura, A. DePalma, J. Hecht (all AlixPartners), M. Clarens, E. Kim (both Davis Polk), and J. Dougherty (Haug Partners) to discuss status of requests and additional follow-ups for TXP and PRA LP.	0.70
01/09/20	RC	Call with M. Clarens (Davis Polk) to discuss status of various work streams and next steps.	0.40
01/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss distributions and other transactions.	1.00
01/09/20	RC	Review updated documentation regarding payments testing analysis.	1.40
01/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss distributions analysis and related supporting documentation.	0.20
01/09/20	RC	Review partnership agreements and information related to tax distributions.	0.80
01/09/20	RC	Prepare communication to team regarding tax distributions.	0.30
01/09/20	RC	Review information related to tax distributions.	0.70
01/09/20	RC	Review and analysis of documentation related to pre-	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		petition payments by debtor entities.	
01/09/20	RC	Review and analysis of financial information related to Purdue Pharma Inc.	0.30
01/09/20	FOS	Call with F. Silva, A. DePalma, and S. Canniff (all AlixPartners) to discuss value transfer report methodology.	0.30
01/09/20	ADD	Call with F. Silva, A. DePalma, and S. Canniff (all AlixPartners) to discuss value transfer report methodology	0.30
01/09/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss distributions analysis and related supporting documentation	0.20
01/09/20	ADD	Call with R. Collura, A. DePalma, J. Hecht (all AlixPartners), M. Clarens, E. Kim (both Davis Polk), and J. Dougherty (Haug Partners) to discuss status of requests and additional follow-ups for TXP and PRA LP.	0.70
01/09/20	ADD	Call with R. Collura, and A. DePalma (both AlixPartners) to discuss distributions and other transactions	1.00
01/09/20	ADD	Review of the transfer pricing report.	0.80
01/09/20	ADD	Research and analyze financial statements to better understand the recording of distributions transactions.	0.40
01/09/20	ADD	Working session with A. DePalma and S. Canniff (both AlixPartners) working session to analyze payments made from Purdue entities.	1.70
01/09/20	JDH	Call with R. Collura, A. DePalma, J. Hecht (all AlixPartners), M. Clarens, E. Kim (both Davis Polk), and J. Dougherty (Haug Partners) to discuss status of requests and additional follow-ups for TXP and PRA LP.	0.70
01/09/20	JDH	Review of family entity database.	2.80
01/09/20	REO	Review of Intercompany transactions re: Lucien and NSH	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		non cash transfers	
01/09/20	REO	Research for financial support of non-cash transfers re: transfer of stock in RSJ	1.10
01/10/20	REO	Update weekly variance report re: Activity up to week ending 1/4/2020 and variances to budget	2.80
01/10/20	FOS	Internal correspondence re: intercompany and non-cash transfers report status.	0.10
01/10/20	RC	Review general ledger detail and other documentation related payments by debtor entities.	1.60
01/10/20	RC	Review presentation materials prepared by the Sackler family attorneys regarding trust structures.	2.40
01/10/20	RC	Review presentation materials prepared by the Sackler family attorneys regarding various legal defenses.	1.40
01/10/20	SJC	Distribution analysis update.	2.90
01/10/20	SJC	Distribution analysis review.	3.00
01/13/20	SJC	Aggregate requested supporting documents for samples requested.	1.80
01/13/20	SJC	Review and documentation of diligence/distribution support	1.90
01/13/20	RC	Review informational materials prepared by the Mortimer-side of the Sackler family.	1.80
01/13/20	RC	Review informational materials prepared by the Raymond-side of the Sackler family.	2.10
01/13/20	RC	Review information provided by TXP through its outside counsel.	1.40
01/13/20	RC	Review contribution and reinvestment information.	0.90
01/13/20	RC	Review information related to rent expense and real estate taxes.	0.40
01/13/20	RC	Review information related to payments to charitable	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		organizations.	
01/13/20	MFR	Revisions to transfer pricing report.	3.50
01/13/20	MFR	Review of documents related to transfer pricing report.	2.20
01/13/20	JDH	Distribution analysis.	2.30
01/14/20	JDH	Documentation of distribution payments.	2.40
01/14/20	JDH	Analysis of corporate bank statements.	1.90
01/14/20	REO	Research for more detailed SAP support re: foreign Mundipharma royalty sales	2.80
01/14/20	REO	Research SAP re: Values of Non-cash transfers	1.00
01/14/20	MFR	Review of documents related to transfer pricing report.	2.20
01/14/20	MFR	Revisions to transfer pricing report.	1.60
01/14/20	MFR	Calls with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
01/14/20	MFR	Meeting with J. Lowne (Purdue), R. Collura, J. DelConte, M. Rule (by phone), and F. Silva (by phone) (all AlixPartners) to review the intercompany and non-cash transfers of value report.	1.30
01/14/20	FOS	Meeting with J. Lowne (Purdue), R. Collura, J. DelConte, M. Rule (by phone), and F. Silva (by phone) (all AlixPartners) to review the intercompany and non-cash transfers of value report.	1.30
01/14/20	FOS	Calls with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
01/14/20	FOS	Compose email to M. Clarens (Davis Polk) re: Mundipharma EDO oncology assets analysis.	0.20
01/14/20	FOS	Compose emails to K. Shibuya and R. Ellis Ochoa (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.30
01/14/20	FOS	Compose email to J. Carlisle (Purdue) re: Rhodes Pharma	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		CMO agreement with Purdue, purchases of API by Purdue from Rhodes Tech, and sale of finished products by Purdue to IACs.	
01/14/20	RC	Review and comment on the intercompany and non-cash transfers of value report.	2.10
01/14/20	RC	Review and analysis of documentation related to non-cash distributions.	1.80
01/14/20	RC	Continue to review intercompany and non-cash transfers of value report.	2.30
01/14/20	RC	Meeting with J. Lowne (Purdue), R. Collura, J. DelConte, M. Rule (by phone), and F. Silva (by phone) (all AlixPartners) to review the intercompany and non-cash transfers of value report.	1.30
01/14/20	RC	Review and respond to information requests from Province.	0.30
01/14/20	RC	Research information requests made by Province.	0.20
01/14/20	JD	Meeting with J. Lowne (Purdue), R. Collura, J. DelConte, M. Rule (by phone), and F. Silva (by phone) (all AlixPartners) to review the intercompany and non-cash transfers of value report.	1.30
01/14/20	SJC	Review of supporting documents for distributions.	2.50
01/15/20	SJC	Review of supporting documents for distributions.	2.80
01/15/20	SJC	Review of payments made to IACs.	2.20
01/15/20	RC	Dial into meeting with the Sackler Family lawyers regarding presentation of asset values.	1.90
01/15/20	RC	Continue Dial in meeting with the Sackler Family lawyers regarding presentation of asset values.	2.10
01/15/20	RC	Review and provide additional comments to the intercompany and non-cash transfers of value report.	2.00
01/15/20	RC	Communicate with Davis Polk regarding requests from	0.10



Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		UCC's financial advisors.	
01/15/20	RC	Perform initial research into requests made by the UCC's financial advisors.	0.60
01/15/20	RC	Review documents provided by TXP and develop next steps for rent analysis.	0.30
01/15/20	RC	Review documentation related to tax distributions.	0.50
01/15/20	RC	Review documentation related to non-tax distributions.	0.50
01/15/20	FOS	Call with A. Whisenant, E. Lee (both Davis Polk), M. Rule, and F. Silva (both AlixPartners) re: transfers of royalties between PALP and Purdue.	0.60
01/15/20	FOS	Call with M. Rule, F. Silva, R. Ellis Ochoa (all AlixPartners) re: accounting for royalties from IACs to Purdue via PALP.	0.30
01/15/20	FOS	Emails to R. Ellis Ochoa (AlixPartners) re: accounting for foreign royalties transferred between PALP and Purdue.	0.20
01/15/20	FOS	Compose email to E. Liesman (Purdue) re: TXP service agreement with Purdue and accounting for shared services provided by Purdue to Rhodes and IACs.	0.30
01/15/20	FOS	Compose email to J. Carlisle (Purdue) re: accounting for foreign sales of finished products to IACs.	0.20
01/15/20	FOS	Compose email to R. Ellis Ochoa and K. Shibuya (both AlixPartners) re: updating draft report on intercompany and non-cash transfers of value.	0.30
01/15/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.30
01/15/20	FOS	Update draft intercompany and non-cash transfers report re: comments and feedback from Purdue, Davis Polk, and AlixPartners.	1.70
01/15/20	MFR	Call with M. Rule, F. Silva, R. Ellis Ochoa (all AlixPartners) re: accounting for royalties from IACs to Purdue via PALP.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
01/15/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.30
01/15/20	MFR	Call with A. Whisenant, E. Lee (both Davis Polk), M. Rule, and F. Silva (both AlixPartners) re: transfers of royalties between PALP and Purdue.	0.60
01/15/20	MFR	Revisions to transfer pricing report.	1.80
01/15/20	MFR	Review of documents related to transfer pricing report.	2.00
01/15/20	MH	Review lease data for equity owners space rental.	0.50
01/15/20	REO	Research SAP re: Support for Royalty Adjusting Entries and reconciliation to total intercompany activity	2.60
01/15/20	REO	Call with M. Rule, F. Silva, R. Ellis Ochoa (all AlixPartners) re: accounting for royalties from IACs to Purdue via PALP	0.30
01/15/20	REO	Review of proposed edits to Transfer Pricing Deck re: Non cash transfer of Infinity Stock	0.50
01/15/20	REO	Research SAP re: Historical Markups for foreign Mundipharma sales in relation to actual product cost	1.50
01/15/20	REO	Preparation of follow up questions re: Historical Markups for foreign Mundipharma sales	0.70
01/15/20	REO	Prepare a reconciliation of values of non-cash transfers re: financial statement and SAP support	1.50
01/15/20	JDH	Review of bank statements for distribution payments.	3.10
01/15/20	JDH	Analysis of bank statements.	1.10
01/15/20	ADD	Review and analysis of distributions payments to prepare response of diligence requests.	1.50
01/15/20	SR	Prepare accounting for offshore investment recorded for partial year 2010	1.50
01/16/20	SR	Call with R. Collura and S. Robertson (both AlixPartners) to discuss distributions testing analysis and related	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		support documents	
01/16/20	JDH	Analysis of supporting documentation related to distributions.	2.80
01/16/20	REO	Edit Transfer Pricing Deck re: Updated SAP support and new language surrounding cost breakup of original product cost, freight and product markup	3.30
01/16/20	MFR	Review of documents related to transfer pricing report.	2.60
01/16/20	MFR	Revisions to transfer pricing report.	2.70
01/16/20	MFR	Calls with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.20
01/16/20	FOS	Calls with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.20
01/16/20	FOS	Compose emails to M. Rule and R. Ellis Ochoa (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.20
01/16/20	FOS	Update draft intercompany and non-cash transfers report re: feedback from Purdue, Davis Polk, and AlixPartners.	3.00
01/16/20	KS	Update the report regarding transfer pricing.	1.30
01/16/20	RC	Call with R. Collura and S. Robertson (both AlixPartners) to discuss distributions testing analysis and related support documentation.	1.30
01/16/20	RC	Review distribution documents and research UCC's requests for additional information.	1.60
01/16/20	RC	Review and analysis of payments documentation in response to requests made by the UCC.	0.80
01/16/20	RC	Review intercompany and non-cash transfer of value report.	1.70
01/16/20	RC	Review information provided by TXP and PRA LP through	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		their outside counsel in response to special committee requests.	
01/16/20	RC	Prepare communications to team regarding requests by UCC for bank account information.	0.20
01/16/20	SJC	Review of supporting documents for distributions.	2.00
01/17/20	RC	Call with M. Clarens, A. Whisenant (both Davis Polk), R. Collura, M. Rule, and F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
01/17/20	RC	Call with R. Collura and J. Hecht (both AlixPartners) to discuss distributions and bank account statements.	0.40
01/17/20	RC	Review bank statement tracing analysis and related supporting documentation.	1.50
01/17/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of payments review.	0.30
01/17/20	RC	Review bank statement tracing analysis in connection with researching requests from UCC's advisors.	1.30
01/17/20	RC	Review documentation related to payments requests.	1.40
01/17/20	FOS	Call with M. Clarens, A. Whisenant (both Davis Polk), R. Collura, M. Rule, and F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
01/17/20	FOS	Calls with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.70
01/17/20	FOS	Update draft intercompany and non-cash transfers report re: feedback from Purdue, Davis Polk, and AlixPartners.	1.40
01/17/20	BSC	Review distribution payments testing support	0.10
01/17/20	MFR	Call with M. Clarens, A. Whisenant (both Davis Polk), R. Collura, M. Rule, and F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
01/17/20	MFR	Calls with M. Rule and F. Silva (both AlixPartners) re:	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		updates to draft intercompany and non-cash transfers report.	
01/17/20	MFR	Revisions to transfer pricing report.	2.10
01/17/20	MFR	Review of documents related to transfer pricing report.	2.40
01/17/20	JDH	Call with R. Collura and J. Hecht (both AlixPartners) to discuss distributions and bank account statements.	0.40
01/17/20	JDH	Review company bank statements.	2.50
01/17/20	JDH	Continue to review company bank statements.	2.10
01/17/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of payments review.	0.30
01/17/20	SR	Review and update files related to office space provided to family members a One Stamford Forum.	0.20
01/18/20	ADD	Review and compile list of vendors receiving distributions as part of UCC cash value of transfer diligence requests.	1.40
01/19/20	ADD	Review and compile list of vendors receiving distributions as part of UCC cash value of transfer diligence requests.	2.40
01/20/20	MFR	Review of documents related to transfer pricing report.	2.10
01/20/20	MFR	Revisions to transfer pricing report.	2.00
01/20/20	MFR	Call with J. Carlisle (Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for sales of finished product to foreign IACs.	0.40
01/20/20	MFR	Calls with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers report.	0.20
01/20/20	FOS	Call with J. Carlisle (Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for sales of finished product to foreign IACs.	0.40
01/20/20	FOS	Calls with M. Rule and F. Silva (both AlixPartners) re: updates to draft intercompany and non-cash transfers	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		report.	
01/20/20	FOS	Compose emails to J. Carlisle (Purdue) re: accounting for sales of finished products to foreign IACS and sales of API from Rhodes Tech to Purdue.	0.40
01/20/20	FOS	Compose email to E. Liesman (Purdue) re: accounting for shared services between Purdue, Rhodes, and IACS.	0.10
01/20/20	FOS	Update draft intercompany and non-cash transfers report re: feedback from Purdue, Davis Polk, and AlixPartners.	3.50
01/20/20	FOS	Continue to update draft intercompany and non-cash transfers report re: feedback from Purdue, Davis Polk, and AlixPartners.	3.50
01/20/20	FOS	Continue to update draft intercompany and non-cash transfers report re: feedback from Purdue, Davis Polk, and AlixPartners.	3.10
01/21/20	FOS	Calls with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
01/21/20	FOS	Compose emails to R. Haberlin and D. Wooten (both Purdue) re: accounting for CMO services provided by Rhodes to Purdue, and accounting for Butrans profit sharing arrangement	0.40
01/21/20	FOS	Compose emails to E. Liesman (Purdue) re: accounting for shared services provided by Purdue to IACS and Rhodes.	0.10
01/21/20	FOS	Edit draft report re: intercompany and non-cash transfers.	1.80
01/21/20	MFR	Calls with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
01/21/20	MFR	Revisions to transfer pricing report.	1.90
01/21/20	MFR	Review of documents related to transfer pricing report.	3.00
01/21/20	RC	Call with R. Collura, A. DePalma and S. Canniff (all	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners) meeting to discuss diligence requests made by the UCC.	
01/21/20	RC	Review bank statement tracing analysis and related support documentation in connection with researching requests made by the UCC.	2.30
01/21/20	RC	Review bank statement and general ledger information in connection with researching requests from the UCC.	1.40
01/21/20	RC	Review and analysis of distribution detail in connection with researching requests from the UCC.	1.10
01/21/20	SJC	Gather support for Province request #5.	1.10
01/21/20	SJC	SAP review of payments to vendors.	3.00
01/21/20	SJC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) meeting to discuss diligence requests made by the UCC.	0.70
01/21/20	SJC	Distribution working session with A. DePalma, and S. Canniff (both AlixPartners) to document analysis	1.10
01/21/20	ADD	Distribution working session with A. DePalma and S. Caniff (both AlixPartners) to document analysis.	1.10
01/21/20	ADD	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) meeting to discuss diligence requests made by the UCC.	0.70
01/21/20	JDH	Trace distributions to company bank accounts.	3.00
01/21/20	JDH	Continue to trace distributions to company bank accounts.	1.80
01/22/20	JDH	Continue to gather support for committee requests	3.00
01/22/20	JDH	Gather support for committee requests	3.40
01/22/20	JDH	Trace distributions to company bank accounts.	1.70
01/22/20	REO	Call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: accounting for sale of finished products from Purdue	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to IACs.	
01/22/20	REO	Edit supporting file for Mundipharma sales re: updated breakdown of Markup, Freight and product cost between 2008-2019	1.20
01/22/20	REO	Review of Box support and updated files supporting slides and edit of outdated files for consistency with latest deck	0.80
01/22/20	REO	Edit Transfer Pricing Deck re: updated slides relating to foreign sales and per comments from the Company	1.50
01/22/20	SJC	Gather support from SAP for sample requests.	2.00
01/22/20	RC	Review tax distributions detail and related support documentation in connection with researching requests by UCC.	2.10
01/22/20	RC	Review Ex-US distributions detail and related support documentation in connection with researching requests by UCC.	1.80
01/22/20	RC	Review and respond to emails from J. Dougherty (Haug Partners) regarding information requests for TXP Services and PRA LP.	0.10
01/22/20	RC	Call with M. Atkinson and J. Crockett (both Province) to discuss recent diligence requests and next steps.	1.10
01/22/20	MFR	Review of documents related to transfer pricing report.	2.40
01/22/20	MFR	Revisions to transfer pricing report.	2.20
01/22/20	MFR	Call with E. Liesman (Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for shared services provided by Purdue to Rhodes and IACs.	0.40
01/22/20	FOS	Call with E. Liesman (Purdue), M. Rule, and F. Silva (both AlixPartners) re: accounting for shared services provided by Purdue to Rhodes and IACs.	0.40
01/22/20	FOS	Call with R. Ellis Ochoa and F. Silva (both AlixPartners) re: accounting for sale of finished products from Purdue	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to IACs.	
01/22/20	FOS	Compose email to M. Rule (AlixPartners) re: accounting for shared services provided by Purdue to IACs and Rhodes.	0.20
01/23/20	FOS	Compose email to M. Clemens (Davis Polk) re: draft intercompany and non-cash transfers report.	0.10
01/23/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
01/23/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
01/23/20	MFR	Revisions to transfer pricing report.	2.50
01/23/20	MFR	Review of documents related to transfer pricing report.	2.50
01/23/20	RC	Review additional requests from Province and perform related research into availability of information.	1.30
01/23/20	RC	Review supporting documentation related to cash distributions tracing analysis.	1.50
01/23/20	RC	Review support documentation related to tax distributions.	1.40
01/23/20	RC	Review support documentation related to Ex-US distributions.	1.60
01/23/20	RC	Call with M. Clarens and A. Whisenant (both Davis Polk) to discuss the latest requests from the UCC.	1.20
01/23/20	SJC	Review of supporting documents gathered for requests from Province.	3.00
01/23/20	SJC	Pull documents from SAP in response to requests from Province.	3.00
01/23/20	SJC	Upload and organize documents on Box.	0.50
01/23/20	JDH	Analysis of bank statements.	2.30
01/24/20	JDH	Trace distributions to company bank statements.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
01/24/20	JDH	Continue to trace distributions to company bank statements.	2.00
01/24/20	SJC	Review of documents for Province request.	3.00
01/24/20	SJC	Pull documents from Province request from SAP.	3.00
01/24/20	RC	Call with M. Clarens (Davis Polk) to discuss tax analysis and status of various special committee work streams and related follow-up.	0.30
01/24/20	RC	Review additional requests from the UCC's advisors and perform additional research.	0.60
01/24/20	RC	Prepare response to the UCC's information requests.	0.40
01/24/20	RC	Review bank statements and other support documentation related to cash distributions.	1.00
01/24/20	MFR	Review of documents related to transfer pricing report.	3.20
01/24/20	MFR	Revisions to transfer pricing report.	3.10
01/24/20	FOS	Call with R. Haberlin (Purdue) re: accounting for CMO services provided by Rhodes to Purdue, and accounting for Butrans profit-sharing arrangement.	0.50
01/24/20	FOS	Email to M. Rule (AlixPartners) re: accounting for CMO services provided by Rhodes to Purdue.	0.10
01/24/20	FOS	Compose email to K. Darragh (Purdue) re: accounting for services provided by Mundipharma International Limited to Purdue.	0.20
01/24/20	FOS	Edit draft report re: intercompany and non-cash transfers report.	3.00
01/24/20	FOS	Continue to edit draft report re: intercompany and non-cash transfers report.	2.70
01/26/20	FOS	Compose email to J. DelConte (AlixPartners) re: Rhodes/Bard oxycontin agreement.	0.10
01/26/20	FOS	Compose email to D. Fogel and W. DiNicola (both Purdue)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		re: markups on API sold by Rhodes to Purdue and IACs.	
01/26/20	FOS	Compose email to E. Liesman (Purdue) re: shared services charges between Purdue and Rhodes.	0.10
01/26/20	FOS	Compose email to M. Rule (AlixPartners) re: pending items on draft intercompany and non-cash report.	0.20
01/26/20	FOS	Review pending follow-ups list re: intercompany and non-cash transfers report.	0.30
01/26/20	NAS	Research Avrio health office rent payment and provide summary of findings to M. Hartley (AlixPartners).	0.30
01/27/20	NAS	Respond to follow-up questions regarding Cash Transfers of Value investigation report.	0.50
01/27/20	SJC	Review of distributions requested by Province and supported documentation available.	2.00
01/27/20	RC	Review cash tracing supporting documentation in connection with responding to questions and requests from Province.	0.80
01/27/20	RC	Communications with FTI regarding requests for information related to the cash transfers of value report.	0.10
01/27/20	RC	Review requests from UCC's advisors and perform related research.	1.70
01/27/20	RC	Review summary of tax returns produced to UCC.	0.30
01/27/20	RC	Review information related to TXP Services.	0.80
01/27/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss diligence requests related to the cash transfers of value report.	0.60
01/27/20	RC	Perform research and prepare communications to team regarding UCC's diligence requests.	0.30
01/27/20	RC	Review and respond to emails from FTI regarding cash transfers of value report.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
01/27/20	RC	Review information gathered in response to the UCC's diligence requests.	1.30
01/27/20	FOS	Compose email to J. DeConte (AlixPartners) re: Rhodes/Bard oxycontin agreement.	0.10
01/27/20	FOS	Compose emails to R. Collura (AlixPartners) re: Services agreements between Purdue and TXP.	0.40
01/27/20	MH	Review data sources and preparatory work to determine historical lease expenses attributable to equity owners.	2.90
01/27/20	JDH	Analysis of distribution payments.	3.10
01/27/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss diligence requests related to the cash transfers of value report.	0.60
01/28/20	ADD	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to consolidate UCC requests and review progress on distribution support compilation.	2.30
01/28/20	JDH	Analysis of family holdings.	2.70
01/28/20	MH	Complete the analysis of historical lease expenses attributable to the equity owners.	2.10
01/28/20	MH	Call with R. Collura and M. Hartley (both AlixPartners) to discuss rent analysis.	0.60
01/28/20	RC	Review, research and respond to various information requests and questions from Province.	1.60
01/28/20	RC	Prepare a draft list of questions and information requests for TXP Service and PRA LP and send to Province.	1.20
01/28/20	RC	Review rent analysis and related lease and sublease agreements.	1.00
01/28/20	RC	Call with R. Collura and M. Hartley (both AlixPartners) to discuss rent analysis.	0.60
01/28/20	RC	Meeting with R. Collura, S. Canniff, and A. DePalma (all AlixPartners) to consolidate UCC's diligence requests and	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		review progress on distribution support compilation.	
01/28/20	RC	Review TXP service agreement.	0.30
01/28/20	RC	Review rent information provided by TXP and PRA LP.	0.60
01/28/20	RC	Review summary of bank account information prepared by TXP and communicate with Davis Polk.	0.40
01/28/20	SJC	Review of SAP entries related to samples requested by Province.	2.70
01/28/20	SJC	Assemble support for Province requests.	3.00
01/28/20	SJC	Working session with A. DePalma, S. Canniff, and R. Collura (all AlixPartners) to consolidate UCC requests and review progress on distribution support compilation.	2.30
01/29/20	SJC	Distribution support consolidation.	3.10
01/29/20	SJC	Review of supporting documentation available for Province requests.	3.00
01/29/20	SJC	Distribution analysis and review.	2.00
01/29/20	RC	Review and comment on the summary of bank account information.	0.50
01/29/20	RC	Review and analysis of Ex-Us Distributions and related support documentation.	1.80
01/29/20	RC	Research tax expertise and credentials based on additional requests from Davis Polk.	1.20
01/29/20	RC	Prepare additional information requests and questions for TXP and PRA LP.	0.80
01/29/20	RC	Review and comment on additional rent analysis.	0.80
01/29/20	RC	Review information related to tax distributions in connection with requests from the UCC's advisors.	0.70
01/29/20	MH	Create attorney ready presentation of the lease expense analysis.	1.10
01/29/20	REO	Research SAP re: recreation of foreign sales queries	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		shared by Jon Carlisle	
01/30/20	JDH	Cash tracing from SAP to bank statements.	2.10
01/30/20	MFR	Revisions to transfer pricing report.	2.10
01/30/20	MFR	Review of documents related to transfer pricing report.	3.40
01/30/20	RC	Review information and update list of ongoing work streams to discuss with Davis Polk.	0.60
01/30/20	RC	Call with M. Clarens (Davis Polk) to discuss status of various ongoing work streams and next steps.	0.40
01/30/20	RC	Review and comment on initial set of support documents gathered in response to the UCC's distribution testing selections.	2.00
01/30/20	RC	Review and comment additional rent analysis and related documentation.	0.70
01/30/20	RC	Review information and documentation related tax distributions.	1.20
01/30/20	RC	Review information related to the Ex-US distributions.	0.70
01/30/20	RC	Review tax documentation for debtor entities.	0.70
01/30/20	RC	Prepare and respond to communications with counsel regarding responses to diligence requests from the UCC.	0.20
01/30/20	RC	Review documentation gathered in response to the UCC's requests for bank account and other documentation.	0.40
01/30/20	RC	Review Purdue audited financial statements for distribution information.	0.30
01/30/20	SJC	Distribution support analysis and review.	2.70
01/31/20	SJC	Review of support for Province requests.	3.00
01/31/20	RC	Review non-cash transfer of value related documentation.	1.30
01/31/20	RC	Review non-cash transfer of value draft report.	1.90
01/31/20	RC	Draft additional requests for TXP and PRA LP.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
01/31/20	RC	Prepare update of status of special committee work streams.	0.30
01/31/20	RC	Review bank statement tracing analysis in connection with responding to requests from the UCC's advisors.	0.80
01/31/20	RC	Review information related to assets of the Sackler family.	1.00
01/31/20	MFR	Review of documents related to transfer pricing report.	3.30
01/31/20	MFR	Revisions to transfer pricing report.	3.60
01/31/20	MFR	Review of work papers related to transfer pricing report.	2.30
01/31/20	JDH	Cash tracing from SAP to bank statements.	1.70
Total			2,758.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	202.30	385.00	77,885.50
Roy Ellis Ochoa	25.70	420.00	10,794.00
Andrew D DePalma	94.00	480.00	45,120.00
Nate A Simon	19.10	480.00	9,168.00
Nate A Simon	1.10	515.00	566.50
Andrew D DePalma	37.00	515.00	19,055.00
Sam J Canniff	311.20	615.00	191,388.00
Fernando O Silva	290.80	615.00	178,842.00
Kyoko Shibuya	151.60	615.00	93,234.00
Loring Hill	16.30	615.00	10,024.50
David Samikkannu	0.80	615.00	492.00
Fernando O Silva	35.50	645.00	22,897.50
Kyoko Shibuya	1.30	645.00	838.50
Sam J Canniff	84.30	645.00	54,373.50
Jon D Hecht	272.50	665.00	181,212.50
Brad S Coppella	1.40	665.00	931.00
Brad S Coppella	0.10	690.00	69.00
Jon D Hecht	65.60	690.00	45,264.00
Isaac Fisboin	0.40	775.00	310.00
Scott Robertson	111.40	830.00	92,462.00
Michael Hartley	11.40	830.00	9,462.00
Scott Robertson	3.00	840.00	2,520.00
Michael Hartley	7.20	840.00	6,048.00
Mark F Rule	351.50	895.00	314,592.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Mark F Rule	68.00	910.00	61,880.00
Jesse DelConte	1.30	950.00	1,235.00
Richard Collura	461.20	1,080.00	498,096.00
Richard Collura	125.10	1,090.00	136,359.00
Louis Dudley	7.80	1,165.00	9,087.00
Total Hours & Fees	2,758.90		2,074,207.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
09/16/19	BF	Travel from Dallas to Stamford	5.00
09/16/19	SKL	Travel from DAL to CT.	5.00
09/16/19	HK	Travel from New York to Stamford.	1.00
09/16/19	SJC	Travel from Chicago, IL to Stamford, CT.	4.00
09/16/19	IA	Travel from NYC to Stamford	1.00
09/16/19	REO	Travel from NYC to CT.	1.00
09/16/19	NAS	Travel from Raleigh, NC to Wilson, NC Purdue facility	0.50
09/16/19	JDH	Travel from NYC to CT	1.00
09/16/19	RC	Commute from Stamford to New York.	0.50
09/16/19	RC	Commute from New York to Stamford, CT.	0.50
09/16/19	JD	Travel to and from Stamford and NYC	2.00
09/16/19	DS	Travel to client	1.00
09/17/19	JD	Travel to and from White Plains courthouse and NYC	2.00
09/17/19	BF	Travel from Stamford to White Plains for hearing	0.80
09/17/19	BF	Travel from White Plains to Stamford from hearing	0.80
09/18/19	BF	Travel from Stamford to Dallas	5.00
09/18/19	DS	Travel from client	1.00
09/19/19	SR	Flight from LGA to PBI	4.50
09/19/19	MH	Travel from HPN to ATL.	4.00
09/19/19	SKL	Travel from CT to DAL.	5.00
09/19/19	HK	Travel from Stamford to New York.	1.00
09/19/19	REO	Travel from CT to NYC.	1.00
09/19/19	JAD	Travel from Coventry, RI to Boston, MA	1.50
09/19/19	JAD	Travel from Coventry, RI to Boston, MA (in excess of	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
		standard)	
09/19/19	IA	Travel from Stamford to NYC	1.00
09/19/19	NAS	Travel from RDU to ORD	4.00
09/20/19	SJC	Travel from Stamford, CT to Florida.	4.50
09/20/19	ADD	Travel to DEN (limited billable travel time to NYC - MSP cap of 4.5 hours)	4.50
09/22/19	ADD	Travel from DEN (limiting travel time to MSP - NYC travel cap)	4.50
09/22/19	SJC	Travel from Florida to Stamford, CT.	4.50
09/22/19	NAS	Travel from ORD to EWR	4.00
09/23/19	IA	Travel from NYC to Stamford	1.00
09/23/19	JAD	Travel from Boston to Stamford	3.00
09/23/19	REO	Travel from NYC to Stamford, CT.	1.00
09/23/19	JD	Non-working travel from NYC to Stamford	1.00
09/23/19	SKL	Travel from DAL to CT.	5.00
09/23/19	MH	Travel from ATL to HPN.	4.00
09/23/19	SR	Flight from PBI to LGA	4.50
09/23/19	DS	Travel to client	1.00
09/24/19	JD	Non-working travel from Stamford to NYC	1.00
09/25/19	RC	Roundtrip commute from New York to Stamford, CT.	1.00
09/25/19	NAS	Travel from HPN to ORD	4.00
09/25/19	SKL	Travel from CT to DAL.	5.00
09/26/19	SJC	Travel from Stamford, CT to Chicago, IL.	4.00
09/26/19	JAD	Travel from Stamford to Boston	3.00
09/26/19	IA	Travel from Stamford to NYC	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
09/26/19	DS	Travel from client	1.00
09/26/19	SR	Flight from LGA to PBI	4.50
09/26/19	ADD	Travel from LGA to MSP	4.50
09/27/19	REO	Travel from Stamford CT to NYC.	1.00
09/27/19	MH	Travel from HPN to ATL.	4.00
09/29/19	JAD	Travel from Boston to Stamford	3.00
09/29/19	JAD	Travel from Boston to Stamford (in excess of standard)	1.00
09/29/19	ADD	Travel from MSP to LGA.	4.50
09/30/19	DS	Travel to client	1.00
09/30/19	REO	Travel from NYC to Stamford CT.	1.00
09/30/19	JD	Non-working travel from NYC to Stamford	1.00
09/30/19	MH	Travel from ATL to HPN.	4.00
09/30/19	MFR	Travel from home to ORD to LGA to Stamford.	4.00
09/30/19	SKL	Travel from DAL to CT	5.00
09/30/19	IA	Travel from NYC to Stamford	1.00
09/30/19	HK	Travel from New York to Stamford	1.00
Total			157.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
10/01/19	SJC	Travel from ORD to HPN	4.00
10/02/19	BF	Travel from DFW to HPN	6.00
10/02/19	RC	Travel to/from New York, NY and Stamford, CT	1.00
10/02/19	SR	Travel from PBI to LGA	4.50
10/03/19	ADD	Travel from HPN to RIC	2.50
10/03/19	MFR	Travel from HPN to LGA to ORD to home.	4.00
10/03/19	SKL	Travel from HPN to DFW	5.00
10/03/19	SJC	Travel from HPN to ORD	4.00
10/03/19	IA	Travel from Stamford, CT to New York, NY	1.00
10/03/19	HK	Travel from Stamford, CT to New York, NY	1.00
10/04/19	MH	Travel from HPN to ATL.	4.00
10/04/19	BF	Travel from HPN to DFW	6.00
10/04/19	JDH	Travel from Stamford, CT to New York, NY	1.00
10/04/19	JAD	Travel from Stamford, CT to Montvale, NJ	1.00
10/04/19	IA	Travel from Stamford, CT to New York, NY	1.00
10/04/19	DS	Travel from Stamford, CT to New York, NY	1.00
10/07/19	DS	Travel from New York, NY to Stamford, CT	1.00
10/07/19	ADD	Travel from New York, NY to Stamford, CT	1.00
10/07/19	IA	Travel from New York, NY to Stamford, CT	1.00
10/07/19	REO	Travel from New York, NY to Stamford CT	1.00
10/07/19	JDH	Travel from Stamford, CT to New York, NY	1.00
10/07/19	JD	Travel from New York, NY to Stamford, CT	1.00
10/07/19	BF	Travel from DFW to HPN	6.00
10/07/19	MFR	Travel from home to ORD to LGA to HPN.	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
10/07/19	HK	Travel from New York, NY to Stamford, CT	1.00
10/07/19	SJC	Travel from ORD to HPN.	4.00
10/09/19	JD	Travel from Stamford, CT to New York, NY	1.00
10/09/19	JDH	Travel from New York, NY to Stamford, CT	1.00
10/10/19	JD	Travel from New York, NY to White Plains, NY	1.00
10/10/19	REO	Travel from Stamford, CT to New York, NY	1.00
10/10/19	IA	Travel from Stamford, CT to New York, NY	1.00
10/10/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
10/10/19	SJC	Travel from HPN to ORD	4.00
10/10/19	HK	Travel from Stamford, CT to New York, NY	1.00
10/10/19	BF	Travel from HPN to DFW	6.00
10/10/19	MFR	Travel from HPN to LGA to ORD to home.	4.00
10/10/19	DS	Travel from Stamford, CT to New York, NY	1.00
10/11/19	ADD	Travel from LGA to MSP	4.50
10/11/19	JD	Travel from White Plains, NY to New York, NY	1.00
10/11/19	JDH	Travel from Stamford, CT to New York, NY	1.00
10/12/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
10/13/19	ADD	Travel from MSP to LGA	4.50
10/14/19	DS	Travel from New York, NY to Stamford, CT	1.00
10/14/19	IA	Travel from New York, NY to Stamford, CT	1.00
10/14/19	REO	Travel from New York, NY to Stamford, CT	1.00
10/14/19	JD	Travel from New York, NY to Stamford, CT	1.00
10/14/19	BF	Travel from DFW to HPN	6.00
10/14/19	SKL	Travel from DAL to HPN.	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
10/14/19	HK	Travel from New York, NY to Stamford, CT	1.00
10/14/19	SJC	Travel from ORD to HPN	4.00
10/15/19	RC	Travel to/from New York, NY and Stamford, CT.	1.00
10/16/19	JD	Travel from Stamford, CT to New York, NY	1.00
10/17/19	IA	Travel from Stamford, CT to New York, NY	1.00
10/17/19	SJC	Travel from HPN to ORD	4.00
10/17/19	HK	Travel from Stamford, CT to New York, NY	1.00
10/17/19	LJD	Travel to and from New York, NY and Stamford, CT	1.00
10/17/19	SKL	Travel from HPN to DFW	5.00
10/17/19	BF	Travel from HPN to DFW	6.00
10/17/19	DS	Travel from Stamford, CT to New York, NY	1.00
10/17/19	ADD	Travel LGA to MSP.	4.50
10/18/19	REO	Travel from Stamford, CT to New York, NY	1.00
10/19/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
10/20/19	ADD	Travel from MSP to LGA.	4.50
10/21/19	DS	Travel from New York, NY to Stamford, CT	1.00
10/21/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
10/21/19	REO	Travel from New York, NY to Stamford, CT	1.00
10/21/19	JD	Travel from New York, NY to Stamford, CT	1.00
10/21/19	MH	Travel from ATL to HPN	4.00
10/21/19	SKL	Travel from DFW to HPN	5.00
10/21/19	HK	Travel from New York, NY to Stamford, CT	1.00
10/21/19	SJC	Travel from ORD to HPN	4.00
10/21/19	IA	Travel from New York, NY to Stamford, CT	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
10/22/19	RC	Travel to/from New York, NY and Stamford, CT.	1.00
10/24/19	JD	Travel from Stamford, CT to New York, NY	1.00
10/24/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
10/24/19	IA	Travel from Stamford, CT to New York, NY	1.00
10/24/19	SJC	Travel from HPN to ORD	4.00
10/24/19	HK	Travel from Stamford, CT to Brooklyn, NY	1.00
10/24/19	SKL	Travel from HPN to DFW	5.00
10/24/19	MH	Travel from HPN to ATL.	4.00
10/24/19	DS	Travel from Stamford, CT to New York, NY	1.00
10/24/19	RDS	Travel from Stamford, CT to New York, NY	0.80
10/24/19	RDS	Travel from Home to New York, NY	0.40
10/24/19	ADD	Travel from LGA to MSP.	4.50
10/24/19	SR	Travel from LGA to PBI	4.50
10/27/19	ADD	Travel from MSP to LGA.	4.50
10/28/19	RDS	Travel from New York, NY to Stamford, CT	1.00
10/28/19	SR	Travel from PBI to LGA	4.50
10/28/19	DS	Travel from New York, NY to Stamford, CT	1.00
10/28/19	SKL	Travel from DFW to HPN	5.00
10/28/19	MH	Travel from ATL to HPN.	4.00
10/28/19	HK	Travel from Brooklyn, NY to Stamford, CT	1.00
10/28/19	SJC	Travel from ORD to HPN	4.00
10/28/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
10/28/19	JD	Travel from New York, NY to Stamford, CT	1.00
10/29/19	RC	Travel to/from New York, NY and Stamford, CT.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
10/29/19	REO	Travel from New York, NY to Stamford, CT	1.00
10/30/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
10/30/19	GJK	Travel from DFW to LGA	2.00
10/30/19	JD	Travel from Stamford, CT to New York, NY	1.00
10/30/19	SJC	Travel from HPN to ORD	4.00
10/30/19	SKL	Travel from HPN to DFW	5.00
10/31/19	MH	Travel from LGA to JAX.	4.00
10/31/19	HK	Travel from Stamford, CT to Brooklyn, NY.	1.00
10/31/19	JDH	Travel from Stamford, CT to New York, NY	1.00
10/31/19	DS	Travel from Stamford, CT to New York, NY	1.00
10/31/19	RDS	Travel from Stamford, CT to New York, NY	1.30
10/31/19	SR	Travel from LGA to PBI	4.50
11/01/19	ADD	Travel from Stamford, CT to New York, NY.	1.00
11/01/19	GJK	Travel from LGA to DFW	4.00
11/03/19	GJK	Travel from DFW to HPN	4.00
11/03/19	SJC	Travel from ORD to HPN	4.00
11/04/19	IA	Travel from New York, NY to Stamford, CT	1.00
11/04/19	SKL	Travel from DFW to HPN	5.00
11/04/19	HK	Travel from New York, NY to Stamford, CT	1.00
11/04/19	JD	Travel from New York, NY to Stamford, CT	1.00
11/04/19	JD	Travel from Stamford, CT to New York, NY	1.00
11/04/19	ADD	Travel from New York, NY to Stamford, CT	1.00
11/04/19	RDS	Travel from New York, NY to Stamford, CT	1.20
11/04/19	DS	Travel from New York, NY to Stamford, CT	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
11/05/19	JD	Travel from New York, NY to Stamford, CT	1.00
11/05/19	HK	Travel from New York, NY to Stamford, CT	1.00
11/05/19	HK	Travel from Stamford, CT to New York, NY	1.00
11/06/19	SKL	Travel from HPN to DFW	5.00
11/06/19	JD	Travel between Stamford, CT and White Plains, NY	1.00
11/06/19	ADD	Travel from LGA to DFW	5.00
11/07/19	DS	Travel from Stamford, CT to New York, NY	1.00
11/07/19	RDS	Travel from Stamford, CT to New York, NY	1.20
11/07/19	JD	Travel from Stamford, CT to New York, NY	1.00
11/07/19	GJK	Travel from Stamford, CT to New York, NY	1.00
11/07/19	HK	Travel from Stamford, CT to New York, NY	1.00
11/07/19	IA	Travel from Stamford, CT to New York, NY	1.00
11/07/19	SJC	Travel from HPN to RSW	4.50
11/08/19	GJK	Travel from LGA to DFW	4.00
11/10/19	SJC	Travel from RSW to HPN	4.50
11/10/19	ADD	Travel from MSP to LGA.	4.50
11/11/19	RDS	Travel from New York, NY to Stamford, CT	1.50
11/11/19	DS	Travel from New York, NY to Stamford, CT	1.00
11/11/19	HK	Travel from New York, NY to Stamford, CT	1.00
11/11/19	IA	Travel from New York, NY to Stamford, CT	1.00
11/11/19	SKL	Travel from DFW to HPN	5.00
11/11/19	MH	Travel from ATL to HPN	4.00
11/11/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
11/11/19	GJK	Travel from DFW to HPN	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
11/12/19	JD	Travel from New York, NY to Stamford, CT	1.00
11/13/19	RC	Travel to/from New York, NY to Stamford, CT	1.00
11/13/19	REO	Travel from Stamford, CT to New York, NY	1.00
11/14/19	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
11/14/19	JD	Travel from Stamford, CT to New York, NY	1.00
11/14/19	MH	Travel from HPN to ATL	4.00
11/14/19	SKL	Travel from HPN to DFW	5.00
11/14/19	IA	Travel from Stamford, CT to New York, NY	1.00
11/14/19	HK	Travel from Stamford, CT to New York, NY	1.00
11/14/19	DS	Travel from Stamford, CT to New York, NY	1.00
11/14/19	RDS	Travel from Stamford, CT to New York, NY	1.30
11/14/19	ADD	Travel from LGA to MSP	4.50
11/15/19	SJC	Travel from Stamford, CT to Boston, MA.	3.00
11/15/19	GJK	Travel from LGA to DFW	4.00
11/17/19	SJC	Travel from Boston, MA to Stamford, CT.	3.00
11/17/19	ADD	Travel from MSP to LGA	4.50
11/18/19	RDS	Travel from New York, NY to Boston, MA to Coventry, CT	3.30
11/18/19	KM	Travel from YYZ to PVD	6.20
11/18/19	DS	Travel from New York, NY to Stamford, CT	1.00
11/18/19	IA	Travel from New York, NY to Stamford, CT	1.00
11/18/19	SKL	Travel from DFW to HPN	5.00
11/18/19	MH	Travel from ATL to HPN	4.00
11/18/19	JD	Travel from New York, NY to Stamford, CT	1.00
11/18/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
11/19/19	GJK	Travel from DFW to HPN	4.00
11/19/19	JD	Travel to and from Stamford, CT and White Plains, NY	1.00
11/19/19	MFR	Travel from ORD to LGA	4.00
11/19/19	KM	Travel PVD to HPN	2.20
11/19/19	RDS	Travel from Coventry, CT to Stamford, CT	1.90
11/20/19	MFR	Travel from LGA to ORD	4.00
11/20/19	IA	Travel from Stamford, CT to New York, NY	1.00
11/20/19	SJC	Travel from HPN to ORD	4.00
11/20/19	JD	Travel from Stamford, CT to New York, NY	1.00
11/20/19	RC	Travel to/from New York, NY to Stamford, CT	1.00
11/20/19	JDH	Travel from HPN to LGA	1.00
11/21/19	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
11/21/19	MH	Travel from Stamford, CT to New York, NY	1.40
11/21/19	SKL	Travel from HPN to DFW	5.00
11/21/19	HK	Travel from HPN to LGA	1.00
11/21/19	RDS	Travel from Stamford, CT to New York, NY	0.70
11/21/19	KM	Travel HPN to LGA	2.50
11/21/19	ADD	Travel from LGA to MSP	4.50
11/22/19	KM	Travel from LGA to New York, NY	3.40
11/22/19	MH	Travel from HPN to ATL	4.00
11/22/19	GJK	Travel from LGA to DFW	4.00
11/25/19	JD	Travel from New York, NY to Stamford, CT	1.00
11/25/19	IA	Travel from New York, NY to Stamford, CT	1.00
11/25/19	KM	Travel from YYZ to PVD	3.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
11/25/19	DS	Travel from New York, NY to Stamford, CT	1.00
11/26/19	DS	Travel Stamford, CT to New York, NY	1.00
11/26/19	IA	Travel from Stamford, CT to New York, NY	1.00
11/26/19	JD	Travel from Stamford, CT to New York, NY	1.00
11/27/19	KM	Travel from PVD to YYZ	3.80
11/27/19	RDS	Travel from PVD to LGA	3.00
12/01/19	SJC	Travel from ORD to HPN	4.00
12/02/19	IA	Travel from New York, NY to Stamford, CT	1.00
12/02/19	MH	Travel from ATL to HPN	4.00
12/02/19	SKL	Travel from DAL to HPN	5.00
12/02/19	JD	Travel from New York, NY to Stamford, CT	1.00
12/02/19	GJK	Travel from DFW to HPN	4.00
12/02/19	NAS	Travel from EWR to HPN	1.50
12/02/19	DS	Travel to Stamford, CT from New York, NY	1.00
12/02/19	ADD	Travel from BWI to JFK	3.50
12/03/19	RDS	Travel from LGA to RDU	4.10
12/03/19	KM	Travel from YYZ to RDU	6.10
12/03/19	HK	Travel from New York, NY to Stamford, CT	1.00
12/04/19	JD	Travel from Stamford, CT to White Plains, NY	0.60
12/04/19	JD	Travel from White Plains, NY to New York, NY	1.00
12/04/19	RC	Travel to/from New York, NY and Stamford, CT	1.00
12/04/19	KM	Travel from RDU to YYZ	5.00
12/04/19	RDS	Travel from RWI to JFK	3.10
12/05/19	RDS	Travel from New York, NY to Stamford, CT	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
12/05/19	DS	Travel from Stamford, CT to New York, NY	1.00
12/05/19	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
12/05/19	GJK	Travel from HPN to DFW	4.00
12/05/19	HK	Travel from Stamford, CT to New York, NY	1.00
12/05/19	SJC	Travel from Stamford, CT to Boston, MA	3.00
12/05/19	IA	Travel from Stamford, CT to New York, NY	1.00
12/05/19	SKL	Travel from HPN to DAL	5.00
12/05/19	MH	Travel from HPN to ATL	4.00
12/06/19	ADD	Travel from LGA to DCA	3.50
12/06/19	RDS	Travel from Stamford, CT to New York, NY	1.10
12/08/19	ADD	Travel from DCA to JFK	3.50
12/08/19	KM	Travel from YYZ to HPN	4.50
12/09/19	RDS	Travel from New York, NY to Stamford, CT	1.50
12/09/19	MH	Travel from ATL to HPN	4.00
12/09/19	HK	Travel from New York, NY to Stamford, CT	1.00
12/09/19	IA	Travel from New York, NY to Stamford, CT	1.00
12/09/19	SJC	Travel from Boston, MA to Stamford, CT	3.00
12/09/19	GJK	Travel from DFW to HPN	4.00
12/09/19	JDH	Travel from New York, NY to Stamford, CT	1.00
12/09/19	JD	Travel from New York, NY to Stamford, CT	1.00
12/10/19	JDH	Travel to/from New York, NY and Stamford, CT	2.00
12/10/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
12/10/19	SKL	Travel from DAL to HPN	5.00
12/11/19	GJK	Travel from LGA to DFW	5.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
12/11/19	RC	Travel to/from New York, NY and Stamford, CT.	1.00
12/11/19	RDS	Travel from Stamford, CT to New York, NY	1.40
12/12/19	KM	Travel from HPN to YYZ	4.50
12/12/19	ADD	Travel from Stamford, CT to New York, NY	1.00
12/12/19	JD	Travel from Stamford, CT to New York, NY	1.00
12/12/19	IA	Travel from New York, NY to Stamford, CT	1.00
12/12/19	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
12/12/19	SKL	Travel from HPN to DAL	5.00
12/12/19	MH	Travel from HPN to ATL.	4.00
12/12/19	HK	Travel from Stamford, CT to New York, NY	1.00
12/12/19	SJC	Travel from HPN to ORD	4.00
12/15/19	ADD	Travel from New York, NY to Stamford, CT	1.00
12/16/19	KM	Travel from YYZ to HPN	4.50
12/16/19	HK	Travel from New York, NY to Stamford, CT	1.00
12/16/19	MH	Travel from ATL to HPN	4.00
12/16/19	SKL	Travel from DAL to HPN	5.00
12/16/19	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
12/16/19	GJK	Travel from DFW to HPN	4.00
12/16/19	JDH	Travel from New York, NY to Stamford, CT	1.00
12/16/19	JD	Travel from New York, NY to Stamford, CT	1.00
12/18/19	JDH	Travel from Stamford, CT to New York, NY	1.00
12/18/19	NAS	Travel from Stamford, CT to Jersey City, NJ.	1.50
12/18/19	ADD	Travel from LGA to MSP	4.50
12/19/19	KM	Travel from HPN to YYZ	4.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
12/19/19	JD	Travel from Stamford, CT to White Plains, NY	0.50
12/19/19	JD	Travel from White Plains, NY to New York, NY	1.00
12/19/19	GJK	Travel from LGA to DFW	4.00
12/19/19	JDH	Travel to/from New York, NY and Stamford, CT	2.00
12/19/19	SKL	Travel from HPN to DAL	5.00
12/19/19	MH	Travel from HPN to ATL	4.00
12/19/19	HK	Travel from Stamford, CT to New York, NY	1.00
12/23/19	JD	Travel to/from New York, NY and Stamford, CT	2.00
01/05/20	ADD	Travel from MSP to LGA	4.50
01/05/20	GJK	Travel from DFW to HPN	4.00
01/06/20	JDH	Travel from New York, NY to Stamford, CT	1.00
01/06/20	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
01/06/20	SKL	Travel from DAL to HPN	5.00
01/06/20	MH	Travel from ATL to HPN	4.00
01/06/20	HK	Travel from New York, NY to Stamford, CT	1.00
01/06/20	SJC	Travel from ORD to HPN	4.00
01/06/20	RDS	Travel from New York, NY to Stamford, CT	1.30
01/06/20	JD	Travel from New York, NY to Stamford, CT	1.00
01/06/20	DS	Travel from New York, NY to Stamford, CT	1.00
01/06/20	KM	Travel from YYZ to HPN	4.50
01/07/20	RC	Travel from New York, NY to Stamford, CT	1.00
01/08/20	JD	Travel from Stamford, CT to New York, NY	1.00
01/08/20	KM	Travel from HPN to PVD	3.50
01/08/20	RDS	Travel from HPN to PVD	3.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
01/09/20	RDS	Travel from PVD to LGA	3.60
01/09/20	ADD	Travel from LGA to MSP	4.50
01/09/20	KM	Travel from PVD to LGA	3.80
01/09/20	DS	Travel from Stamford, CT to New York, NY	1.00
01/09/20	JDH	Travel from Stamford, CT to New York, NY	1.00
01/09/20	GJK	Travel from HPN to DFW	4.00
01/09/20	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
01/09/20	SJC	Travel from HPN to ORD	4.00
01/09/20	MH	Travel from HPN to ATL	4.00
01/09/20	SKL	Travel from HPN to DAL	5.00
01/09/20	HK	Travel from Stamford, CT to New York, NY	1.00
01/10/20	KM	Travel from LGA to YYZ	4.50
01/12/20	KM	Travel from YYG to PVD	4.50
01/12/20	ADD	Travel from MSP to LGA	4.50
01/12/20	NAS	Travel from EWR to LHR	8.60
01/12/20	GJK	Travel from DFW to LHR	10.00
01/13/20	JDH	Travel from New York, NY to Stamford, CT	1.00
01/13/20	JD	Travel from New York, NY to Stamford, CT	1.00
01/13/20	SKL	Travel from DAL to HPN	5.00
01/13/20	HK	Travel from New York, NY to Stamford, CT	1.00
01/13/20	SJC	Travel from ORD to HPN.	4.00
01/13/20	KM	Travel from PVD to RDU	5.90
01/13/20	RDS	Travel from LGA to RWI	4.80
01/13/20	DS	Travel from New York, NY to Stamford, CT	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
01/14/20	JD	Travel from Stamford, CT to New York, NY	1.00
01/14/20	RC	Travel from New York, NY to Stamford, CT	1.00
01/15/20	RDS	Travel from RWI to LGA	2.10
01/15/20	KM	Travel from RWI to HPN	4.50
01/16/20	RDS	Travel from New York, NY to Stamford, CT	0.50
01/16/20	DS	Travel from Stamford, CT to New York, NY	1.00
01/16/20	JD	Travel from New York, NY to Stamford, CT	1.00
01/16/20	JD	Travel from Stamford, CT to New York, NY	1.00
01/16/20	ADD	Travel from LGA to DCA	3.50
01/16/20	GJK	Travel from London, UK to Cambridge, UK	1.50
01/16/20	JDH	Travel from Stamford, CT to New York, NY	1.00
01/16/20	NAS	Travel from London, UK to Cambridge, UK	1.50
01/16/20	HK	Travel from Stamford, CT to New York, NY	1.00
01/16/20	SJC	Travel from HPN to ORD	4.00
01/16/20	SKL	Travel from HPN to DAL	5.00
01/17/20	NAS	Travel from Cambridge, UK to London, UK	2.00
01/17/20	GJK	Travel from Cambridge, UK to London, UK	2.00
01/17/20	RDS	Travel from Stamford, CT to New York, NY	1.00
01/17/20	KM	Travel from HPN to YYZ	4.50
01/18/20	NAS	Travel from LHR to EWR	10.00
01/19/20	GJK	Travel from LHR to DFW	11.00
01/20/20	JD	Travel from New York, NY to Stamford, CT	1.00
01/20/20	MH	Travel from ATL to HPN.	4.00
01/20/20	SJC	Travel from ORD to HPN	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
01/20/20	KM	Travel from YYZ to HPN	4.50
01/20/20	ADD	Travel from DCA to LGA	3.50
01/20/20	RDS	Travel from New York, NY to Stamford, CT	1.10
01/21/20	DS	Travel from New York, NY to Stamford, CT	1.00
01/21/20	HK	Travel from New York, NY to Stamford, CT	1.00
01/21/20	SKL	Travel from DAL to HPN	5.00
01/21/20	JDH	Travel from New York, NY to Stamford, CT	1.00
01/21/20	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
01/21/20	GJK	Travel from DFW to HPN	4.00
01/22/20	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
01/22/20	JD	Travel from Stamford, CT to New York, NY	1.00
01/22/20	HK	Travel from Stamford, CT to New York, NY	1.00
01/22/20	SJC	Travel from HPN to ORD	4.00
01/22/20	DS	Travel from Stamford, CT to New York, NY	1.00
01/22/20	RDS	Travel from Stamford, CT to New York, NY	1.10
01/23/20	KM	Travel from HPN to YYZ	4.50
01/23/20	JDH	Travel from Stamford, CT to New York, NY	1.00
01/24/20	GJK	Travel from LGA to DFW	5.00
01/24/20	SKL	Travel from HPN to DAL.	5.00
01/24/20	MH	Travel from LGA to ATL	4.00
01/24/20	ADD	Travel from JFK to TPA	4.00
01/26/20	ADD	Travel from TPA to LGA	4.00
01/27/20	RDS	Travel from New York, NY to Stamford, CT	1.00
01/27/20	KM	Travel from YYZ to HPN	4.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
01/27/20	DS	Travel from New York, NY to Stamford, CT	1.00
01/27/20	SKL	Travel from DAL to HPN	5.00
01/27/20	SJC	Travel from ORD to HPN	4.00
01/27/20	HK	Travel from New York, NY to Stamford, CT	1.00
01/27/20	GJK	Travel from DFW to HPN	4.00
01/27/20	NAS	Travel from Jersey City, NJ to Stamford, CT	1.50
01/27/20	JDH	Travel to/from New York, NY to Stamford, CT	2.00
01/27/20	JD	Travel from New York, NY to Stamford, CT	1.00
01/28/20	RC	Travel from New York, NY to Stamford, CT	1.00
01/28/20	JDH	Travel to/from New York, NY to Stamford, CT	2.00
01/29/20	JD	Travel from Stamford, CT to New York, NY	1.00
01/29/20	NAS	Travel from Stamford, CT to Jersey City, NJ	1.50
01/29/20	RDS	Travel from Stamford, CT to New York, NY	1.00
01/29/20	KM	Travel from Stamford, CT to New York, NY	1.00
01/30/20	KM	Travel from LGA to BNA	3.90
01/30/20	DS	Travel from Stamford, CT to New York, NY	1.00
01/30/20	ADD	Travel from LGA to MSP	4.50
01/30/20	GJK	Travel from HPN to DFW	5.00
01/30/20	HK	Travel from Stamford, CT to New York, NY	1.00
01/30/20	SJC	Travel from HPN to ORD	4.00
01/30/20	SKL	Travel from HPN to DAL.	5.00
01/31/20	JDH	Travel from Stamford, CT to New York, NY	1.00
Total			981.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	19.00	385.00	7,315.00
Sam K Lemack	215.00	440.00	94,600.00
Hart Ku	47.00	440.00	20,680.00
Andrew D DePalma	163.0	480.00	78,240.00
Nate A Simon	63.50	480.00	30,480.00
Julie A Doherty	14.00	480.00	6,720.00
Sam K Lemack	80.00	515.00	41,200.00
Andrew D DePalma	66.00	515.00	33,990.00
Hart Ku	16.00	515.00	8,240.00
Nate A Simon	62.20	515.00	32,033.00
David Samikkannu	41.00	615.00	25,215.00
Isabel Arana de Uriarte	45.00	615.00	27,675.00
Sam J Canniff	171.00	615.00	105,165.00
Sam J Canniff	64.00	645.00	41,280.00
Jon D Hecht	27.00	665.00	17,955.00
David Samikkannu	16.00	690.00	11,040.00
Jon D Hecht	22.00	690.00	15,180.00
Ryan D Sublett	60.20	725.00	43,645.00
Ryan D Sublett	42.00	735.00	30,870.00
Scott Robertson	49.50	830.00	41,085.00
Michael Hartley	138.80	830.00	115,204.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Travel

Client/Matter # 012589.00150

Fee Recap:

Consultant	Hours	Rate	Amount
Gabe J Koch	112.00	830.00	92,960.00
Gabe J Koch	101.00	840.00	84,840.00
Michael Hartley	32.00	840.00	26,880.00
Kevin M McCafferty	102.20	895.00	91,469.00
Mark F Rule	44.00	895.00	39,380.00
Jesse DelConte	69.20	945.00	65,394.00
Jesse DelConte	20.00	950.00	19,000.00
Kevin M McCafferty	108.20	950.00	102,790.00
Richard Collura	18.00	1,080.00	19,440.00
Richard Collura	6.00	1,090.00	6,540.00
Lisa Donahue	2.00	1,165.00	2,330.00
Total Hours & Fees	1,139.00		785,203.00
Less 50% Travel			(392,601.50)
Total Fees			392,601.50